Engineered muscle targeting compositions

ABSTRACT

Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of and priority to U.S. Provisional Patent Application Nos. 62/916,207, filed on Oct. 16, 2019, entitled “Engineered Adeno-Associated Virus Capsids”; 62/916,221, filed on Oct. 16, 2019, entitled “Engineered Adeno-Associated Virus Capsids”; 63/018,454, filed on Apr. 30, 2020, entitled “Engineered Adeno-Associated Virus Capsids”; and 63/055,252, filed on Jul. 22, 2020, entitled “Engineered Muscle Targeting Compositions” the contents of which are incorporated by reference herein in their entirety.

SEQUENCE LISTING

This application contains a sequence listing filed in electronic form as an ASCII.txt file entitled BROD-5005WP.txt, created on Oct. 16, 2020 and having a size of 1,800,000 bytes. The content of the sequence listing is incorporated herein in its entirety.

TECHNICAL FIELD

The subject matter disclosed herein is generally directed to muscle targeting compositions including, but not limited to, recombinant adeno-associated virus (AAV) vectors and systems thereof, compositions, and uses thereof.

BACKGROUND

Recombinant AAVs (rAAVs) are the most commonly used delivery vehicles for gene therapy and gene editing. Nonetheless, rAAVs that contain natural capsid variants have limited cell tropism. Indeed, rAAVs used today mainly infect the liver after systemic delivery. Further, the transduction efficiency of conventional rAAVs in other cell-types, tissues, and organs by these conventional rAAVs with natural capsid variants is limited. Therefore, AAV-mediated polynucleotide delivery for diseased that affect cells, tissues, and organs other than the liver (e.g. nervous system, skeletal muscle, and cardiac muscle) typically requires an injection of a large dose of virus (typically about 1×10¹⁴ vg/kg), which often results in liver toxicity. Furthermore, because large doses are required when using conventional rAAVs, manufacturing sufficient amounts of a therapeutic rAAV needed to dose adult patients is extremely challenging. Additionally, due to differences in gene expression and physiology, mouse and primate models respond differently to viral capsids. Transduction efficiency of different virus particles varies between different species, and as a result, preclinical studies in mice often do not accurately reflect results in primates, including humans. As such, there exists a need for improved rAAVs for use in the treatment of various genetic diseases.

SUMMARY

Described in certain example embodiments herein are compositions comprising a targeting moiety effective to target a muscle cell, wherein the targeting moiety comprises an n-mer motif; and a cargo, wherein the cargo is coupled to or is otherwise associated with the targeting moiety.

In certain example embodiments, the n-mer motif comprises an RGD motif or a non-RGD n-mer motif.

In certain example embodiments, the RGD motif has a formula of X_(m)RGDX_(n), wherein m is 0-4 amino acids, wherein n is 0-15 amino acids, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.

In certain example embodiments, the RGD motif has the formula RGDXn, wherein n is 4 or 5, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.

In certain example embodiments, the n-mer motif is any one of SEQ ID NO: 13-50, 1277-2493, 3737-4979, 6647-8313, 8314-8502, or 8692-8889.

In certain example embodiments, the targeting moiety comprises a polypeptide, a polynucleotide, a lipid, a polymer, a sugar, or a combination thereof.

In certain example embodiments, the targeting moiety comprises a viral protein.

In certain example embodiments, the viral protein is a capsid protein.

In certain example embodiments, the viral protein is an adeno associated virus (AAV) protein.

In certain example embodiments, the n-mer motif is located between two amino acids of the viral protein such that the n-mer motif is external to a viral capsid of which the viral capsid protein is part.

In certain example embodiments, the n-mer motif is inserted between any two contiguous amino acids between amino acids 262-269, 327-332, 382-386, 452-460, 488-505, 527-539, 545-558, 581-593, 704-714, or any combination thereof in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.

In certain example embodiments, the n-mer motif is inserted between amino acids 588 and 589 in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.

In certain example embodiments, the composition is an engineered viral particle.

In certain example embodiments, the engineered viral particle is an engineered AAV viral particle.

In certain example embodiments, the AAV viral particle is an engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, or AAV rh.10 viral particle.

In certain example embodiments, the cargo is capable of treating or preventing a muscle disease or disorder.

In certain example embodiments, the muscle disease or disorder is

a. an auto immune disease;

b. a cancer;

c. a muscular dystrophy;

d. a neuro-muscular disease;

e. a sugar or glycogen storage disease;

f. an expanded repeat disease;

g. a dominant negative disease;

h. a cardiomyopathy;

i. a viral disease;

j. a progeroid disease; or

k. any combination thereof.

In certain example embodiments, the cargo is

-   -   a. a morpholino;     -   b. a peptide-linked morpholino;     -   c. an antisense oligonucleotide;     -   d. a PMO, a therapeutic transgene;     -   e. a polynucleotide encoding a therapeutic polypeptide or         peptide;     -   f. a PPMO;     -   g. one or more peptides or polypeptides;     -   h. one or more polynucleotides encoding a CRISPR-Cas protein, a         guide RNA, or both;     -   i. a ribonucleoprotein, wherein the ribonucleoprotein comprises         a CRISPR-Cas system molecule;     -   j. a therapeutic transgene RNA, or other gene modifying or         therapeutic RNA and/or protein; or     -   k. any combination thereof.

In certain example embodiments, the cargo is capable of inducing exon skipping in a gene.

In certain example embodiments, the cargo is capable of inducing exon skipping in a dystrophin gene.

In certain example embodiments, the cargo is a mini- or micro-dystrophin gene.

In certain example embodiments, the mini- or micro-dystrophin gene comprises spectrin-like repeats 1, 1′, 2, 3, 16, 17, 20, 21, 22, 23, 24, or any combination thereof, and optionally an nNOS domain, an actin binding domain, one or more hinge regions, a dystroglycan binding domain, or any combination thereof.

In certain example embodiments, the cargo is operably coupled to a muscle specific promoter.

In certain example embodiments, the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).

In certain example embodiments, the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.

In certain example embodiments, the myotonic dystrophy is a Type 1 or a Type 2 myotonic dystrophy.

In certain example embodiments, the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, Duchene muscular dystrophy-associated cardiomyopathy, or Dannon disease.

In certain example embodiments, the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.

In certain example embodiments, the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID.

In certain example embodiments, the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.

In certain example embodiments, the composition has increased muscle cell potency, muscle cell specificity, reduced immunogenicity, or any combination thereof.

Described in certain example embodiments herein are vector systems comprising a vector comprising: one or more polynucleotides each encoding all or part of one or more targeting moieties effective to target a muscle cell, wherein each targeting moiety comprises one or more n-mer motifs, wherein each n-mer motif an RGD motif or a non-RGD n-mer motif, and wherein each polynucleotide at least encodes one or more of the one or more n-mer motifs; and optionally, a regulatory element operatively coupled to one or more of the one or more polynucleotides.

In certain example embodiments, the RGD motif has a formula of X_(m)RGDX_(n), wherein m is 0-4 amino acids, wherein n is 0-15 amino acids, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.

In certain example embodiments, the RGD motif has the formula RGDXn, wherein n is 4 or 5, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid

In certain example embodiments, the n-mer motif is any one of SEQ ID NO: 13-50, 1277-2493, 3737-4979, 6647-8313, 8314-8502, or 8692-8889.

In certain example embodiments, the vector system further comprises a cargo.

In certain example embodiments, the cargo is a cargo polynucleotide and is optionally coupled to one or more of the one or more polynucleotides encoding the targeting moiety, the regulatory element, or both.

In certain example embodiments, the cargo polynucleotide is present on the same vector or a different vector as the one or more polynucleotides encoding the targeting moiety.

In certain example embodiments, the vector system is capable of producing virus particles that contain the cargo.

In certain example embodiments, the vector system is capable of producing a viral capsid polypeptide comprising one or more of the targeting moieties.

In certain example embodiments, the vector system is capable of producing AAV virus particles.

In certain example embodiments, AAV viral particles are engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, or AAV rh.10 viral particle.

In certain example embodiments, the capsid polypeptide is an engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, AAV rh.10 capsid polypeptide.

In certain example embodiments, wherein at least one of the one or more polynucleotides encoding the n-mer motif(s) is inserted between two codons corresponding to two amino acids of the viral protein such that at least one of the n-mer motifs is external to the viral capsid.

In certain example embodiments, the two codons correspond to any two contiguous amino acids between amino acids 262-269, 327-332, 382-386, 452-460, 488-505, 527-539, 545-558, 581-593, 704-714, or any combination thereof in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.

In certain example embodiments, the two codons correspond to amino acid 588 and 589 in the AAV9 capsid polynucleotide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.

In certain example embodiments, the vector comprising the one or more polynucleotides each encoding all or part of one or more targeting moieties does not comprise splice regulatory elements.

In certain example embodiments, the vector system further comprises a polynucleotide encoding a viral rep protein.

In certain example embodiments, the viral rep protein is an AAV rep protein.

In certain example embodiments, the polynucleotide encoding the viral rep protein is on the same vector or different vector as the one or more polynucleotides each encoding all or part of one or more targeting moieties.

In certain example embodiments, the viral rep protein is operatively coupled to a regulatory element.

Described in certain example embodiments herein are polypeptides produced by expressing a vector system as described herein, for example as in any of paragraphs [0038]-[0057].

In certain example embodiments, the polypeptide is a viral polypeptide.

In certain example embodiments, the viral polypeptide is an AAV polypeptide.

Described in certain example embodiments herein are particles produced by expressing a vector system as described herein, for example as in any of paragraphs [0038]-[0057].

In certain example embodiments, the particle is a viral particle.

In certain example embodiments, the viral particle is an adeno-associated virus (AAV) particle.

In certain example embodiments, the viral particle has a muscle-specific tropism.

Described in certain example embodiments, a vector system as described herein, for example as in any of paragraphs [0038]-[0057], a polypeptide as described herein, for example as in any one of paragraphs [0058]-[0060], or a particle as described herein, for example as in any one of paragraphs [0061]-[0064], the cargo is capable of treating or preventing a muscle disease or disorder.

In certain example embodiments, the muscle disease or disorder is

a. an auto immune disease;

b. a cancer;

c. a muscular dystrophy;

d. a neuro-muscular disease;

e. a sugar or glycogen storage disease;

f. an expanded repeat disease;

g. a dominant negative disease;

h. a cardiomyopathy;

i. a viral disease;

j. a progeroid disease; or

k. any combination thereof.

In certain example embodiments, the cargo is

-   -   a. a morpholino;     -   b. a peptide-linked morpholino;     -   c. an antisense oligonucleotide;     -   d. a PMO, a therapeutic transgene;     -   e. a polynucleotide encoding a therapeutic polypeptide or         peptide;     -   f. a PPMO;     -   g. one or more peptides or polypeptides;     -   h. one or more polynucleotides encoding a CRISPR-Cas protein, a         guide RNA, or both;     -   i. a ribonucleoprotein, wherein the ribonucleoprotein comprises         a CRISPR-Cas system molecule;     -   j. a therapeutic transgene RNA, or other gene modifying or         therapeutic RNA and/or protein; or     -   k. any combination thereof.

In certain example embodiments, the cargo is capable of inducing exon skipping in a gene.

In certain example embodiments, the cargo is capable of inducing exon skipping in a dystrophin gene.

In certain example embodiments, the cargo is a mini- or micro-dystrophin gene.

In certain example embodiments, the mini- or micro-dystrophin gene comprises spectrin-like repeats 1, 1′, 2, 3, 16, 17, 20, 21, 22, 23, 24, or any combination thereof, and optionally an nNOS domain, an actin binding domain, one or more hinge regions, a dystroglycan binding domain, or any combination thereof.

In certain example embodiments, the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).

In certain example embodiments, the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.

In certain example embodiments, the myotonic dystrophy is Type 1 or Type 2.

In certain example embodiments, the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, DMD-associated cardiomyopathy, or Dannon disease.

In certain example embodiments, the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.

In certain example embodiments, the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID.

In certain example embodiments, the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.

In certain example embodiments, the polypeptide, the particle, or both have increased muscle cell potency, muscle cell specificity, reduced immunogenicity, or any combination thereof.

A cell comprising:

-   -   a. a composition as described herein, for example as in any one         of paragraphs [0007]-[0037];     -   b. a vector system as described herein, for example as in any         one of paragraphs [0038]-[0057] or [0065]-[0078];     -   c. a polypeptide as described herein, for example as in any one         of paragraphs [0058]-[0060] or [0065]-[0079];     -   d. a particle as described herein, for example as in any one of         paragraphs [0061]-[0079]; or     -   e. a combination thereof.

In certain example embodiments, wherein the cell is prokaryotic.

In certain example embodiments, wherein the cell is eukaryotic.

A pharmaceutical formulation comprising:

-   -   a. a composition as described herein, for example as in any one         of paragraphs [0007]-[0037];     -   b. a vector system as described herein, for example as in any         one of paragraphs [0038]-[0057] or [0065]-[0078];     -   c. a polypeptide as described herein, for example as in any one         of paragraphs [0058]-[0060] or [0065]-[0079];     -   d. a particle as described herein, for example as in any one of         paragraphs [0061]-[0079];     -   e. a cell as described herein, for example as in any one of         paragraphs [0080]-[0082]; or     -   f. a combination thereof; and

a pharmaceutically acceptable carrier.

A method comprising:

-   -   administering, to a subject in need thereof, a     -   a. a composition as described herein, for example as in any one         of paragraphs [0007]-[0037];     -   b. a vector system as described herein, for example as in any         one of paragraphs [0038]-[0057] or [0065]-[0078];     -   c. a polypeptide as described herein, for example as in any one         of paragraphs [0058]-[0060] or [0065]-[0079];     -   d. a particle as described herein, for example as in any one of         paragraphs [0061]-[0079];     -   e. a cell as described herein, for example as in any one of         paragraphs [0080]-[0082];     -   f. a pharmaceutical formulation as described herein, for example         as in paragraph [0083]; or     -   g. a combination thereof;

In certain example embodiments, the subject in need thereof has a muscle disease or disorder.

In certain example embodiments, the muscle disease or disorder is

a. an auto immune disease;

b. a cancer;

c. a muscular dystrophy;

d. a neuro-muscular disease;

e. a sugar or glycogen storage disease;

f. an expanded repeat disease;

g. a dominant negative disease;

h. a cardiomyopathy;

i. a viral disease;

j. a progeroid disease; or

k. any combination thereof.

In certain example embodiments, the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).

In certain example embodiments, the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.

In certain example embodiments, the myotonic dystrophy is Type 1 or Type 2.

In certain example embodiments, the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, DMD-associated cardiomyopathy, or Dannon disease.

In certain example embodiments, the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.

In certain example embodiments, the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID.

In certain example embodiments, the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.

These and other embodiments, objects, features, and advantages of the example embodiments will become apparent to those having ordinary skill in the art upon consideration of the following detailed description of illustrated example embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

An understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention may be utilized, and the accompanying drawings of which:

FIG. 1 demonstrates the adeno-associated virus (AAV) transduction mechanism, which results in production of mRNA from the transgene.

FIG. 2 shows a graph that can demonstrate that mRNA-based selection of AAV variants can be more stringent than DNA-based selection. The virus library was expressed under the control of a CMV promoter.

FIGS. 3A-3B show graphs that can demonstrate a correlation between the virus library and vector genome DNA (FIG. 3A) and mRNA (FIG. 3B) in the liver.

FIGS. 4A-4F show graphs that can demonstrate capsid variants present at the DNA level and expressed at the mRNA level identified in different tissues. For this experiment, the virus library was expressed under the control of a CMV promoter.

FIGS. 5A-5C show graphs that can demonstrate capsid mRNA expression in different tissues under the control of cell-type specific promoters (as noted on x-axis). CMV was included as an exemplary constitutive promoter. CK8 is a muscle-specific promoter. MHCK7 is a muscle-specific promoter. hSyn is a neuron specific promoter. Expression levels from the cell type-specific promoters have been normalized based on expression levels from the constitutive CMV promoter in each tissue.

FIG. 6 shows a schematic demonstrating embodiments of a method of producing and selecting capsid variants for tissue-specific gene delivery across species.

FIG. 7 shows a schematic demonstrating embodiments of generating an AAV capsid variant library, particularly insertion of a random n-mer (n=3-15 amino acids) into a wild-type AAV, e.g. AAV9.

FIG. 8 shows a schematic demonstrating embodiments of generating an AAV capsid variant library, particularly variant AAV particle production. Each capsid variant encapsulates its own coding sequence as the vector genome.

FIG. 9 shows schematic vector maps of representative AAV capsid plasmid library vectors (see e.g. FIG. 8) that can be used in an AAV vector system to generate an AAV capsid variant library.

FIG. 10 shows a graph that can demonstrate the viral titer (calculated as AAV9 vector genome/15 cm dish) produced by constructs containing different constitutive and cell-type specific mammalian promoters.

FIGS. 11A-11F show graphs that can demonstrate the results obtained after the first round of selection in C57BL/6 mice using a capsid library expressed under the control of the MHCK7 muscle-specific promoter.

FIGS. 12A-12D show graphs that can demonstrate the results obtained after the second round of selection in C57BL/6 mice using a capsid library expressed under the control of the MHCK7 muscle-specific promoter.

FIGS. 13A-13B shows graphs that can demonstrate a correlation between the abundance of variants encoded by synonymous codons.

FIG. 14 shows a graph that can demonstrate a correlation between the abundance of the same variants expressed under the control of two different muscle specific promoters (MHCK7 and CK8).

FIG. 15 shows a graph that can demonstrate muscle-tropic capsid variants that produce rAAV with similar titers to wild-type AAV9 capsid.

FIG. 16 shows images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 17 shows a panel of images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-G.

FIG. 18 shows a panel of images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GF.

FIG. 19 shows a schematic of selection of potent capsid variants for muscle-directed gene delivery across species.

FIGS. 20A-20C show tables that can demonstrate selection in different strains of mice identifies the same variants as the top muscle-tropic hits.

FIG. 21 shows images that can demonstrate a comparison of mouse muscle transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 22 shows graphs that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 23 shows graphs that can demonstrate a comparison of vector genome biodistribution between rAAV9-GFP and rMyoAAV-GFP.

FIGS. 24A-24B show images that can demonstrate faster kinetics of in vivo gene expression in muscle by MyoAAV as compared to AAV9 and AAV8.

FIG. 25 can demonstrate a mechanism of correction of a DMD mutation in model mdx mice by MyoAAV-CRISPR as compared to AAV9-CRISPR.

FIGS. 26A-26C can demonstrate correction of a DMD mutation in model mdx mice with MyoAAV-CRISPR as compared to AAV9-CRISPR.

FIG. 27 can demonstrate that MyoAAV uses integrin heterodimers as the receptor to enter cells.

FIG. 28 shows graphs that can demonstrate that myoAAV can transduce both mouse and human primary myotubes 50-100 times more effectively than AAV9.

FIGS. 29A-29B can demonstrate that integrin alpha V small molecule inhibitors suppress transduction of human primary myotubes by MyoAAV.

The figures herein are for illustrative purposes only and are not necessarily drawn to scale.

DETAILED DESCRIPTION OF THE EXAMPLE EMBODIMENTS General Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Definitions of common terms and techniques in molecular biology may be found in Molecular Cloning: A Laboratory Manual, 2nd edition (1989) (Sambrook, Fritsch, and Maniatis); Molecular Cloning: A Laboratory Manual, 4th edition (2012) (Green and Sambrook); Current Protocols in Molecular Biology (1987) (F. M. Ausubel et al. eds.); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (1995) (M. J. MacPherson, B. D. Hames, and G. R. Taylor eds.): Antibodies, A Laboratory Manual (1988) (Harlow and Lane, eds.): Antibodies A Laboraotry Manual, 2nd edition 2013 (E. A. Greenfield ed.); Animal Cell Culture (1987) (R. I. Freshney, ed.); Benjamin Lewin, Genes IX, published by Jones and Bartlet, 2008 (ISBN 0763752223); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0632021829); Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 9780471185710); Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992); and Marten H. Hofker and Jan van Deursen, Transgenic Mouse Methods and Protocols, 2nd edition (2011).

As used herein, the singular forms “a”, “an”, and “the” include both singular and plural referents unless the context clearly dictates otherwise.

The term “optional” or “optionally” means that the subsequent described event, circumstance or substituent may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further embodiment. For example, if the value “about 10” is disclosed, then “10” is also disclosed.

It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible sub-ranges) within the indicated range. Where a range is expressed, a further embodiment includes from the one particular value and/or to the other particular value.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure. For example, where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g. the phrase “x to y” includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’. The range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘less than x’, less than y’, and ‘less than z’. Likewise, the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘greater than x’, greater than y’, and ‘greater than z’. In addition, the phrase “about ‘x’ to ‘y’”, where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’”.

The terms “about” or “approximately” as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, are meant to encompass variations of and from the specified value, such as variations of +/−10% or less, +/−5% or less, +/−1% or less, and +/−0.1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention. It is to be understood that the value to which the modifier “about” or “approximately” refers is itself also specifically, and preferably, disclosed. As used herein, the terms “about,” “approximate,” “at or about,” and “substantially” can mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art such that equivalent results or effects are obtained. In some circumstances, the value that provides equivalent results or effects cannot be reasonably determined. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about,” “approximate,” or “at or about” whether or not expressly stated to be such. It is understood that where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.

As used herein, a “biological sample” may contain whole cells and/or live cells and/or cell debris. The biological sample may contain (or be derived from) a “bodily fluid”. The present invention encompasses embodiments wherein the bodily fluid is selected from amniotic fluid, aqueous humour, vitreous humour, bile, blood serum, breast milk, cerebrospinal fluid, cerumen (earwax), chyle, chyme, endolymph, perilymph, exudates, feces, female ejaculate, gastric acid, gastric juice, lymph, mucus (including nasal drainage and phlegm), pericardial fluid, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum (skin oil), semen, sputum, synovial fluid, sweat, tears, urine, vaginal secretion, vomit and mixtures of one or more thereof. Biological samples include cell cultures, bodily fluids, cell cultures from bodily fluids. Bodily fluids may be obtained from a mammal organism, for example by puncture, or other collecting or sampling procedures.

The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.

Various embodiments are described hereinafter. It should be noted that the specific embodiments are not intended as an exhaustive description or as a limitation to the broader embodiments discussed herein. One embodiment described in conjunction with a particular embodiment is not necessarily limited to that embodiment and can be practiced with any other embodiment(s). Reference throughout this specification to “one embodiment”, “an embodiment,” “an example embodiment,” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” or “an example embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention. For example, in the appended claims, any of the claimed embodiments can be used in any combination.

Reference is made to U.S. Provisional Application No. 62/899,453 and International Application No. PCT/US20/50534.

All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.

Overview

Embodiments disclosed herein provide muscle-specific targeting moieties that can be coupled to or otherwise associated with a cargo. Embodiments disclosed herein provide polypeptides and particles that can incorporate one or more of the muscle-specific targeting moieties. The polypeptides and/or particles can be coupled to, attached to, encapsulate, or otherwise incorporate a cargo, thereby associating the cargo with the targeting moiety(ies).

Embodiments disclosed herein provide muscle-specific targeting moieties that can contain one or more of an n-mer motif as further described herein, an RGD motif as further described herein, or both. In some embodiments, the n-mer motif and/or the RGD motif can confer muscle-specificity of the targeting moiety.

Embodiments disclosed herein provide engineered adeno-associated virus (AAV) capsids that can be engineered to confer cell-specific and/or species-specific tropism to an engineered AAV particle.

Embodiments disclosed herein also provide methods of generating the rAAVs having engineered capsids that can involve systematically directing the generation of diverse libraries of variants of modified surface structures, such as variant capsid proteins. Embodiments of the method of generating rAAVs having engineered capsids can also include stringent selection of capsid variants capable of targeting a specific cell, tissue, and/or organ type. Embodiments of the method of generating rAAVs having engineered capsids can include stringent selection of capsid variants capable of efficient and/or homogenous transduction in at least two or more species.

Embodiments disclosed herein provide vectors and systems thereof capable of producing an engineered AAV described herein.

Embodiments disclosed herein provide cells that can be capable of producing the engineered AAV particles described herein. In some embodiments, the cells include one or more vectors or system thereof described herein.

Embodiments disclosed herein provide engineered AAVs that can include an engineered capsid described herein. In some embodiments, the engineered AAV can include a cargo polynucleotide to be delivered to a cell. In some embodiments, the cargo polynucleotide is a gene modification polynucleotide.

Embodiments disclosed herein provide formulations that can contain an engineered AAV vector or system thereof, an engineered AAV capsid, engineered AAV particles including an engineered AAV capsid described herein, and/or an engineered cell described herein that contains an engineered AAV capsid, and/or an engineered AAV vector or system thereof. In some embodiments, the formulation can also include a pharmaceutically acceptable carrier. The formulations described herein can be delivered to a subject in need thereof or a cell.

Embodiments disclosed herein also provide kits that contain one or more of the one or more of the polypeptides, polynucleotides, vectors, engineered AAV capsids, engineered AAV particles, cells, or other components described herein and combinations thereof and pharmaceutical formulations described herein. In embodiments, one or more of the polypeptides, polynucleotides, vectors, engineered AAV capsids, engineered AAV particles cells, and combinations thereof described herein can be presented as a combination kit

Embodiments disclosed herein provide methods of using the engineered AAVs having a cell-specific tropism described herein to deliver, for example, a therapeutic polynucleotide to a cell. In this way, the engineered AAVs described herein can be used to treat and/or prevent a disease in a subject in need thereof. Embodiments disclosed herein also provide methods of delivering the engineered AAV capsids, engineered AAV virus particles, engineered AAV vectors or systems thereof and/or formulations thereof to a cell. Also provided herein are methods of treating a subject in need thereof by delivering an engineered AAV particle, engineered AAV capsid, engineered AAV capsid vector or system thereof, an engineered cell, and/or formulation thereof to the subject.

Additional features and advantages of the embodiments engineered AAVs and methods of making and using the engineered AAVs are further described herein.

Muscle-Specific Targeting Moieties and Compositions Thereof

Described herein are targeting moieties that are capable of specifically targeting, binding, associating with, or otherwise interact specifically with a muscle cell. N-mer motifs are short peptide motifs that can confer cell and/or tissue type-targeting capabilities to another molecule, such as a cargo, to which it is incorporated, coupled to, attached, or otherwise associated with. In one example embodiment, the n-mer motif is incorporated into a viral capsid such that it is expressed on the capsid surface and confers tissue-specific targeting capability to the viral particle to facilitate tissue-specific delivery of viral particle and any optional cargo contained therein. In certain example embodiments, the n-mer motif is about 1-20 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids long. The term n-mer motif encompasses both n-mer motifs that have an RGD motif and those that do not (referred to herein as “non-RGD n-mer motifs”). In some example embodiments, the n-mer motif confers muscle cell/tissue specificity. In some example embodiments, the n-mer motif that confers muscle cell/tissue specificity is an RGD motif. In some example embodiments, the n-mer motif that confers muscle cell/tissue specificity is a non-RGD n-mer motif.

In some embodiments, the targeting moiety is or includes one or more n-mer motifs, where each of the one or more n-mer motifs is independently selected from an RGD motif or a non-RGD n-mer motif. N-mer motifs, RGD motifs and non-RGD n-mer motifs are described in greater detail elsewhere herein. In some embodiments, the targeting moiety includes more than one n-mer motifs, where each of the more than one n-mer motifs is independently selected from an RGD motif or a non-RGD n-mer motif. In some embodiments, the targeting moiety can include 1, 2, 3, 4, 5, 6, 7, 8, 9 10 or more n-mer motifs, where each n-mer motif is independently selected from an RGD motif or a non-RGD n-mer motif. In some embodiments, all the n-mer motifs included in the targeting moiety can be the same (i.e. have the same amino acid sequence). In some embodiments where more than one n-mer motif is included, at least two of the n-mer motifs are different from each other (i.e. have a different amino acid sequence). In some embodiments where more than one n-mer motif is included, all the n-mer motifs are different from each other. In some embodiments, each n-mer motif included in the targeting moiety can be any one of those set forth in any of Tables 1-6 and 8-9, which correspond to SEQ ID NOs: 13-50, 1277-2493, 3737-4979, 6647-8313, 8314-8502, or 8692-8889.

TABLE 1 CK8 Results mRNA Second Round of Capsid Variant Selection in C57BL6 mice-score capped at 100 Sum of muscle mRNA Variant Amino Acid score_capped ID Nucleotide Sequence SEQ ID NO: Sequence SEQ ID NO: at 100 1 AGGGGTGATCTTTCTACGCCT 60 RGDLSTP 1277 715.366 2 AGGGGCGACCTGAACCAATAC 61 RGDLNQY 1278 712.149 3 CGGGGTGATCTTACTACGCCT 62 RGDLTTP 1279 461.536 4 AGGGGGGATGCGACGGAGCTT 63 RGDATEL 1280 452.77 5 CGGGGTGATCAGCTTTATCAT 64 RGDQLYH 1281 444.505 6 AGAGGCGACTTATCCACACCC 65 RGDLSTP 1282 411.692 7 CGTGGTGATGTGGCGGCTAAG 66 RGDVAAK 1283 371.7 8 AGAGGAGACTTGACAACCCCA 67 RGDLTTP 1284 361.486 9 CGGGGTGATCTTAATCAGTAT 68 RGDLNQY 1285 342.712 10 CGAGGAGACACCATGAGCAAA 69 RGDTMSK 1286 325.632 11 CGCGGAGACGTAGCCGCCAAA 70 RGDVAAK 1287 315.01 12 CGGGGGGATACTATGTCTAAG 71 RGDTMSK 1288 309.567 13 CGGGGTGACGCAACAGAATTG 72 RGDATEL 1289 306.99 14 GCACGGTCAAACGACTCGGTC 73 ARSNDSV 1290 293.22 15 CGGGGTGACATGAACAACTCA 74 RGDMNNS 1291 268.677 16 ACGATGGGTGCTAATGGTACT 75 TMGANGT 1292 260.853 17 CCTAATGTTACGCAGTCTTAT 76 PNVTQSY 1293 259.718 18 CGTTTGGACCTGCAAGTCCAC 77 RLDLQVH 1294 257.65 19 GGGCTTTCTAAGGCGTCTGAT 78 GLSKASD 1295 255.938 20 GATCCTGGTCGGACGGGTACG 79 DPGRTGT 1296 253.325 21 TATCGGGGTAGGGAGGATTGG 80 YRGREDW 1297 244.83 22 AGATACGGAGAATCCATCGAA 81 RYGESIE 1298 231.696 23 AGTCTGAACAACATGGGATCG 82 SLNNMGS 1299 229.6044 24 AATAGTGATCAGCGGAATTGG 83 NSDQRNW 1300 229.031 25 CGTGGTGATATGTCTCGTGAG 84 RGDMSRE 1301 227.081 26 ATGACTGATGCGAATAGGATT 85 MTDANRI 1302 226.194 27 GTCTACAACGGCAACGTAGTA 86 VYNGNVV 1303 223.663 28 CGTGGGGATATGATTAATACG 87 RGDMINT 1304 223.46 29 AGTGGTCTTTCGCATGGTCAG 88 SGLSHGQ 1305 221.726 30 ACTGGCCAATTAGTAGGAACC 89 TGQLVGT 1306 221.181 31 GCTAATTCTATTGGGGGTCCG 90 ANSIGGP 1307 220.304 32 TACAGTCAATCGCTGTCTGAA 91 YSQSLSE 1308 220.02 33 TATCATAAGTATAGTACGGAT 92 YHKYSTD 1309 217.64 34 GCTCGTCATGATGAGCATGTG 93 ARHDEHV 1310 217 35 GCCATAGACTCTATCAAACAA 94 AIDSIKQ 1311 216.071 36 CGTTTGGACCTGCAAGTCAAC 95 RLDLQVN 1312 215 37 CGCGGCGACATGATAAACACC 96 RGDMINT 1313 214.271 38 AGTGTGTTGTCTCAGGCTAAT 97 SVLSQAN 1314 213.907 39 TTTACGGTGAATCAGGATCTT 98 FTVNQDL 1315 213.78 40 ACGGATAATGGTCTTCTTGTG 99 TDNGLLV 1316 211.787 41 TATCAGCAGACTTCTAGTACG 100 YQQTSST 1317 211.386 42 ACAGAACAATCTTACTCACGA 101 TEQSYSR 1318 210.762 43 ATTATGGGGCTTAGTCAGGCT 102 IMGLSQA 1319 208.157 44 GCTACTGCGCATCAGGATGGT 103 ATAHQDG 1320 207.212 45 TATAATGCTACTCCTTCGCAG 104 YNATPSQ 1321 206.964 46 TATACGCAGGGTATTATGAAT 105 YTQGIMN 1322 206.672 47 GAATCCCTCCCAATCTCTAAA 106 ESLPISK 1323 206.576 48 GGCACCGTCGTTCCGGGCTCC 107 GTVVPGS 1324 206.111 49 GGATTAGCTAGTCTACACCTG 108 GLASLHL 1325 204.394 50 TATATTGCTGCGGGTGAGCAG 109 YIAAGEQ 1326 204.24 51 AACACCTACCCCTTCAACGCC 110 NTYPFNA 1327 203.931 52 GTTGGTGCGAGTACGGCTTCG 111 VGASTAS 1328 202.92 53 GGATCCAACTACTTAGCAAAC 112 GSNYLAN 1329 202.857 54 GATACTGGTCGGACGGGTACG 113 DTGRTGT 1330 202.83 55 AAGCCGAATACGATGAGTGAT 114 KPNTMSD 1331 202.7282 56 GTAGACAAATCTAGCCCAGTG 115 VDKSSPV 1332 201.849 57 AGTTCGGACCCAAAAGGTCAA 116 SSDPKGQ 1333 201.825 58 TGGCAGACGAATGGTATGCAG 117 WQTNGMQ 1334 201.6943 59 ACCGGTAGCTTGAACTCTATG 118 TGSLNSM 1335 201.671 60 CATTCTAATTCGAGTCAGAAT 119 HSNSSQN 1336 200.954 61 GGCCGTGACGACCTCACAAAC 120 GRDDLTN 1337 200.911 62 GATACTTATAAGGGTAAGTGG 121 DTYKGKW 1338 200.7787 63 TATACGGCGCAGACCGGCTGG 122 YTAQTGW 1339 200 64 AATCAGGTGGGTGCGTCTGCG 123 NQVGASA 1340 200 65 ATCGACGTACTGAACGGAAGT 124 IDVLNGS 1341 200 66 TTTCGGACGGTGTATACTGGT 125 FRTVYTG 1342 200 67 GGAAACATGGTGACTCCAAAC 126 GNMVTPN 1343 200 68 GATACTTATAACGGTAAGTGG 127 DTYNGKW 1344 200 69 ACCATCCAAGACCACATAAAA 128 TIQDHIK 1345 200 70 GGAGCAAAAGGAACCATGGGC 129 GAKGTMG 1346 200 71 ACGAGGAGCAACTCCGACGAA 130 TRSNSDE 1347 200 72 GCTACTACTCTTACTGGTGAT 131 ATTLTGD 1348 200 73 TCATACGGAGGATCTGGCCCC 132 SYGGSGP 1349 198.715 74 GAAAAATCCGTCGAATCCAAA 133 EKSVESK 1350 196.418 75 CGAGGCGACACAATGAACTAC 134 RGDTMNY 1351 195.3082 76 CGGGATCTGGGGCAGACCGGC 135 RDLGQTG 1352 194.34 77 AGTCCGCAGCTGAGTGTGATG 136 SPQLSVM 1353 194.21 78 CGAGGAGACAACAGCACACCG 137 RGDNSTP 1354 193.05 79 CCTATGGCAGGACACCCCCCG 138 PMAGHPP 1355 192.726 80 ACGGCGTATCAGGCTGGTCTG 139 TAYQAGL 1356 191.778 81 GTGGTAAACCAAGGAAACCAA 140 VVNQGNQ 1357 191.737 82 GATAAGACTGAGATGCTGCAG 141 DKTEMLQ 1358 191.13 83 ACTGTGATGATGAGTACGAGG 142 TVMMSTR 1359 191.063 84 CAGCAGAATACGCGTTTGCCG 143 QQNTRLP 1360 190.1825 85 TACCAACACAACCAAGCCCAC 144 YQHNQAH 1361 189.595 86 AATCAGAGTATTAATAATATT 145 NQSINNI 1362 188.654 87 CGAGGAGACCACAGCACACCG 146 RGDHSTP 1363 187.365 88 GACTCTACACTTCACTTAAGT 147 DSTLHLS 1364 187.36 89 GCGAACATAGAAAACACGTCA 148 ANIENTS 1365 187.03 90 ACAAACGCTGCTCTAGTACCA 149 TNAALVP 1366 185.9743 91 GGGCAGAAGGAGACTACTGCG 150 GQKETTA 1367 184.457 92 GAACTTAACACCGCACACGCA 151 ELNTAHA 1368 184.059 93 GGTGTTAGTAGTAATTCTGCG 152 GVSSNSA 1369 183.964 94 AGCACAAACGCGGGACAAAGG 153 STNAGQR 1370 183.571 95 GAACAACAAAAAACAGACAAC 154 EQQKTDN 1371 182.331 96 GCTGTTGTGAATGAGAATATG 155 AVVNENM 1372 182.3 97 GGCAGCGTCAGCACCAGCGCA 156 GSVSTSA 1373 181.451 98 GAGTTGGGTAGTCAGCGTATG 157 ELGSQRM 1374 181.36 99 AGAGGCGACTTATCCACACAC 158 RGDLSTH 1375 181.15 100 GACCACCAACAAGCCCTAGCT 159 DHQQALA 1376 180.295 101 AACAGATCTGACGCTCACGAA 160 NRSDAHE 1377 180.265 102 AATGTTAATGCGCAGAGTAGG 161 NVNAQSR 1378 179.918 103 ACCCAAGGGAACAACATGGTA 162 TQGNNMV 1379 179.575 104 ACGGCGCTGAATACGTATCCT 163 TALNTYP 1380 179.568 105 GTCTCTACATACCTCCTGGCA 164 VSTYLLA 1381 179.172 106 GGCGGCAACTACAACACAACT 165 GGNYNTT 1382 178.62 107 AGTAATATTAAGCCGGAGATT 166 SNIKPEI 1383 178.567 108 CCGAGGGTGCATGGTCAGGTT 167 PRVHGQV 1384 178.479 109 TCTAATTCTAATACTGCTGCT 168 SNSNTAA 1385 178.119 110 CTTGAGGTGGCGACGAGTCCG 169 LEVATSP 1386 177.75 111 CACGACGCCGACAAATTAGCT 170 HDADKLA 1387 177.05 112 GGTGTGTATATTGATGGTCGG 171 GVYIDGR 1388 176.229 113 TCGATGCAGTCGTATACGATG 172 SMQSYTM 1389 175.538 114 TCTAAAGGAAACGAACAAATG 173 SKGNEQM 1390 175.311 115 GGTCGGGATTATGCTATGAGT 174 GRDYAMS 1391 174.17 116 ACTGATGGTATTTTTCAGCCT 175 TDGIFQP 1392 174.014 117 GGGAGCCCAGTGATAGTAAAC 176 GSPVIVN 1393 173.652 118 ACATTAACAGACGTTCACCGA 177 TLTDVHR 1394 172.837 119 AAAAGCGAAGTACCCGCCCGA 178 KSEVPAR 1395 172.72 120 GTCAACACTGGCGCACTCTTG 179 VNTGALL 1396 172.648 121 AGTCAGCAGGGTTTTACTCTG 180 SQQGFTL 1397 172.124 122 AATAATAAGTCTGTGCCGGAT 181 NNKSVPD 1398 172.0753 123 AGTGTGATGGTGGGTACGAAT 182 SVMVGTN 1399 171.86 124 CGAAACGAAAACACTTACAAC 183 RNENTYN 1400 170.674 125 CAAGCTAACTTATCAATAATC 184 QANLSII 1401 170.5862 126 CCCGGACGGGACAGCAGAACG 185 PGRDSRT 1402 169.875 127 TTTCCGGCTAATGGTGGTGCT 186 FPANGGA 1403 169.639 128 GCTGGTAAGGATCTTAGTAAT 187 AGKDLSN 1404 169.592 129 GCACAATTCGAATCAGGCCGA 188 AQFESGR 1405 169.281 130 GGATACGGCAGTTACAGCAAC 189 GYGSYSN 1406 169.247 131 ACAATCGTTTCCGCTTACGCC 190 TIVSAYA 1407 168.87 132 AATGTGAGTCCTAATTTGACT 191 NVSPNLT 1408 168.739 133 AGAGGCGACTTATCAACACCC 192 RGDLSTP 1409 167.66 134 TTCTTAGAAGGAGTCGCTCAA 193 FLEGVAQ 1410 167.647 135 GGCTCCGAACGAGGAGAACGA 194 GSERGER 1411 167.585 136 TTGAATGTTGGTTCGAGTCTT 195 LNVGSSL 1412 167.104 137 CGTATTGTGGCTAATGAGCAG 196 RIVANEQ 1413 166.96 138 CAATCTATCGGCCACCCCGTT 197 QSIGHPV 1414 166.7759 139 GGTGGTATGTCGGCGCATTCG 198 GGMSAHS 1415 166.775 140 CATTCTACGACGTCTATGACG 199 HSTTSMT 1416 166.711 141 ACTGTAAACGGTACGAACGTA 200 TVNGTNV 1417 166.64 142 CTTGCGCCTGATAATATTGGG 201 LAPDNIG 1418 166.005 143 CAAACAGCGACTCTCGTGGCA 202 QTATLVA 1419 165.921 144 GCATCAGCACCGTCTGAATTC 203 ASAPSEF 1420 165.64 145 TCGATGGAGGGTCAGCAGCAT 204 SMEGQQH 1421 165.62 146 CAAGACGTAGGACGCACGAAC 205 QDVGRTN 1422 164.147 147 GTCTACAACGGCAACGAAGTA 206 VYNGNEV 1423 164.11 148 GCACAGGCGCAGACAGGCTGG 207 AQAQTGW 1424 163.93 149 CGGCTGGATCTGACGCATACG 208 RLDLTHT 1425 163.75 150 GCTGCACACGGCCGCGAACAA 209 AAHGREQ 1426 163.577 151 AGAGGCGACTTATACACACCC 210 RGDLYTP 1427 163.43 152 GGTATGCAGCAGAGGGAGAAG 211 GMQQREK 1428 163.075 153 CAGACTCAGGCGAGTACTAAT 212 QTQASTN 1429 161.336 154 CGGGACACCAACGCCCTCGGA 213 RDTNALG 1430 161.225 155 TCGAGTCAGATTTCTAATAGT 214 SSQISNS 1431 161.063 156 CAGTCGGTTAATAGTACGAGT 215 QSVNSTS 1432 160.873 157 GCTCTGGAGAGGGCTCAGTAT 216 ALERAQY 1433 160.837 158 CATACTGGGCATAGTTCTGTG 217 HTGHSSV 1434 160.068 159 CGGGGAGACATGACCCGAGCA 218 RGDMTRA 1435 159.605 160 TTTCAGCGTGATCTTGGGCAT 219 FQRDLGH 1436 159.442 161 ACAACCGGCGACATAATACGC 220 TTGDIIR 1437 159.11 162 TCTTTTCAGACGGATCGTGCG 221 SFQTDRA 1438 159.04 163 CAATCCAGCGACGGCCGAGTG 222 QSSDGRV 1439 158.634 164 ACTTCTGGGGCTTTGACCCGG 223 TSGALTR 1440 158.32 165 AATTCGAATACTGTGAATACG 224 NSNTVNT 1441 157.71 166 ATCTCCGGTAGTAGCAGTCTA 225 ISGSSSL 1442 157.64 167 AACGACAAATCAACCAACGTA 226 NDKSTNV 1443 157.594 168 ATCGTACTTGCTCCCACATCG 227 IVLAPTS 1444 157.48 169 TCAGGCGTCAACTACGGTGTC 228 SGVNYGV 1445 157.321 170 GTCGGCGCCCAACGGGACCCC 229 VGAQRDP 1446 157.055 171 ACGGGTATGAATAGTAATAAG 230 TGMNSNK 1447 156.85 172 ATCGAAGCCTACTCACGAGAC 231 IEAYSRD 1448 156.774 173 TTACACACAACACTAATGCCC 232 LHTTLMF 1449 156.364 174 TCTGATAATCATCTGAAGACT 233 SDNHLKT 1450 156.334 175 CGAAACGAAGACAAAGGAGGA 234 RNEDKGG 1451 156.027 176 ACGAAGGGTGCTAATGGTACT 235 TKGANGT 1452 155.56 177 GTCTACAACGGCAACGTAGAA 236 VYNGNVE 1453 155.56 178 TCAAACAGCGGAGGCAACCAC 237 SNSGGNH 1454 155.294 179 GTAGCCGCGGGACCAGAAGCG 238 VAAGPEA 1455 154.25 180 ACGTCTCTTAGTGGTAGTGCG 239 TSLSGSA 1456 153.988 181 GTTGGGCTGCAGAGTAATACT 240 VGLQSNT 1457 153.453 182 CACACCGCCCACAGCGTGGAC 241 HTAHSVD 1458 153.3866 183 AACGTGGGAATGAGCTCAACC 242 NVGMSST 1459 153.212 184 CATGCGGATGTGAATGCTGGG 243 HADVNAG 1460 153.21 185 AAAGCGGGACAACTAGTGGAA 244 KAGQLVE 1461 153.178 186 AGTACTTTTAGTGTGCTGCCT 245 STFSVLP 1462 153.09 187 CCTCAGTCTCCGAGTCGGGTT 246 PQSPSRV 1463 152.823 188 CACACCGCCACCCTTAGCAGC 247 HTATLSS 1464 152.8 189 CTTCCGCGTCATGATCAGTAT 248 LPRHDQY 1465 152.412 190 CAAGTGAACAACCCACTCACA 249 QVNNPLT 1466 151.574 191 ACAACAGAAACCGCACGAGGT 250 TTETARG 1467 151.4255 192 GTTCATGGGACGTTGACTTAT 251 VHGTLTY 1468 150.654 193 TATAGTACTGATCTTAGGATG 252 YSTDLRM 1469 150.626 194 GCACACGCTACCTCAAGCACT 253 AHATSST 1470 150.587 195 AGGGAGAGTGCTGCTCTGGCG 254 RESAALA 1471 150.506 196 AAGGATACTAATCAGCAGATT 255 KDTNQQI 1472 150.189 197 AGTATGCAATCATACACCATG 256 SMQSYTM 1473 148.994 198 ACAGCCTACTCGCCCACAGTC 257 TAYSPTV 1474 148.946 199 GAATCTGCCCACCAAAGAATA 258 ESAHQRI 1475 148.867 200 AGATACACAACAGCACAACAA 259 RYTTAQQ 1476 148.802 201 ACGTCTGTGGCGAATGTGAGT 260 TSVANVS 1477 148.731 202 AGGGATCAGCATACTTCTATT 261 RDQHTSI 1478 148.687 203 TCTGTTACGTCTTCTGGTCCG 262 SVTSSGP 1479 148.574 204 GCGGTTGTTCTGAATAGTAAT 263 AVVLNSN 1480 148.476 205 CCTGGGAATCCGTCTAGTAAT 264 PGNPSSN 1481 147.792 206 ACGGGGTCTACTACTCAGCTT 265 TGSTTQL 1482 147.767 207 GCTAATGAGCATAATGTGGGT 266 ANEHNVG 1483 147.569 208 ATGCAAAGAGAAGCAGCCAAC 267 MQREAAN 1484 147.562 209 TTAACCGACACAAACACCCGG 268 LTDTNTR 1485 147.306 210 CGAATGACCGAAATATCATAC 269 RMTEISY 1486 146.933 211 AAAGTGGACATGACCTCCAAA 270 KVDMTSK 1487 146.392 212 AGAGGAGACTTATCCACACCC 271 RGDLSTP 1488 146.3 213 CAAGCAAAAGCTAGCACAACT 272 QAKASTT 1489 146.214 214 CTACCCTCAACAGAAACTTTG 273 LPSTETL 1490 145.892 215 AGTAGTGCGCTTAATGCGTAT 274 SSALNAY 1491 145.667 216 TCGTCTGATCCTAAGGGGCAG 275 SSDPKGQ 1492 145.644 217 TTAGACGTGACGAGAATGAGA 276 LDVTRMR 1493 145.51 218 GCGGATGGTGGTGATAAGGGG 277 ADGGDKG 1494 145.45 219 ATGCTGTCTCAGGTTACGTTG 278 MLSQVTL 1495 145.32 220 AGTGTTAGTTCTGTGGTGTTG 279 SVSSVVL 1496 145.202 221 ACCGAATCGCAAACCATGAGG 280 TESQTMR 1497 145.0149 222 TTCGGATCCCAAGAAAAACTC 281 FGSQEKL 1498 144.467 223 ACAGCCGGCGGCGAACGCGCC 282 TAGGERA 1499 144.445 224 GATCATAGTAAGCAGAGTTCG 283 DHSKQSS 1500 144.0179 225 ATTGATAGTACTTGGAATACG 284 IDSTWNT 1501 143.92 226 TCGCCTCGCCCCGAACTCCGA 285 SPRPELR 1502 143.362 227 AGTATTGCGACTGCTACTAGT 286 SIATATS 1503 143.312 228 GTAATAGGCGGACACGGGACT 287 VIGGHGT 1504 143.136 229 AGCACCGCCATGTACCCCCAC 288 STAMYPH 1505 142.798 230 CGGGACTTGAGACCCGTGACG 289 RDLRPVT 1506 142.461 231 GCTCATCTGACTGATCTTCCG 290 AHLTDLP 1507 142.37 232 TTTCTGAATAGTACGCAGCTT 291 FLNSTQL 1508 142.276 233 TTAAACAACAGTGCCACAGTC 292 LNNSATV 1509 142.021 234 GATCGTCCGAATAATATGACG 293 DRPNNMT 1510 141.945 235 TCATCGTCAGACTCACCCAGA 294 SSSDSPR 1511 141.849 236 CGCTTGGACGTTGGAAGCCCG 295 RLDVGSP 1512 141.82 237 GCGCAGCAGAGTCTTCATGGT 296 AQQSLHG 1513 141.401 238 ATGGGGAAGCATGAGGGTCTT 297 MGKHEGL 1514 141.2916 239 GAGAATGCTCGTGAGGGTGTG 298 ENAREGV 1515 140.87 240 ACCGTATCTCTCTCGGAAGGC 299 TVSLSEG 1516 140.529 241 CTTAACACACTAATCGACCGG 300 LNTLIDR 1517 140.256 242 GAACTCTCCGTTCCGAAACCA 301 ELSVPKP 1518 140.203 243 AAAGACAAAAACGTATACATA 302 KDKNVYI 1519 140.171 244 AATGCGAATGGGCCTGTGAGT 303 NANGPVS 1520 140.158 245 CTTACTACGAATGGTATGCTG 304 LTTNGML 1521 140.147 246 GCCGGCGAATCTTCACCCACA 305 AGESSPT 1522 139.95 247 AGTGGGATTGGTACTTATTCT 306 SGIGTYS 1523 139.76 248 GTCAGATCTATGGACGAATTG 307 VRSMDEL 1524 139.74 249 ATGAACACCGGCTCTTCGAGT 308 MNTGSSS 1525 139.328 250 GGGGTGACTGTTAGGGAGCTT 309 GVTVREL 1526 139.099 251 CAGATTTTGAATTATAGTGTG 310 QILNYSV 1527 138.991 252 ATGGCGGGTGAGTATAGGGTT 311 MAGEYRV 1528 138.933 253 TGGTCGCATGATCGGCCTACT 312 WSHDRPT 1529 138.703 254 TGCAAAAACAACTCAGAATGC 313 CKNNSEC 1530 138.668 255 TTGACGACGAATAGTCATTAT 314 LTTNSHY 1531 138.525 256 ATGCTTGTTCAGAATACTCCT 315 MLVQNTP 1532 138.3 257 CGTGGTGCGACTGAGCATGCG 316 RGATEHA 1533 138.186 258 GCTTCGAATGGGAGTATGGGT 317 ASNGSMG 1534 138.1181 259 AATAGTTATACTGCTGGGAAG 318 NSYTAGK 1535 137.4033 260 TCCACCCAAGGAGCCATCCTC 319 STQGAIL 1536 137.294 261 TGGAATACGAATATGGCGATT 320 WNTNMAI 1537 137.17 262 GTCTCATCGTACGAAAAAATA 321 VSSYEKI 1538 137.055 263 GTGCTGAGTACGGGGCAGCGG 322 VLSTGQR 1539 136.9001 264 CCTATACCCCACGGTTCATCC 323 PIPHGSS 1540 136.523 265 AACGTGTCACTAACGCAAACG 324 NVSLTQT 1541 136.4003 266 TCTACCATCGGCAACAGCACG 325 STIGNST 1542 136.393 267 TCTGAGAAGCTGACTGATAAG 326 SEKLTDK 1543 136.36 268 TCCAAAGACTCGAACATAAGT 327 SKDSNIS 1544 136.166 269 GCGAATAGTAATCATGAGCGT 328 ANSNHER 1545 136.102 270 AGGGATACGGGTGATAAGGCT 329 RDTGDKA 1546 135.913 271 AGAACAGACACGCCGTCAACC 330 RTDTPST 1547 135.583 272 CCTACTATGTCGAGTCTGAAT 331 PTMSSLN 1548 135.539 273 GATATTACTAATCAGTCGTAT 332 DITNQSY 1549 135.473 274 CTTGTAAAACCGGAAACTTGG 333 LVKPETW 1550 134.988 275 GGGACTTCCTTGGAAAACCGA 334 GTSLENR 1551 134.981 276 GCTGCTGGTAATCCTACTCGT 335 AAGNPTR 1552 134.779 277 CACAACGTCGGCCTAGGACAC 336 HNVGLGH 1553 134.677 278 GTATCAACGACAACGGACCGG 337 VSTTTDR 1554 134.639 279 TATTTGTCGTCTGGTAAGATG 338 YLSSGKM 1555 134.553 280 GATAGTCGGAATGCTGCTTTG 339 DSRNAAL 1556 134.213 281 GTGGAGCGGAATACTGATATG 340 VERNTDM 1557 133.962 282 ACTGTTGGGAGTAATTCTATT 341 TVGSNSI 1558 133.95 283 GTGCGGTCTGGTAATAAGCCG 342 VRSGNKP 1559 133.87 284 GGCAGTTCGGGGAACAGCGGA 343 GSSGNSG 1560 133.776 285 TCTACTTCAATAGGAGTGGTA 344 STSIGVV 1561 133.69 286 CCGAGTCAGAGTAGGTCGCTT 345 PSQSRSL 1562 133.6751 287 CGGAATGAGAATCTTAATAAT 346 RNENLNN 1563 133.26 288 TCGTTGGGTAAGAGGGAGGAG 347 SLGKREE 1564 133.032 289 TCACGCTTGGACTCGAGCTCC 348 SRLDSSS 1565 132.783 290 GATTCGACGTATGTTTTGGCT 349 DSTYVLA 1566 132.54 291 GAGCGTAATCCTATTTCTGAT 350 ERNPISD 1567 132.49 292 GTTAGCTCCGGCCACACGAAA 351 VSSGHTK 1568 132.466 293 AAGTATACGGAGTCGAATGCG 352 KYTESNA 1569 132.305 294 AACCGCAACTCAGTTGGGACT 353 NRNSVGT 1570 132.2576 295 CACGAAAGCCACTACGTGTCA 354 HESHYVS 1571 132.014 296 ACGACTGGGGGGACGGGGATG 355 TTGGTGM 1572 131.954 297 GCGACTGATAAGATGACTCCT 356 ATDKMTP 1573 131.931 298 TCCGCGTCTAGCGGCGCTACA 357 SASSGAT 1574 131.886 299 TCAACCACTACTGGCCACATG 358 STTTGHM 1575 131.581 300 ATAATAGCATCCTCTACCACG 359 IIASSTT 1576 131.506 301 GATACTGGGTCTAGGATTGCG 360 DTGSRIA 1577 131.486 302 TGGGCTGATGATTCGCAGCGG 361 WADDSQR 1578 131.47 303 AGGGGTAACACTCTCGAAATG 362 RGNTLEM 1579 131.381 304 AATCTGCAGGTGAATGCGAAT 363 NLQVNAN 1580 131.172 305 GCGACGACTCAGCTGATGACT 364 ATTQLMT 1581 130.96 306 GCTGATACGAATATTATTGTG 365 ADTNIIV 1582 130.47 307 GCCATAACAATCACTCAAAAA 366 AITITQK 1583 130.225 308 GACTCCAACAAAGGAGCGACG 367 DSNKGAT 1584 130.1749 309 GGCAACGCTTCCGGAAACCCA 368 GNASGNP 1585 129.97 310 ACGATGGGTGCTAAAGGTACT 369 TMGAKGT 1586 129.92 311 TATCTGCAGACGGGTACTCTG 370 YLQTGTL 1587 129.907 312 GCATTACACACCAAAGACCTA 371 ALHTKDL 1588 129.846 313 GTCGACAAAAGCGAAGCCGTC 372 VDKSEAV 1589 129.734 314 GGGAGGACGGATCTTATGGCG 373 GRTDLMA 1590 129.651 315 GGCACGGAACCGCGCACTGCA 374 GTEPRTA 1591 129.37 316 AGAGGCGACATGTCACGAGAA 375 RGDMSRE 1592 129.137 317 CGGGGGGATACTAAGTCTAAG 376 RGDTKSK 1593 128.94 318 GGGACATTAGCCTCAATGTCC 377 GTLASMS 1594 128.734 319 CAGAAGTCTGTGACGTATTCG 378 QKSVTYS 1595 128.602 320 AGTACGGGGCAGACTCTTGTT 379 STGQTLV 1596 128.1669 321 TCGCACATAAACATGGGGTCG 380 SHINMGS 1597 128.101 322 GCGTTGAATGGTACTGGTAAT 381 ALNGTGN 1598 128.045 323 ACTACGAGTTCGAATCAGCAT 382 TTSSNQH 1599 128.003 324 AAAAACTACGCAAGCACCGAC 383 KNYASTD 1600 127.84 325 GAATCCACAAGCAGGACGTAC 384 ESTSRTY 1601 127.765 326 CCGCGTTCTATTACGGAGTTG 385 PRSITEL 1602 127.623 327 TACATAGCCGGAGGAGAAAAA 386 YIAGGEK 1603 127.544 328 ACTAGTAATTATATGCATGAG 387 TSNYMBE 1604 127.522 329 TTGGATCCTAATAGTACTCGG 388 LDPNSTR 1605 127.175 330 CACAGTGACATGGGCTCAAGC 389 HSDMGSS 1606 127.01 331 GACACCGCCAACCGATCCACA 390 DTANRST 1607 127.01 332 AACGCCGGACACAGCGGTCAA 391 NAGHSGQ 1608 126.611 333 AGTTTGGGGTCGGATCGTATG 392 SLGSDRM 1609 126.579 334 GACAACCAACAAGCCCTAGCT 393 DNQQALA 1610 126.49 335 CCATCCTCAGCGGGTAGCACA 394 PSSAGST 1611 126.201 336 GACAGGAAAGGGTACGACGCA 395 DRKGYDA 1612 126.06 337 GGAGGAAACCAAAACCTTACT 396 GGNQNLT 1613 125.7806 338 GTGAATCTGAATGAGACGGAG 397 VNLNETE 1614 125.719 339 TCCCCCGGCAACGGGTTGCTA 398 SPGNGLL 1615 125.687 340 TCTGTCGGGGACCTCACAAAA 399 SVGDLTK 1616 125.627 341 CGATACGAATCCGTCGGACTC 400 RYESVGL 1617 125.54 342 ACGAGAGAATTGACAAAAAAC 401 TRELTKN 1618 125.47 343 ACTCCAACTAACGGGAACCCT 402 TPTNGNP 1619 125.37 344 GCGACTGATCAGCGTTCGAGG 403 ATDQRSR 1620 125.26 345 GGAACATCGGCAGAATCACGC 404 GTSAESR 1621 125.214 346 AGGATGCTCTCTACTTTGCCT 405 RMLSTLP 1622 125.088 347 GGTATCAACTCCTCACACTTC 406 GINSSHF 1623 125.044 348 AGTAGCTCAACTGAAGGGCAA 407 SSSTEGQ 1624 124.971 349 GACAAACAACAAACCGGACAA 408 DKQQTGQ 1625 124.923 350 ACCCAACACCTACCATCCACA 409 TQHLPST 1626 124.773 351 GGTCTGGGGCAGCCTCAGTTG 410 GLGQPQL 1627 124.752 352 GTGACTAATGAGAGTCGTGCT 411 VTNESRA 1628 124.728 353 GGCAACTCGAACTACCGAGAA 412 GNSNYRE 1629 124.482 354 TGGAATGCTGAGAATAGTAAG 413 WNAENSK 1630 124.373 355 CCTGGGAGTCAGCGTCAGGAT 414 PGSQRQD 1631 124.325 356 CATACGTATTCGCAGGCTGAT 415 HTYSQAD 1632 124.3 357 ACTGCCGGCAACCTAAGAAGT 416 TAGNLRS 1633 124.203 358 GGCAGACACCTTCAATCGGAC 417 GRHLQSD 1634 124.19 359 AACAACGCACACACCGCCACT 418 NNAHTAT 1635 124.118 360 AGTACGAGTCAGGAGAATAGG 419 STSQENR 1636 124.0658 361 AGGGGTGATACTATGAATTAT 420 RGDTMNY 1637 124.04 362 CCGGTTGCTACTCAGCATGCG 421 PVATQHA 1638 123.9189 363 GGGCATTTGAATGCTCCGACT 422 GHLNAPT 1639 123.495 364 CAAATATTAAACTACTCAGTC 423 QILNYSV 1640 123.4 365 CAAAACCACGCGTCTGGTGAA 424 QNHASGE 1641 123.372 366 GGTTTAACAGGGCGGGAACTA 425 GLTGREL 1642 123.32 367 GACGTAGCCGTGACTCAACAC 426 DVAVTQH 1643 123.31 368 GCAACTTACACCGGGCGAACA 427 ATYTGRT 1644 123.292 369 AAAGAACTACAATGGCAACGA 428 KELQWQR 1645 123.251 370 GCTAGTTATAGTAGTATGGTG 429 ASYSSMV 1646 123.193 371 GTTATTAGTCATGGGGCGCTG 430 VISHGAL 1647 123.094 372 CCTATACACCACGGTTCATCC 431 PIHHGSS 1648 123.09 373 GTGGATAAGAATCATCCTTTG 432 VDKNHPL 1649 123.04 374 ACCTCGGGTGACCGGTACACG 433 TSGDRYT 1650 122.844 375 GGGACAAAAAGCTGGCCTGTC 434 GTKSWPV 1651 122.8432 376 TACAACGCCCACGAATCATTC 435 YNAHESF 1652 122.813 377 AGAGTCCACGACACTCCTTCA 436 RVHDTPS 1653 122.7503 378 GCACAAATCGAATCAGGCCGA 437 AQIESGR 1654 122.66 379 TGGAAGGATAATATGCGGATG 438 WKDNMRM 1655 122.624 380 ATGCCTAGTGAACCACCAGGG 439 MPSEPPG 1656 122.51 381 CGTGGTGATTATCCGACGTCG 440 RGDYPTS 1657 122.487 382 TTTCATAATGAGTCTTATGGG 441 FHNESYG 1658 122.36 383 TTGAATACGATGATTGATAAG 442 LNTMIDK 1659 122.272 384 TCCACACTAAGCCAAGGAGCA 443 STLSQGA 1660 122.2662 385 CCTTTGCACAACATACCTCCT 444 PLHNIPP 1661 122.24 386 GCTTCGTCTACGTTTTTGCCT 445 ASSTFLP 1662 122.24 387 ATGGAAGGAATGGGACTCGGA 446 MEGMGLG 1663 122.04 388 AAGGATTATAAGCCGTATGCT 447 KDYKPYA 1664 121.95 389 AATTTGCAGTCTGGTGTTCAG 448 NLQSGVQ 1665 121.91 390 ACAACTCTTAGCCAACAAAGC 449 TTLSQQS 1666 121.82 391 CTTATGTCGTCTACTTCCTCA 450 LMSSTSS 1667 121.536 392 ACTGGCCAAGGATTCTCGGCA 451 TGQGFSA 1668 121.45 393 TCTACAATCGGCAACAGCACG 452 STIGNST 1669 121.27 394 CTGAGGGCGAGTGAGGCTCCG 453 LRASEAP 1670 121.2297 395 CAGCCTAATAATGGTAATCAT 454 QPNNGNH 1671 121.02 396 TCGTCAGACGTTACCAGACAA 455 SSDVTRQ 1672 120.98 397 CGGGGTGACGCAACAGAAATG 456 RGDATEM 1673 120.74 398 TATAGGGGTAGGGAGGATTGG 457 YRGREDW 1674 120.58 399 AGCTTGCAACAATCACAATTG 458 SLQQSQL 1675 120.491 400 AAGCCGACTGCGAATGATTGG 459 KPTANDW 1676 120.3784 401 CGTCTGACTGATACTATGCAT 460 RLTDTMH 1677 120.35 402 CTTCATGGGAATTATAGTCCG 461 LHGNYSP 1678 120.346 403 ATTCCGGTTGGGGCGATGGCT 462 IPVGAMA 1679 120.248 404 CCGAACACCGCCTCAAACTTC 463 PNTASNF 1680 120.24 405 ACGAGTAGAGAAGTCAAAGGG 464 TSREVKG 1681 120.171 406 GACACGTCCTCCGGCAACAGG 465 DTSSGNR 1682 119.94 407 GAAGCAGTAACAAGTAAATGG 466 EAVTSKW 1683 119.919 408 CTAATCACAGCCACCACTAAC 467 LITATTN 1684 119.872 409 GATGGGGGTCGTTCGGGTATT 468 DGGRSGI 1685 119.847 410 TTCATGGAAGTCATGAAAAAC 469 FMEVMKN 1686 119.82 411 TCCTACCAAAACCCACCACCA 470 SYQNPPP 1687 119.701 412 ACTAATGTGACGTTTAAGCTT 471 TNVTFKL 1688 119.681 413 ATTTCTACGCATACGATGACG 472 ISTHTMT 1689 119.64 414 GAAACCCAAGGAGCAAGATAC 473 ETQGARY 1690 119.591 415 GCGGCTTATGAGCATGCGCCT 474 AAYEHAP 1691 119.588 416 TCAACGAACGACCGTGCGTTA 475 STNDRAL 1692 119.57 417 TTCACCGAACGCGCACTCCAA 476 FTERALQ 1693 119.423 418 GTAGCGGGCTTAGTCGACATA 477 VAGLVDI 1694 119.41 419 AGCTCGGTAACTAACCTTGCA 478 SSVTNLA 1695 119.38 420 GATACTACTACTGGTCATCTT 479 DTTTGHL 1696 119.27 421 ACGCGTAATTTGTCTGAGAGT 480 TRNLSES 1697 118.919 422 CAGGTGAATGTTGGGCCTGGT 481 QVNVGPG 1698 118.831 423 AAACAAACGATGTCCGACACA 482 KQTMSDT 1699 118.829 424 ATGTCGACAACCAGCAAAACT 483 MSTTSKT 1700 118.7215 425 ACTACAATAGGGACAAACCAA 484 TTIGTNQ 1701 118.676 426 GGGACTCTGACGCCGAATCTT 485 GTLTPNL 1702 118.622 427 TTTGATAGTTATAATATTGTG 486 FDSYNIV 1703 118.51 428 CGTGGTGCGCCTGAGCAAGCG 487 RGAPEQA 1704 118.47 429 ATCGAAAACGTAAACCACTTG 488 IENVNHL 1705 118.42 430 AGGTCTCTGGAGAGTCAGGCT 489 RSLESQA 1706 118.231 431 CAGTATACGAGTCTGAGTCCG 490 QYTSLSP 1707 118.006 432 ACGAAGGGTTATAATGATCTT 491 TKGYNDL 1708 117.876 433 GTCGCCTCGATGGTACACAAC 492 VASMVHN 1709 117.874 434 TCCACAACCCACACCTCAGCA 493 STTHTSA 1710 117.821 435 CTTGCGCACCCACAACCAAAC 494 LAHPQPN 1711 117.542 436 TCGATAAACAACATAGGCGCA 495 SINNIGA 1712 117.538 437 GCTATAGACTCCATCAAAATG 496 AIDSIKM 1713 117.472 438 TCTATGTATGGGCAGGCTGGG 497 SMYGQAG 1714 117.362 439 GAGTATGCTAATGCTAAGACT 498 EYANAKT 1715 117.351 440 TATCGGGCTTCGGATGTGGCG 499 YRASDVA 1716 117.348 441 GTTAGTTTGGAGAGTCGGTTG 500 VSLESRL 1717 117.332 442 ATTGAGACTAGTTCGCGTTCG 501 IETSSRS 1718 117.176 443 ATGGGAGTGAAACCCGAACAA 502 MGVKPEQ 1719 116.975 444 GCGCTTCCGTCTCGTGAGCGG 503 ALPSRER 1720 116.914 445 GGCACCGGATCTTCAGCGCAC 504 GTGSSAH 1721 116.896 446 CAAACGAACACCAACGACAGA 505 QTNTNDR 1722 116.664 447 GTATTACACTCTGTATCAGCA 506 VLHSVSA 1723 116.583 448 CCTTATTCTGCTACTGATCGG 507 PYSATDR 1724 116.577 449 GCAAACTCCGGATTACACAAC 508 ANSGLHN 1725 116.505 450 TATGAGAGTACTCATGTTAAT 509 YESTHVN 1726 116.418 451 AACAACGCACTAGTAGGAAGT 510 NNALVGS 1727 116.34 452 GGTATCAACTCCTCACACATC 511 GINSSHI 1728 116.28 453 AGTATTTCTGATAAGAATCAG 512 SISDKNQ 1729 116.141 454 GACCACCAACAAGCCCTAGCA 513 DHQQALA 1730 116.13 455 GACTCTACCAAAGCCATGCAA 514 DSTKAMQ 1731 116.116 456 ACTATTACTAGTCAGTCGGTG 515 TITSQSV 1732 115.95 457 GGCGCCCGTACAATCTTAGAC 516 GARTILD 1733 115.938 458 GAGCATAGTCCTACGACTGGT 517 EHSPTTG 1734 115.8995 459 GGGCTCACAGGATACCCAATG 518 GLTGYPM 1735 115.844 460 ACGATGGAATCCGGCCGCCAC 519 TMESGRH 1736 115.82 461 TCTGCGTCGAAAGTGGAATAC 520 SASKVEY 1737 115.719 462 GATAAGTCTAATTATAGTATT 521 DKSNYSI 1738 115.714 463 TTCAACGAAACTGCCGGGCGA 522 FNETAGR 1739 115.65 464 CAAAAATCGGAAACCTACACT 523 QKSETYT 1740 115.528 465 GCACTTACCCGTATGCCTAAC 524 ALTRMPN 1741 115.476 466 CGTAACGGCTCCGCCCAAAGC 525 RNGSAQS 1742 115.465 467 GCGAGGGATACGCCTGGGATT 526 ARDTPGI 1743 115.432 468 ATTGTTAATGCTGAGATTTAT 527 IVNAEIY 1744 115.31 469 CGACAAGGCGACTTAAAAGAA 528 RQGDLKE 1745 115.3059 470 CGAAACAACCCATCGCACGAC 529 RNNPSHD 1746 115.224 471 CTCGCCCACAACTACTTAAGC 530 LAHNYLS 1747 115.195 472 AACACCCACAACCTACAAATG 531 NTHNLQM 1748 115.171 473 CGAGGAGACCACAGCACACAG 532 RGDHSTQ 1749 115.12 474 CTCCACGGAGTCAGCAGTATA 533 LHGVSSI 1750 115.105 475 GGTATTAATCATGTGGCGTCT 534 GINHVAS 1751 115.102 476 ACTGATAAGCTTCAGGGTGTG 535 TDKLQGV 1752 115.062 477 GGAACCTCCATAGACTACGTA 536 GTSIDYV 1753 115.053 478 TCGAACACTGCCCCCCCCCCC 537 SNTAPPP 1754 115.034 479 ACTGCTAAGAGTTATGGGCCT 538 TAKSYGP 1755 115.006 480 GACCACCAACAAGCACTAGCT 539 DHQQALA 1756 114.98 481 ACACAAGTAGTCGCAAGAACA 540 TQVVART 1757 114.9299 482 AGTCCTCCTAGTACGTCGGGT 541 SPPSTSG 1758 114.816 483 CCTATGCGAACACCACCGTAC 542 PMRTPPY 1759 114.806 484 GCTGCTGGTAATACTACTCGT 543 AAGNTTR 1760 114.78 485 AGAGGCGACTAATCCACACCC 544 RGD*STP 1761 114.78 486 CTAGCGAAAACTGTCGCTATC 545 LAKTVAI 1762 114.722 487 TCTAAATCTGAAAACCTGCAA 546 SKSENLQ 1763 114.59 488 ACTCAGACGTCGTATGCTACG 547 TQTSYAT 1764 114.505 489 ACTGGGGATAGGACTTCGGTG 548 TGDRTSV 1765 114.4766 490 ATATCGCAAGGCTCGAGCCTC 549 ISQGSSL 1766 114.305 491 CTTGTTCAGATGGGGAGTGTG 550 LVQMGSV 1767 114.256 492 TTATCCGCAACATCTACGATG 551 LSATSTM 1768 114.245 493 CAAAACCACAACGAACTAAAA 552 QNHNELK 1769 114.217 494 CGTGGTGCGCCTGAGCATGCG 553 RGAPEHA 1770 114.09 495 TCTTCTTTCGGAAAAGACAAC 554 SSFGKDN 1771 113.982 496 AACGCTAACGCCGGTGGAAAC 555 NANAGGN 1772 113.958 497 GATCATCATCCTCAGAGTCGT 556 DHHPQSR 1773 113.83 498 ATGAGGCATGAGGCTCCTCTT 557 MRHEAPL 1774 113.819 499 AAGGGGGATGGTGCTTATGAG 558 KGDGAYE 1775 113.742 500 CCTATGAATGGTATTCTGTTG 559 PMNGILL 1776 113.722 501 AGTAGTGGGGGTATGAAGGCG 560 SSGGMKA 1777 113.69 502 GTGCTGGTTACTCAGAATCAT 561 VLVTQNH 1778 113.631 503 GAGATTAATAATCGGACTGGT 562 EINNRTG 1779 113.588 504 TTACCAACAGGCGTCCTGCCC 563 LPTGVLP 1780 113.561 505 GCCTACGGTATCAGAGAAGTG 564 AYGIREV 1781 113.547 506 TCGACAAACTCTATAGGCGCC 565 STNSIGA 1782 113.471 507 GTGCAGTTGACGCATAATGGG 566 VQLTHNG 1783 113.43 508 GTTCAGTTGGAGAATGCGAAT 567 VQLENAN 1784 113.43 509 GGAAAAGCCAACGACGGTTCT 568 GKANDGS 1785 113.427 510 ACCGGGGTTCGAGAAACCATA 569 TGVRETI 1786 113.41 511 GGCCTGAACCAGATCACATCG 570 GLNQITS 1787 113.4 512 ACGGAGAAGGCGAGTCCTCTG 571 TEKASPL 1788 113.381 513 TTTCTGGAGGGTGTTGCGCAG 572 FLEGVAQ 1789 113.333 514 ACGAATTATAATATTGGTCCG 573 TNYNIGP 1790 113.318 515 AGAGGAGACTTGACAACCACA 574 RGDLTTT 1791 113.29 516 ATGATGAATGTGAGTGGTCAT 575 MMNVSGH 1792 113.09 517 TCTCAGTCGATTAATGGGCTT 576 SQSINGL 1793 113.084 518 CTCACGACTTTAACTAACCAC 577 LTTLTNH 1794 113.033 519 AACTCTGTTCAATCCACCCCA 578 NSVQSTP 1795 113.021 520 TATAATACGGATCGGACTAAT 579 YNTDRTN 1796 113.001 521 GAGAAGCCTCAGCATAATAGT 580 EKPQHNS 1797 112.98 522 ACGATGGCTACAAACTTAAGT 581 TMATNLS 1798 112.937 523 GTGGGGACGCATTTGCATTCG 582 VGTHLHS 1799 112.918 524 GACGCCCACCACTCAAGCAGC 583 DAHHSSS 1800 112.88 525 CTTGTGGGGACTTTGGTGTAT 584 LVGTLVY 1801 112.853 526 TATGGTGTGCAGGCGAATAGT 585 YGVQANS 1802 112.806 527 GTTTTGTCTGATAAGGCGTAT 586 VLSDKAY 1803 112.787 528 CTTGAGGGTCAGAATAAGACG 587 LEGQNKT 1804 112.731 529 GAGGTTAGTAATAATAATTAT 588 EVSNNNY 1805 112.69 530 GCCCACCAACAAGCCCTAGCT 589 AHQQALA 1806 112.67 531 CTTCCGACCACACTCAACCAC 590 LPTTLNH 1807 112.667 532 TACATAGCAGGTGGTGAACAA 591 YIAGGEQ 1808 112.6513 533 AATTCTGGTACTCTTTATCAG 592 NSGTLYQ 1809 112.609 534 CGGGGTCTGCCTGATGTTAAT 593 RGLPDVN 1810 112.43 535 AACCAACAACTATCCCACTCA 594 NQQLSHS 1811 112.375 536 AATCCTAGTTATGATCATCGG 595 NPSYDHR 1812 112.363 537 ATAGACAGCGACACCTTCGTA 596 IDSDTFV 1813 112.355 538 ACCGCTTACCTTGCGGGATTA 597 TAYLAGL 1814 112.17 539 CATAGTAATGTTAGTCTTGAG 598 HSNVSLE 1815 112.162 540 GGTAATAATTTGAGTTTGTCT 599 GNNLSLS 1816 112.16 541 GTTATGGATACGCATGGGATG 600 VMDTHGM 1817 112.145 542 GCGTATAATATGTCGTCTGTT 601 AYNMSSV 1818 112.14 543 ACTAACGCCATCTCTCAAACG 602 TNAISQT 1819 112.063 544 GCAACACACGCCATGCGCCCA 603 ATHAMRP 1820 112.016 545 ATGTTAAACAACACAATGATG 604 MLNNTMM 1821 111.939 546 ATTAGTTCGGGGATTTTGTCG 605 ISSGILS 1822 111.907 547 CGCCAAGGCAGCTTGATGATA 606 RQGSLMI 1823 111.83 548 ACGACTGATAAGGGTATTAAT 607 TTDKGIN 1824 111.818 549 CACAACTTAATGACCCAAATA 608 HNLMTQI 1825 111.77 550 AACCAAAACACCTACGAACTG 609 NQNTYEL 1826 111.756 551 GCTAACACCGTCACAGAACGA 610 ANTVTER 1827 111.7323 552 TCTACGCTGCAGACTAATGGT 611 STLQTNG 1828 111.683 553 CCCAACGAATACAAAGCACCG 612 PNEYKAP 1829 111.646 554 ATGCAAACACGCTCGGACACA 613 MQTRSDT 1830 111.629 555 GGAACAGGGTACGCTGGATCA 614 GTGYAGS 1831 111.6183 556 ATGGGTATGCAGAATACGCAT 615 MGMQNTH 1832 111.599 557 TCTAGTAAGGAGCGTACATCG 616 SSKERTS 1833 111.57 558 CGAACGGACACCCCCTACACC 617 RTDTPYT 1834 111.562 559 ACTGCGCTGCGGGATAATAAG 618 TALRDNK 1835 111.51 560 AGGATGTCTGAGAGTTCGGAT 619 RMSESSD 1836 111.51 561 AACCAATCTATAAGCATGGAC 620 NQSISMD 1837 111.491 562 TCGCTTGGGCATAGTAATAAT 621 SLGHSNN 1838 111.432 563 CTTAATAGTGGTGGTGCGATG 622 LNSGGAM 1839 111.361 564 AACGAACAATTCGAAAAAGTC 623 NEQFEKV 1840 111.341 565 ATGATGGCGAATAATATGCAG 624 MMANNMQ 1841 111.28 566 AGTCGGCGCGAAGAACAACCA 625 SRREEQP 1842 111.2512 567 GCGACTATGACTTCGTCGACG 626 ATMTSST 1843 111.238 568 CGTGGTTCAGACGGAGGATTG 627 RGSDGGL 1844 111.172 569 AGTTTGACGCCTAATAATCTT 628 SLTPNNL 1845 111.152 570 GCTACTCTTTCTCCGCATGCT 629 ATLSPHA 1846 111.132 571 TATCTGCAGGAGAAGTTTCCT 630 YLQEKFP 1847 111.112 572 GGCACCGGGTACCCAAACCAA 631 GTGYPNQ 1848 111.111 573 AATTATCCTTCGGTTCAGGAG 632 NYPSVQE 1849 111.07 574 ACTGACGCATCGGGTAGATCA 633 TDASGRS 1850 111.017 575 CGTGTGATTACTGCGGGTGAT 634 RVITAGD 1851 111.009 576 GTGACTGTGAGTAATAGTCTG 635 VTVSNSL 1852 110.95 577 TTGTTGACGGCTCCGCATAGG 636 LLTAPHR 1853 110.908 578 TCAATCGCAAACCACATGATA 637 SIANHMI 1854 110.861 579 ATGCCTTCGAAAGGCGAAGTA 638 MPSKGEV 1855 110.816 580 AACATGACCAACGAACGGCTC 639 NMTNERL 1856 110.801 581 TCATTCTCTTCAGGCATAATG 640 SFSSGIM 1857 110.771 582 CGCGACCGTCAAGACTCGGTA 641 RDRQDSV 1858 110.754 583 CACGGTGACCGAACAGCTTTA 642 HGDRTAL 1859 110.748 584 GAAGTACGGGGCAGCGTGCCA 643 EVRGSVP 1860 110.747 585 CTGATTTCGACTGGTAATAAT 644 LISTGNN 1861 110.735 586 CCAACATCTGGGGACAAACCG 645 PTSGDKP 1862 110.735 587 AAAGCGGACCACAGTGGGGCA 646 KADHSGA 1863 110.73 588 CTAAACGACGTCTACCGTAAA 647 LNDVYRK 1864 110.724 589 AACAGTTTGCAAGCAAGTGCA 648 NSLQASA 1865 110.72 590 TATCATAATGAGATTATGACG 649 YHNEIMT 1866 110.708 591 AACAACACCCTAAACATCCTA 650 NNTLNIL 1867 110.69 592 TCTTATGGGCAGGGTCTGGAG 651 SYGQGLE 1868 110.684 593 ATGATAAAAACCAACATGTTG 652 MIKTNML 1869 110.668 594 ACCGAAGCGGGCCGCCCCCAA 653 TEAGRPQ 1870 110.663 595 AGGATTGATCAGACTAATGTG 654 RIDQTNV 1871 110.624 596 GAGGGGCATAATCGTGGTATT 655 EGHNRGI 1872 110.559 597 ATGGGGACTGAGTATCGTATG 656 MGTEYRM 1873 110.524 598 TCGGGTATGAATAGTAATAAG 657 SGMNSNK 1874 110.499 599 TTGACTAATGATAATAAGTTG 658 LTNDNKL 1875 110.479 600 TTACACAACTACCAAGACCGT 659 LHNYQDR 1876 110.438 601 AAGTCTAATTTGGAGGGTAAG 660 KSNLEGK 1877 110.438 602 CTTACTGGTCAGAATGCGATT 661 LTGQNAI 1878 110.416 603 CATACTGTGGGGGCTATGCAT 662 HTVGAMH 1879 110.41 604 CTCCAACTGGCTACATCCCAC 663 LQLATSH 1880 110.384 605 AGTCTGAATGGGGTGTTGGTT 664 SLNGVLV 1881 110.359 606 AGTCACAACCAAGTAAACGTA 665 SHNQVNV 1882 110.349 607 AGTTTGAGTACTGATGTGTTT 666 SLSTDVF 1883 110.261 608 ATGGTAGGTCGTGCCGAAATC 667 MVGRAEI 1884 110.224 609 TTGTCTAGTATGAGTACGGAT 668 LSSMSTD 1885 110.204 610 TCCTACAGTACTTCAACACCG 669 SYSTSTP 1886 110.189 611 TCCGAATTAATGGTCAGACCC 670 SELMVRP 1887 110.0813 612 TGGAACGGAAACGCCACACAA 671 WNGNATQ 1888 110.039 613 ATGGATACTGAGCTTTATAGG 672 MDTELYR 1889 109.985 614 AGGACGAGTCCTGATACGAAT 673 RTSPDTN 1890 109.977 615 TTCTCAACGCAAGACATAAGC 674 FSTQDIS 1891 109.948 616 ACGACTGTGCTGGGGAATAAT 675 TTVLGNN 1892 109.94 617 CAGCGTGATGCTGCGTATGCT 676 QRDAAYA 1893 109.927 618 CACCAAACCGTGGTCCCTACT 677 HQTVVPT 1894 109.8948 619 TCTAATCCGGGTAATCATAAT 678 SNPGNHN 1895 109.853 620 TGGGAGACTATGGCTAAGCCT 679 WETMAKP 1896 109.818 621 GGTCTTTATCAGAATCCTACG 680 GLYQNPT 1897 109.73 622 CTTAATCTTACTAATCATAAT 681 LNLTNHN 1898 109.727 623 ATGAGTCTCGCCTCCACCCAA 682 MSLASTQ 1899 109.672 624 ACGTCCCAAACCGTCCGAGTA 683 TSQTVRV 1900 109.654 625 GGAGCAACGGTCAACACGCGA 684 GATVNTR 1901 109.64 626 AAAGGGGGAAACCTCACCGCA 685 KGGNLTA 1902 109.632 627 GCGTGGTCTCAAGTCCTGACG 686 AWSQVLT 1903 109.587 628 GTAGAACACGTAGCCCACCAA 687 VEHVAHQ 1904 109.552 629 CTAATGTCGTCCTACTCATCA 688 LMSSYSS 1905 109.546 630 TCTCTGGGTGGGAATCCGCCT 689 SLGGNPP 1906 109.511 631 AAGAATGAGAATACGAATTAT 690 KNENTNY 1907 109.5055 632 ATATTGGACAACCACCGTTTC 691 ILDNHRF 1908 109.489 633 AATTCGTCGCATGTTAATTCT 692 NSSHVNS 1909 109.473 634 CAGGTGCAGCATGAGAGGGTG 693 QVQHERV 1910 109.47 635 TTGGGAGGAACCCTGGGAATA 694 LGGTLGI 1911 109.46 636 ACTCAAGAACGACCACTAATC 695 TQERPLI 1912 109.455 637 CGTAAGACTGAGGATAGGATG 696 RKTEDRM 1913 109.429 638 ACCGAACTCACAGCGCGGAAC 697 TELTARN 1914 109.398 639 CGCGGCGACAACACTTACTCC 698 RGDNTYS 1915 109.387 640 CAGTCTAATACTAATAATAGT 699 QSNTNNS 1916 109.372 641 GCTTCTTATAGTATTTCTGAT 700 ASYSISD 1917 109.309 642 AGCGAACACCACGCCGGAATA 701 SEHHAGI 1918 109.281 643 CGTGGTGCGCCAGAGCATGCG 702 RGAPEHA 1919 109.237 644 AATTTTAGTAGTGGTGATGTT 703 NFSSGDV 1920 109.229 645 AGTGGCATCAACGCCACCGAC 704 SGINATD 1921 109.22 646 CGGGCTGATGTTTCTTGGTCT 705 RADVSWS 1922 109.213 647 TGTATGGATGTTGGTAAGGCG 706 CMDVGKA 1923 109.203 648 GGGGTCGGAGCCACTTCGGTA 707 GVGATSV 1924 109.193 649 AAAAACAACAACTCAGACAGT 708 KNNNSDS 1925 109.177 650 AATGTTGCGAGTATTGATAGG 709 NVASIDR 1926 109.174 651 AATAGTGTGAATGGTCTTCTG 710 NSVNGLL 1927 109.154 652 ACACTAGACCGAAACCAAACC 711 TLDRNQT 1928 109.132 653 GACCAAAACTTCGAACGTAGA 712 DQNFERR 1929 109.108 654 GTCGGTGACAGGAACTTGGTC 713 VGDRNLV 1930 109.062 655 TTAGAAGTAAACCTGCAAACG 714 LEVNLQT 1931 109.057 656 ACTAATGGGGGGTCGCTTAAT 715 TNGGSLN 1932 109.049 657 TTCACGCGCACACCAGTAACC 716 FTRTPVT 1933 109.033 658 ACACCGGCGGAAAGCAAAGTT 717 TPAESKV 1934 108.991 659 TTTCCTTCGCATAATGGGGCG 718 FPSHNGA 1935 108.959 660 GCCAGGAACGTAATGCTGGGG 719 ARNVMLG 1936 108.958 661 ACGATTCAGGATCATATTAAG 720 TIQDHIK 1937 108.942 662 ATTAATTCGTATTTGCATGAG 721 INSYLHE 1938 108.918 663 GCGCATGATGTTACTGTGAAT 722 AHDVTVN 1939 108.918 664 ACTGTGGGGGTTCAGCAGACG 723 TVGVQQT 1940 108.8891 665 ACAGGTAGTTCAGACAGATTA 724 TGSSDRL 1941 108.887 666 AATCATGATACTGCTCATGCT 725 NHDTAHA 1942 108.884 667 GCCGAATCCCAACTAGCTAGC 726 AESQLAS 1943 108.8752 668 GGTAATGCGTATAATACGACT 727 GNAYNTT 1944 108.818 669 AATCATCAGGCTGGTACTACT 728 NHQAGTT 1945 108.807 670 ACGGTAGGAGAAAACCACCGA 729 TVGENHR 1946 108.779 671 CTAACTACTAAAATACCCCTC 730 LTTKIPL 1947 108.773 672 ACTAATTATCCTGAGGCGAAT 731 TNYPEAN 1948 108.748 673 AATACTGCTCCGCCGAATCAT 732 NTAPPNH 1949 108.733 674 GTGCTGAGTACGGGGCTGCGG 733 VLSTGLR 1950 108.677 675 CTCACGTCCCACTCTGCGGGC 734 LTSHSAG 1951 108.648 676 ATGAATAAGCATGGTGTGCTT 735 MNKHGVL 1952 108.5736 677 GACCTGACCAGAGCTGCAATA 736 DLTRAAI 1953 108.552 678 TATATTGTGGATCATGCGAAT 737 YIVDHAN 1954 108.526 679 AGTGGGCCTGAGAATACGTTG 738 SGPENTL 1955 108.526 680 CGTTATGGTGATACGGGTATG 739 RYGDTGM 1956 108.512 681 GATGGTAAGAATAGTTATGCG 740 DGKNSYA 1957 108.451 682 GAGGCGCATAATCGTGTTATT 741 EAHNRVI 1958 108.451 683 AGTTTGCAGGCTGGTAGGATG 742 SLQAGRM 1959 108.3681 684 GATGCGAAGGCTCTTACGACT 743 DAKALTT 1960 108.368 685 ACCGACACCCGAAAAAACGAC 744 TDTRKND 1961 108.357 686 GACTCTTCACACTACTCGACA 745 DSSHYST 1962 108.219 687 ACAATGCACCTTCCCAACCTG 746 TMHLPNL 1963 108.214 688 CGAGACGGCTCTACTAAAGTT 747 RDGSTKV 1964 108.207 689 TCAGGGTACCAAATGACAGAA 748 SGYQMTE 1965 108.16 690 TGCGACTTGTCACAATCATGC 749 CDLSQSC 1966 108.133 691 AGAAACGCGTCAAACGGCGTA 750 RNASNGV 1967 108.044 692 CAGTCGCAGAATGTGACTCAG 751 QSQNVTQ 1968 108.033 693 GATTCTGCTCCGAGTACTATT 752 DSAPSTI 1969 108.003 694 AGGTCCGTACCATCACCACAC 753 RSVPSPH 1970 108.001 695 ATGACGTCTGCGTCTCGTGGT 754 MTSASRG 1971 107.974 696 GCTCTTGCTAGTCGTCCTATG 755 ALASRPM 1972 107.907 697 CTAAACCTCTCCAACGACTGG 756 LNLSNDW 1973 107.899 698 GTTTCTACGGCGCAGAGGCAG 757 VSTAQRQ 1974 107.896 699 CACGCCGACGTTGGCATGAGC 758 HADVGMS 1975 107.888 700 GCGGGGGGTTTGCTGTCGCGG 759 AGGLLSR 1976 107.878 701 CATCTTAGTCAGGCTAATCAT 760 HLSQANH 1977 107.848 702 GTGCATAATCCTACTACTACG 761 VHNPTTT 1978 107.8152 703 TCTCAGCGGAATCCGGATGAT 762 SQRNPDD 1979 107.784 704 AGGGAGACTAATAATTTTGCG 763 RETNNFA 1980 107.771 705 AATGCGGGGGCTCTTATGGGT 764 NAGALMG 1981 107.764 706 TTGCCGAAGACTGTGAATATG 765 LPKTVNM 1982 107.738 707 GCAAGTGACCTACAAATGACG 766 ASDLQMT 1983 107.723 708 CAAGCCCTGGCCACCACAAAC 767 QALATTN 1984 107.716 709 CATGAGTCGTCTGGTTATCAT 768 HESSGYH 1985 107.696 710 GGGGTGAATGATCGTGCTAGG 769 GVNDRAR 1986 107.69 711 CCTCGGGATGCTCTTCGTACT 770 PRDALRT 1987 107.673 712 AACGACTCCTCGTCAATGTCC 771 NDSSSMS 1988 107.641 713 GAATACAACACGCGCCACGAC 772 EYNTRHD 1989 107.611 714 GCGTCTCCGGCGCATACGTCT 773 ASPAHTS 1990 107.598 715 CAAAACAGCAACACTCCCTCA 774 QNSNTPS 1991 107.546 716 TTGGCAAAACTAGGGAACTAC 775 LAKLGNY 1992 107.541 717 GCTAGTGATAGGCAGTCTGGT 776 ASDRQSG 1993 107.527 718 TATCAGAATGGTGTGCTTCCT 777 YQNGVLP 1994 107.5199 719 AATAAGTTTGGTTATAATCCT 778 NKFGYNP 1995 107.513 720 AAAAAAACCAACGGAATCCCC 779 KKTNGIP 1996 107.5 721 GTTAACGACAACCGAGGAAAC 780 VNDNRGN 1997 107.4937 722 ATGCACACCATAACGGGATCC 781 MHTITGS 1998 107.491 723 ATTGATGGTGTTCAGAAGCTT 782 IDGVQKL 1999 107.489 724 GCGCAGGTTAATAATCATGAT 783 AQVNNHD 2000 107.489 725 GTTTCTTCGCCTAATGGTACG 784 VSSPNGT 2001 107.487 726 GATTCTGCTCCGAGGGCTATT 785 DSAPRAI 2002 107.455 727 TCTGCGAGTGATAGTCAGCAT 786 SASDSQH 2003 107.455 728 TCGGCTCATCAGACGCCGACG 787 SAHQTPT 2004 107.427 729 GCGACGCTGAATAATAGTTAT 788 ATLNNSY 2005 107.411 730 GAAGACAGTATGAGATTCTCT 789 EDSMRFS 2006 107.407 731 GAACGAAACGGACTAATAGAA 790 ERNGLIE 2007 107.405 732 TTAGTACTTGACTCACGGAAC 791 LVLDSRN 2008 107.382 733 ACCGTCGAACAAATAAACTCG 792 TVEQINS 2009 107.349 734 GGGACAGGTACCGTTGGATGG 793 GTGTVGW 2010 107.203 735 AATCAGCAGCGTATTGATAAT 794 NQQRIDN 2011 107.185 736 ATCCAAAACGGGGTCCTGCCA 795 IQNGVLP 2012 107.184 737 GGAGACATCTCAAGCAGAAAC 796 GDISSRN 2013 107.1386 738 GTCACTGGCACTACCCCGGGA 797 VTGTTPG 2014 107.137 739 ACAAGGGAATCAATGTCCATC 798 TRESMSI 2015 107.071 740 CACACTTACTCACAAGCAGAC 799 HTYSQAD 2016 107.012 741 TCCAACATGGGCGTAGCCTCT 800 SNMGVAS 2017 106.985 742 CACGACTTGAACCACGGAAAA 801 HDLNHGK 2018 106.942 743 CTGTACGGGGGAGCACACCAA 802 LYGGAHQ 2019 106.904 744 AACGTGTACGGAGACGGAATA 803 NVYGDGI 2020 106.87 745 TCTACTATTAATATGCGTGCG 804 STINMRA 2021 106.868 746 AAGATGGGGAGTATTGAGGTT 805 KMGSIEV 2022 106.864 747 TCCGAAACGCGCGCTGGATAC 806 SETRAGY 2023 106.85 748 AATGTGGGTAATACTCTTGGG 807 NVGNTLG 2024 106.842 749 ATTGGTGGGACTGATACGCGG 808 IGGTDTR 2025 106.786 750 GCCGACAAAGGATTCGGCCAC 809 ADKGFGH 2026 106.73 751 TGGCAGGATCATAATAAGGTG 810 WQDHNKV 2027 106.719 752 AACTACGGTTCCGGACGAATC 811 NYGSGRI 2028 106.701 753 ACTCATAAGCAGGTGGATCTT 812 THKQVDL 2029 106.695 754 CGGCAGAATGATAAGGGTAAT 813 RQNDKGN 2030 106.658 755 GGTAGGAATGAGAGTCCGGAG 814 GRNESPE 2031 106.658 756 GTTTTTACTGGGCAGACGGAG 815 VFTGQTE 2032 106.632 757 TATGTTGATCGTAAGGATAAT 816 YVDRKDN 2033 106.631 758 AATAATACTTTGAATATTTTG 817 NNTLNIL 2034 106.63 759 TTGAGCTACAGCATCCAACAC 818 LSYSIQH 2035 106.621 760 GCTACCAACAGATCGCCCCTA 819 ATNRSPL 2036 106.5898 761 GTTCACACCGCAGACACAATA 820 VHTADTI 2037 106.564 762 GGGCATTTGGTTAATATGTCT 821 GHLVNMS 2038 106.56 763 TTAGACTACACCCCTCAAAAC 822 LDYTPQN 2039 106.519 764 TCCGCCTCTTACTCCAGGATG 823 SASYSRM 2040 106.501 765 TCCGGAGCGGCACAAAACCCA 824 SGAAQNP 2041 106.499 766 AGAAACACACTTGCTGACCTT 825 RNTLADL 2042 106.496 767 GGTTCTACGGTGTCGGCGCAG 826 GSTVSAQ 2043 106.491 768 TCTAAGGATAGTACTATGTAT 827 SKDSTMY 2044 106.48 769 GTGGTGGTTCACACTATCCCA 828 VVVHTIP 2045 106.45 770 CCACGTACTGTCTCATTGGAC 829 PRTVSLD 2046 106.4434 771 ATGATGAAGAGTGAGGAGAAT 830 MMKSEEN 2047 106.425 772 ACCACCGACCGGCCAAACGGA 831 TTDRPNG 2048 106.406 773 CATAGTCCTCCTACGACTATG 832 HSPPTTM 2049 106.376 774 GGCCAATGGACAACAGGGACA 833 GQWTTGT 2050 106.357 775 GACGGTATGAACGGAGTGGGT 834 DGMNGVG 2051 106.317 776 CTTCATACTGTTGCGAATGAG 835 LHTVANE 2052 106.312 777 TATACGTCGCAGACGTCTACG 836 YTSQTST 2053 106.2842 778 AACTTCTCCGAAATGTCCACA 837 NFSEMST 2054 106.27 779 ATTAATATTCGTAGTGATTTG 838 INIRSDL 2055 106.266 780 CCCTCCAACAGTGAAAGATTC 839 PSNSERF 2056 106.249 781 TATACGAATTATGGGGATCTT 840 YTNYGDL 2057 106.241 782 GATAAGAGTACGGCGCAGGCG 841 DKSTAQA 2058 106.238 783 CACACCGACATGGTATCCTCT 842 HTDMVSS 2059 106.222 784 AACAAAAGTCTGTCAATGGAC 843 NKSLSMD 2060 106.196 785 GGGCACTACGCTACAAACACA 844 GHYATNT 2061 106.158 786 GTCATCGTATCTACAAAATCA 845 VIVSTKS 2062 106.124 787 ACTCATAGTCTTATGAATGAT 846 THSLMND 2063 106.116 788 AACTACCACGGAGACAACGTT 847 NYHGDNV 2064 106.106 789 CGTGATGATCAGCAGCTTGAT 848 RDDQQLD 2065 106.064 790 GATGATAAGACTGGTCGGTAT 849 DDKTGRY 2066 106.055 791 GGGTCGAGCCAACACCACGAA 850 GSSQHHE 2067 106.042 792 CGTGTTACAGGTGTCTCAACA 851 RVTGVST 2068 106.017 793 AGTACTGCGTCGGGGCATACT 852 STASGHT 2069 106.007 794 ACTAACAACCTCTCATACGAA 853 TNNLSYE 2070 105.998 795 CAGCATAATAGTGCGTCGGCG 854 QHNSASA 2071 105.987 796 CCGGCTAAGGGTTTTGGTCAT 855 PAKGFGH 2072 105.9781 797 TGGTACGAAACAATCAGCCCG 856 WYETISP 2073 105.959 798 ACGGATGCTACGGGGAGGCAT 857 TDATGRH 2074 105.942 799 ATTCAGGCGAAGAATTCTGAG 858 IQAKNSE 2075 105.939 800 AGTACTGAGACTAGGGGTGGG 859 STETRGG 2076 105.926 801 TTCTCAACAAACTCTGTAATC 860 FSTNSVI 2077 105.918 802 TCTAACCTTCGAAACACAATA 861 SNLRNTI 2078 105.854 803 GGGATGATCGGGCACAACGCA 862 GMIGHNA 2079 105.832 804 TCTGGCCAAGGATTCTCGGCA 863 SGQGFSA 2080 105.831 805 ACCCACAACTCTACAGGCCTT 864 THNSTGL 2081 105.802 806 AGGATTGATAGTGCTATGGTG 865 RIDSAMV 2082 105.8 807 GTCGCTATGGGAGGCGGTCCC 866 VAMGGGP 2083 105.795 808 GGCTCTCACAACGGCCCAGCC 867 GSHNGPA 2084 105.763 809 CACTCCGCAGCGGGTGACGGT 868 HSAAGDG 2085 105.73 810 GCACAAGGCATAACCCACGCT 869 AQGITHA 2086 105.711 811 TCTGCGCTTTTGCGGATGGAT 870 SALLRMD 2087 105.707 812 TGGCAAATGGGGGCCGGGAGC 871 WQMGAGS 2088 105.698 813 ATAGACTCGCACGCCAGCATA 872 IDSHASI 2089 105.695 814 AGCCTAGACCACGCCCCTCTA 873 SLDHAPL 2090 105.661 815 GAAAACAACATGCAACACGGC 874 ENNMQHG 2091 105.651 816 AAGGGTGCGCAGGGTGTTCAG 875 KGAQGVQ 2092 105.646 817 GTCGCTGTATCGAACACTCCA 876 VAVSNTP 2093 105.643 818 GTTGAGTCTTCTTATTCTCGG 877 VESSYSR 2094 105.633 819 CATAATACGGAGTCTAAGACT 878 HNTESKT 2095 105.625 820 AATGAGAGTACGAAGGAGAGT 879 NESTKES 2096 105.599 821 GATGTTTATCTTAAGAGTCCG 880 DVYLKSP 2097 105.586 822 CAGTCGGGGGCTAGGACTCTG 881 QSGARTL 2098 105.5854 823 TCGAACAGTCAAGTACACAAC 882 SNSQVHN 2099 105.573 824 GTAGTCTCATCGGGCGGCTGG 883 VVSSGGW 2100 105.551 825 CCATCAAGTTTCAACAGCGCC 884 PSSFNSA 2101 105.542 826 AAGCAGACTGATAGTAGGGGT 885 KQTDSRG 2102 105.5 827 AACACAACGCCACCTAACCAC 886 NTTPPNH 2103 105.483 828 CAAAACGGAACCTCGTCTATA 887 QNGTSSI 2104 105.483 829 CTCATGAAAGACATGGAATCC 888 LMKDMES 2105 105.458 830 ACTCAGACTGGTCATGTTTCT 889 TQTGHVS 2106 105.4558 831 GAAATACACACGACCACAGGC 890 EIHTTTG 2107 105.449 832 ATACAAACTACTACAAAATGC 891 IQTTTKC 2108 105.442 833 CCCGCTGAAGGAAACAACCGT 892 PAEGNNR 2109 105.442 834 TACATCGCCGGAGGGGAACAA 893 YIAGGEQ 2110 105.415 835 GAAGTACGCGACCAAAAAACA 894 EVRDQKT 2111 105.375 836 TACGCCGTCGCGATAGGCACA 895 YAVAIGT 2112 105.366 837 TCCGCTAACGAACACAACCAC 896 SANEHNH 2113 105.337 838 GGGATGAGGGATACGCCGCCG 897 GMRDTPP 2114 105.322 839 GCTCAGCAGATTGTTAATGGG 898 AQQIVNG 2115 105.321 840 TCAAGTTCCCAAACGGTTTTG 899 SSSQTVL 2116 105.321 841 GTTATTCAGTCTGATAATACG 900 VIQSDNT 2117 105.32 842 GTTCCGGCGCATTCTCGGGGT 901 VPAHSRG 2118 105.305 843 TCGAATACGGGGTCGTTGGGT 902 SNTGSLG 2119 105.2779 844 TGGGCCAAAGACGTCAACGTC 903 WAKDVNV 2120 105.273 845 AATGTGTTGGGTGCTTCGAGT 904 NVLGASS 2121 105.187 846 ACTCCGGAGGCTAGTGCGCGT 905 TPEASAR 2122 105.173 847 AATTATAATGGGGTTAATGTG 906 NYNGVNV 2123 105.152 848 AACACAACCGGTAGCTCGGGC 907 NTTGSSG 2124 105.145 849 TCCAGCGGCCAACCGCTCGTC 908 SSGQPLV 2125 105.136 850 CAGGCGGGGGGTGTGGCGAGT 909 QAGGVAS 2126 105.133 851 CCGCTTCAATCCCAATCGGGA 910 PLQSQSG 2127 105.133 852 CAACGTACCTCGGAAGCGCCA 911 QRTSEAP 2128 105.128 853 TTGGCTAAGACGGTTGCGATT 912 LAKTVAI 2129 105.1155 854 ACCCACACCCTTGGGGGAACA 913 THTLGGT 2130 105.08 855 CACGACTACAGTATGAACGCG 914 HDYSMNA 2131 105.079 856 GGGAAACCTGCGGAAGCGCCG 915 GKPAEAP 2132 105.055 857 AGAAACGAAAACGTAAACGCT 916 RNENVNA 2133 105.051 858 AGTTCTCGGGAGGCGAAGTTT 917 SSREAKF 2134 105.0379 859 TCTTCTTCTGATAGTCCGCGT 918 SSSDSPR 2135 105.035 860 ATGAATACGACTTATAATGAG 919 MNTTYNE 2136 105.031 861 GTAAGGAGTGGAATAAAACCA 920 VRSGIKP 2137 105.008 862 CAGGAGAATCCTATGAAGATG 921 QENPMKM 2138 104.926 863 ACTGAGCCGCTTCCGATGTCT 922 TEPLPMS 2139 104.869 864 CGCCACGGGGACACACCGATG 923 RHGDTPM 2140 104.844 865 GCGGTGAATACGTATAATAGT 924 AVNTYNS 2141 104.82 866 GCGTCGACTGAGTCTCATGTG 925 ASTESHV 2142 104.816 867 ACAAACCTAAGTCAATCGGCC 926 TNLSQSA 2143 104.791 868 GAGCTGTCTACTCCTATGGTT 927 ELSTPMV 2144 104.783 869 TATGCGCATCCTGTGACTCAT 928 YAHPVTH 2145 104.76 870 CGGGGGTCTACTGGTACGCAG 929 RGSTGTQ 2146 104.749 871 TGTGTTGGTTCGTGTGGTGTG 930 CVGSCGV 2147 104.738 872 TCGGTTGCTAAGGATCAGACG 931 SVAKDQT 2148 104.736 873 ACGAATCTTTCTCCTAAGACG 932 TNLSPKT 2149 104.6855 874 CTAGGTTTCACACCCCAACCG 933 LGFTPQP 2150 104.677 875 AATATTAGTAGTATTAATCAG 934 NISSINQ 2151 104.657 876 GTTTACGACAACGTTTCTTCT 935 VYDNVSS 2152 104.657 877 AGTGGAAAACAAGACAAATAC 936 SGKQDKY 2153 104.654 878 AGACTTACAGAACTGGTCATA 937 RLTELVI 2154 104.651 879 CATAAGAGTGAGAGTCATAAT 938 HKSESHN 2155 104.626 880 GAGGCGACTCATGGTTCTTAT 939 EATHGSY 2156 104.613 881 AACCTACTTGTCGACCAACGT 940 NLLVDQR 2157 104.579 882 AATATTAATGATACTAAGAAT 941 NINDTKN 2158 104.522 883 CTTGCGGTTACGAATGTGCGG 942 LAVTNVR 2159 104.498 884 CCGTCGACACTCGCTGAAACA 943 PSTLAET 2160 104.449 885 CCGAAGCCTGGGACGGGGGAG 944 PKPGTGE 2161 104.427 886 GTGCTGTTGCAGAATTCTCAT 945 VLLQNSH 2162 104.416 887 TACGGTAACGCGAACACCGTA 946 YGNANTV 2163 104.386 888 ACATCTGGAGTTCTGACACGC 947 TSGVLTR 2164 104.375 889 AAAATAACGGAAACCAACCTC 948 KITETNL 2165 104.359 890 GTTCGCAGAGACGAAACACCT 949 VRRDETP 2166 104.359 891 TCTAAAATGTCAAACCCAGTG 950 SKMSNPV 2167 104.352 892 TGGGAATCCCTCTCCAACGCA 951 WESLSNA 2168 104.349 893 GCCAACGGAGGAGGATACCCC 952 ANGGGYP 2169 104.34 894 ATGTTGGCTTCTCGGGTGCCT 953 MLASRVP 2170 104.336 895 TGCGGCCTGAACTGCGGTAAA 954 CGLNCGK 2171 104.331 896 ACTATTACTAGTCCGTCGGTG 955 TITSPSV 2172 104.3055 897 TGGTCGAATGCTCAGAGTCCG 956 WSNAQSP 2173 104.288 898 ACAGAAAGCCCCAAACTACTA 957 TESPKLL 2174 104.283 899 CATTTGGTTACTAGTGGTATT 958 HLVTSGI 2175 104.273 900 CCTCCTAAGTCGGATTCGAAT 959 PPKSDSN 2176 104.265 901 ATTGCGGTGCATGTGCTGAGT 960 IAVHVLS 2177 104.254 902 ACTGGTACTGCGACTTTGCCT 961 TGTATLP 2178 104.254 903 AATACTACTCCGCCTAATCAT 962 NTTPPNH 2179 104.232 904 TGCACCGCCACAAAATGCTCA 963 CTATKCS 2180 104.23 905 CACAGTGACATGGTCAGCGGC 964 HSDMVSG 2181 104.208 906 CCAAACGCACACCACCTGCCC 965 PNAHHLP 2182 104.2 907 TCTAATAATATGAATCAGGCG 966 SNNMNQA 2183 104.187 908 AGTGATAATAATAGGGCTAAT 967 SDNNRAN 2184 104.1865 909 TTGCAGACGCCTGGGACGACG 968 LQTPGTT 2185 104.169 910 GTGCGCGGCGTTCAAGACGCC 969 VRGVQDA 2186 104.167 911 TCTCTAGACTCGCGCTCCTCG 970 SLDSRSS 2187 104.14 912 GTTTGTGTTACTACTTGTGCT 971 VCVTTCA 2188 104.137 913 CCGAATACTAATCATCTTGTG 972 PNTNHLV 2189 104.121 914 CTCATGTCAGGGAAAGAAAAC 973 LMSGKEN 2190 104.109 915 ACTTCTGCTAGTGAGAATTGG 974 TSASENW 2191 104.108 916 TTTTTGCCGCAGCTGGGGCAG 975 FLPQLGQ 2192 104.094 917 CCTTTTAATCCTGGGAATGTG 976 PFNPGNV 2193 104.0922 918 GGGACACCTGGTCAAAGTATA 977 GTPGQSI 2194 104.092 919 TATAATAATGGTGGGCATGTT 978 YNNGGHV 2195 104.085 920 CTCGGAAACCACTACACACCC 979 LGNHYTP 2196 104.064 921 CAAGTCAACCAACCGAGAATA 980 QVNQPRI 2197 104.061 922 TTAGGAAACAACCGGCCACTA 981 LGNNRPL 2198 104.06 923 CCTCCGGAAAGTGCCAGGGGC 982 PPESARG 2199 104.023 924 AAATCTGTAGGCGACGGGAGA 983 KSVGDGR 2200 104.0009 925 TCACTTCGGACGGACGAATTC 984 SLRTDEF 2201 103.997 926 AGTACTACTAATGTTGCGTAT 985 STTNVAY 2202 103.987 927 AGGATGTCGGATCCTAGTGAT 986 RMSDPSD 2203 103.981 928 AGTCTGTCTATTACTTCGGCG 987 SLSITSA 2204 103.963 929 GAAAGTGCCACATCTCTAAAA 988 ESATSLK 2205 103.954 930 TACACTGACGGAAGAAACACC 989 YTDGRNT 2206 103.949 931 TCCATATCCAACCTGCGTACC 990 SISNLRT 2207 103.935 932 CAAAACGACAAATCTGACAAC 991 QNDKSDN 2208 103.9165 933 GGTGGAACAGGTCTTTCCAAA 992 GGTGLSK 2209 103.916 934 AGTCAGGCTCAGATTCGTGTT 993 SQAQIRV 2210 103.915 935 GGTTTGATGGCGCATGTGACT 994 GLMAHVT 2211 103.877 936 CTGGTTGTTTCGAATAGTCTG 995 LVVSNSL 2212 103.865 937 CATGATTCTGTGAATACGGCG 996 HDSVNTA 2213 103.8588 938 ACTCTTGCGAAGGATGGGAAT 997 TLAKDGN 2214 103.842 939 TCCGACGGATCGAAACTACTA 998 SDGSKLL 2215 103.829 940 ATAGACAAAACGTTCTCGGTC 999 IDKTFSV 2216 103.812 941 CGGCTGGTTAACATCGACCAC 1000 RLVNIDH 2217 103.8026 942 AAAAACTACGACAGTGACTCA 1001 KNYDSDS 2218 103.794 943 AGTACGCAGAGTACTAATCCG 1002 STQSTNP 2219 103.7868 944 CAAATATCACTACAACTCGGC 1003 QISLQLG 2220 103.77 945 TCCGAACCCCTTAGAGTTGGA 1004 SEPLRVG 2221 103.749 946 AGTCGTCTGCAGACTCAGCAG 1005 SRLQTQQ 2222 103.7406 947 GAAGGTTCACAAGGAAACCAC 1006 EGSQGNH 2223 103.739 948 CGTTCTGACCTTACTGAAAGT 1007 RSDLTES 2224 103.736 949 CATACTGGTGTTCAGACTAAT 1008 HTGVQTN 2225 103.724 950 GAGTTGGATCATCTTTCGCAT 1009 ELDHLSH 2226 103.714 951 GTTACTGGTGTTGATTATGCG 1010 VTGVDYA 2227 103.713 952 GGCGGCGCACACACTCGTGTA 1011 GGAHTRV 2228 103.676 953 GCCTACGGTATACACGAAGTG 1012 AYGIHEV 2229 103.653 954 GCGATGCTGCGTATGGAGCAG 1013 AMLRMEQ 2230 103.652 955 AGGCAGGCGAATCAGACGTAT 1014 RQANQTY 2231 103.652 956 TTTTCTGGTCAGGCGTTGGCT 1015 FSGQALA 2232 103.646 957 GATAATGTGAATTCTCAGCCT 1016 DNVNSQP 2233 103.646 958 GGGTTGCATGGGACGAGTAAT 1017 GLHGTSN 2234 103.633 959 GAGAGGGAGCCTCCTAAGAAT 1018 EREPPKN 2235 103.621 960 GTGGTGACGCTTGGGATGCTG 1019 VVTLGML 2236 103.619 961 CATAATAATAATTTGCTGAAT 1020 HNNNLLN 2237 103.612 962 TTGATTAATATGAGTCAGAAT 1021 LINMSQN 2238 103.6 963 AATACTAATGCGTCGTATTCT 1022 NTNASYS 2239 103.599 964 AGGCTTAATGCGGGTGAGCAT 1023 RLNAGEH 2240 103.594 965 GCTGTTATTCTGAATCCTGTT 1024 AVILNPV 2241 103.576 966 CCGAGTACTCATGGGTATGTT 1025 PSTHGYV 2242 103.571 967 CTTAGGGCGTCTGTGTCGGAG 1026 LRASVSE 2243 103.564 968 ATGATGACCTCTATGACGTTA 1027 MMTSMTL 2244 103.561 969 TCGGCACACAACATAGTATAC 1028 SAHNIVY 2245 103.556 970 CACGACAGCACAACCCGCCCA 1029 HDSTTRP 2246 103.545 971 ATCAAAGACTCGTACCTTACT 1030 IKDSYLT 2247 103.542 972 TATACGCCTGGGCTTACTGAG 1031 YTPGLTE 2248 103.541 973 AAGATGGGTGGTTCTCAGAGT 1032 KMGGSQS 2249 103.477 974 TCACGTCAAACAGCGCTAACA 1033 SRQTALT 2250 103.4599 975 GTAGAAACCAGCAGATTGTAC 1034 VETSRLY 2251 103.45 976 AAATCCAACAACGGGGAATAC 1035 KSNNGEY 2252 103.424 977 TCGGGTGTTCATAGTGCGCGT 1036 SGVHSAR 2253 103.3881 978 CCTAACAACGAAAAAAACCCG 1037 PNNEKNP 2254 103.326 979 ACTATTGGTGAGGGGTATCAT 1038 TIGEGYH 2255 103.325 980 CTGCAGACTTCTGTTGCTACT 1039 LQTSVAT 2256 103.316 981 CTATTGGGAAACGCACCCACA 1040 LLGNAPT 2257 103.308 982 ATTTCGGGGTCTCATTTGAAT 1041 ISGSHLN 2258 103.297 983 AAGTCTCTTAGTAGTGATGAT 1042 KSLSSDD 2259 103.285 984 ACGAGGACTCAGGGGACGTCT 1043 TRTQGTS 2260 103.2635 985 GTTAGTAGGTCTGGGAGTACT 1044 VSRSGST 2261 103.257 986 AGCGCCGACACCCGGTCCCCC 1045 SADTRSP 2262 103.242 987 CGTGATACTGCTAATGGGCCG 1046 RDTANGP 2263 103.2389 988 ATGATGTCTAACAGCCTCGCG 1047 MMSNSLA 2264 103.232 989 ACTGGGAGGATTGAGCTTAGG 1048 TGRIELR 2265 103.214 990 GCTAATAATGCGGCTGCGTCG 1049 ANNAAAS 2266 103.209 991 CAGTTGAATATTAATGATAAG 1050 QLNINDK 2267 103.208 992 ATGGACGGGGCTCACACGTCA 1051 MDGAHTS 2268 103.202 993 ACTAGTGCGACTGATTCGATG 1052 TSATDSM 2269 103.197 994 GCCGCCAGCTTGTCGCAAAGC 1053 AASLSQS 2270 103.152 995 TCTCAGGCGGGTCTGCTTGTG 1054 SQAGLLV 2271 103.116 996 ACGACTTATTCGGATCTGAGT 1055 TTYSDLS 2272 103.104 997 TTCTCCTCCGGAACAACCATA 1056 FSSGTTI 2273 103.102 998 GTCTTCACAGAAATAGAATCG 1057 VFTEIES 2274 103.101 999 GCAGACCCCGCTAAAGGCAAA 1058 ADPAKGK 2275 103.083 1000 AAAGAATCTGAATACAGAGTT 1059 KESEYRV 2276 103.07 1001 GGGATGGTGTCTCTTAATAGG 1060 GMVSLNR 2277 103.06 1002 ACCGTTATCGAACGCAAAGAC 1061 TVIERKD 2278 103.0575 1003 AGGATTGATACGTTGTTGGTG 1062 RIDTLLV 2279 103.055 1004 GGATCCACAGGCCTACCCCCG 1063 GSTGLPP 2280 103.047 1005 ATGGAGTTGACTTCTACTAGT 1064 MELTSTS 2281 103.026 1006 CAACCAGGAGCCCCCCAAACC 1065 QPGAPQT 2282 103.014 1007 AATTCGATGGGTAATGGGGGT 1066 NSMGNGG 2283 103.009 1008 GGTAGTACTAAGTCTGGGCAG 1067 GSTKSGQ 2284 103.0049 1009 ACTTTTTTGCCTCAGCTTGGG 1068 TFLPQLG 2285 102.994 1010 ATGGGAATAAACGTACTGAGC 1069 MGINVLS 2286 102.986 1011 GTGAATCTTGGTATTTCGGGG 1070 VNLGISG 2287 102.985 1012 AGTGAGAATCGGGCTGGTAAT 1071 SENRAGN 2288 102.945 1013 CACTCCAACGCGACTACGATA 1072 HSNATTI 2289 102.916 1014 CCGGGGTCGTCCGCTTCCATC 1073 PGSSASI 2290 102.914 1015 ATTACGTCGTTGAATGGGATG 1074 ITSLNGM 2291 102.909 1016 TATCTGGAGGGTGCTCATCGT 1075 YLEGAHR 2292 102.896 1017 AGGCAGGTTGAGCAGTCTGAT 1076 RQVEQSD 2293 102.889 1018 AGCTCTCAAAGTTCCGGGTCG 1077 SSQSSGS 2294 102.8836 1019 CAGCTTACTGTTGGGAAGCCG 1078 QLTVGKP 2295 102.8762 1020 GTTGTGCATTCGAGTATTACT 1079 VVHSSIT 2296 102.8257 1021 CTAGAACAACTACGGGTCCCA 1080 LEQLRVP 2297 102.815 1022 CAGCATTCTCCGAAGCCGGTT 1081 QHSPKPV 2298 102.81 1023 GCGGGCAGTTCGCCATCACGC 1082 AGSSPSR 2299 102.8035 1024 GGAGTAACAATCGGTAGCAGG 1083 GVTIGSR 2300 102.7752 1025 TACATCGCGGGAGGCGACCAA 1084 YIAGGDQ 2301 102.75 1026 ATTAGTAGTGAGAGGTTTTCT 1085 ISSERFS 2302 102.729 1027 AGGAGTGAGGGTAATCATGCT 1086 RSEGNHA 2303 102.719 1028 GAGAAGGGGAATAGTGGGGTT 1087 EKGNSGV 2304 102.71 1029 TACATAGTTGACCACGCTAAC 1088 YIVDHAN 2305 102.71 1030 CGTCGGTTGAGTACGGATCTT 1089 RRLSTDL 2306 102.702 1031 GCGAATAGTAGGCTTGGGGCG 1090 ANSRLGA 2307 102.6979 1032 GGTACTGCTGAGAATACGAGT 1091 GTAENTS 2308 102.696 1033 GTGAGGGATGTTGCTAAGGAG 1092 VRDVAKE 2309 102.691 1034 GGAGGCCTTACCAACGGTCTA 1093 GGLTNGL 2310 102.67 1035 CCTTCGATTCCGTCGTTTTCG 1094 PSIPSFS 2311 102.657 1036 AACGCTCTCCTCAACGCACCT 1095 NALLNAP 2312 102.628 1037 GACGACATGGTCAAAAACTCA 1096 DDMVKNS 2313 102.623 1038 ACTGCGAATACGCATGCTCTG 1097 TANTHAL 2314 102.613 1039 GTATACGCCACCGCACTCGCA 1098 VYATALA 2315 102.611 1040 GGTATATACCCGGCATCCACC 1099 GIYPAST 2316 102.61 1041 GGTTTTGATGGTAAGCAGCTT 1100 GFDGKQL 2317 102.606 1042 CACTCTATGTCCGCAAACACC 1101 HSMSANT 2318 102.605 1043 TGGAGCATCAAAAACCAAACA 1102 WSIKNQT 2319 102.586 1044 ACCCTCCACACCAAAGACCTA 1103 TLHTKDL 2320 102.57 1045 TCTTATGGTAATACTCATGAT 1104 SYGNTHD 2321 102.566 1046 CAGTCGGGGTCTCTGGTGCCG 1105 QSGSLVP 2322 102.552 1047 AATACTTTGCAGAATAGTCAT 1106 NTLQNSH 2323 102.5506 1048 ACGGCTGAGTCTAGTCATCCG 1107 TAESSHP 2324 102.548 1049 GCCTCTACAGTCTCACTCTAC 1108 ASTVSLY 2325 102.547 1050 CTGACTGCTGTTGCGATTAGT 1109 LTAVAIS 2326 102.542 1051 GTCTCGGGACAAAGTGCGTAC 1110 VSGQSAY 2327 102.541 1052 GGTGAAACTAACTTCCCAACT 1111 GETNFPT 2328 102.532 1053 AATGATAATAGGTCGATGAAT 1112 NDNRSMN 2329 102.526 1054 CGATCAGGCGACCCTAAAAAC 1113 RSGDPKN 2330 102.519 1055 TGGGAGAGTGATAAGTTTCGT 1114 WESDKFR 2331 102.514 1056 CAGGTTAATCATAATACTAGT 1115 QVNHNTS 2332 102.514 1057 GGGTGGTCGAACAACGAACTA 1116 GWSNNEL 2333 102.507 1058 CGGGCTGTGCTTGCGACTAAT 1117 RAVLATN 2334 102.49 1059 CATATGGGTTTGAATGAGCTT 1118 HMGLNEL 2335 102.484 1060 GGAGAAAGCTCCTCAATAAGC 1119 GESSSIS 2336 102.477 1061 ATACACAAATCTAGCGTCGAA 1120 IHKSSVE 2337 102.473 1062 ATGTCCGGATCCATGATATCA 1121 MSGSMIS 2338 102.463 1063 TTGAGTCTGGCTGGGAATAGG 1122 LSLAGNR 2339 102.448 1064 TCTGCAACAACGAACCACGGA 1123 SATTNHG 2340 102.441 1065 TCTACGGAGTCTAATGCTAGT 1124 STESNAS 2341 102.43 1066 CCGATTGCTGAGAGGCCTTCT 1125 PIAERPS 2342 102.428 1067 TTACTTCCAAACAACACCCAC 1126 LLPNNTH 2343 102.424 1068 GGGACTCTTAAGAAGGATGCG 1127 GTLKKDA 2344 102.412 1069 GCTCTTGAGAATCGGAGTCTG 1128 ALENRSL 2345 102.408 1070 ACCACCGGGAACTCCACGATG 1129 TTGNSTM 2346 102.383 1071 GTGTATGATAGTGCGCCTAAT 1130 VYDSAPN 2347 102.366 1072 CTACTATCTAAAGGGGACTCC 1131 LLSKGDS 2348 102.346 1073 TCTTACGCCATAAACCAATCA 1132 SYAINQS 2349 102.335 1074 GGAGGAGGGGAACGTTCCACG 1133 GGGERST 2350 102.323 1075 ATTCAGGTTAGTGGTAGTCAG 1134 IQVSGSQ 2351 102.315 1076 TATCCTGTTTCGCTTTCGCCG 1135 YPVSLSP 2352 102.312 1077 GAGTTGGGTAATAAGACGGCT 1136 ELGNKTA 2353 102.311 1078 TCGGGGGTAAACTTCGGAGTA 1137 SGVNFGV 2354 102.287 1079 GCGTGGAGTTCGCCGAGTGGG 1138 AWSSPSG 2355 102.285 1080 GGTGTGAATTATCATACTACG 1139 GVNYHTT 2356 102.261 1081 CTGATTGGGGAGCTTAAGATG 1140 LIGELKM 2357 102.255 1082 TATCTGAATAGTAAGCAGCTT 1141 YLNSKQL 2358 102.212 1083 ACTGTTGATAGGCCGATTGTG 1142 TVDRPIV 2359 102.191 1084 GTCAGCAAAACCAAAGACTCG 1143 VSKTKDS 2360 102.184 1085 CAAGCTGGGAACGCGCCAAGG 1144 QAGNAPR 2361 102.1806 1086 CAAGACCAAACGAGCAACCGT 1145 QDQTSNR 2362 102.177 1087 GATACTACGTATCGGAATACT 1146 DTTYRNT 2363 102.173 1088 GGGACAACCGAAGTTAACAAA 1147 GTTEVNK 2364 102.17 1089 GGGTTTACTAATACGAGTAAG 1148 GFTNTSK 2365 102.152 1090 GTGCAGAAGAATGATGTGCTT 1149 VQKNDVL 2366 102.14 1091 AGCGTCAACAACATGCGACTC 1150 SVNNMRL 2367 102.1324 1092 TTCAGTGCCGCCTTACCGTTA 1151 FSAALPL 2368 102.13 1093 GACGTCCCAAACAACAAAAGG 1152 DVPNNKR 2369 102.126 1094 GGTGAGACTATGCGTCATAAT 1153 GETMRHN 2370 102.119 1095 ATTCGGACTTCTGTGATTAAT 1154 IRTSVIN 2371 102.103 1096 CCGCGTGCTCCTGGTCATAAT 1155 PRAPGHN 2372 102.101 1097 AGTGTTGCGCATCCTTTGTCT 1156 SVAHPLS 2373 102.101 1098 ATGACAATAACCGTCGAACCG 1157 MTITVEP 2374 102.096 1099 CCATTAAACGCGAACGGCTCC 1158 PLNANGS 2375 102.094 1100 AATAGGCAGCGGGATTTTGAG 1159 NRQRDFE 2376 102.073 1101 GATATTCATAATCCGCGTACG 1160 DIHNPRT 2377 102.073 1102 TGGATAGCAGGAAACCACTCC 1161 WIAGNHS 2378 102.07 1103 TCTACTCATCATGCTGATCGT 1162 STHHADR 2379 102.069 1104 CCGGAATCCGCCGCCAAAAGC 1163 PESAAKS 2380 102.058 1105 CACTCCGACAAAGTCTCCTCA 1164 HSDKVSS 2381 102.051 1106 TCAAACAGCGCCGACGCGGGG 1165 SNSADAG 2382 102.047 1107 GAGTTTCAGAGGATTCGTGAG 1166 EFQRIRE 2383 102.039 1108 TCCGCGGGGATGACATTGGAC 1167 SAGMTLD 2384 102.016 1109 ACTCAAACTTCTACCTGGACC 1168 TQTSTWT 2385 102.009 1110 ACGACACTAACGCAAACGGAC 1169 TTLTQTD 2386 102.003 1111 GCCTCGAAAGGCTTCGGCCAC 1170 ASKGFGH 2387 101.991 1112 CCGGCTACGATGATTAGTGAG 1171 PATMISE 2388 101.985 1113 ACTGACTCATCTGCAGACTCC 1172 TDSSADS 2389 101.981 1114 TCAACCAGAAAAGAACACGAC 1173 STRKEHD 2390 101.98 1115 GGTGATATTTCTTATAGGGTT 1174 GDISYRV 2391 101.977 1116 ATGGGGTATGTTGATAGTCTG 1175 MGYVDSL 2392 101.953 1117 CAAACCATCACCTCACAAATG 1176 QTITSQM 2393 101.941 1118 TCGATTGGGTATTCGCCTCCG 1177 SIGYSPP 2394 101.939 1119 TCATCCCCAGACTCGTACAGA 1178 SSPDSYR 2395 101.921 1120 ATTAGTCCGAGTGCTTCTAAT 1179 ISPSASN 2396 101.855 1121 TATCCGGCTGATCATCGGACT 1180 YPADHRT 2397 101.85 1122 CACACCGGCCAAACACCATCA 1181 HTGQTPS 2398 101.837 1123 CAGACGACTATTCTGGCTGCT 1182 QTTILAA 2399 101.837 1124 GATGGTACGAGGCAGGTTCAT 1183 DGTRQVH 2400 101.836 1125 AGGAGTAGTCCTGCGACGAAT 1184 RSSPATN 2401 101.829 1126 GCGATGAGTCATACGTATAAG 1185 AMSHTYK 2402 101.813 1127 ATGGCGGCTCCGCCGGAGCAT 1186 MAAPPEH 2403 101.802 1128 GGTCCTAGTACTTCGGAGGCG 1187 GPSTSEA 2404 101.794 1129 CATAATCATGATAGGTCGTCT 1188 HNHDRSS 2405 101.7829 1130 GTGGTCCCATCGACCCAAGCA 1189 VVPSTQA 2406 101.781 1131 ATTCCTGTGACTACTCGTAAT 1190 IPVTTRN 2407 101.722 1132 AACCAACTCGTACGCGGGACA 1191 NQLVRGT 2408 101.717 1133 GGGTTTGCGCTTACGGGTACG 1192 GFALTGT 2409 101.696 1134 TCTAAGGGTGGTGATATGGTG 1193 SKGGDMV 2410 101.666 1135 GCTCGACCAGGCCAATCTATG 1194 ARPGQSM 2411 101.6287 1136 AAAGCAGACTACGAATCCTCC 1195 KADYESS 2412 101.626 1137 GGACCAAGTTCGCACATCGTT 1196 GPSSHIV 2413 101.616 1138 GAAGTTGTCAAAACCACGCAC 1197 EVVKTTH 2414 101.61 1139 ACTTTGGATAATAATCATTCT 1198 TLDNNHS 2415 101.604 1140 ACGATTTATAATATGGGTCCG 1199 TIYNMGP 2416 101.599 1141 TCTACCATGAACACGATCACG 1200 STMNTIT 2417 101.597 1142 ACGCTGGCGCGGACTACTGAG 1201 TLARTTE 2418 101.581 1143 TTGATTTCTTCGCAGACTTCT 1202 LISSQTS 2419 101.553 1144 CAGACTGCGTCTGGTGATACT 1203 QTASGDT 2420 101.497 1145 GCGCATGGTGCTTTTCCGGTT 1204 AHGAFPV 2421 101.495 1146 GGGGAGACGCGGTCGACTGCT 1205 GETRSTA 2422 101.494 1147 AACAACTACGCCTACTCCGCT 1206 NNYAYSA 2423 101.493 1148 GAGGCTTATCAGACTGAGAAG 1207 EAYQTEK 2424 101.49 1149 TCTCTAGCACACGCCGTAAGC 1208 SLAHAVS 2425 101.485 1150 ACGTATCAGTTGAGTGGGAAT 1209 TYQLSGN 2426 101.452 1151 ATGAGCGAAAGGTTGCGGATA 1210 MSERLRI 2427 101.431 1152 GGGTCGGGGAAAGACCCAGGG 1211 GSGKDPG 2428 101.43 1153 TACAACAGCAACGCTTCTGTA 1212 YNSNASV 2429 101.428 1154 ACGAGGGGTGATATGGAGTTT 1213 TRGDMEF 2430 101.424 1155 GGAATCACCGGAAGCCCCGGC 1214 GITGSPG 2431 101.42 1156 CAACACACCGCCCACCCCATG 1215 QHTAHPM 2432 101.416 1157 GATACGGCGAATCGTTCGACT 1216 DTANRST 2433 101.407 1158 TCGGCACACGACGCAAGACTA 1217 SAHDARL 2434 101.387 1159 CTTAATCATACTCTGGGGCAT 1218 LNHTLGH 2435 101.385 1160 GGGTTTGAGACGAGTAGTCCT 1219 GFETSSP 2436 101.369 1161 GGTACGAGTGCGGAGAGTCGG 1220 GTSAESR 2437 101.366 1162 CATGCTAATTATGTTGAGGTG 1221 HANYVEV 2438 101.345 1163 ACAACGAAACCGGTCGCGGAA 1222 TTKPVAE 2439 101.338 1164 TCGACCGCCGTTACTAACTCA 1223 STAVTNS 2440 101.304 1165 CTGGGGCTTGCTGGTCAGGTT 1224 LGLAGQV 2441 101.304 1166 GTGCTTAAGGGTACGTTTCCG 1225 VLKGTFP 2442 101.298 1167 ATGAATGAGCCTGGTAGGACG 1226 MNEPGRT 2443 101.283 1168 ACTTCTGATCCTTTGAGGAAT 1227 TSDPLRN 2444 101.252 1169 CGTGATACTAATACGGATAAG 1228 RDTNTDK 2445 101.234 1170 GAGTCTGATTTGCGTCAGCGG 1229 ESDLRQR 2446 101.225 1171 TCCGGAATGGCCGGCCTTTCC 1230 SGMAGLS 2447 101.211 1172 ATAGCAACAACGTCTGGGCGG 1231 IATTSGR 2448 101.21 1173 ACGATTAGGAGTGAGGGTTTT 1232 TIRSEGF 2449 101.202 1174 GGTCTGTCTATTACTATTGCG 1233 GLSITIA 2450 101.176 1175 CCGCCTACTAATGGGCGTATG 1234 PPTNGRM 2451 101.17 1176 CTACAAGACCGGGCAACGAAC 1235 LQDRATN 2452 101.165 1177 CTTAAATCGACCGGTGACCAC 1236 LKSTGDH 2453 101.132 1178 GATAATAATAATCAGGTTTAT 1237 DNNNQVY 2454 101.13 1179 GTGCATATGGAGTCGTATGCG 1238 VHMESYA 2455 101.111 1180 GACCAAATAGGGCACGGAACA 1239 DQIGHGT 2456 101.106 1181 GGGACGGGGCCGCATGGTACT 1240 GTGPHGT 2457 101.0712 1182 ATTGGGAATAATACTGGTCTT 1241 IGNNTGL 2458 101.0529 1183 TTAAACGCAGAATACACCAAC 1242 LNAEYTN 2459 101.047 1184 GTGACGTCGTCTGCTAGTGGT 1243 VTSSASG 2460 101.027 1185 ACGCATGTTGCTAAGCCTGAT 1244 THVAKPD 2461 101.017 1186 CCGATGAACAAAGACATACTG 1245 PMNKDIL 2462 100.9906 1187 CTTAGTTTGAATATGAATGAG 1246 LSLNMNE 2463 100.99 1188 GTCGGCAACTCAAGCACTCAC 1247 VGNSSTH 2464 100.99 1189 GGCCACGGAAGTGACTTGACC 1248 GHGSDLT 2465 100.9576 1190 CTTACACAAAACCCAACGAAC 1249 LTQNPTN 2466 100.934 1191 CCGAGTGATCATATGCGGACT 1250 PSDHMRT 2467 100.8849 1192 CCTGATAGTCGTTTGGCGGCT 1251 PDSRLAA 2468 100.843 1193 TGGGGTAGTGAGGGGACGATT 1252 WGSEGTI 2469 100.84 1194 AAACCGACAAACGACTCGTAC 1253 KPTNDSY 2470 100.821 1195 AACCGCGGAACAGAAGTTTAC 1254 NRGTEVY 2471 100.8147 1196 CACGTGATCACAACAAAAGAC 1255 HVITTKD 2472 100.7896 1197 ATTGTGTCTAATCCGCCGGCG 1256 IVSNPPA 2473 100.76 1198 ATGCGTAACGACCAACAACTT 1257 MRNDQQL 2474 100.7503 1199 TTTCAGCGTGATGTTGGTCAT 1258 FQRDVGH 2475 100.7392 1200 GCCAACGACAACACCAAACAA 1259 ANDNTKQ 2476 100.7364 1201 TCTGTTCCGCATGCGGGGGAT 1260 SVPHAGD 2477 100.7276 1202 AATGCTACTCCGCCGAATCAT 1261 NATPPNH 2478 100.6678 1203 TCAGAACACACATCAGTTCTA 1262 SEHTSVL 2479 100.64 1204 GCCATGTCCCAAACGGACATC 1263 AMSQTDI 2480 100.628 1205 CCTAAGGCTCCGCTTAATAAT 1264 PKAPLNN 2481 100.627 1206 ACCAACAACTTACTCGCACAA 1265 TNNLLAQ 2482 100.55 1207 CAGCGTCAGGGTTCGGGGGTT 1266 QRQGSGV 2483 100.5318 1208 CGCAGTGACACCACTAACGCC 1267 RSDTTNA 2484 100.51 1209 GAGGCTGATAAGAATGGTGTT 1268 EADKNGV 2485 100.386 1210 ATGCTGGGGGGTTTTGCGCAG 1269 MLGGFAQ 2486 100.3622 1211 ATGACACACCTCAGCACAGAC 1270 MTHLSTD 2487 100.267 1212 GTTTTGTCTGATAAGGCGTTT 1271 VLSDKAF 2488 100.231 1213 ACACCCTCCGGTACCATAAAA 1272 TPSGTIK 2489 100.22 1214 ATTATTCTTATGGGTCAGAGT 1273 IILMGQS 2490 100.213 1215 CTTTCGGGGGGTGAGACTCTT 1274 LSGGETL 2491 100.154 1216 ACCGACGGCGCCCTGGGTTAC 1275 TDGALGY 2492 100.129 1217 GGGAATAAGGCTGCGCTGACG 1276 GNKAALT 2493 100.066

TABLE 2 MHCK7 Results mRNA Second Round of Capsid Variant Selection in C57BL6 mice-score capped at 100 Variant SEQ ID Sum of muscle mRNA ID Nucleotide Sequence SEQ ID NO: aa NO: score capped at 100 1 AGAGGAGACTTGACAACCCCA 2494 RGDLTTP 3737 576.12 2 CGGGGTGATCTTAATCAGTAT 2495 RGDLNQY 3738 496.41 3 AGGGGTGATCTTTCTACGCCT 2496 RGDLSTP 3739 475.909 4 CGGGGTGATCAGCTTTATCAT 2497 RGDQLYH 3740 460.578 5 CGAGGAGACACCATGAGCAAA 2498 RGDTMSK 3741 439.771 6 AGGGGGGATGCGACGGAGCTT 2499 RGDATEL 3742 429.74 7 AGAGGCGACTTATCCACACCC 2500 RGDLSTP 3743 429.182 8 CGCGGCGACATGATAAACACC 2501 RGDMINT 3744 397.62 9 AGGGGCGACCTGAACCAATAC 2502 RGDLNQY 3745 388.417 10 CGGGGGGATACTATGTCTAAG 2503 RGDTMSK 3746 352.268 11 CGGGGTGATCTTACTACGCCT 2504 RGDLTTP 3747 320.042 12 AGGGGCGACCTCAACGACAGC 2505 RGDLNDS 3748 315.615 13 GCAAACCCCAACATACTAGAC 2506 ANPNILD 3749 302.02 14 CGAGGCGACACAATGAACTAC 2507 RGDTMNY 3750 285.332 15 ATGAGTAATTTGGGGTATGAG 2508 MSNLGYE 3751 270.74 16 TACACCTCTCAAACCAGCACT 2509 YTSQTST 3752 256.544 17 CTCGGAGGAAACAGCAGGTTC 2510 LGGNSRF 3753 255.425 18 CAAAGCCAAGCGATACAACTA 2511 QSQAIQL 3754 254.191 19 AACACGTACACACCGGGAAAA 2512 NTYTPGK 3755 239.565 20 GGGGCGGAAGCGGGCCGCCAA 2513 GAEAGRQ 3756 237.2829 21 GAACACGCTACAGCAAAACAA 2514 EHATAKQ 3757 236.826 22 GCGGCACAACTCGTCAGTCCA 2515 AAQLVSP 3758 225.034 23 GATCAGACGGCTAGTATTGTT 2516 DQTASIV 3759 224.832 24 GTTCAAACCCACATAGGAGTC 2517 VQTHIGV 3760 224.306 25 TCTTATGGTAATACTCATGAT 2518 SYGNTHD 3761 224.26 26 ACCTCCACGGCTTCAAAACAA 2519 TSTASKQ 3762 221.617 27 TTGGTGACTCATGAGCGGATT 2520 LVTHERI 3763 219.227 28 ATGGATAAGTCTAATAATTCT 2521 MDKSNNS 3764 216.638 29 CGTGGTGATATGTCTCGTGAG 2522 RGDMSRE 3765 214.708 30 CGCGGTGACGTGGCAGAAATA 2523 RGDVAEI 3766 212.967 31 GGTGGCGAAAACAGAACCCCA 2524 GGENRTP 3767 210.4 32 GCTGGGCATCAGCAGCTTGCT 2525 AGHQQLA 3768 210.1746 33 CGTCTTAATAGTAGTATGAAT 2526 RLNSSMN 3769 209.449 34 TATTATGAGAAGCTTAGTGCG 2527 YYEKLSA 3770 209.263 35 GAAGCGTCCAACTACGAACGA 2528 EASNYER 3771 209.09 36 TTCCAAACTGACACGCACCGA 2529 FQTDTHR 3772 208.95 37 AACAGTTCCCAATGGCCCAAC 2530 NSSQWPN 3773 208.638 38 GATGGTAAGACTACGTCTAAT 2531 DGKTTSN 3774 207.638 39 GCTGTGCATGCGACTAGTAGT 2532 AVHATSS 3775 205.952 40 AAAACACTCCCCGGCAGGGAA 2533 KTLPGRE 3776 205.926 41 ATACTGAAATCCGACGCACCA 2534 ILKSDAP 3777 204.523 42 AGTACGAATGAGGCTCCTAAG 2535 STNEAPK 3778 204.522 43 TTTGATAGTGCGAATGGTCGG 2536 FDSANGR 3779 203.996 44 ATGGACGCTGCGTACGGTAGT 2537 MDAAYGS 3780 203.401 45 AACAAAGACCACAACCACCTG 2538 NKDHNHL 3781 202.878 46 GGTCAGTATAGTCAGACGCTT 2539 GQYSQTL 3782 202.553 47 GAAGCATTCCCGCGAGCGGGC 2540 EAFPRAG 3783 202.275 48 GAACACACTCACTTAAACCCG 2541 EHTHLNP 3784 201.959 49 ATGCAACGCGAAGACGCGAAC 2542 MQREDAN 3785 201.523 50 CTAACCGGCTCTGACATGAAA 2543 LTGSDMK 3786 200.376 51 CGAGTAAACAACGACGCAATA 2544 RVNNDAI 3787 200 52 CGTGGTGACCAAGGCACACAC 2545 RGDQGTH 3788 200 53 ATTAATATTAGTAGTGATTTT 2546 INISSDF 3789 200 54 AATAATGATAATGGTTTTGTT 2547 NNDNGFV 3790 200 55 TTCATCGCTAACACTAACCCA 2548 FIANTNP 3791 200 56 GGACTGCACGGCACCAACGCA 2549 GLHGTNA 3792 200 57 AAAACCATCGACATAGCACAA 2550 KTIDIAQ 3793 200 58 TCGAGTGATTCTCGTATTCCG 2551 SSDSRIP 3794 200 59 TCTACATCTCCGGTTAACAGC 2552 STSPVNS 3795 200 60 GCCAGCATGCCCTCTGTAGAC 2553 ASMPSVD 3796 200 61 GGTCATAATATGGCACAGGCG 2554 GHNMAQA 3797 200 62 CACAACAAACCAAACGGAGAC 2555 HNKPNGD 3798 197.851 63 TACAGGATGGAAACGAACCCA 2556 YRMETNP 3799 197.46 64 CTTGGGAATGTGGTTCATCCG 2557 LGNVVHP 3800 197.383 65 GTAACGGCACACCAATTATCC 2558 VTAHQLS 3801 196.095 66 ACTATGGTAGAAGTACTGCCA 2559 TMVEVLP 3802 195.586 67 ATCAAAGGGTCTGGGTCGCAA 2560 IKGSGSQ 3803 195.296 68 ACTAATGGGGGGTCGCTTAAT 2561 TNGGSLN 3804 193.959 69 CTCGGAGGAAACAGCAGGATC 2562 LGGNSRI 3805 193.21 70 AGGGGTGATGCGGCGAATAAG 2563 RGDAANK 3806 193.16 71 GCGTTAAACGCCCAAGGGATC 2564 ALNAQGI 3807 192.986 72 GCTGAGCATGCGACTAGTAGT 2565 AEHATSS 3808 192.59 73 TACTTGACCACCGGTACTGCC 2566 YLTTGTA 3809 191.521 74 GCGGAGGCTCAGACGCGTGTG 2567 AEAQTRV 3810 189.899 75 GCTGAGCAGGGGCTGTCTTCG 2568 AEQGLSS 3811 188.94 76 CTGATTGTTACTCAGCATGTG 2569 LIVTQHV 3812 188.588 77 TCTAGTTATCAGTCTGGGCTG 2570 SSYQSGL 3813 188.4 78 GCTACGGTTTATAATGAGTTG 2571 ATVYNEL 3814 188.18 79 CATGATACGGTTGGGGAGAGG 2572 HDTVGER 3815 187.269 80 CGTGGGGATTTGAATGATTCT 2573 RGDLNDS 3816 187.25 81 CATGATATTAGTCTGGATCGT 2574 HDISLDR 3817 186.65 82 ACAGAACAATCTTACTCACGA 2575 TEQSYSR 3818 186.237 83 TGGTGAGGGGCTGAGTTTGCC 2576 W*GAEFA 3819 186.1 84 GCTGTGCATGCGACTAGTAGA 2577 AVHATSR 3820 185.9 85 ATTGAGAGTAAGACTGTGCAG 2578 IESKTVQ 3821 185.818 86 ACGAATGTTAGTACGCTTTTG 2579 TNVSTLL 3822 184.365 87 CCACCCAACGGCAGCAGTAGA 2580 PPNGSSR 3823 183.258 88 CCCTCTACACACGGCTACGTA 2581 PSTHGYV 3824 183.235 89 ACTGCGGCTAGTACTGCGAGG 2582 TAASTAR 3825 182.452 90 TACAACGCAGGCGGAGAACAA 2583 YNAGGEQ 3826 182.14 91 ACCCACAACCAACGTGAACTG 2584 THNQREL 3827 181.989 92 ACCTTCACGGTCGACGGTAGA 2585 TFTVDGR 3828 181.724 93 CACTCCAGCCCCGGGTCGTCA 2586 HSSPGSS 3829 181.331 94 AGTACGAGTGGTTATAATACT 2587 STSGYNT 3830 180.372 95 TCTGAGAAGCTGACTGATAAG 2588 SEKLTDK 3831 180.174 96 GGGAGGAACACAAGTAACTTG 2589 GRNTSNL 3832 180.156 97 ACCGGAACAGCGATCTCCCGA 2590 TGTAISR 3833 180.148 98 TCTATGCAGGATCCTTCTTTG 2591 SMQDPSL 3834 179.222 99 ACTCGGAGTGATATTGGTGTG 2592 TRSDIGV 3835 178.75 100 ACGCAGAATCATCAGTTGTCT 2593 TQNHQLS 3836 178.39 101 TTTGTTGATAATAGGCAGCCT 2594 FVDNRQP 3837 178.388 102 AGTTTGAATTCTTCGAGTACT 2595 SLNSSST 3838 177.704 103 AAGGCGGTTTCGGAGATTATT 2596 KAVSEII 3839 177.335 104 GGTACGAGTGATAATTATAGG 2597 GTSDNYR 3840 176.93 105 ATGTCTAGCCACACCGTCCAA 2598 MSSHTVQ 3841 176.741 106 AGTATCACCCACAGCAACACC 2599 SITHSNT 3842 176.571 107 GTTCAGACTAGTACTGGTGCT 2600 VQTSTGA 3843 176.399 108 CGTGGTGATATGACTCGTGCG 2601 RGDMTRA 3844 176.36 109 ATTGGTCTGCAGAATTCTACT 2602 IGLQNST 3845 176.164 110 AGTGCGGATCGTGATAATAAG 2603 SADRDNK 3846 173.544 111 TACTCTCAATCCATAAAAAAC 2604 YSQSIKN 3847 172.725 112 CGCTCGTTGGACAGCGGGATG 2605 RSLDSGM 3848 172.632 113 GCTGTGCCTCAGTCTCTGCCT 2606 AVPQSLP 3849 172.274 114 GCGAATGATAGTATTAAGCTG 2607 ANDSIKL 3850 172.18 115 AATGGTAATATTTATCCGTCT 2608 NGNIYPS 3851 171.981 116 GGGCAAACAAACGCAGTACAC 2609 GQTNAVH 3852 171.5364 117 CAAGGAGACCTACGTGGCTCG 2610 QGDLRGS 3853 171.042 118 GTTAAGGCGAGTGCTGGGGTT 2611 VKASAGV 3854 170.5608 119 ATCGCGTCAACGTGGAACATG 2612 IASTWNM 3855 170.52 120 AACTCGGCTGAATCCTCGAGA 2613 NSAESSR 3856 170.31 121 GTCTTCACGGGCCAAACTGAA 2614 VFTGQTE 3857 170.216 122 TTTGGTACTTCTTATACGACT 2615 FGTSYTT 3858 169.719 123 GCGGTTAATGAGACTAGGCTT 2616 AVNETRL 3859 168.767 124 GGTCGGACGGATACTCCTAAT 2617 GRTDTPN 3860 168.735 125 AACGACCGACCGCTTGCCAGC 2618 NDRPLAS 3861 168.71 126 GCTTATCAGCTGACTCCGGCT 2619 AYQLTPA 3862 168.579 127 ATGGGTGAGATGGGTAATATT 2620 MGEMGNI 3863 168.24 128 GCGGACATGCAACACACCGTA 2621 ADMQHTV 3864 168.055 129 GCGGTTGTTCTGAATAGTAAT 2622 AVVLNSN 3865 168.021 130 TTTCGTGATGGTCAGGGTATG 2623 FRDGQGM 3866 167.193 131 AAATCGACATCAAACATCGAA 2624 KSTSNIE 3867 166.8294 132 ACCCAAGCCTTCTCCCTAGGC 2625 TQAFSLG 3868 166.751 133 TGGTCGAGAACTGGAAACACC 2626 WSRTGNT 3869 166.483 134 AGCACAAACACCGAACCTAGG 2627 STNTEPR 3870 165.304 135 GAGAATAGTGATTTGTCTTAT 2628 ENSDLSY 3871 165.08 136 ATAGACGAACGTTCCTCGATA 2629 IDERSSI 3872 165.02 137 GATGTGCATTCGAGTATTCCT 2630 DVHSSIP 3873 164.85 138 ATAAGCGGTTCCACTACACAC 2631 ISGSTTH 3874 164.788 139 TGGCAAACCCAAGTCACTACA 2632 WQTQVTT 3875 164.759 140 AACATGGGTCCAATGGGCCGG 2633 NMGPMGR 3876 164.41 141 GTTACCCAATCGTCCACGCTA 2634 VTQSSTL 3877 164.175 142 ATTGATCGTAGTGCTAGTTTG 2635 IDRSASL 3878 164.016 143 TCTCATAGTATTACGGGTCTT 2636 SHSITGL 3879 163.92 144 AAAGCGGGACAACTAGTGGAA 2637 KAGQLVE 3880 163.845 145 AGCGGTGTATCAGAAGGAAAC 2638 SGVSEGN 3881 163.413 146 ACGCTTACATTATCTACCCTC 2639 TLTLSTL 3882 163.242 147 GCCCACAACAAACACGAAAGT 2640 AHNKHES 3883 162.975 148 CACAACAACAACCTGCAAAAC 2641 HNNNLQN 3884 162.633 149 TATAATGAGTCTTCGAATGCG 2642 YNESSNA 3885 161.92 150 CGTGAGCAGGCTGCGGAGAGG 2643 REQAAER 3886 161.523 151 ACTCAGTATGGTACTCTGCCG 2644 TQYGTLP 3887 161.32 152 CATCCTGGGAATAGTTCTGTG 2645 HPGNSSV 3888 161.2 153 AGTTCTAGGGAGGTGAGTCCG 2646 SSREVSP 3889 161.091 154 GCAAACTCCACAAGCCAATGG 2647 ANSTSQW 3890 160.842 155 CGCGACATGATCAACTCATCA 2648 RDMINSS 3891 160.83 156 GCATTGCCCAGCGGCGCACGA 2649 ALPSGAR 3892 160.765 157 CCTGGCACCAGTGGATCCCGA 2650 PGTSGSR 3893 159.7012 158 TGGAACGGAAACGCCACACAA 2651 WNGNATQ 3894 158.413 159 GGTAAAGCAACCTTAGTCCTC 2652 GKATLVL 3895 158.386 160 TACACCAACGGGGGCCACCTA 2653 YTNGGHL 3896 158.346 161 TCACAATACAACGGAACGCAA 2654 SQYNGTQ 3897 157.872 162 TATTCTAGTGAGAGTGCTTAT 2655 YSSESAY 3898 157.56 163 GTTAAGGCGGGGGTGGCTGAT 2656 VKAGVAD 3899 157.534 164 ACGATGGGGACGGTGCAGATT 2657 TMGTVQI 3900 157.384 165 GGTGTGGCTGGTGCGGTGGTG 2658 GVAGAVV 3901 156.882 166 TATGATAAGACTTTGAGTGTT 2659 YDKTLSV 3902 156.791 167 CATGGGAGTGCGTATTCGCAG 2660 HGSAYSQ 3903 156.45 168 ACGGCTAATATTATGAGTAAG 2661 TANIMSK 3904 155.935 169 TTTTCGCGGGAGACGCTGGCG 2662 FSRETLA 3905 155.888 170 TTGAGTGGTGCTGGTAGTCAG 2663 LSGAGSQ 3906 155.554 171 AGTAATGCGAATCAGATGAGT 2664 SNANQMS 3907 155.28 172 TCGGTCCTTTCGCCTTCGAAC 2665 SVLSPSN 3908 154.987 173 GATAATGTGCATGGGCAGGTG 2666 DNVHGQV 3909 154.72 174 GACGGACGAGAATACGCCTCG 2667 DGREYAS 3910 154.33 175 ATTTCGAATCAGATTAAGATG 2668 ISNQIKM 3911 154.262 176 GGTCGAGACAACCAACACGTA 2669 GRDNQHV 3912 154.136 177 CGTAATCATGAGACTGGGGCT 2670 RNHETGA 3913 153.8093 178 AGTGGGAGTGGTGCGAATATT 2671 SGSGANI 3914 153.55 179 TCTATGTCTGATGGGCTTCGG 2672 SMSDGLR 3915 153.296 180 AAGGAGAGTAGTGCTATGGAG 2673 KESSAME 3916 153.04 181 GCTAATGCTAGTACTAGTCTG 2674 ANASTSL 3917 152.807 182 AGTGCTTCTGGTTATTTGGTT 2675 SASGYLV 3918 152.79 183 GATACTACTCAGAAGCCTCAT 2676 DTTQKPH 3919 152.687 184 CTAATACGAGGTTCCATGGAA 2677 LIRGSME 3920 152.55 185 GACCGCACCTACTCAAACACA 2678 DRTYSNT 3921 152.447 186 GCTCTTGGGCATCAGGGGAAT 2679 ALGHQGN 3922 152.38 187 GCTAATCATACGTCGCAGGAG 2680 ANHTSQE 3923 152.056 188 GAGAGGGGTTTGAATACTAAT 2681 ERGLNTN 3924 151.4 189 ACTGTTGGTGGTAATCATCAT 2682 TVGGNHH 3925 151.384 190 CCGAGTGATAGGACTACTTAT 2683 PSDRTTY 3926 151.365 191 TCCAGGCAAGAAAACTTCTCC 2684 SRQENFS 3927 151.22 192 AATAAGACGACGATGGAGTTT 2685 NKTTMEF 3928 151.16 193 AAACACACAGAAAACGGGACC 2686 KHTENGT 3929 150.985 194 GAAACCGGAGCTATGACCTCT 2687 ETGAMTS 3930 150.803 195 GGTCATAGGGATTCGGGTGGT 2688 GHRDSGG 3931 149.991 196 AGAAACGCCGAAGGCGGATTG 2689 RNAEGGL 3932 149.919 197 GGGCAGCGTACGACGAATGAT 2690 GQRTTND 3933 149.903 198 TATAATGATGCTCTTAGGCCG 2691 YNDALRP 3934 149.88 199 GGGTATGCGACTACGGTTCAG 2692 GYATTVQ 3935 149.694 200 ATAGGGGGAGGCATAGGAAAC 2693 IGGGIGN 3936 149.622 201 GTGGCGGTGTCTAATACGCCT 2694 VAVSNTP 3937 148.5637 202 CTTGCGAATGGTATGACGGCT 2695 LANGMTA 3938 148.449 203 ATTTCTGGGTCGTCGTCTCTT 2696 ISGSSSL 3939 148.328 204 TCTAATGTTCATGTTGTTAAT 2697 SNVHVVN 3940 148.32 205 GTGGAGACTTCGCGTCTGTAT 2698 VETSRLY 3941 148.302 206 TCGAACGCAGACATCCTCGCC 2699 SNADILA 3942 148.08 207 AACAACGTAAACCCGTACTCG 2700 NNVNPYS 3943 148.016 208 ATAAGTGTAGGTGTGTCCGTA 2701 ISVGVSV 3944 147.84 209 TCCGCAAACAACATAGCCCCC 2702 SANNIAP 3945 147.813 210 GGTGTTCAGATGACTGCGGGG 2703 GVQMTAG 3946 147.527 211 CGTTACATCGCCAACCAAACA 2704 RYIANQT 3947 147.305 212 ACCACCGAAAGTCTACACCTT 2705 TTESLHL 3948 146.899 213 GGCTACCAAGACAAAACACGA 2706 GYQDKTR 3949 146.705 214 GCTTCGCGGCCTGCGGCTCAG 2707 ASRPAAQ 3950 146.364 215 TCTATTCAGGAGCTGTTGAGG 2708 SIQELLR 3951 146.287 216 ACTGTGCGTTCGCCTCAGCAG 2709 TVRSPQQ 3952 145.74 217 GCGGTTCTTGGTGGTAGTAAT 2710 AVLGGSN 3953 145.633 218 ATGAGTACGGTTCTTCGGGAG 2711 MSTVLRE 3954 144.928 219 ACTTATGGTATTACTCATGAT 2712 TYGITHD 3955 144.751 220 GATGCGAATGCGGGTACGAGG 2713 DANAGTR 3956 144.597 221 TTCAACGGGTACGTCATGGCA 2714 FNGYVMA 3957 144.536 222 ATTAATAATTTTAATACTCTG 2715 INNFNTL 3958 144.08 223 GTAGCCAACGAACGCCTACCG 2716 VANERLP 3959 143.64 224 ACTAATTCTAATCAGGGTTCG 2717 TNSNQGS 3960 143.617 225 GCGACGCTGAATAATAGTTAT 2718 ATLNNSY 3961 143.512 226 AAAAACGCTCAAATAGACCTA 2719 KNAQIDL 3962 142.66 227 CCTGCTACGCTACACCTGACA 2720 PATLHLT 3963 142.552 228 TTAGGATCGAGCACAGTATCG 2721 LGSSTVS 3964 142.325 229 AATTGGAATTCTGAGGGTACG 2722 NWNSEGT 3965 142.257 230 CCAACAAACAACTTAAGTATG 2723 PTNNLSM 3966 141.91 231 GCGCTTAAGCCGAATTCTACG 2724 ALKPNST 3967 141.737 232 ATGGTGAATTCGGAGAATACT 2725 MVNSENT 3968 141.624 233 AGTATGGATGCTCGGTTGACG 2726 SMDARLT 3969 141.6 234 AATAATGTTGTTAGGGATGAT 2727 NNVVRDD 3970 141.597 235 ACAAGGGACCAAAGGTCTACA 2728 TRDQRST 3971 141.592 236 GCTGACATCCGGAACGACAAA 2729 ADIRNDK 3972 141.468 237 ATGCGGGATAAGATTAATCCG 2730 MRDKINP 3973 141.468 238 CCGACTCCTAATGAGCATATG 2731 PTPNEHM 3974 141.465 239 GGATACTCACACAACTCCGAC 2732 GYSHNSD 3975 141.448 240 CTTCGGGATGGGATTGCTTCT 2733 LRDGIAS 3976 141.105 241 ATGAACCAAATGGGCGGCCTG 2734 MNQMGGL 3977 141.089 242 TCTTCGCCTACTAAGGGTACT 2735 SSPTKGT 3978 140.803 243 TATTTGGATAATCCGTTGACG 2736 YLDNPLT 3979 140.516 244 GTCATGCAACGATCTGCACAA 2737 VMQRSAQ 3980 140.2 245 TCTCTGCAACTCACAGCGGGT 2738 SLQLTAG 3981 140.161 246 GTGGGGTCTGGGGGTTATAAT 2739 VGSGGYN 3982 140.139 247 GATCGTCCGAATAATGTGTCG 2740 DRPNNVS 3983 140.036 248 TTGACTGAGAAGGCTTCTATT 2741 LTEKASI 3984 139.945 249 ACCACAAAAACGACATCTATG 2742 TTKTTSM 3985 139.556 250 CGTTTGGACCTGCAAGTCCAC 2743 RLDLQVH 3986 139.528 251 ACTCATGTGATTGGGGCTGTG 2744 THVIGAV 3987 139.34 252 ACCCTGACACACCTAAACCCA 2745 TLTHLNP 3988 139.142 253 ACCTCAATATCGTCGCAAAGC 2746 TSISSQS 3989 138.884 254 TACCACACCCACCAAGTCGCA 2747 YHTHQVA 3990 138.871 255 ATGCAAGGGCTTAACAACATG 2748 MQGLNNM 3991 138.848 256 GGTAGTGCGAGTAATAGTGGT 2749 GSASNSG 3992 138.841 257 GCGAATACTACGGGGCAGGTG 2750 ANTTGQV 3993 138.7122 258 AGCGTTGTCAACACCAACATC 2751 SVVNTNI 3994 138.699 259 TCTAATAATCTGAATCAGGAG 2752 SNNLNQE 3995 138.543 260 ATGAATGGGAGTGGGATGCAG 2753 MNGSGMQ 3996 138.484 261 ATAAGTCACGACCTTAAATAC 2754 ISHDLKY 3997 138.458 262 ACGGTTAATGCGGATGGGTCG 2755 TVNADGS 3998 138.21 263 AATCATATTAGGAATCCTATG 2756 NHIRNPM 3999 138.143 264 AGTACGCGGGTTACTCTGGAT 2757 STRVTLD 4000 137.85 265 GCTATGGGAGCACTCGTGCAC 2758 AMGALVH 4001 137.838 266 GCGCAAGCCATGTCAAACAGC 2759 AQAMSNS 4002 137.76 267 AATGCTAATGGTATGAATACT 2760 NANGMNT 4003 137.343 268 TTGACGCTTCCTAGTGCTAAT 2761 LTLPSAN 4004 137.264 269 TACCAAACGGGAGACAAAGAC 2762 YQTGDKD 4005 137.017 270 AGACGGGAAGAAAACGTCAAC 2763 RREENVN 4006 136.962 271 GGAACTACCACGGCAGTCGCG 2764 GTTTAVA 4007 136.8811 272 ACGGCTGGTGGGGAGCGTGCG 2765 TAGGERA 4008 136.6 273 GCCGGTAACGAACCTAGACCC 2766 AGNEPRP 4009 136.593 274 GCAAACAACACAGCCAACAGT 2767 ANNTANS 4010 136.498 275 CATGTGAATAGTAGGGATCTT 2768 HVNSRDL 4011 136.187 276 ACATACCAACTTTCCGGCAAC 2769 TYQLSGN 4012 136.059 277 CGGGGTGATTCGATGGCTCGG 2770 RGDSMAR 4013 135.8517 278 TTGAATAATTCTGCGACTGTT 2771 LNNSATV 4014 135.76 279 CTACACGCTAACAACGAACGG 2772 LHANNER 4015 135.723 280 ATGGGTTCTACGACTGGTGTG 2773 MGSTTGV 4016 135.16 281 GTAGTTGCAGGGCACGCAATG 2774 VVAGHAM 4017 135.1261 282 GGCAACGAAAAACCATCAGGG 2775 GNEKPSG 4018 135.016 283 CGTGGTACGGAGGGGACGCCG 2776 RGTEGTP 4019 134.8972 284 TGGTCCCCCGGACCCGAAGCC 2777 WSPGPEA 4020 134.66 285 ATTAATGTGAATCAGATGGCG 2778 INVNQMA 4021 134.472 286 CGGTCGGACGTTATGCAAAGT 2779 RSDVMQS 4022 134.362 287 AGGGACGTAAGTACAAAAGAA 2780 RDVSTKE 4023 134.36 288 AAAAAGTCACCCAGACTTGAA 2781 KKSPRLE 4024 134.35 289 ACGAGCAACACAATGTCAGAC 2782 TSNTMSD 4025 134.345 290 TCTAAAGGAAACGAACAAATG 2783 SKGNEQM 4026 134.224 291 GGTTACGCTACGACCGTGCAA 2784 GYATTVQ 4027 134.185 292 GGATACATGTCTAACGTCATA 2785 GYMSNVI 4028 133.922 293 GTGACTGTTAGTCTGGATGGG 2786 VTVSLDG 4029 133.879 294 ACGAATAATTTGCTGGCTCAG 2787 TNNLLAQ 4030 133.517 295 GCGCAGACGACGGGGTATACG 2788 AQTTGYT 4031 133.295 296 AGTAAGTCGACTGAGATTATG 2789 SKSTEIM 4032 133.249 297 TCTGCGATGCACACATTAGTC 2790 SAMHTLV 4033 133.226 298 GCTGGGGTGCGTGAGTCGTTT 2791 AGVRESF 4034 133.15 299 CAAGGCAACTCAATGGCGTCC 2792 QGNSMAS 4035 132.82 300 AAAAACCCGAGTGTCCAAGAA 2793 KNPSVQE 4036 132.519 301 CCCATAACACGGGAATCGGGA 2794 PITRESG 4037 132.424 302 AGCCGCTCGGCAGAAATATCG 2795 SRSAEIS 4038 131.747 303 AACGACATCCCCACACGAGCC 2796 NDIPTRA 4039 131.424 304 GCATACGGATCGTCCGGAAGA 2797 AYGSSGR 4040 131.375 305 CTTCATGGGAATTTTAGTCAG 2798 LHGNFSQ 4041 131.002 306 GCATCCAACGGGCAAGTTAAC 2799 ASNGQVN 4042 130.736 307 CAGAAGGGGACGGTTACTCTG 2800 QKGTVTL 4043 130.375 308 AACTCTAGTAACACTGGTTGG 2801 NSSNTGW 4044 130.26 309 ACGTATCAGCATCAGGGTCCG 2802 TYQHQGP 4045 130.231 310 GACGGGGTCGCACACCGCTCA 2803 DGVAHRS 4046 130.216 311 GACGGGCTCACGCTGGAACGC 2804 DGLTLER 4047 130.09 312 AGGGGTGATCTATCTACGCCT 2805 RGDLSTP 4048 130.02 313 ATTAATGAGATTGGTAGGATG 2806 INEIGRM 4049 129.944 314 CCCCAATGGGGAACTGACCCG 2807 PQWGTDP 4050 129.94 315 AAGCAGGTGGCGCATATTGAT 2808 KQVAHID 4051 129.831 316 AATACTTTGCAGAATAGTCAT 2809 NTLQNSH 4052 129.563 317 TGGAGCCAAGGGAACACAGCG 2810 WSQGNTA 4053 129.438 318 AACGAAACGCACGTACCTAAA 2811 NETHVPK 4054 129.35 319 GTAACGAACGAATCCCGCGCC 2812 VTNESRA 4055 129.059 320 CCCGAAGGCCACATGCAAGAC 2813 PEGHMQD 4056 129 321 TTGGATTCGACTAATTCTAGG 2814 LDSTNSR 4057 128.63 322 CAGTCGATTGGGCATCCGGTG 2815 QSIGHPV 4058 128.17 323 GTCCTGGTTAACGTACACAAC 2816 VLVNVHN 4059 128.078 324 GTGCATAATCCTACTACTACG 2817 VHNPTTT 4060 127.727 325 GGGGATAAGGCGAGTTTGGCG 2818 GDKASLA 4061 127.698 326 CTAAACGAATCCCGAGCGTCG 2819 LNESRAS 4062 127.597 327 GGTTTTCATATTAATGGTGAG 2820 GFHINGE 4063 127.526 328 AGTGTTAGTTCTGTGGTGTTG 2821 SVSSVVL 4064 127.19 329 CTTTCGACTACTTCGACGAAG 2822 LSTTSTK 4065 127.153 330 ACTAATACGCAGAATAATCCG 2823 TNTQNNP 4066 127.089 331 ACTAATCTTGCTGTTACGCTG 2824 TNLAVTL 4067 127.0208 332 ATGTCGGATCGTACTTCTGAT 2825 MSDRTSD 4068 126.91 333 TCCGCGCAATCTTTCGTAGTT 2826 SAQSFVV 4069 126.906 334 ATGCACACAAGTAGACCCCCA 2827 MHTSAPP 4070 126.861 335 ATGTCTAGCCACACAGTCCAA 2828 MSSHTVQ 4071 126.79 336 AGGGATACGGCTAAGGGGGTG 2829 RDTAKGV 4072 126.773 337 GCGTTAAAATCCGACAGCGCC 2830 ALKSDSA 4073 126.73 338 CAATACGACGCCAGCCGACAA 2831 QYDASRQ 4074 126.66 339 TTAGCCGACTCAAACAGCAAA 2832 LADSNSK 4075 126.48 340 TTTCAGTTGGCTAGTAATCCG 2833 FQLASNP 4076 126.372 341 AACTCTGTCGTAGGGAACATC 2834 NSVVGNI 4077 126.308 342 AGGTATGAGAGTACTAGTGCT 2835 RYESTSA 4078 126.21 343 GCGGATCATAATCATATTGCT 2836 ADHNHIA 4079 126.21 344 GTAGGCGACCAATCCCGCCCG 2837 VGDQSRP 4080 126.106 345 TTCAACGAAACTGCCGGGCGA 2838 FNETAGR 4081 125.693 346 AGCAACTCGTACTTACTCAAC 2839 SNSYLLN 4082 125.52 347 CGAGGCGACACAAAGAACTAC 2840 RGDTKNY 4083 125.09 348 ACGACTACTACTATGGCATAC 2841 TTTTMAY 4084 125.064 349 CGACCCCCGAACGAAAACAGA 2842 RPPNENR 4085 124.7157 350 TGCGCCAACATGACCAACGGC 2843 CANMTNG 4086 124.6 351 AATCGGTCGGATAGTTTTGCG 2844 NRSDSFA 4087 124.567 352 AATCTTTTGACTTCGTCGCCT 2845 NLLTSSP 4088 124.54 353 AACTCCAGGGAAATGGGTGTA 2846 NSREMGV 4089 124.539 354 ATGGGGAATCAGAGTGGTGCG 2847 MGNQSGA 4090 124.506 355 ATGCTCACAGAAACCAAAGCA 2848 MLTETKA 4091 124.3 356 CAAAACATCAAAAACATGACA 2849 QNIKNMT 4092 124.1 357 ATGAGTACGGTTCTTCGCGAG 2850 MSTVLRE 4093 124.05 358 GACCGTGCCCAAAACAACGAA 2851 DRAQNNE 4094 123.95 359 CATACGCAGTCGACGGGTTAT 2852 HTQSTGY 4095 123.943 360 ATGAGTGTGGGGAAGGTTTAT 2853 MSVGKVY 4096 123.919 361 GCCGGAAACTACCAATCATCA 2854 AGNYQSS 4097 123.855 362 AGAAACGAAAACGTAAACGCT 2855 RNENVNA 4098 123.777 363 GACACCCACCACACATCCAGT 2856 DTHHTSS 4099 123.766 364 ACTAGCTCCCCTGTTCTACAA 2857 TSSPVLQ 4100 123.762 365 GTGGGCCGTGACGCAGAAGCT 2858 VGRDAEA 4101 123.74 366 AACATGGAAAGAGGATCGCAA 2859 NMERGSQ 4102 123.646 367 GACAGACAAACAGGCCAAAAA 2860 DRQTGQK 4103 123.6413 368 GTCTTCCGGGAAGGCATCGTG 2861 VFREGIV 4104 123.54 369 TCCGCAAACAACATAGCCACC 2862 SANNIAT 4105 123.32 370 GTATCAGAAGGACAACGAATC 2863 VSEGQRI 4106 123.005 371 CACTACGGTAACAAAGACATA 2864 HYGNKDI 4107 122.894 372 GATGTTTTGCTTAAGAATTTT 2865 DVLLKNF 4108 122.89 373 CACACGGTTCAAATACGCGAA 2866 HTVQIRE 4109 122.8082 374 ACATCAGCACTAGCACACCAA 2867 TSALAHQ 4110 122.78 375 ATCCCAACCGGCCAAACTAGC 2868 IPTGQTS 4111 122.752 376 CGCAGCGACAAAGGAACGTTG 2869 RSDKGTL 4112 122.7439 377 AATGGTCTTACGGTTCAGCGG 2870 NGLTVQR 4113 122.718 378 ACGGTTGAGGGTTCTTATCCG 2871 TVEGSYP 4114 122.67 379 ACTAGCCACTTAGTACTTGCA 2872 TSHLVLA 4115 122.653 380 AATCATAGTCTGTCGGAGCAT 2873 NHSLSEH 4116 122.5 381 TTAACAGGCATGAACAGAGAC 2874 LTGMNRD 4117 122.335 382 AGTCACAACGCTGGGGTCGCC 2875 SHNAGVA 4118 122.285 383 GCGCACCAAACCGCCGGGCCA 2876 AHQTAGP 4119 122.22 384 AATTCTCATGATTTGAAGTAT 2877 NSHDLKY 4120 121.99 385 ACTACAATGAGTACCGGTCAA 2878 TTMSTGQ 4121 121.98 386 GGGTTCGGGCACGTGCCCGAA 2879 GFGHVPE 4122 121.974 387 ATCACCGCCGCGTCACCGCAA 2880 ITAASPQ 4123 121.868 388 GTTAAGGCGAGTGCTGGGGAT 2881 VKASAGD 4124 121.75 389 AGTATCACACACAGCAACACC 2882 SITHSNT 4125 121.75 390 CATAATAATAATATGCTGAAT 2883 HNNNMLN 4126 121.659 391 CCCAAAACTCTAACTTCGACA 2884 PKTLTST 4127 121.479 392 ATAACCGGCAACACCGTCGGA 2885 ITGNTVG 4128 121.385 393 CTCGGAAACCACTACACACCC 2886 LGNHYTP 4129 121.38 394 TCGTTTACTAATACGAATCCT 2887 SFTNTNP 4130 121.294 395 ACGTTGGATCGGAATCAGACT 2888 TLDRNQT 4131 121.25 396 ATCTCTACGCAAAGACCGCAC 2889 ISTQRPH 4132 121.2071 397 ACATTCACTACTCTGGGCAAA 2890 TFTTLGK 4133 121.179 398 GAGAAGCCTTCTCTTGTGATG 2891 EKPSLVM 4134 120.927 399 CACATCGAAACCAACACTTCG 2892 HIETNTS 4135 120.834 400 GGTACGAAGGATATTCTGATT 2893 GTKDILI 4136 120.792 401 GCGACTTTTAGTCATGCTGGT 2894 ATFSHAG 4137 120.788 402 GCCAACGGCATATTCCAACCG 2895 ANGIFQP 4138 120.646 403 CTTAATGTGAATACGCTTAAT 2896 LNVNTLN 4139 120.55 404 ACTTCTGCTAGTGAGAATTGG 2897 TSASENW 4140 120.5 405 CTTCTTCAGGGTGCGACTAAG 2898 LLQGATK 4141 120.358 406 GCTCTTGAGACTACTCGTGCT 2899 ALETTRA 4142 120.26 407 TTAACGGGACAAAACGAATTC 2900 LTGQNEF 4143 120.24 408 ATTTCTCATGATTTGAAGAAT 2901 ISHDLKN 4144 120.191 409 GCACAATACAACAACGGCGTA 2902 AQYNNGV 4145 120.19 410 ACGACGTCTGTGGAGAAGACT 2903 TTSVEKT 4146 120.106 411 GGTACGTCGGCTATTATGCCT 2904 GTSAIMP 4147 120.093 412 CAGCTGCAGGGGACTGAGGCG 2905 QLQGTEA 4148 120.02 413 GCCTTAAAATCCCAAGAACCA 2906 ALKSQEP 4149 120.007 414 TCTAACAGCAGTGTTGCGGTA 2907 SNSSVAV 4150 119.89 415 AATCATGGTCGTGCTATTGAT 2908 NHGRAID 4151 119.776 416 GATACGTATAATAGTAATACT 2909 DTYNSNT 4152 119.6 417 ACATTCCACCAAGCGGTCAAA 2910 TFHQAVK 4153 119.54 418 TGGCATACTGGTGTGTTTCAG 2911 WHTGVFQ 4154 119.48 419 AGGGGTGATCTTTCTACGCCA 2912 RGDLSTP 4155 119.47 420 ATGCTTAGTCAGGTTCTGACG 2913 MLSQVLT 4156 119.414 421 GAAAACGAAAAACGAGAAAGC 2914 ENEKRES 4157 119.391 422 ATTTCGAGTTATGATGGTAAT 2915 ISSYDGN 4158 119.38 423 ACTCGTGGCGACATGGAATTC 2916 TRGDMEF 4159 119.36 424 AATGTGCAGAATGTGCCTGGG 2917 NVQNVPG 4160 119.3363 425 TCTTTCACGAACACAAACCCA 2918 SFTNTNP 4161 119.24 426 TCGAACGCTGGCTACCACTCG 2919 SNAGYHS 4162 119.169 427 GACTACAAAAACAGCGCGCCA 2920 DYKNSAP 4163 119.136 428 GTCGGGAAAAACTCGTACGAA 2921 VGKNSYE 4164 119.129 429 GCTTACGCAGGTGTACTTGGG 2922 AYAGVLG 4165 119.123 430 ACGACGTCTGAGCGTGTGAAT 2923 TTSERVN 4166 119.105 431 GACACCGGAATCAAAAACGTT 2924 DTGIKNV 4167 119.05 432 TCGACCAGCTCTCTGGTTCCC 2925 STSSLVP 4168 119.006 433 TGGAGCGCCGGCGAACGGGTG 2926 WSAGERV 4169 118.995 434 AGTTCGGGGAGTTTGATTACT 2927 SSGSLIT 4170 118.945 435 TGGATTTCTACTGAGATGAGG 2928 WISTEMR 4171 118.93 436 TTTGCGGCTGGGGCGCATGGT 2929 FAAGAHG 4172 118.92 437 ATAGGCGACCGCGACCAACGT 2930 IGDRDQR 4173 118.886 438 AGTACGATTGGTAATTCTACT 2931 STIGNST 4174 118.8619 439 GGAAGTGGCACCGTCGGTCGA 2932 GSGTVGR 4175 118.714 440 CATGTTACGGCGGTGGTTGAT 2933 HVTAVVD 4176 118.706 441 GATAAGGCGGGGGTGGCTAAT 2934 DKAGVAN 4177 118.67 442 CGTCTGACTGATACTATGCAT 2935 RLTDTMH 4178 118.589 443 CTGAACACTCTAATCCACAAA 2936 LNTLIHK 4179 118.565 444 AGTTATCAGAATCCTCCGCCT 2937 SYQNPPP 4180 118.512 445 TTGACAGGATTAAACGCTTTC 2938 LTGLNAF 4181 118.45 446 AGTCCTGTGCTTTCTCCTTCG 2939 SPVLSPS 4182 118.377 447 GTTCAAACACACATAGGAGTC 2940 VQTHIGV 4183 118.36 448 CATATGTCTTCTGTTGCGACT 2941 HMSSVAT 4184 118.34 449 GGAAAAGCCAACGACGGTTCT 2942 GKANDGS 4185 118.333 450 AGTACTAACGACGAACGCAAA 2943 STNDERK 4186 118.28 451 CAGGGGGGGAATAGTCGGTTT 2944 QGGNSRF 4187 118.236 452 CCTAACAACGAAAAAAACCCG 2945 PNNEKNP 4188 118.22 453 GTGGCTGCGACGGGTGGTACT 2946 VAATGGT 4189 118.173 454 GCGATTGTGGATAGGGGGAGT 2947 AIVDRGS 4190 118.167 455 TCCCAACACCACACGCCACTG 2948 SQHHTPL 4191 118.137 456 TTACAAAGCTCGATGAACGTA 2949 LQSSMNV 4192 118.073 457 CGAGAAACCAACCCGTCTGAA 2950 RETNPSE 4193 117.941 458 GGGTTCGGGCACCTGCCCGAA 2951 GFGHLPE 4194 117.86 459 CGGAATGCTACTGTGACTGTT 2952 RNATVTV 4195 117.852 460 GTTTCAAACGCTTCGGGCTTA 2953 VSNASGL 4196 117.707 461 GATCGTCCGAATAATGAGTCG 2954 DRPNNES 4197 117.7 462 CAGGTTAGTCTGGTGAAGTTG 2955 QVSLVKL 4198 117.643 463 AGTAATATGCGTGAGGAGATT 2956 SNMREEI 4199 117.629 464 GATATTGGGCGTTCGAATAGT 2957 DIGRSNS 4200 117.45 465 GATCATATGAATTTGAGGTCT 2958 DHMNLRS 4201 117.365 466 ATTGAGCGTAGTAGTGATCGT 2959 IERSSDR 4202 117.358 467 TTGTCTCAGAATTTTAATCCT 2960 LSQNFNP 4203 117.3026 468 TATTCTATGGGTCAGCAGCCG 2961 YSMGQQP 4204 117.283 469 TACACACAAGGGATAATGAAC 2962 YTQGIMN 4205 117.22 470 ATGCTGTCTCATGGTGCGCTT 2963 MLSHGAL 4206 117.165 471 GCTTATAATGCTCGTCTGCCT 2964 AYNARLP 4207 116.957 472 AGACACTACTCCGACAACGCC 2965 RHYSDNA 4208 116.945 473 GCACACACAGCCATGACCTAC 2966 AHTAMTY 4209 116.935 474 CTAACAGGCTCTGACATGAAA 2967 LTGSDMK 4210 116.89 475 ACCTTACACACGAAAGACTTG 2968 TLHTKDL 4211 116.879 476 TCGGGTCAAAACGGTACATCA 2969 SGQNGTS 4212 116.851 477 CGTGGGGACGTCCACACCAAC 2970 RGDVHTN 4213 116.829 478 ACCGGAACGGCTACACTCCCA 2971 TGTATLP 4214 116.72 479 CTGGGTACGCTGCTTAGTCAG 2972 LGTLLSQ 4215 116.72 480 GTCCTCTCCTCCAACCTGTAC 2973 VLSSNLY 4216 116.707 481 AGTTTGGGGTCGGATCGTATG 2974 SLGSDRM 4217 116.61 482 AGGGGAGATCTTTCTACGCCT 2975 RGDLSTP 4218 116.59 483 AGGATGTCGGAGAGTTCTGAT 2976 RMSESSD 4219 116.585 484 ATGACTGAGAAGGCTTCTATT 2977 MTEKASI 4220 116.54 485 ACAGAACAATCTTACTAACGA 2978 TEQSY*R 4221 116.54 486 GTTGAATCTAAATCCGAACCA 2979 VESKSEP 4222 116.536 487 ATGAATCTTGTGAGGGATTCG 2980 MNLVRDS 4223 116.526 488 CAAAACCACTCTATAACAACA 2981 QNHSITT 4224 116.51 489 ACGCTGGACAACAACCACAGC 2982 TLDNNHS 4225 116.42 490 ACGAAGAGTTTTAATGATCTT 2983 TKSFNDL 4226 116.38 491 GCCACAGAACACTCAGGGCGC 2984 ATEHSGR 4227 116.34 492 CAAGGGACTCTCTTGTCTCCA 2985 QGTLLSP 4228 116.293 493 ACATTCCACCAAGGGGTCAAA 2986 TFHQGVK 4229 116.175 494 TGTCAGCGGGCTGATTGTGCG 2987 CQRADCA 4230 116.17 495 CGGTATGATGGTACTCTTAAT 2988 RYDGTLN 4231 115.929 496 CAAGGCGGTACAAACAACCCC 2989 QGGTNNP 4232 115.853 497 GGGGGTAACTACCACACCACT 2990 GGNYHTT 4233 115.838 498 CTGGTTGTTCAGAGTGCGCAG 2991 LVVQSAQ 4234 115.7942 499 TATCCTCATGAGAGTAAGAAT 2992 YPHESKN 4235 115.731 500 GAGATTGTTAGGCATACGCAT 2993 EIVRHTH 4236 115.724 501 GACCGGACAAACAACATGAGC 2994 DRTNNMS 4237 115.705 502 TCCGTAACCAACGGAGCGGAA 2995 SVTNGAE 4238 115.66 503 AGCGGACAAAAAAACTCAGAA 2996 SGQKNSE 4239 115.653 504 GAGCAGAAGAAGACTGATCAT 2997 EQKKTDH 4240 115.565 505 AATATTAATGGTGGGGGGAAT 2998 NINGGGN 4241 115.563 506 AAGCTGCATACTAAGGATCTT 2999 KLHTKDL 4242 115.54 507 AGCTTCTTGGTAGCCCACCCA 3000 SFLVAHP 4243 115.4 508 TACCAACAAAACATAGAAATC 3001 YQQNIEI 4244 115.388 509 AGGGGTGATCTTTCTACGACT 3002 RGDLSTT 4245 115.31 510 GCGAACCTCAACTTGACCAGT 3003 ANLNLTS 4246 115.305 511 ACGGTGCAGCATGCGGCGACG 3004 TVQHAAT 4247 115.231 512 ACCGTAAACCTCCTAGCGGCA 3005 TVNLLAA 4248 115.223 513 AACCAAAGAGTTGAACAAAAA 3006 NQRVEQK 4249 115.222 514 AATACTTATACTGCTGCGAAG 3007 NTYTAAK 4250 115.189 515 ATCCAAAGAGACGTGGGCCAC 3008 IQRDVGH 4251 115.098 516 ATCTCAGAAATGACTAGGTAC 3009 ISEMTRY 4252 115.098 517 ATTGCTACTAATGTGATTTAT 3010 IATNVIY 4253 115.089 518 AACGGCAACCACTCCATAGAC 3011 NGNHSID 4254 115.062 519 ACGAGTATTGGTAGTGCTAAG 3012 TSIGSAK 4255 115.036 520 AACGTACACTCTGTTGACAAA 3013 NVHSVDK 4256 114.987 521 GAACTCTCCGTTCCGAAACCA 3014 ELSVPKP 4257 114.93 522 TTCCTCGACAAATACAACTAC 3015 FLDKYNY 4258 114.888 523 TACATCCCGAACAACTCAGGA 3016 YIPNNSG 4259 114.881 524 GGGCTAGGACAACCCCAACTC 3017 GLGQPQL 4260 114.817 525 GAGGGGAGTCAGGGGAATCAT 3018 EGSQGNH 4261 114.66 526 AATATTTATATGGCGAGTGGT 3019 NIYMASG 4262 114.66 527 AATTTGCAGACTGGTGTTCAG 3020 NLQTGVQ 4263 114.65 528 ACCGTCGCTCCCTACAGTAGC 3021 TVAPYSS 4264 114.65 529 TCAAACTACTCTGACGGAATA 3022 SNYSDGI 4265 114.649 530 GCTACTTACGTTGTCGGAACA 3023 ATYVVGT 4266 114.64 531 TCAAGGGAAGCGGGTTCAACT 3024 SREAGST 4267 114.622 532 GCCGGAAAAACCCACGCCGAC 3025 AGKTHAD 4268 114.6 533 CCGCTTTCTCTTCATAATAGT 3026 PLSLHNS 4269 114.589 534 CTTCGAGACCTAAACGGAGGA 3027 LRDLNGG 4270 114.553 535 GATAGGACGTATTCGAATACG 3028 DRTYSNT 4271 114.548 536 TCGGTCACCAGTGGAACACAA 3029 SVTSGTQ 4272 114.541 537 AATATGACTTCGGCTTATCAT 3030 NMTSAYH 4273 114.52 538 GTTATGGGTGGTCCTGGGATT 3031 VMGGPGI 4274 114.491 539 GCTGGGACTCATACTGATAAG 3032 AGTHTDK 4275 114.444 540 GGTACTATGAATATTGGTATT 3033 GTMNIGI 4276 114.356 541 ACAGCCGGCGGCGAACGCGCC 3034 TAGGERA 4277 114.34 542 GGTATGACTTCTAATCAGGTT 3035 GMTSNQV 4278 114.298 543 CATTTTTCGCAGATTACTAAT 3036 HFSQITN 4279 114.278 544 AGCAGGATAGAAAACAACAAC 3037 SRIENNN 4280 114.055 545 GATACGGCGAGTTATAATAAT 3038 DTASYNN 4281 114 546 GTGAATCAGAGTCCTGGGGCT 3039 VNQSPGA 4282 113.85 547 AATAATATGGGTCATGGTCAT 3040 NNMGHGH 4283 113.837 548 TCGCGGCTATCACAAGACCCC 3041 SRLSQDP 4284 113.832 549 TCTACGTCTCAGGCTGTGCAG 3042 STSQAVQ 4285 113.802 550 CGATGGCAAGGACTGAGCGCG 3043 RWQGLSA 4286 113.76 551 GCGCATATGCATTCGGAGTTG 3044 AHMHSEL 4287 113.74 552 AATAATCTTACGAATTCGACG 3045 NNLTNST 4288 113.736 553 CAGCCTAGTGCGAGTGAGCTT 3046 QPSASEL 4289 113.731 554 GGGACTTCCTTGGAAAACCGA 3047 GTSLENR 4290 113.709 555 CTGTCTAATTCGATTACGCCT 3048 LSNSITP 4291 113.683 556 ACCATAGTGTCCACTTCTTAC 3049 TIVSTSY 4292 113.628 557 ACCCTAGGCTACCCAGACAAA 3050 TLGYPDK 4293 113.563 558 TCAAGACACGACGTCCGAAAC 3051 SRHDVRN 4294 113.559 559 AATGGTAGTGTGGCTAATCCT 3052 NGSVANP 4295 113.48 560 GCGATGGATGGGTATAGGGTT 3053 AMDGYRV 4296 113.462 561 TGGACGGGCGCACAACCTTCT 3054 WTGAQPS 4297 113.3493 562 AAAAACGGCGCCATAGGAACA 3055 KNGAIGT 4298 113.335 563 GTACTTCCAAGTCGGATCGCG 3056 VLPSRIA 4299 113.3 564 GATAATGTGAATTCTCAGCCT 3057 DNVNSQP 4300 113.207 565 GGCGTAAACGCTAGCTACAGC 3058 GVNASYS 4301 113.174 566 CTGTCTCACGCCATGGACCGG 3059 LSHAMDR 4302 113.127 567 AGGGCTCATGGGGATAATCAG 3060 RAHGDNQ 4303 113.036 568 TTGCAGACGCCTGGGACGACG 3061 LQTPGTT 4304 113.01 569 ACTCAGGTTGTTAGTATTTAT 3062 TQVVSIY 4305 113.001 570 CAGGTTCAGGGGACTCTGGGG 3063 QVQGTLG 4306 112.9928 571 GTGGGCAACCAAAACTTACCC 3064 VGNQNLP 4307 112.889 572 TATGTTGATTATAGTAAGTCG 3065 YVDYSKS 4308 112.872 573 CTGCTTAATTCTTCGGGTGTG 3066 LLNSSGV 4309 112.857 574 AATCAGTCGCTTACTATGGAT 3067 NQSLTMD 4310 112.793 575 GCTGGTAAGGATCTTAGTAAT 3068 AGKDLSN 4311 112.792 576 TCTTACGTTAGCGTCCCCGCC 3069 SYVSVPA 4312 112.668 577 AATGAGGGGCGTGTGCAGACT 3070 NEGRVQT 4313 112.6219 578 ACTTTGACGCAGACTGGGATG 3071 TLTQTGM 4314 112.588 579 GGCTTCGCATTAACTGGCACC 3072 GFALTGT 4315 112.564 580 CAGTCGACGCTGAATAGGCCT 3073 QSTLNRP 4316 112.5575 581 ACAACAACACACTCCATCTCC 3074 TTTHSIS 4317 112.547 582 AACACACACAGACAAGAATAC 3075 NTHRQEY 4318 112.522 583 TCCCAAATAGTCAACACCACA 3076 SQIVNTT 4319 112.519 584 CTGGTGCTTGAGATGCAGACG 3077 LVLEMQT 4320 112.492 585 AACGACATCTCCACCCAACGG 3078 NDISTQR 4321 112.444 586 TACACCGCCGACAAAAAACAA 3079 YTADKKQ 4322 112.402 587 TTCGGAGCAACCACCACAGCA 3080 FGATTTA 4323 112.399 588 GTTCAGATTTCTATGAATAAT 3081 VQISMNN 4324 112.364 589 ATGCATGCGCAGGAGTCTCGT 3082 MHAQESR 4325 112.324 590 CATGTGAATACTGCTGATCGG 3083 HVNTADR 4326 112.313 591 TACAGTACAGACTCCACCAAA 3084 YSTDSTK 4327 112.271 592 GGACACGACCGAACACCAAAC 3085 GHDRTPN 4328 112.213 593 ACGAGTGGTGTGCTTACGCGG 3086 TSGVLTR 4329 112.212 594 AATATTGCTATGTCTAAGATT 3087 NIAMSKI 4330 112.204 595 ATGGGGACTGAGTATCGTATG 3088 MGTEYRM 4331 112.185 596 CCTTATGCGAATAGGCTTGAG 3089 PYANRLE 4332 112.174 597 CCGCTTCAGAATAATAAGACG 3090 PLQNNKT 4333 112.172 598 TCCTTGACGGAAAAAGCGCCG 3091 SLTEKAP 4334 112.15 599 AATATGGTGTATACGAATGTG 3092 NMVYTNV 4335 112.077 600 ATGTTAAGTGCCACCCAAGGG 3093 MLSATQG 4336 112.047 601 AACATGACTCACTCAACCGTA 3094 NMTHSTV 4337 112.0108 602 ATTTATACGAATAGTCATGTT 3095 IYTNSHV 4338 111.93 603 TGGTCGCATGATCGGCCTACT 3096 WSHDRPT 4339 111.926 604 GAAAAAGGCACACCAAGTAGC 3097 EKGTPSS 4340 111.922 605 CATCATTCTACTGAGTCGTTG 3098 HHSTESL 4341 111.911 606 CCAAAAAGCACCCAAGTAATG 3099 PKSTQVM 4342 111.846 607 AGTGATAGGACTGCTCAGCAG 3100 SDRTAQQ 4343 111.845 608 GCTACCCTCGCACGGACCTCA 3101 ATLARTS 4344 111.8417 609 ATTTCTCAGGTGTCTTTTAAT 3102 ISQVSFN 4345 111.81 610 CATTATGGGAATAAGGATATT 3103 HYGNKDI 4346 111.805 611 AATGATGGGACTGATCGTAGG 3104 NDGTDRR 4347 111.574 612 ACCAACCACATAACCGGTCCA 3105 TNHITGP 4348 111.551 613 ACTAATTCTAATCAGAGTTCG 3106 TNSNQSS 4349 111.532 614 GTGGCGACTCATTATAATGAG 3107 VATHYNE 4350 111.52 615 GACCTCGGTACGGCTAGAACC 3108 DLGTART 4351 111.516 616 GCTCTTAGTCAGAGTGCGGGT 3109 ALSQSAG 4352 111.4957 617 AAAACCACCCTACACCAAGCA 3110 KTTLHQA 4353 111.46 618 ATGATAAACGCCATAACTCCA 3111 MINAITP 4354 111.432 619 GGGTCTACGCCGGGGGCGAGT 3112 GSTPGAS 4355 111.327 620 AATGAGAAGCCGCAGTCGACG 3113 NEKPQST 4356 111.309 621 TCATTGATGGGCAGTGCAGGA 3114 SLMGSAG 4357 111.287 622 ACCGACACGCTCAGCGAAAGA 3115 TDTLSER 4358 111.25 623 GCCTCGCAATCAGAAAAAAAC 3116 ASQSEKN 4359 111.223 624 GCTGTTAGAACACCGGCAATG 3117 AVRTPAM 4360 111.215 625 CCTAATGCTAGTTTTGGTCCG 3118 PNASFGP 4361 111.172 626 AAAGCCCACGTTGTAGAAATA 3119 KAHVVEI 4362 111.166 627 TATATTTCGGCGCCTCCGATG 3120 YISAPPM 4363 111.15 628 CCAATCCAAAACGAATCGTCC 3121 PIQNESS 4364 111.128 629 GGCGTAACCAACGCTTCCAAA 3122 GVTNASK 4365 111.107 630 GTAAACGGGGGAAAACCAGTC 3123 VNGGKPV 4366 111.096 631 AGTGTTCTGAGTAGTTCGACT 3124 SVLSSST 4367 111.07 632 TTAGCACAAGGCACGGACCGG 3125 LAQGTDR 4368 111.032 633 CAGTCTGTGTCGACTGGGGCG 3126 QSVSTGA 4369 110.982 634 TTGACGCAGGTTTATCATGAG 3127 LTQVYHE 4370 110.91 635 AGAGAAATGAGCAGCCTATCT 3128 REMSSLS 4371 110.891 636 ACGAGTACGATGACTGCGCGT 3129 TSTMTAR 4372 110.835 637 ACTATTCAGCAGGTTAGTAAT 3130 TIQQVSN 4373 110.832 638 AGGACGCAAGCAGGGGACTCA 3131 RTQAGDS 4374 110.83 639 AATACTTATACTGCTGGGAAG 3132 NTYTAGK 4375 110.816 640 AATGAGCAGAATACGCCGAGT 3133 NEQNTPS 4376 110.79 641 GGATTCGCCCAACAAGAAGCG 3134 GFAQQEA 4377 110.775 642 AGTCCGCAGCATGGTGTTATT 3135 SPQHGVI 4378 110.7 643 GCAGTCCACGCAACATCATCA 3136 AVHATSS 4379 110.653 644 GGAGACACCCGTGGTGCACAC 3137 GDTRGAH 4380 110.63 645 GTAAGAGAAACCACACACCTC 3138 VRETTHL 4381 110.627 646 CTTTCTCAACAACGCGACTAC 3139 LSQQRDY 4382 110.6 647 GCGACTAGGGGTGAGTCGTCT 3140 ATRGESS 4383 110.56 648 ACTAATGATTCTGTGGGTAGT 3141 TNDSVGS 4384 110.545 649 CTTACTAATAATTTTAAGGAT 3142 LTNNFKD 4385 110.519 650 GTGAATGGGACTCAGATTTTT 3143 VNGTQIF 4386 110.47 651 GGTAATACTGGGAGTCCGGGG 3144 GNTGSPG 4387 110.431 652 TGGACAGCTAACCAAGGCTTA 3145 WTANQGL 4388 110.43 653 AATACTACTCCGACGAATCAT 3146 NTTPTNH 4389 110.42 654 GAACGAGTCAACGGGATGGCA 3147 ERVNGMA 4390 110.405 655 AAAGTCACAAACAACGCATAC 3148 KVTNNAY 4391 110.363 656 TTATCCTCCGAATCACCCAGG 3149 LSSESPR 4392 110.346 657 CATACGGCGGCGGTTGCTACT 3150 HTAAVAT 4393 110.27 658 TACGACAGCCGACTCTACGCG 3151 YDSRLYA 4394 110.263 659 ATAGAACACATGCTTAGACCC 3152 IEHMLRP 4395 110.221 660 TACCTAGAATCCAACTACACC 3153 YLESNYT 4396 110.18 661 GCGTACTCATCTACCGGGCAC 3154 AYSSTGH 4397 110.176 662 ATCGACATATCGACGCAAAGC 3155 IDISTQS 4398 110.14 663 ACAACAAACTCAGGCGCGACG 3156 TTNSGAT 4399 110.139 664 AACGTGCTAACCACGGTTGTC 3157 NVLTTVV 4400 110.107 665 ACAACCGGAATCGAACGTTCC 3158 TTGIERS 4401 110.106 666 GCACGAGTGGACACCAACCAA 3159 ARVDTNQ 4402 110.09 667 CAGAGTGTGAAGGAGGCGATT 3160 QSVKEAI 4403 110.069 668 GCGTTGCTTAGTGTGAATGAG 3161 ALLSVNE 4404 110.013 669 GGGCGTGATAATCATCATGCG 3162 GRDNHHA 4405 109.959 670 ATTCAGTCGCAGTCGCAGTTG 3163 IQSQSQL 4406 109.941 671 AGTGAGGGTAGTTCGCGGTCG 3164 SEGSSRS 4407 109.9403 672 GACGTCCAAAACATACGCGAA 3165 DVQNIRE 4408 109.921 673 AAAGGCCACGCCTACGAAGCC 3166 KGHAYEA 4409 109.897 674 TATGTTAGGGCGCAGGATCAG 3167 YVRAQDQ 4410 109.876 675 GTCGACGAATACCGAAGCCGC 3168 VDEYRSR 4411 109.853 676 ACTCTCTCAGGCTACATGAGA 3169 TLSGYMR 4412 109.808 677 CCTAGTGTCCGTTTGCCCTTA 3170 PSVRLPL 4413 109.742 678 AACATAGCAGGCGGAGAACAA 3171 NIAGGEQ 4414 109.702 679 CTGCTCCAATCGACCTACTTG 3172 LLQSTYL 4415 109.672 680 CAGTCGGATACGACTTCGATT 3173 QSDTTSI 4416 109.605 681 ATTAGGTCTGGGAATGCGATG 3174 IRSGNAM 4417 109.554 682 ATGCTGTCTCAAGTCTTAACA 3175 MLSQVLT 4418 109.536 683 ACAGAACGCCAAATCGAATTA 3176 TERQIEL 4419 109.488 684 GGAACCCACGCCTCAGCATAC 3177 GTHASAY 4420 109.477 685 GTTGAGTCTTCTTATTCTCGG 3178 VESSYSR 4421 109.457 686 GGTGGGAATTATCATACTAAG 3179 GGNYHTK 4422 109.445 687 CCCACCAGTCACCAAGAACCC 3180 PTSHQEP 4423 109.418 688 ACCATAATCGGTGTCTTACCC 3181 TIIGVLP 4424 109.381 689 TCTAACAGCGGTTCTACCCTC 3182 SNSGSTL 4425 109.379 690 TCGATAACGACCGTAGCGAAC 3183 SITTVAN 4426 109.347 691 GCGTCTCCGGCGCAGACCGGC 3184 ASPAQTG 4427 109.331 692 TCGTTGCCGAGTCATAGTAAT 3185 SLPSHSN 4428 109.3106 693 CTACACAACGCCGTCGGACCC 3186 LHNAVGP 4429 109.307 694 CAAGCCCCGCCAACAGCACAA 3187 QAPPTAQ 4430 109.294 695 CCTAATACTGCTAGTAATTTT 3188 PNTASNF 4431 109.249 696 CCCTCCAACAGTGAAAGATTC 3189 PSNSERF 4432 109.227 697 GAACTCCACGCACAACAACCA 3190 ELHAQQP 4433 109.194 698 GGTTCTTATTCTGATGGTAGT 3191 GSYSDGS 4434 109.162 699 TATGGTGTGCAGGCGAATAGT 3192 YGVQANS 4435 109.152 700 GAAGTAGGTAAAACCACCCAC 3193 EVGKTTH 4436 109.116 701 ACTTCGCAGGGTAGGAGTCCT 3194 TSQGRSP 4437 109.097 702 GTAGAACACGTAGCCCACCAA 3195 VEHVAHQ 4438 109.092 703 ATCCAAAGCAGCTACAACCGC 3196 IQSSYNR 4439 109.073 704 ACGCTATCGGTTACCCTGGGT 3197 TLSVTLG 4440 109.046 705 CGGAATGAGCCGGTTAGTACT 3198 RNEPVST 4441 108.981 706 GTGATTGTGGGGAGTAATGAG 3199 VIVGSNE 4442 108.955 707 GAGCTGTCTACTCCTATGGTT 3200 ELSTPMV 4443 108.948 708 GCTTACAACGACCTACGATCA 3201 AYNDLRS 4444 108.942 709 AACGCGAACTCCGGTGAACGA 3202 NANSGER 4445 108.906 710 TTGTCATCACAATGGACACAA 3203 LSSQWTQ 4446 108.9 711 ATCAACGCCGGCAACTACCGA 3204 INAGNYR 4447 108.883 712 CTGAGGTCGAGTGAGGCTCCG 3205 LRSSEAP 4448 108.866 713 ACGTCTGATACGAATGCTAGG 3206 TSDTNAR 4449 108.858 714 CCGAATTCTCCGCATGGTTCT 3207 PNSPHGS 4450 108.84 715 ACCCAACACCTACCATCCACA 3208 TQHLPST 4451 108.803 716 GTGCATGGGAATGCTCCGGCT 3209 VHGNAPA 4452 108.783 717 TCTTCTCAGCGTGATTCTGTT 3210 SSQRDSV 4453 108.754 718 CCCCCCTCAGTTGACCGAAAA 3211 PPSVDRK 4454 108.751 719 GAGACTCTGCCGTATAAGAGT 3212 ETLPYKS 4455 108.728 720 CATCTTAGTCAGGCTAATCAT 3213 HLSQANH 4456 108.727 721 AAACCGCTAAACGGTACCAAC 3214 KPLNGTN 4457 108.683 722 TGGCAAACCAACGGCATGCAA 3215 WQTNGMQ 4458 108.68 723 ACCGTGAACGTCCACTCCGAC 3216 TVNVHSD 4459 108.659 724 ACCCAATACGTCGTTGCCCCT 3217 TQYVVAP 4460 108.64 725 AACGTCGACTCCTCTAACGTG 3218 NVDSSNV 4461 108.62 726 AACGGATACCAACTACAAATC 3219 NGYQLQI 4462 108.573 727 GAAGAAACACGGACCAGAATG 3220 EETRTRM 4463 108.571 728 ACCTCTCCAGCCTCTGACCGG 3221 TSPASDR 4464 108.552 729 CATAGTGGTGCTGGGGTTCTG 3222 HSGAGVL 4465 108.539 730 GCTGCTAATCCTAGTACGGAG 3223 AANPSTE 4466 108.527 731 ATGTTGGTACAAAACACACCC 3224 MLVQNTP 4467 108.482 732 GTGCAGCAGAATAATATTAAT 3225 VQQNNIN 4468 108.473 733 CATGATGGTTATGTTCCTAAT 3226 HDGYVPN 4469 108.469 734 AACTCAGGTAACAACCCCATC 3227 NSGNNPI 4470 108.467 735 ACGGACAACCCGTCCTACAAA 3228 TDNPSYK 4471 108.453 736 GGAGGCTTAAGTTTATCCTCG 3229 GGLSLSS 4472 108.431 737 AATAATGAGAATACGCGTAAT 3230 NNENTRN 4473 108.418 738 AAGAATAATAATTCTGATTCT 3231 KNNNSDS 4474 108.367 739 AAGGATGAGCATCTTCATTAT 3232 KDEHLHY 4475 108.358 740 AATTTTACTATTACGGAGGCG 3233 NFTITEA 4476 108.32 741 TTGAACCAAAACAGTGTCTCC 3234 LNQNSVS 4477 108.304 742 AATTCTCATGTTCCTAATAAT 3235 NSHVPNN 4478 108.289 743 AATTCTACGCATATTAATTCG 3236 NSTHINS 4479 108.2563 744 CATATGTCTAGTTATTCGTCG 3237 HMSSYSS 4480 108.253 745 AACGTACCCAACGGACAAGGA 3238 NVPNGQG 4481 108.25 746 AACGGTCCGACCGGATCCGCC 3239 NGPTGSA 4482 108.245 747 AAAAGCAACGCGGGATTCGGT 3240 KSNAGFG 4483 108.23 748 GCGGCCGCACTAGAAACAATA 3241 AAALETI 4484 108.223 749 AACCGTCAAAGGGACTTCGAA 3242 NRQRDFE 4485 108.196 750 GGGTCAGGGAACGAACCCGGG 3243 GSGNEPG 4486 108.192 751 GTTAGTGTGGCTGTGCCTGCG 3244 VSVAVPA 4487 108.11 752 CACTCTAACACACACTACGAA 3245 HSNTHYE 4488 108.11 753 CCTGACAGAGCGAACGACAAA 3246 PDRANDK 4489 108.058 754 CAAGTTGGGGCTCTAATGGTT 3247 QVGALMV 4490 108.037 755 TTAACACCCCAAGGGACTAGT 3248 LTPQGTS 4491 108.028 756 CTATACGACGGAAAACACGTC 3249 LYDGKHV 4492 107.972 757 CTAACCGAATCTGTGAGAAAC 3250 LTESVRN 4493 107.93 758 AGTACTTATGGGAATACTTAT 3251 STYGNTY 4494 107.929 759 AATGCTATTTCTACTAATAAT 3252 NAISTNN 4495 107.907 760 ATTGCTCATGTGTCTACTAAT 3253 IAHVSTN 4496 107.849 761 AGTGAGGAGAGGACGCGTGCG 3254 SEERTRA 4497 107.833 762 CGTTGGTCTGAAAACAACTCC 3255 RWSENNS 4498 107.83 763 GATGGTAATAATACGACTTAT 3256 DGNNTTY 4499 107.748 764 GTGACGACTGTTGATAGTGCT 3257 VTTVDSA 4500 107.738 765 ACCGTAAAACAAACAAGTCCG 3258 TVKQTSP 4501 107.7213 766 TCTATCTACCTCGCGTCCACT 3259 SIYLAST 4502 107.712 767 ACGACCCGAAACGAACACTCG 3260 TTRNEHS 4503 107.707 768 TCGTATGATATGCATACGAAT 3261 SYDMHTN 4504 107.705 769 GTCTCTACATACCTCCTGGCA 3262 VSTYLLA 4505 107.687 770 GGAGAACAAAGCCACAACCAA 3263 GEQSHNQ 4506 107.684 771 ACTGCCAACAACCACTCTCCG 3264 TANNHSP 4507 107.671 772 CAATTCCACGGGACATCTGAA 3265 QFHGTSE 4508 107.652 773 AACGTTCTGGGAGCGTCTAGC 3266 NVLGASS 4509 107.64 774 AGGGATAGTACTATTAGTCGG 3267 RDSTISR 4510 107.635 775 GTTATTGGGACTTCTAGGGAT 3268 VIGTSRD 4511 107.5934 776 AATTATGAGAAGGAGTTTGTT 3269 NYEKEFV 4512 107.592 777 ATGGACCAAAGCCACTCCCGA 3270 MDQSHSR 4513 107.563 778 AATTCTCAGAATCCTCAGGGT 3271 NSQNPQG 4514 107.562 779 CACACGGGCACGGACAACCGA 3272 HTGTDNR 4515 107.5323 780 TATAATACTGTTGATCAGCGG 3273 YNTVDQR 4516 107.523 781 AAAGAAAGCCTCGAAGACGTC 3274 KESLEDV 4517 107.49 782 ACTGCGAATAGTACGTATGTG 3275 TANSTYV 4518 107.479 783 TATCTGAATAGTACGCAGATT 3276 YLNSTQI 4519 107.436 784 CGTGTTGAAGACACCAACTCC 3277 RVEDTNS 4520 107.416 785 AACGACGCACGCAACCGTGCA 3278 NDARNRA 4521 107.37 786 AATACTAATAATCAGGAGCAG 3279 NTNNQEQ 4522 107.332 787 ACCGTCGGATCGAACAGTATA 3280 TVGSNSI 4523 107.3 788 TATGGGGAGCGTGCTAGGACG 3281 YGERART 4524 107.297 789 CCGACCGGAGGCTCACCACCA 3282 PTGGSPP 4525 107.265 790 CTTGGGCAGGTTAATTCTACG 3283 LGQVNST 4526 107.229 791 GTCTCGGGTCCGGTATCGGTC 3284 VSGPVSV 4527 107.222 792 GGTACTAATCATGATTTTTCG 3285 GTNHDFS 4528 107.169 793 AAGACGCTTGATAATAATGCT 3286 KTLDNNA 4529 107.165 794 CACAGTGAACTACGTCAAAAC 3287 HSELRQN 4530 107.157 795 GAGAAGAATCTGACTAATGCT 3288 EKNLTNA 4531 107.131 796 ACCGGACTCGGAGGCAACAGT 3289 TGLGGNS 4532 107.113 797 AAAGACCACATCCTCAGCCTC 3290 KDHILSL 4533 107.108 798 ATAACTACTGGCGGAGTGCTA 3291 ITTGGVL 4534 107.108 799 CTGGCTGATTCGAATTCTAAG 3292 LADSNSK 4535 107.1 800 AGTATTTCTGATAAGAATCAG 3293 SISDKNQ 4536 107.08 801 TATATTGCTGGGGGGGAGCAG 3294 YIAGGEQ 4537 107.069 802 TTGCCGGATAAGGGGCGGATT 3295 LPDKGRI 4538 107.06 803 TTGATCCAAACGCAAGGCACG 3296 LIQTQGT 4539 107.042 804 TACTCCGGAGAACTAAACAAA 3297 YSGELNK 4540 107.037 805 TGCGCATCAGAAGTTTGCCAA 3298 CASEVCQ 4541 107.035 806 CTTATGGCTGCTAATACTGCG 3299 LMAANTA 4542 107.032 807 CATCAGTCTTTTGATGCTGGT 3300 HQSFDAG 4543 107.001 808 GGGGAGACGCTGAGGTCTCAG 3301 GETLRSQ 4544 106.999 809 CAGACTGATGGTCCTAATTTT 3302 QTDGPNF 4545 106.978 810 ACGACGACTAATGTGAATTTT 3303 TTTNVNF 4546 106.969 811 AACATGACCAACGAAAACGGA 3304 NMTNENG 4547 106.938 812 GGGTATAGTCCTTCGACGCCG 3305 GYSPSTP 4548 106.892 813 TTGCAGGTTACGGTTCATAAT 3306 LQVTVHN 4549 106.879 814 GATCTGACGCATGTTCATCGT 3307 DLTHVHR 4550 106.874 815 ACGGAGCTTAGTGAGTATACT 3308 TELSEYT 4551 106.852 816 ATGACAGTCGCCAGTACTAGC 3309 MTVASTS 4552 106.843 817 AGCAGTCAAGCCCACGGCCCA 3310 SSQAHGP 4553 106.822 818 ACCAGAAGCCCGAACGAAGAC 3311 TRSPNED 4554 106.81 819 GATAATAATAAGCATGGTACT 3312 DNNKHGT 4555 106.806 820 AGGGAGATTGTTCATAGTAAT 3313 REIVHSN 4556 106.802 821 CGGAAACTTGAACTCGACCTA 3314 RKLELDL 4557 106.801 822 ATCTACGAAACCGTAACCTTG 3315 IYETVTL 4558 106.801 823 AATAGTGGTAGTACGAGTTTT 3316 NSGSTSF 4559 106.783 824 CCAAGTACGAACGAAAGCCGC 3317 PSTNESR 4560 106.782 825 CAAGCCGACCTCAGGTACAAA 3318 QADLRYK 4561 106.773 826 GATCAGCCGGGGTATGTGCGT 3319 DQPGYVR 4562 106.7387 827 GATGCTATGCTTGCTCATCCG 3320 DAMLAHP 4563 106.735 828 ACACGTCACGACGGCAGTACG 3321 TRHDGST 4564 106.675 829 CTGGCGAATATGAGTGCGCCG 3322 LANMSAP 4565 106.664 830 ACTGGTCATCCGCCGGCGGCG 3323 TGHPPAA 4566 106.654 831 TCGAGTATTAGTCTGCGGTAT 3324 SSISLRY 4567 106.645 832 ATGCACGTCGACAAAACGAGT 3325 MHVDKTS 4568 106.639 833 GGGAGTGATTCTAAGCATCCT 3326 GSDSKHP 4569 106.5782 834 GGAGAAAGCTCCTCAATAAGC 3327 GESSSIS 4570 106.551 835 GTCGTCCACTCACACAGTGAA 3328 VVHSHSE 4571 106.496 836 AGTGTGCGGGCGCATGTTTTG 3329 SVRAHVL 4572 106.487 837 GCGGATGGGGCTAAGTCTGCT 3330 ADGAKSA 4573 106.485 838 GGGGAAGCACGCCGAGAAGCC 3331 GEARREA 4574 106.442 839 TTTAATGCTACGGTGGTGCAT 3332 FNATVVH 4575 106.437 840 TGGACGGAAGGGGGCTCAGGA 3333 WTEGGSG 4576 106.423 841 GATTCTTCTTATACGCATCCG 3334 DSSYTHP 4577 106.422 842 TTCCCAAGTAGGGACAACGTA 3335 FPSRDNV 4578 106.39 843 GCCATCACGCACATCGGTACA 3336 AITHIGT 4579 106.365 844 GCTTTTAAGTCGGGTAGTATT 3337 AFKSGSI 4580 106.334 845 ATGTCAAACGCCTCCTACATA 3338 MSNASYI 4581 106.319 846 GCGGAGAGGAATGATAGGACG 3339 AERNDRT 4582 106.305 847 ACATTAGAAACAACCCGCAGC 3340 TLETTRS 4583 106.244 848 CGCTTACACGGCTCAGACTCG 3341 RLHGSDS 4584 106.237 849 TATGAGGGGCATATGAATACT 3342 YEGHMNT 4585 106.2354 850 TCTGTGACGACTAATCTGATG 3343 SVTTNLM 4586 106.217 851 TTGCGTGATCAGACTAGTATG 3344 LRDQTSM 4587 106.167 852 CCCGCCAGTCACAGCGCGGGA 3345 PASHSAG 4588 106.151 853 GTGGTTGAGAATTTGAGGCAG 3346 VVENLRQ 4589 106.147 854 CAACAATCACAAAACTCTATA 3347 QQSQNSI 4590 106.115 855 CTTGTTGATACGGATAGGAAT 3348 LVDTDRN 4591 106.108 856 AACGAAATGGGAAACTACGTC 3349 NEMGNYV 4592 106.104 857 TCCACCGACCCCCGATACTCA 3350 STDPRYS 4593 106.097 858 ACTAATGGTATTTATCAGCCT 3351 TNGIYQP 4594 106.095 859 TGGGTAAACAGTGTGGGCAAC 3352 WVNSVGN 4595 106.084 860 GGGGTATCTAACAACTCTAGC 3353 GVSNNSS 4596 106.079 861 AATGTTAATGCGCAGAGTAGG 3354 NVNAQSR 4597 106.064 862 ACGACGCCGCCTTTTTCTAAT 3355 TTPPFSN 4598 106.044 863 ACAGGCAGCTCCCACACCAAC 3356 TGSSHTN 4599 106.0345 864 TACGTCGACAAATCAATGACA 3357 YVDKSMT 4600 106.009 865 CTAATCAAAAACAACATGCTC 3358 LIKNNML 4601 105.9827 866 GGGGGTACGGGGTTGTCGAAG 3359 GGTGLSK 4602 105.98 867 GCTCTTCATAATCTGATGAAT 3360 ALHNLMN 4603 105.977 868 GTGCATGTGACTAATGTGTTG 3361 VHVTNVL 4604 105.924 869 TCGACGACGCACCCTTCCGAA 3362 STTHPSE 4605 105.898 870 AGCGTAGGTAGTCCAACACAC 3363 SVGSPTH 4606 105.8936 871 ATGAGTAATGATTTGCCTGGG 3364 MSNDLPG 4607 105.877 872 TTCTCGTCAACCGAAGCCAGA 3365 FSSTEAR 4608 105.858 873 GCCGGTCACCAACAACTGGCC 3366 AGHQQLA 4609 105.846 874 GGTACCATATTACCAAACCAA 3367 GTILPNQ 4610 105.829 875 AGCGCGGTTTCTGGTAGCAGC 3368 SAVSGSS 4611 105.825 876 GAGGTGTCTAGGGATGGTCTG 3369 EVSRDGL 4612 105.814 877 CAATCACTCAAAGACGGCACT 3370 QSLKDGT 4613 105.804 878 ACGCGTGAGGGTAATCATGCT 3371 TREGNHA 4614 105.8 879 GTGGCGACCCAAAACCTTCTT 3372 VATQNLL 4615 105.795 880 GCCGAAATGACGCACCGCCTC 3373 AEMTHRL 4616 105.771 881 CAACGGCCAGACCCGCTTAAA 3374 QRPDPLK 4617 105.764 882 GAACACATCTCTAGCTACGGA 3375 EHISSYG 4618 105.752 883 CAAAAAAGCAACGACCAAAAC 3376 QKSNDQN 4619 105.744 884 AATCTTGTGATGAGTGGGACG 3377 NLVMSGT 4620 105.742 885 GGAGCGGGACAATCTCACGTG 3378 GAGQSHV 4621 105.721 886 CTCAACCACACAATGCCCCTC 3379 LNHTMPL 4622 105.713 887 GTATCACAATCACACGACGTG 3380 VSQSHDV 4623 105.687 888 GCTAATTCTGCTACTAATCAG 3381 ANSATNQ 4624 105.679 889 GGCACAGGAGGTAACCGAGAA 3382 GTGGNRE 4625 105.671 890 GCGAAGTCGTCGATTATTTTG 3383 AKSSIIL 4626 105.661 891 GGAGGAACAGCCCTTGGGAGC 3384 GGTALGS 4627 105.613 892 AACAAAGTAGAATCTGACCCA 3385 NKVESDP 4628 105.59 893 AACTCGAAACAACCCGACGTC 3386 NSKQPDV 4629 105.572 894 AGTTATGCTGATCGTCGGCTG 3387 SYADRRL 4630 105.567 895 AATGTGAATCCGAATGGGCCG 3388 NVNPNGP 4631 105.53 896 GAACACAACTCAAAAACTTAC 3389 EHNSKTY 4632 105.496 897 ACCCAAGGATCTAACACCACA 3390 TQGSNTT 4633 105.489 898 AGCAACGTATCAGCTTACGCA 3391 SNVSAYA 4634 105.48 899 GCGTACAGTGACAGCGCCCGC 3392 AYSDSAR 4635 105.457 900 GGGTCGCAATACGCGAACCGC 3393 GSQYANR 4636 105.402 901 ACAATGAGCGTAACTCTGGAA 3394 TMSVTLE 4637 105.393 902 CAGACGACTATTCTGGCTGCT 3395 QTTILAA 4638 105.386 903 TTGCTCCAATCCATAGTGGTA 3396 LLQSIVV 4639 105.381 904 GTTCACGCTAACGCTACATTA 3397 VHANATL 4640 105.38 905 AACAAAACAAACGCCGACTAC 3398 NKTNADY 4641 105.38 906 AACTACGACACCGGCGCCAAA 3399 NYDTGAK 4642 105.378 907 GTCTACCACAACCGCGACGTT 3400 VYHNRDV 4643 105.358 908 GATTCTGCTCCGAGGTCTATT 3401 DSAPRSI 4644 105.351 909 TTGATTGCGAATCTGAGTAAT 3402 LIANLSN 4645 105.341 910 CCGCAAGACGTCCGCCAAACA 3403 PQDVRQT 4646 105.331 911 ACAATGACAGCAATAGCAATG 3404 TMTAIAM 4647 105.327 912 ACATACGCCTCTACTGAAGCG 3405 TYASTEA 4648 105.324 913 CCTCACGCCAACGGAGTGACA 3406 PHANGVT 4649 105.298 914 CGGGCTGATGTTTCTTGGTCT 3407 RADVSWS 4650 105.286 915 CTGACGCACATGACCGGAACC 3408 LTHMTGT 4651 105.272 916 GCAAACGACTCTGCCAAAACA 3409 ANDSAKT 4652 105.269 917 GCTAATTCTGGGTTGCATAAT 3410 ANSGLHN 4653 105.246 918 AACGTGGGCACCGACAGAGAC 3411 NVGTDRD 4654 105.231 919 GTCGGAACAACCTCGAACGGC 3412 VGTTSNG 4655 105.226 920 GGAGTTCTTGGGATACTGGTC 3413 GVLGILV 4656 105.184 921 CGAATCAACGCAGCAATCGAC 3414 RINAAID 4657 105.1475 922 CCCGACACTCGCCCATCCATA 3415 PDTRPSI 4658 105.135 923 GGTGAATCACGTACAAACATG 3416 GESRTNM 4659 105.119 924 ATTTTGCTTGCTCAGTCTGCT 3417 ILLAQSA 4660 105.117 925 TATAATAGGGATAATGGTTCT 3418 YNRDNGS 4661 105.083 926 TGGAATAGTCCGGGTGAGGCG 3419 WNSPGEA 4662 105.053 927 CTGTTGGGGGCTCATCAGCCG 3420 LLGAHQP 4663 105.052 928 ATTGGTAAGGATAGTGTTCCG 3421 IGKDSVP 4664 105.044 929 ACGCGGGAGAGTCTGGTGGAT 3422 TRESLVD 4665 105.022 930 GCCTCTAACCACCTACAAGCC 3423 ASNHLQA 4666 105.013 931 AATCTTCAGACGGGTAAGGCT 3424 NLQTGKA 4667 104.976 932 ACTGTAGGATCCTCATACGCT 3425 TVGSSYA 4668 104.9737 933 GACACTAACGGAATAAAATCA 3426 DTNGIKS 4669 104.968 934 AGTCTGCGGATGGAGAATAGT 3427 SLRMENS 4670 104.957 935 ACTAAGGGTAATAATCTGGTT 3428 TKGNNLV 4671 104.92 936 CATACGAATCAGATGCAGCCT 3429 HTNQMQP 4672 104.919 937 AACGGCAACTACGACGGCGCG 3430 NGNYDGA 4673 104.912 938 GAGGCGCATAATCGTGGTAAT 3431 EAHNRGN 4674 104.898 939 GGGACGGTTAACTCAAGTGCA 3432 GTVNSSA 4675 104.861 940 GGGCCGACGATGAATCATAAT 3433 GPTMNHN 4676 104.854 941 GTACCCAACAACAACACTTCG 3434 VPNNNTS 4677 104.834 942 GTTTCTAACAAATCTGGAAGT 3435 VSNKSGS 4678 104.818 943 TGGGGAGTCAGTAACTCAGCA 3436 WGVSNSA 4679 104.795 944 GTCTCTAACGTCCTCTACAGC 3437 VSNVLYS 4680 104.772 945 GCCGGCCAAAACAGTGTGGGC 3438 AGQNSVG 4681 104.77 946 GGTACGAGTCTGGAGAATAGG 3439 GTSLENR 4682 104.754 947 CAGATGAATATTCATGATAAG 3440 QMNIHDK 4683 104.736 948 CCTCAACTAAGCGGCACAGCG 3441 PQLSGTA 4684 104.733 949 AGTTCGACTCCGCAGGATACT 3442 SSTPQDT 4685 104.713 950 GTGCAGGGGCAGACCGGCTGG 3443 VQGQTGW 4686 104.688 951 GGTCTGACGGGTGATTTGGTT 3444 GLTGDLV 4687 104.682 952 AACCACCCCGCACCAAGCTCA 3445 NHPAPSS 4688 104.679 953 AAAGAAAAAACCACCCGCGAA 3446 KEKTTRE 4689 104.665 954 ACTACTAATCCGCAGACGCAG 3447 TTNPQTQ 4690 104.663 955 GGAGGTGAACACGCAAGAAAC 3448 GGEHARN 4691 104.66 956 ACGACCGAAGCTGTTGTAGCA 3449 TTEAVVA 4692 104.656 957 CAAAACAGTGACCTCGCCAGC 3450 QNSDLAS 4693 104.638 958 TACTCTACAGAAGCACGAGTC 3451 YSTEARV 4694 104.609 959 ACCGGACAAGCGGGCGGATCG 3452 TGQAGGS 4695 104.571 960 ACTTCGTCTAATCTTTATGTG 3453 TSSNLYV 4696 104.559 961 ACGGCTCGTGCGATTGATATG 3454 TARAIDM 4697 104.551 962 CAGGAGTCTAATAGGGGGGTG 3455 QESNRGV 4698 104.547 963 AGTATCGGATTCTCAGTAGGC 3456 SIGFSVG 4699 104.529 964 GAGCGGAGTACGCATAATGTT 3457 ERSTHNV 4700 104.513 965 GCAAACCACGACAACATCGTG 3458 ANHDNIV 4701 104.501 966 TGGGCTATGAATAATGTGCCG 3459 WAMNNVP 4702 104.498 967 TATATTGCTGCGGGTGAGCAG 3460 YIAAGEQ 4703 104.498 968 AGTTCGAATACTTCTGGTAGT 3461 SSNTSGS 4704 104.4928 969 ATGGGGAAGCATGAGGGTCTT 3462 MGKHEGL 4705 104.481 970 GTGCTTACTCATCTGCCGACG 3463 VLTHLPT 4706 104.4786 971 GAAATGGGTAACCAATACCCA 3464 EMGNQYP 4707 104.453 972 AGTCTGCGTCCAACCCTACCT 3465 SLAPTLP 4708 104.448 973 TCGGCTAACTTATACAAACAA 3466 SANLYKQ 4709 104.394 974 CAAAACGACAGAAAACCGGAC 3467 QNDRKPD 4710 104.391 975 ATTATTTCGGGTATTACGGTG 3468 IISGITV 4711 104.365 976 CCATCCGAAATGAGGGCCGTA 3469 PSEMRAV 4712 104.361 977 TTGGTTACGCAGACGCCGAAT 3470 LVTQTPN 4713 104.337 978 ATTGCGCAGAATGAGACGTAT 3471 IAQNETY 4714 104.336 979 CCATACTTAAGAAACATGGCG 3472 PYLRNMA 4715 104.321 980 GGCGTGAACACAAAAATCGAA 3473 GVNTKIE 4716 104.311 981 TACTCTTCTGAAATGAGCGAA 3474 YSSEMSE 4717 104.31 982 TTAGAAAACCCAACACCAGCA 3475 LENPTPA 4718 104.305 983 GGTGTTATGTCTAATGCTACT 3476 GVMSNAT 4719 104.289 984 GCCCACACTGCATTAGCGGGG 3477 AHTALAG 4720 104.27 985 CCTGTTGTGAGGGATCGTTCT 3478 PVVRDRS 4721 104.2336 986 TCTGCGGGTATGGTGAGTCTG 3479 SAGMVSL 4722 104.229 987 TCGGGTGTTAATAGTGAGCGT 3480 SGVNSER 4723 104.2093 988 AATGGGGATGTTACTAATATG 3481 NGDVTNM 4724 104.179 989 TCTGTTGTGCCTACGGATAAG 3482 SVVPTDK 4725 104.174 990 AGTAAGGGTGATCAGCTTAAT 3483 SKGDQLN 4726 104.166 991 GACGGAGAATCCCGATTATCA 3484 DGESRLS 4727 104.158 992 GGTAATATGAATCATAGTATT 3485 GNMNHSI 4728 104.15 993 AGTGGGCATGCTTCTCAGGGT 3486 SGHASQG 4729 104.148 994 GGTTGGAGTAATAATGAGTTG 3487 GWSNNEL 4730 104.145 995 GGTGTGCATACTCATACTGTT 3488 GVHTHTV 4731 104.139 996 CACGTGACAGTAACGTTAAAC 3489 HVTVTLN 4732 104.124 997 ACCCGTGGCAACGACATATCA 3490 TRGNDIS 4733 104.058 998 AGCAAAGGCGGCGACATGGTT 3491 SKGGDMV 4734 104.043 999 ACGCATGGTGATCATATTCAG 3492 THGDHIQ 4735 104.032 1000 ACTACGAATTCTCATGCGATT 3493 TTNSHAI 4736 104.021 1001 GTCAGAACAGTCCTTCAACAA 3494 VRTVLQQ 4737 104.017 1002 ACTGTGCGTTCGCCTCAGCCG 3495 TVRSPQP 4738 104.015 1003 AATACTTATACTGCTGGTAAG 3496 NTYTAGK 4739 104.005 1004 ATTAGTAATCCGGAGAATACG 3497 ISNPENT 4740 103.998 1005 ATCGGGTCGCCGTTGGCCAAC 3498 IGSPLAN 4741 103.928 1006 TATACGGGTACTCTTGTTGTT 3499 YTGTLVV 4742 103.911 1007 GGGCGGCACACATTAGCGGAC 3500 GRHTLAD 4743 103.908 1008 ACTGATGGGCCGCGTCTGGCT 3501 TDGPRLA 4744 103.881 1009 GGGGCAGGAAACCTGGGTACC 3502 GAGNLGT 4745 103.873 1010 CTGATGAATCGTAATGCTCCT 3503 LMNRNAP 4746 103.8648 1011 AATGCTATGGCTTCTAGTAGG 3504 NAMASSR 4747 103.826 1012 CAGCATCGTGCGCAGGATGTG 3505 QHRAQDV 4748 103.8248 1013 AAAATAGAAAGCGGAACCATA 3506 KIESGTI 4749 103.822 1014 ACTAATTATCCTGAGGCGAAT 3507 TNYPEAN 4750 103.806 1015 GTATACCACGGGGTAGCCAGC 3508 VYHGVAS 4751 103.803 1016 TCCAACGTCCACGTAGTAAAC 3509 SNVHVVN 4752 103.791 1017 ACATACACCGACGGGAACCCC 3510 TYTDGNP 4753 103.788 1018 TTTATTGCGAATACGAATCCT 3511 FIANTNP 4754 103.787 1019 GACGCCGGGTACGGCCACGAC 3512 DAGYGHD 4755 103.785 1020 GGTCTTAGTCGGAATGATGGT 3513 GLSRNDG 4756 103.783 1021 ATGATGGGCGCGACAACGAAA 3514 MMGATTK 4757 103.779 1022 CCCATCAACGTACTCACGACA 3515 PINVLTT 4758 103.771 1023 GCCGTAGACCAATCACGTTTG 3516 AVDQSRL 4759 103.765 1024 AACGCTTCTACCTACATGGAC 3517 NASTYMD 4760 103.728 1025 ACACAAGCAGGTCTTGCGTCA 3518 TQAGLAS 4761 103.696 1026 GCACAATTCGAATCAGGCCGA 3519 AQFESGR 4762 103.693 1027 CGGAATGGTGGTACTACGGAT 3520 RNGGTTD 4763 103.669 1028 GCTAATACGTATAATGTTCAG 3521 ANTYNVQ 4764 103.64 1029 TCGGGTGTTCATAGTGAGCGT 3522 SGVHSER 4765 103.636 1030 AACACCGGCACCACGAGTGTC 3523 NTGTTSV 4766 103.635 1031 AGTACGAGTAATAGTCATATG 3524 STSNSHM 4767 103.632 1032 GGTGAACAACACAACGCCCCC 3525 GEQHNAP 4768 103.629 1033 GCTCATCATATGACGACGGAG 3526 AHHMTTE 4769 103.614 1034 TTGATGACTGGTACTGCGTCG 3527 LMTGTAS 4770 103.575 1035 GCTGCCGGAGCCGACTCTCCA 3528 AAGADSP 4771 103.568 1036 GTGTCTCTGAGTTCGCCTCCG 3529 VSLSSPP 4772 103.563 1037 CGTGTTGTAGCCGGTCCCAAC 3530 RVVAGPN 4773 103.534 1038 GATAAGACTGAGATGCTGCAG 3531 DKTEMLQ 4774 103.525 1039 GCACGAGACGACACGATACAA 3532 ARDDTIQ 4775 103.523 1040 TTACACCTTGGGTTATCATCT 3533 LHLGLSS 4776 103.513 1041 CTCGAAGGACAACGGGACGTC 3534 LEGQRDV 4777 103.505 1042 GCGTCGTTGTCGGCTCCGGCG 3535 ASLSAPA 4778 103.5036 1043 AGCAACCCTGGGAACCACAAC 3536 SNPGNHN 4779 103.502 1044 GGGCTGAATTCTAAGGGGACT 3537 GLNSKGT 4780 103.471 1045 AAAACACCCTCAGCTTCAGAA 3538 KTPSASE 4781 103.47 1046 GTGCTGGCGTCGACTGAGAAG 3539 VLASTEK 4782 103.451 1047 TCGGTATTGAACAAACCAACA 3540 SVLNKPT 4783 103.441 1048 CCCGGTAACGGACAAAGTCCG 3541 PGNGQSP 4784 103.396 1049 ATCTTGATGGGCGCTAGGACA 3542 ILMGART 4785 103.385 1050 GCACTACCATCCCACTCCTCC 3543 ALPSHSS 4786 103.382 1051 AGGGATCAGACTCATCCGAAT 3544 RDQTHPN 4787 103.378 1052 TCTGGTCCGATTCCTGCTGTT 3545 SGPIPAV 4788 103.376 1053 TACGTGGACGACAACAGTCGC 3546 YVDDNSR 4789 103.35 1054 TTGACTCGGGGGGTCGCCGCA 3547 LTRGVAA 4790 103.334 1055 TCTGAGAAGGAGGCTCGGCTG 3548 SEKEARL 4791 103.326 1056 TCCACAACGCCTCCCTTCAAA 3549 STTPPFK 4792 103.308 1057 TACTCGACAACCATGCTTAAC 3550 YSTTMLN 4793 103.299 1058 AAAAACGGTGTTATAAACGAC 3551 KNGVIND 4794 103.292 1059 TTCGGTATAGGGCACGGAACA 3552 FGIGHGT 4795 103.278 1060 CCTCTTCATGTTGCTTCTCCT 3553 PLHVASP 4796 103.245 1061 TTGGGTAATGGTAGTTCTTTG 3554 LGNGSSL 4797 103.239 1062 AGTGGCAACGCGAACATAGTA 3555 SGNANIV 4798 103.225 1063 GGGATTAATCGTACTAGTGAG 3556 GINRTSE 4799 103.19 1064 TCGGATAATAGGAATACTGCG 3557 SDNRNTA 4800 103.19 1065 CGATTAGGAACCGTCACCAAC 3558 RLGTVTN 4801 103.189 1066 GTGGAGCATGTTGCTCATCAG 3559 VEHVAHQ 4802 103.185 1067 TATACTAAGCATCCTGTTGAG 3560 YTKHPVE 4803 103.172 1068 TCCCGAATCACGGTGAACGCA 3561 SRITVNA 4804 103.154 1069 ACAGTATCGTCATACGTACAA 3562 TVSSYVQ 4805 103.134 1070 CGCGCCGAAGGGAGCTCTGGC 3563 RAEGSSG 4806 103.127 1071 GCTGTGGGGCGGTCGGATGAT 3564 AVGRSDD 4807 103.119 1072 CGCATAGGCGTTGGAGCACCA 3565 RIGVGAP 4808 103.113 1073 TACTCAAACCTCGTACTTTCC 3566 YSNLVLS 4809 103.095 1074 TCGACGAATTCTGAGGCGGTT 3567 STNSEAV 4810 103.068 1075 GCAATGTCAACCCACATGATA 3568 AMSTHMI 4811 103.067 1076 AGGGTTGATATTTCGCATTTT 3569 RVDISHF 4812 103.049 1077 ATTCTTACGCCTTTGGATAAG 3570 ILTPLDK 4813 103.039 1078 GTTGCGAGTACGACGCAGACT 3571 VASTTQT 4814 103.033 1079 GACCGTAGCTCCGCGACGCTC 3572 DRSSATL 4815 103.014 1080 GATCATAGTGAGCAGAATTCG 3573 DHSEQNS 4816 102.995 1081 ATACGCAGCGAATTGGAAGTA 3574 IRSELEV 4817 102.969 1082 GCGAATCTGGGTGATGTTGAG 3575 ANLGDVE 4818 102.969 1083 GAGCTTAAGGAGAGTCAGAAG 3576 ELKESQK 4819 102.956 1084 TCATACACAGCAGGAAGACCC 3577 SYTAGRP 4820 102.953 1085 GGACCAGCCTACAACCAAAGC 3578 GPAYNQS 4821 102.924 1086 CATGAGAGTCATTATGTTAGT 3579 HESHYVS 4822 102.921 1087 AATGGTAAGCTGGGTACGACT 3580 NGKLGTT 4823 102.921 1088 CTTCCGCCTGCGTCGGCGGGT 3581 LPPASAG 4824 102.917 1089 TTGTCGTATCAGACTGGTCAT 3582 LSYQTGH 4825 102.916 1090 GACAGCCAAATCACAAGACTA 3583 DSQITRL 4826 102.909 1091 AACGTATACGAAGGGCACCGC 3584 NVYEGHR 4827 102.909 1092 TTGTTTACTGCTGGGAGTACT 3585 LFTAGST 4828 102.863 1093 CTTGTGAATAATGATGGGACT 3586 LVNNDGT 4829 102.861 1094 GCGATGAATGTGCGGAGTGAT 3587 AMNVRSD 4830 102.858 1095 GCCAGCCTTGACCGCCTTCCA 3588 ASLDRLP 4831 102.857 1096 GGCTCTCGGAACGGACCCACA 3589 GSRNGPT 4832 102.8532 1097 ATGAGTGATGGGCATTCGAAG 3590 MSDGHSK 4833 102.833 1098 TCTAACCGTACGGAAATGCCA 3591 SNRTEMF 4834 102.815 1099 AACGTGGTGAAAAACAACACA 3592 NVVKNNT 4835 102.801 1100 GTGGTCGACTCAACATACCCG 3593 VVDSTYP 4836 102.793 1101 GTGGCTGGGGGGACTTCGGAG 3594 VAGGTSE 4837 102.789 1102 CGGGCAGACATGACTCCCTTA 3595 RADMTPL 4838 102.77 1103 GGACACGAACAAACTGACGCA 3596 GHEQTDA 4839 102.764 1104 AGTGCTTTGATTAGTGTGGTT 3597 SALISVV 4840 102.756 1105 AACTCGACAACGGCACAATCA 3598 NSTTAQS 4841 102.75 1106 TACGGCGACCTAACTACAGTC 3599 YGDLTTV 4842 102.737 1107 GCACGCAACGACGGACAAGGA 3600 ARNDGQG 4843 102.734 1108 CTGAACGTTAGTTCATCCAAA 3601 LNVSSSK 4844 102.693 1109 TCTGGCGTCTCGAAAGAACGG 3602 SGVSKER 4845 102.692 1110 AACATGGAACACACCATGGCG 3603 NMEHTMA 4846 102.687 1111 GCTCGTCCGGCTTCGTCTGAT 3604 ARPASSD 4847 102.6705 1112 CTTAGGGAAGAATCTGCACGT 3605 LREESAR 4848 102.639 1113 TTGGCCAACATGTCCGCACCA 3606 LANMSAP 4849 102.61 1114 AACCACACGGTAGAAGGACGC 3607 NHTVEGR 4850 102.598 1115 CCTCAGCATCAGCATGAGCAT 3608 PQHQHEH 4851 102.582 1116 AATTCTTCGGAGCTGAAGACG 3609 NSSELKT 4852 102.564 1117 CTTGTTGCTGAGCGTTTGCCG 3610 LVAERLP 4853 102.552 1118 AACGTTATGCACTCTTCCTCC 3611 NVMHSSS 4854 102.525 1119 GCGAGTGATAAGGGGGCGAAT 3612 ASDKGAN 4855 102.509 1120 AGTCTGGATCGGAAGCCTCCG 3613 SLDRKPP 4856 102.5032 1121 ACAGAACACGAAAAATCCACT 3614 TEHEKST 4857 102.459 1122 CCTCATAATCAGGAGATGGGT 3615 PHNQEMG 4858 102.449 1123 GAGTCTAAGACTGTGGTTATT 3616 ESKTVVI 4859 102.442 1124 TCGACGGGCCAAAACTTAAAA 3617 STGQNLK 4860 102.442 1125 GTTCTTCATGTTTCTGATGTT 3618 VLHVSDV 4861 102.441 1126 CCTGACGCAGCGCGTAGCCCG 3619 PDAARSP 4862 102.421 1127 GCTCCTCGGCATGCTCATCCT 3620 APRHAHP 4863 102.414 1128 CATGTGAATCCTACGCCGGCG 3621 HVNPTPA 4864 102.401 1129 TTGCCTAATGAGCGTCCGGGT 3622 LPNERPG 4865 102.397 1130 GAGGCTAAGGGTTTTGGTCAT 3623 EAKGFGH 4866 102.395 1131 TCAGAAAACACCTCTGTACCC 3624 SENTSVP 4867 102.388 1132 GGTCCCGGAGAAAACTACCGA 3625 GPGENYR 4868 102.375 1133 TCTCATGAGATGAATAATGGT 3626 SHEMNNG 4869 102.366 1134 GTAGACACCTACAGCGGTCTG 3627 VDTYSGL 4870 102.35 1135 GGAGTCCTAGGAAACATGGTA 3628 GVLGNMV 4871 102.325 1136 GCGCTGGATAATAGTAGTCGG 3629 ALDNSSR 4872 102.322 1137 TTTCTGGGTTCTAGTAATCAT 3630 FLGSSNH 4873 102.321 1138 CCTGTGGTTCATGGTGAGCCT 3631 PVVHGEP 4874 102.3142 1139 CGCAGGGAAGGTATCCTAATG 3632 RREGILM 4875 102.305 1140 CAGCAGGGGGCGCCTACTTCT 3633 QQGAPTS 4876 102.303 1141 AAGGTTAGTGGTGGGGAGACG 3634 KVSGGET 4877 102.275 1142 GCGAAACACGAAAGCTCGTCT 3635 AKHESSS 4878 102.272 1143 ATTCTTATGGGTGCGCGTACT 3636 ILMGART 4879 102.235 1144 ACGCTAGGCAGCAGCAGCACC 3637 TLGSSST 4880 102.222 1145 CTAAGATCTGAACCGACACAA 3638 LRSEPTQ 4881 102.218 1146 CGCTCGGAACAAAAAACTCCG 3639 RSEQKTP 4882 102.207 1147 CACGCTCCAAGCGGCGCCATA 3640 HAPSGAI 4883 102.2 1148 AGTAGTGTTACTTCGAGGGAG 3641 SSVTSRE 4884 102.197 1149 GTGAATCCGCATCCTGCGCAG 3642 VNPHPAQ 4885 102.185 1150 CAATACTCGATGGACACGCGC 3643 QYSMDTR 4886 102.173 1151 ACTCCTGGTGTTACTAGGACG 3644 TPGVTRT 4887 102.172 1152 CTTTATGAGGTTGGTACTCCT 3645 LYEVGTP 4888 102.165 1153 ACGATGACGAGTGAGCTTTCG 3646 TMTSELS 4889 102.16 1154 TCAGGTTCGGAATACCGTACC 3647 SGSEYRT 4890 102.153 1155 GAAATGCAAACCAAAAACGCC 3648 EMQTKNA 4891 102.144 1156 GGCCACGAAAACATGGGCGTG 3649 GHENMGV 4892 102.135 1157 GGGGCGCATACGTCGGCTTCG 3650 GAHTSAS 4893 102.116 1158 GCTGATACGCTGCTGCGTAGG 3651 ADTLLRR 4894 102.095 1159 GACAACAGCAACAACGTCCCA 3652 DNSNNVP 4895 102.092 1160 ATGACTGCTAACTTGGTGGAA 3653 MTANLVE 4896 102.076 1161 GAAGCGGGACGCACGCTTCAA 3654 EAGRTLQ 4897 102.07 1162 AGACACGTCGTCCCCGACTCC 3655 RHVVPDS 4898 102.039 1163 GTGAGTTCTGAGCAGTATAGG 3656 VSSEQYR 4899 102.03 1164 GGTATCGAAGCAAGTCGCGGA 3657 GIEASRG 4900 102.008 1165 AGACAAGGCGTGAACGGAGTA 3658 RQGVNGV 4901 101.991 1166 ACTGTGATGATGAGTACGAGG 3659 TVMMSTR 4902 101.976 1167 TGGCAAGACCACAACAAAGTC 3660 WQDHNKV 4903 101.948 1168 GGAATCACAGGATCAACAGGA 3661 GITGSTG 4904 101.943 1169 AATTATGCTCAGAGGGATGGT 3662 NYAQRDG 4905 101.936 1170 AAACAAGAAGCTCTGTCCTCA 3663 KQEALSS 4906 101.872 1171 TCAACTTTAGACCGAAGCGAA 3664 STLDRSE 4907 101.8665 1172 GCGATTACGAATACGCAGCAG 3665 AITNTQQ 4908 101.8615 1173 AGGCTGGCGACTCAGAGTGCT 3666 RLATQSA 4909 101.847 1174 TGGCAGCTTACGACGAGTCAT 3667 WQLTTSH 4910 101.775 1175 GGTGGTAGTGGTTCTAATACT 3668 GGSGSNT 4911 101.759 1176 AACTTAGTAGCGTACACGAAA 3669 NLVAYTK 4912 101.732 1177 AAGGCTTCGCATGATACTAGT 3670 KASHDTS 4913 101.721 1178 GCCATAACGATAATAGGCACT 3671 AITIIGT 4914 101.711 1179 AACGCATCGTCGGACCGCTTC 3672 NASSDRF 4915 101.686 1180 GAAACGCAACGTATCGAACTG 3673 ETQRIEL 4916 101.636 1181 GTGATTGAGGTTAATTCGCGT 3674 VIEVNSR 4917 101.614 1182 GATAGGGATATGGAGGGTGTT 3675 DRDMEGV 4918 101.609 1183 ATTTCGGAGATGACGCGGTAT 3676 ISEMTRY 4919 101.59 1184 GAGCATGATGTGAGTACGCGT 3677 EHDVSTR 4920 101.539 1185 CGTATGGAGGAGACTGCTTAT 3678 RMEETAY 4921 101.533 1186 TATAGTACTGATCTTAGGATG 3679 YSTDLRM 4922 101.52 1187 GTGCCTGAGCCTAAGAAGGCG 3680 VPEPKKA 4923 101.495 1188 ACTTATGCGCCTAGGTCGCCT 3681 TYAPRSP 4924 101.484 1189 GCTGCGGCTTCGCCTTTGGCT 3682 AAASPLA 4925 101.484 1190 AGTGGGACGTATGCTAGTCGT 3683 SGTYASR 4926 101.456 1191 ACTGAAGCATCAATCGCGGCG 3684 TEASIAA 4927 101.456 1192 CGCATCGTAGACACGTTGGGA 3685 RIVDTLG 4928 101.447 1193 TATCTGCAGGAGAAGTTTCCT 3686 YLQEKFP 4929 101.437 1194 GTTCATGATCAGGGGGCTGGG 3687 VHDQGAG 4930 101.436 1195 CCCCAAGCCACTCTCAACAAC 3688 PQATLNN 4931 101.432 1196 TGCGGAATGTCCGAATGCTCG 3689 CGMSECS 4932 101.429 1197 GGTTCGCACAACGGGCCGACA 3690 GSHNGPT 4933 101.429 1198 TTTGGGTCTGGGCCGAATCTT 3691 FGSGPNL 4934 101.413 1199 ATGGATACGAATACGCATCGT 3692 MDTNTHR 4935 101.411 1200 AAGAATAATCCTGAGGATGGT 3693 KNNPEDG 4936 101.41 1201 CTGCCTACGGCTACTGGTCAG 3694 LPTATGQ 4937 101.406 1202 ACGGCTGAGCGTACTGAGTAT 3695 TAERTEY 4938 101.383 1203 AACTACAGGGACATCACAATG 3696 NYRDITM 4939 101.375 1204 CCCGCGAGAAGCGACGCCCTT 3697 PARSDAL 4940 101.359 1205 TCCGTTGTAACTCTTGGGGTG 3698 SVVTLGV 4941 101.324 1206 GTTGTTAAGGAGATTAAGCTG 3699 VVKEIKL 4942 101.324 1207 GACCACTCGAAACAAAACTCT 3700 DHSKQNS 4943 101.293 1208 CAGTCTAATTTGGTTATTAAT 3701 QSNLVIN 4944 101.292 1209 ATTCCGGTTGGGGCGATGGCT 3702 IPVGAMA 4945 101.286 1210 ACGTCGGAGATGCGTACTGCT 3703 TSEMRTA 4946 101.255 1211 GGTAGTCAGCGTGCTATGAAT 3704 GSQRAMN 4947 101.251 1212 CACCTGTCACAAGCAAACCAC 3705 HLSQANH 4948 101.24 1213 GGAGGGAACTCCCACGGGGTA 3706 GGNSHGV 4949 101.219 1214 GTGACTCGTAGTACGAAGGAG 3707 VTRSTKE 4950 101.178 1215 ATGCTCAGAGCAAGCACCGCC 3708 MLRASTA 4951 101.171 1216 GGCAGGCAAATACCAGAACAA 3709 GRQIPEQ 4952 101.146 1217 TGGAATCAGAATGTGTCTCAT 3710 WNQNVSH 4953 101.125 1218 CAGCGGGGGGAGCTTCCTGCG 3711 QRGELPA 4954 101.114 1219 GCGAATGATAGTTTGCGTTCT 3712 ANDSLRS 4955 101.079 1220 AACATGCCACCGGAATCGCAC 3713 NMPPESH 4956 101.037 1221 AATTTGAGTCTTCAGAGTCTG 3714 NLSLQSL 4957 101.03 1222 ACATCAGACGGTCTACTAAGT 3715 TSDGLLS 4958 101.028 1223 GCGGGCCAAGCGTACCAATCC 3716 AGQAYQS 4959 101.016 1224 CTGAGTGTGAAGGAGGAGATT 3717 LSVKEEI 4960 101.007 1225 GATAATAGTCCTGCTAATCAT 3718 DNSPANH 4961 100.9812 1226 ATGCACAACCTACCCTCATAC 3719 MHNLPSY 4962 100.9629 1227 TACCAAGCCTCAAACAACAGT 3720 YQASNNS 4963 100.9594 1228 GCGCGGGCAGAAGGGGTCTTC 3721 ARAEGVF 4964 100.9325 1229 GGCCGAGAAGGAAACCTACCA 3722 GREGNLP 4965 100.913 1230 CAAGCTGCAGAAAGGGACAGA 3723 QAAERDR 4966 100.8877 1231 GTTGAGAATAATCGTATGAGT 3724 VENNRMS 4967 100.8183 1232 AATATGTCGCATAGTACTCTG 3725 NMSHSTL 4968 100.7704 1233 TCTTCGTTGGGTCTTGCTCCG 3726 SSLGLAP 4969 100.7249 1234 AACGTCGCTCCCTACAGTAGC 3727 NVAPYSS 4970 100.7069 1235 AGGCCTGCGCAGCTGCCTGAG 3728 RPAQLPE 4971 100.615 1236 ATGTCGGGTTCTGGGAACGCA 3729 MSGSGNA 4972 100.597 1237 CACGGGGGGGAACACCGGAAC 3730 HGGEHRN 4973 100.5793 1238 GCATCCGGCGCACGCTACGTC 3731 ASGARYV 4974 100.5302 1239 CAAAACCACGCGTCTGGTGAA 3732 QNHASGE 4975 100.499 1240 GCACACCAAAAAGACCTACGC 3733 AHQKDLR 4976 100.4529 1241 TTTGGGAAGGTTGGTACTGCT 3734 FGKVGTA 4977 100.433 1242 CTGCAGAAGTCGACTCTGGCT 3735 LQKSTLA 4978 100.3439 1243 ATTCATAATGAGTCTTATGGT 3736 IHNESYG 4979 100.15

TABLE 3 MHCK7/CK8 Combined Results mRNA Second Round of Capsid Variant Selection in C57BL6 mice-score capped at 100 Variant ID for Amino Acid SEQ ID Sum of muscle mRNA Table Nucleotide Sequence SEQ ID NO: seq. NO: score_capped at 100 1 AGGGGTGATCTTTCTACGCCT 4980 RGDLSTP 6647 856.3525 2 AGAGGCGACTTATCCACACCC 4981 RGDLSTP 6648 732.672 3 AGAGGAGACTTGACAACCCCA 4982 RGDLTTP 6649 683.373 4 AGGGGCGACCTGAACCAATAC 4983 RGDLNQY 6650 680.6265 5 CGGGGTGATCAGCTTTATCAT 4984 RGDQLYH 6651 624.3915 6 AGGGGGGATGCGACGGAGCTT 4985 RGDATEL 6652 620.5 7 CGAGGAGACACCATGAGCAAA 4986 RGDTMSK 6653 599.497 8 CGGGGTGATCTTAATCAGTAT 4987 RGDLNQY 6654 579.731 9 CGGGGTGATCTTACTACGCCT 4988 RGDLTTP 6655 531.1525 10 CGCGGCGACATGATAAACACC 4989 RGDMINT 6656 528.2405 11 CGGGGGGATACTATGTCTAAG 4990 RGDTMSK 6657 469.5075 12 CGAGGCGACACAATGAACTAC 4991 RGDTMNY 6658 412.3247 13 CGGGGTGACGCAACAGAATTG 4992 RGDATEL 6659 408.0865 14 CGTTTGGACCTGCAAGTCCAC 4993 RLDLQVH 6660 397.178 15 CGTGGTGATGTGGCGGCTAAG 4994 RGDVAAK 6661 395.174 16 AGGGGCGACCTCAACGACAGC 4995 RGDLNDS 6662 360.4535 17 CGTGGGGATTTGAATGATTCT 4996 RGDLNDS 6663 349.6835 18 TCTTATGGTAATACTCATGAT 4997 SYGNTHD 6664 326.826 19 CGTTTGGACCTGCAAGTCAAC 4998 RLDLQVN 6665 317.78 20 AAAGCGGGACAACTAGTGGAA 4999 KAGQLVE 6666 317.023 21 GATCAGACGGCTAGTATTGTT 5000 DQTASIV 6667 313.224 22 TATATTGCTGCGGGTGAGCAG 5001 YIAAGEQ 6668 308.738 23 GCGGTTGTTCTGAATAGTAAT 5002 AVVLNSN 6669 307.8445 24 TCTAAAGGAAACGAACAAATG 5003 SKGNEQM 6670 305.016 25 GCAAACCCCAACATACTAGAC 5004 ANPNILD 6671 302.02 26 CACAACAAACCAAACGGAGAC 5005 HNKPNGD 6672 297.851 27 GATAAGACTGAGATGCTGCAG 5006 DKTEMLQ 6673 294.655 28 ACAGAACAATCTTACTCACGA 5007 TEQSYSR 6674 290.3555 29 ACTGTGATGATGAGTACGAGG 5008 TVMMSTR 6675 289.3945 30 GTCTCTACATACCTCCTGGCA 5009 VSTYLLA 6676 286.859 31 CCTAATGTTACGCAGTCTTAT 5010 PNVTQSY 6677 285.178 32 ATGAGTAATTTGGGGTATGAG 5011 MSNLGYE 6678 284 33 ACGATGGGTGCTAATGGTACT 5012 TMGANGT 6679 278.291 34 AATGTTAATGCGCAGAGTAGG 5013 NVNAQSR 6680 275.45 35 GACCAAAACTTCGAACGTAGA 5014 DQNFERR 6681 274.6045 36 AACACGTACACACCGGGAAAA 5015 NTYTPGK 6682 273.83545 37 CGTGGGGATATGATTAATACG 5016 RGDMINT 6683 270.333 38 GCACAATTCGAATCAGGCCGA 5017 AQFESGR 6684 267.7345 39 ACGGCGTATCAGGCTGGTCTG 5018 TAYQAGL 6685 267.054 40 AGTGTTAGTTCTGTGGTGTTG 5019 SVSSVVL 6686 266.91 41 GGGCTTTCTAAGGCGTCTGAT 5020 GLSKASD 6687 266.825 42 TGGAACGGAAACGCCACACAA 5021 WNGNATQ 6688 265.11 43 ACAGCCGGCGGCGAACGCGCC 5022 TAGGERA 6689 258.785 44 TACACCTCTCAAACCAGCACT 5023 YTSQTST 6690 258.1818 45 GCGAACATAGAAAACACGTCA 5024 ANIENTS 6691 257.015 46 GAACTCTCCGTTCCGAAACCA 5025 ELSVPKP 6692 255.133 47 GATCCTGGTCGGACGGGTACG 5026 DPGRTGT 6693 254.7 48 GATCGTCCGAATAATATGACG 5027 DRPNNMT 6694 254.383 49 TATAGTACTGATCTTAGGATG 5028 YSTDLRM 6695 252.146 50 CAGTCGGTTAATAGTACGAGT 5029 QSVNSTS 6696 251.508 51 GCGGCACAACTCGTCAGTCCA 5030 AAQLVSP 6697 250.413 52 CTCGGAGGAAACAGCAGGTTC 5031 LGGNSRF 6698 247.9775 53 GCGACGCTGAATAATAGTTAT 5032 ATLNNSY 6699 247.2955 54 CGCTTGGACGTTGGAAGCCCG 5033 RLDVGSP 6700 245.839 55 TATCGGGGTAGGGAGGATTGG 5034 YRGREDW 6701 244.83 56 AGGGGAGATCTTTCTACGCCT 5035 RGDLSTP 6702 243.25 57 AGTGGTCTTTCGCATGGTCAG 5036 SGLSHGQ 6703 242.486 58 GAACACGCTACAGCAAAACAA 5037 EHATAKQ 6704 241.816 59 GGGGCGGAAGCGGGCCGCCAA 5038 GAEAGRQ 6705 241.46345 60 ATAAGCGGTTCCACTACACAC 5039 ISGSTTH 6706 240.8811 61 GGCACCGTCGTTCCGGGCTCC 5040 GTVVPGS 6707 240.8455 62 CATAATAATAATATGCTGAAT 5041 HNNNMLN 6708 239.0755 63 CGTCTGACTGATACTATGCAT 5042 RLTDTMH 6709 238.939 64 AACACCTACCCCTTCAACGCC 5043 NTYPFNA 6710 235.89 65 TCAACCACTACTGGCCACATG 5044 STTTGHM 6711 231.581 66 GTGCATAATCCTACTACTACG 5045 VHNPTTT 6712 231.5537 67 AATCTGCAGGTGAATGCGAAT 5046 NLQVNAN 6713 231.172 68 AGATACGGAGAATCCATCGAA 5047 RYGESIE 6714 230.66 69 AATACTACTCCGCCTAATCAT 5048 NTTPPNH 6715 230.225 70 AATACTTTGCAGAATAGTCAT 5049 NTLQNSH 6716 229.0666 71 AGTCTGAACAACATGGGATCG 5050 SLNNMGS 6717 228.9154 72 AGAAACGAAAACGTAAACGCT 5051 RNENVNA 6718 228.828 73 GCTGTGCATGCGACTAGTAGT 5052 AVHATSS 6719 227.882 74 ACCCAACACCTACCATCCACA 5053 TQHLPST 6720 227.0845 75 AGTGTGTTGTCTCAGGCTAAT 5054 SVLSQAN 6721 225.4035 76 AGTAGCTCAACTGAAGGGCAA 5055 SSSTEGQ 6722 224.971 77 GGTCGGACGGATACTCCTAAT 5056 GRTDTPN 6723 224.945 78 GTTCAAACCCACATAGGAGTC 5057 VQTHIGV 6724 224.616 79 ACTTCTGCTAGTGAGAATTGG 5058 TSASENW 6725 224.608 80 GGAAAAGCCAACGACGGTTCT 5059 GKANDGS 6726 224.5935 81 GTGGAGCGGAATACTGATATG 5060 VERNTDM 6727 223.9975 82 CAAAACCACGCGTCTGGTGAA 5061 QNHASGE 6728 223.871 83 TATTATGAGAAGCTTAGTGCG 5062 YYEKLSA 6729 222.1725 84 TTCATCGCTAACACTAACCCA 5063 FIANTNP 6730 221.76 85 ACCTCCACGGCTTCAAAACAA 5064 TSTASKQ 6731 221.617 86 AATAATGATAATGGTTTTGTT 5065 NNDNGFV 6732 220.61 87 GCTAATTCTATTGGGGGTCCG 5066 ANSIGGP 6733 220.304 88 ACTGGCCAATTAGTAGGAACC 5067 TGQLVGT 6734 220.262 89 TACAGTCAATCGCTGTCTGAA 5068 YSQSLSE 6735 220.02 90 GTCTACAACGGCAACGTAGTA 5069 VYNGNVV 6736 219.824 91 AACTCGGCTGAATCCTCGAGA 5070 NSAESSR 6737 219.5415 92 ACGCGTAATTTGTCTGAGAGT 5071 TRNLSES 6738 218.919 93 TCTATGTCTGATGGGCTTCGG 5072 SMSDGLR 6739 218.868 94 GTAGGCGACCAATCCCGCCCG 5073 VGDQSRP 6740 218.8565 95 TTTACGGTGAATCAGGATCTT 5074 FTVNQDL 6741 218.069 96 TATCATAAGTATAGTACGGAT 5075 YHKYSTD 6742 217.64 97 TATGGTGTGCAGGCGAATAGT 5076 YGVQANS 6743 217.293 98 TTGCAGACGCCTGGGACGACG 5077 LQTPGTT 6744 217.179 99 TATCAGCAGACTTCTAGTACG 5078 YQQTSST 6745 216.8135 100 CAAACGAACACCAACGACAGA 5079 QTNTNDR 6746 216.664 101 ATGGATAAGTCTAATAATTCT 5080 MDKSNNS 6747 216.638 102 CATCTTAGTCAGGCTAATCAT 5081 HLSQANH 6748 216.575 103 GTTGGTGCGAGTACGGCTTCG 5082 VGASTAS 6749 215.9195 104 CACAACAACAACCTGCAAAAC 5083 HNNNLQN 6750 215.084 105 AGTACTTATGGGAATACTTAT 5084 STYGNTY 6751 214.971 106 CGGGCTGATGTTTCTTGGTCT 5085 RADVSWS 6752 214.499 107 CGAGGAGACAACAGCACACCG 5086 RGDNSTP 6753 214.29 108 GGTCGGGATTATGCTATGAGT 5087 GRDYAMS 6754 214.166 109 CCTAACAACGAAAAAAACCCG 5088 PNNEKNP 6755 214.048 110 GATAATGTGAATTCTCAGCCT 5089 DNVNSQP 6756 213.6615 111 ATGGGGACTGAGTATCGTATG 5090 MGTEYRM 6757 213.606 112 AATCAGAGTATTAATAATATT 5091 NQSINNI 6758 213.36 113 GCCATAGACTCTATCAAACAA 5092 AIDSIKQ 6759 213.304 114 GTTGAGTCTTCTTATTCTCGG 5093 VESSYSR 6760 212.9405 115 GGTCAGTATAGTCAGACGCTT 5094 GQYSQTL 6761 212.242 116 ACCATCCAAGACCACATAAAA 5095 TIQDHIK 6762 212.116 117 AACAGTTCCCAATGGCCCAAC 5096 NSSQWPN 6763 211.938 118 ACGGATAATGGTCTTCTTGTG 5097 TDNGLLV 6764 211.787 119 GTAAGAGAAACCACACACCTC 5098 VRETTHL 6765 211.44 120 CGTGGTGATATGACTCGTGCG 5099 RGDMTRA 6766 211.181 121 ACTTATGGTATTACTCATGAT 5100 TYGITHD 6767 210.641 122 ACGGCGCTGAATACGTATCCT 5101 TALNTYP 6768 210.568 123 GGTGGCGAAAACAGAACCCCA 5102 GGENRTP 6769 210.4 124 TATCTGCAGGAGAAGTTTCCT 5103 YLQEKFP 6770 210.3715 125 CTTAATCTTACTAATCATAAT 5104 LNLTNHN 6771 209.727 126 GGATTAGCTAGTCTACACCTG 5105 GLASLHL 6772 209.3585 127 GTAGAACACGTAGCCCACCAA 5106 VEHVAHQ 6773 209.322 128 AGCGAACACCACGCCGGAATA 5107 SEHHAGI 6774 209.188 129 GAAGCGTCCAACTACGAACGA 5108 EASNYER 6775 208.926 130 CCCTCCAACAGTGAAAGATTC 5109 PSNSERF 6776 208.6635 131 TCCCCCGGCAACGGGTTGCTA 5110 SPGNGLL 6777 208.4985 132 ATACTGAAATCCGACGCACCA 5111 ILKSDAP 6778 208.297 133 TTTGATAGTGCGAATGGTCGG 5112 FDSANGR 6779 208.26 134 GATGGTAAGACTACGTCTAAT 5113 DGKTTSN 6780 207.768 135 ACTAATTATCCTGAGGCGAAT 5114 TNYPEAN 6781 207.706 136 CGAGGAGACCACAGCACACCG 5115 RGDHSTP 6782 207.4315 137 CAGACGACTATTCTGGCTGCT 5116 QTTILAA 6783 207.223 138 GCTACTGCGCATCAGGATGGT 5117 ATAHQDG 6784 207.212 139 CAAGCCCTGGCCACCACAAAC 5118 QALATTN 6785 207.096 140 TATAATGCTACTCCTTCGCAG 5119 YNATPSQ 6786 206.964 141 GAGCTGTCTACTCCTATGGTT 5120 ELSTPMV 6787 206.8655 142 ATTAATATTAGTAGTGATTTT 5121 INISSDF 6788 206.753 143 GTAACGGCACACCAATTATCC 5122 VTAHQLS 6789 206.7385 144 GGAGAAAGCTCCTCAATAAGC 5123 GESSSIS 6790 206.656 145 GAATCCCTCCCAATCTCTAAA 5124 ESLPISK 6791 206.576 146 ACGAATGTTAGTACGCTTTTG 5125 TNVSTLL 6792 206.455 147 TGGCAGACGAATGGTATGCAG 5126 WQTNGMQ 6793 206.4378 148 TACAGGATGGAAACGAACCCA 5127 YRMETNP 6794 206.121 149 ATAACCGGCAACACCGTCGGA 5128 ITGNTVG 6795 205.9135 150 CTGAACACTCTAATCCACAAA 5129 LNTLIHK 6796 205.873 151 GGGACTTCCTTGGAAAACCGA 5130 GTSLENR 6797 205.8535 152 TACCAACACAACCAAGCCCAC 5131 YQHNQAH 6798 205.473 153 ATTGAGAGTAAGACTGTGCAG 5132 IESKTVQ 6799 205.0365 154 TATACGCAGGGTATTATGAAT 5133 YTQGIMN 6800 204.5275 155 AGTACGAATGAGGCTCCTAAG 5134 STNEAPK 6801 204.522 156 TTGTCTCAGAATTTTAATCCT 5135 LSQNFNP 6802 204.3926 157 TACTCTTCTGAAATGAGCGAA 5136 YSSEMSE 6803 204.31 158 TCATACGGAGGATCTGGCCCC 5137 SYGGSGP 6804 204.28 159 ATGGACGCTGCGTACGGTAGT 5138 MDAAYGS 6805 203.959 160 CCTTTTAATCCTGGGAATGTG 5139 PFNPGNV 6806 203.2041 161 CAAAAATCGGAAACCTACACT 5140 QKSETYT 6807 203.1248 162 AACAAAGACCACAACCACCTG 5141 NKDHNHL 6808 202.8605 163 CTAACCGGCTCTGACATGAAA 5142 LTGSDMK 6809 202.379 164 TCTAAGGATAGTACTATGTAT 5143 SKDSTMY 6810 202.335 165 GAAGCATTCCCGCGAGCGGGC 5144 EAFPRAG 6811 202.275 166 GAACACACTCACTTAAACCCG 5145 EHTHLNP 6812 201.959 167 AGTTCGGACCCAAAAGGTCAA 5146 SSDPKGQ 6813 201.825 168 AAAACCATCGACATAGCACAA 5147 KTIDIAQ 6814 201.699 169 ACCGGTAGCTTGAACTCTATG 5148 TGSLNSM 6815 201.671 170 ATGCAACGCGAAGACGCGAAC 5149 MQREDAN 6816 201.523 171 GCCTCTACAGTCTCACTCTAC 5150 ASTVSLY 6817 201.407 172 GGCCGTGACGACCTCACAAAC 5151 GRDDLTN 6818 200.911 173 TCTAATCCGGGTAATCATAAT 5152 SNPGNHN 6819 200.872 174 GATACTTATAAGGGTAAGTGG 5153 DTYKGKW 6820 200.7787 175 CCACCCAACGGCAGCAGTAGA 5154 PPNGSSR 6821 200.32615 176 GCTTCTTATAGTATTTCTGAT 5155 ASYSISD 6822 200.269 177 GTGACTGTTAGTCTGGATGGG 5156 VTVSLDG 6823 200.021 178 ATGGCCATAGGCCACTCCCCA 5157 MAIGHSP 6824 200 179 TTTCGGACGGTGTATACTGGT 5158 FRTVYTG 6825 200 180 AAAAAACGGCAGCCCATCGCC 5159 KKRQPIA 6826 200 181 AAAAATAAGCTCTACTATGGC 5160 KNKLYYG 6827 200 182 TCTACATCTCCGGTTAACAGC 5161 STSPVNS 6828 200 183 GGGTCTGGGATTGCGGGGACT 5162 GSGIAGT 6829 200 184 ATCGACGTACTGAACGGAAGT 5163 IDVLNGS 6830 200 185 GGTCATAATATGGCACAGGCG 5164 GHNMAQA 6831 200 186 ACGAGGAGCAACTCCGACGAA 5165 TRSNSDE 6832 200 187 GGAGCAAAAGGAACCATGGGC 5166 GAKGTMG 6833 200 188 GCTACTACTCTTACTGGTGAT 5167 ATTLTGD 6834 200 189 TTCAACACATCGTCGGAATTC 5168 FNTSSEF 6835 200 190 TATACGGCGCAGACCGGCTGG 5169 YTAQTGW 6836 200 191 CGAGTAAACAACGACGCAATA 5170 RVNNDAI 6837 200 192 ACTATTCAGCTTACTGATACT 5171 TIQLTDT 6838 200 193 GCCAGCATGCCCTCTGTAGAC 5172 ASMPSVD 6839 200 194 AATCAGGTGGGTGCGTCTGCG 5173 NQVGASA 6840 200 195 GGAAACATGGTGACTCCAAAC 5174 GNMVTPN 6841 200 196 CGTGGTGACCAAGGCACACAC 5175 RGDQGTH 6842 200 197 TCGAGTGATTCTCGTATTCCG 5176 SSDSRIP 6843 200 198 GGACTGCACGGCACCAACGCA 5177 GLHGTNA 6844 200 199 TCTAGTTATCAGTCTGGGCTG 5178 SSYQSGL 6845 199.609 200 ACAGCCTACTCGCCCACAGTC 5179 TAYSPTV 6846 199.236 201 CGCAGTGACACCACTAACGCC 5180 RSDTTNA 6847 198.59 202 CGTATTGTGGCTAATGAGCAG 5181 RIVANEQ 6848 197.795 203 ATCCACAACGAATCATACGTC 5182 IHNESYV 6849 197.72 204 CAGCAGAATACGCGTTTGCCG 5183 QQNTRLP 6850 197.4665 205 GGTATCAACTCCTCACACTTC 5184 GINSSHF 6851 197.224 206 GGTATGACTTCTAATCAGGTT 5185 GMTSNQV 6852 196.916 207 AGGGAGATTGTTCATAGTAAT 5186 REIVHSN 6853 196.5775 208 GCAGAACACACGTACACGGTC 5187 AEHTYTV 6854 196.501 209 CCTGCTACGCTACACCTGACA 5188 PATLHLT 6855 196.1975 210 AAGCAGACTGATAGTAGGGGT 5189 KQTDSRG 6856 196.15 211 ACTATGGTAGAAGTACTGCCA 5190 TMVEVLP 6857 195.586 212 ATCCCAACCGGCCAAACTAGC 5191 IPTGQTS 6858 195.499 213 ATGATAAAAACCAACATGTTG 5192 MIKTNML 6859 195.198 214 GCGGAACGACCCACTAGAGAC 5193 AERPTRD 6860 194.842 215 CGGGATCTGGGGCAGACCGGC 5194 RDLGQTG 6861 194.34 216 AATGAGGGGCGTGTGCAGACT 5195 NEGRVQT 6862 194.00545 217 ACTGCGGCTAGTACTGCGAGG 5196 TAASTAR 6863 193.5855 218 ACCCAAGGGAACAACATGGTA 5197 TQGNNMV 6864 193.362 219 CATAGTACTTTTCCTACGACT 5198 HSTFPTT 6865 193.274 220 CAATCTATCGGCCACCCCGTT 5199 QSIGHPV 6866 191.64595 221 TCGGGTGTTAATAGTGAGCGT 5200 SGVNSER 6867 191.3763 222 CCTCACGCCAACGGAGTGACA 5201 PHANGVT 6868 191.349 223 GACCACCAACAAGCCCTAGCT 5202 DHQQALA 6869 191.305 224 AGTCAGCAGGGTTTTACTCTG 5203 SQQGFTL 6870 191.2955 225 ACAAACGCTGCTCTAGTACCA 5204 TNAALVP 6871 191.1973 226 GGTGTTAGTAGTAATTCTGCG 5205 GVSSNSA 6872 190.1595 227 CATGATACGGTTGGGGAGAGG 5206 HDTVGER 6873 189.859 228 GCGTTAAACGCCCAAGGGATC 5207 ALNAQGI 6874 189.3825 229 CATGATAGTATGTGTTGTGCG 5208 HDSMCCA 6875 189.35 230 TACATCGCGGCAGGGGAACAA 5209 YIAAGEQ 6876 189.046 231 GAGAATGCTCGTGAGGGTGTG 5210 ENAREGV 6877 188.331 232 GCTACGGTTTATAATGAGTTG 5211 ATVYNEL 6878 188.18 233 GACACTAACGGAATAAAATCA 5212 DTNGIKS 6879 187.628 234 AAGCCGACTGCGAATGATTGG 5213 KPTANDW 6880 187.4884 235 TATGAGAGTACTCATGTTAAT 5214 YESTHVN 6881 187.1195 236 TACACCAACGGGGGCCACCTA 5215 YTNGGHL 6882 187.0304 237 GTAGACAAATCTAGCCCAGTG 5216 VDKSSPV 6883 186.9365 238 CCAATCCAAAACGAATCGTCC 5217 PIQNESS 6884 186.748 239 ATACACAAATCTAGCGTCGAA 5218 IHKSSVE 6885 186.654 240 CATGATATTAGTCTGGATCGT 5219 HDISLDR 6886 186.65 241 TGGTGAGGGGCTGAGTTTGCC 5220 W*GAEFA 6887 186.1 242 TACTCTCAATCCATAAAAAAC 5221 YSQSIKN 6888 186.0095 243 GCCCAAGACAACAACCACGAC 5222 AQDNNHD 6889 185.6231 244 GGGCAGAAGGAGACTACTGCG 5223 GQKETTA 6890 184.948 245 AAAAGCGAAGTACCCGCCCGA 5224 KSEVPAR 6891 184.116 246 GAACTTAACACCGCACACGCA 5225 ELNTAHA 6892 184.059 247 AGCACAAACGCGGGACAAAGG 5226 STNAGQR 6893 183.7145 248 AAGGCGGTTTCGGAGATTATT 5227 KAVSEII 6894 183.539 249 ACCTTCACGGTCGACGGTAGA 5228 TFTVDGR 6895 183.2535 250 AGTACGAGTGGTTATAATACT 5229 STSGYNT 6896 182.703 251 AATCATAGTCTGTCGGAGCAT 5230 NHSLSEH 6897 182.427 252 TCTATGCAGGATCCTTCTTTG 5231 SMQDPSL 6898 182.375 253 GAACAACAAAAAACAGACAAC 5232 EQQKTDN 6899 182.331 254 GCTGTTGTGAATGAGAATATG 5233 AVVNENM 6900 182.3 255 GGTCCCGGAGAAAACTACCGA 5234 GPGENYR 6901 182.165 256 TACAACGCAGGCGGAGAACAA 5235 YNAGGEQ 6902 182.14 257 GTCCTCTCCTCCAACCTGTAC 5236 VLSSNLY 6903 181.3605 258 GGTCTTTATCAGAATCCTACG 5237 GLYQNPT 6904 181.2475 259 AGTTCGGGGAGTTTGATTACT 5238 SSGSLIT 6905 180.8125 260 TATAATACGGATCGGACTAAT 5239 YNTDRTN 6906 180.0485 261 GAGAAGCCTCAGCATAATAGT 5240 EKPQHNS 6907 179.9715 262 GCGGCTTATGAGCATGCGCCT 5241 AAYEHAP 6908 178.7065 263 GGCGGCAACTACAACACAACT 5242 GGNYNTT 6909 178.62 264 TATCTGAATAGTACGCAGATT 5243 YLNSTQI 6910 178.4905 265 TCTAATTCTAATACTGCTGCT 5244 SNSNTAA 6911 178.119 266 TCGGATAATAGGAATACTGCG 5245 SDNRNTA 6912 178.09355 267 CGCTCGTTGGACAGCGGGATG 5246 RSLDSGM 6913 177.6395 268 GTTATGGATACGCATGGGATG 5247 VMDTHGM 6914 177.54 269 CATGTTACGGCGGTGGTTGAT 5248 HVTAVVD 6915 177.447 270 AGTATCACCCACAGCAACACC 5249 SITHSNT 6916 177.4093 271 GGATACGGCAGTTACAGCAAC 5250 GYGSYSN 6917 177.0995 272 CGTTGGTCTGAAAACAACTCC 5251 RWSENNS 6918 176.788 273 ATGTCTAGCCACACCGTCCAA 5252 MSSHTVQ 6919 176.741 274 TATGTTAGGGCGCAGGATCAG 5253 YVRAQDQ 6920 176.713 275 TTTGAGGGTGATAAGACTTAT 5254 FEGDKTY 6921 176.655 276 GTTAGCTCCGGCCACACGAAA 5255 VSSGHTK 6922 176.4715 277 TCGATGAACCTGCCAACTTCA 5256 SMNLPTS 6923 176.425 278 CTGAATCCTCAGCATGAGTTG 5257 LNPQHEL 6924 176.19 279 CTTCCGCCTGCGTCGGCGGGT 5258 LPPASAG 6925 176.057 280 GGAGGGAACTCCCACGGGGTA 5259 GGNSHGV 6926 175.7625 281 GGGGGTACGGGGTTGTCGAAG 5260 GGTGLSK 6927 175.714 282 AGTTTGAATTCTTCGAGTACT 5261 SLNSSST 6928 175.4585 283 ATGCCTAGTGAACCACCAGGG 5262 MPSEPPG 6929 175.45 284 GTTGTGCATTCGAGTATTACT 5263 VVHSSIT 6930 175.18685 285 TTGAGTCTGGCTGGGAATAGG 5264 LSLAGNR 6931 175.0985 286 GCGGACATGCAACACACCGTA 5265 ADMQHTV 6932 175.003 287 TTTCGTGATGGTCAGGGTATG 5266 FRDGQGM 6933 174.983 288 ACCGGAACAGCGATCTCCCGA 5267 TGTAISR 6934 174.5465 289 ATGGGGAAGCATGAGGGTCTT 5268 MGKHEGL 6935 174.3418 290 CCGGAATCCGCCGCCAAAAGC 5269 PESAAKS 6936 174.268 291 ACCCAAGCCTTCTCCCTAGGC 5270 TQAFSLG 6937 174.2365 292 ACTGATGGTATTTTTCAGCCT 5271 TDGIFQP 6938 174.014 293 GGGAGCCCAGTGATAGTAAAC 5272 GSPVIVN 6939 173.652 294 GGGCGTGATAATCATCATGCG 5273 GRDNHHA 6940 173.4132 295 CCGCGTTCTATTACGGAGTTG 5274 PRSITEL 6941 173.403 296 TGGGTAAACAGTGTGGGCAAC 5275 WVNSVGN 6942 173.244 297 GTTCATGGGACGTTGACTTAT 5276 VHGTLTY 6943 173.1685 298 GGTGTGTATATTGATGGTCGG 5277 GVYIDGR 6944 173.081 299 ATGAGTAATGATTTGCCTGGG 5278 MSNDLPG 6945 172.671 300 AATCGGTCGGATAGTTTTGCG 5279 NRSDSFA 6946 172.6595 301 GGGCAAACAAACGCAGTACAC 5280 GQTNAVH 6947 172.4582 302 TACGTCGACAAATCAATGACA 5281 YVDKSMT 6948 172.1735 303 AGTGTGATGGTGGGTACGAAT 5282 SVMVGTN 6949 171.86 304 ATTGGTCTGCAGAATTCTACT 5283 IGLQNST 6950 171.84715 305 AACGACCGACCGCTTGCCAGC 5284 NDRPLAS 6951 171.464 306 CTCATGGGCAGTCCAGGCGCG 5285 LMGSPGA 6952 171.27 307 ATTGATCGTAGTGCTAGTTTG 5286 IDRSASL 6953 171.009 308 ATTCAGGCGAAGAATTCTGAG 5287 IQAKNSE 6954 170.983 309 CATCAGTCTTTTGATGCTGGT 5288 HQSFDAG 6955 170.699 310 GCGGTTAATGAGACTAGGCTT 5289 AVNETRL 6956 170.564 311 ATCGCGTCAACGTGGAACATG 5290 IASTWNM 6957 170.52 312 AAAGTGGACATGACCTCCAAA 5291 KVDMTSK 6958 170.4035 313 TCTCATAGTATTACGGGTCTT 5292 SHSITGL 6959 170.333 314 ACTATTACTAGTCCGTCGGTG 5293 TITSPSV 6960 170.18 315 GAACACATCTCTAGCTACGGA 5294 EHISSYG 6961 169.832 316 TTCTCAACAAACTCTGTAATC 5295 FSTNSVI 6962 169.7245 317 TCGATGGAGGGTCAGCAGCAT 5296 SMEGQQH 6963 169.71 318 GTCGACAAAAGCGAAGCCGTC 5297 VDKSEAV 6964 169.6265 319 CAAGCTAACTTATCAATAATC 5298 QANLSII 6965 169.3842 320 GTTAAGGCGAGTGCTGGGGTT 5299 VKASAGV 6966 169.1112 321 TTTGGTACTTCTTATACGACT 5300 FGTSYTT 6967 168.915 322 GGGCTCACAGGATACCCAATG 5301 GLTGYPM 6968 168.8625 323 GCTATGGGAGCACTCGTGCAC 5302 AMGALVH 6969 168.807 324 GTATACGCCACCGCACTCGCA 5303 VYATALA 6970 168.7005 325 ACATTAACAGACGTTCACCGA 5304 TLTDVHR 6971 168.7 326 CCATCCTCAGCGGGTAGCACA 5305 PSSAGST 6972 168.601 327 AAAAAACGAAAACACTAACTA 5306 KKRKH*L 6973 168.58 328 GCTTATCAGCTGACTCCGGCT 5307 AYQLTPA 6974 168.579 329 CTTGCGCCTGATAATATTGGG 5308 LAPDNIG 6975 168.515 330 ACAATCGTTTCCGCTTACGCC 5309 TIVSAYA 6976 168.3875 331 GGTAATAATTTGAGTTTGTCT 5310 GNNLSLS 6977 168.1503 332 AGCACAAACACCGAACCTAGG 5311 STNTEPR 6978 168.122 333 TCTTTTCAGACGGATCGTGCG 5312 SFQTDRA 6979 167.793 334 TTCTTAGAAGGAGTCGCTCAA 5313 FLEGVAQ 6980 167.647 335 CAAGACGTAGGACGCACGAAC 5314 QDVGRTN 6981 167.4595 336 ACGCATGGTGATCATATTCAG 5315 THGDHIQ 6982 167.197 337 GTATCAGAAGGACAACGAATC 5316 VSEGQRI 6983 167.049 338 AACATGGGTCCAATGGGCCGG 5317 NMGPMGR 6984 166.961 339 CTACCCTCAACAGAAACTTTG 5318 LPSTETL 6985 166.942 340 GGTGGTATGTCGGCGCATTCG 5319 GGMSAHS 6986 166.775 341 GGGATGATCGGGCACAACGCA 5320 GMIGHNA 6987 166.716 342 ATAGACGAACGTTCCTCGATA 5321 IDERSSI 6988 166.601 343 CATGTGAATCCTACGCCGGCG 5322 HVNPTPA 6989 166.586 344 TGGTCGAGAACTGGAAACACC 5323 WSRTGNT 6990 166.483 345 ATCAAAGACTCGTACCTTACT 5324 IKDSYLT 6991 166.205 346 TTGAACCAAAACAGTGTCTCC 5325 LNQNSVS 6992 166.174 347 TCTGGTCCGATTCCTGCTGTT 5326 SGPIPAV 6993 166.146 348 ATGCAAGGGCTTAACAACATG 5327 MQGLNNM 6994 165.268 349 TCAAACAGCGGAGGCAACCAC 5328 SNSGGNH 6995 165.1895 350 ACGAGTACGATGACTGCGCGT 5329 TSTMTAR 6996 165.115 351 GAGAATAGTGATTTGTCTTAT 5330 ENSDLSY 6997 165.08 352 CATCCTGGGAATAGTTCTGTG 5331 HPGNSSV 6998 165.062 353 TTAACACCCCAAGGGACTAGT 5332 LTPQGTS 6999 165.0315 354 ACCGACACCCGAAAAAACGAC 5333 TDTRKND 7000 164.843 355 GGGGAGACGCTGAGGTCTCAG 5334 GETLRSQ 7001 164.72165 356 AGCGGTGTATCAGAAGGAAAC 5335 SGVSEGN 7002 164.715 357 ACTCAGTATGGTACTCTGCCG 5336 TQYGTLP 7003 164.526 358 GGGACGGTTAACTCAAGTGCA 5337 GTVNSSA 7004 164.3765 359 GGTAAAGCAACCTTAGTCCTC 5338 GKATLVL 7005 164.3755 360 GGTATATACCCGGCATCCACC 5339 GIYPAST 7006 164.34 361 GGTGTTATGTCTAATGCTACT 5340 GVMSNAT 7007 164.06 362 ACTCATGTGATTGGGGCTGTG 5341 THVIGAV 7008 163.918 363 ACTCGGAGTGATATTGGTGTG 5342 TRSDIGV 7009 163.7255 364 ACGCTTACATTATCTACCCTC 5343 TLTLSTL 7010 163.5555 365 TATAATGAGTCTTCGAATGCG 5344 YNESSNA 7011 163.314 366 TCGACGCAGGCGCAGACCGGC 5345 STQAQTG 7012 163.15 367 CGCGACATGATCAACTCATCA 5346 RDMINSS 7013 162.984 368 ACTAAGGGTAATAATCTGGTT 5347 TKGNNLV 7014 162.899 369 GGTTCTACGGTGTCGGCGCAG 5348 GSTVSAQ 7015 162.631 370 AGGGGTGATACTATGAATTAT 5349 RGDTMNY 7016 162.425 371 CATGCGGATGTGAATGCTGGG 5350 HADVNAG 7017 161.99 372 AGCGTTGTCAACACCAACATC 5351 SVVNTNI 7018 161.9445 373 TCTAATGTTCATGTTGTTAAT 5352 SNVHVVN 7019 161.753 374 TCGGTTGATAAGCCGCCGGGG 5353 SVDKPPG 7020 161.487 375 GACCGCACCTACTCAAACACA 5354 DRTYSNT 7021 161.475 376 TACTCCGGAGAACTAAACAAA 5355 YSGELNK 7022 161.125 377 TATGATAAGACTTTGAGTGTT 5356 YDKTLSV 7023 160.90695 378 CACACCGCCACCCTTAGCAGC 5357 HTATLSS 7024 160.8605 379 GCTCTGGAGAGGGCTCAGTAT 5358 ALERAQY 7025 160.837 380 GGTACGAGTGATAATTATAGG 5359 GTSDNYR 7026 160.175 381 CATGTGAATAGTAGGGATCTT 5360 HVNSRDL 7027 160.127 382 TCGTCAGACGTTACCAGACAA 5361 SSDVTRQ 7028 160.07 383 GCTCATCATATGACGACGGAG 5362 AHHMTTE 7029 160.019 384 GAGGTGTCTAGGGATGGTCTG 5363 EVSRDGL 7030 159.7445 385 GTGGGCCGTGACGCAGAAGCT 5364 VGRDAEA 7031 159.58 386 GCACACCAAAAAGACCTACGC 5365 AHQKDLR 7032 159.3139 387 AGTGTTCTGAGTAGTTCGACT 5366 SVLSSST 7033 159.208 388 CTGGGTACGCTGCTTAGTCAG 5367 LGTLLSQ 7034 159.04 389 TCACAAAAACCAATCGACGAC 5368 SQKPIDD 7035 158.663 390 GATAATGTGCATGGGCAGGTG 5369 DNVHGQV 7036 158.321 391 GGTTCGCACAACGGGCCGACA 5370 GSHNGPT 7037 157.748 392 ATCTCCGGTAGTAGCAGTCTA 5371 ISGSSSL 7038 157.64 393 GGTTTTCATATTAATGGTGAG 5372 GFHINGE 7039 157.326 394 ATGAGTGATGGGCATTCGAAG 5373 MSDGHSK 7040 157.296 395 ACTGTTGGTGGTAATCATCAT 5374 TVGGNHH 7041 156.895 396 AATGCTACTCCGCCGAATCAT 5375 NATPPNH 7042 156.8609 397 ACGGGTATGAATAGTAATAAG 5376 TGMNSNK 7043 156.85 398 ATCGAAGCCTACTCACGAGAC 5377 IEAYSRD 7044 156.774 399 CGCGACCGTCAAGACTCGGTA 5378 RDRQDSV 7045 156.7165 400 CACACGGTTCAAATACGCGAA 5379 HTVQIRE 7046 156.6241 401 ACTTTGACGCAGACTGGGATG 5380 TLTQTGM 7047 156.5735 402 ATTAATAATTTTAATACTCTG 5381 INNFNTL 7048 156.48 403 GTAGCCGCGGGACCAGAAGCG 5382 VAAGPEA 7049 156.315 404 GATGGTAAGAATAGTTATGCG 5383 DGKNSYA 7050 156.294 405 TCCAGGCAAGAAAACTTCTCC 5384 SRQENFS 7051 156.182 406 TCTAACAGCAGTGTTGCGGTA 5385 SNSSVAV 7052 156.048 407 GATCATAGTAAGCAGAGTTCG 5386 DHSKQSS 7053 155.89425 408 TTGAGTGGTGCTGGTAGTCAG 5387 LSGAGSQ 7054 154.9295 409 GGTTGGAGTAATAATGAGTTG 5388 GWSNNEL 7055 154.4735 410 CTAATACGAGGTTCCATGGAA 5389 LIRGSME 7056 154.426 411 AATACTTATACTGCTGGTAAG 5390 NTYTAGK 7057 154.346 412 ACTCGTGGCGACATGGAATTC 5391 TRGDMEF 7058 154.246 413 CTCATGTCAGGGAAAGAAAAC 5392 LMSGKEN 7059 154.155 414 AAGGATACTAATCAGCAGATT 5393 KDTNQQI 7060 153.7595 415 CACAACGTCGGCCTAGGACAC 5394 HNVGLGH 7061 153.7 416 CCTGATCAGCCTGGTCCTTCT 5395 PDQPGPS 7062 153.51 417 ATGCAAAGAGAAGCAGCCAAC 5396 MQREAAN 7063 153.45 418 GGGCAGCGTACGACGAATGAT 5397 GQRTTND 7064 153.425 419 AAACACACAGAAAACGGGACC 5398 KHTENGT 7065 153.394 420 TTAGACGTGACGAGAATGAGA 5399 LDVTRMR 7066 153.086 421 ACGTTGGATCGGAATCAGACT 5400 TLDRNQT 7067 152.9552 422 ATCAACGCCGGCAACTACCGA 5401 INAGNYR 7068 152.8475 423 GCCGTAGACCAATCACGTTTG 5402 AVDQSRL 7069 152.8359 424 GCTCTTGGGCATCAGGGGAAT 5403 ALGHQGN 7070 152.467 425 CTTCCGCGTCATGATCAGTAT 5404 LPRHDQY 7071 152.412 426 ATTTCTGGGTCGTCGTCTCTT 5405 ISGSSSL 7072 152.2375 427 TGGAATACGAATATGGCGATT 5406 WNTNMAI 7073 151.8755 428 ATGTCGGATCGTACTTCTGAT 5407 MSDRTSD 7074 151.677 429 ACAAGGGAATCAATGTCCATC 5408 TRESMSI 7075 151.6105 430 CAGCGGGGGGAGCTTCCTGCG 5409 QRGELPA 7076 151.533 431 TCGTCTGATCCTAAGGGGCAG 5410 SSDPKGQ 7077 151.4265 432 CCGAGTGATAGGACTACTTAT 5411 PSDRTTY 7078 151.3695 433 TCTTCTTCTGATAGTCCGCGT 5412 SSSDSPR 7079 151.2845 434 GTATTACACTCTGTATCAGCA 5413 VLHSVSA 7080 151.217 435 AGTATGCAATCATACACCATG 5414 SMQSYTM 7081 151.1285 436 TCTCTGCAACTCACAGCGGGT 5415 SLQLTAG 7082 151.106 437 AACAACGTAAACCCGTACTCG 5416 NNVNPYS 7083 151.0935 438 CTTGCGAATGGTATGACGGCT 5417 LANGMTA 7084 150.9825 439 GGAATCACAGGATCAACAGGA 5418 GITGSTG 7085 150.979 440 ATGCTTGTTCAGAATACTCCT 5419 MLVQNTP 7086 150.943 441 GATGCGAATGCGGGTACGAGG 5420 DANAGTR 7087 150.871 442 GAAACCGGAGCTATGACCTCT 5421 ETGAMTS 7088 150.803 443 ATACAAACTACTACAAAATGC 5422 IQTTTKC 7089 150.692 444 GCGCAGCAGAGTCTTCATGGT 5423 AQQSLHG 7090 150.673 445 ATTGATAGTACTTGGAATACG 5424 IDSTWNT 7091 150.518 446 ACCGAATCGCAAACCATGAGG 5425 TESQTMR 7092 150.4394 447 TTGATCCAAACGCAAGGCACG 5426 LIQTQGT 7093 150.329 448 ATAGTAAACATAACTCAATCG 5427 IVNITQS 7094 150.305 449 GTGGCGGTGTCTAATACGCCT 5428 VAVSNTP 7095 150.03285 450 GGTCATAGGGATTCGGGTGGT 5429 GHRDSGG 7096 149.991 451 CGGAATGAGAATCTTAATAAT 5430 RNENLNN 7097 149.913 452 GTCATGCAACGATCTGCACAA 5431 VMQRSAQ 7098 149.77 453 GTCTCGGGTCCGGTATCGGTC 5432 VSGPVSV 7099 149.7645 454 GGGGATATTCAGAGTCATAGT 5433 GDIQSHS 7100 149.392 455 GTTGAGAAGCCTCTGGAGACT 5434 VEKPLET 7101 149.24 456 GGTGTTCAGATGACTGCGGGG 5435 GVQMTAG 7102 149.14805 457 ACCACAAAAACGACATCTATG 5436 TTKTTSM 7103 149.0935 458 CCTGGGAATCCGTCTAGTAAT 5437 PGNPSSN 7104 148.9075 459 GCTTCGCGGCCTGCGGCTCAG 5438 ASRPAAQ 7105 148.8831 460 GTTCATGATCAGGGGGCTGGG 5439 VHDQGAG 7106 148.829 461 TCAGGTTCGGAATACCGTACC 5440 SGSEYRT 7107 148.812 462 TACGTGGACGACAACAGTCGC 5441 YVDDNSR 7108 148.744 463 ATGGCCGGTGACCAAGAACTC 5442 MAGDQEL 7109 148.7 464 CCTTTGCACAACATACCTCCT 5443 PLHNIPP 7110 148.609 465 AGTGGGATTGGTACTTATTCT 5444 SGIGTYS 7111 148.357 466 TCGAACGCAGACATCCTCGCC 5445 SNADILA 7112 148.08 467 AGTCACAACCAAGTAAACGTA 5446 SHNQVNV 7113 147.981 468 CAGCATTCTCCGAAGCCGGTT 5447 QHSPKPV 7114 147.97 469 TCCGCAAACAACATAGCCCCC 5448 SANNIAP 7115 147.813 470 GAAGAAACACGGACCAGAATG 5449 EETRTRM 7116 147.667 471 CTGTCTAATTCGATTACGCCT 5450 LSNSITP 7117 147.594 472 AGTGCTTTGAATAGTGTGGAT 5451 SALNSVD 7118 147.326 473 ACTAATCTTGCTGTTACGCTG 5452 TNLAVTL 7119 147.1589 474 CAGTCGACGCTGAATAGGCCT 5453 QSTLNRP 7120 147.0302 475 ATAGAACACATGCTTAGACCC 5454 IEHMLRP 7121 146.9635 476 CCGACTCCTAATGAGCATATG 5455 PTPNEHM 7122 146.84 477 ATTAATGAGATTGGTAGGATG 5456 INEIGRM 7123 146.786 478 AACAACGACAACGTCTACGTG 5457 NNDNVYV 7124 146.764 479 ATAGTCCACACCCCGCAAGTG 5458 IVHTPQV 7125 146.309 480 CATAAGAGTGAGAGTCATAAT 5459 HKSESHN 7126 146.142 481 TCATCGTCAGACTCACCCAGA 5460 SSSDSPR 7127 146.067 482 TACTCTACAGAAGCACGAGTC 5461 YSTEARV 7128 145.9845 483 ACCTCGGGTGACCGGTACACG 5462 TSGDRYT 7129 145.963 484 GAGAAGAATCTGACTAATGCT 5463 EKNLTNA 7130 145.88775 485 ACAAGGGACCAAAGGTCTACA 5464 TRDQRST 7131 145.8855 486 GCGACTGATAAGATGACTCCT 5465 ATDKMTP 7132 145.881 487 AATAGTTATACTGCTGGGAAG 5466 NSYTAGK 7133 145.87565 488 ACGCTGGATACTAAGGATCTT 5467 TLDTKDL 7134 145.82 489 GCATCCAACGGGCAAGTTAAC 5468 ASNGQVN 7135 145.7395 490 ACCTCAATATCGTCGCAAAGC 5469 TSISSQS 7136 145.707 491 GATAATAGTCCTGCTAATCAT 5470 DNSPANH 7137 145.5712 492 AACTCCAGGGAAATGGGTGTA 5471 NSREMGV 7138 145.562 493 ACCAGCGCGTCTGAAAACTGG 5472 TSASENW 7139 145.56 494 ACTGTAGGATCCTCATACGCT 5473 TVGSSYA 7140 145.0453 495 CAACAATCACAAAACTCTATA 5474 QQSQNSI 7141 144.9825 496 CTTCGGGATGGGATTGCTTCT 5475 LRDGIAS 7142 144.9725 497 GTGCAAAAAACGACGGCTTGG 5476 VQKTTAW 7143 144.78 498 ATGAGTACGGTTCTTCGGGAG 5477 MSTVLRE 7144 144.5125 499 AGTATGGATGCTCGGTTGACG 5478 SMDARLT 7145 144.404 500 GGCGCCCGTACAATCTTAGAC 5479 GARTILD 7146 144.3975 501 CACGAAAGCCACTACGTGTCA 5480 HESHYVS 7147 144.2755 502 CTTGAGGGTCAGAATAAGACG 5481 LEGQNKT 7148 144.137 503 CGGGACTTGAGACCCGTGACG 5482 RDLRPVT 7149 143.788 504 CAGATTTTGAATTATAGTGTG 5483 QILNYSV 7150 143.741 505 ATAAGTGTAGGTGTGTCCGTA 5484 ISVGVSV 7151 143.727 506 AAGGCGGGTGAGTATAGGGAT 5485 KAGEYRD 7152 143.693 507 CTTACTACGAATGGTATGCTG 5486 LTTNGML 7153 143.66 508 ACTAGTAATTATATGCATGAG 5487 TSNYMHE 7154 143.642 509 ACCCACAACTCTACAGGCCTT 5488 THNSTGL 7155 143.502 510 AATAATGTTGTTAGGGATGAT 5489 NNVVRDD 7156 143.142 511 AGTGGGACGTATGCTAGTCGT 5490 SGTYASR 7157 143.123 512 CTGTCTCACGCCATGGACCGG 5491 LSHAMDR 7158 142.937 513 AATTGGAATTCTGAGGGTACG 5492 NWNSEGT 7159 142.7425 514 AGTCTGCGTCCAACCCTACCT 5493 SLRPTLP 7160 142.4292 515 TACCAAACGGGAGACAAAGAC 5494 YQTGDKD 7161 142.104 516 CGCAGCGACAAAGGAACGTTG 5495 RSDKGTL 7162 142.1004 517 TCTACCATCGGCAACAGCACG 5496 STIGNST 7163 142.0895 518 GAAAACAACATGCAACACGGC 5497 ENNMQHG 7164 142.037 519 AAGTATACGGAGTCGAATGCG 5498 KYTESNA 7165 142.0295 520 CCAACAAACAACTTAAGTATG 5499 PTNNLSM 7166 141.91 521 TGCAAAAACAACTCAGAATGC 5500 CKNNSEC 7167 141.874 522 ACGGTTAATGCGGATGGGTCG 5501 TVNADGS 7168 141.672 523 TTTTCTGGTCAGGCGTTGGCT 5502 FSGQALA 7169 141.6645 524 AATCATATTAGGAATCCTATG 5503 NHIRNPM 7170 141.628 525 ATGGTGAATTCGGAGAATACT 5504 MVNSENT 7171 141.624 526 ACTGATGGGCCGCGTCTGGCT 5505 TDGPRLA 7172 141.5814 527 TTCAACGGGTACGTCATGGCA 5506 FNGYVMA 7173 141.042 528 AATGCGAATGGGCCTGTGAGT 5507 NANGPVS 7174 141.0385 529 AGTACGAGTCAGGAGAATAGG 5508 STSQENR 7175 140.9233 530 CAAGGGACTCTCTTGTCTCCA 5509 QGTLLSP 7176 140.773 531 CTAATCACAGCCACCACTAAC 5510 LITATTN 7177 140.4315 532 TCTGGCGTCTCGAAAGAACGG 5511 SGVSKER 7178 140.3655 533 TCTACTTCAATAGGAGTGGTA 5512 STSIGVV 7179 140.351 534 TCTCATGTGACTGTTACGGAT 5513 SHVTVTD 7180 140.31 535 TCTAATAATCTGAATCAGGAG 5514 SNNLNQE 7181 140.282 536 GCAAACCACGACAACATCGTG 5515 ANHDNIV 7182 140.0405 537 GACACGTCCTCCGGCAACAGG 5516 DTSSGNR 7183 140.01 538 GTGGTTCCTATGCCTACTACT 5517 VVPMPTT 7184 139.945 539 CTTACTAATAATTTTAAGGAT 5518 LTNNFKD 7185 139.782 540 TCTTCGCCTACTAAGGGTACT 5519 SSPTKGT 7186 139.7594 541 GATATTCCGTCTGATAATACG 5520 DIPSDNT 7187 139.44 542 TACACGGGATTCGAATTGAGA 5521 YTGFELR 7188 139.43 543 AACTCAGGTAACAACCCCATC 5522 NSGNNPI 7189 139.4185 544 ACGACCCGAAACGAACACTCG 5523 TTRNEHS 7190 139.3175 545 AATGTGGGTAATACTCTTGGG 5524 NVGNTLG 7191 139.128 546 TACCACACCCACCAAGTCGCA 5525 YHTHQVA 7192 138.871 547 GGTAGTGCGAGTAATAGTGGT 5526 GSASNSG 7193 138.841 548 GGGAAGAATCAGCCTACTCCG 5527 GKNQPTP 7194 138.839 549 TTCACCGCCACTTTAGGAACC 5528 FTATLGT 7195 138.809 550 ATGAACCAAATGGGCGGCCTG 5529 MNQMGGL 7196 138.794 551 AACGTGTCACTAACGCAAACG 5530 NVSLTQT 7197 138.62365 552 TCGTCTAGCAACACAAACGCT 5531 SSSNTNA 7198 138.538 553 ACTAATTCTAATCAGAGTTCG 5532 TNSNQSS 7199 138.513 554 ATAAGTCACGACCTTAAATAC 5533 ISHDLKY 7200 138.4685 555 GATTCGACGTATGTTTTGGCT 5534 DSTYVLA 7201 138.402 556 ATGAACACCGGCTCTTCGAGT 5535 MNTGSSS 7202 138.35 557 GCCGGAAACTACCAATCATCA 5536 AGNYQSS 7203 138.2335 558 ACGATTTATAATATGGGTCCG 5537 TIYNMGP 7204 138.1385 559 GTATCAACGACAACGGACCGG 5538 VSTTTDR 7205 137.9925 560 GGGGTGACTGTTAGGGAGCTT 5539 GVTVREL 7206 137.96205 561 GATATTACTAATCAGTCGTAT 5540 DITNQSY 7207 137.802 562 AATCAGTCGCTTACTATGGAT 5541 NQSLTMD 7208 137.363 563 ACGAATTATAATATTGGTCCG 5542 TNYNIGP 7209 137.0645 564 CGTGGTACGGAGGGGACGCCG 5543 RGTEGTP 7210 137.0621 565 CCCATAACACGGGAATCGGGA 5544 PITRESG 7211 136.943 566 ACCGGACAAGCGGGCGGATCG 5545 TGQAGGS 7212 136.857 567 ATGACTAAACACGACGCGACG 5546 MTKHDAT 7213 136.624 568 CCTATACCCCACGGTTCATCC 5547 PIPHGSS 7214 136.299 569 ACGACTGGGGGGACGGGGATG 5548 TTGGTGM 7215 136.1295 570 CTAACCGAATCTGTGAGAAAC 5549 LTESVRN 7216 135.933 571 AGTAGTAATCTGACTTTGTCT 5550 SSNLTLS 7217 135.86 572 TTGAATAATTCTGCGACTGTT 5551 LNNSATV 7218 135.76 573 GCATACGGATCGTCCGGAAGA 5552 AYGSSGR 7219 135.5095 574 GTTTCTTATGATAATGGGTCG 5553 VSYDNGS 7220 135.48 575 CCGAGTCAGAGTAGGTCGCTT 5554 PSQSRSL 7221 135.38455 576 GTCCTGGTTAACGTACACAAC 5555 VLVNVHN 7222 135.346 577 TTGATGACTGGTACTGCGTCG 5556 LMTGTAS 7223 135.327 578 GCTGCTGGTAATCCTACTCGT 5557 AAGNPTR 7224 135.3067 579 TCCGCGCAATCTTTCGTAGTT 5558 SAQSFVV 7225 134.721 580 CAAGACCAAACGAGCAACCGT 5559 QDQTSNR 7226 134.721 581 CAGTCGATTGGGCATCCGGTG 5560 QSIGHPV 7227 134.625 582 GCTGGGGTGCGTGAGTCGTTT 5561 AGVRESF 7228 134.586 583 AATACTAATTATGCGATGCAT 5562 NTNYAMH 7229 134.493 584 GAGCGGAGTACGCATAATGTT 5563 ERSTHNV 7230 134.479 585 ATGTCCGGATCCATGATATCA 5564 MSGSMIS 7231 134.414 586 TCTGGCCAAGGATTCTCGGCA 5565 SGQGFSA 7232 134.3465 587 ACATTCACTACTCTGGGCAAA 5566 TFTTLGK 7233 134.2015 588 GACGCAAACGCTGGCACAAGA 5567 DANAGTR 7234 134.063 589 AGGGATACGGCTAAGGGGGTG 5568 RDTAKGV 7235 133.882 590 GTGCGGTCTGGTAATAAGCCG 5569 VRSGNKP 7236 133.87 591 CCCCAATGGGGAACTGACCCG 5570 PQWGTDP 7237 133.743 592 GCCTTCCAAAACACCGGCGCA 5571 AFQNTGA 7238 133.743 593 GCGACGACTCAGCTGATGACT 5572 ATTQLMT 7239 133.675 594 ACGAACGCGAGCGAAGGCTCA 5573 TNASEGS 7240 133.642 595 ATGCTCACAGAAACCAAAGCA 5574 MLTETKA 7241 133.57 596 ACGAATAATTTGCTGGCTCAG 5575 TNNLLAQ 7242 133.517 597 GATGTTTTGCTTAAGAATTTT 5576 DVLLKNF 7243 133.49 598 TATACGCCTGGGCTTACTGAG 5577 YTPGLTE 7244 133.356 599 CGGCATGCTTCGGATGCTAAT 5578 RHASDAN 7245 133.22 600 AGTAAGGGTGATCAGCTTAAT 5579 SKGDQLN 7246 133.1865 601 GTGCTGGTTACTCAGAATCAT 5580 VLVTQNH 7247 133.0645 602 CGACAAGGCGACTTAAAAGAA 5581 RQGDLKE 7248 132.97895 603 ATTCAGTCGCAGTCGCAGTTG 5582 IQSQSQL 7249 132.832 604 AAAATAGAAAGCGGAACCATA 5583 KIESGTI 7250 132.825 605 ACAACTCTTAGCCAACAAAGC 5584 TTLSQQS 7251 132.567 606 TTTCAGTTGGCTAGTAATCCG 5585 FQLASNP 7252 132.4465 607 TGGATTTCTACTGAGATGAGG 5586 WISTEMR 7253 132.356 608 GCCATAACAATCACTCAAAAA 5587 AITITQK 7254 132.1895 609 GTTACTGGTGTTGATTATGCG 5588 VTGVDYA 7255 131.7275 610 ATAATAGCATCCTCTACCACG 5589 IIASSTT 7256 131.506 611 ATTTATACGAATAGTCATGTT 5590 IYTNSHV 7257 131.43 612 AACGACATCCCCACACGAGCC 5591 NDIPTRA 7258 131.424 613 GGCGTAACCAACGCTTCCAAA 5592 GVTNASK 7259 131.404 614 AGGGGTAACACTCTCGAAATG 5593 RGNTLEM 7260 131.381 615 GGTATTAATCATGTGGCGTCT 5594 GINHVAS 7261 131.36 616 TTCAACGAAACTGCCGGGCGA 5595 FNETAGR 7262 131.2915 617 GCCTCGCAATCAGAAAAAAAC 5596 ASQSEKN 7263 131.243 618 GAACTTAACGAAAGGAACCTC 5597 ELNERNL 7264 131.06 619 GGAGAACAAAGCCACAACCAA 5598 GEQSHNQ 7265 130.951 620 TTGACTAATGATAATAAGTTG 5599 LTNDNKL 7266 130.846 621 TCTTATGGGCAGGGTCTGGAG 5600 SYGQGLE 7267 130.8108 622 CACAGTGACATGGGCTCAAGC 5601 HSDMGSS 7268 130.758 623 GCGTTAAAATCCGACAGCGCC 5602 ALKSDSA 7269 130.684 624 ACGAATCTTTCTCCTAAGACG 5603 TNLSPKT 7270 130.64725 625 GCTGATACGAATATTATTGTG 5604 ADTNIIV 7271 130.47 626 AGTGAGGGTAGTTCGCGGTCG 5605 SEGSSRS 7272 130.30865 627 AACTCTAGTAACACTGGTTGG 5606 NSSNTGW 7273 130.26 628 GTAACGAACGAATCCCGCGCC 5607 VTNESRA 7274 130.2145 629 GGGCGGCACACATTAGCGGAC 5608 GRHTLAD 7275 130.1035 630 GCTGTTGTGAATGTTGCGCAG 5609 AVVNVAQ 7276 130.094 631 AAAAAACCACAACAGTGACTA 5610 KKPQQ*L 7277 130.08 632 GGCAACGCTTCCGGAAACCCA 5611 GNASGNP 7278 129.97 633 TTTGCGGCTGGGGCGCATGGT 5612 FAAGAHG 7279 129.69 634 GGAGGAAACCAAAACCTTACT 5613 GGNQNLT 7280 129.6198 635 CATACGCAGTCGACGGGTTAT 5614 HTQSTGY 7281 129.541 636 CTATTGGGAAACGCACCCACA 5615 LLGNAPT 7282 129.534 637 GAGAAGGGGAATAGTGGGGTT 5616 EKGNSGV 7283 129.5155 638 GGCACGGAACCGCGCACTGCA 5617 GTEPRTA 7284 129.37 639 ATGCATGCGCAGGAGTCTCGT 5618 MHAQESR 7285 129.14615 640 CTGATTTCGACTGGTAATAAT 5619 LISTGNN 7286 129.021 641 AAGAATAATAATTCTGATTCT 5620 KNNNSDS 7287 128.767 642 GGGACATTAGCCTCAATGTCC 5621 GTLASMS 7288 128.734 643 AGGATTGATACGTTGTTGGTG 5622 RIDTLLV 7289 128.385 644 ATTTCGGGGTCTCATTTGAAT 5623 ISGSHLN 7290 128.3305 645 ACGGTTGAGGGTTCTTATCCG 5624 TVEGSYP 7291 128.288 646 ACGGAGTATCTGGCTGGTCTG 5625 TEYLAGL 7292 128.224 647 TATCTGGAGGGTGCTCATCGT 5626 YLEGAHR 7293 128.166 648 TTATCCGCAACATCTACGATG 5627 LSATSTM 7294 128.1455 649 ATGCTTAGTCAGGTTCTGACG 5628 MLSQVLT 7295 128.142 650 GCCAGGAACGTAATGCTGGGG 5629 ARNVMLG 7296 128.128 651 CTTCATGGGAATTTTAGTCAG 5630 LHGNFSQ 7297 128.112 652 GGCCACGGAAGTGACTTGACC 5631 GHGSDLT 7298 128.0576 653 GGTGTGAATTATCATACTACG 5632 GVNYHTT 7299 127.702 654 TATCTGCAGACGGGTACTCTG 5633 YLQTGTL 7300 127.624 655 GTAAACGGGGGAAAACCAGTC 5634 VNGGKPV 7301 127.5325 656 GAAGTAGGTAAAACCACCCAC 5635 EVGKTTH 7302 127.5065 657 CGACCCCCGAACGAAAACAGA 5636 RPPNENR 7303 127.49235 658 GTGGATAAGAATCATCCTTTG 5637 VDKNHPL 7304 127.431 659 AGTAAGTCGACTGAGATTATG 5638 SKSTEIM 7305 127.281 660 ACCGCTCTTCTATCTAACTTA 5639 TALLSNL 7306 127.228 661 ATGCACACAAGTAGACCCCCA 5640 MHTSRPP 7307 126.861 662 ACTCCAACTAACGGGAACCCT 5641 TPTNGNP 7308 126.785 663 ACGACGTCTGTGGAGAAGACT 5642 TTSVEKT 7309 126.7725 664 CAATACGACGCCAGCCGACAA 5643 QYDASRQ 7310 126.66 665 TACAACGCCCACGAATCATTC 5644 YNAHESF 7311 126.521 666 GACAACCAACAAGCCCTAGCT 5645 DNQQALA 7312 126.49 667 ACGAAGAGTTTTAATGATCTT 5646 TKSFNDL 7313 126.488 668 TTAGCCGACTCAAACAGCAAA 5647 LADSNSK 7314 126.48 669 CCGAGTACTCATGGGTATGTT 5648 PSTHGYV 7315 126.4775 670 CAGGTTCAGGGGACTCTGGGG 5649 QVQGTLG 7316 126.4394 671 CTGACTGCTGTTGCGATTAGT 5650 LTAVAIS 7317 126.235 672 AGGTATGAGAGTACTAGTGCT 5651 RYESTSA 7318 126.21 673 GCGGATCATAATCATATTGCT 5652 ADHNHIA 7319 126.21 674 TGGAATGCTGAGAATAGTAAG 5653 WNAENSK 7320 126.112 675 AACTCTGTCGTAGGGAACATC 5654 NSVVGNI 7321 126.111 676 TTCGGAGCAACCACCACAGCA 5655 FGATTTA 7322 126.048 677 GCTTCAGGGTCTGAAATGCCT 5656 ASGSEMF 7323 125.971 678 GACGGAACAAAAAGCGGAATG 5657 DGTKSGM 7324 125.871 679 TACACCGCCGACAAAAAACAA 5658 YTADKKQ 7325 125.562 680 CCGATTGCTGAGAGGCCTTCT 5659 PIAERPS 7326 125.558 681 AGCAACTCGTACTTACTCAAC 5660 SNSYLLN 7327 125.52 682 ACGAGAGAATTGACAAAAAAC 5661 TRELTKN 7328 125.47 683 CTCGGAAACCACTACACACCC 5662 LGNHYTP 7329 125.444 684 TTGCTCCAATCCATAGTGGTA 5663 LLQSIVV 7330 125.441 685 ATGATGGCGAATAATATGCAG 5664 MMANNMQ 7331 125.38 686 GGCGCGGACACCTCGACCCGG 5665 GADTSTR 7332 125.369 687 GGGTTCGGGCACGTGCCCGAA 5666 GFGHVPE 7333 125.324 688 AACGTTATGCACTCTTCCTCC 5667 NVMHSSS 7334 125.313 689 TCTGCGTCGAAAGTGGAATAC 5668 SASKVEY 7335 125.2945 690 ATTTCGAGTTATGATGGTAAT 5669 ISSYDGN 7336 125.273 691 AAAAAAACGAAAACACTAACT 5670 KKTKTLT 7337 125.26 692 GGTACCATATTACCAAACCAA 5671 GTILPNQ 7338 125.236 693 TTAAACGTCGTACCAACACAA 5672 LNVVPTQ 7339 125.09 694 AGTAGTGTTACTTCGAGGGAG 5673 SSVTSRE 7340 124.987 695 CCCATCAACGTACTCACGACA 5674 PINVLTT 7341 124.911 696 GGGGATAAGGCGAGTTTGGCG 5675 GDKASLA 7342 124.8255 697 AGGATGTCGGAGAGTTCTGAT 5676 RMSESSD 7343 124.5625 698 AATCTTTTGACTTCGTCGCCT 5677 NLLTSSP 7344 124.54 699 TCGCGGCTATCACAAGACCCC 5678 SRLSQDP 7345 124.3495 700 TGGTCGAATGCTCAGAGTCCG 5679 WSNAQSP 7346 124.231 701 GGCAGACACCTTCAATCGGAC 5680 GRHLQSD 7347 124.19 702 ATGAGTCTCGCCTCCACCCAA 5681 MSLASTQ 7348 124.092 703 ATGAGTACGGTTCTTCGCGAG 5682 MSTVLRE 7349 124.05 704 TCTAAATCTGAAAACCTGCAA 5683 SKSENLQ 7350 124.043 705 TGGACGGAAGGGGGCTCAGGA 5684 WTEGGSG 7351 124 706 TCGACTACGGTTTGGACTGCT 5685 STTVWTA 7352 123.99 707 GTTAGTTTGGAGAGTCGGTTG 5686 VSLESRL 7353 123.799 708 TCTATGTATGGGCAGGCTGGG 5687 SMYGQAG 7354 123.777 709 ACTAATACGCAGAATAATCCG 5688 TNTQNNP 7355 123.702 710 GTCGGTGACAGGAACTTGGTC 5689 VGDRNLV 7356 123.663 711 CTCGCCCACAACTACTTAAGC 5690 LAHNYLS 7357 123.6175 712 TGGACAGCTAACCAAGGCTTA 5691 WTANQGL 7358 123.566 713 GTCTTCCGGGAAGGCATCGTG 5692 VFREGIV 7359 123.54 714 CAGGTGCAGCATGAGAGGGTG 5693 QVQHERV 7360 123.5 715 CAAATATTAAACTACTCAGTC 5694 QILNYSV 7361 123.4 716 AGTACGATTGGTAATTCTACT 5695 STIGNST 7362 123.3029 717 CCTATACACCACGGTTCATCC 5696 PIHHGSS 7363 123.09 718 ATTGCTACTAATGTGATTTAT 5697 IATNVIY 7364 123.055 719 CAAGGCGGTACAAACAACCCC 5698 QGGTNNP 7365 123.037 720 ACCCGTGGCAACGACATATCA 5699 TRGNDIS 7366 123.023 721 CAAACGCTCATAGTGGGGTCC 5700 QTLIVGS 7367 123.007 722 CGGGGTCTGCCTGATGTTAAT 5701 RGLPDVN 7368 122.952 723 CTTAATGTGAATACGCTTAAT 5702 LNVNTLN 7369 122.896 724 GGGACAAAAAGCTGGCCTGTC 5703 GTKSWPV 7370 122.8432 725 ACGCATCTTGTGAGTGATTCG 5704 THLVSDS 7371 122.78 726 TGGACGGGCGCACAACCTTCT 5705 WTGAQPS 7372 122.73955 727 TCTGCGATGCACACATTAGTC 5706 SAMHTLV 7373 122.5735 728 TCCCAACACCACACGCCACTG 5707 SQHHTPL 7374 122.4691 729 GATAATCGGATGGAGGCTACG 5708 DNRMEAT 7375 122.416 730 TTGGGAGGAACCCTGGGAATA 5709 LGGTLGI 7376 122.38 731 TTTCATAATGAGTCTTATGGG 5710 FHNESYG 7377 122.36 732 ATTCGGACTTCTGTGATTAAT 5711 IRTSVIN 7378 122.333 733 TATAATACTGTTGATCAGCGG 5712 YNTVDQR 7379 122.2905 734 GCGCACCAAACCGCCGGGCCA 5713 AHQTAGP 7380 122.22 735 CCTCCGGAAAGTGCCAGGGGC 5714 PPESARG 7381 122.2044 736 AATAATACTTTGAATATTTTG 5715 NNTLNIL 7382 122.18 737 GCTAGTTATAGTAGTATGGTG 5716 ASYSSMV 7383 122.0975 738 TCGGGTCAAAACGGTACATCA 5717 SGQNGTS 7384 122.017 739 TTGTCTAGTATGAGTACGGAT 5718 LSSMSTD 7385 121.935 740 GTCGCCTCGATGGTACACAAC 5719 VASMVHN 7386 121.8215 741 ACGCAATTGTCAGACGGCTGC 5720 TQLSDGC 7387 121.81 742 GCGATTGTGGATAGGGGGAGT 5721 AIVDRGS 7388 121.757 743 AACCGTCAAAGGGACTTCGAA 5722 NRQRDFE 7389 121.734 744 GCACACCAAAAAGACATACGC 5723 AHQKDIR 7390 121.7 745 TTCACCGAACGCGCACTCCAA 5724 FTERALQ 7391 121.6915 746 ATGCTGTCTCATGGTGCGCTT 5725 MLSHGAL 7392 121.682 747 TCCGTAACCAACGGAGCGGAA 5726 SVTNGAE 7393 121.549 748 ATCACCGCCGCGTCACCGCAA 5727 ITAASPQ 7394 121.5325 749 CAAAACACGCAACGATACTTG 5728 QNTQRYL 7395 121.5036 750 ACTGGCCAAGGATTCTCGGCA 5729 TGQGFSA 7396 121.45 751 AGTTTTGAGAAGAATGGTATT 5730 SFEKNGI 7397 121.45 752 CTCACGTCCCACTCTGCGGGC 5731 LTSHSAG 7398 121.378 753 TCTACAATCGGCAACAGCACG 5732 STIGNST 7399 121.27 754 GGTCTTAGTCGGAATGATGGT 5733 GLSRNDG 7400 121.2415 755 TCGACGACGCACCCTTCCGAA 5734 STTHPSE 7401 121.238 756 CCAAGTACGAACGAAAGCCGC 5735 PSTNESR 7402 121.099 757 GGTACGAAGGATATTCTGATT 5736 GTKDILI 7403 121.039 758 TCTACTATTAATATGCGTGCG 5737 STINMRA 7404 120.929 759 TATATTGCTGGGGGGGAGCAG 5738 YIAGGEQ 7405 120.9 760 TCCAGCGGCCAACCGCTCGTC 5739 SSGQPLV 7406 120.7415 761 GACAAACAACAAACCGGACAA 5740 DKQQTGQ 7407 120.6775 762 GGGCTAGGACAACCCCAACTC 5741 GLGQPQL 7408 120.644 763 AGTCCGCAGCATGGTGTTATT 5742 SPQHGVI 7409 120.6145 764 TATAGGGGTAGGGAGGATTGG 5743 YRGREDW 7410 120.58 765 GCGGGGGGTTTGCTGTCGCGG 5744 AGGLLSR 7411 120.552 766 CCGATACAACAAGCCTCATTG 5745 PIQQASL 7412 120.375 767 TGGAGCGCCGGCGAACGGGTG 5746 WSAGERV 7413 120.3415 768 AGGGGTGATGTTGCTACGACG 5747 RGDVATT 7414 120.26 769 TTAACGGGACAAAACGAATTC 5748 LTGQNEF 7415 120.24 770 ACGACGCCGCCTTTTTCTAAT 5749 TTPPFSN 7416 120.2205 771 ACGAGTATTGGTAGTGCTAAG 5750 TSIGSAK 7417 120.195 772 AATGTGCAGAATGTGCCTGGG 5751 NVQNVPG 7418 120.16215 773 TATACGGGTACTCTTGTTGTT 5752 YTGTLVV 7419 120.047 774 GGAACCCACGCCTCAGCATAC 5753 GTHASAY 7420 119.959 775 CTGGTTGTTTCGAATAGTCTG 5754 LVVSNSL 7421 119.934 776 ACGCATCTTGTGAGGGATTCG 5755 THLVRDS 7422 119.7893 777 AATCATGGTCGTGCTATTGAT 5756 NHGRAID 7423 119.776 778 CCCAAAACTCTAACTTCGACA 5757 PKTLTST 7424 119.754 779 TTCGGTATAGGGCACGGAACA 5758 FGIGHGT 7425 119.734 780 GCGCTTCCGTCTCGTGAGCGG 5759 ALPSRER 7426 119.7235 781 GCGACTAGGGGTGAGTCGTCT 5760 ATRGESS 7427 119.715 782 GGGACAACCGAAGTTAACAAA 5761 GTTEVNK 7428 119.685 783 ACCCACACCCTTGGGGGAACA 5762 THTLGGT 7429 119.68 784 GAAGCAGTAACAAGTAAATGG 5763 EAVTSKW 7430 119.6575 785 CACTACGGTAACAAAGACATA 5764 HYGNKDI 7431 119.643 786 ATTTCTACGCATACGATGACG 5765 ISTHTMT 7432 119.64 787 GATACGTATAATAGTAATACT 5766 DTYNSNT 7433 119.6 788 GTTTTTACTGGGCAGACGGAG 5767 VFTGQTE 7434 119.544 789 TCGGTCACCAGTGGAACACAA 5768 SVTSGTQ 7435 119.502 790 CATACGTATTCGCAGGCTGAT 5769 HTYSQAD 7436 119.47455 791 GTAGCGGGCTTAGTCGACATA 5770 VAGLVDI 7437 119.41 792 GACTCTACCAAAGCCATGCAA 5771 DSTKAMQ 7438 119.403 793 GAGGGGCATAATCGTGGTATT 5772 EGHNRGI 7439 119.354 794 GGGTTGCATGGGACGAGTAAT 5773 GLHGTSN 7440 119.343 795 CCGCTTTCTCTTCATAATAGT 5774 PLSLHNS 7441 119.312 796 GCGAGTGATAAGGGGGCGAAT 5775 ASDKGAN 7442 119.249 797 GTGCTGTTGCAGAATTCTCAT 5776 VLLQNSH 7443 119.2225 798 CTATACGACGGAAAACACGTC 5777 LYDGKHV 7444 119.20995 799 ACCCAAGGATCTAACACCACA 5778 TQGSNTT 7445 119.08 800 TTCCTCGACAAATACAACTAC 5779 FLDKYNY 7446 119.058 801 GACACCGGAATCAAAAACGTT 5780 DTGIKNV 7447 119.05 802 TCCGGAGCGGCACAAAACCCA 5781 SGAAQNP 7448 119.019 803 ACCCTCCACACCAAAGACCTA 5782 TLHTKDL 7449 118.854 804 GCTACTTACGTTGTCGGAACA 5783 ATYVVGT 7450 118.84 805 CTTGTGGGGACTTTGGTGTAT 5784 LVGTLVY 7451 118.809 806 TCTAATACGACTGTGCAGCTT 5785 SNTTVQL 7452 118.76 807 AAGGCTCAGATTAATCAGATG 5786 KAQINQM 7453 118.727 808 CGGAATGCTACTGTGACTGTT 5787 RNATVTV 7454 118.655 809 GCAACCAGAGTGGGCAACCAC 5788 ATRVGNH 7455 118.599 810 AGTTATCAGAATCCTCCGCCT 5789 SYQNPPP 7456 118.512 811 TTTGATAGTTATAATATTGTG 5790 FDSYNIV 7457 118.51 812 GCTACTCTTTCTCCGCATGCT 5791 ATLSPHA 7458 118.497 813 TGGGAGAGTCCGACTAATGCG 5792 WESPTNA 7459 118.49 814 ATCGAAAACGTAAACCACTTG 5793 IENVNHL 7460 118.42 815 TATCGGGCTTCGGATGTGGCG 5794 YRASDVA 7461 118.372 816 CATATGTCTTCTGTTGCGACT 5795 HMSSVAT 7462 118.34 817 ATCCAAAGAGACGTGGGCCAC 5796 IQRDVGH 7463 118.2825 818 GAGAGTGTTAGGGAGACTATT 5797 ESVRETI 7464 118.25 819 CAGGGGGGGAATAGTCGGTTT 5798 QGGNSRF 7465 118.236 820 GAAAAAGGCACACCAAGTAGC 5799 EKGTPSS 7466 118.233 821 CACGACAGCACAACCCGCCCA 5800 HDSTTRP 7467 118.225 822 TTACCAACAGGCGTCCTGCCC 5801 LPTGVLP 7468 118.2065 823 ACCCTAGGCTACCCAGACAAA 5802 TLGYPDK 7469 118.1855 824 GCTAACACCGTCACAGAACGA 5803 ANTVTER 7470 118.17415 825 CACGACAAATCTATCCAACCA 5804 HDKSIQP 7471 118.16 826 GGAGGAACAGCCCTTGGGAGC 5805 GGTALGS 7472 118.123 827 GGGGGTAACTACCACACCACT 5806 GGNYHTT 7473 118.046 828 ATCTCAGAAATGACTAGGTAC 5807 ISEMTRY 7474 118.041 829 GTTGAATCTAAATCCGAACCA 5808 VESKSEP 7475 118.026 830 GACCGTGCCCAAAACAACGAA 5809 DRAQNNE 7476 118.006 831 ACGGCGCAGACCGGCTGGGTT 5810 TAQTGWV 7477 117.96 832 GGGTTCGGGCACCTGCCCGAA 5811 GFGHLPE 7478 117.86 833 CCTATTACGGGTTTTAGTGTT 5812 PITGFSV 7479 117.828 834 GATAGGACGTATTCGAATACG 5813 DRTYSNT 7480 117.7875 835 ATGTCAAACGCCTCCTACATA 5814 MSNASYI 7481 117.743 836 GATAATAGTAGGCCTGAGGTG 5815 DNSRPEV 7482 117.658 837 TCAAGTTCCCAAACGGTTTTG 5816 SSSQTVL 7483 117.655 838 AGTAATCTTGATGGTACTATT 5817 SNLDGTI 7484 117.643 839 AGTAATATGCGTGAGGAGATT 5818 SNMREEI 7485 117.629 840 AGACTTACAGAACTGGTCATA 5819 RLTELVI 7486 117.583 841 CAGGTTAGTCTGGTGAAGTTG 5820 QVSLVKL 7487 117.558 842 GAAATACACACGACCACAGGC 5821 EIHTTTG 7488 117.5505 843 AGCAGGATAGAAAACAACAAC 5822 SRIENNN 7489 117.5425 844 GGAACAGGCAAAGAAGTTCGA 5823 GTGKEVR 7490 117.521 845 TGGCAGGATCATAATAAGGTG 5824 WQDHNKV 7491 117.476 846 TCGACAAACTCTATAGGCGCC 5825 STNSIGA 7492 117.414 847 TCCGAATTAATGGTCAGACCC 5826 SELMVRP 7493 117.3623 848 CCGCTTCAGAATAATAAGACG 5827 PLQNNKT 7494 117.2175 849 CCTTATGCGAATAGGCTTGAG 5828 PYANRLE 7495 117.21145 850 GGGACGGTTTCGCTTATTCCT 5829 GTVSLIP 7496 117.175 851 GATGTTTATCTTAAGAGTCCG 5830 DVYLKSP 7497 117.1435 852 TTGCCGGATAAGGGGCGGATT 5831 LPDKGRI 7498 117.116 853 TCGATAACGACCGTAGCGAAC 5832 SITTVAN 7499 117.112 854 CCGCTTCAATCCCAATCGGGA 5833 PLQSQSG 7500 117.1045 855 AATAATATGGGTCATGGTCAT 5834 NNMGHGH 7501 117.0365 856 AGCGGACAAAAAAACTCAGAA 5835 SGQKNSE 7502 116.9665 857 ACCGAAGCGGGCCGCCCCCAA 5836 TEAGRPQ 7503 116.907 858 ACCTTACACACGAAAGACTTG 5837 TLHTKDL 7504 116.879 859 CTTCGAGACCTAAACGGAGGA 5838 LRDLNGG 7505 116.8691 860 GTTTGTGTTACTACTTGTGCT 5839 VCVTTCA 7506 116.861 861 GTCACAGCTGCTCAACCCCAA 5840 VTAAQPQ 7507 116.79 862 GCGACTTTTAGTCATGCTGGT 5841 ATFSHAG 7508 116.788 863 ACTTATGCGCCTAGGTCGCCT 5842 TYAPRSP 7509 116.75715 864 ACGTCGGAGATGCGTACTGCT 5843 TSEMRTA 7510 116.5885 865 TACTCGACAACCATGCTTAAC 5844 YSTTMLN 7511 116.584 866 TCTTTCACGAACACAAACCCA 5845 SFTNTNP 7512 116.5665 867 AGTCCTCCTAGTACGTCGGGT 5846 SPPSTSG 7513 116.551 868 GTGACGACTGTTGATAGTGCT 5847 VTTVDSA 7514 116.477 869 GAGGCGCATAATCGTGTTATT 5848 EAHNRVI 7515 116.461 870 ATGGAGTTGACTTCTACTAGT 5849 MELTSTS 7516 116.456 871 CATTTGGTTACTAGTGGTATT 5850 HLVTSGI 7517 116.45 872 CAAACCATCACCTCACAAATG 5851 QTITSQM 7518 116.431 873 ACTGCGAATAGTACGTATGTG 5852 TANSTYV 7519 116.329 874 CTTATCCAATTATCGGGTCAA 5853 LIQLSGQ 7520 116.317 875 TCTTACGTTAGCGTCCCCGCC 5854 SYVSVPA 7521 116.3005 876 GTGCATGGGAATGCTCCGGCT 5855 VHGNAPA 7522 116.2665 877 GCCGGAAAAACCCACGCCGAC 5856 AGKTHAD 7523 116.228 878 ACATTCCACCAAGGGGTCAAA 5857 TFHQGVK 7524 116.175 879 TTAGGAAACAACCGGCCACTA 5858 LGNNRPL 7525 116.17 880 CTGCACCTCGTCCGGAGCTTC 5859 LHLVRSF 7526 116.08 881 TCCTACAGTACTTCAACACCG 5860 SYSTSTP 7527 116.036 882 ATATCGCAAGGCTCGAGCCTC 5861 ISQGSSL 7528 116.025 883 CTCCAACTGGCTACATCCCAC 5862 LQLATSH 7529 116.0035 884 GTGACTCAGCGGTTTGCTGAG 5863 VTQRFAE 7530 115.952 885 GCTATAGACTCCATCAAAATG 5864 AIDSIKM 7531 115.9415 886 GACGCACACACTTTCAGCCGG 5865 DAHTFSR 7532 115.93 887 CGTGGTTCAGACGGAGGATTG 5866 RGSDGGL 7533 115.911 888 TTAGCACAAGGCACGGACCGG 5867 LAQGTDR 7534 115.884 889 AAAAACAACAACTCAGACAGT 5868 KNNNSDS 7535 115.7595 890 GAAAACGAAAAACGAGAAAGC 5869 ENEKRES 7536 115.741 891 AACGAACAATTCGAAAAAGTC 5870 NEQFEKV 7537 115.705 892 ACACAAGTAGTCGCAAGAACA 5871 TQVVART 7538 115.68045 893 GGAGTAAACGTCACCAACAGC 5872 GVNVTNS 7539 115.64 894 GCCGACAAAGGATTCGGCCAC 5873 ADKGFGH 7540 115.5886 895 ACTCATAAGCAGGTGGATCTT 5874 THKQVDL 7541 115.54825 896 TCGGCTAACTTATACAAACAA 5875 SANLYKQ 7542 115.544 897 AAGCTGCATACTAAGGATCTT 5876 KLHTKDL 7543 115.54 898 GTGGTGGTTCACACTATCCCA 5877 VVVHTIP 7544 115.52 899 TCTACGTCTCAGGCTGTGCAG 5878 STSQAVQ 7545 115.496 900 CGTAACGGCTCCGCCCAAAGC 5879 RNGSAQS 7546 115.465 901 CATTATGGGAATAAGGATATT 5880 HYGNKDI 7547 115.402 902 AGCTTCTTGGTAGCCCACCCA 5881 SFLVAHP 7548 115.4 903 CAGCAGAATACGAGTTTGCCG 5882 QQNTSLP 7549 115.39 904 ATGCACGTCGACAAAACGAGT 5883 MHVDKTS 7550 115.379 905 AATAATGAGAATACGCGTAAT 5884 NNENTRN 7551 115.363 906 TCGATAAACAACATAGGCGCA 5885 SINNIGA 7552 115.3425 907 GCTACTATATCGGACCGAGCC 5886 ATISDRA 7553 115.327 908 TACTCAAACCTCGTACTTTCC 5887 YSNLVLS 7554 115.285 909 ATGATGAATGTGAGTGGTCAT 5888 MMNVSGH 7555 115.2555 910 GGGGAGACGCGGTCGACTGCT 5889 GETRSTA 7556 115.18 911 ACGAAGGGTTATAATGATCTT 5890 TKGYNDL 7557 115.1635 912 GCGTATAATATGTCGTCTGTT 5891 AYNMSSV 7558 115.148 913 GCAGACCCCGCTAAAGGCAAA 5892 ADPAKGK 7559 115.1435 914 TATATTTCGGCGCCTCCGATG 5893 YISAPPM 7560 115.1145 915 CGAAACAACCCATCGCACGAC 5894 RNNPSHD 7561 115.069 916 GGAACCTCCATAGACTACGTA 5895 GTSIDYV 7562 115.053 917 GGCACCGGGTACCCAAACCAA 5896 GTGYPNQ 7563 115.038 918 GATCATATGAATTTGAGGTCT 5897 DHMNLRS 7564 114.9475 919 ATTAATTCGTATTTGCATGAG 5898 INSYLHE 7565 114.887 920 TGGCAAATGGGGGCCGGGAGC 5899 WQMGAGS 7566 114.833 921 ATGGGTATCGGGTCATACAAA 5900 MGIGSYK 7567 114.827 922 CAAAACCACAACGAACTAAAA 5901 QNHNELK 7568 114.749 923 GATAAGTCTAATTATAGTATT 5902 DKSNYSI 7569 114.736 924 ACAACGAAACCGGTCGCGGAA 5903 TTKPVAE 7570 114.7315 925 GTGACTGTGAGTAATAGTCTG 5904 VTVSNSL 7571 114.685 926 ACGGCGTATCTGGATGGTCTG 5905 TAYLDGL 7572 114.665 927 AATTTGCAGACTGGTGTTCAG 5906 NLQTGVQ 7573 114.65 928 ACCGTCGCTCCCTACAGTAGC 5907 TVAPYSS 7574 114.65 929 GTTCAGATTTCTATGAATAAT 5908 VQISMNN 7575 114.617 930 TACATAGCAGGTGGTGAACAA 5909 YIAGGEQ 7576 114.60015 931 TTCATGGAAGTCATGAAAAAC 5910 FMEVMKN 7577 114.547 932 ACGACTGATAAGGGTATTAAT 5911 TTDKGIN 7578 114.539 933 TTGAGCTACAGCATCCAACAC 5912 LSYSIQH 7579 114.53 934 GCTTATAATGCTCGTCTGCCT 5913 AYNARLP 7580 114.49305 935 AACACCGGCACCACGAGTGTC 5914 NTGTTSV 7581 114.475 936 GTGCTGAGTACGGGGCTGCGG 5915 VLSTGLR 7582 114.4165 937 AACGACTCCTCGTCAATGTCC 5916 NDSSSMS 7583 114.397 938 CGCCAAGGCAGCTTGATGATA 5917 RQGSLMI 7584 114.37 939 ATCAGCACCGCATACATGTTG 5918 ISTAYML 7585 114.36 940 GGTACTATGAATATTGGTATT 5919 GTMNIGI 7586 114.356 941 CATAATAATAATTTGCTGAAT 5920 HNNNLLN 7587 114.292 942 CATTTTTCGCAGATTACTAAT 5921 HFSQITN 7588 114.278 943 GACCTGACCAGAGCTGCAATA 5922 DLTRAAI 7589 114.256 944 GTCGCTATGGGAGGCGGTCCC 5923 VAMGGGP 7590 114.1845 945 GCCTACGGTATCAGAGAAGTG 5924 AYGIREV 7591 114.1465 946 ACATCAGACGGTCTACTAAGT 5925 TSDGLLS 7592 114.128 947 ACGATGGCTACAAACTTAAGT 5926 TMATNLS 7593 114.082 948 AACAACGGCAACTCATCAAGG 5927 NNGNSSR 7594 114.047 949 ACGGAGAAGGCGAGTCCTCTG 5928 TEKASPL 7595 114.031 950 CTCAACCACACAATGCCCCTC 5929 LNHTMPL 7596 114.027 951 GATACGGCGAGTTATAATAAT 5930 DTASYNN 7597 114 952 AACATGACCAACGAACGGCTC 5931 NMTNERL 7598 113.9675 953 GTAGTCTCATCGGGCGGCTGG 5932 VVSSGGW 7599 113.966 954 GTGAATCAGAGTCCTGGGGCT 5933 VNQSPGA 7600 113.85 955 GATCATCATCCTCAGAGTCGT 5934 DHRPQSR 7601 113.83 956 CGATGGCAAGGACTGAGCGCG 5935 RWQGLSA 7602 113.76 957 GCGGTTACGACAAGCGTGAGG 5936 AVTTSVR 7603 113.752 958 TGGGGAGTCAGTAACTCAGCA 5937 WGVSNSA 7604 113.7505 959 GCGCATATGCATTCGGAGTTG 5938 AHMHSEL 7605 113.74 960 AATAATCTTACGAATTCGACG 5939 NNLTNST 7606 113.736 961 AGTAGTGGGGGTATGAAGGCG 5940 SSGGMKA 7607 113.69 962 GTTGGGTATGGGGAGCATGTT 5941 VGYGEHV 7608 113.64 963 ACCATAGTGTCCACTTCTTAC 5942 TIVSTSY 7609 113.628 964 CCCACCAGTCACCAAGAACCC 5943 PTSHQEP 7610 113.62 965 TCTAACCTTCGAAACACAATA 5944 SNLRNTI 7611 113.58 966 TCAAGACACGACGTCCGAAAC 5945 SRHDVRN 7612 113.559 967 CAGATGAATATTCATGATAAG 5946 QMNIHDK 7613 113.543 968 TGGGCTATGAATAATGTGCCG 5947 WAMNNVP 7614 113.531 969 GCGATGGATGGGTATAGGGTT 5948 AMDGYRV 7615 113.462 970 AAAGGGGGAAACCTCACCGCA 5949 KGGNLTA 7616 113.4525 971 ATTGGTAAGGATAGTGTTCCG 5950 IGKDSVP 7617 113.448 972 GTGCAGTTGACGCATAATGGG 5951 VQLTHNG 7618 113.43 973 GGCCTGAACCAGATCACATCG 5952 GLNQITS 7619 113.4 974 AGGGGTGATCCTTCTACGCCT 5953 RGDPSTP 7620 113.4 975 GTTCCCTCCGACCCCCACTGG 5954 VPSDPHW 7621 113.35 976 ACGTTAAGTTCCCAAGTCACA 5955 TLSSQVT 7622 113.327 977 AACCAAAGAGTTGAACAAAAA 5956 NQRVEQK 7623 113.3075 978 GTACTTCCAAGTCGGATCGCG 5957 VLPSRIA 7624 113.3 979 GGGCACTACGCTACAAACACA 5958 GHYATNT 7625 113.212 980 CCTTCGATTCCGTCGTTTTCG 5959 PSIPSFS 7626 113.207 981 ACTTATGAGTATCCGACTCGG 5960 TYEYPTR 7627 113.19 982 AAAGACCACATCCTCAGCCTC 5961 KDHILSL 7628 113.1795 983 GGCACAGGAGGTAACCGAGAA 5962 GTGGNRE 7629 113.173 984 AAGGGGGATGGTGCTTATGAG 5963 KGDGAYE 7630 113.162 985 TCTTCTTTCGGAAAAGACAAC 5964 SSFGKDN 7631 113.1603 986 ACAGTATCGTCATACGTACAA 5965 TVSSYVQ 7632 113.0595 987 AGGGCTCATGGGGATAATCAG 5966 RAHGDNQ 7633 113.036 988 TATCATGCTCATAGTAATGAG 5967 YHAHSNE 7634 113.03 989 GCAAACTTGCCCAGCGGTCAC 5968 ANLPSGH 7635 113.03 990 GCGAACCTCAACTTGACCAGT 5969 ANLNLTS 7636 113.015 991 AGGCTTAATGCGGGTGAGCAT 5970 RLNAGEH 7637 113.0105 992 TATGTTGATTATAGTAAGTCG 5971 YVDYSKS 7638 112.9935 993 GCTAATTCTGGGTTGCATAAT 5972 ANSGLHN 7639 112.9695 994 ACGAGTGGTGTGCTTACGCGG 5973 TSGVLTR 7640 112.9485 995 GGAAAACCAGCACAAGAATTC 5974 GKPAQEF 7641 112.933 996 GTGGGGACGCATTTGCATTCG 5975 VGTHLHS 7642 112.918 997 CCGATGAACAAAGACATACTG 5976 PMNKDIL 7643 112.9116 998 GACGCCCACCACTCAAGCAGC 5977 DAHHSSS 7644 112.88 999 ACTAACGCCATCTCTCAAACG 5978 TNAISQT 7645 112.7997 1000 GTTTTGTCTGATAAGGCGTAT 5979 VLSDKAY 7646 112.787 1001 AACCTACTTGTCGACCAACGT 5980 NLLVDQR 7647 112.78 1002 ACTGGTCATCCGCCGGCGGCG 5981 TGHPPAA 7648 112.7735 1003 ATTAGTTCGGGGATTTTGTCG 5982 ISSGILS 7649 112.7205 1004 AATACGAATTTGTTGGGTTAT 5983 NTNLLGY 7650 112.72 1005 ACGCTATCGGTTACCCTGGGT 5984 TLSVTLG 7651 112.71 1006 CATACTGGTGTTCAGACTAAT 5985 HTGVQTN 7652 112.704 1007 GAGGTTAGTAATAATAATTAT 5986 EVSNNNY 7653 112.69 1008 CTGGCTAATATTTCGCTGTAT 5987 LANISLY 7654 112.69 1009 GTGGAGCATGTTGCTCATCAG 5988 VEHVAHQ 7655 112.656 1010 GTCGACAAAAGCGAAGCCGAC 5989 VDKSEAD 7656 112.6 1011 GGCTTCGCATTAACTGGCACC 5990 GFALTGT 7657 112.564 1012 TTGTTGACGGCTCCGCATAGG 5991 LLTAPHR 7658 112.53 1013 AATGCGGGGGCTCTTATGGGT 5992 NAGALMG 7659 112.518 1014 AGGACGCAAGCAGGGGACTCA 5993 RTQAGDS 7660 112.483 1015 AACACACACAGACAAGAATAC 5994 NTHRQEY 7661 112.461 1016 AACATAGCAGGCGGAGAACAA 5995 NIAGGEQ 7662 112.442 1017 GAGATTAATAATCGGACTGGT 5996 EINNRTG 7663 112.43235 1018 ACCGTTAACACAATGTACACG 5997 TVNTMYT 7664 112.4 1019 CCTATGAATGGTATTCTGTTG 5998 PMNGILL 7665 112.388 1020 AATCCTAGTTATGATCATCGG 5999 NPSYDHR 7666 112.363 1021 GCTGTTATTCTGAATCCTGTT 6000 AVILNPV 7667 112.36 1022 CTGTACGGGGGAGCACACCAA 6001 LYGGAHQ 7668 112.3455 1023 CAAGTCAACCAACCGAGAATA 6002 QVNQPRI 7669 112.33 1024 GCTGTTAGAACACCGGCAATG 6003 AVRTPAM 7670 112.326 1025 AGTTTGACGCCTAATAATCTT 6004 SLTPNNL 7671 112.283 1026 CTTGGGCAGGTTAATTCTACG 6005 LGQVNST 7672 112.205 1027 GCTAATTCTGCTACTAATCAG 6006 ANSATNQ 7673 112.1605 1028 TCCTTGACGGAAAAAGCGCCG 6007 SLTEKAP 7674 112.15 1029 CAATTCCACGGGACATCTGAA 6008 QFHGTSE 7675 112.125 1030 AAAAACGGCGCCATAGGAACA 6009 KNGAIGT 7676 112.0867 1031 GTGCTGGCGTCGACTGAGAAG 6010 VLASTEK 7677 112.058 1032 AGTAATATGAGTGAGGCGATT 6011 SNMSEAI 7678 112.02 1033 AACGCTAACGCCGGTGGAAAC 6012 NANAGGN 7679 112.0148 1034 CACTCTAACACACACTACGAA 6013 HSNTHYE 7680 112.005 1035 AGTGCTTTGATTAGTGTGGTT 6014 SALISVV 7681 111.993 1036 GTGGCGACTCATTATAATGAG 6015 VATHYNE 7682 111.971 1037 AACCAAACGTTACAAGTAGAC 6016 NQTLQVD 7683 111.97 1038 AAAACACCCTCAGCTTCAGAA 6017 KTPSASE 7684 111.957 1039 GGTGAATCACGTACAAACATG 6018 GESRTNM 7685 111.9393 1040 CGGAATGAGCCGGTTAGTACT 6019 RNEPVST 7686 111.912 1041 GCAACACACGCCATGCGCCCA 6020 ATHAMRP 7687 111.9005 1042 TGGGAATCCCTCTCCAACGCA 6021 WESLSNA 7688 111.885 1043 CATAGTCCTCCTACGACTATG 6022 HSPPTTM 7689 111.847 1044 TCTACCATGAACACGATCACG 6023 STMNTIT 7690 111.8162 1045 AACATGGAACACACCATGGCG 6024 NMEHTMA 7691 111.78965 1046 CATAATACGGAGTCTAAGACT 6025 HNTESKT 7692 111.778 1047 CACAACTTAATGACCCAAATA 6026 HNLMTQI 7693 111.77 1048 AACCAAAACACCTACGAACTG 6027 NQNTYEL 7694 111.756 1049 TACGCCACTCTCGACACCATC 6028 YATLDTI 7695 111.752 1050 GTTCAGTTGGAGAATGCGAAT 6029 VQLENAN 7696 111.7215 1051 GGGCTCACAGGATACACAATG 6030 GLTGYTM 7697 111.71 1052 TTAGTACTTGACTCACGGAAC 6031 LVLDSRN 7698 111.704 1053 ATGTTGGTACAAAACACACCC 6032 MLVQNTP 7699 111.702 1054 CCTCATAATCAGGAGATGGGT 6033 PHNQEMG 7700 111.6865 1055 TCGTTGGGGGATGCGATGTTG 6034 SLGDAML 7701 111.6776 1056 CGCGCCGAAGGGAGCTCTGGC 6035 RAEGSSG 7702 111.6645 1057 AGTGAGGAGAGGACGCGTGCG 6036 SEERTRA 7703 111.616 1058 TCTAGTAAGGAGCGTACATCG 6037 SSKERTS 7704 111.57 1059 CCTGTTGTGAGGGATCGTTCT 6038 PVVRDRS 7705 111.5643 1060 AGGATGTCTGAGAGTTCGGAT 6039 RMSESSD 7706 111.51 1061 AACCAATCTATAAGCATGGAC 6040 NQSISMD 7707 111.491 1062 GTCGCTGTATCGAACACTCCA 6041 VAVSNTP 7708 111.482 1063 GGAGACATCTCAAGCAGAAAC 6042 GDISSRN 7709 111.4603 1064 GCTGCCGGAGCCGACTCTCCA 6043 AAGADSP 7710 111.429 1065 TTCGGCACATCGTACACAACC 6044 FGTSYTT 7711 111.401 1066 CGTGATACTAATACGGATAAG 6045 RDTNTDK 7712 111.336 1067 GGGTCTACGCCGGGGGCGAGT 6046 GSTPGAS 7713 111.327 1068 GGTACTAATCATGATTTTTCG 6047 GTNHDFS 7714 111.302 1069 AATGAGAGTACGAAGGAGAGT 6048 NESTKES 7715 111.2845 1070 GTGCATGTGACTAATGTGTTG 6049 VHVTNVL 7716 111.2295 1071 AGTACTACTAATGTTGCGTAT 6050 STTNVAY 7717 111.2015 1072 ATTACGTCGTTGAATGGGATG 6051 ITSLNGM 7718 111.1615 1073 GAAGTACGGGGCAGCGTGCCA 6052 EVRGSVP 7719 111.1435 1074 GCACTTACCCGTATGCCTAAC 6053 ALTRMPN 7720 111.1235 1075 CTCAGTGTAGCCGACAGGCCA 6054 LSVADRP 7721 111.06 1076 GTTTCTACGGCGCAGAGGCAG 6055 VSTAQRQ 7722 111.056 1077 TTAAACGCAGAATACACCAAC 6056 LNAEYTN 7723 111.02 1078 AATGAGAAGCCGCAGTCGACG 6057 NEKPQST 7724 111.009 1079 TTGAATACGCTGATTGATAAG 6058 LNTLIDK 7725 111.003 1080 GTCACACACACACTGATCGAA 6059 VTHTLIE 7726 110.987 1081 GAGCAGAAGAAGACTGATCAT 6060 EQKKTDH 7727 110.936 1082 ACATCAGGCATGTACGACACG 6061 TSGMYDT 7728 110.92 1083 CCTGACGCAGCGCGTAGCCCG 6062 PDAARSP 7729 110.916 1084 TTGACGCAGGTTTATCATGAG 6063 LTQVYHE 7730 110.91 1085 AGAGAAATGAGCAGCCTATCT 6064 REMSSLS 7731 110.891 1086 ATGCCTTCGAAAGGCGAAGTA 6065 MPSKGEV 7732 110.816 1087 AATGAGCAGAATACGCCGAGT 6066 NEQNTPS 7733 110.79 1088 AAAAACTACGCAAGCACCGAC 6067 KNYASTD 7734 110.7435 1089 TGTATGGATGTTGGTAAGGCG 6068 CMDVGKA 7735 110.711 1090 GCTCTTCATAATCTGATGAAT 6069 ALHNLMN 7736 110.711 1091 CCTGACAGAGCGAACGACAAA 6070 PDRANDK 7737 110.6835 1092 ATTGCTCATGTGTCTACTAAT 6071 IAHVSTN 7738 110.6805 1093 AACGGTCCGACCGGATCCGCC 6072 NGPTGSA 7739 110.6652 1094 TCTACTCATCATGCTGATCGT 6073 STHHADR 7740 110.629 1095 GGTTCGCAGTATGGGCGGCAT 6074 GSQYGRH 7741 110.629 1096 ACCGGAACGGCTACACTCCCA 6075 TGTATLP 7742 110.5825 1097 AAAGCCCACGTTGTAGAAATA 6076 KAHVVEI 7743 110.5795 1098 ACTTCGCAGGGTAGGAGTCCT 6077 TSQGRSP 7744 110.511 1099 TTATCCTCCGAATCACCCAGG 6078 LSSESPR 7745 110.5015 1100 ACCGGGGTTCGAGAAACCATA 6079 TGVRETI 7746 110.4575 1101 ATGGATACTGAGCTTTATAGG 6080 MDTELYR 7747 110.4475 1102 ACACCTGAAGCGAGCGCTCGC 6081 TPEASAR 7748 110.44 1103 CACGACTTGAACCACGGAAAA 6082 HDLNHGK 7749 110.428 1104 CTTACTGGTCAGAATGCGATT 6083 LTGQNAI 7750 110.416 1105 ACCGTCGGATCGAACAGTATA 6084 TVGSNSI 7751 110.411 1106 CATACTGTGGGGGCTATGCAT 6085 HTVGAMH 7752 110.41 1107 GAACGAGTCAACGGGATGGCA 6086 ERVNGMA 7753 110.405 1108 TCCGAACCCCTTAGAGTTGGA 6087 SEPLRVG 7754 110.3725 1109 GTCTCTAACGTCCTCTACAGC 6088 VSNVLYS 7755 110.346 1110 TTCTCCTCCGGAACAACCATA 6089 FSSGTTI 7756 110.3 1111 ACAAACCTAAGTCAATCGGCC 6090 TNLSQSA 7757 110.24435 1112 CCTAATACTGCTAGTAATTTT 6091 PNTASNF 7758 110.2274 1113 TGCGGCCTGAACTGCGGTAAA 6092 CGLNCGK 7759 110.211 1114 CCGACCGGAGGCTCACCACCA 6093 PTGGSPP 7760 110.201 1115 TACCTAGAATCCAACTACACC 6094 YLESNYT 7761 110.18 1116 ACATTAGAAACAACCCGCAGC 6095 TLETTRS 7762 110.167 1117 TCCGCTAACGAACACAACCAC 6096 SANEHNH 7763 110.137 1118 GCACGAGTGGACACCAACCAA 6097 ARVDTNQ 7764 110.09 1119 AACGTGGTGAAAAACAACACA 6098 NVVKNNT 7765 110.077 1120 GGTTCTTATTCTGATGGTAGT 6099 GSYSDGS 7766 110.0355 1121 CCCGGTAACGGACAAAGTCCG 6100 PGNGQSP 7767 110.0275 1122 TCGGGGGTAAACTTCGGAGTA 6101 SGVNFGV 7768 109.998 1123 CGAATCAACGCAGCAATCGAC 6102 RINAAID 7769 109.99675 1124 CAAGCTGGGAACGCGCCAAGG 6103 QAGNAPR 7770 109.98825 1125 CAGTCGGGGTCTCTGGTGCCG 6104 QSGSLVP 7771 109.962 1126 TTCTCAACGCAAGACATAAGC 6105 FSTQDIS 7772 109.948 1127 GTGAATCCGCATCCTGCGCAG 6106 VNPHPAQ 7773 109.948 1128 AAAGGCCACGCCTACGAAGCC 6107 KGHAYEA 7774 109.897 1129 GAAGACAGTATGAGATTCTCT 6108 EDSMRFS 7775 109.874 1130 GGTAGGAATGAGAGTCCGGAG 6109 GRNESPE 7776 109.855 1131 TCCGACGGATCGAAACTACTA 6110 SDGSKLL 7777 109.8205 1132 ACTCTCTCAGGCTACATGAGA 6111 TLSGYMR 7778 109.808 1133 GATATTCATAATCCGCGTACG 6112 DIHNPRT 7779 109.789 1134 TGGGCCAAAGACGTCAACGTC 6113 WAKDVNV 7780 109.782 1135 GCTGTGGGGCGGTCGGATGAT 6114 AVGRSDD 7781 109.711 1136 AAAGAAAAAACCACCCGCGAA 6115 KEKTTRE 7782 109.697 1137 CTGCTCCAATCGACCTACTTG 6116 LLQSTYL 7783 109.672 1138 AAGTCTAATTTGGAGGGTAAG 6117 KSNLEGK 7784 109.6285 1139 ACGAGGACGCCTTTTCTGGGG 6118 TRTPFLG 7785 109.613 1140 CAGTCGGATACGACTTCGATT 6119 QSDTTSI 7786 109.605 1141 GCGTGGTCTCAAGTCCTGACG 6120 AWSQVLT 7787 109.587 1142 ACTCAAGAACGACCACTAATC 6121 TQERPLI 7788 109.56 1143 GATGATAAGACTGGTCGGTAT 6122 DDKTGRY 7789 109.549 1144 TTTCCTTCGCATAATGGGGCG 6123 FPSHNGA 7790 109.54 1145 ATGCTGTCTCAAGTCTTAACA 6124 MLSQVLT 7791 109.536 1146 TCTGTGACGACTAATCTGATG 6125 SVTTNLM 7792 109.484 1147 GAACACAACTCAAAAACTTAC 6126 EHNSKTY 7793 109.4745 1148 TATGCGCATCCTGTGACTCAT 6127 YAHPVTH 7794 109.4635 1149 CCTAATCCGTCTCCGAGGCAG 6128 PNPSPRQ 7795 109.449 1150 CATATGGGTTTGAATGAGCTT 6129 HMGLNEL 7796 109.427 1151 AACAGTTTGCAAGCAAGTGCA 6130 NSLQASA 7797 109.402 1152 GACCTCGGTACGGCTAGAACC 6131 DLGTART 7798 109.388 1153 TACGACAGCCGACTCTACGCG 6132 YDSRLYA 7799 109.3853 1154 CCGAAGCCTGGGACGGGGGAG 6133 PKPGTGE 7800 109.3721 1155 AGTCTGAATGGGGTGTTGGTT 6134 SLNGVLV 7801 109.3685 1156 CAGTCTAATTTGGTTATTAAT 6135 QSNLVIN 7802 109.359 1157 GCGTCTCCGGCGCAGACCGGC 6136 ASPAQTG 7803 109.331 1158 AACATGACCAACGAAAACGGA 6137 NMTNENG 7804 109.324 1159 TCACTTCGGACGGACGAATTC 6138 SLRTDEF 7805 109.31815 1160 ATATTGGACAACCACCGTTTC 6139 ILDNHRF 7806 109.2685 1161 TTGATTAATATGAGTCAGAAT 6140 LINMSQN 7807 109.264 1162 CCGCAAGACGTCCGCCAAACA 6141 PQDVRQT 7808 109.2625 1163 CCCTTCGTAGCGAACGAACCA 6142 PFVANEP 7809 109.256 1164 AATATTAATGATACTAAGAAT 6143 NINDTKN 7810 109.253 1165 AATTTTAGTAGTGGTGATGTT 6144 NFSSGDV 7811 109.229 1166 GAACGAAACGGACTAATAGAA 6145 ERNGLIE 7812 109.215 1167 AATTCTCATGTTCCTAATAAT 6146 NSHVPNN 7813 109.2115 1168 AACACAACCGGTAGCTCGGGC 6147 NTTGSSG 7814 109.1925 1169 TCAACCAGAAAAGAACACGAC 6148 STRKEHD 7815 109.1875 1170 GCTGCTAATCCTAGTACGGAG 6149 AANPSTE 7816 109.1357 1171 TCGGGTATGAATAGTAATAAG 6150 SGMNSNK 7817 109.129 1172 AAGACGCTTGATAATAATGCT 6151 KTLDNNA 7818 109.09305 1173 ACCGTAAAACAAACAAGTCCG 6152 TVKQTSP 7819 109.0863 1174 ATTTCTCAGGTGTCTTTTAAT 6153 ISQVSFN 7820 109.082 1175 TTAGAAGTAAACCTGCAAACG 6154 LEVNLQT 7821 109.057 1176 GAAATGCAAACCAAAAACGCC 6155 EMQTKNA 7822 109.052 1177 GCCGACAACAGAAACGACAAA 6156 ADNRNDK 7823 109.008 1178 GCGTATGATACGCTGAATAGT 6157 AYDTLNS 7824 108.982 1179 ACGATTCAGGATCATATTAAG 6158 TIQDHIK 7825 108.942 1180 GACCCCACTAAAGTTGGATCC 6159 DPTKVGS 7826 108.939 1181 TCCCTCCAACGAACCCCCGAC 6160 SLQRTPD 7827 108.937 1182 GCAAACGACTCTGCCAAAACA 6161 ANDSAKT 7828 108.9125 1183 AAAAAAGTCGAACAAGAACCA 6162 KKVEQEP 7829 108.907 1184 GCAAGTCGGGACCTGGGACAA 6163 ASRDLGQ 7830 108.906 1185 TGGGAGAGTGATAAGTTTCGT 6164 WESDKFR 7831 108.876 1186 AACCGCGGAACAGAAGTTTAC 6165 NRGTEVY 7832 108.8187 1187 AATATTAGTAGTATTAATCAG 6166 NISSINQ 7833 108.8155 1188 GCCTCGAAAGGCTTCGGCCAC 6167 ASKGFGH 7834 108.7886 1189 CAGTCGCAGAATGTGACTCAG 6168 QSQNVTQ 7835 108.7825 1190 AACGGATACCAACTACAAATC 6169 NGYQLQI 7836 108.779 1191 TGTACTAATGCGTCGGATCTT 6170 CTNASDL 7837 108.74 1192 ACCGTCGCCTCGCCCAACACC 6171 TVASPNT 7838 108.738 1193 AATACTGCTCCGCCGAATCAT 6172 NTAPPNH 7839 108.733 1194 CTTTCTCAACAACGCGACTAC 6173 LSQQRDY 7840 108.69245 1195 TGGAATCAGAATGTGTCTCAT 6174 WNQNVSH 7841 108.6785 1196 ACAGGTAGTTCAGACAGATTA 6175 TGSSDRL 7842 108.676 1197 AACACAACGCCACCTAACCAC 6176 NTTPPNH 7843 108.602 1198 GTGGTCGACTCAACATACCCG 6177 VVDSTYP 7844 108.592 1199 ACGGATGCTACGGGGAGGCAT 6178 TDATGRH 7845 108.5905 1200 TTGTTTACTGCTGGGAGTACT 6179 LFTAGST 7846 108.58 1201 TTGCGTGATCAGACTAGTATG 6180 LRDQTSM 7847 108.566 1202 ATCGAAACGGACCGCCACCGG 6181 IETDRHR 7848 108.531 1203 AGTGGGCCTGAGAATACGTTG 6182 SGPENTL 7849 108.526 1204 GACAACCAAAACGCCGACAGG 6183 DNQNADR 7850 108.486 1205 CATGATGGTTATGTTCCTAAT 6184 HDGYVPN 7851 108.469 1206 CATATGTCTAGTTATTCGTCG 6185 HMSSYSS 7852 108.436 1207 AGTCGTCTGCAGACTCAGCAG 6186 SRLQTQQ 7853 108.4358 1208 TCATACACAGCAGGAAGACCC 6187 SYTAGRP 7854 108.417 1209 GTGCAGCAGAATAATATTAAT 6188 VQQNNIN 7855 108.376 1210 GATGCGAAGGCTCTTACGACT 6189 DAKALTT 7856 108.368 1211 AAGGATGAGCATCTTCATTAT 6190 KDEHLHY 7857 108.358 1212 CACGGTGACCGAACAGCTTTA 6191 HGDRTAL 7858 108.327 1213 AATTTTACTATTACGGAGGCG 6192 NFTITEA 7859 108.32 1214 GACACTCACATGAACAAACTG 6193 DTHMNKL 7860 108.316 1215 CAACCAGGAGCCCCCCAAACC 6194 QPGAPQT 7861 108.312 1216 GGGGAAGCACGCCGAGAAGCC 6195 GEARREA 7862 108.302 1217 AAGTCTCTTAGTAGTGATGAT 6196 KSLSSDD 7863 108.2375 1218 ATGAATACGACTTATAATGAG 6197 MNTTYNE 7864 108.231 1219 GCGGCCGCACTAGAAACAATA 6198 AAALETI 7865 108.223 1220 AACGTCGCTCCCTACAGTAGC 6199 NVAPYSS 7866 108.21595 1221 TCTGCGGGTATGGTGAGTCTG 6200 SAGMVSL 7867 108.2145 1222 TGCGACTTGTCACAATCATGC 6201 CDLSQSC 7868 108.133 1223 GTTTTGATTACGATGAGTTCG 6202 VLITMSS 7869 108.118 1224 CAAGTTGGGGCTCTAATGGTT 6203 QVGALMV 7870 108.037 1225 CAACGTACCTCGGAAGCGCCA 6204 QRTSEAP 7871 108.0315 1226 TTGGGTAATGGTAGTTCTTTG 6205 LGNGSSL 7872 108.0135 1227 CCTAGTGTCCGTTTGCCCTTA 6206 PSVRLPL 7873 108.007 1228 GATTCTGCTCCGAGTACTATT 6207 DSAPSTI 7874 108.003 1229 AATTATAATGGGGTTAATGTG 6208 NYNGVNV 7875 107.956 1230 TCGGCTCATCAGACGCCGACG 6209 SAHQTPT 7876 107.932 1231 GATCATAGTAAGCAGATTTCG 6210 DHSKQIS 7877 107.923 1232 GCCGCCAGCTTGTCGCAAAGC 6211 AASLSQS 7878 107.914 1233 CACGCCGACGTTGGCATGAGC 6212 HADVGMS 7879 107.888 1234 CACGTGACAGTAACGTTAAAC 6213 HVTVTLN 7880 107.8865 1235 AATTCTACGCATATTAATTCG 6214 NSTHINS 7881 107.8843 1236 CTGGGGCTTGCTGGTCAGGTT 6215 LGLAGQV 7882 107.884 1237 AGCAGTCAAGCCCACGGCCCA 6216 SSQAHGP 7883 107.872 1238 GCTTTTAAGTCGGGTAGTATT 6217 AFKSGSI 7884 107.866 1239 CACTCCCCATCCCACGACTCG 6218 HSPSHDS 7885 107.844 1240 CCAAACGGCGAAAGTTCGCGA 6219 PNGESSR 7886 107.8303 1241 ATTCTTACGCCTTTGGATAAG 6220 ILTPLDK 7887 107.825 1242 TCCGCCTCTTACTCCAGGATG 6221 SASYSRM 7888 107.815 1243 GAGGCGTTGCATGATCGGAAT 6222 EALHDRN 7889 107.793 1244 GGTGAACAACACAACGCCCCC 6223 GEQHNAP 7890 107.778 1245 GGGAATATGGTTACGCCTAAT 6224 GNMVTPN 7891 107.753 1246 AACGCTCTCCTCAACGCACCT 6225 NALLNAP 7892 107.742 1247 GCAAGTGACCTACAAATGACG 6226 ASDLQMT 7893 107.723 1248 TCGTATGATATGCATACGAAT 6227 SYDMHTN 7894 107.705 1249 AATATGTCGCATAGTACTCTG 6228 NMSHSTL 7895 107.6777 1250 ACTGCCAACAACCACTCTCCG 6229 TANNHSP 7896 107.671 1251 CAAGCCCCGCCAACAGCACAA 6230 QAPPTAQ 7897 107.668 1252 AACTACCACGGAGACAACGTT 6231 NYHGDNV 7898 107.637 1253 AGGGATAGTACTATTAGTCGG 6232 RDSTISR 7899 107.635 1254 GTTTCTTCGCCTAATGGTACG 6233 VSSPNGT 7900 107.6095 1255 TCCCGAATCACGGTGAACGCA 6234 SRITVNA 7901 107.593 1256 GTCGGAACAACCTCGAACGGC 6235 VGTTSNG 7902 107.575 1257 CATACGAATCAGATGCAGCCT 6236 HTNQMQP 7903 107.5573 1258 AAAAGCAACGCGGGATTCGGT 6237 KSNAGFG 7904 107.5065 1259 AAAGAAAGCCTCGAAGACGTC 6238 KESLEDV 7905 107.49 1260 GCGCAGGTTAATAATCATGAT 6239 AQVNNHD 7906 107.489 1261 AACGCTTCTACCTACATGGAC 6240 NASTYMD 7907 107.479 1262 ACGTCTGATACGAATGCTAGG 6241 TSDTNAR 7908 107.4605 1263 GAGAGTCGTATGCGTAGTATT 6242 ESRMRSI 7909 107.451 1264 CGTGTTGAAGACACCAACTCC 6243 RVEDTNS 7910 107.416 1265 GCCTCTAACCACCTACAAGCC 6244 ASNHLQA 7911 107.3863 1266 CGCTTACACGGCTCAGACTCG 6245 RLHGSDS 7912 107.358 1267 ACCGTCGAACAAATAAACTCG 6246 TVEQINS 7913 107.349 1268 AGGTCCGTACCATCACCACAC 6247 RSVPSPH 7914 107.343 1269 GAATACCTCGCCCTGGGACAC 6248 EYLALGH 7915 107.336 1270 AATACTAATAATCAGGAGCAG 6249 NTNNQEQ 7916 107.332 1271 AACTACGGTTCCGGACGAATC 6250 NYGSGRI 7917 107.3205 1272 CGCCACGGGGACACACCGATG 6251 RHGDTPM 7918 107.303 1273 AACGACACCATCGGCAGACCA 6252 NDTIGRP 7919 107.2995 1274 TATGGGGAGCGTGCTAGGACG 6253 YGERART 7920 107.297 1275 GTTCTTGGGATGCAGAGGTCT 6254 VLGMQRS 7921 107.295 1276 CTTCATTTTCATGCTTCGCAG 6255 LHFHASQ 7922 107.281 1277 ACCGACACGCTCAGCGAAAGA 6256 TDTLSER 7923 107.247 1278 GGGACAGGTACCGTTGGATGG 6257 GTGTVGW 7924 107.203 1279 ACAGAAAGCCCCAAACTACTA 6258 TESPKLL 7925 107.2015 1280 ACGATTAGGAGTGAGGGTTTT 6259 TIRSEGF 7926 107.1495 1281 GCGTCTAGTTATATTAATAAT 6260 ASSYINN 7927 107.144 1282 TTACACCTTGGGTTATCATCT 6261 LHLGLSS 7928 107.1415 1283 GTCACTGGCACTACCCCGGGA 6262 VTGTTPG 7929 107.137 1284 GTGACGTCGTCTGCTAGTGGT 6263 VTSSASG 7930 107.0606 1285 CAAATGCACCTACACATGCAA 6264 QMHLHMQ 7931 107.057 1286 GGTACCATGAGTCTATTAATG 6265 GTMSLLM 7932 107.046 1287 TGCGCATCAGAAGTTTGCCAA 6266 CASEVCQ 7933 107.035 1288 AATCTTGTGATGAGTGGGACG 6267 NLVMSGT 7934 107.0225 1289 CAATCACTCAAAGACGGCACT 6268 QSLKDGT 7935 106.991 1290 GCGTTGAATGGTTCTGGTATT 6269 ALNGSGI 7936 106.976 1291 AGACACGTCGTCCCCGACTCC 6270 RHVVPDS 7937 106.9705 1292 CTGTATCATGATTCGCATCTT 6271 LYHDSHL 7938 106.963 1293 GGGAGTACGCCTATTACTTCT 6272 GSTPITS 7939 106.957 1294 CCCAACGACCAAATCAGCGGA 6273 PNDQISG 7940 106.936 1295 AGTGGAAAACAAGACAAATAC 6274 SGKQDKY 7941 106.925 1296 AGTGGGCATGCTTCTCAGGGT 6275 SGHASQG 7942 106.8675 1297 AAGATGGGGAGTATTGAGGTT 6276 KMGSIEV 7943 106.864 1298 TCAACTTTAGACCGAAGCGAA 6277 STLDRSE 7944 106.8615 1299 ACGGAGCTTAGTGAGTATACT 6278 TELSEYT 7945 106.852 1300 GCCAACGGAGGAGGATACCCC 6279 ANGGGYP 7946 106.847 1301 GTAACCGAATCTAACTCTCTA 6280 VTESNSL 7947 106.83 1302 CCAGTCTACGACCGCGACGTC 6281 PVYDRDV 7948 106.812 1303 GATAATAATAAGCATGGTACT 6282 DNNKHGT 7949 106.806 1304 ATCTACGAAACCGTAACCTTG 6283 IYETVTL 7950 106.801 1305 ACTCAGACTGGTCATGTTTCT 6284 TQTGHVS 7951 106.7868 1306 CAAGCCGACCTCAGGTACAAA 6285 QADLRYK 7952 106.773 1307 TGTAAGACGAATAATGCTGGT 6286 CKTNNAG 7953 106.749 1308 GCCGGTCACCAACAACTGGCC 6287 AGHQQLA 7954 106.7459 1309 GATAGGGATATGGAGGGTGTT 6288 DRDMEGV 7955 106.742 1310 GATCAGCCGGGGTATGTGCGT 6289 DQPGYVR 7956 106.7387 1311 GATGCTATGCTTGCTCATCCG 6290 DAMLAHP 7957 106.735 1312 GCCCTTAACCTGTACTCCAGC 6291 ALNLYSS 7958 106.732 1313 CTACTATCTAAAGGGGACTCC 6292 LLSKGDS 7959 106.709 1314 TCGAGTATTAGTCTGCGGTAT 6293 SSISLRY 7960 106.645 1315 GGGTCGAGCCAACACCACGAA 6294 GSSQHHE 7961 106.62 1316 TCGATTGGGTATTCGCCTCCG 6295 SIGYSPP 7962 106.5773 1317 CACTCCAACGCGACTACGATA 6296 HSNATTI 7963 106.567 1318 TCGGCACACGACGCAAGACTA 6297 SAHDARL 7964 106.5665 1319 GTTCACACCGCAGACACAATA 6298 VHTADTI 7965 106.564 1320 CGAGACGGCTCTACTAAAGTT 6299 RDGSTKV 7966 106.55855 1321 TTGCAGGAGTCTCTTCCTGGT 6300 LQESLPG 7967 106.542 1322 TTAGACTACACCCCTCAAAAC 6301 LDYTPQN 7968 106.519 1323 GGACCAAGTTCGCACATCGTT 6302 GPSSHIV 7969 106.507 1324 AGCGCCGACACCCGGTCCCCC 6303 SADTRSP 7970 106.466 1325 ATGATGAAGAGTGAGGAGAAT 6304 MMKSEEN 7971 106.425 1326 GGTATGACGAGTGAGTTGACG 6305 GMTSELT 7972 106.417 1327 GTAGACACCTACAGCGGTCTG 6306 VDTYSGL 7973 106.415 1328 GGGATGAGGGATACGCCGCCG 6307 GMRDTPP 7974 106.385 1329 GAGCATGATGTGAGTACGCGT 6308 EHDVSTR 7975 106.302 1330 GAGGTGGTGAAGACTACTCAT 6309 EVVKTTH 7976 106.269 1331 GTTTACGACAACGTTTCTTCT 6310 VYDNVSS 7977 106.268 1332 CTCATGAAAGACATGGAATCC 6311 LMKDMES 7978 106.2609 1333 CCTCTTCATGTTGCTTCTCCT 6312 PLHVASP 7979 106.239 1334 GAAGTACGCGACCAAAAAACA 6313 EVRDQKT 7980 106.2075 1335 CCAACTCCCTACTACACCGCC 6314 PTPYYTA 7981 106.124 1336 AACAACTACGCCTACTCCGCT 6315 NNYAYSA 7982 106.1085 1337 CTTGTTGATACGGATAGGAAT 6316 LVDTDRN 7983 106.108 1338 TATCCGGCTGATCATCGGACT 6317 YPADHRT 7984 106.088 1339 TCTGCAACAACGAACCACGGA 6318 SATTNHG 7985 106.066 1340 CGTGATGATCAGCAGCTTGAT 6319 RDDQQLD 7986 106.064 1341 GGAGCGGGACAATCTCACGTG 6320 GAGQSHV 7987 106.0351 1342 GATAGGACTTATCATGAGGTG 6321 DRTYHEV 7988 105.996 1343 GATGGTAATAATACGACTTAT 6322 DGNNTTY 7989 105.99 1344 GTGCATATGGAGTCGTATGCG 6323 VHMESYA 7990 105.983 1345 TGGTACGAAACAATCAGCCCG 6324 WYETISP 7991 105.959 1346 CTGTTGGGGGCTCATCAGCCG 6325 LLGAHQP 7992 105.9002 1347 CACGTACCTAACACTGAAGCA 6326 HVPNTEA 7993 105.893 1348 AATTCTCAGAATCCTCAGGGT 6327 NSQNPQG 7994 105.8895 1349 CTACAAGACCGGGCAACGAAC 6328 LQDRATN 7995 105.864 1350 ATTGTGAATCAGCATTCGGAG 6329 IVNQHSE 7996 105.832 1351 TTTGAGCAGGGTAAGGTTGAG 6330 FEQGKVE 7997 105.811 1352 GTGGCGACGGGTGTGTTTGCT 6331 VATGVFA 7998 105.808 1353 GACAAAATACAAAACGAAACA 6332 DKIQNET 7999 105.784 1354 ACGGACAACCCGTCCTACAAA 6333 TDNPSYK 8000 105.771 1355 GGCGTGAACACAAAAATCGAA 6334 GVNTKIE 8001 105.7665 1356 GGCTCTCACAACGGCCCAGCC 6335 GSHNGPA 8002 105.763 1357 TCCAACATGGGCGTAGCCTCT 6336 SNMGVAS 8003 105.76 1358 AACACGGACACTAACGAAAAA 6337 NTDTNEK 8004 105.759 1359 TCTGCGCTTTTGCGGATGGAT 6338 SALLRMD 8005 105.707 1360 CCTCAACTAAGCGGCACAGCG 6339 PQLSGTA 8006 105.6914 1361 TCTATTGTTAATAATGGGGCT 6340 SIVNNGA 8007 105.684 1362 AGCCTAGACCACGCCCCTCTA 6341 SLDHAPL 8008 105.661 1363 GACCACTCGAAACAAAACTCT 6342 DHSKQNS 8009 105.653 1364 CACAGTGACATGGTCAGCGGC 6343 HSDMVSG 8010 105.642 1365 CAGCATCGTGCGCAGGATGTG 6344 QHRAQDV 8011 105.5608 1366 GGTAGTACTAAGTCTGGGCAG 6345 GSTKSGQ 8012 105.5509 1367 ACAATGAGCGTAACTCTGGAA 6346 TMSVTLE 8013 105.526 1368 TATAATAATGGTGGGCATGTT 6347 YNNGGHV 8014 105.516 1369 GGTACTGCTGAGAATACGAGT 6348 GTAENTS 8015 105.494 1370 AATAGTTATGATGCGACGAGG 6349 NSYDATR 8016 105.488 1371 AGCGTCAACAACATGCGACTC 6350 SVNNMRL 8017 105.4477 1372 CTTAACTTACAATACACTCTG 6351 LNLQYTL 8018 105.443 1373 GAGGCGCAGACCGGCTGGGTT 6352 EAQTGWV 8019 105.443 1374 CCCGCTGAAGGAAACAACCGT 6353 PAEGNNR 8020 105.442 1375 TCTCTGGGTGGGAATCCGCCT 6354 SLGGNPP 8021 105.4335 1376 TATAATAGGGATAATGGTTCT 6355 YNRDNGS 8022 105.4285 1377 TTGACTGATCCTAAGGGGCAG 6356 LTDPKGQ 8023 105.404 1378 ACCCCAACAGGCACCAACAAA 6357 TPTGTNK 8024 105.403 1379 GTTCACGCTAACGCTACATTA 6358 VHANATL 8025 105.38 1380 CGCGAAATAGTGCACTCAAAC 6359 REIVHSN 8026 105.376 1381 TACGCCGTCGCGATAGGCACA 6360 YAVAIGT 8027 105.366 1382 AACACAACACCTCCCGACCAC 6361 NTTPPDH 8028 105.348 1383 GTTATTCAGTCTGATAATACG 6362 VIQSDNT 8029 105.32 1384 GTTCCGGCGCATTCTCGGGGT 6363 VPAHSRG 8030 105.305 1385 CAAAACAGTGACCTCGCCAGC 6364 QNSDLAS 8031 105.296 1386 CGCATCGTAGACACGTTGGGA 6365 RIVDTLG 8032 105.2825 1387 CACACTTACTCACAAGCAGAC 6366 HTYSQAD 8033 105.267 1388 ACGGCTCCATCCGTAGGGTCT 6367 TAPSVGS 8034 105.259 1389 AACGTGGGCACCGACAGAGAC 6368 NVGTDRD 8035 105.231 1390 GGGATTAATCGTACTAGTGAG 6369 GINRTSE 8036 105.2145 1391 GTAGAAACAGACAGCTTAATA 6370 VETDSLI 8037 105.195 1392 CACTCCGCAGCGGGTGACGGT 6371 HSAAGDG 8038 105.195 1393 GATGCTGGGATTAGTTCTTAT 6372 DAGISSY 8039 105.102 1394 TGCACCGCCACAAAATGCTCA 6373 CTATKCS 8040 105.0959 1395 CGCATAGACACTCTCCTAGTC 6374 RIDTLLV 8041 105.089 1396 GTATCACAATCACACGACGTG 6375 VSQSHDV 8042 105.087 1397 GCACTACCATCCCACTCCTCC 6376 ALPSHSS 8043 105.059 1398 GGGAAACCTGCGGAAGCGCCG 6377 GKPAEAP 8044 105.055 1399 TGGAATAGTCCGGGTGAGGCG 6378 WNSPGEA 8045 105.053 1400 AGGCTGGAGCGTCCGGATTAT 6379 RLERPDY 8046 105.04 1401 ACGCGGGAGAGTCTGGTGGAT 6380 TRESLVD 8047 105.022 1402 AGACACGAAGGTCCGTACTCC 6381 RHEGPYS 8048 105.002 1403 GTTTTGTCTGATAAGGCGTTT 6382 VLSDKAF 8049 104.981 1404 ACTAGTGCGACTGATTCGATG 6383 TSATDSM 8050 104.908 1405 ACTGAGCCGCTTCCGATGTCT 6384 TEPLPMS 8051 104.869 1406 ATGCCTTACGTCGGGACAGTA 6385 MPYVGTV 8052 104.838 1407 CGTGATTATTCTCCTACTGAT 6386 RDYSPTD 8053 104.836 1408 CGGAATGGTGGTACTACGGAT 6387 RNGGTTD 8054 104.7625 1409 ATGATGGGCGCGACAACGAAA 6388 MMGATTK 8055 104.7503 1410 GCTGCCGTTGGCGGAGACACC 6389 AAVGGDT 8056 104.742 1411 CTTGTGAATAATGATGGGACT 6390 LVNNDGT 8057 104.7255 1412 AGTTCGACTCCGCAGGATACT 6391 SSTPQDT 8058 104.713 1413 AGTCTGCGGATGGAGAATAGT 6392 SLRMENS 8059 104.7025 1414 GTGCAGGGGCAGACCGGCTGG 6393 VQGQTGW 8060 104.688 1415 CTAGGTTTCACACCCCAACCG 6394 LGFTPQP 8061 104.677 1416 TCGGTTGCTAAGGATCAGACG 6395 SVAKDQT 8062 104.675 1417 CCGCGGCATGAGTTGAGTAAT 6396 PRHELSN 8063 104.645 1418 AAAATGGGATCGAACCCCGCA 6397 KMGSNPA 8064 104.6241 1419 GAGGCGACTCATGGTTCTTAT 6398 EATHGSY 8065 104.613 1420 CCTGAGGTTGCGTGTCCTGGG 6399 PEVACPG 8066 104.595 1421 GTGAATACGCGGGAGGTTACG 6400 VNTREVT 8067 104.583 1422 ACGGCTCGTGCGATTGATATG 6401 TARAIDM 8068 104.551 1423 ACCGACGGCGCCCTGGGTTAC 6402 TDGALGY 8069 104.5325 1424 GGGTCGCAATACGCGAACCGC 6403 GSQYANR 8070 104.524 1425 GAAATGGGTAACCAATACCCA 6404 EMGNQYP 8071 104.453 1426 CCGTCGACACTCGCTGAAACA 6405 PSTLAET 8072 104.449 1427 CGCATAGGCGTTGGAGCACCA 6406 RIGVGAP 8073 104.4405 1428 CTGAGTGTGAAGGAGGAGATT 6407 LSVKEEI 8074 104.435 1429 TATACTACTCATGAGAGTGGG 6408 YTTHESG 8075 104.433 1430 CTTACTGCTGTTCTGACTGTT 6409 LTAVLTV 8076 104.424 1431 CTGCAGACTTCTGTTGCTACT 6410 LQTSVAT 8077 104.42 1432 ACTGTGCGTTCGCCTCAGCCG 6411 TVRSPQP 8078 104.391 1433 CATCCTGATGGTACTCGGCCG 6412 HPDGTRP 8079 104.375 1434 GGAGTAACAATCGGTAGCAGG 6413 GVTIGSR 8080 104.3732 1435 ACATACGCCTCTACTGAAGCG 6414 TYASTEA 8081 104.3675 1436 AGGAGTAGTCCTGCGACGAAT 6415 RSSPATN 8082 104.355 1437 ATCGGGTCGCCGTTGGCCAAC 6416 IGSPLAN 8083 104.35 1438 GCGTCGACTGAGTCTCATGTG 6417 ASTESHV 8084 104.344 1439 ATTGCGCAGAATGAGACGTAT 6418 IAQNETY 8085 104.336 1440 ATGGAGTCTAAGCCGTGGCAG 6419 MESKPWQ 8086 104.307 1441 TTAGAAAACCCAACACCAGCA 6420 LENPTPA 8087 104.305 1442 CCCAACCCCAGTCCAAGACAA 6421 PNPSPRQ 8088 104.258 1443 TCGACTAGTAATCCGCCTTAT 6422 STSNPPY 8089 104.242 1444 TATTTGACGGATACTCCTACT 6423 YLTDTPT 8090 104.241 1445 ATACGTGCATTGATGACGGAC 6424 IRALMTD 8091 104.237 1446 CCTATGGGTACGGATACGGTT 6425 PMGTDTV 8092 104.221 1447 ACGAGGACTCAGGGGACGTCT 6426 TRTQGTS 8093 104.19625 1448 TCTAATAATATGAATCAGGCG 6427 SNNMNQA 8094 104.187 1449 GAAGACTCTGTAAACCACATC 6428 EDSVNHI 8095 104.185 1450 TCTGTTGTGCCTACGGATAAG 6429 SVVPTDK 8096 104.174 1451 GTGCGCGGCGTTCAAGACGCC 6430 VRGVQDA 8097 104.167 1452 CATGATGTGACTGTGCGGAAT 6431 HDVTVRN 8098 104.164 1453 CATAATAATCATGCGGGTGAG 6432 HNNHAGE 8099 104.153 1454 GGTAATATGAATCATAGTATT 6433 GNMNHSI 8100 104.15 1455 GGTGTGCATACTCATACTGTT 6434 GVHTHTV 8101 104.139 1456 TTTTTGCCGCAGCTGGGGCAG 6435 FLPQLGQ 8102 104.094 1457 TTGGCCAACATGTCCGCACCA 6436 LANMSAP 8103 104.093 1458 GTTCGCAGAGACGAAACACCT 6437 VRRDETP 8104 104.0585 1459 TGCCGCGACAACGTCTTAGCT 6438 CRDNVLA 8105 104.046 1460 ATGTTGGCTTCTCGGGTGCCT 6439 MLASRVP 8106 104.0205 1461 GTCAGAACAGTCCTTCAACAA 6440 VRTVLQQ 8107 104.017 1462 TCGAATCAGAATGTGGATTGG 6441 SNQNVDW 8108 104 1463 ACTGAGGTTACGGGGGATAGT 6442 TEVTGDS 8109 103.965 1464 GAAAGTGCCACATCTCTAAAA 6443 ESATSLK 8110 103.9355 1465 AACCACCCCGCACCAAGCTCA 6444 NHPAPSS 8111 103.9235 1466 TACGGTAACGCGAACACCGTA 6445 YGNANTV 8112 103.92115 1467 CAAAACGACAAATCTGACAAC 6446 QNDKSDN 8113 103.9165 1468 AGTCAGGCTCAGATTCGTGTT 6447 SQAQIRV 8114 103.915 1469 TTTCAGCGTGATGTTGGTCAT 6448 FQRDVGH 8115 103.8651 1470 CTGATGAATCGTAATGCTCCT 6449 LMNRNAP 8116 103.8648 1471 GCGGGCAGTTCGCCATCACGC 6450 AGSSPSR 8117 103.8635 1472 TTATTCCACAGCCAAATGACC 6451 LFHSQMT 8118 103.849 1473 ATGATGTCTAACAGCCTCGCG 6452 MMSNSLA 8119 103.8275 1474 GTTACCACCGTCCTCCAATCA 6453 VTTVLQS 8120 103.818 1475 GGTAGTCAGCGTGCTATGAAT 6454 GSQRAMN 8121 103.8086 1476 GCATCCGGCGCACGCTACGTC 6455 ASGARYV 8122 103.7981 1477 AAAAACTACGACAGTGACTCA 6456 KNYDSDS 8123 103.794 1478 GTGGGTTCTGGGGTTGGGGTT 6457 VGSGVGV 8124 103.793 1479 CGTTCTGACCTTACTGAAAGT 6458 RSDLTES 8125 103.736 1480 AGGGCGGAGTTTATTGATACG 6459 RAEFIDT 8126 103.735 1481 ACATCTGAAATGCGGACAGCC 6460 TSEMRTA 8127 103.725 1482 GAGTTGGATCATCTTTCGCAT 6461 ELDHLSH 8128 103.714 1483 ACACAAGCAGGTCTTGCGTCA 6462 TQAGLAS 8129 103.696 1484 GCGGCTCAGCATCATGATACG 6463 AAQHHDT 8130 103.693 1485 GGCGGCGCACACACTCGTGTA 6464 GGAHTRV 8131 103.676 1486 GCCTACGGTATACACGAAGTG 6465 AYGIHEV 8132 103.653 1487 GCGATGCTGCGTATGGAGCAG 6466 AMLRMEQ 8133 103.652 1488 ACGGATCGTTCGCGGCTGGGG 6467 TDRSRLG 8134 103.622 1489 GAGAGGGAGCCTCCTAAGAAT 6468 EREPPKN 8135 103.621 1490 GTTGTTAAGGAGATTAAGCTG 6469 VVKEIKL 8136 103.6125 1491 CACACCGGCCAAACACCATCA 6470 HTGQTPS 8137 103.5945 1492 GTGTCTCTGAGTTCGCCTCCG 6471 VSLSSPP 8138 103.563 1493 GGGGCAGGAAACCTGGGTACC 6472 GAGNLGT 8139 103.5615 1494 GCACGAGACGACACGATACAA 6473 ARDDTIQ 8140 103.523 1495 GGGACTTATACTAATATGCCG 6474 GTYTNMP 8141 103.522 1496 ATGCTGGGGGGTTTTGCGCAG 6475 MLGGFAQ 8142 103.5051 1497 CCATCCGAAATGAGGGCCGTA 6476 PSEMRAV 8143 103.503 1498 CGTATAAGCCCAGAAAACTCA 6477 RISPENS 8144 103.497 1499 AAGATGGGTGGTTCTCAGAGT 6478 KMGGSQS 8145 103.477 1500 GGTTTGATGGCGCATGTGACT 6479 GLMAHVT 8146 103.464 1501 TCACGTCAAACAGCGCTAACA 6480 SRQTALT 8147 103.4599 1502 AGTGATCTGAATCTTCCGCCG 6481 SDLNLPP 8148 103.455 1503 TATGTGTCTGATTATTTGCAT 6482 YVSDYLH 8149 103.393 1504 ACTAATGATAATAGTGATCGT 6483 TNDNSDR 8150 103.374 1505 TACTTAATGCACGACAGCGCA 6484 YLMHDSA 8151 103.369 1506 GGCTCTCGGAACGGACCCACA 6485 GSRNGPT 8152 103.3096 1507 AAAAACGGTGTTATAAACGAC 6486 KNGVIND 8153 103.292 1508 GAGTCTGTTGCTAATCTTAAG 6487 ESVANLK 8154 103.162 1509 GCATCGGACTCGACGACACCA 6488 ASDSTTP 8155 103.149 1510 CTGAACGTTAGTTCATCCAAA 6489 LNVSSSK 8156 103.149 1511 GAGGCTAAGGGTTTTGGTCAT 6490 EAKGFGH 8157 103.1228 1512 GGTACGAGTGCGGAGAGTCGG 6491 GTSAESR 8158 103.111 1513 ATGCACAACCTACCCTCATAC 6492 MHNLPSY 8159 103.10145 1514 GTCTTCACAGAAATAGAATCG 6493 VFTEIES 8160 103.101 1515 ACTCAAACTTCTACCTGGACC 6494 TQTSTWT 8161 103.094 1516 CCTATGAATAAGGATATTTTG 6495 PMNKDIL 8162 103.07 1517 AAAGAATCTGAATACAGAGTT 6496 KESEYRV 8163 103.07 1518 TCGACGAATTCTGAGGCGGTT 6497 STNSEAV 8164 103.068 1519 GATACGGCGAATCGTTCGACT 6498 DTANRST 8165 103.03715 1520 CCTAAGGCTCCGCTTAATAAT 6499 PKAPLNN 8166 103.032 1521 TTAGCTACATACCCCTCCCAC 6500 LATYPSH 8167 103.028 1522 GCTACGGTTCAGTCGGTTGAT 6501 ATVQSVD 8168 103.011 1523 AATTCGATGGGTAATGGGGGT 6502 NSMGNGG 8169 103.009 1524 GATCATAGTGAGCAGAATTCG 6503 DHSEQNS 8170 102.995 1525 ACTTTTTTGCCTCAGCTTGGG 6504 TFLPQLG 8171 102.994 1526 GGGTTTACTAATACGAGTAAG 6505 GFTNTSK 8172 102.9895 1527 ACGATGAATTATAGTCATACT 6506 TMNYSHT 8173 102.962 1528 AGTATCGGATTCTCAGTAGGC 6507 SIGFSVG 8174 102.9565 1529 AGTGAGAATCGGGCTGGTAAT 6508 SENRAGN 8175 102.945 1530 AGTCTTAATCTGCATAGTGTG 6509 SLNLHSV 8176 102.93 1531 CATGAGAGTCATTATGTTAGT 6510 HESHYVS 8177 102.921 1532 AATGTTGTTAATGGGATGGAT 6511 NVVNGMD 8178 102.908 1533 CACTCCGACAAAGTCTCCTCA 6512 HSDKVSS 8179 102.8992 1534 AAATCTGTAGGCGACGGGAGA 6513 KSVGDGR 8180 102.8979 1535 AGGCAGGTTGAGCAGTCTGAT 6514 RQVEQSD 8181 102.889 1536 AGGGAGCTGGTGAATACGGAT 6515 RELVNTD 8182 102.87 1537 AACTACAGGGACATCACAATG 6516 NYRDITM 8183 102.8605 1538 GCCAGCCTTGACCGCCTTCCA 6517 ASLDRLP 8184 102.857 1539 AGACAACTTGCTTCTCTCCCA 6518 RQLASLP 8185 102.846 1540 GTCAGCAAAACCAAAGACTCG 6519 VSKTKDS 8186 102.832 1541 AACGTATACGAAGGGCACCGC 6520 NVYEGHR 8187 102.815 1542 CTAGAACAACTACGGGTCCCA 6521 LEQLRVP 8188 102.815 1543 ATGACCTACACATCCCCAACC 6522 MTYTSPT 8189 102.807 1544 AACTCCCACACCGACAGAGGA 6523 NSHTDRG 8190 102.801 1545 GTGGCTGGGGGGACTTCGGAG 6524 VAGGTSE 8191 102.789 1546 GTCGACGCACACAGGGCTAAC 6525 VDAHRAN 8192 102.77 1547 CGGGCAGACATGACTCCCTTA 6526 RADMTPL 8193 102.77 1548 GGACACGAACAAACTGACGCA 6527 GHEQTDA 8194 102.764 1549 TACATCGCGGGAGGCGACCAA 6528 YIAGGDQ 8195 102.75 1550 TACGGCGACCTAACTACAGTC 6529 YGDLTTV 8196 102.737 1551 AGATTAGACCTGCAAGAACAC 6530 RLDLQEH 8197 102.719 1552 CACCTTAACCCGGCGGCCCAA 6531 HLNPAAQ 8198 102.719 1553 GGGGTTAACGAACAAACAAAC 6532 GVNEQTN 8199 102.703 1554 CGTCGGTTGAGTACGGATCTT 6533 RRLSTDL 8200 102.702 1555 GGATCCACAGGCCTACCCCCG 6534 GSTGLPP 8201 102.7015 1556 GACGACATGGTCAAAAACTCA 6535 DDMVKNS 8202 102.6815 1557 GTTATAGACCTAGTCACTCGC 6536 VIDLVTR 8203 102.673 1558 GGAGGCCTTACCAACGGTCTA 6537 GGLTNGL 8204 102.67 1559 CGTATGGAGGAGACTGCTTAT 6538 RMEETAY 8205 102.6535 1560 ACCGACATCTCCGGTTACGGA 6539 TDISGYG 8206 102.642 1561 CAGGTTAATCATAATACTAGT 6540 QVNHNTS 8207 102.637 1562 GCGACTACTGAGGATGTTCGT 6541 ATTEDVR 8208 102.626 1563 TGGAGCATCAAAAACCAAACA 6542 WSIKNQT 8209 102.586 1564 TCCCCTACCAGCAACACAATA 6543 SPTSNTI 8210 102.584 1565 ATGAAAAACTCTGGATTCGAC 6544 MKNSGFD 8211 102.583 1566 CTTGTTGCTGAGCGTTTGCCG 6545 LVAERLP 8212 102.552 1567 GGTGAAACTAACTTCCCAACT 6546 GETNFPT 8213 102.532 1568 AATGGTAAGCTGGGTACGACT 6547 NGKLGTT 8214 102.52735 1569 AACTTAGTAGCGTACACGAAA 6548 NLVAYTK 8215 102.5245 1570 TGGCAGCTTACGACGAGTCAT 6549 WQLTTSH 8216 102.497 1571 AGTTTGGACCTAGGAGGCAAC 6550 SLDLGGN 8217 102.491 1572 AACGAAAGCACCAAAGAATCT 6551 NESTKES 8218 102.483 1573 GGTTTTGATGGTAAGCAGCTT 6552 GFDGKQL 8219 102.462 1574 CATCTGTATATTTCGGCGGAT 6553 HLYISAD 8220 102.442 1575 TTACTTCCAAACAACACCCAC 6554 LLPNNTH 8221 102.424 1576 TCCGGAATGGCCGGCCTTTCC 6555 SGMAGLS 8222 102.423 1577 ATCACCTCACTCCCCGAAACC 6556 ITSLPET 8223 102.414 1578 GAGCTTAAGGAGAGTCAGAAG 6557 ELKESQK 8224 102.408 1579 AATATTGTGCAGGATTATCCG 6558 NIVQDYP 8225 102.404 1580 TCAGAAAACACCTCTGTACCC 6559 SENTSVP 8226 102.388 1581 GACCCCAACCAACCCAAAACA 6560 DPNQPKT 8227 102.376 1582 GCGGGTTTGGATGTGAATACG 6561 AGLDVNT 8228 102.372 1583 TCTCATGAGATGAATAATGGT 6562 SHEMNNG 8229 102.366 1584 TCTTACGCCATAAACCAATCA 6563 SYAINQS 8230 102.335 1585 GGTCATCTGCCTGCGGCTAAG 6564 GHLPAAK 8231 102.315 1586 GAGTTGGGTAATAAGACGGCT 6565 ELGNKTA 8232 102.311 1587 CTTGAGTCTACTCGTAAGGCT 6566 LESTRKA 8233 102.31 1588 ACTCAAGGCAACTCTGAAGCA 6567 TQGNSEA 8234 102.31 1589 ATCTCTATAGACTCCGCTATG 6568 ISIDSAM 8235 102.301 1590 GAGTTTCAGAGGATTCGTGAG 6569 EFQRIRE 8236 102.259 1591 GCTAGTCTCTCCGCACCAGCC 6570 ASLSAPA 8237 102.227 1592 GACAGCCAAATCACAAGACTA 6571 DSQITRL 8238 102.218 1593 GGCCACGAAAACATGGGCGTG 6572 GHENMGV 8239 102.215 1594 ATGTCGGCGGGGCATCCTACG 6573 MSAGHPT 8240 102.207 1595 CACGCTCCAAGCGGCGCCATA 6574 HAPSGAI 8241 102.2 1596 ACGACTATTACTAATTCGGTT 6575 TTITNSV 8242 102.187 1597 CCTCAGCATCAGCATGAGCAT 6576 PQHQHEH 8243 102.1805 1598 CAATACTCGATGGACACGCGC 6577 QYSMDTR 8244 102.173 1599 CTTTATGAGGTTGGTACTCCT 6578 LYEVGTP 8245 102.165 1600 GGTGAGACTATGCGTCATAAT 6579 GETMRHN 8246 102.119 1601 ATGACAATAACCGTCGAACCG 6580 MTITVEP 8247 102.096 1602 GCGCAGCATCCTGAGCGTTCG 6581 AQHPERS 8248 102.084 1603 ACGCATGTTGCTAAGCCTGAT 6582 THVAKPD 8249 102.082 1604 ATGACTGCTAACTTGGTGGAA 6583 MTANLVE 8250 102.076 1605 AATAGGCAGCGGGATTTTGAG 6584 NRQRDFE 8251 102.073 1606 TCAAACAGCGCCGACGCGGGG 6585 SNSADAG 8252 102.047 1607 GGTGAGTATGGTGCGTCGGTT 6586 GEYGASV 8253 102.037 1608 GACGGCATGGTCAGGTCGACA 6587 DGMVRST 8254 102.025 1609 AATGGTCAGCTGCTGGCTAAT 6588 NGQLLAN 8255 102.023 1610 TCCGCGGGGATGACATTGGAC 6589 SAGMTLD 8256 102.016 1611 GATCATGTGCATCTGACTTAT 6590 DHVHLTY 8257 102.008 1612 ACGACACTAACGCAAACGGAC 6591 TTLTQTD 8258 102.003 1613 GTGCAGTTGGCTGATGGGCAT 6592 VQLADGH 8259 102.003 1614 ACTGACTCATCTGCAGACTCC 6593 TDSSADS 8260 101.981 1615 GCGATGAATGTGCGGAGTGAT 6594 AMNVRSD 8261 101.9805 1616 GGTGATATTTCTTATAGGGTT 6595 GDISYRV 8262 101.977 1617 ATGGGGTATGTTGATAGTCTG 6596 MGYVDSL 8263 101.953 1618 CTTTATTTGGCGGCGGCTTCG 6597 LYLAAAS 8264 101.948 1619 TCATCCCCAGACTCGTACAGA 6598 SSPDSYR 8265 101.921 1620 AGTTATAATGTGGATCTGCAT 6599 SYNVDLH 8266 101.892 1621 CAACACACCGCCCACCCCATG 6600 QHTAHPM 8267 101.892 1622 GCAGTTATGGCTACACACCCC 6601 AVMATHP 8268 101.87 1623 ATTAGTCCGAGTGCTTCTAAT 6602 ISPSASN 8269 101.855 1624 ACTTTGGATAATAATCATTCT 6603 TLDNNHS 8270 101.833 1625 AGTGGGTCTTATGTGGCGACG 6604 SGSYVAT 8271 101.806 1626 ATGGCGGCTCCGCCGGAGCAT 6605 MAAPPEH 8272 101.802 1627 CAGACTGCGTCTGGTGATACT 6606 QTASGDT 8273 101.7725 1628 GAGTCTAAGACTGTGGTTATT 6607 ESKTVVI 8274 101.7695 1629 ACGGTATTACCACAATCAGAC 6608 TVLPQSD 8275 101.744 1630 CCATTAAACGCGAACGGCTCC 6609 PLNANGS 8276 101.7415 1631 CCCCTGAACACAGGATTAACC 6610 PLNTGLT 8277 101.718 1632 GCCATAACGATAATAGGCACT 6611 AITIIGT 8278 101.711 1633 AATCCTAGTGCGATTAGTTAT 6612 NPSAISY 8279 101.687 1634 ACAGAACACGAAAAATCCACT 6613 TEHEKST 8280 101.66205 1635 GCTGAGAGTCAGCTGGCGTCG 6614 AESQLAS 8281 101.655 1636 GTGCTTAAGGGTACGTTTCCG 6615 VLKGTFP 8282 101.652 1637 TCGTTCGCCGAAATAACGACT 6616 SFAEITT 8283 101.651 1638 CCGTTAAACGGCCGCGTAACC 6617 PLNGRVT 8284 101.642 1639 TCCGAACGCCCCCAATCGTCA 6618 SERPQSS 8285 101.579 1640 GCTCAGCTTCAGGATTCGGTG 6619 AQLQDSV 8286 101.568 1641 CCCAACCGTGTAACAGCACCC 6620 PNRVTAP 8287 101.5542 1642 GCGCTTATTGTTTCGAGTATG 6621 ALIVSSM 8288 101.54 1643 GCGCATGGTGCTTTTCCGGTT 6622 AHGAFPV 8289 101.495 1644 GAGGCTTATCAGACTGAGAAG 6623 EAYQTEK 8290 101.49 1645 GCTGCGGCTTCGCCTTTGGCT 6624 AAASPLA 8291 101.484 1646 CCCCAAGCCACTCTCAACAAC 6625 PQATLNN 8292 101.432 1647 ACGAGGGGTGATATGGAGTTT 6626 TRGDMEF 8293 101.424 1648 AGCAACCTAGGCGAAGCATCT 6627 SNLGEAS 8294 101.423 1649 GGAATCACCGGAAGCCCCGGC 6628 GITGSPG 8295 101.42 1650 GGGTTTGAGACGAGTAGTCCT 6629 GFETSSP 8296 101.369 1651 CCCGCGAGAAGCGACGCCCTT 6630 PARSDAL 8297 101.359 1652 CATGCTAATTATGTTGAGGTG 6631 HANYVEV 8298 101.345 1653 GTGACTCGTAGTACGAAGGAG 6632 VTRSTKE 8299 101.32381 1654 GATGTTGCGTTGAGGTCGAAT 6633 DVALRSN 8300 101.254 1655 GAGTCTGATTTGCGTCAGCGG 6634 ESDLRQR 8301 101.225 1656 CCGTTACTCGCAGCGAACCCG 6635 PLLAANP 8302 101.207 1657 ATAAACGCCGCGCACAGGCCC 6636 INAAHRP 8303 101.163 1658 GCTCGGAGAGACGTAAACTCG 6637 ARRDVNS 8304 101.15 1659 AGTATGGATAAGGTGGAGAAG 6638 SMDKVEK 8305 101.144 1660 AACGTCAGCGCACGGGAAACA 6639 NVSARET 8306 101.113 1661 CTGACGACGGCTGGTATGTGG 6640 LTTAGMW 8307 100.9605 1662 GCGCGGGCAGAAGGGGTCTTC 6641 ARAEGVF 8308 100.9325 1663 CCGAGTGATCATATGCGGACT 6642 PSDHMRT 8309 100.8849 1664 AGTAGGACGGTTATTTTGTCG 6643 SRTVILS 8310 100.8697 1665 CAGAGTAATGCTGCTGAGGGT 6644 QSNAAEG 8311 100.8152 1666 TGGACCGAAACGGCCGCTCAC 6645 WTETAAH 8312 100.7753 1667 AAGGAGAATCAGCTTAGTAAG 6646 KENQLSK 8313 100.7556

TABLE 4 RGD Motifs from expression by a CK8 promoter Rank Sequence SEQ ID NO: 1 RGDLSTP 13 2 RGDLNQY 14 3 RGDLTTP 15 4 RGDATEL 16 5 RGDQLYH 17 6 RGDLSTP 18 7 RGDVAAK 19 8 RGDLTTP 20 9 RGDLNQY 21 10 RGDTMSK 22 11 RGDVAAK 23 12 RGDTMSK 24 13 RGDATEL 25

TABLE 5 RGD Motifs from expression by MHCK7 promoter Rank Sequence SEQ ID NO: 1 RGDLTTP 26 2 RGDLNQY 27 3 RGDLSTP 28 4 RGDQLYH 29 5 RGDTMSK 30 6 RGDATEL 31 7 RGDLSTP 32 8 RGDMINT 33 9 RGDLNQY 34 10 RGDTMSK 35 11 RGDLTTP 36 12 RGDLNDS 37

TABLE 6 RGD Motifs from expression by MHCK7 and CK8 combined. Rank Sequence SEQ ID NO: 1 RGDLSTP 38 2 RGDLSTP 39 3 RGDLTTP 40 4 RGDLNQY 41 5 RGDQLYH 42 6 RGDATEL 43 7 RGDTMSK 44 8 RGDLNQY 45 9 RGDLTTP 46 10 RGDMINT 47 11 RGDTMSK 48 12 RGDTMNY 49 13 RGDATEL 50

In some embodiments, the n-mer motif is or includes an “RGD” motif. An “RGD” motif refers to n-mer motifs having the presence of the amino acids R, G, D and as the three consecutive amino acids in that order of the n-mer motif. In some embodiments, the RGD motif can have the general formula X_(m)RGDX_(n), where m can be 0-4 amino acids, n can be 0-15 amino acids, and where X is any amino acid, where each amino acid present can each be independently selected from the others and can be selected from the group of any amino acid. It will be appreciated that when m=0 or n=0, that this means that there are no amino acids preceding the “RGD” in the RGD motif and/or there are no amino acids following the “RGD” in the RGD motif. In some embodiments, when m=0, RGD is the first three amino acids of the RGD motif. In some embodiments, when n=0, RGD is the last three amino acids of the RGD motif. In some embodiments, where m=0 and n=0, the RGD motif contains only the amino acids RGD. Exemplary RGD motifs are shown in e.g. Tables 1-6 and 8-9.

In some exemplary embodiments, the RGD motif is X₁RGDX₂ (SEQ ID NO: 9100), X₁RGDX₂X₃ (SEQ ID NO: 9101), X₁RGDX₂X₃X₄ (SEQ ID NO: 9102), X₁RGDX₂X₃X₄X₅ (SEQ ID NO: 9103), X₁RGDX₂X₃X₄X₅X₆ (SEQ ID NO: 9104), X₁RGDX₂X₃X₄X₅X₆X₇ (SEQ ID NO: 9105) X₁RGDX₂X₃X₄X₅X₆X₇X₈ (SEQ ID NO: 9106), X₁RGDX₂X₃X₄X₅X₆X₇X₈X₉ (SEQ ID NO: 9107), X₁RGDX₂X₃X₄X₅X₆X₇X₈X₉X₁₀ (SEQ ID NO: 9108), X₁RGDX₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁ (SEQ ID NO: 9109), or X₁RGDX₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂ (SEQ ID NO: 9110).

In some exemplary embodiments, the RGD motif is X₁X₂RGDX₃ (SEQ ID NO: 9111), X₁X₂RGDX₃X₄ (SEQ ID NO: 9112), X₁X₂RGDX₃X₄X₅ (SEQ ID NO: 9113), X₁X₂RGDX₃X₄X₅X₆ (SEQ ID NO: 9114), X₁X₂RGDX₃X₄X₅X₆X₇ (SEQ ID NO: 9115), X₁X₂RGDX₃X₄X₅X₆X₇X₈ (SEQ ID NO: 9116), X₁X₂RGDX₃X₄X₅X₆X₇X₈X₉ (SEQ ID NO: 9117), X₁X₂RGDX₃X₄X₅X₆X₇X₈X₉X₁₀ (SEQ ID NO: 9118), X₁X₂RGDX₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁ (SEQ ID NO: 9119), or X₁X₂RGDX₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂ (SEQ ID NO: 9120).

In some exemplary embodiments, the RGD motif is X₁X₂X₃RGDX₄ (SEQ ID NO: 9121), X₁X₂X₃RGDX₄X₅ (SEQ ID NO: 9122), X₁X₂X₃RGDX₄X₅X₆ (SEQ ID NO: 9123), X₁X₂X₃RGDX₄X₅X₆X₇ (SEQ ID NO: 9124), X₁X₂X₃RGDX₄X₅X₆X₇X₈ (SEQ ID NO: 9125), X₁X₂X₃RGDX₄X₅X₆X₇X₈X₉ (SEQ ID NO: 9126), X₁X₂X₃RGDX₄X₅X₆X₇X₈X₉X₁₀ (SEQ ID NO: 9127), X₁X₂X₃RGDX₄X₅X₆X₇X₈X₉X₁₀X₁₁ (SEQ ID NO: 9128), or X₁X₂X₃RGDX₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂ (SEQ ID NO: 9129).

In some exemplary embodiments, the RGD motif is X₁X₂X₃X₄RGDX₅ (SEQ ID NO: 9130), X₁X₂X₃X₄RGDX₅X₆ (SEQ ID NO: 9131), X₁X₂X₃X₄RGDX₅X₆X₇ (SEQ ID NO: 9132), X₁X₂X₃X₄RGDX₅X₆X₇X₈ (SEQ ID NO: 9133), X₁X₂X₃X₄RGDX₅X₆X₇X₈X₉ (SEQ ID NO: 9134), X₁X₂X₃X₄RGDX₅X₆X₇X₈X₉X₁₀ (SEQ ID NO: 9135), X₁X₂X₃X₄RGDX₅X₆X₇X₈X₉X₁₀X₁₁ (SEQ ID NO: 9136), or X₁X₂X₃X₄RGDX₅X₆X₇X₈X₉X₁₀X₁₁X₁₂ (SEQ ID NO: 9137).

In some embodiments, the RGD motif has the amino acids RGD as the first three consecutive amino acids of the n-mer motif (i.e. m=0). In some exemplary embodiments, the n-mer can have a sequence of RGD or RGDX_(n), where n can be 1-15 amino acids and X can be any amino acid, where each amino acid present can each be independently selected from the others and can be selected from the group of any amino acid. In some embodiments, the n-mer motif can be RGD (3-mer), RGDX₁ (4-mer), RGDX₁X₂ (5-mer) (SEQ ID NO: 2), RGDX₁X₂X₃ (6-mer) (SEQ ID NO: 3), RGDX₁X₂X₃X₄ (7 mer) (SEQ ID NO: 4), RGDX₁X₂X₃X₄X₅ (8 mer) (SEQ ID NO: 5), RGDX₁X₂X₃X₄X₅X₆ (9-mer) (SEQ ID NO: 6), RGD₁X₂X₃X₄X₅X₆X₇ (10-mer) (SEQ ID NO: 7), RGD₁X₂X₃X₄X₅X₆X₇X₈ (11-mer) (SEQ ID NO: 8), RGDX₁X₂X₃X₄X₅X₆X₇X₈X₉ (12-mer) (SEQ ID NO: 9), RGDX₁X₂X₃X₄X₅X₆X₇X₈X₉X₁₀ (13-mer) (SEQ ID NO: 10), RGDX₁X₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁ (14-mer) (SEQ ID NO: 11), or RGDX₁X₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂ (15-mer) (SEQ ID NO: 12), where X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂ are each be independently selected from any amino acid. In some embodiments, X₁ is L, T, A, M, V, Q, or M. In some embodiments, X₂ is T, M, S, N, L, A, or I. In some embodiments, X₃ is T, E, N, O, S, Q, Y, A, or D. In some embodiments, X₄ is P, Y, K, L, H, T, or S. In some embodiments, n-mer motifs including the RGD motif is included in a muscle-specific engineered AAV capsids.

In some embodiments, the n-mer motif can be in any one of Tables 1-6. In some embodiments, the n-mer motif in any of Tables 1-6 and 8-9 can be included in a muscle specific engineered capsid.

In some embodiments, the n-mer motif can be in any one of Tables 4-6. In some embodiments, the n-mer motif in any of Tables 4-6 and 8-9 can be included in a muscle specific engineered capsid.

The muscle-specific targeting moiety can be coupled to or otherwise associated with a cargo. In some embodiments, one or more muscle-specific targeting moieties described herein is directly attached to the cargo. In some embodiments, one or more muscle-specific targeting moieties described herein is indirectly coupled to the cargo, such as via a linker molecule. In some embodiments, one or more one or more muscle-specific targeting moieties described herein is coupled to associated with a polypeptide or other particle that is coupled to, attached to, encapsulates, and/or contains a cargo.

Exemplary particles include, without limitation, viral particles (e.g. viral capsids, which is inclusive of bacteriophage capsids), polysomes, liposomes, nanoparticles, microparticles, exosomes, micelles, and the like. The term “nanoparticle” as used herein includes a nanoscale deposit of a homogenous or heterogeneous material. Nanoparticles may be regular or irregular in shape and may be formed from a plurality of co-deposited particles that form a composite nanoscale particle. Nanoparticles may be generally spherical in shape or have a composite shape formed from a plurality of co-deposited generally spherical particles. Exemplary shapes for the nanoparticles include, but are not limited to, spherical, rod, elliptical, cylindrical, disc, and the like. In some embodiments, the nanoparticles have a substantially spherical shape.

As used herein, the term “specific” when used in relation to described an interaction between two moieties, refers to non-covalent physical association of a first and a second moiety wherein the association between the first and second moieties is at least 2 times as strong, at least 5 times as strong as, at least 10 times as strong as, at least 50 times as strong as, at least 100 times as strong as, or stronger than the association of either moiety with most or all other moieties present in the environment in which binding occurs. Binding of two or more entities may be considered specific if the equilibrium dissociation constant, Kd, is 10⁻³ M or less, 10⁻⁴ M or less, 10⁻⁵ M or less, 10⁻⁶ M or less, 10⁻⁷ M or less, 10⁻⁸M or less, 10⁻⁹ M or less, 10⁻¹⁰ M or less, 10⁻¹¹ M or less, or 10⁻¹² M or less under the conditions employed, e.g., under physiological conditions such as those inside a cell or consistent with cell survival. In some embodiments, specific binding can be accomplished by a plurality of weaker interactions (e.g., a plurality of individual interactions, wherein each individual interaction is characterized by a Kd of greater than 10⁻³ M). In some embodiments, specific binding, which can be referred to as “molecular recognition,” is a saturable binding interaction between two entities that is dependent on complementary orientation of functional groups on each entity. Examples of specific interactions include primer-polynucleotide interaction, aptamer-aptamer target interactions, antibody-antigen interactions, avidin-biotin interactions, ligand-receptor interactions, metal-chelate interactions, hybridization between complementary nucleic acids, etc.

In some embodiments, in addition to the one or more n-mer motifs the targeting moiety can include a polypeptide, a polynucleotide, a lipid, a polymer, a sugar, or a combination thereof.

Engineered Muscle Targeting Viral Capsids

In some embodiments, the muscle engineered muscle-specific targeting moiety is incorporated into a viral capsid protein, which can in turn be incorporated into an engineered viral capsid of an engineered virus particle, thus providing a muscle-specific virus particle. The muscle-specific engineered virus particle can be useful for delivering a cargo to muscle cells. In some embodiments, the targeting moiety is incorporated into a viral protein, such as a capsid protein, including but not limited to lentiviral, adenoviral, AAV, bacteriophage, retroviral proteins. In some embodiments, one or more n-mer motifs (such as an RGD or non-RGD n-mer motif) is located between two amino acids of the viral protein such that one or more of the one or more n-mer motifs are external (i.e. is presented on the surface of) to a viral capsid.

In some embodiments, the composition containing one or more of the muscle-specific targeting moieties described herein has increased muscle cell potency, muscle cell specificity, reduced immunogenicity, or any combination thereof.

Cargos include any molecule that is capable of being coupled to or associated with the muscle-specific targeting moieties described herein. Cargos include, without limitation, nucleotides, oligonucleotides, polynucleotides, amino acids, peptides, polypeptides, riboproteins, lipids, sugars, pharmaceutically active agents (e.g. drugs, imaging and other diagnostic agents, and the like), chemical compounds, and combinations thereof. In some embodiments, the cargo is or includes, DNA, RNA, amino acids, peptide(s), polypeptide(s), antibody(ies), aptamer(s), ribozyme(s), guide sequence(s) for ribozymes that inhibit translation or transcription of essential tumor proteins and genes, hormone(s), immunomodulator(s), antipyretic(s), anxiolytic(s), antipsychotic(s), analgesic(s), antispasmodic(s), anti-inflammatory(ries), anti-histamine(s), anti-infective(s), radiation sensitizer(s), chemotherapeutic(s), radioactive compound(s), imaging agent(s), genetic modifying agent(s), and combinations thereof.

In some embodiments, the cargo is capable of treating or preventing a muscle disease or disorder. In some embodiments, the muscle disease or disorder is (a) an auto immune disease; (b) a cancer; (c) a muscular dystrophy; (d) a neuro-muscular disease; (e) a sugar or glycogen storage disease; (f) an expanded repeat disease; (g) a dominant negative disease; (h) a cardiomyopathy; (i) a viral disease; (j) a progeroid disease; or (k) any combination thereof. In some embodiments, the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD. In some embodiments, the myotonic dystrophy is Type 1 or Type 2. In some embodiments, the sugar or glycogen storage disease is a MPS type III disease or Pompe disease. In some embodiments, the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID. In some embodiments, the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.

In some embodiments, the cargo is a morpholino, a peptide-linked morpholino, an antisense oligonucleotide, a PMO, a therapeutic transgene, a polynucleotide encoding a therapeutic polypeptide or peptide, a PPMO, one or more peptides, one or more polynucleotides encoding a CRISPR-Cas protein, a guide RNA, or both, a ribonucleoprotein, wherein the ribonucleoprotein comprises a CRISPR-Cas system molecule, a therapeutic transgene RNA, or other gene modifying or therapeutic RNA and/or protein, or any combination thereof.

In some embodiments, the cargo is capable of inducing exon skipping in a gene.

In some embodiments, the cargo is capable of inducing exon skipping in a dystrophin gene.

In some embodiments, the cargo is a mini- or micro-dystrophin gene. In some embodiments, the mini- or micro-dystrophin gene comprises spectrin-like repeats 1, 2, 3, 16, 17, and 24, and optionally an nNOS domain.

Engineered Muscle Targeting AAV Capsids and AAVs

In some embodiments, the engineered muscle-specific targeting moiety is incorporated an adeno-associated virus (AAV) capsid. Described herein are various embodiments of engineered AAV capsids that can be engineered to confer cell-specific tropism to an engineered AAV particle. The engineered capsids can be included in an engineered virus particle and can confer cell-specific tropism, reduced immunogenicity, or both to the engineered AAV particle. The engineered AAV capsids described herein can include one or more engineered AAV capsid proteins described herein. In some embodiments, the AAV capsid protein comprises one or more n-mer motifs. In some embodiments, one or more of the n-mer motifs contains or is an RGD motif or a non-RGD n-mer motif. Such motifs are defined and described in greater detail elsewhere herein. In some embodiments, one or more of the one or more n-mer motifs incorporated into one or more AAV capsid proteins can confer muscle specificity to an AAV virus particle having the engineered capsid with the n-mer motif(s).

The engineered AAV capsid and/or capsid proteins can be encoded by one or more engineered AAV capsid polynucleotides. In some embodiments, an engineered AAV capsid polynucleotide can include a 3′ polyadenylation signal. The polyadenylation signal can be an SV40 polyadenylation signal.

The engineered AAV capsids can be variants of wild-type AAV capsids. In some embodiments, the wild-type AAV capsids can be composed of VP1, VP2, VP3 capsid proteins or a combination thereof. In other words, the engineered AAV capsids can include one or more variants of a wild-type VP1, wild-type VP2, and/or wild-type VP3 capsid proteins. In some embodiments, the serotype of the reference wild-type AAV capsid can be AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10, or any combination thereof. In some embodiments, the serotype of the wild-type AAV capsid can be AAV-9. The engineered AAV capsids can have a different tropism than that of the reference wild-type AAV capsid.

The engineered AAV capsid can contain 1-60 engineered capsid proteins. In some embodiments, the engineered AAV capsids can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, to/or 60 engineered capsid proteins. In some embodiments, the engineered AAV capsid can contain 0-59 wild-type AAV capsid proteins. In some embodiments, the engineered AAV capsid can contain 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, to/or 59 wild-type AAV capsid proteins.

In some embodiments, the engineered AAV capsid protein has an n-mer amino acid motif, where n can be at least 3 amino acids. In some embodiments, n can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids. In some embodiments, the engineered AAV capsid can have a 6-mer or 7-mer amino acid motif. In some embodiments, the n-mer amino acid motif is inserted between two amino acids in the wild-type viral protein (VP) (or capsid protein). In some embodiments, the n-mer motif can be inserted between two amino acids in a variable amino acid region in an AAV capsid protein. The core of each wild-type AAV viral protein contains an eight-stranded beta-barrel motif (betaB to betaI) and an alpha-helix (alphaA) that are conserved in autonomous parovirus capsids (see e.g. DiMattia et al. 2012. J. Virol. 86(12):6947-6958). Structural variable regions (VRs) occur in the surface loops that connect the beta-strands, which cluster to produce local variations in the capsid surface. AAVs have 12 variable regions (also referred to as hypervariable regions) (see e.g. Weitzman and Linden. 2011. “Adeno-Associated Virus Biology.” In Snyder, R. O., Moullier, P. (eds.) Totowa, N.J.: Humana Press). In some embodiments, one or more n-mer motifs are inserted between two amino acids in one or more of the 12 variable regions in the wild-type AVV capsid proteins. In some embodiments, the one or more n-mer motifs are each inserted between two amino acids in VR-I, VR-II, VR-III, VR-IV, VR-V, VR-VI, VR-VII, VR-III, VR-IX, VR-X, VR-XI, VR-XII, or a combination thereof. In some embodiments, the n-mer is be inserted between two amino acids in the VR-III of a capsid protein. In some embodiments, the engineered capsid can have an n-mer inserted between any two contiguous amino acids between amino acids 262 and 269, between any two contiguous amino acids between amino acids 327 and 332, between any two contiguous amino acids between amino acids 382 and 386, between any two contiguous amino acids between amino acids 452 and 460, between any two contiguous amino acids between amino acids 488 and 505, between any two contiguous amino acids between amino acids 545 and 558, between any two contiguous amino acids between amino acids 581 and 593, between any two contiguous amino acids between amino acids 704 and 714 of an AAV9 viral protein. In some embodiments, the engineered capsid can have an n-mer inserted between amino acids 588 and 589 of an AAV9 viral protein. In some embodiments, the engineered capsid can have a 7-mer motif inserted between amino acids 588 and 589 of an AAV9 viral protein. SEQ ID NO: 1 is a reference AAV9 capsid sequence for at least referencing the insertion sites discussed above. It will be appreciated that n-mers can be inserted in analogous positions in AAV viral proteins of other serotypes. In some embodiments as previously discussed, the n-mer(s) can be inserted between any two contiguous amino acids within the AAV viral protein and in some embodiments the insertion is made in a variable region.

SEQ ID NO: 1 AAV9 capsid reference sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGY KYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEF QERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSP QEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGS LTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALP TYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQR LINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDY QLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYF PSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKT INGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSE FAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGR DNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQG ILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIK NTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQ YTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL

In some embodiments, the n-mer motif can be any amino acid motif as shown or encoded by a nucleic acid as shown in Tables 1-3. In some embodiments, insertion of the n-mer motif in an AAV capsid can result in cell, tissue, organ, specific engineered AAV capsids. In some embodiments, the engineered capsid has a specificity (or tropism) for muscle cells. In some embodiments, the engineered capsid can have a specificity for bone tissue and/or cells, lung tissue and/or cells, liver tissues and/or cells, bladder tissue and/or cells, kidney tissue and/or cells, cardiac tissue and/or cells, skeletal muscle tissue and/or cells, smooth muscle and/or cells, neuronal tissue and/or cells, intestinal tissue and/or cells, pancreases tissue and/or cells, adrenal gland tissue and/or cells, brain tissue and/or cells, tendon tissues or cells, skin tissues and/or cells, spleen tissue and/or cells, eye tissue and/or cells, blood cells, synovial fluid cells, immune cells (including specificity for particular types of immune cells), and combinations thereof.

In some embodiments, the AAV capsids are muscle-specific. In some embodiments, muscle-specificity of the engineered AAV capsid is conferred by a muscle specific n-mer motif incorporated in the engineered AAV capsid. While not intending to be bound by theory, it is believed that the n-mer motif confers a 3D structure to or within a domain or region of the engineered AAV capsid such that the interaction of an engineered AAV containing said engineered AAV capsid has increased or improved interactions (e.g. increased affinity) with a cell surface receptor and/or other molecule on the surface of a muscle cell. In some embodiments, the cell surface receptor is AAV receptor (AAVR). In some embodiments, the cell surface receptor is a muscle cell specific AAV receptor. In some embodiments, a muscle specific engineered AAV containing the muscle-specific capsid can have an increased transduction rate, efficiency, amount, or a combination thereof in a muscle cell as compared to other cells types and/or other AAVs that do not contain a muscle-specific engineered AAV capsid as described herein.

Methods of Generating Muscle Specific Targeting Moieties

Also provided herein are methods of generating engineered AAV capsids. The engineered AAV capsid variants can be variants of wild-type AAV capsids. FIGS. 6-8 can illustrate various embodiments of methods capable of generating engineered AAV capsids described herein. Generally, an AAV capsid library can be generated by expressing engineered capsid vectors each containing an engineered AAV capsid polynucleotide previously described in an appropriate AAV producer cell line. See e.g. FIG. 8. It will be appreciated that although FIG. 8 shows a helper-dependent method of AAV particle production, it will be appreciated that this can be done via a helper-free method as well. This can generate an AAV capsid library that can contain one more desired cell-specific engineered AAV capsid variant. As shown in FIG. 6 the AAV capsid library can be administered to various non-human animals for a first round of mRNA-based selection. As shown in FIG. 1, the transduction process by AAVs and related vectors can result in the production of an mRNA molecule that is reflective of the genome of the virus that transduced the cell. As is at least demonstrated in the Examples herein, mRNA based-selection can be more specific and effective to determine a virus particle capable of functionally transducing a cell because it is based on the functional product produced as opposed to just detecting the presence of a virus particle in the cell by measuring the presence of viral DNA.

After first-round administration, one or more engineered AAV virus particles having a desired capsid variant can then be used to form a filtered AAV capsid library. Desirable AAV virus particles can be identified by measuring the mRNA expression of the capsid variants and determining which variants are highly expressed in the desired cell type(s) as compared to non-desired cells type(s). Those that are highly expressed in the desired cell, tissue, and/or organ type are the desired AAV capsid variant particles. In some embodiments, the AAV capsid variant encoding polynucleotide is under control of a tissue-specific promoter that has selective activity in the desired cell, tissue, or organ.

The engineered AAV capsid variant particles identified from the first round can then be administered to various non-human animals. In some embodiments, the animals used in the second round of selection and identification are not the same as those animals used for first round selection and identification. Similar to round 1, after administration the top expressing variants in the desired cell, tissue, and/or organ type(s) can be identified by measuring viral mRNA expression in the cells. The top variants identified after round two can then be optionally barcoded and optionally pooled. In some embodiments, top variants from the second round can then be administered to a non-human primate to identify the top cell-specific variant(s), particularly if the end use for the top variant is in humans. Administration at each round can be systemic.

In some embodiments, the method of generating an AAV capsid variant can include the steps of: (a) expressing a vector system described herein that contains an engineered AAV capsid polynucleotide in a cell to produce engineered AAV virus particle capsid variants; (b) harvesting the engineered AAV virus particle capsid variants produced in step (a); (c) administering engineered AAV virus particle capsid variants to one or more first subjects, wherein the engineered AAV virus particle capsid variants are produced by expressing an engineered AAV capsid variant vector or system thereof in a cell and harvesting the engineered AAV virus particle capsid variants produced by the cell; and (d) identifying one or more engineered AAV capsid variants produced at a significantly high level by one or more specific cells or specific cell types in the one or more first subjects. In this context, “significantly high” can refer to a titer that can range from between about 2×10¹¹ to about 6×10¹² vector genomes per 15 cm dish.

The method can further include the steps of: (e) administering some or all engineered AAV virus particle capsid variants identified in step (d) to one or more second subjects; and (f) identifying one or more engineered AAV virus particle capsid variants produced at a significantly high level in one or more specific cells or specific cell types in the one or more second subjects. The cell in step (a) can be a prokaryotic cell or a eukaryotic cell. In some embodiments, the administration in step (c), step (e), or both is systemic. In some embodiments, one or more first subjects, one or more second subjects, or both, are non-human mammals. In some embodiments, one or more first subjects, one or more second subjects, or both, are each independently selected from the group consisting of: a wild-type non-human mammal, a humanized non-human mammal, a disease-specific non-human mammal model, and a non-human primate.

Other methods and details of developing muscle-specific targeting moieties are described in, for example, U.S. Provisional Application Ser. Nos. 62/899,453, 62/916,207, 63/018,454, 63/055,252, and 62/916,221 and International Application No. PCT/US20/50534.

Engineered Muscle-Specific Targeting Moiety Encoding Polynucleotides, Vectors, and Vector Systems

Described herein are polynucleotides that encode the one or more muscle-specific engineered targeting moieties and vectors and/or vector systems thereof. In some embodiments, the encoding polynucleotides, vectors, and/or vector systems can be used to express and/or produce the engineered muscle-specific targeting moieties, couple the engineered muscle-specific targeting moiety to one or more other polypeptides, and/or produce particles, such as viral particles that optionally contain a cargo, that include one or more engineered muscle-specific targeting moieties described herein. The term “engineered muscle-specific targeting moiety polynucleotide” as used herein refers to a polynucleotide that encodes an engineered muscle-specific targeting moiety. As used herein, the term “encode” refers to principle that DNA can be transcribed into RNA, which can then be translated into amino acid sequences that can form proteins. Thus, polynucleotides said to encode a subsequent polynucleotide (such as an RNA species) or proteins can also be referred to as encoding polynucleotides and refer to DNA molecules that are subsequently transcribed and/or translated as well as RNA molecules that are translated.

Also provided herein are vectors and vector systems that can contain one or more of the engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) described herein. As used in this context, engineered AAV capsid polynucleotides refers to any one or more of the polynucleotides described herein capable of encoding an engineered AAV capsid as described elsewhere herein and/or polynucleotide(s) capable of encoding one or more engineered AAV capsid proteins described elsewhere herein. Further, where the vector includes an engineered muscle-specific targeting moiety polynucleotide (including, but not limited to, an engineered AAV capsid polynucleotide) described herein, the vector can also be referred to and considered an engineered vector or system thereof although not specifically noted as such. In embodiments, the vector can contain one or more polynucleotides encoding one or more elements of an engineered viral capsid, such as an AAV capsid, described herein. The vectors and systems thereof can be useful in producing bacterial, fungal, yeast, plant cells, animal cells, and transgenic animals that can express a muscle-specific targeting moiety or composition containing a muscle-specific targeting moiety described herein. In some embodiments, the vectors and systems thereof can be useful in producing bacterial cells, fungal cells, yeast cells, plant cells, animal cells, or transgenic organisms (e.g. plants, animals) that can express the one or more components of the engineered AAV capsid described herein. Within the scope of this disclosure are vectors containing one or more of the polynucleotide sequences described herein. One or more of the polynucleotides that are part of the engineered AAV capsid and system thereof described herein can be included in a vector or vector system.

The vectors and/or vector systems can be used, for example, to express one or more of the engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) in a cell, such as a producer cell, to produce engineered viral particles containing an engineered viral capsid (e.g. an AAV containing an engineered AAV capsid) described elsewhere herein. Other uses for the vectors and vector systems described herein are also within the scope of this disclosure. In general, and throughout this specification, the term is a tool that allows or facilitates the transfer of an entity from one environment to another. In some contexts which will be appreciated by those of ordinary skill in the art, “vector” can be a term of art to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. A vector can be a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. Generally, a vector is capable of replication when associated with the proper control elements.

Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

Recombinant expression vectors can be composed of a nucleic acid (e.g. a polynucleotide) of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which can be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” and “operatively-linked” are used interchangeably herein and further defined elsewhere herein. In the context of a vector, the term “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). Advantageous vectors include adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells, such as those engineered AAV vectors containing an engineered AAV capsid polynucleotide with a desired cell-specific tropism, such as a muscle-specific tropism. These and other embodiments of the vectors and vector systems are described elsewhere herein.

In some embodiments, the vector can be a bicistronic vector. In some embodiments, a bicistronic vector can be used for expressing one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) system described herein. In some embodiments, expression of an engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) described herein can be driven by the a suitable constitutive or tissue specific promoter. Such embodiments can be advantageous for generating muscle-specific targeting moieties, which are described in greater detail elsewhere herein. Where the element of the engineered AAV capsid system is an RNA, its expression can be driven by a Pol III promoter, such as a U6 promoter. In some embodiments, the two are combined.

Cell-Based Vector Amplification and Expression

Vectors can be designed for expression of one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) or a system including one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) or product thereof described herein (e.g. nucleic acid transcripts, proteins, enzymes, and combinations thereof) in a suitable host cell. In some embodiments, the suitable host cell is a prokaryotic cell. Suitable host cells include, but are not limited to, bacterial cells, yeast cells, insect cells, and mammalian cells. The vectors can be viral-based or non-viral based. In some embodiments, the suitable host cell is a eukaryotic cell. In some embodiments, the suitable host cell is a suitable bacterial cell. Suitable bacterial cells include, but are not limited to, bacterial cells from the bacteria of the species Escherichia coli. Many suitable strains of E. coli are known in the art for expression of vectors. These include, but are not limited to Pir1, Stbl2, Stbl3, Stbl4, TOP10, XL1 Blue, and XL10 Gold. In some embodiments, the host cell is a suitable insect cell. Suitable insect cells include those from Spodoptera frugiperda. Suitable strains of S. frugiperda cells include, but are not limited to, Sf9 and Sf21. In some embodiments, the host cell is a suitable yeast cell. In some embodiments, the yeast cell can be from Saccharomyces cerevisiae. In some embodiments, the host cell is a suitable mammalian cell. Many types of mammalian cells have been developed to express vectors. Suitable mammalian cells include, but are not limited to, HEK293, Chinese Hamster Ovary Cells (CHOs), mouse myeloma cells, HeLa, U205, A549, HT1080, CAD, P19, NIH 3T3, L929, N2a, MCF-7, Y79, SO-Rb50, HepG G2, DIKX-X11, J558L, Baby hamster kidney cells (BHK), and chicken embryo fibroblasts (CEFs). Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).

In some embodiments, the vector can be a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerevisiae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kuijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). As used herein, a “yeast expression vector” refers to a nucleic acid that contains one or more sequences encoding an RNA and/or polypeptide and may further contain any desired elements that control the expression of the nucleic acid(s), as well as any elements that enable the replication and maintenance of the expression vector inside the yeast cell. Many suitable yeast expression vectors and features thereof are known in the art; for example, various vectors and techniques are illustrated in in Yeast Protocols, 2nd edition, Xiao, W., ed. (Humana Press, New York, 2007) and Buckholz, R. G. and Gleeson, M. A. (1991) Biotechnology (NY) 9(11): 1067-72. Yeast vectors can contain, without limitation, a centromeric (CEN) sequence, an autonomous replication sequence (ARS), a promoter, such as an RNA Polymerase III promoter, operably linked to a sequence or gene of interest, a terminator such as an RNA polymerase III terminator, an origin of replication, and a marker gene (e.g., auxotrophic, antibiotic, or other selectable markers). Examples of expression vectors for use in yeast may include plasmids, yeast artificial chromosomes, 2p, plasmids, yeast integrative plasmids, yeast replicative plasmids, shuttle vectors, and episomal plasmids.

In some embodiments, the vector is a baculovirus vector or expression vector and can be suitable for expression of polynucleotides and/or proteins in insect cells. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39). rAAV (recombinant Adeno-associated viral) vectors are preferably produced in insect cells, e.g., Spodoptera frugiperda Sf9 insect cells, grown in serum-free suspension culture. Serum-free insect cells can be purchased from commercial vendors, e.g., Sigma Aldrich (EX-CELL 405).

In some embodiments, the vector is a mammalian expression vector. In some embodiments, the mammalian expression vector is capable of expressing one or more polynucleotides and/or polypeptides in a mammalian cell. Examples of mammalian expression vectors include, but are not limited to, pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). The mammalian expression vector can include one or more suitable regulatory elements capable of controlling expression of the one or more polynucleotides and/or proteins in the mammalian cell. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. More detail on suitable regulatory elements are described elsewhere herein.

For other suitable expression vectors and vector systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In some embodiments, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546). With regards to these prokaryotic and eukaryotic vectors, mention is made of U.S. Pat. No. 6,750,059, the contents of which are incorporated by reference herein in their entirety. Other embodiments can utilize viral vectors, with regards to which mention is made of U.S. patent application Ser. No. 13/092,085, the contents of which are incorporated by reference herein in their entirety. Tissue-specific regulatory elements are known in the art and in this regard, mention is made of U.S. Pat. No. 7,776,321, the contents of which are incorporated by reference herein in their entirety. In some embodiments, a regulatory element can be operably linked to or coupled to one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) and/or one or more elements of a system comprising one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) or product thereof so as to drive expression of the one or more elements of the engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides) or system thereof described herein.

Vectors may be introduced and propagated in a prokaryote or prokaryotic cell. In some embodiments, a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). In some embodiments, a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism.

In some embodiments, the vector can be a fusion vector or fusion expression vector. In some embodiments, fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus, carboxy terminus, or both of a recombinant protein. Such fusion vectors can serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. In some embodiments, expression of polynucleotides (such as non-coding polynucleotides) and proteins in prokaryotes can be carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polynucleotides and/or proteins. In some embodiments, the fusion expression vector can include a proteolytic cleavage site, which can be introduced at the junction of the fusion vector backbone or other fusion moiety and the recombinant polynucleotide or protein to enable separation of the recombinant polynucleotide or protein from the fusion vector backbone or other fusion moiety subsequent to purification of the fusion polynucleotide or protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

In some embodiments, one or more vectors driving expression of one or more engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides), vector, and/or vector system thereof described herein are introduced into a host cell such that expression of one or more the engineered muscle-specific targeting moiety polynucleotides (including, but not limited to, engineered AAV capsid polynucleotides), vectors, and/or vector systems described herein direct formation of an engineered muscle-specific targeting moiety and/or compositions or engineered muscle-specific delivery systems that include one or more engineered muscle-specific targeting moieties described herein. In some embodiments, the engineered muscle-specific delivery system is a viral particle such as an engineered AAV particle that contains an engineered capsid that contains one or more engineered muscle-specific targeting moieties described elsewhere herein. For example, different elements of an engineered muscle-specific delivery system can each be operably linked to separate regulatory elements on the same or separate vectors. RNA(s) of different elements of the engineered muscle-specific delivery system described herein that can include one or more engineered muscle-specific targeting moiety can be delivered to an animal or mammal or cell thereof to produce an animal or mammal or cell thereof that constitutively, inducibly, or conditionally expresses different elements of the engineered muscle-specific delivery system described herein or contains one or more cells that incorporates and/or expresses one or more elements of the engineered muscle-specific delivery system described herein.

In some embodiments, two or more of the elements expressed from the same or different regulatory element(s) can be combined in a single vector along with one or more additional vectors providing any components of the system not included in the first vector. Engineered muscle-specific delivery system polynucleotides (including but not limited to engineered muscle-specific targeting moiety polynucleotides) that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5′ with respect to (“upstream” of) or 3′ with respect to (“downstream” of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding one or more engineered muscle-specific targeting moiety polynucleotides, embedded within one or more intron sequences (e.g., each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, two or more engineered muscle-specific targeting moiety polynucleotides can be operably linked to and expressed from the same promoter.

Vector Features

The vectors can include additional features that can confer one or more functionalities to the vector, the polynucleotide to be delivered, a virus particle produced there from, or polypeptide expressed thereof. Such features include, but are not limited to, regulatory elements, selectable markers, molecular identifiers (e.g. molecular barcodes), stabilizing elements, and the like. It will be appreciated by those skilled in the art that the design of the expression vector and additional features included can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc.

Regulatory Elements

In embodiments, the polynucleotides and/or vectors thereof described herein (such as the engineered muscle-specific targeting moiety polynucleotides of the present invention) can include one or more regulatory elements that can be operatively linked to the polynucleotide. The term “regulatory element” is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter can direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g., liver, pancreas), or particular cell types (e.g., lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) (see, e.g., Boshart et al, Cell, 41:521-530 (1985)), the SV40 promoter, the dihydrofolate reductase promoter, the (3-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981).

In some embodiments, the regulatory sequence can be a regulatory sequence described in U.S. Pat. No. 7,776,321, U.S. Pat. Pub. No. 2011/0027239, and PCT publication WO 2011/028929, the contents of which are incorporated by reference herein in their entirety. In some embodiments, the vector can contain a minimal promoter. In some embodiments, the minimal promoter is the Mecp2 promoter, tRNA promoter, or U6. In a further embodiment, the minimal promoter is tissue specific. In some embodiments, the length of the vector polynucleotide the minimal promoters and polynucleotide sequences is less than 4.4 Kb.

To express a polynucleotide, the vector can include one or more transcriptional and/or translational initiation regulatory sequences, e.g. promoters, that direct the transcription of the gene and/or translation of the encoded protein in a cell. In some embodiments a constitutive promoter may be employed. Suitable constitutive promoters for mammalian cells are generally known in the art and include, but are not limited to SV40, CAG, CMV, EF-1α, β-actin, RSV, and PGK. Suitable constitutive promoters for bacterial cells, yeast cells, and fungal cells are generally known in the art, such as a T-7 promoter for bacterial expression and an alcohol dehydrogenase promoter for expression in yeast.

In some embodiments, the regulatory element can be a regulated promoter. “Regulated promoter” refers to promoters that direct gene expression not constitutively, but in a temporally- and/or spatially-regulated manner, and includes tissue-specific, tissue-preferred and inducible promoters. In some embodiments, the regulated promoter is a tissue specific promoter as previously discussed elsewhere herein. Regulated promoters include conditional promoters and inducible promoters. In some embodiments, conditional promoters can be employed to direct expression of a polynucleotide in a specific cell type, under certain environmental conditions, and/or during a specific state of development. Suitable tissue specific promoters can include, but are not limited to, liver specific promoters (e.g. APOA2, SERPIN A1 (hAAT), CYP3A4, and MIR122), pancreatic cell promoters (e.g. INS, IRS2, Pdx1, Alx3, Ppy), cardiac specific promoters (e.g. Myh6 (alpha MHC), MYL2 (MLC-2v), TNI3 (cTnl), NPPA (ANF), Slc8a1 (Ncx1)), central nervous system cell promoters (SYN1, GFAP, INA, NES, MOBP, MBP, TH, FOXA2 (HNF3 beta)), skin cell specific promoters (e.g. FLG, K14, TGM3), immune cell specific promoters, (e.g. ITGAM, CD43 promoter, CD14 promoter, CD45 promoter, CD68 promoter), urogenital cell specific promoters (e.g. Pbsn, Upk2, Sbp, Ferl14), endothelial cell specific promoters (e.g. ENG), pluripotent and embryonic germ layer cell specific promoters (e.g. Oct4, NANOG, Synthetic Oct4, T brachyury, NES, SOX17, FOXA2, MIR122), and muscle cell specific promoter (e.g. Desmin). Other tissue and/or cell specific promoters are discussed elsewhere herein and can be generally known in the art and are within the scope of this disclosure.

Inducible/conditional promoters can be positively inducible/conditional promoters (e.g. a promoter that activates transcription of the polynucleotide upon appropriate interaction with an activated activator, or an inducer (compound, environmental condition, or other stimulus) or a negative/conditional inducible promoter (e.g. a promoter that is repressed (e.g. bound by a repressor) until the repressor condition of the promotor is removed (e.g. inducer binds a repressor bound to the promoter stimulating release of the promoter by the repressor or removal of a chemical repressor from the promoter environment). The inducer can be a compound, environmental condition, or other stimulus. Thus, inducible/conditional promoters can be responsive to any suitable stimuli such as chemical, biological, or other molecular agents, temperature, light, and/or pH. Suitable inducible/conditional promoters include, but are not limited to, Tet-On, Tet-Off, Lac promoter, pBad, AlcA, LexA, Hsp70 promoter, Hsp90 promoter, pDawn, XVE/OlexA, GVG, and pOp/LhGR.

Where expression in a plant cell is desired, the components of the engineered AAV capsid system described herein are typically placed under control of a plant promoter, i.e. a promoter operable in plant cells. The use of different types of promoters is envisaged. In some embodiments, inclusion of a engineered AAV capsid system vector in a plant can be for AAV vector production purposes.

A constitutive plant promoter is a promoter that is able to express the open reading frame (ORF) that it controls in all or nearly all of the plant tissues during all or nearly all developmental stages of the plant (referred to as “constitutive expression”). One non-limiting example of a constitutive promoter is the cauliflower mosaic virus 35S promoter. Different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. In particular embodiments, one or more of the engineered AAV capsid system components are expressed under the control of a constitutive promoter, such as the cauliflower mosaic virus 35S promoter issue-preferred promoters can be utilized to target enhanced expression in certain cell types within a particular plant tissue, for instance vascular cells in leaves or roots or in specific cells of the seed. Examples of particular promoters for use in the engineered AAV capsid system are found in Kawamata et al., (1997) Plant Cell Physiol 38:792-803; Yamamoto et al., (1997) Plant J 12:255-65; Hire et al, (1992) Plant Mol Biol 20:207-18, Kuster et al, (1995) Plant Mol Biol 29:759-72, and Capana et al., (1994) Plant Mol Biol 25:681-91.

Examples of promoters that are inducible and that can allow for spatiotemporal control of gene editing or gene expression may use a form of energy. The form of energy may include but is not limited to sound energy, electromagnetic radiation, chemical energy and/or thermal energy. Examples of inducible systems include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc.), or light inducible systems (Phytochrome, LOV domains, or cryptochrome)., such as a Light Inducible Transcriptional Effector (LITE) that direct changes in transcriptional activity in a sequence-specific manner. The components of a light inducible system may include one or more elements of the engineered muscle-specific delivery system described herein, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain. In some embodiments, the vector can include one or more of the inducible DNA binding proteins provided in PCT publication WO 2014/018423 and US Publications, 2015/0291966, 2017/0166903, 2019/0203212, which describe e.g. embodiments of inducible DNA binding proteins and methods of use and can be adapted for use with the present invention.

In some embodiments, transient or inducible expression can be achieved by including, for example, chemical-regulated promotors, i.e. whereby the application of an exogenous chemical induces gene expression. Modulation of gene expression can also be obtained by including a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters include, but are not limited to, the maize ln2-2 promoter, activated by benzene sulfonamide herbicide safeners (De Veylder et al., (1997) Plant Cell Physiol 38:568-77), the maize GST promoter (GST-11-27, WO93/01294), activated by hydrophobic electrophilic compounds used as pre-emergent herbicides, and the tobacco PR-1 a promoter (Ono et al., (2004) Biosci Biotechnol Biochem 68:803-7) activated by salicylic acid. Promoters which are regulated by antibiotics, such as tetracycline-inducible and tetracycline-repressible promoters (Gatz et al., (1991) Mol Gen Genet 227:229-37; U.S. Pat. Nos. 5,814,618 and 5,789,156) can also be used herein.

In some embodiments, the vector or system thereof can include one or more elements capable of translocating and/or expressing an engineered muscle-specific targeting moiety polynucleotide to/in a specific cell component or organelle. Such organelles can include, but are not limited to, nucleus, ribosome, endoplasmic reticulum, golgi apparatus, chloroplast, mitochondria, vacuole, lysosome, cytoskeleton, plasma membrane, cell wall, peroxisome, centrioles, etc.

Selectable Markers and Tags

One or more of the engineered muscle-specific targeting moiety polynucleotides can be operably linked, fused to, or otherwise modified to include a polynucleotide that encodes or is a selectable marker or tag, which can be a polynucleotide or polypeptide. In some embodiments, the polynucleotide encoding a polypeptide selectable marker is incorporated in the engineered muscle-specific delivery system polynucleotide such that the selectable marker polynucleotide, when translated, is inserted between two amino acids between the N- and C-terminus of the engineered muscle-specific targeting moiety polypeptide (including but not limited to an engineered AAV capsid polypeptide) or at the N- and/or C-terminus of the engineered muscle-specific targeting moiety polypeptide (including but not limited to an engineered AAV capsid polypeptide). In some embodiments, the selectable marker or tag is a polynucleotide barcode or unique molecular identifier (UMI).

The term “barcode” as used herein refers to a short sequence of nucleotides (for example, DNA or RNA) that is used as an identifier for an associated molecule, such as a target molecule and/or target nucleic acid, or as an identifier of the source of an associated molecule, such as a cell-of-origin. A barcode may also refer to any unique, non-naturally occurring, nucleic acid sequence that may be used to identify the originating source of a nucleic acid fragment. Although it is not necessary to understand the mechanism of an invention, it is believed that the barcode sequence provides a high-quality individual read of a barcode associated with a single cell, a viral vector, labeling ligand (e.g., an aptamer), protein, shRNA, sgRNA or cDNA such that multiple species can be sequenced together.

Barcoding may be performed based on any of the compositions or methods disclosed in patent publication WO 2014047561 A1, Compositions and methods for labeling of agents, incorporated herein in its entirety. In certain embodiments barcoding uses an error correcting scheme (T. K. Moon, Error Correction Coding: Mathematical Methods and Algorithms (Wiley, New York, ed. 1, 2005)). Not being bound by a theory, amplified sequences from single cells can be sequenced together and resolved based on the barcode associated with each cell.

In preferred embodiments, sequencing is performed using unique molecular identifiers (UMI). The term “unique molecular identifiers” (UMI) as used herein refers to a sequencing linker or a subtype of nucleic acid barcode used in a method that uses molecular tags to detect and quantify unique amplified products. A UMI is used to distinguish effects through a single clone from multiple clones. The term “clone” as used herein may refer to a single mRNA or target nucleic acid to be sequenced. The UMI may also be used to determine the number of transcripts that gave rise to an amplified product, or in the case of target barcodes as described herein, the number of binding events. In preferred embodiments, the amplification is by PCR or multiple displacement amplification (MDA).

It will be appreciated that the polynucleotide encoding such selectable markers or tags can be incorporated into a polynucleotide encoding one or more components of the engineered muscle-specific delivery system described herein in an appropriate manner to allow expression of the selectable marker or tag. Such techniques and methods are described elsewhere herein and will be instantly appreciated by one of ordinary skill in the art in view of this disclosure. Many such selectable markers and tags are generally known in the art and are intended to be within the scope of this disclosure.

Suitable selectable markers and tags include, but are not limited to, affinity tags, such as chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), poly(His) tag; solubilization tags such as thioredoxin (TRX) and poly(NANP), MBP, and GST; chromatography tags such as those consisting of polyanionic amino acids, such as FLAG-tag; epitope tags such as V5-tag, Myc-tag, HA-tag and NE-tag; protein tags that can allow specific enzymatic modification (such as biotinylation by biotin ligase) or chemical modification (such as reaction with FlAsH-EDT2 for fluorescence imaging), DNA and/or RNA segments that contain restriction enzyme or other enzyme cleavage sites; DNA segments that encode products that provide resistance against otherwise toxic compounds including antibiotics, such as, spectinomycin, ampicillin, kanamycin, tetracycline, Basta, neomycin phosphotransferase II (NEO), hygromycin phosphotransferase (HPT)) and the like; DNA and/or RNA segments that encode products that are otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); DNA and/or RNA segments that encode products which can be readily identified (e.g., phenotypic markers such as β-galactosidase, GUS; fluorescent proteins such as green fluorescent protein (GFP), cyan (CFP), yellow (YFP), red (RFP), luciferase, and cell surface proteins); polynucleotides that can generate one or more new primer sites for PCR (e.g., the juxtaposition of two DNA sequences not previously juxtaposed), DNA sequences not acted upon or acted upon by a restriction endonuclease or other DNA modifying enzyme, chemical, etc.; epitope tags (e.g. GFP, FLAG- and His-tags), and, DNA sequences that make a molecular barcode or unique molecular identifier (UMI), DNA sequences required for a specific modification (e.g., methylation) that allows its identification. Other suitable markers will be appreciated by those of skill in the art.

Selectable markers and tags can be operably linked to one or more components of the engineered AAV capsid system described herein via suitable linker, such as a glycine or glycine serine linkers as short as GS or GG up to (GGGGG)₃ (SEQ ID NO: 51) or (GGGGS)₃ (SEQ ID NO: 56). Other suitable linkers are described elsewhere herein.

The vector or vector system can include one or more polynucleotides encoding one or more engineered muscle-specific targeting moiety(ies) described elsewhere herein. In some embodiments, the targeting moiety encoding polynucleotides can be included in the vector or vector system, such as a viral vector system, such that they are expressed within and/or on the virus particle(s) produced such that the virus particles can be targeted to specific cells, tissues, organs, etc. In some embodiments, one or more engineered muscle-specific targeting moiety encoding polynucleotides are included in the vector or vector system such that the engineered muscle-specific targeting moiety polynucleotide(s) and/or products expressed therefrom include the targeting moiety and can be targeted to specific cells, tissues, organs, etc., such as muscle cells, muscle tissue, or muscle containing organs (e.g. heart). In some embodiments, such as non-viral carriers, the targeting moiety can be attached to the carrier (e.g. polymer, lipid, inorganic molecule etc.) and can be capable of targeting the carrier and any attached or associated engineered muscle-specific targeting moiety polynucleotide(s) to specific cells, tissues, organs, etc., such as such as muscle cells, muscle tissue, or muscle containing organs (e.g. heart).

Cell-Free Vector and Polynucleotide Expression

In some embodiments, the polynucleotide encoding one or more features of the engineered muscle-specific delivery system containing one or more engineered muscle-specific targeting moieties described herein is expressed from a vector or suitable polynucleotide in a cell-free in vitro system. In other words, the polynucleotide can be transcribed and optionally translated in vitro. In vitro transcription/translation systems and appropriate vectors are generally known in the art and commercially available. Generally, in vitro transcription and in vitro translation systems replicate the processes of RNA and protein synthesis, respectively, outside of the cellular environment. Vectors and suitable polynucleotides for in vitro transcription can include T7, SP6, T3, promoter regulatory sequences that can be recognized and acted upon by an appropriate polymerase to transcribe the polynucleotide or vector.

In vitro translation can be stand-alone (e.g. translation of a purified polyribonucleotide) or linked/coupled to transcription. In some embodiments, the cell-free (or in vitro) translation system can include extracts from rabbit reticulocytes, wheat germ, and/or E. coli. The extracts can include various macromolecular components that are needed for translation of exogenous RNA (e.g. 70S or 80S ribosomes, tRNAs, aminoacyl-tRNA, synthetases, initiation, elongation factors, termination factors, etc.). Other components can be included or added during the translation reaction, including but not limited to, amino acids, energy sources (ATP, GTP), energy regenerating systems (creatine phosphate and creatine phosphokinase (eukaryotic systems)) (phosphoenol pyruvate and pyruvate kinase for bacterial systems), and other co-factors (Mg2+, K+, etc.). As previously mentioned, in vitro translation can be based on RNA or DNA starting material. Some translation systems can utilize an RNA template as starting material (e.g. reticulocyte lysates and wheat germ extracts). Some translation systems can utilize a DNA template as a starting material (e.g. E. coli-based systems). In these systems, transcription and translation are coupled and DNA is first transcribed into RNA, which is subsequently translated. Suitable standard and coupled cell-free translation systems are generally known in the art and are commercially available.

Codon Optimization of Vector Polynucleotides

As described elsewhere herein, the polynucleotide encoding one or more embodiments of the engineered muscle-specific delivery system described herein is codon optimized. In some embodiments, one or more polynucleotides contained in a vector (“vector polynucleotides”) described herein that are in addition to an optionally codon optimized polynucleotide encoding embodiments of the engineered muscle-specific delivery system described herein described herein can be codon optimized. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the “Codon Usage Database” available at www.kazusa.orjp/codon/ and these tables can be adapted in a number of ways. See Nakamura, Y., et al. “Codon usage tabulated from the international DNA sequence databases: status for the year 2000” Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, Pa.), are also available. In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a DNA/RNA-targeting Cas protein corresponds to the most frequently used codon for a particular amino acid. As to codon usage in yeast, reference is made to the online Yeast Genome database available at http://www.yeastgenome.org/community/codon_usage.shtml, or Codon selection in yeast, Bennetzen and Hall, J Biol Chem. 1982 Mar. 25; 257(6):3026-31. As to codon usage in plants including algae, reference is made to Codon usage in higher plants, green algae, and cyanobacteria, Campbell and Gowri, Plant Physiol. 1990 January; 92(1): 1-11; as well as Codon usage in plant genes, Murray et al, Nucleic Acids Res. 1989 Jan. 25; 17(2):477-98; or Selection on the codon bias of chloroplast and cyanelle genes in different plant and algal lineages, Morton B R, J Mol Evol. 1998 April; 46(4):449-59.

The vector polynucleotide can be codon optimized for expression in a specific cell-type, tissue type, organ type, and/or subject type. In some embodiments, a codon optimized sequence is a sequence optimized for expression in a eukaryote, e.g., humans (i.e. being optimized for expression in a human or human cell), or for another eukaryote, such as another animal (e.g. a mammal or avian) as is described elsewhere herein. Such codon optimized sequences are within the ambit of the ordinary skilled artisan in view of the description herein. In some embodiments, the polynucleotide is codon optimized for a specific cell type. Such cell types can include, but are not limited to, epithelial cells (including skin cells, cells lining the gastrointestinal tract, cells lining other hollow organs), nerve cells (nerves, brain cells, spinal column cells, nerve support cells (e.g. astrocytes, glial cells, Schwann cells etc.), muscle cells (e.g. cardiac muscle, smooth muscle cells, and skeletal muscle cells), connective tissue cells (fat and other soft tissue padding cells, bone cells, tendon cells, cartilage cells), blood cells, stem cells and other progenitor cells, immune system cells, germ cells, and combinations thereof. Such codon optimized sequences are within the ambit of the ordinary skilled artisan in view of the description herein. In some embodiments, the polynucleotide is codon optimized for a specific tissue type. Such tissue types can include, but are not limited to, muscle tissue, connective tissue, connective tissue, nervous tissue, and epithelial tissue. Such codon optimized sequences are within the ambit of the ordinary skilled artisan in view of the description herein. In some embodiments, the polynucleotide is codon optimized for a specific organ. Such organs include, but are not limited to, muscles, skin, intestines, liver, spleen, brain, lungs, stomach, heart, kidneys, gallbladder, pancreas, bladder, thyroid, bone, blood vessels, blood, and combinations thereof. Such codon optimized sequences are within the ambit of the ordinary skilled artisan in view of the description herein.

In some embodiments, a vector polynucleotide is codon optimized for expression in particular cells, such as prokaryotic or eukaryotic cells. he eukaryotic cells may be those of or derived from a particular organism, such as a plant or a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as discussed herein, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate.

Non-Viral Vectors

In some embodiments, the vector is a non-viral vector or carrier. In some embodiments, non-viral vectors can have the advantage(s) of reduced toxicity and/or immunogenicity and/or increased bio-safety as compared to viral vectors The terms of art “Non-viral vectors and carriers” and as used herein in this context refers to molecules and/or compositions that are not based on one or more component of a virus or virus genome (excluding any nucleotide to be delivered and/or expressed by the non-viral vector) that can be capable of attaching to, incorporating, coupling, and/or otherwise interacting with an engineered muscle-specific targeting moiety polynucleotide of the present invention and can be capable of ferrying the polynucleotide to a cell and/or expressing the polynucleotide. It will be appreciated that this does not exclude the inclusion of a virus-based polynucleotide that is to be delivered. For example, if a gRNA to be delivered is directed against a virus component and it is inserted or otherwise coupled to an otherwise non-viral vector or carrier, this would not make said vector a “viral vector”. Non-viral vectors and carriers include naked polynucleotides, chemical-based carriers, polynucleotide (non-viral) based vectors, and particle-based carriers. It will be appreciated that the term “vector” as used in the context of non-viral vectors and carriers refers to polynucleotide vectors and “carriers” used in this context refers to a non-nucleic acid or polynucleotide molecule or composition that be attached to or otherwise interact with a polynucleotide to be delivered, such as an engineered muscle-specific targeting moiety polynucleotide of the present invention.

Naked Polynucleotides

In some embodiments, one or more engineered muscle specific targeting moiety polynucleotides described elsewhere herein can be included in a naked polynucleotide. The term of art “naked polynucleotide” as used herein refers to polynucleotides that are not associated with another molecule (e.g. proteins, lipids, and/or other molecules) that can often help protect it from environmental factors and/or degradation. As used herein, associated with includes, but is not limited to, linked to, adhered to, adsorbed to, enclosed in, enclosed in or within, mixed with, and the like. Naked polynucleotides that include one or more of the engineered muscle specific targeting moiety polynucleotides described herein can be delivered directly to a host cell and optionally expressed therein. The naked polynucleotides can have any suitable two- and three-dimensional configurations. By way of non-limiting examples, naked polynucleotides can be single-stranded molecules, double stranded molecules, circular molecules (e.g. plasmids and artificial chromosomes), molecules that contain portions that are single stranded and portions that are double stranded (e.g. ribozymes), and the like. In some embodiments, the naked polynucleotide contains only the engineered muscle specific targeting moiety polynucleotide(s) of the present invention. In some embodiments, the naked polynucleotide can contain other nucleic acids and/or polynucleotides in addition to the engineered muscle specific targeting moiety polynucleotide(s) of the present invention. The naked polynucleotides can include one or more elements of a transposon system. Transposons and system thereof are described in greater detail elsewhere herein.

Non-Viral Polynucleotide Vectors

In some embodiments, one or more of the engineered muscle specific targeting moiety polynucleotides can be included in a non-viral polynucleotide vector. Suitable non-viral polynucleotide vectors include, but are not limited to, transposon vectors and vector systems, plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, AR (antibiotic resistance)-free plasmids and miniplasmids, circular covalently closed vectors (e.g. minicircles, minivectors, miniknots), linear covalently closed vectors (“dumbbell shaped”), MIDGE (minimalistic immunologically defined gene expression) vectors, MiLV (micro-linear vector) vectors, Ministrings, mini-intronic plasmids, PSK systems (post-segregationally killing systems), ORT (operator repressor titration) plasmids, and the like. See e.g. Hardee et al. 2017. Genes. 8(2):65.

In some embodiments, the non-viral polynucleotide vector can have a conditional origin of replication. In some embodiments, the non-viral polynucleotide vector can be an ORT plasmid. In some embodiments, the non-viral polynucleotide vector can have a minimalistic immunologically defined gene expression. In some embodiments, the non-viral polynucleotide vector can have one or more post-segregationally killing system genes. In some embodiments, the non-viral polynucleotide vector is AR-free. In some embodiments, the non-viral polynucleotide vector is a minivector. In some embodiments, the non-viral polynucleotide vector includes a nuclear localization signal. In some embodiments, the non-viral polynucleotide vector can include one or more CpG motifs. In some embodiments, the non-viral polynucleotide vectors can include one or more scaffold/matrix attachment regions (S/MARs). See e.g. Mirkovitch et al. 1984. Cell. 39:223-232, Wong et al. 2015. Adv. Genet. 89:113-152, whose techniques and vectors can be adapted for use in the present invention. S/MARs are AT-rich sequences that play a role in the spatial organization of chromosomes through DNA loop base attachment to the nuclear matrix. S/MARs are often found close to regulatory elements such as promoters, enhancers, and origins of DNA replication. Inclusion of one or S/MARs can facilitate a once-per-cell-cycle replication to maintain the non-viral polynucleotide vector as an episome in daughter cells. In embodiments, the S/MAR sequence is located downstream of an actively transcribed polynucleotide (e.g. one or more engineered muscle specific targeting moiety polynucleotides of the present invention) included in the non-viral polynucleotide vector. In some embodiments, the S/MAR can be a S/MAR from the beta-interferon gene cluster. See e.g. Verghese et al. 2014. Nucleic Acid Res. 42:e53; Xu et al. 2016. Sci. China Life Sci. 59:1024-1033; Jin et al. 2016. 8:702-711; Koirala et al. 2014. Adv. Exp. Med. Biol. 801:703-709; and Nehlsen et al. 2006. Gene Ther. Mol. Biol. 10:233-244, whose techniques and vectors can be adapted for use in the present invention.

In some embodiments, the non-viral vector is a transposon vector or system thereof. As used herein, “transposon” (also referred to as transposable element) refers to a polynucleotide sequence that is capable of moving form location in a genome to another. There are several classes of transposons. Transposons include retrotransposons and DNA transposons. Retrotransposons require the transcription of the polynucleotide that is moved (or transposed) in order to transpose the polynucleotide to a new genome or polynucleotide. DNA transposons are those that do not require reverse transcription of the polynucleotide that is moved (or transposed) in order to transpose the polynucleotide to a new genome or polynucleotide. In some embodiments, the non-viral polynucleotide vector can be a retrotransposon vector. In some embodiments, the retrotransposon vector includes long terminal repeats. In some embodiments, the retrotransposon vector does not include long terminal repeats. In some embodiments, the non-viral polynucleotide vector can be a DNA transposon vector. DNA transposon vectors can include a polynucleotide sequence encoding a transposase. In some embodiments, the transposon vector is configured as a non-autonomous transposon vector, meaning that the transposition does not occur spontaneously on its own. In some of these embodiments, the transposon vector lacks one or more polynucleotide sequences encoding proteins required for transposition. In some embodiments, the non-autonomous transposon vectors lack one or more Ac elements.

In some embodiments, a non-viral polynucleotide transposon vector system can include a first polynucleotide vector that contains the engineered muscle specific targeting moiety polynucleotide(s) of the present invention flanked on the 5′ and 3′ ends by transposon terminal inverted repeats (TIRs) and a second polynucleotide vector that includes a polynucleotide capable of encoding a transposase coupled to a promoter to drive expression of the transposase. When both are expressed in the same cell the transposase can be expressed from the second vector and can transpose the material between the TIRs on the first vector (e.g. the engineered muscle specific targeting moiety polynucleotide(s) of the present invention) and integrate it into one or more positions in the host cell's genome. In some embodiments, the transposon vector or system thereof can be configured as a gene trap. In some embodiments, the TIRs can be configured to flank a strong splice acceptor site followed by a reporter and/or other gene (e.g. one or more of the engineered muscle specific targeting moiety polynucleotide(s) of the present invention) and a strong poly A tail. When transposition occurs while using this vector or system thereof, the transposon can insert into an intron of a gene and the inserted reporter or other gene can provoke a mis-splicing process and as a result it in activates the trapped gene.

Any suitable transposon system can be used. Suitable transposon and systems thereof can include, Sleeping Beauty transposon system (Tc1/mariner superfamily) (see e.g. Ivics et al. 1997. Cell. 91(4): 501-510), piggyBac (piggyBac superfamily) (see e.g. Li et al. 2013 110(25): E2279-E2287 and Yusa et al. 2011. PNAS. 108(4): 1531-1536), To12 (superfamily hAT), Frog Prince (Tc1/mariner superfamily) (see e.g. Miskey et al. 2003 Nucleic Acid Res. 31(23):6873-6881) and variants thereof.

Viral Vectors

In some embodiments, the vector is a viral vector. The term of art “viral vector” and as used herein in this context refers to polynucleotide based vectors that contain one or more elements from or based upon one or more elements of a virus that can be capable of expressing and packaging a polynucleotide, such as an engineered muscle specific targeting moiety polynucleotide of the present invention, into a virus particle and producing said virus particle when used alone or with one or more other viral vectors (such as in a viral vector system). Viral vectors and systems thereof can be used for producing viral particles for delivery of and/or expression of one or more components of the engineered muscle-specific system described herein. The viral vector can be part of a viral vector system involving multiple vectors. In some embodiments, systems incorporating multiple viral vectors can increase the safety of these systems. Suitable viral vectors can include adenoviral-based vectors, adeno associated vectors, helper-dependent adenoviral (HdAd) vectors, hybrid adenoviral vectors, and the like. Other embodiments of viral vectors and viral particles produce therefrom are described elsewhere herein. In some embodiments, the viral vectors are configured to produce replication incompetent viral particles for improved safety of these systems.

Adenoviral Vectors, Helper-Dependent Adenoviral Vectors, and Hybrid Adenoviral Vectors

In some embodiments, the vector can be an adenoviral vector. Accordingly, the present invention is applicable to a virus within the family Adenoviridae, such as Atadenovirus, e.g., Ovine atadenovirus D, Aviadenovirus, e.g., Fowl aviadenovirus A, Ichtadenovirus, e.g., Sturgeon ichtadenovirus A, Mastadenovirus (which includes adenoviruses such as all human adenoviruses), e.g., Human mastadenovirus C, and Siadenovirus, e.g., Frog siadenovirus A. Thus, a virus of within the family Adenoviridae is contemplated as within the invention with discussion herein as to adenovirus applicable to other family members. In some embodiments, the adenoviral vector can include elements such that the virus particle produced using the vector or system thereof can be serotype 2, 5, or 9. In some embodiments, the polynucleotide to be delivered via the adenoviral particle can be up to about 8 kb. Thus, in some embodiments, an adenoviral vector can include a DNA polynucleotide to be delivered that can range in size from about 0.001 kb to about 8 kb. Adenoviral vectors have been used successfully in several contexts (see e.g. Teramato et al. 2000. Lancet. 355:1911-1912; Lai et al. 2002. DNA Cell. Biol. 21:895-913; Flotte et al., 1996. Hum. Gene. Ther. 7:1145-1159; and Kay et al. 2000. Nat. Genet. 24:257-261. The engineered muscle specific targeting moiety(ies) can be included in an adenoviral vector to produce adenoviral particles containing said engineered AAV capsids containing the engineered muscle specific targeting moiety(ies).

In some embodiments, the vector can be a helper-dependent adenoviral vector or system thereof. These are also referred to in the field as “gutless” or “gutted” vectors and are a modified generation of adenoviral vectors (see e.g. Thrasher et al. 2006. Nature. 443:E5-7). In embodiments of the helper-dependent adenoviral vector system, one vector (the helper) can contain all the viral genes required for replication but contains a conditional gene defect in the packaging domain. The second vector of the system can contain only the ends of the viral genome, one or more engineered AAV capsid polynucleotides, and the native packaging recognition signal, which can allow selective packaged release from the cells (see e.g. Cideciyan et al. 2009. N Engl J Med. 361:725-727). Helper-dependent Adenoviral vector systems have been successful for gene delivery in several contexts (see e.g. Simonelli et al. 2010. J Am Soc Gene Ther. 18:643-650; Cideciyan et al. 2009. N Engl J Med. 361:725-727; Crane et al. 2012. Gene Ther. 19(4):443-452; Alba et al. 2005. Gene Ther. 12:18-S27; Croyle et al. 2005. Gene Ther. 12:579-587; Amalfitano et al. 1998. J. Virol. 72:926-933; and Morral et al. 1999. PNAS. 96:12816-12821). The techniques and vectors described in these publications can be adapted for inclusion of the engineered AAV capsid polynucleotides described herein. In some embodiments, the viral particle containing an engineered muscle specific targeting moiety or encoding polynucleotide is produced from a helper-dependent adenoviral vector or system thereof can be up to about 38 kb. Thus, in some embodiments, an adenoviral vector can range in size from about 0.001 kb to about 37 kb (see e.g. Rosewell et al. 2011. J. Genet. Syndr. Gene Ther. Suppl. 5:001).

In some embodiments, the vector is a hybrid-adenoviral vector or system thereof. Hybrid adenoviral vectors are composed of the high transduction efficiency of a gene-deleted adenoviral vector and the long-term genome-integrating potential of adeno-associated, retroviruses, lentivirus, and transposon based-gene transfer. In some embodiments, such hybrid vector systems can result in stable transduction and limited integration site. See e.g. Balague et al. 2000. Blood. 95:820-828; Morral et al. 1998. Hum. Gene Ther. 9:2709-2716; Kubo and Mitani. 2003. J. Virol. 77(5): 2964-2971; Zhang et al. 2013. PloS One. 8(10) e76771; and Cooney et al. 2015. Mol. Ther. 23(4):667-674), whose techniques and vectors described therein can be modified and adapted for use in the engineered AAV muscle-specific delivery system of the present invention. In some embodiments, a hybrid-adenoviral vector can include one or more features of a retrovirus and/or an adeno-associated virus. In some embodiments, the hybrid-adenoviral vector can include one or more features of a spuma retrovirus or foamy virus (FV). See e.g. Ehrhardt et al. 2007. Mol. Ther. 15:146-156 and Liu et al. 2007. Mol. Ther. 15:1834-1841, whose techniques and vectors described therein can be modified and adapted for use in the engineered AAV capsid system of the present invention. Advantages of using one or more features from the FVs in the hybrid-adenoviral vector or system thereof can include the ability of the viral particles produced therefrom to infect a broad range of cells, a large packaging capacity as compared to other retroviruses, and the ability to persist in quiescent (non-dividing) cells. See also e.g. Ehrhardt et al. 2007. Mol. Ther. 156:146-156 and Shuji et al. 2011. Mol. Ther. 19:76-82, whose techniques and vectors described therein can be modified and adapted for use in the engineered AAV capsid system of the present invention.

Adeno Associated Vectors

In an embodiment, the engineered vector or system thereof can be an adeno-associated vector (AAV). See, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994); and Muzyczka, J. Clin. Invest. 94:1351 (1994). Although similar to adenoviral vectors in some of their features, AAVs have some deficiency in their replication and/or pathogenicity and thus can be safer that adenoviral vectors. In some embodiments the AAV can integrate into a specific site on chromosome 19 of a human cell with no observable side effects. In some embodiments, the capacity of the AAV vector, system thereof, and/or AAV particles can be up to about 4.7 kb. The AAV vector or system thereof can include one or more engineered capsid polynucleotides described herein.

The AAV vector or system thereof can include one or more regulatory molecules. In some embodiments the regulatory molecules can be promoters, enhancers, repressors and the like, which are described in greater detail elsewhere herein. In some embodiments, the AAV vector or system thereof can include one or more polynucleotides that can encode one or more regulatory proteins. In some embodiments, the one or more regulatory proteins can be selected from Rep78, Rep68, Rep52, Rep40, variants thereof, and combinations thereof. In some embodiments, the promoter can be a tissue specific promoter as previously discussed. In some embodiments, the tissue specific promoter can drive expression of an engineered capsid AAV capsid polynucleotide described herein. This can be advantageous such as for determining muscle-specific targeting moieties as previously described and as set forth in Ser. Nos. 62/899,453, 62/916,207, 63/018,454, 63/055,252, and 62/916,221 and International Application No. PCT/US20/50534.

The AAV vector or system thereof can include one or more polynucleotides that can encode one or more capsid proteins, such as the engineered AAV capsid proteins described elsewhere herein. The engineered capsid proteins can be capable of assembling into a protein shell (an engineered capsid) of the AAV virus particle. The engineered capsid can have a cell-, tissue,- and/or organ-specific tropism. In some embodiments, the AAV capsid protein can include one or more engineered muscle-specific targeting moieties described elsewhere herein. In some embodiments, one or more muscle-specific targeting moieties included in the AAV capsid includes an RGD motif as described in greater detail elsewhere herein.

In some embodiments, the AAV vector or system thereof can include one or more adenovirus helper factors or polynucleotides that can encode one or more adenovirus helper factors. Such adenovirus helper factors can include, but are not limited, E1A, E1B, E2A, E4ORF6, and VA RNAs. In some embodiments, a producing host cell line expresses one or more of the adenovirus helper factors.

The AAV vector or system thereof can be configured to produce AAV particles having a specific serotype. In some embodiments, the serotype can be AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, AAV rh.10, or any combination thereof. In some embodiments, the AAV can be AAV1, AAV-2, AAV-5, AAV-9 or any combination thereof. One can select the AAV of the AAV with regard to the cells to be targeted; e.g., one can select AAV serotypes 1, 2, 5, 9 or a hybrid capsid AAV-1, AAV-2, AAV-5, AAV-9 or any combination thereof for targeting brain and/or neuronal cells; and one can select AAV-4 for targeting cardiac tissue; and one can select AAV-8 for delivery to the liver. Thus, in some embodiments, an AAV vector or system thereof capable of producing AAV particles capable of targeting the brain and/or neuronal cells can be configured to generate AAV particles having serotypes 1, 2, 5 or a hybrid capsid AAV-1, AAV-2, AAV-5 or any combination thereof. In some embodiments, an AAV vector or system thereof capable of producing AAV particles capable of targeting cardiac tissue can be configured to generate an AAV particle having an AAV-4 serotype. In some embodiments, an AAV vector or system thereof capable of producing AAV particles capable of targeting the liver can be configured to generate an AAV having an AAV-8 serotype. See also Srivastava. 2017. Curr. Opin. Virol. 21:75-80.

It will be appreciated that while the different serotypes can provide some level of cell, tissue, and/or organ specificity, each serotype still is multi-tropic and thus can result in tissue-toxicity if using that serotype to target a tissue that the serotype is less efficient in transducing. Thus, in addition to achieving some tissue targeting capacity via selecting an AAV of a particular serotype, it will be appreciated that the tropism of the AAV serotype can be modified by an engineered AAV capsid described herein. As described elsewhere herein, variants of wild-type AAV of any serotype can be generated via a method described herein and determined to have a particular cell-specific tropism, which can be the same or different as that of the reference wild-type AAV serotype. In some embodiments, the cell, tissue, and/or specificity of the wild-type serotype can be enhanced (e.g. made more selective or specific for a particular cell type that the serotype is already biased towards). For example, wild-type AAV-9 is biased towards muscle and brain in humans (see e.g. Srivastava. 2017. Curr. Opin. Virol. 21:75-80.) By including an engineered AAV capsid and/or capsid protein variant of wild-type AAV-9 as described herein, the bias for e.g. brain can be reduced or eliminated and/or the muscle septicity increased such that the brain specificity appears reduced in comparison, thus enhancing the specificity for the muscle as compared to the wild-type AAV-9. As previously mentioned, inclusion of an engineered capsid and/or capsid protein variant of a wild-type AAV serotype can have a different tropism than the wild-type reference AAV serotype. For example, an engineered AAV capsid and/or capsid protein variant of AAV-9 can have specificity for a tissue other than muscle or brain in humans.

In some embodiments, the AAV vector is a hybrid AAV vector or system thereof. Hybrid AAVs are AAVs that include genomes with elements from one serotype that are packaged into a capsid derived from at least one different serotype. For example, if it is the rAAV2/5 that is to be produced, and if the production method is based on the helper-free, transient transfection method discussed above, the 1st plasmid and the 3rd plasmid (the adeno helper plasmid) will be the same as discussed for rAAV2 production. However, the 2nd plasmid, the pRepCap will be different. In this plasmid, called pRep2/Cap5, the Rep gene is still derived from AAV2, while the Cap gene is derived from AAV5. The production scheme is the same as the above-mentioned approach for AAV2 production. The resulting rAAV is called rAAV2/5, in which the genome is based on recombinant AAV2, while the capsid is based on AAV5. It is assumed the cell or tissue-tropism displayed by this AAV2/5 hybrid virus should be the same as that of AAV5. It will be appreciated that wild-type hybrid AAV particles suffer the same specificity issues as with the non-hybrid wild-type serotypes previously discussed.

Advantages achieved by the wild-type based hybrid AAV systems can be combined with the increased and customizable cell-specificity that can be achieved with the engineered AAV capsids can be combined by generating a hybrid AAV that can include an engineered AAV capsid described elsewhere herein. It will be appreciated that hybrid AAVs can contain an engineered AAV capsid containing a genome with elements from a different serotype than the reference wild-type serotype that the engineered AAV capsid is a variant of. For example, a hybrid AAV can be produced that includes an engineered AAV capsid that is a variant of an AAV-9 serotype that is used to package a genome that contains components (e.g. rep elements) from an AAV-2 serotype. As with wild-type based hybrid AAVs previously discussed, the tropism of the resulting AAV particle will be that of the engineered AAV capsid.

A tabulation of certain wild-type AAV serotypes as to these cells can be found in Grimm, D. et al, J. Virol. 82: 5887-5911 (2008) reproduced below as Table 7. Further tropism details can be found in Srivastava. 2017. Curr. Opin. Virol. 21:75-80 as previously discussed.

TABLE 7 Cell Line AAV-1 AAV-2 AAV-3 AAV-4 AAV-5 AAV-6 AAV-8 AAV-9 Huh-7 13 100 2.5 0.0 0.1 10 0.7 0.0 HEK293 25 100 2.5 0.1 0.1 5 0.7 0.1 HeLa 3 100 2.0 0.1 6.7 1 0.2 0.1 HepG2 3 100 16.7 0.3 1.7 5 0.3 ND Hep1A 20 100 0.2 1.0 0.1 1 0.2 0.0 911 17 100 11 0.2 0.1 17 0.1 ND CHO 100 100 14 1.4 333 50 10 1.0 COS 33 100 33 3.3 5.0 14 2.0 0.5 MeWo 10 100 20 0.3 6.7 10 1.0 0.2 NIH3T3 10 100 2.9 2.9 0.3 10 0.3 ND A549 14 100 20 ND 0.5 10 0.5 0.1 HT1180 20 100 10 0.1 0.3 33 0.5 0.1 Monocytes 1111 100 ND ND 125 1429 ND ND Immature DC 2500 100 ND ND 222 2857 ND ND Mature DC 2222 100 ND ND 333 3333 ND ND

In some embodiments, the AAV vector or system thereof is AAV rh.74 or AAV rh.10.

In some embodiments, the AAV vector or system thereof is configured as a “gutless” vector, similar to that described in connection with a retroviral vector. In some embodiments, the “gutless” AAV vector or system thereof can have the cis-acting viral DNA elements involved in genome amplification and packaging in linkage with the heterologous sequences of interest (e.g. the engineered AAV capsid polynucleotide(s)).

Retroviral and Lentiviral Vectors

In some embodiments, the engineered muscle-specific delivery system or component thereof is or is incorporated into a retroviral or lentiviral vector. Retroviral vectors can be composed of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Suitable retroviral vectors for the CRISPR-Cas systems can include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommnerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT/US94/05700). Selection of a retroviral gene transfer system may therefore depend on the target tissue.

The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and are described in greater detail elsewhere herein. A retrovirus can also be engineered to allow for conditional expression of the inserted transgene, such that only certain cell types are infected by the lentivirus. In some embodiments where the end product is a muscle-specific viral particle, the tropism is defined at least in part by the presence of a muscle-specific targeting moiety described herein, such as incorporated within a capsid protein and/or capsid of the retrovirus or lentivirus particles.

Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells. Advantages of using a lentiviral approach can include the ability to transduce or infect non-dividing cells and their ability to typically produce high viral titers, which can increase efficiency or efficacy of production and delivery. Suitable lentiviral vectors include, but are not limited to, human immunodeficiency virus (HIV)-based lentiviral vectors, feline immunodeficiency virus (FIV)-based lentiviral vectors, simian immunodeficiency virus (SIV)-based lentiviral vectors, Moloney Murine Leukaemia Virus (Mo-MLV), Visna.maedi virus (VMV)-based lentiviral vector, carpine arthritis-encephalitis virus (CAEV)-based lentiviral vector, bovine immune deficiency virus (BIV)-based lentiviral vector, and Equine infectious anemia (EIAV)-based lentiviral vector. In some embodiments, an HIV-based lentiviral vector system can be used. In some embodiments, a FIV-based lentiviral vector system can be used.

In some embodiments, the lentiviral vector is an EIAV-based lentiviral vector or vector system. EIAV vectors have been used to mediate expression, packaging, and/or delivery in other contexts, such as for ocular gene therapy (see, e.g., Balagaan, J Gene Med 2006; 8: 275-285). In another embodiment, RetinoStat®, (see, e.g., Binley et al., HUMAN GENE THERAPY 23:980-991 (September 2012)), which describes RetinoStat®, an equine infectious anemia virus-based lentiviral gene therapy vector that expresses angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the wet form of age-related macular degeneration. Any of these vectors described in these publications can be modified for the elements of the engineered muscle-specific delivery system described herein.

In some embodiments, the lentiviral vector or vector system thereof can be a first-generation lentiviral vector or vector system thereof. First-generation lentiviral vectors can contain a large portion of the lentivirus genome, including the gag and pol genes, other additional viral proteins (e.g. VSV-G) and other accessory genes (e.g. vif, vprm vpu, nef, and combinations thereof), regulatory genes (e.g. tat and/or rev) as well as the gene of interest between the LTRs. First generation lentiviral vectors can result in the production of virus particles that can be capable of replication in vivo, which may not be appropriate for some instances or applications.

In some embodiments, the lentiviral vector or vector system thereof can be a second-generation lentiviral vector or vector system thereof. Second-generation lentiviral vectors do not contain one or more accessory virulence factors and do not contain all components necessary for virus particle production on the same lentiviral vector. This can result in the production of a replication-incompetent virus particle and thus increase the safety of these systems over first-generation lentiviral vectors. In some embodiments, the second-generation vector lacks one or more accessory virulence factors (e.g. vif, vprm, vpu, nef, and combinations thereof). Unlike the first-generation lentiviral vectors, no single second generation lentiviral vector includes all features necessary to express and package a polynucleotide into a virus particle. In some embodiments, the envelope and packaging components are split between two different vectors with the gag, pol, rev, and tat genes being contained on one vector and the envelope protein (e.g. VSV-G) are contained on a second vector. The gene of interest, its promoter, and LTRs can be included on a third vector that can be used in conjunction with the other two vectors (packaging and envelope vectors) to generate a replication-incompetent virus particle.

In some embodiments, the lentiviral vector or vector system thereof can be a third-generation lentiviral vector or vector system thereof. Third-generation lentiviral vectors and vector systems thereof have increased safety over first- and second-generation lentiviral vectors and systems thereof because, for example, the various components of the viral genome are split between two or more different vectors but used together in vitro to make virus particles, they can lack the tat gene (when a constitutively active promoter is included upstream of the LTRs), and they can include one or more deletions in the 3′LTR to create self-inactivating (SIN) vectors having disrupted promoter/enhancer activity of the LTR. In some embodiments, a third-generation lentiviral vector system can include (i) a vector plasmid that contains the polynucleotide of interest and upstream promoter that are flanked by the 5′ and 3′ LTRs, which can optionally include one or more deletions present in one or both of the LTRs to render the vector self-inactivating; (ii) a “packaging vector(s)” that can contain one or more genes involved in packaging a polynucleotide into a virus particle that is produced by the system (e.g. gag, pol, and rev) and upstream regulatory sequences (e.g. promoter(s)) to drive expression of the features present on the packaging vector, and (iii) an “envelope vector” that contains one or more envelope protein genes and upstream promoters. In certain embodiments, the third-generation lentiviral vector system can include at least two packaging vectors, with the gag-pol being present on a different vector than the rev gene.

In some embodiments, self-inactivating lentiviral vectors with an siRNA targeting a common exon shared by HIV tat/rev, a nucleolar-localizing TAR decoy, and an anti-CCR5-specific hammerhead ribozyme (see, e.g., DiGiusto et al. (2010) Sci Transl Med 2:36ra43) can be used/and or adapted to the CRISPR-Cas system of the present invention.

In some embodiments, the pseudotype and infectivity or tropisim of a lentivirus particle can be tuned by altering the type of envelope protein(s) included in the lentiviral vector or system thereof. As used herein, an “envelope protein” or “outer protein” means a protein exposed at the surface of a viral particle that is not a capsid protein. For example, envelope or outer proteins typically comprise proteins embedded in the envelope of the virus. In some embodiments, a lentiviral vector or vector system thereof can include a VSV-G envelope protein. VSV-G mediates viral attachment to an LDL receptor (LDLR) or an LDLR family member present on a host cell, which triggers endocytosis of the viral particle by the host cell. Because LDLR is expressed by a wide variety of cells, viral particles expressing the VSV-G envelope protein can infect or transduce a wide variety of cell types. Other suitable envelope proteins can be incorporated based on the host cell that a user desires to be infected by a virus particle produced from a lentiviral vector or system thereof described herein and can include, but are not limited to, feline endogenous virus envelope protein (RD114) (see e.g. Hanawa et al. Molec. Ther. 2002 5(3) 242-251), modified Sindbis virus envelope proteins (see e.g. Morizono et al. 2010. J. Virol. 84(14) 6923-6934; Morizono et al. 2001. J. Virol. 75:8016-8020; Morizono et al. 2009. J. Gene Med. 11:549-558; Morizono et al. 2006 Virology 355:71-81; Morizono et al J. Gene Med. 11:655-663, Morizono et al. 2005 Nat. Med. 11:346-352), baboon retroviral envelope protein (see e.g. Girard-Gagnepain et al. 2014. Blood. 124: 1221-1231); Tupaia paramyxovirus glycoproteins (see e.g. Enkirch T. et al., 2013. Gene Ther. 20:16-23); measles virus glycoproteins (see e.g. Funke et al. 2008. Molec. Ther. 16(8): 1427-1436), rabies virus envelope proteins, MLV envelope proteins, Ebola envelope proteins, baculovirus envelope proteins, filovirus envelope proteins, hepatitis E1 and E2 envelope proteins, gp41 and gp120 of HIV, hemagglutinin, neuraminidase, M2 proteins of influenza virus, and combinations thereof.

In some embodiments, the tropism of the resulting lentiviral particle can be tuned by incorporating cell targeting peptides into a lentiviral vector such that the cell targeting peptides are expressed on the surface of the resulting lentiviral particle. In some embodiments, a lentiviral vector can contain an envelope protein that is fused to a cell targeting protein (see e.g. Buchholz et al. 2015. Trends Biotechnol. 33:777-790; Bender et al. 2016. PLoS Pathog. 12(e1005461); and Friedrich et al. 2013. Mol. Ther. 2013. 21: 849-859.

In some embodiments, a split-intein-mediated approach to target lentiviral particles to a specific cell type can be used (see e.g. Chamoun-Emaneulli et al. 2015. Biotechnol. Bioeng. 112:2611-2617, Ramirez et al. 2013. Protein. Eng. Des. Sel. 26:215-233. In these embodiments, a lentiviral vector can contain one half of a splicing-deficient variant of the naturally split intein from Nostoc punctiforme fused to a cell targeting peptide and the same or different lentiviral vector can contain the other half of the split intein fused to an envelope protein, such as a binding-deficient, fusion-competent virus envelope protein. This can result in production of a virus particle from the lentiviral vector or vector system that includes a split intein that can function as a molecular Velcro linker to link the cell-binding protein to the pseudotyped lentivirus particle. This approach can be advantageous for use where surface-incompatibilities can restrict the use of, e.g., cell targeting peptides.

In some embodiments, a covalent-bond-forming protein-peptide pair can be incorporated into one or more of the lentiviral vectors described herein to conjugate a cell targeting peptide to the virus particle (see e.g. Kasaraneni et al. 2018. Sci. Reports (8) No. 10990). In some embodiments, a lentiviral vector can include an N-terminal PDZ domain of InaD protein (PDZ1) and its pentapeptide ligand (TEFCA) from NorpA, which can conjugate the cell targeting peptide to the virus particle via a covalent bond (e.g. a disulfide bond). In some embodiments, the PDZ1 protein can be fused to an envelope protein, which can optionally be binding deficient and/or fusion competent virus envelope protein and included in a lentiviral vector. In some embodiments, the TEFCA can be fused to a cell targeting peptide and the TEFCA-CPT fusion construct can be incorporated into the same or a different lentiviral vector as the PDZ1-envelope protein construct. During virus production, specific interaction between the PDZ1 and TEFCA facilitates producing virus particles covalently functionalized with the cell targeting peptide and thus capable of targeting a specific cell-type based upon a specific interaction between the cell targeting peptide and cells expressing its binding partner. This approach can be advantageous for use where surface-incompatibilities can restrict the use of, e.g., cell targeting peptides.

Lentiviral vectors have been disclosed as in the treatment for Parkinson's Disease, see, e.g., US Patent Publication No. 20120295960 and U.S. Pat. Nos. 7,303,910 and 7,351,585. Lentiviral vectors have also been disclosed for the treatment of ocular diseases, see e.g., US Patent Publication Nos. 20060281180, 20090007284, US20110117189; US20090017543; US20070054961, US20100317109. Lentiviral vectors have also been disclosed for delivery to the brain, see, e.g., US Patent Publication Nos. US20110293571; US20110293571, US20040013648, US20070025970, US20090111106 and U.S. Pat. No. 7,259,015. Any of these systems or a variant thereof can be used to deliver an engineered muscle-specific polynucleotide to a cell and/or incorporate a muscle-specific targeting moiety described herein for muscle-specific delivery to a cell.

In some embodiments, a lentiviral vector system can include one or more transfer plasmids. Transfer plasmids can be generated from various other vector backbones and can include one or more features that can work with other retroviral and/or lentiviral vectors in the system that can, for example, improve safety of the vector and/or vector system, increase virial titers, and/or increase or otherwise enhance expression of the desired insert to be expressed and/or packaged into the viral particle. Suitable features that can be included in a transfer plasmid can include, but are not limited to, 5′LTR, 3′LTR, SIN/LTR, origin of replication (Ori), selectable marker genes (e.g. antibiotic resistance genes), Psi (ψ), RRE (rev response element), cPPT (central polypurine tract), promoters, WPRE (woodchuck hepatitis post-transcriptional regulatory element), SV40 polyadenylation signal, pUC origin, SV40 origin, F1 origin, and combinations thereof.

In another embodiment, Cocal vesiculovirus envelope pseudotyped retroviral or lentiviral vector particles are contemplated (see, e.g., US Patent Publication No. 20120164118 assigned to the Fred Hutchinson Cancer Research Center). Cocal virus is in the Vesiculovirus genus and is a causative agent of vesicular stomatitis in mammals. Cocal virus was originally isolated from mites in Trinidad (Jonkers et al., Am. J. Vet. Res. 25:236-242 (1964)), and infections have been identified in Trinidad, Brazil, and Argentina from insects, cattle, and horses. Many of the vesiculoviruses that infect mammals have been isolated from naturally infected arthropods, suggesting that they are vector-borne. Antibodies to vesiculoviruses are common among people living in rural areas where the viruses are endemic and laboratory-acquired; infections in humans usually result in influenza-like symptoms. The Cocal virus envelope glycoprotein shares 71.5% identity at the amino acid level with VSV-G Indiana, and phylogenetic comparison of the envelope gene of vesiculoviruses shows that Cocal virus is serologically distinct from, but most closely related to, VSV-G Indiana strains among the vesiculoviruses. Jonkers et al., Am. J. Vet. Res. 25:236-242 (1964) and Travassos da Rosa et al., Am. J. Tropical Med. & Hygiene 33:999-1006 (1984). The Cocal vesiculovirus envelope pseudotyped retroviral vector particles may include for example, lentiviral, alpharetroviral, betaretroviral, gammaretroviral, deltaretroviral, and epsilonretroviral vector particles that may comprise retroviral Gag, Pol, and/or one or more accessory protein(s) and a Cocal vesiculovirus envelope protein. In certain embodiments of these embodiments, the Gag, Pol, and accessory proteins are lentiviral and/or gammaretroviral. In some embodiments, a retroviral vector can contain encoding polypeptides for one or more Cocal vesiculovirus envelope proteins such that the resulting viral or pseudoviral particles are Cocal vesiculovirus envelope pseudotyped.

Herpes Simplex Viral Vectors

In some embodiments, the vector can be a Herpes Simplex Viral (HSV)-based vector or system thereof. HSV systems can include the disabled infections single copy (DISC) viruses, which are composed of a glycoprotein H defective mutant HSV genome. When the defective HSV is propagated in complementing cells, virus particles can be generated that are capable of infecting subsequent cells permanently replicating their own genome but are not capable of producing more infectious particles. See e.g. 2009. Trobridge. Exp. Opin. Biol. Ther. 9:1427-1436, whose techniques and vectors described therein can be modified and adapted for use in the CRISPR-Cas system of the present invention. In some embodiments where an HSV vector or system thereof is utilized, the host cell can be a complementing cell. In some embodiments, HSV vector or system thereof can be capable of producing virus particles capable of delivering a polynucleotide cargo of up to 150 kb. Thus, in some embodiment the engineered muscle-specific targeting moiety polynucleotide(s) included in the HSV-based viral vector or system thereof can sum from about 0.001 to about 150 kb. HSV-based vectors and systems thereof have been successfully used in several contexts including various models of neurologic disorders. See e.g. Cockrell et al. 2007. Mol. Biotechnol. 36:184-204; Kafri T. 2004. Mol. Biol. 246:367-390; Balaggan and Ali. 2012. Gene Ther. 19:145-153; Wong et al. 2006. Hum. Gen. Ther. 2002. 17:1-9; Azzouz et al. J. Neruosci. 22L10302-10312; and Betchen and Kaplitt. 2003. Curr. Opin. Neurol. 16:487-493. Any of these systems or a variant thereof can be used to deliver an engineered muscle-specific polynucleotide to a cell and/or incorporate a muscle-specific targeting moiety described herein for muscle-specific delivery to a cell.

Poxvirus Vectors

In some embodiments, the vector can be a poxvirus vector or system thereof. In some embodiments, the poxvirus vector can result in cytoplasmic expression of one or more cargos that can be packaged by such virus of the present invention. In some embodiments, the capacity of a poxvirus vector or system thereof can be about 25 kb or more. In some embodiments, a poxvirus vector or system thereof can include one or more engineered muscle-specific targeting moiety polynucleotides and/or muscle-specific targeting moieties, engineered capsid proteins, and/or capsids described herein.

Viral Vectors for Delivery to Plants

The systems and compositions may be delivered to plant cells using viral vehicles. Plant cells can be engineered to express compositions (such as proteins) that can contain muscle-specific targeting moiety(ies) that can be subsequently harvested and used as appropriate, such as a therapy for humans or non-human animals. In particular embodiments, the compositions and systems may be introduced in the plant cells using a plant viral vector (e.g., as described in Scholthof et al. 1996, Annu Rev Phytopathol. 1996; 34:299-323). Such viral vector may be a vector from a DNA virus, e.g., geminivirus (e.g., cabbage leaf curl virus, bean yellow dwarf virus, wheat dwarf virus, tomato leaf curl virus, maize streak virus, tobacco leaf curl virus, or tomato golden mosaic virus) or nanovirus (e.g., Faba bean necrotic yellow virus). The viral vector may be a vector from an RNA virus, e.g., tobravirus (e.g., tobacco rattle virus, tobacco mosaic virus), potexvirus (e.g., potato virus X), or hordeivirus (e.g., barley stripe mosaic virus). The replicating genomes of plant viruses may be non-integrative vectors.

Vector Construction

The vectors described herein can be constructed using any suitable process or technique. In some embodiments, one or more suitable recombination and/or cloning methods or techniques can be used to the vector(s) described herein. Suitable recombination and/or cloning techniques and/or methods can include, but not limited to, those described in U.S. Application publication No. US 2004-0171156 A1. Other suitable methods and techniques are described elsewhere herein.

Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989). Any of the techniques and/or methods can be used and/or adapted for constructing an AAV or other vector described herein. AAV vectors are discussed elsewhere herein.

In some embodiments, the vector can have one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a “cloning site”). In some embodiments, one or more insertion sites (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors.

Delivery vehicles, vectors, particles, nanoparticles, formulations and components thereof for expression of one or more elements of an engineered AAV capsid system described herein are as used in the foregoing documents, such as WO 2014/093622 (PCT/US2013/074667) and are discussed in greater detail herein.

Virus Particle Production from Viral Vectors

AAV Particle Production

There are two main strategies for producing AAV particles from AAV vectors and systems thereof, such as those described herein, which depend on how the adenovirus helper factors are provided (helper v. helper free). In some embodiments, a method of producing AAV particles from AAV vectors and systems thereof can include adenovirus infection into cell lines that stably harbor AAV replication and capsid encoding polynucleotides along with AAV vector containing the polynucleotide to be packaged and delivered by the resulting AAV particle (e.g. the engineered AAV capsid polynucleotide(s)). In some embodiments, a method of producing AAV particles from AAV vectors and systems thereof can be a “helper free” method, which includes co-transfection of an appropriate producing cell line with three vectors (e.g. plasmid vectors): (1) an AAV vector that contains a polynucleotide of interest (e.g. the engineered AAV capsid polynucleotide(s)) between 2 ITRs; (2) a vector that carries the AAV Rep-Cap encoding polynucleotides; and (helper polynucleotides. One of skill in the art will appreciate various methods and variations thereof that are both helper and -helper free and as well as the different advantages of each system.

The engineered AAV vectors and systems thereof described herein can be produced by any of these methods.

Retroviral Production

In some embodiments, one or more viral vectors and/or system thereof can be delivered to a suitable cell line for production of virus particles containing the polynucleotide or other payload to be delivered to a host cell. Suitable host cells for virus production from viral vectors and systems thereof described herein are known in the art and are commercially available. For example, suitable host cells include HEK 293 cells and its variants (HEK 293T and HEK 293TN cells). In some embodiments, the suitable host cell for virus production from viral vectors and systems thereof described herein can stably express one or more genes involved in packaging (e.g. pol, gag, and/or VSV-G) and/or other supporting genes.

In some embodiments, after delivery of one or more viral vectors to the suitable host cells for or virus production from viral vectors and systems thereof, the cells are incubated for an appropriate length of time to allow for viral gene expression from the vectors, packaging of the polynucleotide or other cargo to be delivered (e.g. an CRISPR-Cas system polynucleotide), and virus particle assembly, and secretion of mature virus particles into the culture media. Various other methods and techniques are generally known to those of ordinary skill in the art.

Mature virus particles can be collected from the culture media by a suitable method. In some embodiments, this can involve centrifugation to concentrate the virus. The titer of the composition containing the collected virus particles can be obtained using a suitable method. Such methods can include transducing a suitable cell line (e.g. NIH 3T3 cells) and determining transduction efficiency, infectivity in that cell line by a suitable method. Suitable methods include PCR-based methods, flow cytometry, and antibiotic selection-based methods. Various other methods and techniques are generally known to those of ordinary skill in the art. The concentration of virus particle can be adjusted as needed. In some embodiments, the resulting composition containing virus particles can contain 1×10¹-1×10²⁰ particles/mL.

Lentiviruses may be prepared from any lentiviral vector or vector system described herein. In one example embodiment, after cloning pCasES10 (which contains a lentiviral transfer plasmid backbone), HEK293FT at low passage (p=5) can be seeded in a T-75 flask to 50% confluence the day before transfection in DMEM with 10% fetal bovine serum and without antibiotics. After 20 hours, the media can be changed to OptiMEM (serum-free) media and transfection of the lentiviral vectors can done 4 hours later. Cells can be transfected with 10 μg of lentiviral transfer plasmid (pCasES10) and the appropriate packaging plasmids (e.g., 5 μg of pMD2.G (VSV-g pseudotype), and 7.5 ug of psPAX2 (gag/pol/rev/tat)). Transfection can be carried out in 4 mL OptiMEM with a cationic lipid delivery agent (50 uL Lipofectamine 2000 and 100 ul Plus reagent). After 6 hours, the media can be changed to antibiotic-free DMEM with 10% fetal bovine serum. These methods can use serum during cell culture, but serum-free methods are preferred.

Following transfection and allowing the producing cells (also referred to as packaging cells) to package and produce virus particles with packaged cargo, the lentiviral particles can be purified. In an exemplary embodiment, virus-containing supernatants can be harvested after 48 hours. Collected virus-containing supernatants can first be cleared of debris and filtered through a 0.45 um low protein binding (PVDF) filter. They can then be spun in an ultracentrifuge for 2 hours at 24,000 rpm. The resulting virus-containing pellets can be resuspended in 50 ul of DMEM overnight at 4 degrees C. They can be then aliquoted and used immediately or immediately frozen at −80 degrees C. for storage.

Vector and Virus Particle Delivery

A vector (including non-viral carriers) described herein can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides encoded by nucleic acids as described herein (e.g., engineered AAV capsid system transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.), and virus particles (such as from viral vectors and systems thereof).

One or more engineered AAV capsid polynucleotides can be delivered using adeno associated virus (AAV), adenovirus or other plasmid or viral vector types as previously described, in particular, using formulations and doses from, for example, U.S. Pat. No. 8,454,972 (formulations, doses for adenovirus), U.S. Pat. No. 8,404,658 (formulations, doses for AAV) and U.S. Pat. No. 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivirus, AAV and adenovirus. For examples, for AAV, the route of administration, formulation and dose can be as in U.S. Pat. No. 8,454,972 and as in clinical trials involving AAV. For Adenovirus, the route of administration, formulation and dose can be as in U.S. Pat. No. 8,404,658 and as in clinical trials involving adenovirus.

For plasmid delivery, the route of administration, formulation and dose can be as in U.S. Pat. No. 5,846,946 and as in clinical studies involving plasmids. In some embodiments, doses can be based on or extrapolated to an average 70 kg individual (e.g. a male adult human), and can be adjusted for patients, subjects, mammals of different weight and species. Frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), depending on usual factors including the age, sex, general health, other conditions of the patient or subject and the particular condition or symptoms being addressed. The viral vectors can be injected into or otherwise delivered to the tissue or cell of interest.

In terms of in vivo delivery, AAV is advantageous over other viral vectors for a couple of reasons such as low toxicity (this may be due to the purification method not requiring ultra-centrifugation of cell particles that can activate the immune response) and a low probability of causing insertional mutagenesis because it doesn't integrate into the host genome.

The vector(s) and virus particles described herein can be delivered in to a host cell in vitro, in vivo, and or ex vivo. Delivery can occur by any suitable method including, but not limited to, physical methods, chemical methods, and biological methods. Physical delivery methods are those methods that employ physical force to counteract the membrane barrier of the cells to facilitate intracellular delivery of the vector. Suitable physical methods include, but are not limited to, needles (e.g. injections), ballistic polynucleotides (e.g. particle bombardment, micro projectile gene transfer, and gene gun), electroporation, sonoporation, photoporation, magnetofection, hydroporation, and mechanical massage. Chemical methods are those methods that employ a chemical to elicit a change in the cells membrane permeability or other characteristic(s) to facilitate entry of the vector into the cell. For example, the environmental pH can be altered which can elicit a change in the permeability of the cell membrane. Biological methods are those that rely and capitalize on the host cell's biological processes or biological characteristics to facilitate transport of the vector (with or without a carrier) into a cell. For example, the vector and/or its carrier can stimulate an endocytosis or similar process in the cell to facilitate uptake of the vector into the cell.

Delivery of engineered AAV capsid system components (e.g. polynucleotides encoding engineered AAV capsid and/or capsid proteins) to cells via particles. The term “particle” as used herein, refers to any suitable sized particles for delivery of the engineered AAV capsid system components described herein. Suitable sizes include macro-, micro-, and nano-sized particles. In some embodiments, any of the of the engineered AAV capsid system components (e.g. polypeptides, polynucleotides, vectors and combinations thereof described herein) can be attached to, coupled to, integrated with, otherwise associated with one or more particles or component thereof as described herein. The particles described herein can then be administered to a cell or organism by an appropriate route and/or technique. In some embodiments, particle delivery can be selected and be advantageous for delivery of the polynucleotide or vector components. It will be appreciated that in embodiments, particle delivery can also be advantageous for other engineered capsid system molecules and formulations described elsewhere herein.

Engineered Virus Particles

Also described herein are engineered virus particles (also referred to herein as “engineered viral particles”) that can contain an engineered muscle-specific capsid (e.g. a capsid containing one or more engineered capsid polypeptides having one or more engineered muscle-specific targeting moieties as described in detail elsewhere herein). Also described herein are virus particles containing, as cargo, one or more engineered muscle-specific targeting moiety polynucleotides described elsewhere herein.

It will be appreciated that the engineered viral particles can be lentiviral-based, retroviral-based, poxvirus-based, herpesvirus-based, adenovirus-based particles, helper adenovirus-based particles, AAV-based particles, or hybrid adenovirus-based particles that contain at least one engineered capsid protein as previously described. An engineered viral capsid is one that that contains one or more engineered capsid proteins that contain one or more muscle-specific targeting moieties as are described elsewhere herein. In some embodiments, the engineered viral capsid is an engineered AAV capsids.

In some embodiments, the engineered AAV particles can include 1-60 engineered AAV capsid proteins described herein. In some embodiments, the engineered AAV particles can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 engineered capsid proteins. In some embodiments, the engineered AAV particles can contain 0-59 wild-type AAV capsid proteins. In some embodiments, the engineered AAV particles can contain 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59 wild-type AAV capsid proteins. The engineered AAV particles can thus include one or more n-mer motifs as is previously described. In some embodiments, the n-mer is an RGD motif.

The engineered virus particles can each include one or more cargo polynucleotides. Cargo polynucleotides are discussed in greater detail elsewhere herein. Methods of making the engineered AAV particles from viral and non-viral vectors are described elsewhere herein. Formulations containing the engineered virus particles are described elsewhere herein.

Engineered Non-Vector Delivery Vehicles

In some embodiments, the muscle-specific targeting moiety is incorporated in a non-vector delivery vehicle. In some embodiments, the muscle specific targeting moiety is operably coupled or otherwise attached to the non-vector delivery vehicle. As used herein, “attached” can refer to covalent or non-covalent interaction between two or more molecules. Non-covalent interactions can include ionic bonds, electrostatic interactions, van der Walls forces, dipole-dipole interactions, dipole-induced-dipole interactions, London dispersion forces, hydrogen bonding, halogen bonding, electromagnetic interactions, π-πinteractions, cation-n interactions, anion-n interactions, polar n-interactions, and hydrophobic effects. In some embodiments, the muscle-specific targeting moiety is incorporated into a composition (such as a protein or polynucleotide) that is operably coupled to or is otherwise attached to the non-vector delivery vehicle. In some embodiments, the engineered muscle-specific targeting moiety is operatively coupled or otherwise attached such that the muscle specific targeting moiety is on a surface of the non-vector delivery vehicle. The delivery vehicles may comprise non-viral vehicles. In general, methods and vehicles capable of delivering nucleic acids and/or proteins may be used for delivering the systems compositions herein. Examples of non-viral vehicles include lipid nanoparticles, cell-penetrating peptides (CPPs), DNA nanoclews, metal nanoparticles, streptolysin O, multifunctional envelope-type nanodevices (MENDs), lipid-coated mesoporous silica particles, and other inorganic nanoparticles.

Lipid Particles

The delivery vehicles may comprise lipid particles, e.g., lipid nanoparticles (LNPs) and liposomes. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, International Patent Publication Nos. WO 91/17424 and WO 91/16024. The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

Lipid Nanoparticles (LNPs)

LNPs may encapsulate nucleic acids within cationic lipid particles (e.g., liposomes) and may be delivered to cells with relative ease. In some examples, lipid nanoparticles do not contain any viral components, which helps minimize safety and immunogenicity concerns. Lipid particles may be used for in vitro, ex vivo, and in vivo deliveries. Lipid particles may be used for various scales of cell populations.

In some embodiments, LNPs may be used for delivering DNA molecules (e.g., those comprising coding sequences of Cas and/or gRNA) and/or RNA molecules (e.g., mRNA of Cas, gRNAs). In certain cases, LNPs may be use for delivering RNP complexes of Cas/gRNA.

Components in LNPs may comprise cationic lipids 1,2-dilineoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxyketo-N,N-dimethyl-3-aminopropane (DLinK-DMA), 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), (3-o-[2″-(methoxypolyethyleneglycol 2000) succinoyl]-1,2-dimyristoyl-sn-glycol (PEG-S-DMG), R-3-[(ro-methoxy-poly(ethylene glycol)2000) carbamoyl]-1,2-dimyristyloxlpropyl-3-amine (PEG-C-DOMG, and any combination thereof. Preparation of LNPs and encapsulation may be adapted from Rosin et al, Molecular Therapy, vol. 19, no. 12, pages 1286-2200, December 2011).

In some embodiments, an LNP delivery vehicle can be used to deliver a virus particle containing a CRISPR-Cas system and/or component(s) thereof. In some embodiments, the virus particle(s) can be adsorbed to the lipid particle, such as through electrostatic interactions, and/or can be attached to the liposomes via a linker.

In some embodiments, the LNP contains a nucleic acid, wherein the charge ratio of nucleic acid backbone phosphates to cationic lipid nitrogen atoms is about 1:1.5-7 or about 1:4.

In some embodiments, the LNP also includes a shielding compound, which is removable from the lipid composition under in vivo conditions. In some embodiments, the shielding compound is a biologically inert compound. In some embodiments, the shielding compound does not carry any charge on its surface or on the molecule as such. In some embodiments, the shielding compounds are polyethylene glycols (PEGs), hydroxyethylglucose (HEG) based polymers, polyhydroxyethyl starch (polyHES) and polypropylene. In some embodiments, the PEG, HEG, polyHES, and a polypropylene weight between about 500 to 10,000 Da or between about 2000 to 5000 Da. In some embodiments, the shielding compound is PEG2000 or PEG5000.

In some embodiments, the LNP can include one or more helper lipids. In some embodiments, the helper lipid can be a phosphor lipid or a steroid. In some embodiments, the helper lipid is between about 20 mol % to 80 mol % of the total lipid content of the composition. In some embodiments, the helper lipid component is between about 35 mol % to 65 mol % of the total lipid content of the LNP. In some embodiments, the LNP includes lipids at 50 mol % and the helper lipid at 50 mol % of the total lipid content of the LNP.

Other non-limiting, exemplary LNP delivery vehicles are described in U.S. Patent Publication Nos. US 20160174546, US 20140301951, US 20150105538, US 20150250725, Wang et al., J. Control Release, 2017 Jan. 31. pii: 50168-3659(17)30038-X. doi: 10.1016/j.jconrel.2017.01.037. [Epub ahead of print]; Altmoglu et al., Biomater Sci., 4(12):1773-80, Nov. 15, 2016; Wang et al., PNAS, 113(11):2868-73 Mar. 15, 2016; Wang et al., PloS One, 10(11): e0141860. doi: 10.1371/journal.pone.0141860. eCollection 2015, Nov. 3, 2015; Takeda et al., Neural Regen Res. 10(5):689-90, May 2015; Wang et al., Adv. Healthc Mater., 3(9):1398-403, September 2014; and Wang et al., Agnew Chem Int Ed Engl., 53(11):2893-8, Mar. 10, 2014; James E. Dahlman and Carmen Barnes et al. Nature Nanotechnology (2014) published online 11 May 2014, doi:10.1038/nnano.2014.84; Coelho et al., N Engl J Med 2013; 369:819-29; Aleku et al., Cancer Res., 68(23): 9788-98 (Dec. 1, 2008), Strumberg et al., Int. J. Clin. Pharmacol. Ther., 50(1): 76-8 (January 2012), Schultheis et al., J. Clin. Oncol., 32(36): 4141-48 (Dec. 20, 2014), and Fehring et al., Mol. Ther., 22(4): 811-20 (Apr. 22, 2014); Novobrantseva, Molecular Therapy—Nucleic Acids (2012) 1, e4; doi:10.1038/mtna.2011.3; WO2012135025; US 20140348900; US 20140328759; US 20140308304; WO 2005/105152; WO 2006/069782; WO 2007/121947; US 2015/082080; US 20120251618; 7,982,027; 7,799,565; 8,058,069; 8,283,333; 7,901,708; 7,745,651; 7,803,397; 8,101,741; 8,188,263; 7,915,399; 8,236,943 and 7,838,658 and European Pat. Nos 1766035; 1519714; 1781593 and 1664316.

Liposomes

In some embodiments, a lipid particle may be liposome. Liposomes are spherical vesicle structures composed of a uni- or multilamellar lipid bilayer surrounding internal aqueous compartments and a relatively impermeable outer lipophilic phospholipid bilayer. In some embodiments, liposomes are biocompatible, nontoxic, can deliver both hydrophilic and lipophilic drug molecules, protect their cargo from degradation by plasma enzymes, and transport their load across biological membranes and the blood brain barrier (BBB).

Liposomes can be made from several different types of lipids, e.g., phospholipids. A liposome may comprise natural phospholipids and lipids such as 1,2-distearoryl-sn-glycero-3-phosphatidyl choline (DSPC), sphingomyelin, egg phosphatidylcholines, monosialoganglioside, or any combination thereof.

Several other additives may be added to liposomes in order to modify their structure and properties. For instance, liposomes may further comprise cholesterol, sphingomyelin, and/or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), e.g., to increase stability and/or to prevent the leakage of the liposomal inner cargo.

In some embodiments, a liposome delivery vehicle can be used to deliver a virus particle containing a CRISPR-Cas system and/or component(s) thereof. In some embodiments, the virus particle(s) can be adsorbed to the liposome, such as through electrostatic interactions, and/or can be attached to the liposomes via a linker.

In some embodiments, the liposome can be a Trojan Horse liposome (also known in the art as Molecular Trojan Horses), see e.g. http://cshprotocols.cshlp.org/content/2010/4/pdb.prot5407.long, the teachings of which can be applied and/or adapted to generated and/or deliver the CRISPR-Cas systems described herein.

Other non-limiting, exemplary liposomes can be those as set forth in Wang et al., ACS Synthetic Biology, 1, 403-07 (2012); Wang et al., PNAS, 113(11) 2868-2873 (2016); Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi:10.1155/2011/469679; WO 2008/042973; U.S. Pat. No. 8,071,082; WO 2014/186366; 20160257951; US20160129120; US 20160244761; 20120251618; WO2013/093648; Lipofectin (a combination of DOTMA and DOPE), Lipofectase, LIPOFECTAMINE® (e.g., LIPOFECTAMINE® 2000, LIPOFECTAMINE® 3000, LIPOFECTAMINE® RNAiMAX, LIPOFECTAMINE® LTX), SAINT-RED (Synvolux Therapeutics, Groningen Netherlands), DOPE, Cytofectin (Gilead Sciences, Foster City, Calif.), and Eufectins (JBL, San Luis Obispo, Calif.).

Stable Nucleic-Acid-Lipid Particles (SNALPs)

In some embodiments, the lipid particles may be stable nucleic acid lipid particles (SNALPs). SNALPs may comprise an ionizable lipid (DLinDMA) (e.g., cationic at low pH), a neutral helper lipid, cholesterol, a diffusible polyethylene glycol (PEG)-lipid, or any combination thereof. In some examples, SNALPs may comprise synthetic cholesterol, dipalmitoylphosphatidylcholine, 3-N-[(w-methoxy polyethylene glycol)2000)carbamoyl]-1,2-dimyrestyloxypropylamine, and cationic 1,2-dilinoleyloxy-3-N,Ndimethylaminopropane. In some examples, SNALPs may comprise synthetic cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, PEG-cDMA, and 1,2-dilinoleyloxy-3-(N;N-dimethyl)aminopropane (DLinDMAo).

Other non-limiting, exemplary SNALPs that can be used to deliver the CRISPR-Cas systems described herein can be any such SNALPs as described in Morrissey et al., Nature Biotechnology, Vol. 23, No. 8, August 2005, Zimmerman et al., Nature Letters, Vol. 441, 4 May 2006; Geisbert et al., Lancet 2010; 375: 1896-905; Judge, J. Clin. Invest. 119:661-673 (2009); and Semple et al., Nature Niotechnology, Volume 28 Number 2 Feb. 2010, pp. 172-177.

Other Lipids

The lipid particles may also comprise one or more other types of lipids, e.g., cationic lipids, such as amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA), DLin-KC2-DMA4, C12-200 and colipids disteroylphosphatidyl choline, cholesterol, and PEG-DMG.

In some embodiments, the delivery vehicle can be or include a lipidoid, such as any of those set forth in, for example, US 20110293703.

In some embodiments, the delivery vehicle can be or include an amino lipid, such as any of those set forth in, for example, Jayaraman, Angew. Chem. Int. Ed. 2012, 51, 8529-8533.

In some embodiments, the delivery vehicle can be or include a lipid envelope, such as any of those set forth in, for example, Korman et al., 2011. Nat. Biotech. 29:154-157.

Lipoplexes/Polyplexes

In some embodiments, the delivery vehicles comprise lipoplexes and/or polyplexes. Lipoplexes may bind to negatively charged cell membrane and induce endocytosis into the cells. Examples of lipoplexes may be complexes comprising lipid(s) and non-lipid components. Examples of lipoplexes and polyplexes include FuGENE-6 reagent, a non-liposomal solution containing lipids and other components, zwitterionic amino lipids (ZALs), Ca2

(e.g., forming DNA/Ca²⁺ microcomplexes), polyethenimine (PEI) (e.g., branched PEI), and poly(L-lysine) (PLL).

Sugar-Based Particles

In some embodiments, the delivery vehicle can be a sugar-based particle. In some embodiments, the sugar-based particles can be or include GalNAc, such as any of those described in WO2014118272; US 20020150626; Nair, J K et al., 2014, Journal of the American Chemical Society 136 (49), 16958-16961; Østergaard et al., Bioconjugate Chem., 2015, 26 (8), pp 1451-1455;

Cell Penetrating Peptides

In some embodiments, the delivery vehicles comprise cell penetrating peptides (CPPs). CPPs are short peptides that facilitate cellular uptake of various molecular cargo (e.g., from nanosized particles to small chemical molecules and large fragments of DNA).

CPPs may be of different sizes, amino acid sequences, and charges. In some examples, CPPs can translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or an organelle. CPPs may be introduced into cells via different mechanisms, e.g., direct penetration in the membrane, endocytosis-mediated entry, and translocation through the formation of a transitory structure.

CPPs may have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively. A third class of CPPs are the hydrophobic peptides, containing only apolar residues, with low net charge or have hydrophobic amino acid groups that are crucial for cellular uptake. Another type of CPPs is the trans-activating transcriptional activator (Tat) from Human Immunodeficiency Virus 1 (HIV-1). Examples of CPPs include to Penetratin, Tat (48-60), Transportan, and (R-AhX-R4) (Ahx refers to aminohexanoyl), Kaposi fibroblast growth factor (FGF) signal peptide sequence, integrin β3 signal peptide sequence, polyarginine peptide Args sequence, Guanine rich-molecular transporters, and sweet arrow peptide. Examples of CPPs and related applications also include those described in U.S. Pat. No. 8,372,951.

CPPs can be used for in vitro and ex vivo work quite readily, and extensive optimization for each cargo and cell type is usually required. In some examples, CPPs may be covalently attached to the Cas protein directly, which is then complexed with the gRNA and delivered to cells. In some examples, separate delivery of CPP-Cas and CPP-gRNA to multiple cells may be performed. CPP may also be used to delivery RNPs.

CPPs may be used to deliver the compositions and systems to plants. In some examples, CPPs may be used to deliver the components to plant protoplasts, which are then regenerated to plant cells and further to plants.

DNA Nanoclews

In some embodiments, the delivery vehicles comprise DNA nanoclews. A DNA nanoclew refers to a sphere-like structure of DNA (e.g., with a shape of a ball of yarn). The nanoclew may be synthesized by rolling circle amplification with palindromic sequences that aide in the self-assembly of the structure. The sphere may then be loaded with a payload. An example of DNA nanoclew is described in Sun W et al, J Am Chem Soc. 2014 Oct. 22; 136(42):14722-5; and Sun W et al, Angew Chem Int Ed Engl. 2015 Oct. 5; 54(41):12029-33. DNA nanoclew may have a palindromic sequences to be partially complementary to the gRNA within the Cas:gRNA ribonucleoprotein complex. A DNA nanoclew may be coated, e.g., coated with PEI to induce endosomal escape.

Metal Nanoparticles

In some embodiments, the delivery vehicles comprise gold nanoparticles (also referred to AuNPs or colloidal gold). Gold nanoparticles may form complex with cargos, e.g., Cas:gRNA RNP. Gold nanoparticles may be coated, e.g., coated in a silicate and an endosomal disruptive polymer, PAsp(DET). Examples of gold nanoparticles include AuraSense Therapeutics' Spherical Nucleic Acid (SNA™) constructs, and those described in Mout R, et al. (2017). ACS Nano 11:2452-8; Lee K, et al. (2017). Nat Biomed Eng 1:889-901. Other metal nanoparticles can also be complexed with cargo(s). Such metal particles include, tungsten, palladium, rhodium, platinum, and iridium particles. Other non-limiting, exemplary metal nanoparticles are described in US 20100129793.

iTOP

In some embodiments, the delivery vehicles comprise iTOP. iTOP refers to a combination of small molecules drives the highly efficient intracellular delivery of native proteins, independent of any transduction peptide. iTOP may be used for induced transduction by osmocytosis and propanebetaine, using NaCl-mediated hyperosmolality together with a transduction compound (propanebetaine) to trigger macropinocytotic uptake into cells of extracellular macromolecules. Examples of iTOP methods and reagents include those described in D'Astolfo D S, Pagliero R J, Pras A, et al. (2015). Cell 161:674-690.

Polymer-Based Particles

In some embodiments, the delivery vehicles may comprise polymer-based particles (e.g., nanoparticles). In some embodiments, the polymer-based particles may mimic a viral mechanism of membrane fusion. The polymer-based particles may be a synthetic copy of Influenza virus machinery and form transfection complexes with various types of nucleic acids ((siRNA, miRNA, plasmid DNA or shRNA, mRNA) that cells take up via the endocytosis pathway, a process that involves the formation of an acidic compartment. The low pH in late endosomes acts as a chemical switch that renders the particle surface hydrophobic and facilitates membrane crossing. Once in the cytosol, the particle releases its payload for cellular action. This Active Endosome Escape technology is safe and maximizes transfection efficiency as it is using a natural uptake pathway. In some embodiments, the polymer-based particles may comprise alkylated and carboxyalkylated branched polyethylenimine. In some examples, the polymer-based particles are VIROMER, e.g., VIROMER RNAi, VIROMER RED, VIROMER mRNA, VIROMER CRISPR. Example methods of delivering the systems and compositions herein include those described in Bawage S S et al., Synthetic mRNA expressed Cas13a mitigates RNA virus infections, www.biorxiv.org/content/10.1101/370460v1.full doi: doi.org/10.1101/370460, Viromer® RED, a powerful tool for transfection of keratinocytes. doi: 10.13140/RG.2.2.16993.61281, Viromer® Transfection—Factbook 2018: technology, product overview, users' data., doi:10.13140/RG.2.2.23912.16642. Other exemplary and non-limiting polymeric particles are described in US 20170079916, US 20160367686, US 20110212179, US 20130302401, 6,007,845, 5,855,913, 5,985,309, 5,543,158, WO2012135025, US 20130252281, US 20130245107, US 20130244279; US 20050019923, 20080267903.

Streptolysin O (SLO)

The delivery vehicles may be streptolysin O (SLO). SLO is a toxin produced by Group A streptococci that works by creating pores in mammalian cell membranes. SLO may act in a reversible manner, which allows for the delivery of proteins (e.g., up to 100 kDa) to the cytosol of cells without compromising overall viability. Examples of SLO include those described in Sierig G, et al. (2003). Infect Immun 71:446-55; Walev I, et al. (2001). Proc Natl Acad Sci USA 98:3185-90; Teng K W, et al. (2017). Elife 6:e25460.

Multifunctional Envelope-Type Nanodevice (MEND)

The delivery vehicles may comprise multifunctional envelope-type nanodevice (MENDs). MENDs may comprise condensed plasmid DNA, a PLL core, and a lipid film shell. A MEND may further comprise cell-penetrating peptide (e.g., stearyl octaarginine). The cell penetrating peptide may be in the lipid shell. The lipid envelope may be modified with one or more functional components, e.g., one or more of: polyethylene glycol (e.g., to increase vascular circulation time), ligands for targeting of specific tissues/cells, additional cell-penetrating peptides (e.g., for greater cellular delivery), lipids to enhance endosomal escape, and nuclear delivery tags. In some examples, the MEND may be a tetra-lamellar MEND (T-MEND), which may target the cellular nucleus and mitochondria. In certain examples, a MEND may be a PEG-peptide-DOPE-conjugated MEND (PPD-MEND), which may target bladder cancer cells. Examples of MENDs include those described in Kogure K, et al. (2004). J Control Release 98:317-23; Nakamura T, et al. (2012). Acc Chem Res 45:1113-21.

Cargo Polynucleotides

The engineered muscle-specific delivery system polynucleotides, viral capsid polynucleotides, other AAV polynucleotide(s), and/or vector polynucleotides, virus particles, and/or non-vector delivery vehicles can contain one or more cargo polynucleotides. In some embodiments, the one or more cargo polynucleotides are operably linked to the engineered muscle-specific delivery system polynucleotides(s) and is, in some embodiments, be part of the engineered viral genome of an engineered viral system of the present invention. The cargo polynucleotides can be packaged into an engineered virus particle, which can be delivered to, e.g., a cell. In some embodiments, the cargo polynucleotide can be capable of modifying a polynucleotide (e.g. gene or transcript) of a cell to which it is delivered. In some embodiments, the cargo is a polynucleotide that encodes a replacement polypeptide to correct for a defective polypeptide. As used herein, “gene” can refer to a hereditary unit corresponding to a sequence of DNA that occupies a specific location on a chromosome and that contains the genetic instruction for a characteristic(s) or trait(s) in an organism. The term gene can refer to translated and/or untranslated regions of a genome. “Gene” can refer to the specific sequence of DNA that is transcribed into an RNA transcript that can be translated into a polypeptide or be a catalytic RNA molecule, including but not limited to, tRNA, siRNA, piRNA, miRNA, long-non-coding RNA and shRNA. Polynucleotide, gene, transcript, etc. modification includes all genetic engineering techniques including, but not limited to, gene editing as well as conventional recombinational gene modification techniques (e.g. whole or partial gene insertion, deletion, and mutagenesis (e.g. insertional and deletional mutagenesis) techniques.

In some embodiments, the cargo molecule is a polynucleotide that is or can encode a vaccine. In some embodiments, the vaccine can stimulate an immune response against a cancer. In some embodiments, the vaccine can stimulate an immune response against colorectal or pancreatic cancer. In some embodiments, the vaccine can create an unstable environment for hCG-producing cells, such as hCG producing cancer cells.

In some embodiments the cargo is a polynucleotide that itself or a product thereof can be effective to treat a muscle disease or a symptom thereof.

Gene Modification Cargo Polynucleotides

In some embodiments, the cargo molecule can be a polynucleotide or polypeptide that can alone or when delivered as part of a system, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered. Such systems include, but are not limited to, CRISPR-Cas systems. Other gene modification systems, e.g. TALENs, Zinc Finger nucleases, Cre-Lox, morpholinos, etc. are other non-limiting examples of gene modification systems whose one or more components can be delivered by the engineered AAV particles described herein.

In some embodiments, the cargo molecule is a gene editing system or component thereof. In some embodiments, the cargo molecule is a CRISPR-Cas system molecule or a component thereof. In some embodiments, the cargo molecule is a polynucleotide that encodes one or more components of a gene modification system (such as a CRISPR-Cas system). In some embodiments, the cargo molecule is a gRNA.

In some embodiments, the cargo molecule can be a polynucleotide or polypeptide that can alone or when delivered as part of a system, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered, is such that it treats or prevents a disease, a disorder, or a symptom thereof of a muscle or skeletal disorder, a neurologic disease or disorder, and/or viruses (such as single stranded RNA viruses). In some embodiments, the cargo molecule, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered, is such that it treats or prevents, a progeroid disease (e.g. progeroid laminopathy) a glycogen storage disease an immune disorder (such as an autoimmune disease), a cancer, Duchenne muscular dystrophy (DMD), 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe disease, or other CNS-related diseases such as Huntington's and other expanded repeat diseases.

In some embodiments, the cargo molecule, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered, is such that can modify the GAA gene, such as any of those described in US Pat. App. Pub. 20190284555, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

In some embodiments, the cargo molecule includes an oligonucleotide coupled to a MHCK7, CK8, or other muscle specific promoter.

In some embodiments, the cargo molecule is a micro-dystrophin oligonucleotide that contains only selected regions of the dystrophin gene optimized for protein functionality. In some embodiments, the selected regions include spectrin-like repeats 1, 2, 3, and 24. See e.g. Harper S Q, Hauser M A, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002; 8(3):253-261. In some embodiments, the micro-dystrophin oligonucleotide is that is delivered by the rAAV agent known as AAVrh74.MHCK7 microdystrophin gene or SRP-9001, which is subject to the clinical trials NCT03375164 and NCT03769116. This microdystrophin gene construct includes NT-H1-R1-R2-R3-H2-R24-H4-CR-CT. In some embodiments, the microdystrophin gene includes ABD-H1-R1-R2-R3-H2-R24-H4-CR-CT. In some embodiments, the microdystrophin gene includes H stands for hinge region. England S B, et al. Nature. 1990; 343(6254):180-182; Wells D J, et al. Hum Mol Genet. 1995; 4(8):1245-1250, Salva M Z, et al. Mol Ther. 2007; 15(2):320-329; Mendell J R, et al. Neurosci Lett. 2012; 527(2):90-99; Rodino-Klapac L R, et al. Hum Mol Genet. 2013; 22(24):4929-4937; Velazquez V M, et al. Mol Ther Methods Clin Dev. 2017; 4:159-168; Harper S Q, et al. Nat Med. 2002; 8(3):253-261; Nelson D M, et al. Hum Mol Genet. 2018; 27(12):2090-2100. In some embodiments, the selected regions at least include spectrin-like repeats 2 and 3. In some embodiments, the micro-dystrophin gene contains a nNOS domain. In some embodiments, the nNOS domain is composed of spectrin-like repeats 16 and/or 17. In some embodiments, the micro-dystrophin gene includes spectrin-like repeats 16 and 17. In some embodiments, the nNOS domain is composed of spectrin-like repeats R1, R16, R17, R23, and R24. In some embodiments, the micro-dystrophin gene is coupled to a muscle specific promoter. In some embodiments, the micro-dystrophin oligonucleotide is coupled to a MHCK7, CK8, SNP18, SP0033, SP0051, SP0173, tmCK, or another muscle specific promoter.

In some embodiments, the cargo microdystrophin includes an ABD (actin binding domain), one or more hinge regions (e.g. H1, H2, H3, H4), and one or more spectrin-like repeats (e.g. R1, R1′ R2, R3, R16, R17, R20, R21, R22, R23, R24, R24′ and optionally a dystroglycan binding domain (DBD). In some embodiments, the microdystrophin is composed of ABD-H1-R1-R16-R17-R23-R24-H4-DBD. In some embodiments, the microdystrophin is composed of ABD-H1-R1-R2-R3-H2-R24-H4-CR. In some embodiments, the microdystrophin gene includes ABD-H1-R1-R2-R3-H2-R24-H4-CR-CT. In some embodiments, the microdystrophin gene includes ABD-H1-R1′-R24′-H4-CR-CT.

In some embodiments, the cargo molecule is a polynucleotide that can encode a microdystrophin gene, where the microdystrophin gene contains spectrin-like repeats, R1, R16, R17, R23 and R24. In some embodiments, the microdystrophin gene contains hinge region (H) 4 and/or H1. In some embodiments, the microdystrophin gene contains the N-terminal actin binding domain. In some embodiments, the microdystrophin gene contains the C-terminal dystroglycan binding domain of the human full-length dystrophin protein. The micro-dystrophin gene can contain an nNOS domain. In some embodiments, the nNOS domain is composed of spectrin-like repeats 16 and/or 17. In some embodiments, the micro-dystrophin gene includes spectrin-like repeats 16 and 17. The microdystrophin gene can be as described in WO2019118806A1 and WO2016/115543, which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention. In some embodiments, the cargo polynucleotide can encode a 5-repeat microdystrophin protein that contains, from N- to C-terminus, the N-terminal actin binding domain, Hinge region 1 (H1), spectrin-like repeats R1, R16, R17, R23, and R24, Hinge region 4 (H4), and the C-terminal dystroglycan binding domain of the human full-length dystrophin protein. The protein sequence of this 5-repeat microdystrophin and the related dystrophin minigene are described in WO2016/115543. In some embodiments, the cargo polynucleotide can correspond to a microdystrophin gene that is part of the agent known as SGT001 as currently in clinical trial having the identifier number NCT03368742.

In some embodiments, the cargo molecule is a minidys gene or vector. In some embodiments, the minidys gene or vector can be composed of ABD-H1-R1-R2-R3-R16-R17-H3-R20-R21; ABD-H1-R1-R2-R3-R16-R17-H3-R20-R21-R22-R23-R24-H4-CR; or H3-R20-R21-R22-R23-R24-H4-CR-CT.

In some embodiments, the cargo molecule is an SCGB cDNA. In some embodiments, the SGCB cDNA is coupled to a MHCK7, CK8 promoter, SNP18 promoter, SP0033 promoter, SP0051, SP0173 promoter, tmCK promoter or another muscle specific promoter. In some embodiments, the cargo molecule is a beta-sarcoglycan cDNA, an alpha-sarcoglycan cDNA, a dysferlin cDNA, a gamma-sarcoglycan cDNA, a Calpin-3 cDNA, a SGSH cDNA (e.g., LYS-SAF302), a neurtropin 3 cDNA, an anoctamin-5 cDNA, or any combination thereof.

In some embodiments, the cargo molecule, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered, is such that treat, prevent, and/or modify a gene or gene product associated with an expanded repeat disease, such as Huntington's disease, such as those described in U.S. Pat. App. Pub. 20190100755, U.S. patent Ser. No. 10/066,228, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

In some embodiments, the cargo molecule is an antisense oligomer or RNA molecule, such as those described in U.S. Pat. App. Pub. US20160251398, US20150267202, US20190015440, US20140287983, US20180216111, WO/2017/062835, US20190177723, US20170051278, US20180271893, WO/2016/14965, U.S. patent Ser. No. 10/076,536, WO/2018/00580, WO/2018/11866, WO/2019/059973, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

In some embodiments, the cargo molecule, whether or not delivered with other components of the system, operate to modify the genome, epigenome, and/or transcriptome of a cell to which it is delivered, is such that it treats or prevents a single stranded RNA virus, such influenza, West Nile Virus, SARS, Hepatitis C, dengue fever, Ebola, Marburg, and/or Calicivirus. In some embodiments the cargo molecule can be an antisense antiviral compound, such as any of those described in U.S. Pat. No. 8,703,735B2, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

Additional, exemplary genetic and gene associated diseases and genes capable of being modified by a cargo molecule described herein are listed elsewhere herein, see e.g. Tables A-B.

In some embodiments, the cargo molecule can add or modify a GALGT2 gene. Instead of acting to resupply missing dystrophin, GALGT2 gene therapy fortifies the structural integrity of muscle in ways that compensate for the absence of dystrophin, by increasing expression of proteins not mutated or lost in the disease. GALGT2 offers the potential to treat DMD irrespective of specific dystrophin mutation, as well as having utility in other muscular dystrophies.

In some embodiments, the cargo molecule is a morpholino, such as in US20180161359, US20190054113 the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention. In some embodiments, the morpholino is a morpholino oligomer (PMO) or a peptide linked morpholino PPMO. PMO based platforms can be used to treat genetic diseases by altering mRNA transcription. PMOs are synthetic chemical structures modeled after the natural framework of RNA. While PMOs have the same nucleic acid bases found in RNA, they are bound to six-sided morpholine rings instead of five-sided ribose rings. In addition, the morpholine rings are connected to each other by phosphorodiamidate linkages instead of the phosphodiester linkages found in RNA. PMOs and PPMOs can be used for exon skipping and translation suppression.

In some embodiments, the cargo molecule can be a peptide-oligomer, conjugate as described in e.g. WO2017106304A1, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

In some embodiments, the morpholino is the morpholino found in Eteplirsen, which can be effective to target Exon 51 of the dystrophin mRNA. In some embodiments, the cargo molecule can generate exon skipping in the context of DMD, such as those described in e.g. US20140315977A1, US2018010581, the contents of which are incorporated by reference as if expressed in their entirety herein and can be adapted for use with the present invention.

Exon Skipping

In some embodiments, the nucleotide sequences may encode nucleic acids capable of inducing exon skipping. Such encoded nucleic acids may be antisense oligonucleotides or antisense nucleotide systems. As used herein, the term “exon skipping” refers to the modification of pre-mRNA splicing by the targeting of splice donor and/or acceptor sites within a pre-mRNA with one or more complementary antisense oligonucleotide(s) (AONs). By blocking access of a spliceosome to one or more splice donor or acceptor site, an AON may prevent a splicing reaction thereby causing the deletion of one or more exons from a fully-processed mRNA. Exon skipping may be achieved in the nucleus during the maturation process of pre-mRNAs. In some examples, exon skipping may include the masking of key sequences involved in the splicing of targeted exons by using antisense oligonucleotides (AON) that are complementary to splice donor sequences within a pre-mRNA.

In some embodiments, the nucleotide sequences encode antisense oligonucleotides or antisense nucleotide systems capable of inducing exon skipping in dystrophin mRNA. For example, a non-sense or frameshift mutation within exon x of a dystrophin gene yields a carboxy-terminally truncated, non-functional dystrophin protein. The expression of that mature mRNA transcript may yield a functional dystrophin protein that is deleted in the amino acids encoded by exon x but that includes dystrophin amino acids both N-terminal and C-terminal to those deleted amino acids.

The nucleotide sequences may encode antisense oligonucleotides or antisense nucleotide systems capable of inducing exon skipping at exon 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 45, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or any combination thereof. In some embodiments, nucleotide sequences may encode antisense oligonucleotides or antisense nucleotide systems capable of inducing exon skipping at exon 43, 44, 50, 51, 52, 55, or any combination thereof.

CRISPR-Cas System Cargo Molecules

In general, a CRISPR-Cas or CRISPR system as used in herein and in documents, such as WO 2014/093622 (PCT/US2013/074667), refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a “direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a “spacer” in the context of an endogenous CRISPR system), or “RNA(s)” as that term is herein used (e.g., RNA(s) to guide Cas, such as Cas9, e.g. CRISPR RNA and transactivating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA)) or other sequences and transcripts from a CRISPR locus. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). See, e.g., Shmakov et al. (2015) “Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems”, Molecular Cell, DOI: dx.doi.org/10.1016/j.molcel.2015.10.008.

Class 1 Systems

The methods, systems, and tools provided herein may be designed for use with Class 1 CRISPR proteins. In certain example embodiments, the Class 1 system may be Type I, Type III or Type IV Cas proteins as described in Makarova et al. “Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants” Nature Reviews Microbiology, 18:67-81 (February 2020)., incorporated in its entirety herein by reference, and particularly as described in FIG. 1, p. 326. The Class 1 systems typically use a multi-protein effector complex, which can, in some embodiments, include ancillary proteins, such as one or more proteins in a complex referred to as a CRISPR-associated complex for antiviral defense (Cascade), one or more adaptation proteins (e.g. Cas1, Cas2, RNA nuclease), and/or one or more accessory proteins (e.g. Cas 4, DNA nuclease), CRISPR associated Rossman fold (CARF) domain containing proteins, and/or RNA transcriptase. Although Class 1 systems have limited sequence similarity, Class 1 system proteins can be identified by their similar architectures, including one or more Repeat Associated Mysterious Protein (RAMP) family subunits, e.g. Cas 5, Cas6, Cas7. RAMP proteins are characterized by having one or more RNA recognition motif domains. Large subunits (for example cas8 or cas10) and small subunits (for example, cast 1) are also typical of Class 1 systems. See, e.g., FIGS. 1 and 2. Koonin E V, Makarova K S. 2019 Origins and evolution of CRISPR-Cas systems. Phil. Trans. R. Soc. B 374: 20180087, DOI: 10.1098/rstb.2018.0087. In one aspect, Class 1 systems are characterized by the signature protein Cas3. The Cascade in particular Class1 proteins can comprise a dedicated complex of multiple Cas proteins that binds pre-crRNA and recruits an additional Cas protein, for example Cas6 or Cas5, which is the nuclease directly responsible for processing pre-crRNA. In one aspect, the Type I CRISPR protein comprises an effector complex comprises one or more Cas5 subunits and two or more Cas7 subunits. Class 1 subtypes include Type I-A, I-B, I-C, I-U, I-D, I-E, and I-F, Type IV-A and IV-B, and Type III-A, III-D, III-C, and III-B. Class 1 systems also include CRISPR-Cas variants, including Type I-A, I-B, I-E, I-F and I-U variants, which can include variants carried by transposons and plasmids, including versions of subtype I-F encoded by a large family of Tn7-like transposon and smaller groups of Tn7-like transposons that encode similarly degraded subtype I-B systems. Peters et al., PNAS 114 (35) (2017); DOI: 10.1073/pnas.1709035114; see also, Makarova et al, the CRISPR Journal, v. 1, n5, FIG. 5.

Class 2 Systems

The compositions, systems, and methods described in greater detail elsewhere herein can be designed and adapted for use with Class 2 CRISPR-Cas systems. Thus, in some embodiments, the CRISPR-Cas system is a Class 2 CRISPR-Cas system. Class 2 systems are distinguished from Class 1 systems in that they have a single, large, multi-domain effector protein. In certain example embodiments, the Class 2 system can be a Type II, Type V, or Type VI system, which are described in Makarova et al. “Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants” Nature Reviews Microbiology, 18:67-81 (February 2020), incorporated herein by reference. Each type of Class 2 system is further divided into subtypes. See Markova et al. 2020, particularly at Figure. 2. Class 2, Type II systems can be divided into 4 subtypes: II-A, II-B, II-C1, and II-C2. Class 2, Type V systems can be divided into 17 subtypes: V-A, V-B1, V-B2, V-C, V-D, V-E, V-F1, V-F1 (V-U3), V-F2, V-F3, V-G, V-H, V-I, V-K (V-U5), V-U1, V-U2, and V-U4. Class 2, Type IV systems can be divided into 5 subtypes: VI-A, VI-B1, VI-B2, VI-C, and VI-D.

The distinguishing feature of these types is that their effector complexes consist of a single, large, multi-domain protein. Type V systems differ from Type II effectors (e.g., Cas9), which contain two nuclear domains that are each responsible for the cleavage of one strand of the target DNA, with the HNH nuclease inserted inside the RuvC-like nuclease domain sequence. The Type V systems (e.g., Cas12) only contain a RuvC-like nuclease domain that cleaves both strands. Type VI (Cas13) are unrelated to the effectors of Type II and V systems and contain two HEPN domains and target RNA. Cas13 proteins also display collateral activity that is triggered by target recognition. Some Type V systems have also been found to possess this collateral activity with two single-stranded DNA in in vitro contexts.

In some embodiments, the Class 2 system is a Type II system. In some embodiments, the Type II CRISPR-Cas system is a II-A CRISPR-Cas system. In some embodiments, the Type II CRISPR-Cas system is a II-B CRISPR-Cas system. In some embodiments, the Type II CRISPR-Cas system is a II-C1 CRISPR-Cas system. In some embodiments, the Type II CRISPR-Cas system is a II-C2 CRISPR-Cas system. In some embodiments, the Type II system is a Cas9 system. In some embodiments, the Type II system includes a Cas9.

In some embodiments, the Class 2 system is a Type V system. In some embodiments, the Type V CRISPR-Cas system is a V-A CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-B1 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-B2 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-C CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-D CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-E CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-F1 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-F1 (V-U3) CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-F2 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-F3 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-G CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-H CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-I CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-K (V-U5) CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-U1 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-U2 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system is a V-U4 CRISPR-Cas system. In some embodiments, the Type V CRISPR-Cas system includes a Cas12a (Cpfl), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas14, and/or CasΦ.

In some embodiments, the Class 2 system is a Type VI system. In some embodiments, the Type VI CRISPR-Cas system is a VI-A CRISPR-Cas system. In some embodiments, the Type VI CRISPR-Cas system is a VI-B1 CRISPR-Cas system. In some embodiments, the Type VI CRISPR-Cas system is a VI-B2 CRISPR-Cas system. In some embodiments, the Type VI CRISPR-Cas system is a VI-C CRISPR-Cas system. In some embodiments, the Type VI CRISPR-Cas system is a VI-D CRISPR-Cas system. In some embodiments, the Type VI CRISPR-Cas system includes a Cas13a (C2c2), Cas13b (Group 29/30), Cas13c, and/or Cas13d.

Cas Molecules

In some embodiments, the cargo molecule can be or include a Cas polypeptide and/or a polynucleotide that can encode a Cas polypeptide or a fragment thereof. Any Cas molecule can be a cargo molecule. In some embodiments, the cargo molecule is Class I CRISPR-Cas system Cas polypeptide. In some embodiments, the cargo molecule is a Class II CRISPR-Cas system Cas polypeptide. In some embodiments, the Cas polypeptide is a Type I Cas polypeptides. In some embodiments, the Cas polypeptide is a Type II Cas polypeptides. In some embodiments, the Cas polypeptides is a Type III Cas polypeptide. In some embodiments, the Cas polypeptides is a Type IV Cas polypeptide. In some embodiments, the Cas polypeptides is a Type V Cas polypeptide. In some embodiments, the Cas polypeptides is a Type VI Cas polypeptide. In some embodiments, the Cas polypeptides is a Type VII Cas polypeptide. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Cas 12, Cas 12a, Cas 13a, Cas 13b, Cas 13c, Cas 13d, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologues thereof, or modified versions thereof. Other suitable Cas proteins or encoding polynucleotides that can be included as cargo are described elsewhere herein such as with discussion related to CRISPR-Cas systems.

Specialized Cas-Based Systems

In some embodiments, the system is a Cas-based system that is capable of performing a specialized function or activity. For example, the Cas protein may be fused, operably coupled to, or otherwise associated with one or more functionals domains. In certain example embodiments, the Cas protein may be a catalytically dead Cas protein (“dCas”) and/or have nickase activity. A nickase is a Cas protein that cuts only one strand of a double stranded target. In such embodiments, the dCas or nickase provide a sequence specific targeting functionality that delivers the functional domain to or proximate a target sequence. Example functional domains that may be fused to, operably coupled to, or otherwise associated with a Cas protein can be or include, but are not limited to a nuclear localization signal (NLS) domain, a nuclear export signal (NES) domain, a translational activation domain, a transcriptional activation domain (e.g. VP64, p65, MyoD1, HSF1, RTA, and SETT/9), a translation initiation domain, a transcriptional repression domain (e.g., a KRAB domain, NuE domain, NcoR domain, and a SID domain such as a SID4X domain), a nuclease domain (e.g., FokI), a histone modification domain (e.g., a histone acetyltransferase), a light inducible/controllable domain, a chemically inducible/controllable domain, a transposase domain, a homologous recombination machinery domain, a recombinase domain, an integrase domain, and combinations thereof. Methods for generating catalytically dead Cas9 or a nickase Cas9 (International Patent Publication No. WO 2014/204725, Ran et al. Cell. 2013 Sep. 12; 154(6):1380-1389), Cas12 (Liu et al. Nature Communications, 8, 2095 (2017), and Cas13 (International Patent Publication Nos. WO 2019/005884 and WO2019/060746) are known in the art and incorporated herein by reference.

In some embodiments, the functional domains can have one or more of the following activities: methylase activity, demethylase activity, translation activation activity, translation initiation activity, translation repression activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, single-strand DNA cleavage activity, double-strand DNA cleavage activity, molecular switch activity, chemical inducibility, light inducibility, and nucleic acid binding activity. In some embodiments, the one or more functional domains may comprise epitope tags or reporters. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporters include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and auto-fluorescent proteins including blue fluorescent protein (BFP).

The one or more functional domain(s) may be positioned at, near, and/or in proximity to a terminus of the effector protein (e.g., a Cas protein). In embodiments having two or more functional domains, each of the two can be positioned at or near or in proximity to a terminus of the effector protein (e.g., a Cas protein). In some embodiments, such as those where the functional domain is operably coupled to the effector protein, the one or more functional domains can be tethered or linked via a suitable linker (including, but not limited to, GlySer linkers) to the effector protein (e.g., a Cas protein). When there is more than one functional domain, the functional domains can be same or different. In some embodiments, all the functional domains are the same. In some embodiments, all of the functional domains are different from each other. In some embodiments, at least two of the functional domains are different from each other. In some embodiments, at least two of the functional domains are the same as each other.

Other suitable functional domains can be found, for example, in International Patent Publication No. WO 2019/018423.

Split CRISPR-Cas Systems

In some embodiments, the CRISPR-Cas system is a split CRISPR-Cas system. See e.g., Zetche et al., 2015. Nat. Biotechnol. 33(2): 139-142 and International Patent Publication WO 2019/018423, the compositions and techniques of which can be used in and/or adapted for use with the present invention. Split CRISPR-Cas proteins are set forth herein and in documents incorporated herein by reference in further detail herein. In certain embodiments, each part of a split CRISPR protein are attached to a member of a specific binding pair, and when bound with each other, the members of the specific binding pair maintain the parts of the CRISPR protein in proximity. In certain embodiments, each part of a split CRISPR protein is associated with an inducible binding pair. An inducible binding pair is one which is capable of being switched “on” or “off” by a protein or small molecule that binds to both members of the inducible binding pair. In some embodiments, CRISPR proteins may preferably split between domains, leaving domains intact. In particular embodiments, said Cas split domains (e.g., RuvC and HNH domains in the case of Cas9) can be simultaneously or sequentially introduced into the cell such that said split Cas domain(s) process the target nucleic acid sequence in the algae cell. The reduced size of the split Cas compared to the wild type Cas allows other methods of delivery of the systems to the cells, such as the use of cell penetrating peptides as described herein.

DNA and RNA Base Editing

In some embodiments, a polynucleotide of the present invention described elsewhere herein can be modified using a base editing system. In some embodiments, a Cas protein is connected or fused to a nucleotide deaminase. Thus, in some embodiments the Cas-based system can be a base editing system. As used herein, “base editing” refers generally to the process of polynucleotide modification via a CRISPR-Cas-based or Cas-based system that does not include excising nucleotides to make the modification. Base editing can convert base pairs at precise locations without generating excess undesired editing byproducts that can be made using traditional CRISPR-Cas systems.

In certain example embodiments, the nucleotide deaminase may be a DNA base editor used in combination with a DNA binding Cas protein such as, but not limited to, Class 2 Type II and Type V systems. Two classes of DNA base editors are generally known: cytosine base editors (CBEs) and adenine base editors (ABEs). CBEs convert a CG base pair into a TA base pair (Komor et al. 2016. Nature. 533:420-424; Nishida et al. 2016. Science. 353; and Li et al. Nat. Biotech. 36:324-327) and ABEs convert an AT base pair to a GC base pair. Collectively, CBEs and ABEs can mediate all four possible transition mutations (C to T, A to G, T to C, and G to A). Rees and Liu. 2018. Nat. Rev. Genet. 19(12): 770-788, particularly at FIGS. 1b, 2a-2c, 3a-3f , and Table 1. In some embodiments, the base editing system includes a CBE and/or an ABE. In some embodiments, a polynucleotide of the present invention described elsewhere herein can be modified using a base editing system. Rees and Liu. 2018. Nat. Rev. Gent. 19(12):770-788. Base editors also generally do not need a DNA donor template and/or rely on homology-directed repair. Komor et al. 2016. Nature. 533:420-424; Nishida et al. 2016. Science. 353; and Gaudeli et al. 2017. Nature. 551:464-471. Upon binding to a target locus in the DNA, base pairing between the guide RNA of the system and the target DNA strand leads to displacement of a small segment of ssDNA in an “R-loop”. Nishimasu et al. Cell. 156:935-949. DNA bases within the ssDNA bubble are modified by the enzyme component, such as a deaminase. In some systems, the catalytically disabled Cas protein can be a variant or modified Cas can have nickase functionality and can generate a nick in the non-edited DNA strand to induce cells to repair the non-edited strand using the edited strand as a template. Komor et al. 2016. Nature. 533:420-424; Nishida et al. 2016. Science. 353; and Gaudeli et al. 2017. Nature. 551:464-471.

Other Example Type V base editing systems are described in International Patent Publication Nos. WO 2018/213708, WO 2018/213726, and International Patent Applications No. PCT/US2018/067207, PCT/US2018/067225, and PCT/US2018/067307, each of which is incorporated herein by reference.

In certain example embodiments, the base editing system may be an RNA base editing system. As with DNA base editors, a nucleotide deaminase capable of converting nucleotide bases may be fused to a Cas protein. However, in these embodiments, the Cas protein will need to be capable of binding RNA. Example RNA binding Cas proteins include, but are not limited to, RNA-binding Cas9s such as Francisella novicida Cas9 (“FnCas9”), and Class 2 Type VI Cas systems. The nucleotide deaminase may be a cytidine deaminase or an adenosine deaminase, or an adenosine deaminase engineered to have cytidine deaminase activity. In certain example embodiments, the RNA base editor may be used to delete or introduce a post-translation modification site in the expressed mRNA. In contrast to DNA base editors, whose edits are permanent in the modified cell, RNA base editors can provide edits where finer, temporal control may be needed, for example in modulating a particular immune response. Example Type VI RNA-base editing systems are described in Cox et al. 2017. Science 358: 1019-1027, International Patent Publication Nos. WO 2019/005884, WO 2019/005886, and WO 2019/071048, and International Patent Application Nos. PCT/US20018/05179 and PCT/US2018/067207, which are incorporated herein by reference. An example FnCas9 system that may be adapted for RNA base editing purposes is described in International Patent Publication No. WO 2016/106236, which is incorporated herein by reference.

An example method for delivery of base-editing systems, including use of a split-intein approach to divide CBE and ABE into reconstitutable halves, is described in Levy et al. Nature Biomedical Engineering doi.org/10.1038/s41441-019-0505-5 (2019), which is incorporated herein by reference.

Prime Editors

In some embodiments, a polynucleotide of the present invention described elsewhere herein can be modified using a prime editing system. See e.g. Anzalone et al. 2019. Nature. 576: 149-157. Like base editing systems, prime editing systems can be capable of targeted modification of a polynucleotide without generating double stranded breaks and does not require donor templates. Further prime editing systems can be capable of all 12 possible combination swaps. Prime editing can operate via a “search-and-replace” methodology and can mediate targeted insertions, deletions, all 12 possible base-to-base conversion and combinations thereof. Generally, a prime editing system, as exemplified by PE1, PE2, and PE3 (Id.), can include a reverse transcriptase fused or otherwise coupled or associated with an RNA-programmable nickase and a prime-editing extended guide RNA (pegRNA) to facility direct copying of genetic information from the extension on the pegRNA into the target polynucleotide. Embodiments that can be used with the present invention include these and variants thereof. Prime editing can have the advantage of lower off-target activity than traditional CRIPSR-Cas systems along with few byproducts and greater or similar efficiency as compared to traditional CRISPR-Cas systems.

In some embodiments, the prime editing guide molecule can specify both the target polynucleotide information (e.g., sequence) and contain a new polynucleotide cargo that replaces target polynucleotides. To initiate transfer from the guide molecule to the target polynucleotide, the PE system can nick the target polynucleotide at a target side to expose a 3′hydroxyl group, which can prime reverse transcription of an edit-encoding extension region of the guide molecule (e.g. a prime editing guide molecule or peg guide molecule) directly into the target site in the target polynucleotide. See e.g. Anzalone et al. 2019. Nature. 576: 149-157, particularly at FIGS. 1b, 1c , related discussion, and Supplementary discussion.

In some embodiments, a prime editing system can be composed of a Cas polypeptide having nickase activity, a reverse transcriptase, and a guide molecule. The Cas polypeptide can lack nuclease activity. The guide molecule can include a target binding sequence as well as a primer binding sequence and a template containing the edited polynucleotide sequence. The guide molecule, Cas polypeptide, and/or reverse transcriptase can be coupled together or otherwise associate with each other to form an effector complex and edit a target sequence. In some embodiments, the Cas polypeptide is a Class 2, Type V Cas polypeptide. In some embodiments, the Cas polypeptide is a Cas9 polypeptide (e.g. is a Cas9 nickase). In some embodiments, the Cas polypeptide is fused to the reverse transcriptase. In some embodiments, the Cas polypeptide is linked to the reverse transcriptase.

In some embodiments, the prime editing system can be a PE1 system or variant thereof, a PE2 system or variant thereof, or a PE3 (e.g. PE3, PE3b) system. See e.g., Anzalone et al. 2019. Nature. 576: 149-157, particularly at pgs. 2-3, FIGS. 2a, 3a-3f, 4a-4b , Extended data FIGS. 3a-3b , and 4.

The peg guide molecule can be about 10 to about 200 or more nucleotides in length, such as 10 to/or 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 or more nucleotides in length. Optimization of the peg guide molecule can be accomplished as described in Anzalone et al. 2019. Nature. 576: 149-157, particularly at pg. 3, FIG. 2a-2b , and Extended Data FIGS. 5a -c.

CRISPR Associated Transposase (CAST) Systems

In some embodiments, a polynucleotide of the present invention described elsewhere herein can be modified using a CRISPR Associated Transposase (“CAST”) system. CAST system can include a Cas protein that is catalytically inactive, or engineered to be catalytically active, and further comprises a transposase (or subunits thereof) that catalyze RNA-guided DNA transposition. Such systems are able to insert DNA sequences at a target site in a DNA molecule without relying on host cell repair machinery. CAST systems can be Class1 or Class 2 CAST systems. An example Class 1 system is described in Klompe et al. Nature, doi:10.1038/s41586-019-1323, which is in incorporated herein by reference. An example Class 2 system is described in Strecker et al. Science.10/1126/science.aax9181 (2019), and PCT/US2019/066835 which are incorporated herein by reference.

Guide Sequences

In some embodiments, the cargo is or includes one or more guide molecules for a CRISPR-Cas system. The terms guide molecule, guide sequence and guide polynucleotide refer to polynucleotides capable of guiding Cas to a target genomic locus and are used interchangeably as in foregoing cited documents such as International Patent Publication No. WO 2014/093622 (PCT/US2013/074667). In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. The guide molecule can be a polynucleotide.

The ability of a guide sequence (within a nucleic acid-targeting guide RNA) to direct sequence-specific binding of a nucleic acid-targeting complex to a target nucleic acid sequence may be assessed by any suitable assay. For example, the components of a nucleic acid-targeting CRISPR system sufficient to form a nucleic acid-targeting complex, including the guide sequence to be tested, may be provided to a host cell having the corresponding target nucleic acid sequence, such as by transfection with vectors encoding the components of the nucleic acid-targeting complex, followed by an assessment of preferential targeting (e.g., cleavage) within the target nucleic acid sequence, such as by Surveyor assay (Qui et al. 2004. BioTechniques. 36(4)702-707). Similarly, cleavage of a target nucleic acid sequence may be evaluated in a test tube by providing the target nucleic acid sequence, components of a nucleic acid-targeting complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible and will occur to those skilled in the art.

In some embodiments, the guide molecule is an RNA. The guide molecule(s) (also referred to interchangeably herein as guide polynucleotide and guide sequence) that are included in the CRISPR-Cas or Cas based system can be any polynucleotide sequence having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of a nucleic acid-targeting complex to the target nucleic acid sequence. In some embodiments, the degree of complementarity, when optimally aligned using a suitable alignment algorithm, can be about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).

A guide sequence, and hence a nucleic acid-targeting guide, may be selected to target any target nucleic acid sequence. The target sequence may be DNA. The target sequence may be any RNA sequence. In some embodiments, the target sequence may be a sequence within an RNA molecule selected from the group consisting of messenger RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), micro-RNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double stranded RNA (dsRNA), non-coding RNA (ncRNA), long non-coding RNA (lncRNA), and small cytoplasmatic RNA (scRNA). In some preferred embodiments, the target sequence may be a sequence within an RNA molecule selected from the group consisting of mRNA, pre-mRNA, and rRNA. In some preferred embodiments, the target sequence may be a sequence within an RNA molecule selected from the group consisting of ncRNA, and lncRNA. In some more preferred embodiments, the target sequence may be a sequence within an mRNA molecule or a pre-mRNA molecule.

In some embodiments, a nucleic acid-targeting guide is selected to reduce the degree secondary structure within the nucleic acid-targeting guide. In some embodiments, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or fewer of the nucleotides of the nucleic acid-targeting guide participate in self-complementary base pairing when optimally folded. Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g., A. R. Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).

In certain embodiments, a guide RNA or crRNA may comprise, consist essentially of, or consist of a direct repeat (DR) sequence and a guide sequence or spacer sequence. In certain embodiments, the guide RNA or crRNA may comprise, consist essentially of, or consist of a direct repeat sequence fused or linked to a guide sequence or spacer sequence. In certain embodiments, the direct repeat sequence may be located upstream (i.e., 5′) from the guide sequence or spacer sequence. In other embodiments, the direct repeat sequence may be located downstream (i.e., 3′) from the guide sequence or spacer sequence.

In certain embodiments, the crRNA comprises a stem loop, preferably a single stem loop. In certain embodiments, the direct repeat sequence forms a stem loop, preferably a single stem loop.

In certain embodiments, the spacer length of the guide RNA is from 15 to 35 nt. In certain embodiments, the spacer length of the guide RNA is at least 15 nucleotides. In certain embodiments, the spacer length is from 15 to 17 nt, e.g., 15, 16, or 17 nt, from 17 to 20 nt, e.g., 17, 18, 19, or 20 nt, from 20 to 24 nt, e.g., 20, 21, 22, 23, or 24 nt, from 23 to 25 nt, e.g., 23, 24, or 25 nt, from 24 to 27 nt, e.g., 24, 25, 26, or 27 nt, from 27 to 30 nt, e.g., 27, 28, 29, or 30 nt, from 30 to 35 nt, e.g., 30, 31, 32, 33, 34, or 35 nt, or 35 nt or longer.

The “tracrRNA” sequence or analogous terms includes any polynucleotide sequence that has sufficient complementarity with a crRNA sequence to hybridize. In some embodiments, the degree of complementarity between the tracrRNA sequence and crRNA sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and crRNA sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin.

In general, degree of complementarity is with reference to the optimal alignment of the sca sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm and may further account for secondary structures, such as self-complementarity within either the sca sequence or tracr sequence. In some embodiments, the degree of complementarity between the tracr sequence and sca sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.

In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence can be about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or 100%; a guide or RNA or sgRNA can be about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length; or guide or RNA or sgRNA can be less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length; and tracr RNA can be 30 or 50 nucleotides in length. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is greater than 94.5% or 95% or 95.5% or 96% or 96.5% or 97% or 97.5% or 98% or 98.5% or 99% or 99.5% or 99.9%, or 100%. Off target is less than 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% or 94% or 93% or 92% or 91% or 90% or 89% or 88% or 87% or 86% or 85% or 84% or 83% or 82% or 81% or 80% complementarity between the sequence and the guide, with it being advantageous that off target is 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% complementarity between the sequence and the guide.

In some embodiments according to the invention, the guide RNA (capable of guiding Cas to a target locus) may comprise (1) a guide sequence capable of hybridizing to a genomic target locus in the eukaryotic cell; (2) a tracr sequence; and (3) a tracr mate sequence. All (1) to (3) may reside in a single RNA, i.e., an sgRNA (arranged in a 5′ to 3′ orientation), or the tracr RNA may be a different RNA than the RNA containing the guide and tracr sequence. The tracr hybridizes to the tracr mate sequence and directs the CRISPR/Cas complex to the target sequence. Where the tracr RNA is on a different RNA than the RNA containing the guide and tracr sequence, the length of each RNA may be optimized to be shortened from their respective native lengths, and each may be independently chemically modified to protect from degradation by cellular RNase or otherwise increase stability.

Many modifications to guide sequences are known in the art and are further contemplated within the context of this invention. Various modifications may be used to increase the specificity of binding to the target sequence and/or increase the activity of the Cas protein and/or reduce off-target effects. Example guide sequence modifications are described in International Patent Application No. PCT US2019/045582, specifically paragraphs [0178]-[0333]. which is incorporated herein by reference.

Target Sequences, PAMs, and PFSs Target Sequences

In the context of formation of a CRISPR complex, “target sequence” refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. A target sequence may comprise RNA polynucleotides. The term “target RNA” refers to an RNA polynucleotide being or comprising the target sequence. In other words, the target polynucleotide can be a polynucleotide or a part of a polynucleotide to which a part of the guide sequence is designed to have complementarity with and to which the effector function mediated by the complex comprising the CRISPR effector protein and a guide molecule is to be directed. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell.

The guide sequence can specifically bind a target sequence in a target polynucleotide. The target polynucleotide may be DNA. The target polynucleotide may be RNA. The target polynucleotide can have one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc. or more) target sequences. The target polynucleotide can be on a vector. The target polynucleotide can be genomic DNA. The target polynucleotide can be episomal. Other forms of the target polynucleotide are described elsewhere herein.

The target sequence may be DNA. The target sequence may be any RNA sequence. In some embodiments, the target sequence may be a sequence within an RNA molecule selected from the group consisting of messenger RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), micro-RNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double stranded RNA (dsRNA), non-coding RNA (ncRNA), long non-coding RNA (lncRNA), and small cytoplasmatic RNA (scRNA). In some preferred embodiments, the target sequence (also referred to herein as a target polynucleotide) may be a sequence within an RNA molecule selected from the group consisting of mRNA, pre-mRNA, and rRNA. In some preferred embodiments, the target sequence may be a sequence within an RNA molecule selected from the group consisting of ncRNA, and lncRNA. In some more preferred embodiments, the target sequence may be a sequence within an mRNA molecule or a pre-mRNA molecule.

PAM and PFS Elements

PAM elements are sequences that can be recognized and bound by Cas proteins. Cas proteins/effector complexes can then unwind the dsDNA at a position adjacent to the PAM element. It will be appreciated that Cas proteins and systems that include them that target RNA do not require PAM sequences (Marraffini et al. 2010. Nature. 463:568-571). Instead, many rely on PFSs, which are discussed elsewhere herein. In certain embodiments, the target sequence should be associated with a PAM (protospacer adjacent motif) or PFS (protospacer flanking sequence or site), that is, a short sequence recognized by the CRISPR complex. Depending on the nature of the CRISPR-Cas protein, the target sequence should be selected, such that its complementary sequence in the DNA duplex (also referred to herein as the non-target sequence) is upstream or downstream of the PAM. In the embodiments, the complementary sequence of the target sequence is downstream or 3′ of the PAM or upstream or 5′ of the PAM. The precise sequence and length requirements for the PAM differ depending on the Cas protein used, but PAMs are typically 2-5 base pair sequences adjacent the protospacer (that is, the target sequence). Examples of the natural PAM sequences for different Cas proteins are provided herein below and the skilled person will be able to identify further PAM sequences for use with a given Cas protein.

The ability to recognize different PAM sequences depends on the Cas polypeptide(s) included in the system. See e.g., Gleditzsch et al. 2019. RNA Biology. 16(4):504-517. Table 10 (from Gleditzsch et al. 2019) below shows several Cas polypeptides and the PAM sequence they recognize.

TABLE 10 Example PAM Sequences Cas Protein PAM Sequence SpCas9 NGG/NRG SaCas9 NGRRT or NGRRN NmeCas9 NNNNGATT CjCas9 NNNNRYAC StCas9 NNAGAAW Cas12a (Cpf1) (including TTTV LbCpf1 and AsCpf1) Cas12b (C2c1) TTT, TTA, and TTC Cas12c (C2c3) TA Cas12d (CasY) TA Cas12e (CasX) 5′-TTCN-3′

In a preferred embodiment, the CRISPR effector protein may recognize a 3′ PAM. In certain embodiments, the CRISPR effector protein may recognize a 3′ PAM which is 5′H, wherein H is A, C or U.

Further, engineering of the PAM Interacting (PI) domain on the Cas protein may allow programing of PAM specificity, improve target site recognition fidelity, and increase the versatility of the CRISPR-Cas protein, for example as described for Cas9 in Kleinstiver B P et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015 Jul. 23; 523(7561):481-5. doi: 10.1038/nature14592. As further detailed herein, the skilled person will understand that Cas13 proteins may be modified analogously. Gao et al, “Engineered Cpfl Enzymes with Altered PAM Specificities,” bioRxiv 091611; doi: http://dx.doi.org/10.1101/091611 (Dec. 4, 2016). Doench et al. created a pool of sgRNAs, tiling across all possible target sites of a panel of six endogenous mouse and three endogenous human genes and quantitatively assessed their ability to produce null alleles of their target gene by antibody staining and flow cytometry. The authors showed that optimization of the PAM improved activity and also provided an on-line tool for designing sgRNAs.

PAM sequences can be identified in a polynucleotide using an appropriate design tool, which are commercially available as well as online. Such freely available tools include, but are not limited to, CRISPRFinder and CRISPRTarget. Mojica et al. 2009. Microbiol. 155 (Pt. 3):733-740; Atschul et al. 1990. J. Mol. Biol. 215:403-410; Biswass et al. 2013 RNA Biol. 10:817-827; and Grissa et al. 2007. Nucleic Acid Res. 35:W52-57. Experimental approaches to PAM identification can include, but are not limited to, plasmid depletion assays (Jiang et al. 2013. Nat. Biotechnol. 31:233-239; Esvelt et al. 2013. Nat. Methods. 10:1116-1121; Kleinstiver et al. 2015. Nature. 523:481-485), screened by a high-throughput in vivo model called PAM-SCNAR (Pattanayak et al. 2013. Nat. Biotechnol. 31:839-843 and Leenay et al. 2016. Mol. Cell. 16:253), and negative screening (Zetsche et al. 2015. Cell. 163:759-771).

As previously mentioned, CRISPR-Cas systems that target RNA do not typically rely on PAM sequences. Instead such systems typically recognize protospacer flanking sites (PFSs) instead of PAMs Thus, Type VI CRISPR-Cas systems typically recognize protospacer flanking sites (PFSs) instead of PAMs. PFSs represents an analogue to PAMs for RNA targets. Type VI CRISPR-Cas systems employ a Cas13. Some Cas13 proteins analyzed to date, such as Cas13a (C2c2) identified from Leptotrichia shahii (LShCAs13a) have a specific discrimination against G at the 3′end of the target RNA. The presence of a C at the corresponding crRNA repeat site can indicate that nucleotide pairing at this position is rejected. However, some Cas13 proteins (e.g., LwaCAs13a and PspCas13b) do not seem to have a PFS preference. See e.g., Gleditzsch et al. 2019. RNA Biology. 16(4):504-517.

Some Type VI proteins, such as subtype B, have 5′-recognition of D (G, T, A) and a 3′-motif requirement of NAN or NNA. One example is the Cas13b protein identified in Bergeyella zoohelcum (BzCas13b). See e.g., Gleditzsch et al. 2019. RNA Biology. 16(4):504-517.

Overall Type VI CRISPR-Cas systems appear to have less restrictive rules for substrate (e.g., target sequence) recognition than those that target DNA (e.g., Type V and type II).

Sequences Related to Nucleus Targeting and Transportation

In some embodiments, one or more components (e.g., the Cas protein and/or deaminase) in the composition for engineering cells may comprise one or more sequences related to nucleus targeting and transportation. Such sequence may facilitate the one or more components in the composition for targeting a sequence within a cell. In order to improve targeting of the CRISPR-Cas protein and/or the nucleotide deaminase protein or catalytic domain thereof used in the methods of the present disclosure to the nucleus, it may be advantageous to provide one or both of these components with one or more nuclear localization sequences (NLSs).

In some embodiments, the NLSs used in the context of the present disclosure are heterologous to the proteins. Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV (SEQ ID NO: 52) or PKKKRKVEAS (SEQ ID NO: 53); the NLS from nucleoplasmin (e.g., the nucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 54)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 55) or RQRRNELKRSP (SEQ ID NO: 57); the hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 58); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 59) of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ ID NO: 9088) and PPKKARED (SEQ ID NO: 9089) of the myoma T protein; the sequence PQPKKKPL (SEQ ID NO: 9090) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: 9091) of mouse c-abl IV; the sequences DRLRR (SEQ ID NO: 9092) and PKQKKRK (SEQ ID NO: 9093) of the influenza virus NS1; the sequence RKLKKKIKKL (SEQ ID NO: 9094) of the Hepatitis virus delta antigen; the sequence REKKKFLKRR (SEQ ID NO: 9095) of the mouse Mx1 protein; the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 9096) of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: 9097) of the steroid hormone receptors (human) glucocorticoid. In general, the one or more NLSs are of sufficient strength to drive accumulation of the DNA-targeting Cas protein in a detectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR-Cas protein, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the nucleic acid-targeting protein, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g., a stain specific for the nucleus such as DAPI). Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of nucleic acid-targeting complex formation (e.g., assay for deaminase activity) at the target sequence, or assay for altered gene expression activity affected by DNA-targeting complex formation and/or DNA-targeting), as compared to a control not exposed to the CRISPR-Cas protein and deaminase protein, or exposed to a CRISPR-Cas and/or deaminase protein lacking the one or more NLSs.

The CRISPR-Cas and/or nucleotide deaminase proteins may be provided with 1 or more, such as with, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more heterologous NLSs. In some embodiments, the proteins comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g., zero or at least one or more NLS at the amino-terminus and zero or at one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. In preferred embodiments of the CRISPR-Cas proteins, an NLS attached to the C-terminal of the protein.

In certain embodiments, the CRISPR-Cas protein and the deaminase protein are delivered to the cell or expressed within the cell as separate proteins. In these embodiments, each of the CRISPR-Cas and deaminase protein can be provided with one or more NLSs as described herein. In certain embodiments, the CRISPR-Cas and deaminase proteins are delivered to the cell or expressed with the cell as a fusion protein. In these embodiments one or both of the CRISPR-Cas and deaminase protein is provided with one or more NLSs. Where the nucleotide deaminase is fused to an adaptor protein (such as MS2) as described above, the one or more NLS can be provided on the adaptor protein, provided that this does not interfere with aptamer binding. In particular embodiments, the one or more NLS sequences may also function as linker sequences between the nucleotide deaminase and the CRISPR-Cas protein.

In certain embodiments, guides of the disclosure comprise specific binding sites (e.g. aptamers) for adapter proteins, which may be linked to or fused to a nucleotide deaminase or catalytic domain thereof. When such a guide forms a CRISPR complex (e.g., CRISPR-Cas protein binding to guide and target), the adapter proteins bind and the nucleotide deaminase or catalytic domain thereof associated with the adapter protein is positioned in a spatial orientation which is advantageous for the attributed function to be effective.

The skilled person will understand that modifications to the guide which allow for binding of the adapter+nucleotide deaminase, but not proper positioning of the adapter+nucleotide deaminase (e.g. due to steric hindrance within the three-dimensional structure of the CRISPR complex) are modifications which are not intended. The one or more modified guide may be modified at the tetra loop, the stem loop 1, stem loop 2, or stem loop 3, as described herein, preferably at either the tetra loop or stem loop 2, and in some cases at both the tetra loop and stem loop 2.

In some embodiments, a component (e.g., the dead Cas protein, the nucleotide deaminase protein or catalytic domain thereof, or a combination thereof) in the systems may comprise one or more nuclear export signals (NES), one or more nuclear localization signals (NLS), or any combinations thereof. In some cases, the NES may be an HIV Rev NES. In certain cases, the NES may be MAPK NES. When the component is a protein, the NES or NLS may be at the C terminus of component. Alternatively, or additionally, the NES or NLS may be at the N terminus of component. In some examples, the Cas protein and optionally said nucleotide deaminase protein or catalytic domain thereof comprise one or more heterologous nuclear export signal(s) (NES(s)) or nuclear localization signal(s) (NLS(s)), preferably an HIV Rev NES or MAPK NES, preferably C-terminal.

Templates

In some embodiments, the composition for engineering cells comprise a template, e.g., a recombination template. A template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a nucleic acid-targeting effector protein as a part of a nucleic acid-targeting complex.

In an embodiment, the template nucleic acid alters the sequence of the target position. In an embodiment, the template nucleic acid results in the incorporation of a modified, or non-naturally occurring base into the target nucleic acid.

The template sequence may undergo a breakage mediated or catalyzed recombination with the target sequence. In an embodiment, the template nucleic acid may include sequence that corresponds to a site on the target sequence that is cleaved by a Cas protein mediated cleavage event. In an embodiment, the template nucleic acid may include a sequence that corresponds to both, a first site on the target sequence that is cleaved in a first Cas protein mediated event, and a second site on the target sequence that is cleaved in a second Cas protein mediated event.

In certain embodiments, the template nucleic acid can include a sequence which results in an alteration in the coding sequence of a translated sequence, e.g., one which results in the substitution of one amino acid for another in a protein product, e.g., transforming a mutant allele into a wild type allele, transforming a wild type allele into a mutant allele, and/or introducing a stop codon, insertion of an amino acid residue, deletion of an amino acid residue, or a nonsense mutation. In certain embodiments, the template nucleic acid can include a sequence which results in an alteration in a non-coding sequence, e.g., an alteration in an exon or in a 5′ or 3′ non-translated or non-transcribed region. Such alterations include an alteration in a control element, e.g., a promoter, enhancer, and an alteration in a cis-acting or trans-acting control element.

A template nucleic acid having homology with a target position in a target gene may be used to alter the structure of a target sequence. The template sequence may be used to alter an unwanted structure, e.g., an unwanted or mutant nucleotide. The template nucleic acid may include a sequence which, when integrated, results in decreasing the activity of a positive control element; increasing the activity of a positive control element; decreasing the activity of a negative control element; increasing the activity of a negative control element; decreasing the expression of a gene; increasing the expression of a gene; increasing resistance to a disorder or disease; increasing resistance to viral entry; correcting a mutation or altering an unwanted amino acid residue conferring, increasing, abolishing or decreasing a biological property of a gene product, e.g., increasing the enzymatic activity of an enzyme, or increasing the ability of a gene product to interact with another molecule.

The template nucleic acid may include a sequence which results in a change in sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides of the target sequence.

A template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In an embodiment, the template nucleic acid may be 20+/−10, 30+/−10, 40+/−10, 50+/−10, 60+/−10, 70+/−10, 80+/−10, 90+/−10, 100+/−10, 110+/−10, 120+/−10, 130+/−10, 140+/−10, 150+/−10, 160+/−10, 170+/−10, 180+/−10, 190+/−10, 200+/−10, 210+/−10, of 220+/−10 nucleotides in length. In an embodiment, the template nucleic acid may be 30+/−20, 40+/−20, 50+/−20, 60+/−20, 70+/−20, 80+/−20, 90+/−20, 100+/−20, 110+/−20, 120+/−20, 130+/−20, 140+/−20, I 50+/−20, 160+/−20, 170+/−20, 180+/−20, 190+/−20, 200+/−20, 210+/−20, of 220+/−20 nucleotides in length. In an embodiment, the template nucleic acid is 10 to 1,000, 20 to 900, 30 to 800, 40 to 700, 50 to 600, 50 to 500, 50 to 400, 50 to 300, 50 to 200, or 50 to 100 nucleotides in length.

In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more nucleotides). In some embodiments, when a template sequence and a polynucleotide comprising a target sequence are optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.

The exogenous polynucleotide template comprises a sequence to be integrated (e.g., a mutated gene). The sequence for integration may be a sequence endogenous or exogenous to the cell. Examples of a sequence to be integrated include polynucleotides encoding a protein or a non-coding RNA (e.g., a microRNA). Thus, the sequence for integration may be operably linked to an appropriate control sequence or sequences. Alternatively, the sequence to be integrated may provide a regulatory function.

An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000.

An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000

In certain embodiments, one or both homology arms may be shortened to avoid including certain sequence repeat elements. For example, a 5′ homology arm may be shortened to avoid a sequence repeat element. In other embodiments, a 3′ homology arm may be shortened to avoid a sequence repeat element. In some embodiments, both the 5′ and the 3′ homology arms may be shortened to avoid including certain sequence repeat elements.

In some methods, the exogenous polynucleotide template may further comprise a marker. Such a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers. The exogenous polynucleotide template of the disclosure can be constructed using recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996).

In certain embodiments, a template nucleic acid for correcting a mutation may designed for use as a single-stranded oligonucleotide. When using a single-stranded oligonucleotide, 5′ and 3′ homology arms may range up to about 200 base pairs (bp) in length, e.g., at least 25, 50, 75, 100, 125, 150, 175, or 200 bp in length.

Suzuki et al. describe in vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration (2016, Nature 540:144-149), which is incorporated by reference herein and can be adapted for use with the present invention.

TALE Nucleases

In some embodiments, a TALE nuclease or TALE nuclease system can be used to modify a polynucleotide. In some embodiments, the methods provided herein use isolated, non-naturally occurring, recombinant or engineered DNA binding proteins that comprise TALE monomers or TALE monomers or half monomers as a part of their organizational structure that enable the targeting of nucleic acid sequences with improved efficiency and expanded specificity.

Naturally occurring TALEs or “wild type TALEs” are nucleic acid binding proteins secreted by numerous species of proteobacteria. TALE polypeptides contain a nucleic acid binding domain composed of tandem repeats of highly conserved monomer polypeptides that are predominantly 33, 34 or 35 amino acids in length and that differ from each other mainly in amino acid positions 12 and 13. In advantageous embodiments the nucleic acid is DNA. As used herein, the term “polypeptide monomers”, “TALE monomers” or “monomers” will be used to refer to the highly conserved repetitive polypeptide sequences within the TALE nucleic acid binding domain and the term “repeat variable di-residues” or “RVD” will be used to refer to the highly variable amino acids at positions 12 and 13 of the polypeptide monomers. As provided throughout the disclosure, the amino acid residues of the RVD are depicted using the IUPAC single letter code for amino acids. A general representation of a TALE monomer which is comprised within the DNA binding domain is X₁₋₁₁-(X₁₂X₁₃)-X₁₄₋₃₃ or ₃₄ or ₃₅, where the subscript indicates the amino acid position and X represents any amino acid. X₁₂X₁₃ indicate the RVDs. In some polypeptide monomers, the variable amino acid at position 13 is missing or absent and in such monomers, the RVD consists of a single amino acid. In such cases the RVD may be alternatively represented as X*, where X represents X₁₂ and (*) indicates that X₁₃ is absent. The DNA binding domain comprises several repeats of TALE monomers and this may be represented as (X₁₋₁₁-(X₁₂X₁₃)-X₁₄₋₃₃ or ₃₄ or ₃₅)_(z), where in an advantageous embodiment, z is at least 5 to 40. In a further advantageous embodiment, z is at least 10 to 26.

The TALE monomers can have a nucleotide binding affinity that is determined by the identity of the amino acids in its RVD. For example, polypeptide monomers with an RVD of NI can preferentially bind to adenine (A), monomers with an RVD of NG can preferentially bind to thymine (T), monomers with an RVD of HD can preferentially bind to cytosine (C) and monomers with an RVD of NN can preferentially bind to both adenine (A) and guanine (G). In some embodiments, monomers with an RVD of IG can preferentially bind to T. Thus, the number and order of the polypeptide monomer repeats in the nucleic acid binding domain of a TALE determines its nucleic acid target specificity. In some embodiments, monomers with an RVD of NS can recognize all four base pairs and can bind to A, T, G or C. The structure and function of TALEs is further described in, for example, Moscou et al., Science 326:1501 (2009); Boch et al., Science 326:1509-1512 (2009); and Zhang et al., Nature Biotechnology 29:149-153 (2011).

The polypeptides used in methods of the invention can be isolated, non-naturally occurring, recombinant or engineered nucleic acid-binding proteins that have nucleic acid or DNA binding regions containing polypeptide monomer repeats that are designed to target specific nucleic acid sequences.

As described herein, polypeptide monomers having an RVD of HN or NH preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In some embodiments, polypeptide monomers having RVDs RN, NN, NK, SN, NH, KN, HN, NQ, HH, RG, KH, RH and SS can preferentially bind to guanine. In some embodiments, polypeptide monomers having RVDs RN, NK, NQ, HH, KH, RH, SS and SN can preferentially bind to guanine and can thus allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In some embodiments, polypeptide monomers having RVDs HH, KH, NH, NK, NQ, RH, RN and SS can preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In some embodiments, the RVDs that have high binding specificity for guanine are RN, NH RH and KH. Furthermore, polypeptide monomers having an RVD of NV can preferentially bind to adenine and guanine. In some embodiments, monomers having RVDs of H*, HA, KA, N*, NA, NC, NS, RA, and S* bind to adenine, guanine, cytosine and thymine with comparable affinity.

The predetermined N-terminal to C-terminal order of the one or more polypeptide monomers of the nucleic acid or DNA binding domain determines the corresponding predetermined target nucleic acid sequence to which the polypeptides of the invention will bind. As used herein the monomers and at least one or more half monomers are “specifically ordered to target” the genomic locus or gene of interest. In plant genomes, the natural TALE-binding sites always begin with a thymine (T), which may be specified by a cryptic signal within the non-repetitive N-terminus of the TALE polypeptide; in some cases, this region may be referred to as repeat 0. In animal genomes, TALE binding sites do not necessarily have to begin with a thymine (T) and polypeptides of the invention may target DNA sequences that begin with T, A, G or C. The tandem repeat of TALE monomers always ends with a half-length repeat or a stretch of sequence that may share identity with only the first 20 amino acids of a repetitive full-length TALE monomer and this half repeat may be referred to as a half-monomer. Therefore, it follows that the length of the nucleic acid or DNA being targeted is equal to the number of full monomers plus two.

As described in Zhang et al., Nature Biotechnology 29:149-153 (2011), TALE polypeptide binding efficiency may be increased by including amino acid sequences from the “capping regions” that are directly N-terminal or C-terminal of the DNA binding region of naturally occurring TALEs into the engineered TALEs at positions N-terminal or C-terminal of the engineered TALE DNA binding region. Thus, in certain embodiments, the TALE polypeptides described herein further comprise an N-terminal capping region and/or a C-terminal capping region.

An exemplary amino acid sequence of a N-terminal capping region is:

(SEQ ID NO: 9098) M D P I R S R T P S P A R E L L S G P Q P D G V Q P T A D R G V S P P A G G P L D G L P A R R T M S R T R L P S P P A P S P A F S A D S F S D L L R Q F D P S L F N T S L F D S L P P F G A H H T E A A T G E W D E V Q S G L R A A D A P P P T M R V A V T A A R P P R A K P A P R R R A A Q P S D A S P A A Q V D L R T L G Y S Q Q Q O E K I K P K V R S T V A Q H H E A L V G H G F T H A H I V A L S Q H P A A L G T V A V K Y Q D M I A A L P E A T H E A I V G V G K Q W S G A R A L E A L L T V A G E L R G P P L Q L D T G Q L L K I A K R G G V T A V E A V H A W R N A L T G A P L N

An exemplary amino acid sequence of a C-terminal capping region is:

(SEQ ID NO: 9099) R P A L E S I V A Q L S R P D P A L A A L T N D H L V A L A C L G G R P A L D A V K K G L P H A P A L I K R T N R R I P E R T S H R V A D H A Q V V R V L G F F Q C H S H P A Q A F D D A M T Q F G M S R H G L L Q L F R R V G V T E L E A R S G T L P P A S Q R W D R I L Q A S G M K R A K P S P T S T Q T P D Q A S L H A F A D S L E R D L D A P S P M H E G D Q T R A S

As used herein the predetermined “N-terminus” to “C terminus” orientation of the N-terminal capping region, the DNA binding domain comprising the repeat TALE monomers and the C-terminal capping region provide structural basis for the organization of different domains in the d-TALEs or polypeptides of the invention.

The entire N-terminal and/or C-terminal capping regions are not necessary to enhance the binding activity of the DNA binding region. Therefore, in certain embodiments, fragments of the N-terminal and/or C-terminal capping regions are included in the TALE polypeptides described herein.

In certain embodiments, the TALE polypeptides described herein contain a N-terminal capping region fragment that included at least 10, 20, 30, 40, 50, 54, 60, 70, 80, 87, 90, 94, 100, 102, 110, 117, 120, 130, 140, 147, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260 or 270 amino acids of an N-terminal capping region. In certain embodiments, the N-terminal capping region fragment amino acids are of the C-terminus (the DNA-binding region proximal end) of an N-terminal capping region. As described in Zhang et al., Nature Biotechnology 29:149-153 (2011), N-terminal capping region fragments that include the C-terminal 240 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 147 amino acids retain greater than 80% of the efficacy of the full length capping region, and fragments that include the C-terminal 117 amino acids retain greater than 50% of the activity of the full-length capping region.

In some embodiments, the TALE polypeptides described herein contain a C-terminal capping region fragment that included at least 6, 10, 20, 30, 37, 40, 50, 60, 68, 70, 80, 90, 100, 110, 120, 127, 130, 140, 150, 155, 160, 170, 180 amino acids of a C-terminal capping region. In certain embodiments, the C-terminal capping region fragment amino acids are of the N-terminus (the DNA-binding region proximal end) of a C-terminal capping region. As described in Zhang et al., Nature Biotechnology 29:149-153 (2011), C-terminal capping region fragments that include the C-terminal 68 amino acids enhance binding activity equal to the full-length capping region, while fragments that include the C-terminal 20 amino acids retain greater than 50% of the efficacy of the full-length capping region.

In certain embodiments, the capping regions of the TALE polypeptides described herein do not need to have identical sequences to the capping region sequences provided herein. Thus, in some embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical or share identity to the capping region amino acid sequences provided herein. Sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. In some preferred embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 95% identical or share identity to the capping region amino acid sequences provided herein.

Sequence homologies can be generated by any of a number of computer programs known in the art, which include but are not limited to BLAST or FASTA. Suitable computer programs for carrying out alignments like the GCG Wisconsin Bestfit package may also be used. Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

In some embodiments described herein, the TALE polypeptides of the invention include a nucleic acid binding domain linked to the one or more effector domains. The terms “effector domain” or “regulatory and functional domain” refer to a polypeptide sequence that has an activity other than binding to the nucleic acid sequence recognized by the nucleic acid binding domain. By combining a nucleic acid binding domain with one or more effector domains, the polypeptides of the invention may be used to target the one or more functions or activities mediated by the effector domain to a particular target DNA sequence to which the nucleic acid binding domain specifically binds.

In some embodiments of the TALE polypeptides described herein, the activity mediated by the effector domain is a biological activity. For example, in some embodiments the effector domain is a transcriptional inhibitor (i.e., a repressor domain), such as an mSin interaction domain (SID). SID4X domain or a Krüppel-associated box (KRAB) or fragments of the KRAB domain. In some embodiments, the effector domain is an enhancer of transcription (i.e., an activation domain), such as the VP16, VP64 or p65 activation domain. In some embodiments, the nucleic acid binding is linked, for example, with an effector domain that includes but is not limited to a transposase, integrase, recombinase, resolvase, invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone deacetylase, nuclease, transcriptional repressor, transcriptional activator, transcription factor recruiting, protein nuclear-localization signal or cellular uptake signal.

In some embodiments, the effector domain is a protein domain which exhibits activities which include but are not limited to transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, transcription factor recruiting activity, or cellular uptake signaling activity. Other preferred embodiments of the invention may include any combination of the activities described herein.

Meganucleases

In some embodiments, a meganuclease or system thereof can be used to modify a polynucleotide. Meganucleases, which are endodeoxyribonucleases characterized by a large recognition site (double-stranded DNA sequences of 12 to 40 base pairs). Exemplary methods for using meganucleases can be found in U.S. Pat. Nos. 8,163,514, 8,133,697, 8,021,867, 8,119,361, 8,119,381, 8,124,369, and 8,129,134, which are specifically incorporated herein by reference.

RNAi

In certain embodiments, the genetic modifying agent is RNAi (e.g., shRNA). As used herein, “gene silencing” or “gene silenced” in reference to an activity of an RNAi molecule, for example a siRNA or miRNA refers to a decrease in the mRNA level in a cell for a target gene by at least about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, about 100% of the mRNA level found in the cell without the presence of the miRNA or RNA interference molecule. In one preferred embodiment, the mRNA levels are decreased by at least about 70%, about 80%, about 90%, about 95%, about 99%, about 100%.

As used herein, the term “RNAi” refers to any type of interfering RNA, including but not limited to, siRNAi, shRNAi, endogenous microRNA and artificial microRNA. For instance, it includes sequences previously identified as siRNA, regardless of the mechanism of down-stream processing of the RNA (i.e. although siRNAs are believed to have a specific method of in vivo processing resulting in the cleavage of mRNA, such sequences can be incorporated into the vectors in the context of the flanking sequences described herein). The term “RNAi” can include both gene silencing RNAi molecules, and also RNAi effector molecules which activate the expression of a gene.

As used herein, a “siRNA” refers to a nucleic acid that forms a double stranded RNA, which double stranded RNA has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is present or expressed in the same cell as the target gene. The double stranded RNA siRNA can be formed by the complementary strands. In one embodiment, a siRNA refers to a nucleic acid that can form a double stranded siRNA. The sequence of the siRNA can correspond to the full-length target gene, or a subsequence thereof. Typically, the siRNA is at least about 15-50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is about 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, preferably about 19-30 base nucleotides, preferably about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length).

As used herein “shRNA” or “small hairpin RNA” (also called stem loop) is a type of siRNA. In one embodiment, these shRNAs are composed of a short, e.g. about 19 to about 25 nucleotide, antisense strand, followed by a nucleotide loop of about 5 to about 9 nucleotides, and the analogous sense strand. Alternatively, the sense strand can precede the nucleotide loop structure and the antisense strand can follow.

The terms “microRNA” or “miRNA” are used interchangeably herein are endogenous RNAs, some of which are known to regulate the expression of protein-coding genes at the posttranscriptional level. Endogenous microRNAs are small RNAs naturally present in the genome that are capable of modulating the productive utilization of mRNA. The term artificial microRNA includes any type of RNA sequence, other than endogenous microRNA, which is capable of modulating the productive utilization of mRNA. MicroRNA sequences have been described in publications such as Lim, et al., Genes & Development, 17, p. 991-1008 (2003), Lim et al Science 299, 1540 (2003), Lee and Ambros Science, 294, 862 (2001), Lau et al., Science 294, 858-861 (2001), Lagos-Quintana et al, Current Biology, 12, 735-739 (2002), Lagos Quintana et al, Science 294, 853-857 (2001), and Lagos-Quintana et al, RNA, 9, 175-179 (2003), which are incorporated herein by reference. Multiple microRNAs can also be incorporated into a precursor molecule. Furthermore, miRNA-like stem-loops can be expressed in cells as a vehicle to deliver artificial miRNAs and short interfering RNAs (siRNAs) for the purpose of modulating the expression of endogenous genes through the miRNA and or RNAi pathways.

As used herein, “double stranded RNA” or “dsRNA” refers to RNA molecules that are comprised of two strands. Double-stranded molecules include those comprised of a single RNA molecule that doubles back on itself to form a two-stranded structure. For example, the stem loop structure of the progenitor molecules from which the single-stranded miRNA is derived, called the pre-miRNA (Bartel et al. 2004. Cell 116:281-297), comprises a dsRNA molecule.

Engineered Cells and Organisms

Described herein are engineered cells that can include one or more of the engineered muscle-specific targeting moiety polynucleotides, polypeptides, vectors, and/or vector systems. In some embodiments, one or more of the engineered muscle-specific targeting moiety polynucleotides can be expressed in the engineered cells. In some embodiments, the engineered cells can be capable of producing engineered muscle-specific viral capsid proteins and/or engineered muscle-specific viral particles that are described elsewhere herein. Also described herein are modified or engineered organisms that can include one or more engineered cells described herein. The engineered cells can be engineered to express a cargo molecule (e.g. a cargo polynucleotide) dependently or independently of an engineered muscle-specific viral capsid polynucleotide as described elsewhere herein.

A wide variety of animals, plants, algae, fungi, yeast, etc. and animal, plant, algae, fungus, yeast cell or tissue systems may be engineered to express one or more nucleic acid constructs of the engineered muscle-specific delivery system described herein using various transformation methods mentioned elsewhere herein. This can produce organisms that can produce engineered muscle-specific targeting moiety or composition thereof, such as for production purposes, engineered muscle-specific viral capsid design and/or generation, and/or model organisms. In some embodiments, the polynucleotide(s) encoding one or more components of the engineered viral capsid system described herein can be stably or transiently incorporated into one or more cells of a plant, animal, algae, fungus, and/or yeast or tissue system. In some embodiments, one or more of engineered viral capsid system polynucleotides are genomically incorporated into one or more cells of a plant, animal, algae, fungus, and/or yeast or tissue system. Further embodiments of the modified organisms and systems are described elsewhere herein. In some embodiments, one or more components of the engineered viral capsid system described herein are expressed in one or more cells of the plant, animal, algae, fungus, yeast, or tissue systems.

Engineered Cells

Described herein are various embodiments of engineered cells that can include one or more of the engineered muscle-specific targeting moiety, composition thereof, and/or delivery system thereof polynucleotides, polypeptides, vectors, and/or vector systems described elsewhere herein. In some embodiments, the cells can express one or more of the engineered muscle-specific targeting moiety polynucleotides and can produce one or more engineered muscle-specific viral particles, which are described in greater detail herein. Such cells are also referred to herein as “producer cells”. It will be appreciated that these engineered cells are different from “modified cells” described elsewhere herein in that the modified cells are not necessarily producer cells (i.e. they do not make engineered muscle-specific delivery particles (i.e. particles that can deliver a cargo to a cell in a muscle-specific manner guided by a muscle-specific targeting moiety described herein) unless they include one or more of the engineered viral capsid polynucleotides, engineered viral capsid vectors or other vectors described herein that render the cells capable of producing an engineered virus particle or are modified to produce compositions (such as proteins) that include one or more engineered muscle-specific targeting moieties.

Modified cells can be recipient cells of a cargo delivered by a delivery vehicle (e.g. viral, vector, or non-vector delivery vehicle) that includes one or more engineered muscle-specific targeting moieties, and can, in some embodiments, be modified by the delivery vehicle and/or a cargo polynucleotide delivered to the recipient cell. Modified cells are discussed in greater detail elsewhere herein. The term modification can be used in connection with modification of a cell that is not dependent on being a recipient cell. For example, isolated cells can be modified prior to receiving an engineered delivery vehicle described herein.

In an embodiment, the invention provides a non-human eukaryotic organism; for example, a multicellular eukaryotic organism, including a eukaryotic host cell containing one or more components of an engineered muscle-specific delivery system described herein according to any of the described embodiments. In other embodiments, the invention provides a eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell containing one or more components of an engineered delivery system described herein according to any of the described embodiments. In some embodiments, the organism is a host of AAV.

In particular embodiments, the plants, algae, fungi, yeast, etc., cells or parts obtained are transgenic plants, comprising an exogenous DNA sequence incorporated into the genome of all or part of the cells.

The engineered cell can be a prokaryotic cell. The prokaryotic cell can be bacterial cell. The prokaryotic cell can be an archaea cell. The bacterial cell can be any suitable bacterial cell. Suitable bacterial cells can be from the genus Escherichia, Bacillus, Lactobacillus, Rhodococcus, Rodhobacter, Synechococcus, Synechoystis, Pseudomonas, Psedoaltermonas, Stenotrophamonas, and Streptomyces Suitable bacterial cells include, but are not limited to Escherichia coli cells, Caulobacter crescentus cells, Rodhobacter sphaeroides cells, Psedoaltermonas haloplanktis cells. Suitable strains of bacterial include, but are not limited to BL21(DE3), DL21(DE3)-pLysS, BL21 Star-pLysS, BL21-SI, BL21-AI, Tuner, Tuner pLysS, Origami, Origami B pLysS, Rosetta, Rosetta pLysS, Rosetta-gami-pLysS, BL21 CodonPlus, AD494, BL2trxB, HMS174, NovaBlue(DE3), BLR, C41(DE3), C43(DE3), Lemo21(DE3), Shuffle T7, ArcticExpress and ArticExpress (DE3).

The engineered cell can be a eukaryotic cell. The eukaryotic cells may be those of or derived from a particular organism, such as a plant or a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as herein discussed, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate. In some embodiments the engineered cell can be a cell line. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huhl, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panc1, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRCS, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial, BALB/3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C3H-10T1/2, C6/36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr −/−, COR-L23, COR-L23/CPR, COR-L23/5010, COR-L23/R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1, EMT6/AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK II, MOR/0.2R, MONO-MAC 6, MTD-1A, MyEnd, NCI-H69/CPR, NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1, NW-145, OPCN/OPCT cell lines, Peer, PNT-1A/PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassas, Va.)).

In some embodiments, the engineered or modified cell is a muscle cell (e.g. cardiac muscle, skeletal muscle, and/or smooth muscle), bone cell, blood cell, immune cell (including but not limited to B cells, macrophages, T-cells, CAR-T cells, and the like), kidney cells, bladder cells, lung cells, heart cells, liver cells, brain cells, neurons, skin cells, stomach cells, neuronal support cells, intestinal cells, epithelial cells, endothelial cells, stem or other progenitor cells, adrenal gland cells, cartilage cells, and combinations thereof.

In some embodiments, the engineered cell can be a fungus cell. As used herein, a “fungal cell” refers to any type of eukaryotic cell within the kingdom of fungi. Phyla within the kingdom of fungi include Ascomycota, Basidiomycota, Blastocladiomycota, Chytridiomycota, Glomeromycota, Microsporidia, and Neocallimastigomycota. Fungal cells may include yeasts, molds, and filamentous fungi. In some embodiments, the fungal cell is a yeast cell.

As used herein, the term “yeast cell” refers to any fungal cell within the phyla Ascomycota and Basidiomycota. Yeast cells may include budding yeast cells, fission yeast cells, and mold cells. Without being limited to these organisms, many types of yeast used in laboratory and industrial settings are part of the phylum Ascomycota. In some embodiments, the yeast cell is an S. cerevisiae, Kluyveromyces marxianus, or Issatchenkia orientalis cell. Other yeast cells may include without limitation Candida spp. (e.g., Candida albicans), Yarrowia spp. (e.g., Yarrowia lipolytica), Pichia spp. (e.g., Pichia pastoris), Kluyveromyces spp. (e.g., Kluyveromyces lactis and Kluyveromyces marxianus), Neurospora spp. (e.g., Neurospora crassa), Fusarium spp. (e.g., Fusarium oxysporum), and Issatchenkia spp. (e.g., Issatchenkia orientalis, a.k.a. Pichia kudriavzevii and Candida acidothermophilum). In some embodiments, the fungal cell is a filamentous fungal cell. As used herein, the term “filamentous fungal cell” refers to any type of fungal cell that grows in filaments, i.e., hyphae or mycelia. Examples of filamentous fungal cells may include without limitation Aspergillus spp. (e.g., Aspergillus niger), Trichoderma spp. (e.g., Trichoderma reesei), Rhizopus spp. (e.g., Rhizopus oryzae), and Mortierella spp. (e.g., Mortierella isabellina).

In some embodiments, the fungal cell is an industrial strain. As used herein, “industrial strain” refers to any strain of fungal cell used in or isolated from an industrial process, e.g., production of a product on a commercial or industrial scale. Industrial strain may refer to a fungal species that is typically used in an industrial process, or it may refer to an isolate of a fungal species that may be also used for non-industrial purposes (e.g., laboratory research). Examples of industrial processes may include fermentation (e.g., in production of food or beverage products), distillation, biofuel production, production of a compound, and production of a polypeptide. Examples of industrial strains can include, without limitation, JAY270 and ATCC4124.

In some embodiments, the fungal cell is a polyploid cell. As used herein, a “polyploid” cell may refer to any cell whose genome is present in more than one copy. A polyploid cell may refer to a type of cell that is naturally found in a polyploid state, or it may refer to a cell that has been induced to exist in a polyploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication). A polyploid cell may refer to a cell whose entire genome is polyploid, or it may refer to a cell that is polyploid in a particular genomic locus of interest.

In some embodiments, the fungal cell is a diploid cell. As used herein, a “diploid” cell may refer to any cell whose genome is present in two copies. A diploid cell may refer to a type of cell that is naturally found in a diploid state, or it may refer to a cell that has been induced to exist in a diploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication). For example, the S. cerevisiae strain S228C may be maintained in a haploid or diploid state. A diploid cell may refer to a cell whose entire genome is diploid, or it may refer to a cell that is diploid in a particular genomic locus of interest. In some embodiments, the fungal cell is a haploid cell. As used herein, a “haploid” cell may refer to any cell whose genome is present in one copy. A haploid cell may refer to a type of cell that is naturally found in a haploid state, or it may refer to a cell that has been induced to exist in a haploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication). For example, the S. cerevisiae strain S228C may be maintained in a haploid or diploid state. A haploid cell may refer to a cell whose entire genome is haploid, or it may refer to a cell that is haploid in a particular genomic locus of interest.

In some embodiments, the engineered cell is a cell obtained from a subject. In some embodiments, the subject is a healthy or non-diseased subject. In some embodiments, the subject is a subject with a desired physiological and/or biological characteristic such that when a engineered AAV capsid particle is produced it can package one or more cargo polynucleotides that can be related to the desired physiological and/or biological characteristic and/or capable of modifying the desired physiological and/or biological characteristic. Thus, the cargo polynucleotides of the produced engineered AAV capsid particle can be capable of transferring the desired characteristic to a recipient cell. In some embodiments, the cargo polynucleotides are capable of modifying a polynucleotide of the engineered cell such that the engineered cell has a desired physiological and/or biological characteristic.

In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences.

The engineered cells can be used to produce engineered AAV capsid polynucleotides, vectors, and/or particles. In some embodiments, the engineered AAV capsid polynucleotides, vectors, and/or particles are produced, harvested, and/or delivered to a subject in need thereof. In some embodiments, the engineered cells are delivered to a subject. Other uses for the engineered cells are described elsewhere herein. In some embodiments, the engineered cells can be included in formulations and/or kits described elsewhere herein.

The engineered cells can be stored short-term or long-term for use at a later time. Suitable storage methods are generally known in the art. Further, methods of restoring the stored cells for use (such as thawing, reconstitution, and otherwise stimulating metabolism in the engineered cell after storage) at a later time are also generally known in the art.

Formulations

The compositions, polynucleotides, polypeptides, particles, cells, vector systems and combinations thereof described herein can be contained in a formulation, such as a pharmaceutical formulation. In some embodiments, the formulations can be used to generate polypeptides and other particles that include one or more muscle-specific targeting moieties described herein. In some embodiments, the formulations can be delivered to a subject in need thereof. In some embodiments, the engineered muscle-specific targeting moieties, compositions thereof, delivery systems thereof, engineered cells, engineered viral particles, and/or combinations thereof described herein can be included in a formulation that can be delivered to a subject or a cell. In some embodiments, the formulation is a pharmaceutical formulation. One or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be provided to a subject in need thereof or a cell alone or as an active ingredient, such as in a pharmaceutical formulation. As such, also described herein are pharmaceutical formulations containing an amount of one or more of the polypeptides, polynucleotides, vectors, cells, or combinations thereof described herein. In some embodiments, the pharmaceutical formulation can contain an effective amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein. The pharmaceutical formulations described herein can be administered to a subject in need thereof or a cell.

In some embodiments, the amount of the one or more of the polypeptides, polynucleotides, vectors, cells, virus particles, nanoparticles, other delivery particles, and combinations thereof described herein contained in the pharmaceutical formulation can range from about 1 μg/kg to about 10 mg/kg based upon the bodyweight of the subject in need thereof or average bodyweight of the specific patient population to which the pharmaceutical formulation can be administered. The amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein in the pharmaceutical formulation can range from about 1 μg to about 10 g or from about 10 nL to about 10 ml. In embodiments where the pharmaceutical formulation contains one or more cells, the amount can range from about 1 cell to 1×10², 1×10³, 1×10⁴, 1×10⁵, 1×10⁶, 1×10⁷, 1×10⁸, 1×10⁹, 1×10¹⁰ or more cells. In embodiments where the pharmaceutical formulation contains one or more cells, the amount can range from about 1 cell to 1×10², 1×10³, 1×10⁴, 1×10⁵, 1×10⁶, 1×10⁷, 1×10⁸, 1×10⁹, 1×10¹⁰ or more cells per nL, μL, mL, or L.

In embodiments, were engineered AAV capsid particles are included in the formulation, the formulation can contain 1 to 1×10¹, 1×10², 1×10³, 1×10⁴, 1×10⁵, 1×10⁶, 1×10⁷, 1×10⁸, 1×10⁹, 1×10¹⁰, 1×10¹¹, 1×10¹², 1×10¹³, 1×10¹⁴, 1×10¹⁵, 1×10¹⁶, 1×10¹⁷, 1×10¹⁸, 1×10¹⁹, or 1×10²⁰ transducing units (TU)/mL of the engineered AAV capsid particles. In some embodiments, the formulation can be 0.1 to 100 mL in volume and can contain 1 to 1×10¹, 1×10², 1×10³, 1×10⁴, 1×10⁵, 1×10⁶, 1×10⁷, 1×10⁸, 1×10⁹, 1×10¹⁰, 1×10¹¹, 1×10¹², 1×10¹³, 1×10¹⁴, 1×10¹⁵, 1×10¹⁶, 1×10¹⁷, 1×10¹⁸, 1×10¹⁹, or 1×10²⁰ transducing units (TU)/mL of the engineered viral particles.

Pharmaceutically Acceptable Carriers and Auxiliary Ingredients and Agents

In embodiments, the pharmaceutical formulation containing an amount of one or more of the polypeptides, polynucleotides, vectors, cells, virus particles, nanoparticles, other delivery particles, and combinations thereof described herein can further include a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxy methylcellulose, and polyvinyl pyrrolidone, which do not deleteriously react with the active composition.

The pharmaceutical formulations can be sterilized, and if desired, mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances, and the like which do not deleteriously react with the active composition.

In addition to an amount of one or more of the polypeptides, polynucleotides, vectors, cells, viral particles, nanoparticles, other delivery particles, and combinations thereof described herein, the pharmaceutical formulation can also include an effective amount of an auxiliary active agent, including but not limited to, polynucleotides, amino acids, peptides, polypeptides, antibodies, aptamers, ribozymes, hormones, immunomodulators, antipyretics, anxiolytics, antipsychotics, analgesics, antispasmodics, anti-inflammatories, anti-histamines, anti-infectives, chemotherapeutics, and combinations thereof.

Suitable hormones include, but are not limited to, amino-acid derived hormones (e.g. melatonin and thyroxine), small peptide hormones and protein hormones (e.g. thyrotropin-releasing hormone, vasopressin, insulin, growth hormone, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone), eicosanoids (e.g. arachidonic acid, lipoxins, and prostaglandins), and steroid hormones (e.g. estradiol, testosterone, tetrahydro testosterone Cortisol). Suitable immunomodulators include, but are not limited to, prednisone, azathioprine, 6-MP, cyclosporine, tacrolimus, methotrexate, interleukins (e.g. IL-2, IL-7, and IL-12), cytokines (e.g. interferons (e.g. IFN-α, IFN-β, IFN-ε, IFN-K, IFN-ω, and IFN-γ), granulocyte colony-stimulating factor, and imiquimod), chemokines (e.g. CCL3, CCL26 and CXCL7), cytosine phosphate-guanosine, oligodeoxynucleotides, glucans, antibodies, and aptamers).

Suitable antipyretics include, but are not limited to, non-steroidal anti-inflammants (e.g. ibuprofen, naproxen, ketoprofen, and nimesulide), aspirin and related salicylates (e.g. choline salicylate, magnesium salicylate, and sodium salicylate), paracetamol/acetaminophen, metamizole, nabumetone, phenazone, and quinine.

Suitable anxiolytics include, but are not limited to, benzodiazepines (e.g. alprazolam, bromazepam, chlordiazepoxide, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam, triazolam, and tofisopam), serotonergic antidepressants (e.g. selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors), mebicar, afobazole, selank, bromantane, emoxypine, azapirones, barbiturates, hydroxyzine, pregabalin, validol, and beta blockers.

Suitable antipsychotics include, but are not limited to, benperidol, bromoperidol, droperidol, haloperidol, moperone, pipaperone, timiperone, fluspirilene, penfluridol, pimozide, acepromazine, chlorpromazine, cyamemazine, dizyrazine, fluphenazine, levomepromazine, mesoridazine, perazine, pericyazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, prothipendyl, thioproperazine, thioridazine, trifluoperazine, triflupromazine, chlorprothixene, clopenthixol, flupentixol, tiotixene, zuclopenthixol, clotiapine, loxapine, prothipendyl, carpipramine, clocapramine, molindone, mosapramine, sulpiride, veralipride, amisulpride, amoxapine, aripiprazole, asenapine, clozapine, blonanserin, iloperidone, lurasidone, melperone, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, trimipramine, ziprasidone, zotepine, alstonie, befeprunox, bitopertin, brexpiprazole, cannabidiol, cariprazine, pimavanserin, pomaglumetad methionil, vabicaserin, xanomeline, and zicronapine.

Suitable analgesics include, but are not limited to, paracetamol/acetaminophen, nonsteroidal anti-inflammants (e.g. ibuprofen, naproxen, ketoprofen, and nimesulide), COX-2 inhibitors (e.g. rofecoxib, celecoxib, and etoricoxib), opioids (e.g. morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine), tramadol, norepinephrine, flupiretine, nefopam, orphenadrine, pregabalin, gabapentin, cyclobenzaprine, scopolamine, methadone, ketobemidone, piritramide, and aspirin and related salicylates (e.g. choline salicylate, magnesium salicylate, and sodium salicylate).

Suitable antispasmodics include, but are not limited to, mebeverine, papaverine, cyclobenzaprine, carisoprodol, orphenadrine, tizanidine, metaxalone, methocarbamol, chlorzoxazone, baclofen, dantrolene, baclofen, tizanidine, and dantrolene. Suitable anti-inflammatories include, but are not limited to, prednisone, non-steroidal anti-inflammants (e.g. ibuprofen, naproxen, ketoprofen, and nimesulide), COX-2 inhibitors (e.g. rofecoxib, celecoxib, and etoricoxib), and immune selective anti-inflammatory derivatives (e.g. submandibular gland peptide-T and its derivatives).

Suitable anti-histamines include, but are not limited to, H1-receptor antagonists (e.g. acrivastine, azelastine, bilastine, brompheniramine, buclizine, bromodiphenhydramine, carbinoxamine, cetirizine, chlorpromazine, cyclizine, chlorpheniramine, clemastine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, dimenhydrinate, dimetindene, diphenhydramine, doxylamine, ebastine, embramine, fexofenadine, hydroxyzine, levocetirizine, loratadine, meclozine, mirtazapine, olopatadine, orphenadrine, phenindamine, pheniramine, phenyltoloxamine, promethazine, pyrilamine, quetiapine, rupatadine, tripelennamine, and triprolidine), H2-receptor antagonists (e.g. cimetidine, famotidine, lafutidine, nizatidine, ranitidine, and roxatidine), tritoqualine, catechin, cromoglicate, nedocromil, and p2-adrenergic agonists.

Suitable anti-infectives include, but are not limited to, amebicides (e.g. nitazoxanide, paromomycin, metronidazole, tinidazole, chloroquine, miltefosine, amphotericin b, and iodoquinol), aminoglycosides (e.g. paromomycin, tobramycin, gentamicin, amikacin, kanamycin, and neomycin), anthelmintics (e.g. pyrantel, mebendazole, ivermectin, praziquantel, albendazole, thiabendazole, oxamniquine), antifungals (e.g. azole antifungals (e.g. itraconazole, fluconazole, parconazole, ketoconazole, clotrimazole, miconazole, and voriconazole), echinocandins (e.g. caspofungin, anidulafungin, and micafungin), griseofulvin, terbinafine, flucytosine, and polyenes (e.g. nystatin, and amphotericin b), antimalarial agents (e.g. pyrimethamine/sulfadoxine, artemether/lumefantrine, atovaquone/proquanil, quinine, hydroxychloroquine, mefloquine, chloroquine, doxycycline, pyrimethamine, and halofantrine), antituberculosis agents (e.g. aminosalicylates (e.g. aminosalicylic acid), isoniazid/rifampin, isoniazid/pyrazinamide/rifampin, bedaquiline, isoniazid, ethambutol, rifampin, rifabutin, rifapentine, capreomycin, and cycloserine), antivirals (e.g. amantadine, rimantadine, abacavir/lamivudine, emtricitabine/tenofovir, cobicistat/elvitegravir/emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, abacavir/lamivudine/zidovudine, lamivudine/zidovudine, emtricitabine/tenofovir, emtricitabine/lopinavir/ritonavir/tenofovir, interferon alfa-2v/ribavirin, peginterferon alfa-2b, maraviroc, raltegravir, dolutegravir, enfuvirtide, foscarnet, fomivirsen, oseltamivir, zanamivir, nevirapine, efavirenz, etravirine, rilpivirine, delavirdine, nevirapine, entecavir, lamivudine, adefovir, sofosbuvir, didanosine, tenofovir, abacavir, zidovudine, stavudine, emtricitabine, zalcitabine, telbivudine, simeprevir, boceprevir, telaprevir, lopinavir/ritonavir, boceprevir, darunavir, ritonavir, tipranavir, atazanavir, nelfinavir, amprenavir, indinavir, sawuinavir, ribavirin, valacyclovir, acyclovir, famciclovir, ganciclovir, and valganciclovir), carbapenems (e.g. doripenem, meropenem, ertapenem, and cilastatin/imipenem), cephalosporins (e.g. cefadroxil, cephradine, cefazolin, cephalexin, cefepime, cefazoline, loracarbef, cefotetan, cefuroxime, cefprozil, loracarbef, cefoxitin, cefaclor, ceftibuten, ceftriaxone, cefotaxime, cefpodoxime, cefdinir, cefixime, cefditoren, ceftizoxime, and ceftazidime), glycopeptide antibiotics (e.g. vancomycin, dalbavancin, oritavancin, and telavancin), glycylcyclines (e.g. tigecycline), leprostatics (e.g. clofazimine and thalidomide), lincomycin and derivatives thereof (e.g. clindamycin and lincomycin), macrolides and derivatives thereof (e.g. telithromycin, fidaxomicin, erythromycin, azithromycin, clarithromycin, dirithromycin, and troleandomycin), linezolid, sulfamethoxazole/trimethoprim, rifaximin, chloramphenicol, Fosfomycin, metronidazole, aztreonam, bacitracin, penicillin (amoxicillin, ampicillin, bacampicillin, carbenicillin, piperacillin, ticarcillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, clavulanate/ticarcillin, penicillin, procaine penicillin, oxacillin, dicloxacillin, and nafcillin), quinolones (e.g. lomefloxacin, norfloxacin, ofloxacin, qatifloxacin, moxifloxacin, ciprofloxacin, levofloxacin, gemifloxacin, moxifloxacin, cinoxacin, nalidixic acid, enoxacin, grepafloxacin, gatifloxacin, trovafloxacin, and sparfloxacin), sulfonamides (e.g. sulfamethoxazole/trimethoprim, sulfasalazine, and sulfasoxazole), tetracyclines (e.g. doxycycline, demeclocycline, minocycline, doxycycline/salicylic acid, doxycycline/omega-3 polyunsaturated fatty acids, and tetracycline), and urinary anti-infectives (e.g. nitrofurantoin, methenamine, Fosfomycin, cinoxacin, nalidixic acid, trimethoprim, and methylene blue).

Suitable chemotherapeutics include, but are not limited to, paclitaxel, brentuximab vedotin, doxorubicin, 5-FU (fluorouracil), everolimus, pemetrexed, melphalan, pamidronate, anastrozole, exemestane, nelarabine, ofatumumab, bevacizumab, belinostat, tositumomab, carmustine, bleomycin, bosutinib, busulfan, alemtuzumab, irinotecan, vandetanib, bicalutamide, lomustine, daunorubicin, clofarabine, cabozantinib, dactinomycin, ramucirumab, cytarabine, Cytoxan, cyclophosphamide, decitabine, dexamethasone, docetaxel, hydroxyurea, decarbazine, leuprolide, epirubicin, oxaliplatin, asparaginase, estramustine, cetuximab, vismodegib, asparginase Erwinia chrysanthemi, amifostine, etoposide, flutamide, toremifene, fulvestrant, letrozole, degarelix, pralatrexate, methotrexate, floxuridine, obinutuzumab, gemcitabine, afatinib, imatinib mesylatem, carmustine, eribulin, trastuzumab, altretamine, topotecan, ponatinib, idarubicin, ifosfamide, ibrutinib, axitinib, interferon alfa-2a, gefitinib, romidepsin, ixabepilone, ruxolitinib, cabazitaxel, ado-trastuzumab emtansine, carfilzomib, chlorambucil, sargramostim, cladribine, mitotane, vincristine, procarbazine, megestrol, trametinib, mesna, strontium-89 chloride, mechlorethamine, mitomycin, busulfan, gemtuzumab ozogamicin, vinorelbine, filgrastim, pegfilgrastim, sorafenib, nilutamide, pentostatin, tamoxifen, mitoxantrone, pegaspargase, denileukin diftitox, alitretinoin, carboplatin, pertuzumab, cisplatin, pomalidomide, prednisone, aldesleukin, mercaptopurine, zoledronic acid, lenalidomide, rituximab, octretide, dasatinib, regorafenib, histrelin, sunitinib, siltuximab, omacetaxine, thioguanine (tioguanine), dabrafenib, erlotinib, bexarotene, temozolomide, thiotepa, thalidomide, BCG, temsirolimus, bendamustine hydrochloride, triptorelin, arsenic trioxide, lapatinib, valrubicin, panitumumab, vinblastine, bortezomib, tretinoin, azacitidinea, pazopanib, teniposide, leucovorin, crizotinib, capecitabine, enzalutamide, ipilimumab, goserelin, vorinostat, idelalisib, ceritinib, abiraterone, epothilone, tafluposide, azathioprine, doxifluridine, vindesine, and all-trans retinoic acid.

In embodiments where there is an auxiliary active agent contained in the pharmaceutical formulation in addition to the one or more of the polypeptides, polynucleotides, vectors, cells, virus particles, nanoparticles, other delivery particles, and combinations thereof described herein, amount, such as an effective amount, of the auxiliary active agent will vary depending on the auxiliary active agent. In some embodiments, the amount of the auxiliary active agent ranges from 0.001 micrograms to about 1 milligram. In other embodiments, the amount of the auxiliary active agent ranges from about 0.01 IU to about 1000 IU. In further embodiments, the amount of the auxiliary active agent ranges from 0.001 mL to about 1 mL. In yet other embodiments, the amount of the auxiliary active agent ranges from about 1% w/w to about 50% w/w of the total pharmaceutical formulation. In additional embodiments, the amount of the auxiliary active agent ranges from about 1% v/v to about 50% v/v of the total pharmaceutical formulation. In still other embodiments, the amount of the auxiliary active agent ranges from about 1% w/v to about 50% w/v of the total pharmaceutical formulation.

Dosage Forms

In some embodiments, the pharmaceutical formulations described herein may be in a dosage form. The dosage forms can be adapted for administration by any appropriate route. Appropriate routes include, but are not limited to, oral (including buccal or sublingual), rectal, epidural, intracranial, intraocular, inhaled, intranasal, topical (including buccal, sublingual, or transdermal), vaginal, intraurethral, parenteral, intracranial, subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal, intraosseous, intracardiac, intraarticular, intracavernous, intrathecal, intravitreal, intracerebral, gingival, subgingival, intracerebroventricular, and intradermal. Such formulations may be prepared by any method known in the art.

Dosage forms adapted for oral administration can be discrete dosage units such as capsules, pellets or tablets, powders or granules, solutions, or suspensions in aqueous or non-aqueous liquids; edible foams or whips, or in oil-in-water liquid emulsions or water-in-oil liquid emulsions. In some embodiments, the pharmaceutical formulations adapted for oral administration also include one or more agents which flavor, preserve, color, or help disperse the pharmaceutical formulation. Dosage forms prepared for oral administration can also be in the form of a liquid solution that can be delivered as foam, spray, or liquid solution. In some embodiments, the oral dosage form can contain about 1 ng to 1000 g of a pharmaceutical formulation containing a therapeutically effective amount or an appropriate fraction thereof of the targeted effector fusion protein and/or complex thereof or composition containing the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein. The oral dosage form can be administered to a subject in need thereof.

Where appropriate, the dosage forms described herein can be microencapsulated.

The dosage form can also be prepared to prolong or sustain the release of any ingredient. In some embodiments, the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be the ingredient whose release is delayed. In other embodiments, the release of an optionally included auxiliary ingredient is delayed. Suitable methods for delaying the release of an ingredient include, but are not limited to, coating or embedding the ingredients in material in polymers, wax, gels, and the like. Delayed release dosage formulations can be prepared as described in standard references such as “Pharmaceutical dosage form tablets,” eds. Liberman et. al. (New York, Marcel Dekker, Inc., 1989), “Remington—The science and practice of pharmacy”, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, and “Pharmaceutical dosage forms and drug delivery systems”, 6th Edition, Ansel et al., (Media, Pa.: Williams and Wilkins, 1995). These references provide information on excipients, materials, equipment, and processes for preparing tablets and capsules and delayed release dosage forms of tablets and pellets, capsules, and granules. The delayed release can be anywhere from about an hour to about 3 months or more.

Examples of suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name EUDRAGIT® (Roth Pharma, Westerstadt, Germany), zein, shellac, and polysaccharides.

Coatings may be formed with a different ratio of water-soluble polymer, water insoluble polymers, and/or pH dependent polymers, with or without water insoluble/water soluble non-polymeric excipient, to produce the desired release profile. The coating is either performed on the dosage form (matrix or simple) which includes, but is not limited to, tablets (compressed with or without coated beads), capsules (with or without coated beads), beads, particle compositions, “ingredient as is” formulated as, but not limited to, suspension form or as a sprinkle dosage form.

Dosage forms adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils. In some embodiments for treatments of the eye or other external tissues, for example the mouth or the skin, the pharmaceutical formulations are applied as a topical ointment or cream. When formulated in an ointment, the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be formulated with a paraffinic or water-miscible ointment base. In some embodiments, the active ingredient can be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Dosage forms adapted for topical administration in the mouth include lozenges, pastilles, and mouth washes.

Dosage forms adapted for nasal or inhalation administration include aerosols, solutions, suspension drops, gels, or dry powders. In some embodiments, the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein is contained in a dosage form adapted for inhalation is in a particle-size-reduced form that is obtained or obtainable by micronization. In some embodiments, the particle size of the size reduced (e.g. micronized) compound or salt or solvate thereof, is defined by a D50 value of about 0.5 to about 10 microns as measured by an appropriate method known in the art. Dosage forms adapted for administration by inhalation also include particle dusts or mists. Suitable dosage forms wherein the carrier or excipient is a liquid for administration as a nasal spray or drops include aqueous or oil solutions/suspensions of an active ingredient (e.g. the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein and/or auxiliary active agent), which may be generated by various types of metered dose pressurized aerosols, nebulizers, or insufflators.

In some embodiments, the dosage forms can be aerosol formulations suitable for administration by inhalation. In some of these embodiments, the aerosol formulation can contain a solution or fine suspension of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein and a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multi-dose quantities in sterile form in a sealed container. For some of these embodiments, the sealed container is a single dose or multi-dose nasal or an aerosol dispenser fitted with a metering valve (e.g. metered dose inhaler), which is intended for disposal once the contents of the container have been exhausted.

Where the aerosol dosage form is contained in an aerosol dispenser, the dispenser contains a suitable propellant under pressure, such as compressed air, carbon dioxide, or an organic propellant, including but not limited to a hydrofluorocarbon. The aerosol formulation dosage forms in other embodiments are contained in a pump-atomizer. The pressurized aerosol formulation can also contain a solution or a suspension of one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein. In further embodiments, the aerosol formulation can also contain co-solvents and/or modifiers incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation. Administration of the aerosol formulation can be once daily or several times daily, for example 2, 3, 4, or 8 times daily, in which 1, 2, or 3 doses are delivered each time.

For some dosage forms suitable and/or adapted for inhaled administration, the pharmaceutical formulation is a dry powder inhalable formulation. In addition to the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein, an auxiliary active ingredient, and/or pharmaceutically acceptable salt thereof, such a dosage form can contain a powder base such as lactose, glucose, trehalose, mannitol, and/or starch. In some of these embodiments, the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein is in a particle-size reduced form. In further embodiments, a performance modifier, such as L-leucine or another amino acid, cellobiose octaacetate, and/or metals salts of stearic acid, such as magnesium or calcium stearate.

In some embodiments, the aerosol dosage forms can be arranged so that each metered dose of aerosol contains a predetermined amount of an active ingredient, such as the one or more of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein.

Dosage forms adapted for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations. Dosage forms adapted for rectal administration include suppositories or enemas.

Dosage forms adapted for parenteral administration and/or adapted for any type of injection (e.g. intravenous, intraperitoneal, subcutaneous, intramuscular, intradermal, intraosseous, epidural, intracardiac, intraarticular, intracavernous, gingival, subgingival, intrathecal, intravitreal, intracerebral, and intracerebroventricular) can include aqueous and/or non-aqueous sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, solutes that render the composition isotonic with the blood of the subject, and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents. The dosage forms adapted for parenteral administration can be presented in a single-unit dose or multi-unit dose containers, including but not limited to sealed ampoules or vials. The doses can be lyophilized and resuspended in a sterile carrier to reconstitute the dose prior to administration. Extemporaneous injection solutions and suspensions can be prepared in some embodiments, from sterile powders, granules, and tablets.

Dosage forms adapted for ocular administration can include aqueous and/or nonaqueous sterile solutions that can optionally be adapted for injection, and which can optionally contain anti-oxidants, buffers, bacteriostats, solutes that render the composition isotonic with the eye or fluid contained therein or around the eye of the subject, and aqueous and nonaqueous sterile suspensions, which can include suspending agents and thickening agents.

For some embodiments, the dosage form contains a predetermined amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein per unit dose. In some embodiments, the predetermined amount of the Such unit doses may therefore be administered once or more than once a day. Such pharmaceutical formulations may be prepared by any of the methods well known in the art.

Kits

Also described herein are kits that contain one or more of the one or more of the compositions, polypeptides, polynucleotides, vectors, cells, viral particles, other delivery vehicles, or other components described herein and combinations thereof and pharmaceutical formulations described herein. In embodiments, one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be presented as a combination kit. As used herein, the terms “combination kit” or “kit of parts” refers to the compounds, or formulations and additional components that are used to package, screen, test, sell, market, deliver, and/or administer the combination of elements or a single element, such as the active ingredient, contained therein. Such additional components include but are not limited to, packaging, syringes, blister packages, bottles, and the like. The combination kit can contain one or more of the components (e.g. one or more of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof) or formulation thereof can be provided in a single formulation (e.g. a liquid, lyophilized powder, etc.), or in separate formulations. The separate components or formulations can be contained in a single package or in separate packages within the kit. The kit can also include instructions in a tangible medium of expression that can contain information and/or directions regarding the content of the components and/or formulations contained therein, safety information regarding the content of the components(s) and/or formulation(s) contained therein, information regarding the amounts, dosages, indications for use, screening methods, component design recommendations and/or information, recommended treatment regimen(s) for the components(s) and/or formulations contained therein. As used herein, “tangible medium of expression” refers to a medium that is physically tangible or accessible and is not a mere abstract thought or an unrecorded spoken word. “Tangible medium of expression” includes, but is not limited to, words on a cellulosic or plastic material, or data stored in a suitable computer readable memory form. The data can be stored on a unit device, such as a flash memory drive or CD-ROM or on a server that can be accessed by a user via, e.g. a web interface.

In one embodiment, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system includes a regulatory element operably linked to one or more engineered polynucleotides, such as those containing a muscle-specific targeting moiety and/or composition thereof, as described elsewhere herein and, optionally, a cargo molecule, which can optionally be operably linked to a regulatory element. The one or more engineered delivery system polynucleotides can be included on the same or different vectors as the cargo molecule in embodiments containing a cargo molecule within the kit.

In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a direct repeat sequence and one or more insertion sites for inserting one or more guide sequences up- or downstream (whichever applicable) of the direct repeat sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a Cas9 CRISPR complex to a target sequence in a eukaryotic cell, wherein the Cas9 CRISPR complex comprises a Cas9 enzyme complexed with the guide sequence that is hybridized to the target sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said Cas9 enzyme comprising a nuclear localization sequence. Where applicable, a tracr sequence may also be provided. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the Cas9 enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type V or VI CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is derived from Francisella tularensis 1, Francisella tularensis subsp. novicida, Prevotella albensis, Lachnospiraceae bacterium MC2017 1, Butyrivibrio proteoclasticus, Peregrinibacteria bacterium GW2011_GWA2_33_10, Parcubacteria bacterium GW2011 GWC2_44_17, Smithella sp. SCADC, Acidaminococcus sp. BV3L6, Lachnospiraceae bacterium MA2020, Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi 237, Leptospira inadai, Lachnospiraceae bacterium ND2006, Porphyromonas crevioricanis 3, Prevotella disiens, or Porphyromonas macacae Cas9 (e.g., modified to have or be associated with at least one DD), and may include further alteration or mutation of the Cas9, and can be a chimeric Cas9. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks or substantially DNA strand cleavage activity (e.g., no more than 5% nuclease activity as compared with a wild type enzyme or enzyme not having the mutation or alteration that decreases nuclease activity). In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 16, 17, 18, 19, 20, 25 nucleotides, or between 16-30, or between 16-25, or between 16-20 nucleotides in length.

Methods of Use General Discussion

The compositions including one or more of the muscle-specific targeting moieties, engineered muscle-specific delivery system, engineered viral capsids and particles, polynucleotides, polypeptides, vector(s), engineered cells of the present invention can be used generally to package and/or deliver one or more cargos to a recipient cell. In some embodiments, delivery is done in cell-specific manner based upon the specificity of the targeting moiety, such as in a muscle specific manner. In some embodiments, this is conferred by the tropism of the engineered viral capsid, which can be influenced at least in part by the inclusion of one or more RGD and or n-mer motifs described elsewhere herein. In some embodiments, the tropism is muscle specific. In some embodiments, compositions including one or more of the muscle-specific targeting moieties, engineered viral capsids and viral particles, can be administered to a subject or a cell, tissue, and/or organ and facilitate the transfer and/or integration of the cargo to the recipient cell. In other embodiments, engineered cells capable of producing compositions, such as polypeptides and other particles (e.g. engineered AAV capsids and viral particles), containing one or more of the muscle-specific targeting moieties can be generated from the polynucleotides, vectors, and vector systems etc., described herein. This includes without limitation, the engineered AAV capsid system molecules (e.g. polynucleotides, vectors, and vector systems, etc.). In some embodiments, the polynucleotides, vectors, and vector systems etc., described herein capable of generating the compositions, such as polypeptides and other particles (e.g. engineered AAV capsids and viral particles), containing one or more of the muscle-specific targeting moieties can be delivered to a cell or tissue, in vivo, ex vivo, or in vitro. In some embodiments, when delivered to a subject, the composition can transform a subject's cell in vivo or ex vivo to produce an engineered cell that can be capable of making a composition described herein that contains one or more of the muscle-specific targeting moieties described herein, including but not limited to the engineered AAV capsid particles, which can be released from the engineered cell and deliver cargo molecule(s) to a recipient cell in vivo or produce personalized engineered compositions (e.g. AAV capsid particles) for reintroduction into the subject from which the recipient cell was obtained.

In some embodiments, an engineered cell can be delivered to a subject, where it can release produced compositions of the present invention (including but not limited to engineered AAV capsid particles) such that they can then deliver a cargo (e.g. a cargo polynucleotide(s)) to a recipient cell. These general processes can be used in a variety of ways to treat and/or prevent disease or a symptom thereof in a subject, generate model cells, generate modified organisms, provide cell selection and screening assays, in bioproduction, and in other various applications.

In some embodiments, the compositions, such as polypeptides and other particles (e.g. engineered AAV capsids and viral particles), containing one or more of the muscle-specific targeting moieties) can be delivered to a subject or a cell, tissue, and/or organ. In this way they can be used to deliver any cargo they may contain or are associated with to a muscle cell.

In some embodiments, the engineered AAV capsid polynucleotides, vectors, and systems thereof can be used to generate engineered AAV capsid variant libraries that can be mined for variants with a desired cell-specificity. The description provided herein as supported by the various Examples can demonstrate that one having a desired cell-specificity in mind could utilize the present invention as described herein to obtain a capsid with the desired cell-specificity.

The subject invention may be used as part of a research program wherein there is transmission of results or data. A computer system (or digital device) may be used to receive, transmit, display and/or store results, analyze the data and/or results, and/or produce a report of the results and/or data and/or analysis. A computer system may be understood as a logical apparatus that can read instructions from media (e.g. software) and/or network port (e.g. from the internet), which can optionally be connected to a server having fixed media. A computer system may comprise one or more of a CPU, disk drives, input devices such as keyboard and/or mouse, and a display (e.g. a monitor). Data communication, such as transmission of instructions or reports, can be achieved through a communication medium to a server at a local or a remote location. The communication medium can include any means of transmitting and/or receiving data. For example, the communication medium can be a network connection, a wireless connection, or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present invention can be transmitted over such networks or connections (or any other suitable means for transmitting information, including but not limited to mailing a physical report, such as a print-out) for reception and/or for review by a receiver. The receiver can be but is not limited to an individual, or electronic system (e.g. one or more computers, and/or one or more servers). In some embodiments, the computer system comprises one or more processors. Processors may be associated with one or more controllers, calculation units, and/or other units of a computer system, or implanted in firmware as desired. If implemented in software, the routines may be stored in any computer readable memory such as in RAM, ROM, flash memory, a magnetic disk, a laser disk, or other suitable storage medium. Likewise, this software may be delivered to a computing device via any known delivery method including, for example, over a communication channel such as a telephone line, the internet, a wireless connection, etc., or via a transportable medium, such as a computer readable disk, flash drive, etc. The various steps may be implemented as various blocks, operations, tools, modules and techniques which, in turn, may be implemented in hardware, firmware, software, or any combination of hardware, firmware, and/or software. When implemented in hardware, some or all of the blocks, operations, techniques, etc. may be implemented in, for example, a custom integrated circuit (IC), an application specific integrated circuit (ASIC), a field programmable logic array (FPGA), a programmable logic array (PLA), etc. A client-server, relational database architecture can be used in embodiments of the invention. A client-server architecture is a network architecture in which each computer or process on the network is either a client or a server. Server computers are typically powerful computers dedicated to managing disk drives (file servers), printers (print servers), or network traffic (network servers). Client computers include PCs (personal computers) or workstations on which users run applications, as well as example output devices as disclosed herein. Client computers rely on server computers for resources, such as files, devices, and even processing power. In some embodiments of the invention, the server computer handles all of the database functionality. The client computer can have software that handles all the front-end data management and can also receive data input from users. A machine readable medium comprising computer-executable code may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution. Accordingly, the invention comprehends performing any method herein-discussed and storing and/or transmitting data and/or results therefrom and/or analysis thereof, as well as products from performing any method herein-discussed, including intermediates.

Therapeutics

In some embodiments, the compositions containing one or more of the muscle-specific targeting moieties described herein, including, but not limited to the engineered AAV capsids, engineered viral particles, engineered cells, and/or formulations thereof described herein can be delivered to a subject in need thereof as a therapy for one or more diseases. In some embodiments, the disease to be treated is a genetic- or epigenetic-based disease. In some embodiments, the disease to be treated is not a genetic- or epigenetic-based disease. In some embodiments, one the compositions containing one or more of the muscle-specific targeting moieties described herein, including, but not limited to, the engineered viral capsids, viral particles, engineered cells, and/or formulations thereof described herein can be delivered to a subject in need thereof as a treatment or prevention (or as a part of a treatment or prevention) of a disease. It will be appreciated that the specific disease to be treated and/or prevented by delivery of a composition, formulation, cell and the like of the present invention, can be dependent on the cargo coupled to, attached to, contained in, or otherwise associated with the composition, formulation, cell and the like of the present invention.

Genetic diseases that can be treated are discussed in greater detail elsewhere herein (see e.g. discussion on Gene-modification based-therapies below). Other diseases include but are not limited to any of the following: cancer, Acubetivacter infections, actinomycosis, African sleeping sickness, AIDS/HIV, ameobiasis, Anaplasmosis, Angiostrongyliasis, Anisakiasis, Anthrax, Acranobacterium haemolyticum infection, Argentine hemorrhagic fever, Ascariasis, Aspergillosis, Astrovirus infection, Babesiosis, Bacterial meningitis, Bacterial pneumonia, Bacterial vaginosis, Bacteroides infection, balantidiasis, Bartonellosis, Baylisascaris infection, BK virus infection, Black Piedra, Blastocytosis, Blastomycosis, Bolivian hemorrhagic fever, Botulism, Brazillian hemorrhagic fever, brucellosis, Bubonic plague, Burkholderia infection, buruli ulcer, calicivirus invention, campylobacteriosis, Candidiasis, Capillariasis, Carrion's disease, Cat-scratch disease, cellulitis, Chagas Disease, Chancroid, Chickenpox, Chikungunya, Chlamydia, Chlamydia pneumoniae, Cholera, Chromoblastomycosis, Chytridiomycosis, Clonochiasis, Clostridium difficile colitis, Coccidioidomycosis, Colorado tick fever, rhinovirus/coronavirus infection (common cold), Cretzfeldt-Jakob disease, Crimean-congo hemorrhagic fever, Cryptococcosis, Cryptosporidiosis, Cutaneous larva migrans (CLM), cyclosporiasis, cysticercosis, cytomegalovirus infection, Dengue fever, Desmodesmus infection, Dientamoebiasis, Diphtheria, Diphylobothriasis, Dracunculiasis, Ebola, Echinococcosis, Ehrlichiosis, Enterobiasis, Enterococcus infection, Enterovirus infection, Epidemic typhus, Erthemia Infectisoum, Exanthem subitum, Fasciolasis, Fasciolopsiasis, fatal familial insomnia, filarisis, Clostridium perfingens infection, Fusobacterium infection, Gas gangrene (clostridial myonecrosis), Geotrichosis, Gerstmann-Straussler-Scheinker syndrome, Giardasis, Glanders, Gnathostomiasis, Gonorrhea, Granuloma inguinales, Group A streptococcal infection, Group B streptococcal infection, Haemophilus influenzae infection, Hand, foot, and mouth disease, hanta virus pulmonary syndrome, heartland virus disease, Helicobacter pylori infection, hemorrhagic fever with renal syndrome, Hendra virus infection, Hepatitis (all groups A, B, C, D, E), herpes simplex, histoplasmosis, hookworm infection, human bocavirus infection, human ewingii ehrlichiosis, Human granulocytic anaplasmosis, human metapneymovirus infection, human monocytic ehrlichiosis, human papilloma virus, Hymenolepiasis, Epstein-Barr infection, mononucleosis, influenza, isoporisis, Kawasaki disease, Kingell kingae infection, Kuru, Lasas fever, Legionellosis (Legionnaire's disease and Potomac Fever), Leishmaniasis, Leprosy, Leptospirosis, Listeriosis, Lyme disease, lymphatic filariasis, lymphocytic choriomeningitis, Malaria, Marburg hemorrhagic fever, measles, Middle East respiratory syndrome, Meliodosis, meningitis, Meningococcal disease, Metagonimiasis, Microsporidosis, Molluscum contagiosum, Monkeypox, Mumps, Murine typhus, Mycoplasma pneumonia, Mycoplasma genitalium infection, Mycetoma, Myiasis, Conjunctivitis, Nipah virus infection, Norovirus, Variant Creutzfeldt-Jakob disease, Nocardosis, Onchocerciasis, Opisthorchiasis, Paracoccidioidomycosis, Paragonimiasis, Pasteurellosis, Pdiculosisi capitis, Pediculosis corpis, Pediculosis pubis, pelvic inflammatory disease, pertussis, plague, pneumococcal infection, pneumocystis pneumonia, pneumonia, poliomyelitis, prevotella infection, primary amoebic menigoencephalitis, progressive multifocal leukoencephalopathy, Psittacosis, Qfever, rabies, relapsing fever, respiratory syncytial virus infection, rhinovirus infection, rickettsia′ infection, Rickettsialpox, Rift Valley Fever, Rocky Mountain Spotted Fever, Rotavirus infection, Rubella, Salmonellosis, SARS, Scabies, Scarlet fever, Schistosomiais, Sepsis, Shigellosis, Shingles, Smallpox, Sporotrichosisi, Staphylococcal infection (including MRSA), strongyloidiasis, subacute sclerosing panecephalitis, Syphilis, Taeniasis, tetanus, Trichophyton species infection, Tocariasis, Toxoplasmosis, Trachoma, Trichinosis, Trichuriasis, Tuberculosis, Tularemia, Typhoid Fever, Typhus Fever, Ureaplasma urealyticum infection, Valley fever, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, Vibrio species infection, Viral pneumonia, West Nile Fever, White Piedra, Yersinia pseudotuberculosis, Yersiniosis, Yellow fever, Zeaspora, Zika fever, Zygomycosis and combinations thereof.

Other diseases and disorders that can be treated using embodiments of the present invention include, but are not limited to, endocrine diseases (e.g. Type I and Type II diabetes, gestational diabetes, hypoglycemia. Glucagonoma, Goiter, Hyperthyroidism, hypothyroidism, thyroiditis, thyroid cancer, thyroid hormone resistance, parathyroid gland disorders, Osteoporosis, osteitis deformans, rickets, ostomalacia, hypopituitarism, pituitary tumors, etc.), skin conditions of infections and non-infectious origin, eye diseases of infectious or non-infectious origin, gastrointestinal disorders of infectious or non-infectious origin, cardiovascular diseases of infectious or non-infectious origin, brain and neuron diseases of infectious or non-infectious origin, nervous system diseases of infectious or non-infectious origin, muscle diseases of infectious or non-infectious origin, bone diseases of infectious or non-infectious origin, reproductive system diseases of infectious or non-infectious origin, renal system diseases of infectious or non-infectious origin, blood diseases of infectious or non-infectious origin, lymphatic system diseases of infectious or non-infectious origin, immune system diseases of infectious or non-infectious origin, mental-illness of infectious or non-infectious origin and the like.

In some embodiments, the disease to be treated is a muscle or muscle related disease or disorder, such as a genetic muscle disease or disorder.

Other diseases and disorders will be appreciated by those of skill in the art.

Adoptive Cell Therapies

Generally speaking, adoptive cell transfer involves the transfer of cells (autologous, allogeneic, and/or xenogeneic) to a subject. The cells may or may not be modified and/or otherwise manipulated prior to delivery to the subject.

In some embodiments, an engineered cell as described herein can be included in an adoptive cell transfer therapy. In some embodiments, an engineered cell as described herein can be delivered to a subject in need thereof. In some embodiments, the cell can be isolated from a subject, manipulated in vitro such that it contains and/or is capable of generating a composition of the present invention containing a muscle-specific targeting moiety described elsewhere herein (including but not limited to an engineered viral particle) described herein to produce an engineered cell and delivered back to the subject in an autologous manner or to a different subject in an allogeneic or xenogeneic manner. The cell isolated, manipulated, and/or delivered can be a eukaryotic cell. The cell isolated, manipulated, and/or delivered can be a stem cell. The cell isolated, manipulated, and/or delivered can be a differentiated cell. The cell isolated, manipulated, and/or delivered can be an immune cell, a blood cell, an endocrine cell, a renal cell, an exocrine cell, a nervous system cell, a vascular cell, a muscle cell, a urinary system cell, a bone cell, a soft tissue cell, a cardiac cell, a neuron, or an integumentary system cell. Other specific cell types will instantly be appreciated by one of ordinary skill in the art.

In some embodiments, the isolated cell can be manipulated such that it becomes an engineered cell as described elsewhere herein (e.g. contain and/or express one or more engineered delivery system molecules or vectors described elsewhere herein). Methods of making such engineered cells are described in greater detail elsewhere herein.

The administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The cells or population of cells may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

The administration of the cells or population of cells can be or involve the administration of 10⁴-10⁹ cells per kg body weight including all integer values of cell numbers within those ranges. In some embodiments, 10⁵ to 10⁶ cells/kg are delivered Dosing in adoptive cell therapies may for example involve administration of from 10⁶ to 10⁹ cells/kg, with or without a course of lymphodepletion, for example with cyclophosphamide. The cells or population of cells can be administrated in one or more doses. In another embodiment, the effective amount of cells are administrated as a single dose. In another embodiment, the effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions are within the skill of one in the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.

In another embodiment, the effective amount of cells or composition comprising those cells are administrated parenterally. The administration can be an intravenous administration. The administration can be directly done by injection within a tissue. In some embodiments, the tissue can be a tumor.

To guard against possible adverse reactions, engineered cells can be equipped with a transgenic safety switch, in the form of a transgene that renders the cells vulnerable to exposure to a specific signal. For example, the herpes simplex viral thymidine kinase (TK) gene may be used in this way, for example by introduction into the engineered cell similar to that discussed in Greco, et al., Improving the safety of cell therapy with the TK-suicide gene. Front. Pharmacol. 2015; 6: 95. In such cells, administration of a nucleoside prodrug such as ganciclovir or acyclovir causes cell death. Alternative safety switch constructs include inducible caspase 9, for example triggered by administration of a small-molecule dimerizer that brings together two nonfunctional icasp9 molecules to form the active enzyme. A wide variety of alternative approaches to implementing cellular proliferation controls have been described (see U.S. Patent Publication No. 20130071414; PCT Patent Publication WO2011146862; PCT Patent Publication WO2014011987; PCT Patent Publication WO2013040371; Zhou et al. BLOOD, 2014, 123/25:3895-3905; Di Stasi et al., The New England Journal of Medicine 2011; 365:1673-1683; Sadelain M, The New England Journal of Medicine 2011; 365:1735-173; Ramos et al., Stem Cells 28(6):1107-15 (2010)).

Methods of modifying isolated cells to obtain the engineered cells with the desired properties are described elsewhere herein. In some embodiments, the methods can include genome modification, including, but not limited to, genome editing using a CRISPR-Cas system to modify the cell. This can be in addition to introduction of an e.g., engineered AAV capsid system molecule describe elsewhere herein.

Allogeneic cells are rapidly rejected by the host immune system. It has been demonstrated that, allogeneic leukocytes present in non-irradiated blood products will persist for no more than 5 to 6 days (Boni, Muranski et al. 2008 Blood 1; 112(12):4746-54). Thus, to prevent rejection of allogeneic cells, the host's immune system usually has to be suppressed to some extent. However, in the case of adoptive cell transfer the use of immunosuppressive drugs also have a detrimental effect on the introduced therapeutic cells, such as engineered cells described herein. Therefore, to effectively use an adoptive immunotherapy approach in these conditions, the introduced cells would need to be resistant to the immunosuppressive treatment. Thus, in a particular embodiment, the present invention further comprises a step of modifying the engineered cells to make them resistant to an immunosuppressive agent, preferably by inactivating at least one gene encoding a target for an immunosuppressive agent. An immunosuppressive agent is an agent that suppresses immune function by one of several mechanisms of action. An immunosuppressive agent can be, but is not limited to a calcineurin inhibitor, a target of rapamycin, an interleukin-2 receptor α-chain blocker, an inhibitor of inosine monophosphate dehydrogenase, an inhibitor of dihydrofolic acid reductase, a corticosteroid or an immunosuppressive antimetabolite. The present invention allows conferring immunosuppressive resistance to engineered cells for adoptive cell therapy by inactivating the target of the immunosuppressive agent in engineered cells. As non-limiting examples, targets for an immunosuppressive agent can be a receptor for an immunosuppressive agent such as: CD52, glucocorticoid receptor (GR), a FKBP family gene member and a cyclophilin family gene member.

Immune checkpoints are inhibitory pathways that slow down or stop immune reactions and prevent excessive tissue damage from uncontrolled activity of immune cells. In certain embodiments, the immune checkpoint targeted is the programmed death-1 (PD-1 or CD279) gene (PDCD1). In other embodiments, the immune checkpoint targeted is cytotoxic T-lymphocyte-associated antigen (CTLA-4). In additional embodiments, the immune checkpoint targeted is another member of the CD28 and CTLA4 Ig superfamily such as BTLA, LAG3, ICOS, PDL1 or MR. In further additional embodiments, the immune checkpoint targeted is a member of the TNFR superfamily such as CD40, OX40, CD137, GITR, CD27 or TIM-3.

Additional immune checkpoints include Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) (Watson H A, et al., SHP-1: the next checkpoint target for cancer immunotherapy? Biochem Soc Trans. 2016 Apr. 15; 44(2):356-62). SHP-1 is a widely expressed inhibitory protein tyrosine phosphatase (PTP). In T-cells, it is a negative regulator of antigen-dependent activation and proliferation. It is a cytosolic protein, and therefore not amenable to antibody-mediated therapies, but its role in activation and proliferation makes it an attractive target for genetic manipulation in adoptive transfer strategies, such as chimeric antigen receptor (CAR) T cells. Immune checkpoints may also include T cell immunoreceptor with Ig and ITIM domains (TIGITNstm3/WUCAM/VSIG9) and VISTA (Le Mercier I, et al., (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol. 6:418).

International Patent Publication No. WO2014172606 relates to the use of MT1 and/or MT1 inhibitors to increase proliferation and/or activity of exhausted CD8+ T-cells and to decrease CD8+ T-cell exhaustion (e.g., decrease functionally exhausted or unresponsive CD8+ immune cells). In certain embodiments, metallothioneins are targeted by gene editing in adoptively transferred T cells.

In certain embodiments, targets of gene editing may be at least one targeted locus involved in the expression of an immune checkpoint protein. Such targets may include, but are not limited to CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, ICOS (CD278), PDL1, KIR, LAG3, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, LAIR1, SIGLEC7, SIGLEC9, CD244 (2B4), TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, VISTA, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, MT1, MT2, CD40, OX40, CD137, GITR, CD27, SHP-1 or TIM-3. In some embodiments, the gene locus involved in the expression of PD-1 or CTLA-4 genes is targeted. In some embodiments, combinations of genes are targeted, such as but not limited to PD-1 and TIGIT.

In some embodiments, at least two genes are edited. Pairs of genes may include, but are not limited to PD1 and TCRα, PD1 and TCRβ, CTLA-4 and TCRα, CTLA-4 and TCRβ, LAG3 and TCRα, LAG3 and TCRβ, Tim3 and TCRα, Tim3 and TCRβ, BTLA and TCRα, BTLA and TCRβ, BY55 and TCRα, BY55 and TCRβ, TIGIT and TCRα, TIGIT and TCRβ, B7H5 and TCRα, B7H5 and TCRβ, LAIR1 and TCRα, LAIR1 and TCRβ, SIGLEC10 and TCRα, SIGLEC10 and TCRβ, 2B4 and TCRα, 2B4 and TCRβ.

Whether prior to or after genetic or other modification of the engineered cells (such as engineered T cells (e.g. the isolated cell is a T cell), the engineered cells can be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and 7,572,631. The engineered cells can be expanded in vitro or in vivo.

In some embodiments, the method comprises editing the engineered cells ex vivo by a suitable gene modification method described elsewhere herein (e.g. gene editing via a CRISPR-Cas system) to eliminate potential alloreactive TCRs or other receptors to allow allogeneic adoptive transfer. In some embodiments, T cells are edited ex vivo by a CRISPR-Cas system or other suitable genome modification technique to knock-out or knock-down an endogenous gene encoding a TCR (e.g., an αβ TCR) or other relevant receptor to avoid graft-versus-host-disease (GVHD). In some embodiments, where the engineered cells are T cells, the engineered cells are edited ex vivo by CRISPR or other appropriate gene modification method to mutate the TRAC locus. In some embodiments, T cells are edited ex vivo via a CRISPR-Cas system using one or more guide sequences targeting the first exon of TRAC. See Liu et al., Cell Research 27:154-157 (2017). In some embodiments, the first exon of TRAC is modified using another appropriate gene modification method. In some embodiments, the method comprises use of CRISPR or other appropriate method to knock-in an exogenous gene encoding a CAR or a TCR into the TRAC locus, while simultaneously knocking-out the endogenous TCR (e.g., with a donor sequence encoding a self-cleaving P2A peptide following the CAR cDNA). See Eyquem et al., Nature 543:113-117 (2017). In some embodiments, the exogenous gene comprises a promoter-less CAR-encoding or TCR-encoding sequence which is inserted operably downstream of an endogenous TCR promoter.

In some embodiments, the method comprises editing the engineered cell, e.g. engineered T cells, ex vivo via a CRISPR-Cas system to knock-out or knock-down an endogenous gene encoding an HLA-I protein to minimize immunogenicity of the edited cells, e.g. engineered T cells. In some embodiments, engineered T cells can be edited ex vivo via a CRISPR-Cas system to mutate the beta-2 microglobulin (B2M) locus. In some embodiments, engineered cell, e.g. engineered T cells, are edited ex vivo via a CRISPR-Cas system using one or more guide sequences targeting the first exon of B2M. The first exon of B2M can also be modified using another appropriate modification method. See Liu et al., Cell Research 27:154-157 (2017). The first exon of B2M can also be modified using another appropriate modification method, which will be appreciated by those of ordinary skill in the art. In some embodiments, the method comprises use a CRISPR-Cas system to knock-in an exogenous gene encoding a CAR or a TCR into the B2M locus, while simultaneously knocking-out the endogenous B2M (e.g., with a donor sequence encoding a self-cleaving P2A peptide following the CAR cDNA). See Eyquem et al., Nature 543:113-117 (2017). This can also be accomplished using another appropriate modification method, which will be appreciated by those of ordinary skill in the art. In some embodiments, the exogenous gene comprises a promoter-less CAR-encoding or TCR-encoding sequence which is inserted operably downstream of an endogenous B2M promoter.

In some embodiments, the method comprises editing the engineered cell, e.g. engineered T cells, ex vivo via a CRISPR-Cas system to knock-out or knock-down an endogenous gene encoding an antigen targeted by an exogenous CAR or TCR. This can also be accomplished using another appropriate modification method, which will be appreciated by those of ordinary skill in the art. In some embodiments, the engineered cells, such as engineered T cells, are edited ex vivo via a CRISPR-Cas system to knock-out or knock-down the expression of a tumor antigen selected from human telomerase reverse transcriptase (hTERT), survivin, mouse double minute 2 homolog (MDM2), cytochrome P450 1B 1 (CYP1B), HER2/neu, Wilms' tumor gene 1 (WT1), livin, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), mucin 16 (MUC16), MUC1, prostate-specific membrane antigen (PSMA), p53 or cyclin (DI) (see WO2016/011210). This can also be accomplished using another appropriate modification method, which will be appreciated by those of ordinary skill in the art. In some embodiments, the engineered cells, such as engineered T cells are edited ex vivo via a CRISPR-Cas system to knock-out or knock-down the expression of an antigen selected from B cell maturation antigen (BCMA), transmembrane activator and CAML Interactor (TACI), or B-cell activating factor receptor (BAFF-R), CD38, CD138, CS-1, CD33, CD26, CD30, CD53, CD92, CD100, CD148, CD150, CD200, CD261, CD262, or CD362 (see WO2017/011804). This can also be accomplished using another appropriate modification method, which will be appreciated by those of ordinary skill in the art.

Gene Drives

The present invention also contemplates use of the compositions containing a muscle-specific targeting moiety described elsewhere herein, formulations thereof, cells thereof, vector systems, and the like to generate a gene drive via delivery of one or more cargo polynucleotides or production of a composition containing a muscle-specific targeting moiety described elsewhere herein (including but not limited to engineered AAV capsid particles) with one or more cargo polynucleotides capable of producing a gene drive. In some embodiments, the gene drive can be a Cas-mediated RNA-guided gene drive e.g. Cas- to provide RNA-guided gene drives, for example in systems analogous to gene drives described in International Patent Publication WO 2015/105928. Systems of this kind may for example provide methods for altering eukaryotic germline cells, by introducing into the germline cell a nucleic acid sequence encoding an RNA-guided DNA nuclease and one or more guide RNAs. The guide RNAs may be designed to be complementary to one or more target locations on genomic DNA of the germline cell. The nucleic acid sequence encoding the RNA guided DNA nuclease and the nucleic acid sequence encoding the guide RNAs may be provided on constructs between flanking sequences, with promoters arranged such that the germline cell may express the RNA guided DNA nuclease and the guide RNAs, together with any desired cargo-encoding sequences that are also situated between the flanking sequences. The flanking sequences will typically include a sequence which is identical to a corresponding sequence on a selected target chromosome, so that the flanking sequences work with the components encoded by the construct to facilitate insertion of the foreign nucleic acid construct sequences into genomic DNA at a target cut site by mechanisms such as homologous recombination, to render the germline cell homozygous for the foreign nucleic acid sequence. In this way, gene-drive systems are capable of introgressing desired cargo genes throughout a breeding population (Gantz et al., 2015, Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi, PNAS 2015, published ahead of print Nov. 23, 2015, doi:10.1073/pnas.1521077112; Esvelt et al., 2014, Concerning RNA-guided gene drives for the alteration of wild populations eLife 2014; 3:e03401). In select embodiments, target sequences may be selected which have few potential off-target sites in a genome. Targeting multiple sites within a target locus, using multiple guide RNAs, may increase the cutting frequency and hinder the evolution of drive resistant alleles. Truncated guide RNAs may reduce off-target cutting. Paired nickases may be used instead of a single nuclease, to further increase specificity. Gene drive constructs (such as gene drive engineered delivery system constructs) may include cargo sequences encoding transcriptional regulators, for example to activate homologous recombination genes and/or repress non-homologous end-joining. Target sites may be chosen within an essential gene, so that non-homologous end-joining events may cause lethality rather than creating a drive-resistant allele. The gene drive constructs can be engineered to function in a range of hosts at a range of temperatures (Cho et al. 2013, Rapid and Tunable Control of Protein Stability in Caenorhabditis elegans Using a Small Molecule, PLoS ONE 8(8): e72393. doi:10.1371/journal.pone.0072393).

Transplantation and Xenotransplantation

The compositions containing a muscle-specific targeting moiety described elsewhere herein, formulations thereof, cells thereof, vector systems, and the like, can be used to deliver cargo polynucleotides and/or otherwise be involved in modifying tissues for transplantation between two different persons (transplantation) or between species (xenotransplantation). Such techniques for generation of transgenic animals is described elsewhere herein. Interspecies transplantation techniques are generally known in the art. For example, RNA-guided DNA nucleases can be delivered using via engineered viral particles or other delivery vehicles, polynucleotides, vectors, and/or engineered cells of the present invention described herein and can be used to knockout, knockdown or disrupt selected genes in an organ for transplant (e.g. ex vivo (e.g. after harvest but before transplantation) or in vivo (in donor or recipient)), animal, such as a transgenic pig (such as the human heme oxygenase-1 transgenic pig line), for example by disrupting expression of genes that encode epitopes recognized by the human immune system, i.e. xenoantigen genes. Candidate porcine genes for disruption may for example include α(1,3)-galactosyltransferase and cytidine monophosphate-N-acetylneuraminic acid hydroxylase genes (see International Patent Publication WO 2014/066505). In addition, genes encoding endogenous retroviruses may be disrupted, for example the genes encoding all porcine endogenous retroviruses (see Yang et al., 2015, Genome-wide inactivation of porcine endogenous retroviruses (PERVs), Science 27 Nov. 2015: Vol. 350 no. 6264 pp. 1101-1104). In addition, RNA-guided DNA nucleases may be used to target a site for integration of additional genes in xenotransplant donor animals, such as a human CD55 gene to improve protection against hyperacute rejection.

Where it is interspecies transplantation (such as human to human) the composition compositions containing a muscle-specific targeting moiety described elsewhere herein, or composition containing a muscle-specific targeting moiety (e.g. an engineered AAV capsid system molecule, vectors, engineered cells, and/or engineered delivery particles described herein), can be used to deliver cargo polynucleotides and/or otherwise be involved to modify the tissue to be transplanted. In some embodiments, the modification can include modifying one or more HLA antigens or other tissue type determinants, such that the immunogenic profile is more similar or identical to the recipient's immunogenic profile than to the donor's so as to reduce the occurrence of rejection by the recipient. Relevant tissue type determinants are known in the art (such as those used to determine organ matching) and techniques to determine the immunogenic profile (which is made up of the expression signature of the tissue type determinants) are generally known in the art.

In some embodiments, the donor (such as before harvest) or recipient (after transplantation) can receive one or more of the compositions containing a muscle-specific targeting moiety described elsewhere herein, formulations thereof, cells thereof, vector systems, engineered muscle-specific delivery system molecules, vectors, engineered cells, and/or engineered delivery particles described herein that are capable of modifying the immunogenic profile of the transplanted cells, tissue, and/or organ. In some embodiments, the transplanted cells, tissue, and/or organ can be harvested from the donor and the compositions containing a muscle-specific targeting moiety described elsewhere herein, formulations thereof, cells thereof, vector systems, engineered muscle-specific delivery system molecules, vectors, engineered cells, and/or engineered delivery particles described herein capable of modifying the harvested cells, tissue, and/or organ to be, for example, less immunogenic or be modified to have some specific characteristic when transplanted in the recipient can be delivered to the harvested cells, tissue, and/or organ ex vivo. After delivery the cells, tissue, and/or organs can be transplanted into the donor.

Gene Modification and Treatment of Diseases with Genetic or Epigenetic Aspects

The engineered muscle-specific delivery system molecules, vectors, engineered cells, and/or engineered delivery particles described herein containing a muscle-specific targeting moiety can be used to modify genes or other polynucleotides and/or treat diseases with genetic and/or epigenetic aspects. As described elsewhere herein the cargo molecule can be a polynucleotide that can be delivered to a cell and, in some embodiments, be integrated into the genome of the cell. In some embodiments, the cargo molecule(s) can be one or more CRISPR-Cas system components. In some embodiments, the CRISPR-Cas components, when delivered by a composition or formulation thereof of the present invention, such as an engineered muscle-specific viral particle or other engineered delivery vehicle described herein, can be optionally expressed in the recipient cell and act to modify the genome of the recipient cell in a sequence specific manner. In some embodiments, the cargo molecules that can be packaged and delivered by the engineered viral particles or other engineered delivery vehicles and/or compositions described herein can facilitate/mediate genome modification via a method that is not dependent on CRISPR-Cas. Such non-CRISPR-Cas genome modification systems will instantly be appreciated by those of ordinary skill in the art and are also, at least in part, described elsewhere herein. In some embodiments, modification is at a specific target sequence. In other embodiments, modification is at locations that appear to be random throughout the genome.

Examples of disease-associated genes and polynucleotides and disease specific information is available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World Wide Web. Any of these can be appropriate to be treated by one or more of the methods described herein. In some embodiments, the disease is a muscle disease or disorder, neuro-muscular disease or disorder, or a cardiomyopathy. In some embodiments, the disease or disorder selected from any one or more of the following:

(a) an auto immune disease;

(b) a cancer;

(c) a muscular dystrophy;

(d) a neuro-muscular disease;

(e) a sugar or glycogen storage disease;

(f) an expanded repeat disease;

(g) a dominant negative disease;

(h) a cardiomyopathy;

(i) a viral disease;

(j) a progeroid disease; or

(k) any combination thereof.

In some embodiments, the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD. In some embodiments, the myotonic dystrophy is Type 1 or Type 2. In some embodiments, the LGMD is subtype 2A, 2B, 2C, 2D, 2E, or 2L. In some embodiments, the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, DMD-associated cardiomyopathy, or Dannon disease. In some embodiments, the sugar or glycogen storage disease is a MPS type III disease or Pompe disease. In some embodiments, the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or IIID. In some embodiments, the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.

More specifically, mutations in these genes and pathways can result in production of improper proteins or proteins in improper amounts which affect function. Further examples of genes, diseases and proteins are hereby incorporated by reference from U.S. Provisional application 61/736,527 filed Dec. 12, 2012. Such genes, proteins and pathways may be the target polynucleotide of a CRISPR complex of the present invention. Examples of disease-associated and/or cell function-associated genes and polynucleotides are listed in Tables A and B.

TABLE A Exemplary Genetic and Other Diseases and Associated Genes Primary Additional Tissues or Tissues/ System Systems Disease Name Affected Affected Genes Achondroplasia Bone and fibroblast growth factor receptor 3 Muscle (FGFR3) Achromatopsia eye CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, ACHM2, ACHM3, Acute Renal Injury kidney NFkappaB, AATF, p85alpha, FAS, Apoptosis cascade elements (e.g. FASR, Caspase 2, 3, 4, 6, 7, 8, 9, 10, AKT, TNF alpha, IGF1, IGF1R, RIPK1), p53 Age Related Macular eye Abcr; CCL2; CC2; CP Degeneration (ceruloplasmin); Timp3; cathepsinD; VLDLR, CCR2 AIDS Immune System KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1, IFNG, CXCL12, SDF1 Albinism (including Skin, hair, eyes, TYR, OCA2, TYRP1, and SLC45A2, oculocutaneous albinism (types SLC24A5 and C10orf11 1-7) and ocular albinism) Alkaptonuria Metabolism of Tissues/organs HGD amino acids where homogentisic acid accumulates, particularly cartilage (joints), heart valves, kidneys alpha-1 antitrypsin deficiency Lung Liver, skin, SERPINA1, those set forth in (AATD or A1AD) vascular system, WO2017165862, PiZ allele kidneys, GI ALS CNS SOD1; ALS2; ALS3; ALS5; ALS7; STEX; FUS; TARDBP; VEGF (VEGF-a; VEGF-b; VEGF-c); DPP6; NEFH, PTGS1, SLC1A2, TNFRSF10B, PRPH, HSP90AA1, CRIA2, IFNG, AMPA2 S100B, FGF2, AOX1, CS, TXN, RAPHJ1, MAP3K5, NBEAL1, GPX1, ICA1L, RAC1, MAPT, ITPR2, ALS2CR4, GLS, ALS2CR8, CNTFR, ALS2CR11, FOLH1, FAM117B, P4HB, CNTF, SQSTM1, STRADB, NAIP, NLR, YWHAQ, SLC33A1, TRAK2, SCA1, NIF3L1, NIF3, PARD3B, COX8A, CDK15, HECW1, HECT, C2, WW 15, NOS1, MET, SOD2, HSPB1, NEFL, CTSB, ANG, HSPA8, RNase A, VAPB, VAMP, SNCA, alpha HGF, CAT, ACTB, NEFM, TH, BCL2, FAS, CASP3, CLU, SMN1, G6PD, BAX, HSF1, RNF19A, JUN, ALS2CR12, HSPA5, MAPK14, APEX1, TXNRD1, NOS2, TIMP1, CASP9, XIAP, GLG1, EPO, VEGFA, ELN, GDNF, NFE2L2, SLC6A3, HSPA4, APOE, PSMB8, DCTN2, TIMP3, KIFAP3, SLC1A1, SMN2, CCNC, STUB1, ALS2, PRDX6, SYP, CABIN1, CASP1, GART, CDK5, ATXN3, RTN4, C1QB, VEGFC, HTT, PARK7, XDH, GFAP, MAP2, CYCS, FCGR3B, CCS, UBL5, MMP9m SLC18A3, TRPM7, HSPB2, AKT1, DEERL1, CCL2, NGRN, GSR, TPPP3, APAF1, BTBD10, GLUD1, CXCR4, S:C1A3, FLT1, PON1, AR, LIF, ERBB3, :GA:S1, CD44, TP53, TLR3, GRIA1, GAPDH, AMPA, GRIK1, DES, CHAT, FLT4, CHMP2B, BAG1, CHRNA4, GSS, BAK1, KDR, GSTP1, OGG1, IL6 Alzheimer's Disease Brain E1; CHIP; UCH; UBB; Tau; LRP; PICALM; CLU; PS1; SORL1; CR1; VLDLR; UBA1; UBA3; CHIP28; AQP1; UCHL1; UCHL3; APP, AAA, CVAP, AD1, APOE, AD2, DCP1, ACE1, MPO, PACIP1, PAXIP1L, PTIP, A2M, BLMH, BMH, PSEN1, AD3, ALAS2, ABCA1, BIN1, BDNF, BTNL8, C1ORF49, CDH4, CHRNB2, CKLFSF2, CLEC4E, CR1L, CSF3R, CST3, CYP2C, DAPK1, ESR1, FCAR, FCGR3B, FFA2, FGA, GAB2, GALP, GAPDHS, GMPB, HP, HTR7, IDE, IF127, IFI6, IFIT2, IL1RN, IL- 1RA, IL8RA, IL8RB, JAG1, KCNJ15, LRP6, MAPT, MARK4, MPHOSPH1, MTHFR, NBN, NCSTN, NIACR2, NMNAT3, NTM, ORM1, P2RY13, PBEF1, PCK1, PICALM, PLAU, PLXNC1, PRNP, PSEN1, PSEN2, PTPRA, RALGPS2, RGSL2, SELENBP1, SLC25A37, SORL1, Mitoferrin-1, TF, TFAM, TNF, TNFRSF10C, UBE1C Amyloidosis APOA1, APP, AAA, CVAP, AD1, GSN, FGA, LYZ, TTR, PALB Amyloid neuropathy TTR, PALB Anemia Blood CDAN1, CDA1, RPS19, DBA, PKLR, PK1, NT5C3, UMPH1, PSN1, RHAG, RH50A, NRAMP2, SPTB, ALAS2, ANH1, ASB, ABCB7, ABC7, ASAT Angelman Syndrome Nervous system, UBE3A brain Attention Deficit Hyperactivity Brain PTCHD1 Disorder (ADHD) Autoimmune lymphoproliferative Immune system TNFRSF6, APT1, FAS, CD95, syndrome ALPS1A Autism, Autism spectrum Brain PTCHD1; Mecp2; BZRAP1; MDGA2; disorders (ASDs), including Sema5A; Neurexin 1; GLO1, RTT, Asperger's and a general PPMX, MRX16, RX79, NLGN3, diagnostic category called NLGN4, KIAA1260, AUTSX2, Pervasive Developmental FMRI, FMR2; FXR1; FXR2; Disorders (PDDs) MGLUR5, ATP10C, CDH10, GRM6, MGLUR6, CDH9, CNTN4, NLGN2, CNTNAP2, SEMA5A, DHCR7, NLGN4X, NLGN4Y, DPP6, NLGN5, EN2, NRCAM, MDGA2, NRXN1, FMR2, AFF2, FOXP2, OR4M2, OXTR, FXR1, FXR2, PAH, GABRA1, PTEN, GABRA5, PTPRZ1, GABRB3, GABRG1, HIRIP3, SEZ6L2, HOXA1, SHANK3, IL6, SHBZRAP1, LAMB1, SLC6A4, SERT, MAPK3, TAS2R1, MAZ, TSC1, MDGA2, TSC2, MECP2, UBE3A, WNT2, see also 20110023145 autosomal dominant polycystic kidney liver PKD1, PKD2 kidney disease (ADPKD) - (includes diseases such as von Hippel-Lindau disease and tubreous sclerosis complex disease) Autosomal Recessive Polycystic kidney liver PKDH1 Kidney Disease (ARPKD) Ataxia-Telangiectasia (a.k.a Nervous system, various ATM Louis Bar syndrome) immune system B-Cell Non-Hodgkin Lymphoma BCL7A, BCL7 Bardet-Biedl syndrome Eye, Liver, ear, ARL6, BBS1, BBS2, BBS4, BBS5, musculoskeletal gastrointestinal BBS7, BBS9, BBS10, BBS12, system, kidney, system, brain CEP290, INPP5E, LZTFL1, MKKS, reproductive MKS1, SDCCAG8, TRIM32, TTC8 organs Bare Lymphocyte Syndrome blood TAPBP, TPSN, TAP2, ABCB3, PSF2, RING11, MHC2TA, C2TA, RFX5, RFXAP, RFX5 Barter's Syndrome (types I, II, kidney SLC12A1 (type I), KCNJ1 (type II), III, IVA and B, and V) CLCNKB (type III), BSND (type IV A), or both the CLCNKA CLCNKB genes (type IV B), CASR (type V). Becker muscular dystrophy Muscle DMD, BMD, MYF6 Best Disease (Vitelliform eye VMD2 Macular Dystrophy type 2) Bleeding Disorders blood TBXA2R, P2RX1, P2X1 Blue Cone Monochromacy eye OPN1LW, OPN1MW, and LCR Breast Cancer Breast tissue BRCA1, BRCA2, COX-2 Bruton's Disease (aka X-linked Immune system, BTK Agammglobulinemia) specifically B cells Cancers (e.g., lymphoma, chronic Various FAS, BID, CTLA4, PDCD1, CBLB, lymphocytic leukemia (CLL), B PTPN6, TRAC, TRBC, those cell acute lymphocytic leukemia described in WO2015048577 (B-ALL), acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma (NHL), diffuse large cell lymphoma (DLCL), multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, colorectal cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, and medulloblastoma Cardiovascular Diseases heart Vascular system IL1B, XDH, TP53, PTGS, MB, IL4, ANGPT1, ABCGu8, CTSK, PTGIR, KCNJ11, INS, CRP, PDGFRB, CCNA2, PDGFB, KCNJ5, KCNN3, CAPN10, ADRA2B, ABCG5, PRDX2, CPAN5, PARP14, MEX3C, ACE, RNF, IL6, TNF, STN, SERPINE1, ALB, ADIPOQ, APOB, APOE, LEP, MTHFR, APOA1, EDN1, NPPB, NOS3, PPARG, PLAT, PTGS2, CETP, AGTR1, HMGCR, IGF1, SELE, REN, PPARA, PON1, KNG1, CCL2, LPL, VWF, F2, ICAM1, TGFB, NPPA, IL10, EPO, SOD1, VCAM1, IFNG, LPA, MPO, ESR1, MAPK, HP, F3, CST3, COG2, MMP9, SERPINC1, F8, HMOX1, APOC3, IL8, PROL1, CBS, NOS2, TLR4, SELP, ABCA1, AGT, LDLR, GPT, VEGFA, NR3C2, IL18, NOS1, NR3C1, FGB, HGF, ILIA, AKT1, LIPC, HSPD1, MAPK14, SPP1, ITGB3, CAT, UTS2, THBD, F10, CP, TNFRSF11B, EGFR, MMP2, PLG, NPY, RHOD, MAPK8, MYC, FN1, CMA1, PLAU, GNB3, ADRB2, SOD2, F5, VDR, ALOX5, HLA- DRB1, PARP1, CD40LG, PON2, AGER, IRS1, PTGS1, ECE1, F7, IRMN, EPHX2, IGFBP1, MAPK10, FAS, ABCB1, JUN, IGFBP3, CD14, PDE5A, AGTR2, CD40, LCAT, CCR5, MMP1, TIMP1, ADM, DYT10, STAT3, MMP3, ELN, USF1, CFH, HSPA4, MMP12, MME, F2R, SELL, CTSB, ANXA5, ADRB1, CYBA, FGA, GGT1, LIPG, HIF1A, CXCR4, PROC, SCARB1, CD79A, PLTP, ADD1, FGG, SAA1, KCNH2, DPP4, NPR1, VTN, KIAA0101, FOS, TLR2, PPIG, IL1R1, AR, CYP1A1, SERPINA1, MTR, RBP4, APOA4, CDKN2A, FGF2, EDNRB, ITGA2, VLA-2, CABIN1, SHBG, HMGB1, HSP90B2P, CYP3A4, GJA1, CAV1, ESR2, LTA, GDF15, BDNF, CYP2D6, NGF, SP1, TGIF1, SRC, EGF, PIK3CG, HLA-A, KCNQ1, CNR1, FBN1, CHKA, BEST1, CTNNB1, IL2, CD36, PRKAB1, TPO, ALDH7A1, CX3CR1, TH, F9, CH1, TF, HFE, IL17A, PTEN, GSTM1, DMD, GATA4, F13A1, TTR, FABP4, PON3, APOC1, INSR, TNFRSF1B, HTR2A, CSF3, CYP2C9, TXN, CYP11B2, PTH, CSF2, KDR, PLA2G2A, THBS1, GCG, RHOA, ALDH2, TCF7L2, NFE2L2, NOTCH1, UGT1A1, IFNA1, PPARD, SIRT1, GNHR1, PAPPA, ARR3, NPPC, AHSP, PTK2, IL13, MTOR, ITGB2, GSTT1, IL6ST, CPB2, CYP1A2, HNF4A, SLC64A, PLA2G6, TNFSF11, SLC8A1, F2RL1, AKR1A1, ALDH9A1, BGLAP, MTTP, MTRR, SULT1A3, RAGE, C4B, P2RY12, RNLS, CREB1, POMC, RAC1, LMNA, CD59, SCM5A, CYP1B1, MIF, MMP13, TIMP2, CYP19A1, CUP21A2, PTPN22, MYH14, MBL2, SELPLG, AOC3, CTSL1, PCNA, IGF2, ITGB1, CAST, CXCL12, IGHE, KCNE1, TFRC, COL1A1, COL1A2, IL2RB, PLA2G10, ANGPT2, PROCR, NOX4, HAMP, PTPN11, SLCA1, IL2RA, CCL5, IRF1, CF:AR, CA:CA, EIF4E, GSTP1, JAK2, CYP3A5, HSPG2, CCL3, MYD88, VIP, SOAT1, ADRBK1, NR4A2, MMP8, NPR2, GCH1, EPRS, PPARGC1A, F12, PECAM1, CCL4, CERPINA34, CASR, FABP2, TTF2, PROS1, CTF1, SGCB, YME1L1, CAMP, ZC3H12A, AKR1B1, MMP7, AHR, CSF1, HDAC9, CTGF, KCNMA1, UGT1A, PRKCA, COMT, S100B, EGR1, PRL, IL15, DRD4, CAMK2G, SLC22A2, CCL11, PGF, THPO, GP6, TACR1, NTS, HNF1A, SST, KCDN1, LOC646627, TBXAS1, CUP2J2, TBXA2R, ADH1C, ALOX12, AHSG, BHMT, GJA4, SLC25A4, ACLY, ALOX5AP, NUMA1, CYP27B1, CYSLTR2, SOD3, LTC4S, UCN, GHRL, APOC2, CLEC4A, KBTBD10, TNC, TYMS, SHC1, LRP1, SOCS3, ADH1B, KLK3, HSD11B1, VKORC1, SERPINB2, TNS1, RNF19A, EPOR, ITGAM, PITX2, MAPK7, FCGR3A, LEEPR, ENG, GPX1, GOT2, HRH1, NR112, CRH, HTR1A, VDAC1, HPSE, SFTPD, TAP2, RMF123, PTK2Bm NTRK2, IL6R, ACHE, GLP1R, GHR, GSR, NQO1, NR5A1, GJB2, SLC9A1, MAOA, PCSK9, FCGR2A, SERPINF1, EDN3, UCP2, TFAP2A, C4BPA, SERPINF2, TYMP, ALPP, CXCR2, SLC3A3, ABCG2, ADA, JAK3, HSPA1A, FASN, FGF1, F11, ATP7A, CR1, GFPA, ROCK1, MECP2, MYLK, BCHE, LIPE, ADORA1, WRN, CXCR3, CD81, SMAD7, LAMC2, MAP3K5, CHGA, IAPP, RHO, ENPP1, PTHLH, NRG1, VEGFC, ENPEP, CEBPB, NAGLU,. F2RL3, CX3CL1, BDKRB1, ADAMTS13, ELANE, ENPP2, CISH, GAST, MYOC, ATP1A2, NF1, GJB1, MEF2A, VCL, BMPR2, TUBB, CDC42, KRT18, HSF1, MYB, PRKAA2, ROCK2, TFP1, PRKG1, BMP2, CTNND1, CTH, CTSS, VAV2, NPY2R, IGFBP2, CD28, GSTA1, PPIA, APOH, S100A8, IL11, ALOX15, FBLN1, NR1H3, SCD, GIP, CHGB, PRKCB, SRD5A1,HSD11B2, CALCRL, GALNT2, ANGPTL4, KCNN4, PIK3C2A, HBEGF, CYP7A1, HLA-DRB5, BNIP3, GCKR, S100A12, PADI4, HSPA14, CXCR1, H19, KRTAP19-3, IDDM2, RAC2, YRY1, CLOCK, NGFR, DBH, CHRNA4, CACNA1C, PRKAG2, CHAT, PTGDS, NR1H2, TEK, VEGFB, MEF2C, MAPKAPK2, TNFRSF11A, HSPA9, CYSLTR1, MATIA, OPRL1, IMPA1, CLCN2, DLD, PSMA6, PSMB8, CHI3L1, ALDH1B1, PARP2,STAR, LBP, ABCC6, RGS2, EFNB2, GJB6, APOA2, AMPD1, DYSF, FDFT1, EMD2, CCR6, GJB3, IL1RL1, ENTPD1, BBS4, CELSR2, F11R, RAPGEF3, HYAL1, ZNF259, ATOX1, ATF6, KHK, SAT1, GGH, TIMP4, SLC4A4, PDE2A, PDE3B, FADS1, FADS2, TMSB4X, TXNIP, LIMS1, RHOB, LY96, FOXO1, PNPLA2,TRH, GJC1, S:C17A5, FTO, GJD2, PRSC1, CASP12, GPBAR1, PXK, IL33, TRIB1, PBX4, NUPR1, 15-SEP, CILP2, TERC, GGT2, MTCO1, UOX, AVP Cataract eye CRYAA, CRYA1, CRYBB2, CRYB2, PITX3, BFSP2, CP49, CP47, CRYAA, CRYA1, PAX6, AN2, MGDA, CRYBA1, CRYB1, CRYGC, CRYG3, CCL, LIM2, MP19, CRYGD, CRYG4, BFSP2, CP49, CP47, HSF4, CTM, HSF4, CTM, MIP, AQP0, CRYAB, CRYA2, CTPP2, CRYBB1, CRYGD, CRYG4, CRYBB2, CRYB2, CRYGC, CRYG3, CCL, CRYAA, CRYA1, GJA8, CX50, CAE1, GJA3, CX46, CZP3, CAE3, CCM1, CAM, KRIT1 CDKL-5 Deficiencies or Brain, CNS CDKL5 Mediated Diseases Charcot-Marie-Tooth (CMT) Nervous system Muscles PMP22 (CMT1A and E), MPZ disease (Types 1, 2, 3, 4,) (dystrophy) (CMT1B), LITAF (CMT1C), EGR2 (CMT1D), NEFL (CMT1F), GJB1 (CMT1X), MFN2 (CMT2A), KIF1B (CMT2A2B), RAB7A (CMT2B), TRPV4 (CMT2C), GARS (CMT2D), NEFL (CMT2E), GAPD1 (CMT2K), HSPB8 (CMT2L), DYNC1H1, CMT20), LRSAM1 (CMT2P), IGHMBP2 (CMT2S), MORC2 (CMT2Z), GDAP1 (CMT4A), MTMR2 or SBF2/MTMR13 (CMT4B), SH3TC2 (CMT4C), NDRG1 (CMT4D), PRX (CMT4F), FIG4 (CMT4J), NT-3 Chédiak-Higashi Syndrome Immune system Skin, hair, eyes, LYST neurons Choroidermia CHM, REP1, Chorioretinal atrophy eye PRDM13, RGR, TEAD1 Chronic Granulomatous Disease Immune system CYBA, CYBB, NCF1, NCF2, NCF4 Chronic Mucocutaneous Immune system AIRE, CARD9, CLEC7A IL12B, Candidiasis IL12B1, IL1F, IL17RA, IL17RC, RORC, STAT1, STAT3, TRAF31P2 Cirrhosis liver KRT18, KRT8, CIRH1A, NAIC, TEX292, KIAA1988 Colon cancer (Familial Gastrointestinal FAP: APC HNPCC: adenomatous polyposis (FAP) MSH2, MLH1, PMS2, SH6, PMS1 and hereditary nonpolyposis colon cancer (HNPCC)) Combined Immunodeficiency Immune System IL2RG, SCIDX1, SCIDX, IMD4); HIV-1 (CCL5, SCYA5, D17S136E, TCP228 Cone(-rod) dystrophy eye AIPL1, CRX, GUA1A, GUCY2D, PITPM3, PROM1, PRPH2, RIMS1, SEMA4A, ABCA4, ADAM9, ATF6, C21ORF2, C8ORF37, CACNA2D4, CDHR1, CERKL, CNGA3, CNGB3, CNNM4, CNAT2, IFT81, KCNV2, PDE6C, PDE6H, POC1B, RAX2, RDH5, RPGRIP1, TTLL5, RetCG1, GUCY2E Congenital Stationary Night eye CABP4, CACNA1F, CACNA2D4, Blindness GNAT1, CPR179, GRK1, GRM6, LRIT3, NYX, PDE6B, RDH5, RHO, RLBP1, RPE65, SAG, SLC24A1, TRPM1, Congenital Fructose Intolerance Metabolism ALDOB Cori's Disease (Glycogen Storage Various- AGL Disease Type III) wherever glycogen accumulates, particularly liver, heart, skeletal muscle Corneal clouding and dystrophy eye APOA1, TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, TACSTD2, TROP2, M1S1, VSX1, RINX, PPCD, PPD, KTCN, COL8A2, FECD, PPCD2, PIP5K3, CFD Cornea plana congenital KERA, CNA2 Cri du chat Syndrome, also Deletions involving only band 5p15.2 known as 5p syndrome and cat to the entire short arm of chromosome cry syndrome 5, e.g. CTNND2, TERT, Cystic Fibrosis (CF) Lungs and Pancreas, liver, CTFR, ABCC7, CF, MRP7, SCNN1A, respiratory digestive those described in WO2015157070 system system, reproductive system, exocrine, glands, Diabetic nephropathy kidney Gremlin, 12/15- lipoxygenase, TIM44, Dent Disease (Types 1 and 2) Kidney Type 1: CLCN5, Type 2: ORCL Dentatorubro-Pallidoluysian CNS, brain, Atrophin-1 and Atn1 Atrophy (DRPLA) (aka Haw muscle River and Naito-Oyanagi Disease) Down Syndrome various Chromosome 21 trisomy Drug Addiction Brain Prkce; Drd2; Drd4; ABAT; GRIA2; Grm5; Grin1; Htr1b; Grin2a; Drd3; Pdyn; Gria1 Duane syndrome (Types 1, 2, and eye CHN1, indels on chromosomes 4 and 8 3, including subgroups A, B and C). Other names for this condition include: Duane's Retraction Syndrome (or DR syndrome), Eye Retraction Syndrome, Retraction Syndrome, Congenital retraction syndrome and Stilling-Turk-Duane Syndrome Duchenne muscular dystrophy muscle Cardiovascular, DMD, BMD, dystrophin gene, intron (DMD) respiratory flanking exon 51 of DMD gene, exon 51 mutations in DMD gene, see also WO2013163628 and US Pat. Pub. 20130145487 Edward's Syndrome Complete or partial trisomy of (Trisomy 18) chromosome 18 Ehlers-Danlos Syndrome (Types Various COL5A1, COL5A2, COL1A1, I-VI) depending on COL3A1, TNXB, PLOD1, COL1A2, type: including FKBP14 and ADAMTS2 musculoskeletal, eye, vasculature, immune, and skin Emery-Dreifuss muscular muscle LMNA, LMN1, EMD2, FPLD, dystrophy CMD1A, HGPS, LGMD1B, LMNA, LMN1, EMD2, FPLD, CMD1A Enhanced S-Cone Syndrome eye NR2E3, NRL Fabry's Disease Various - GLA including skin, eyes, and gastrointestinal system, kidney, heart, brain, nervous system Facioscapulohumeral muscular muscles FSHMD1A, FSHD1A, FRG1, dystrophy Factor H and Factor H-like 1 blood HF1, CFH, HUS Factor V Leiden thrombophilia blood Factor V (F5) and Factor V deficiency Factor V and Factor VII blood MCFD2 deficiency Factor VII deficiency blood F7 Factor X deficiency blood F10 Factor XI deficiency blood F11 Factor XII deficiency blood F12, HAF Factor XIIIA deficiency blood F13A1, F13A Factor XIIIB deficiency blood F13B Familial Hypercholestereolemia Cardiovascular APOB, LDLR, PCSK9 system Familial Mediterranean Fever Various- Heart, kidney, MEFV (FMF) also called recurrent organs/tissues brain/CNS, polyserositis or familial with serous or reproductive paroxysmal polyserositis synovial organs membranes, skin, joints Fanconi Anemia Various - blood FANCA, FACA, FA1, FA, FAA, (anemia), FAAP95, FAAP90, FLJ34064, immune system, FANCC, FANCG, RAD51, BRCA1, cognitive, BRCA2, BRIP1, BACH1, FANCJ, kidneys, eyes, FANCB, FANCD1, FANCD2, musculoskeletal FANCD, FAD, FANCE, FACE, FANCF, FANCI, ERCC4, FANCL, FANCM, PALB2, RAD51C, SLX4, UBE2T, FANCB, XRCC9, PHF9, KIAA1596 Fanconi Syndrome Types I kidneys FRTS1, GATM (Childhood onset) and II (Adult Onset) Fragile X syndrome and related brain FMR1, FMR2; FXR1; FXR2; disorders mGLUR5 Fragile XE Mental Retardation Brain, nervous FMR1 (aka Martin Bell syndrome) system Friedreich Ataxia (FRDA) Brain, nervous heart FXN/X25 system Fuchs endothelial corneal Eye TCF4; COL8A2 dystrophy Galactosemia Carbohydrate Various-where GALT, GALK1, and GALE metabolism galactose disorder accumulates - liver, brain, eyes Gastrointestinal Epithelial CISH Cancer, GI cancer Gaucher Disease (Types 1, 2, and Fat metabolism Various-liver, GBA 3, as well as other unusual forms disorder spleen, blood, that may not fit into these types) CNS, skeletal system Griscelli syndrome Glaucoma eye MYOC, TIGR, GLC1A, JOAG, GPOA, OPTN, GLC1E, FIP2, HYPL, NRP, CYP1B1, GLC3A, OPA1, NTG, NPG, CYP1B1, GLC3A, those described in WO2015153780 Glomerulo sclerosis kidney CC chemokine ligand 2 Glycogen Storage Diseases Metabolism SLC2A2, GLUT2, G6PC, G6PT, Types I-VI -See also Cori's Diseases G6PT1, GAA, LAMP2, LAMPB, Disease, Pompe's Disease, AGL, GDE, GBE1, GYS2, PYGL, McArdle's disease, Hers Disease, PFKM, see also Cori's Disease, and Von Gierke's disease Pompe's Disease, McArdle's disease, Hers Disease, and Von Gierke's disease RBC Glycolytic enzyme blood any mutations in a gene for an enzyme deficiency in the glycolysis pathway including mutations in genes for hexokinases I and II, glucokinase, phosphoglucose isomerase, phosphofructokinase, aldolase Bm triosephosphate isomerease, glyceraldehydee-3- phosphate dehydrogenase, phosphoglycerokinase, phosphoglycerate mutase, enolase I, pyruvate kinase Hartnup's disease Malabsorption Various- brain, SLC6A19 disease gastrointestinal, skin, Hearing Loss ear NOX3, Hes5, BDNF, Hemochromatosis (HH) Iron absorption Various- HFE and H63D regulation wherever iron disease accumulates, liver, heart, pancreas, joints, pituitary gland Hemophagocytic blood PRF1, HPLH2, UNC13D, MUNC13- lymphohistiocytosis disorders 4, HPLH3, HLH3, FHL3 Hemorrhagic disorders blood PI, ATT, F5 Hers disease (Glycogen storage liver muscle PYGL disease Type VI) Hereditary angioedema (HAE) kalikrein B1 Hereditary Hemorrhagic Skin and ACVRL1, ENG and SMAD4 Telangiectasia (Osler-Weber- mucous Rendu Syndrome) membranes Hereditary Spherocytosis blood NK1, EPB42, SLC4A1, SPTA1, and SPTB Hereditary Persistence of Fetal blood HBG1, HBG2, BCL11A, promoter Hemoglobin region of HBG 1 and/or 2 (in the CCAAT box) Hemophilia (hemophilia A blood A: FVIII, F8C, HEMA (Classic) a B (aka Christmas B: FVIX, HEMB, FIX disease) and C) C: F9, F11 Hepatic adenoma liver TCF1, HNF1A, MODY3 Hepatic failure, early onset, and liver SCOD1, SCO1 neurologic disorder Hepatic lipase deficiency liver LIPC Hepatoblastoma, cancer and liver CTNNB1, PDGFRL, PDGRL, PRLTS, carcinomas AXIN1, AXIN, CTNNB1, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5 Hermansky-Pudlak syndrome Skin, eyes, HPS1, HPS3, HPS4, HPS5, HPS6, blood, lung, HPS7, DTNBP1, BLOC1, BLOC1S2, kidneys, BLOC3 intestine HIV susceptibility or infection Immune system IL10, CSIF, CMKBR2, CCR2, CMKBR5, CCCKR5 (CCR5), those in WO2015148670A1 Holoprosencephaly (HPE) brain ACVRL1, ENG, SMAD4 (Alobar, Semilobar, and Lobar) Homocystinuria Metabolic Various- CBS, MTHFR, MTR, MTRR, and disease connective MMADHC tissue, muscles, CNS, cardiovascular system HPV HPV16 and HPV18 E6/E7 HSV1, HSV2, and related eye HSV1 genes (immediate early and late keratitis HSV-1 genes (UL1, 1.5, 5, 6, 8, 9, 12, 15, 16, 18, 19, 22, 23, 26, 26.5, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 42, 48, 49.5, 50, 52, 54, S6, RL2, RS1, those described in WO2015153789, WO2015153791 Hunter's Syndrome (aka Lysosomal Various- liver, IDS Mucopolysaccharidosis type II) storage disease spleen, eye, joint, heart, brain, skeletal Huntington's disease (HD) and Brain, nervous HD, HTT, IT15, PRNP, PRIP, JPH3, HD-like disorders system JP3, HDL2, TBP, SCA17, PRKCE; IGF1; EP300; RCOR1; PRKCZ; HDAC4; and TGM2, and those described in WO2013130824, WO2015089354 Hurler's Syndrome (aka Lysosomal Various- liver, IDUA, α-L-iduronidase mucopolysaccharidosis type I H, storage disease spleen, eye, MPS IH) joint, heart, brain, skeletal Hurler-Scheie syndrome (aka Lysosomal Various- liver, IDUA, α-L-iduronidase mucopolysaccharidosis type I H- storage disease spleen, eye, S, MPS I H-S) joint, heart, brain, skeletal hyaluronidase deficiency (aka Soft and HYAL1 MPS IX) connective tissues Hyper IgM syndrome Immune system CD40L Hyper- tension caused renal kidney Mineral corticoid receptor damage Immunodeficiencies Immune System CD3E, CD3G, AICDA, AID, HIGM2, TNFRSF5, CD40, UNG, DGU, HIGM4, TNFSF5, CD40LG, HIGM1, IGM, FOXP3, IPEX, AIID, XPID, PIDX, TNFRSF14B, TACI Inborn errors of metabolism: Metabolism Various organs See also: Carbohydrate metabolism including urea cycle disorders, diseases, liver and cells disorders (e.g. galactosemia), Amino organic acidemias), fatty acid acid Metabolism disorders (e.g. oxidation defects, amino phenylketonuria), Fatty acid acidopathies, carbohydrate metabolism (e.g. MCAD deficiency), disorders, mitochondrial Urea Cycle disorders (e.g. disorders Citrullinemia), Organic acidemias (e.g. Maple Syrup Urine disease), Mitochondrial disorders (e.g. MELAS), peroxisomal disorders (e.g. Zellweger syndrome) Inflammation Various IL-10; IL-1 (IL-1a; IL-1b); IL-13; IL- 17 (IL-17a (CTLA8); IL- 17b; IL-17c; IL-17d; IL-17f); II-23; Cx3cr1; ptpn22; TNFa; NOD2/CARD15 for IBD; IL-6; IL-12 (IL-12a; IL-12b); CTLA4; Cx3cl1 Inflammatory Bowel Diseases Gastrointestinal Joints, skin NOD2, IRGM, LRRK2, ATG5, (e.g. Ulcerative Colitis and ATG16L1, IRGM, GATM, ECM1, Chron's Disease) CDH1, LAMB1, HNF4A, GNA12, IL10, CARD9/15. CCR6, IL2RA, MST1, TNFSF15, REL, STAT3, IL23R, IL12B, FUT2 Interstitial renal fibrosis kidney TGF-β type II receptor Job's Syndrome (aka Hyper IgE Immune System STAT3, DOCK8 Syndrome) Juvenile Retinoschisis eye RS1, XLRS1 Kabuki Syndrome 1 MLL4, KMT2D Kennedy Disease (aka Muscles, brain, SBMA/SMAX1/AR Spinobulbar Muscular Atrophy) nervous system Klinefelter syndrome Various- Extra X chromosome in males particularly those involved in development of male characteristics Lafora Disease Brain, CNS EMP2A and EMP2B Leber Congenital Amaurosis eye CRB1, RP12, CORD2, CRD, CRX, IMPDH1, OTX2, AIPL1, CABP4, CCT2, CEP290, CLUAP1, CRB1, CRX, DTHD1, GDF6, GUCY2D, IFT140, IQCB1, KCNJ13, LCA5, LRAT, NMNAT1, PRPH2, RD3, RDH12, RPE65, RP20, RPGRIP1, SPATA7, TULP1, LCA1, LCA4, GUC2D, CORD6, LCA3, Lesch-Nyhan Syndrome Metabolism Various - joints, HPRT1 disease cognitive, brain, nervous system Leukocyte deficiencies and blood ITGB2, CD18, LCAMB, LAD, disorders EIF2B1, EIF2BA, EIF2B2, EIF2B3, EIF2B5, LVWM, CACH, CLE, EIF2B4 Leukemia Blood TAL1, TCL5, SCL, TAL2, FLT3, NBS1, NBS, ZNFN1A1, IK1, LYF1, HOXD4, HOX4B, BCR, CML, PHL, ALL, ARNT, KRAS2, RASK2, GMPS, AF10, ARHGEF12, LARG, KIAA0382, CALM, CLTH, CEBPA, CEBP, CHIC2, BTL, FLT3, KIT, PBT, LPP, NPM1, NUP214, D9S46E, CAN, CAIN, RUNX1, CBFA2, AML1, WHSC1L1, NSD3, FLT3, AF1Q, NPM1, NUMA1, ZNF145, PLZF, PML, MYL, STAT5B, AF10, CALM, CLTH, ARL11, ARLTS1, P2RX7, P2X7, BCR, CML, PHL, ALL, GRAF, NF1, VRNF, WSS, NFNS, PTPN11, PTP2C, SHP2, NS1, BCL2, CCND1, PRAD1, BCL1, TCRA, GATA1, GF1, ERYF1, NFE1, ABL1, NQO1, DIA4, NMOR1, NUP214, D9S46E, CAN, CAIN Limb-girdle muscular dystrophy muscle LGMD diseases Lowe syndrome brain, eyes, OCRL kidneys Lupus glomerulo- nephritis kidney MAPK1 Machado- Brain, CNS, ATX3 Joseph's Disease (also known as muscle Spinocerebellar ataxia Type 3) Macular degeneration eye ABC4, CBC1, CHM1, APOE, C1QTNF5, C2, C3, CCL2, CCR2, CD36, CFB, CFH, CFHR1, CFHR3, CNGB3, CP, CRP, CST3, CTSD, CX3CR1, ELOVL4, ERCC6, FBLN5, FBLN6, FSCN2, HMCN1, HIRAI, IL6, IL8, PLEKHA1, PROM1, PRPH2, RPGR, SERPING1, TCOF1, TIMP3, TLR3 Macular Dystrophy eye BEST1, C1QTNF5, CTNNA1, EFEMP1, ELOVL4, FSCN2, GUCA1B, HMCN1, IMPG1, OTX2, PRDM13, PROM1, PRPH2, RP1L1, TIMP3, ABCA4, CFH, DRAM2, IMG1, MFSD8, ADMD, STGD2, STGD3, RDS, RP7, PRPH, AVMD, AOFMD, VMD2 Malattia Leventinesse eye EFEMP1, FBLN3 Maple Syrup Urine Disease Metabolism BCKDHA, BCKDHB, and DBT disease Marfan syndrome Connective Musculoskeletal FBN1 tissue Maroteaux-Lamy Syndrome (aka Musculoskeletal Liver, spleen ARSB MPS VI) system, nervous system McArdle's Disease (Glycogen Glycogen muscle PYGM Storage Disease Type V) storage disease Medullary cystic kidney disease kidney UMOD, HNFJ, FJHN, MCKD2, ADMCKD2 Metachromatic leukodystrophy Lysosomal Nervous system ARSA storage disease Methylmalonic acidemia (MMA) Metabolism MMAA, MMAB, MUT, MMACHC, disease MMADHC, LMBRD1 Morquio Syndrome (aka MPS IV Connective heart GALNS A and B) tissue, skin, bone, eyes Mucopolysaccharidosis diseases Lysosomal See also Hurler/Scheie syndrome, (Types I H/S, I H, II, III A B and storage disease - Hurler disease, Sanfillipo syndrome, C, I S, IVA and B, IX, VII, and affects various Scheie syndrome, Morquio syndrome, VI) organs/tissues hyaluronidase deficiency, Sly syndrome, and Maroteaux-Lamy syndrome Muscular Atrophy muscle VAPB, VAPC, ALS8, SMN1, SMA1, SMA2, SMA3, SMA4, BSCL2, SPG17, GARS, SMAD1, CMT2D, HEXB, IGHMBP2, SMUBP2, CATF1, SMARD1 Muscular dystrophy muscle FKRP, MDC1C, LGMD2I, LAMA2, LAMM, LARGE, KIAA0609, MDC1D, FCMD, TTID, MYOT, CAPN3, CANP3, DYSF, LGMD2B, SGCG, LGMD2C, DMDA1, SCG3, SGCA, ADL, DAG2, LGMD2D, DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD2G, CMD1N, TRIM32, HT2A, LGMD2H, FKRP, MDC1C, LGMD2I, TTN, CMD1G, TMD, LGMD2J, POMT1, CAV3, LGMD1C, SEPN1, SELN, RSMD1, PLEC1, PLTN, EBS1 Myotonic dystrophy (Type 1 and Muscles Eyes, heart, CNBP (Type 2) and DMPK (Type 1) Type 2) endocrine Neoplasia PTEN; ATM; ATR; EGFR; ERBB2; ERBB3; ERBB4; Notch1; Notch2; Notch3; Notch4; AKT; AKT2; AKT3; HIF; HIF1a; HIF3a; Met; HRG; Bcl2; PPAR alpha; PPAR gamma; WT1 (Wilms Tumor); FGF Receptor Family members (5 members: 1, 2, 3, 4, 5); CDKN2a; APC; RB (retinoblastoma); MEN1; VHL; BRCA1; BRCA2; AR (Androgen Receptor); TSG101; IGF; IGF Receptor; Igf1 (4 variants); Igf2 (3 variants); Igf 1 Receptor; Igf 2 Receptor; Bax; Bcl2; caspases family (9 members: 1, 2, 3, 4, 6, 7, 8, 9, 12); Kras; Apc Neurofibromatosis (NF) (NF1, brain, spinal NF1, NF2 formerly Recklinghausen's NF, cord, nerves, and NF2) and skin Niemann-Pick Lipidosis (Types Lysosomal Various- where Types A and B: SMPD1; Type C: A, B, and C) Storage Disease sphingomyelin NPC1 or NPC2 accumulates, particularly spleen, liver, blood, CNS Noonan Syndrome Various - PTPN11, SOS1, RAF1 and KRAS musculoskeletal, heart, eyes, reproductive organs, blood Norrie Disease or X-linked eye NDP Familial Exudative Vitreoretinopathy North Carolina Macular eye MCDR1 Dystrophy Osteogenesis imperfecta (OI) bones, COL1A1, COL1A2, CRTAP, P3H (Types I, II, III, IV, V, VI, VII) musculoskeletal Osteopetrosis bones LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, CLCN7, CLC7, OPTA2, OSTM1, GL, TCIRG1, TIRC7, OC116, OPTB1 Patau's Syndrome Brain, heart, Additional copy of chromosome 13 (Trisomy 13) skeletal system Parkinson's disease (PD) Brain, nervous SNCA (PARK1), UCHL1 (PARK 5), system and LRRK2 (PARK8), (PARK3), PARK2, PARK4, PARK7 (PARK7), PINK1 (PARK6); x-Synuclein, DJ-1, Parkin, NR4A2, NURR1, NOT, TINUR, SNCAIP, TBP, SCA17, NCAP, PRKN, PDJ, DBH, NDUFV2 Pattern Dystrophy of the RPE eye RDS/peripherin Phenylketonuria (PKU) Metabolism Various due to PAH, PKU1, QDPR, DHPR, PTS disorder build-up of phenylalanine, phenyl ketones in tissues and CNS Polycystic kidney and hepatic Kidney, liver FCYT, PKHD1, ARPKD, PKD1, disease PKD2, PKD4, PKDTS, PRKCSH, G19P1, PCLD, SEC63 Pompe's Disease Glycogen Various - heart, GAA storage disease liver, spleen Porphyria (actually refers to a Various- ALAD, ALAS2, CPOX, FECH, group of different diseases all wherever heme HMBS, PPOX, UROD, or UROS having a specific heme precursors production process abnormality) accumulate posterior polymorphous corneal eyes TCF4; COL8A2 dystrophy Primary Hyperoxaluria (e.g. type Various - eyes, LDHA (lactate dehydrogenase A) and 1) heart, kidneys, hydroxyacid oxidase 1 (HAO1) skeletal system Primary Open Angle Glaucoma eyes MYOC (POAG) Primary sclerosing cholangitis Liver, TCF4; COL8A2 gallbladder Progeria (also called Hutchinson- All LMNA Gilford progeria syndrome) Prader-Willi Syndrome Musculoskeletal Deletion of region of short arm of system, brain, chromosome 15, including UBE3A reproductive and endocrine system Prostate Cancer prostate HOXB13, MSMB, GPRC6A, TP53 Pyruvate Dehydrogenase Brain, nervous PDHA1 Deficiency system Kidney/Renal carcinoma kidney RLIP76, VEGF Rett Syndrome Brain MECP2, RTT, PPMX, MRX16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16, MRX79, x- Synuclein, DJ-1 Retinitis pigmentosa (RP) eye ADIPOR1, ABCA4, AGBL5, ARHGEF18, ARL2BP, ARL3, ARL6, BEST1, BBS1, BBS2, C2ORF71, C8ORF37, CA4, CERKL, CLRN1, CNGA1, CMGB1, CRB1, CRX, CYP4V2, DHDDS, DHX38, EMC1, EYS, FAM161A, FSCN2, GPR125, GUCA1B, HK1, HPRPF3, HGSNAT, IDH3B, IMPDH1, IMPG2, IFT140, IFT172, KLHL7, KIAA1549, KIZ, LRAT, MAK, MERTK, MVK, NEK2, NUROD1, NR2E3, NRL, OFD1, PDE6A, PDE6B, PDE6G, POMGNT1, PRCD, PROM1, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, PRPH2, RPB3, RDH12, REEP6, RP39, RGR, RHO, RLBP1, ROM1, RP1, RP1L1, RPY, RP2, RP9, RPE65, RPGR, SAMD11, SAG, SEMA4A, SLC7A14, SNRNP200, SPP2, SPATA7, TRNT1, TOPORS, TTC8, TULP1, USH2A, ZFN408, ZNF513, see also 20120204282 Scheie syndrome (also known as Various- liver, IDUA, α-L-iduronidase mucopolysaccharidosis type I spleen, eye, S(MPS I-S)) joint, heart, brain, skeletal Schizophrenia Brain Neuregulin1 (Nrg1); Erb4 (receptor for Neuregulin); Complexin1 (Cplx1); Tph1 Tryptophan hydroxylase; Tph2 Tryptophan hydroxylase 2; Neurexin 1; GSK3; GSK3a; GSK3b; 5-HTT (Slc6a4); COMT; DRD (Drd1a); SLC6A3; DAOA; DTNBP1; Dao (Dao1); TCF4; COL8A2 Secretase Related Disorders Various APH-1 (alpha and beta); PSEN1; NCSTN; PEN-2; Nos1, Parp1, Nat1, Nat2, CTSB, APP, APH1B, PSEN2, PSENEN, BACE1, ITM2B, CTSD, NOTCH1, TNF, INS, DYT10, ADAM17, APOE, ACE, STN, TP53, IL6, NGFR, IL1B, ACHE, CTNNB1, IGF1, IFNG, NRG1, CASP3, MAPK1, CDH1, APBB1, HMGCR, CREB1, PTGS2, HES1, CAT, TGFB1, ENO2, ERBB4, TRAPPC10, MAOB, NGF, MMP12, JAG1, CD40LG, PPARG, FGF2, LRP1, NOTCH4, MAPK8, PREP, NOTCH3, PRNP, CTSG, EGF, REN, CD44, SELP, GHR, ADCYAP1, INSR, GFAP, MMP3, MAPK10, SP1, MYC, CTSE, PPARA, JUN, TIMP1, IL5, IL1A, MMP9, HTR4, HSPG2, KRAS, CYCS, SMG1, IL1R1, PROK1, MAPK3, NTRK1, IL13, MME, TKT, CXCR2, CHRM1, ATXN1, PAWR, NOTCJ2, M6PR, CYP46A1, CSNK1D, MAPK14, PRG2, PRKCA, L1 CAM, CD40, NR1I2, JAG2, CTNND1, CMA1, SORT1, DLK1, THEM4, JUP, CD46, CCL11, CAV3, RNASE3, HSPA8, CASP9, CYP3A4, CCR3, TFAP2A, SCP2, CDK4, JOF1A, TCF7L2, B3GALTL, MDM2, RELA, CASP7, IDE, FANP4, CASK, ADCYAP1R1, ATF4, PDGFA, C21ORF33, SCG5, RMF123, NKFB1, ERBB2, CAV1, MMP7, TGFA, RXRA, STX1A, PSMC4, P2RY2, TNFRSF21, DLG1, NUMBL, SPN, PLSCR1, UBQLN2, UBQLN1, PCSK7, SPON1, SILV, QPCT, HESS, GCC1 Selective IgA Deficiency Immune system Type 1: MSH5; Type 2: TNFRSF13B Severe Combined Immune system JAK3, JAKL, DCLRE1C, ARTEMIS, Immunodeficiency (SCID) and SCIDA, RAG1, RAG2, ADA, PTPRC, SCID-χI, and ADA-SCID CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX1, SCIDX, IMD4, those identified in US Pat. App. Pub. 20110225664, 20110091441, 20100229252, 20090271881 and 20090222937; Sickle cell disease blood HBB, BCL11A, BCL11Ae, cis- regulatory elements of the B-globin locus, HBG ½ promoter, HBG distal CCAAT box region between −92 and −130 of the HBG Transcription Start Site, those described in WO2015148863, WO 2013/126794, US Pat. Pub. 20110182867 Sly Syndrome (aka MPS VII) GUSB Spinocerebellar Ataxias (SCA ATXN1, ATXN2, ATX3 types 1, 2, 3, 6, 7, 8, 12 and 17) Sorsby Fundus Dystrophy eye TIMP3 Stargardt disease eye ABCR, ELOVL4, ABCA4, PROM1 Tay-Sachs Disease Lysosomal Various - CNS, HEX-A Storage disease brain, eye Thalassemia (Alpha, Beta, Delta) blood HBA1, HBA2 (Alpha), HBB (Beta), HBB and HBD (delta), LCRB, BCL11A, BCL11Ae, cis-regulatory elements of the B-globin locus, HBG ½ promoter, those described in WO2015148860, US Pat. Pub. 20110182867, 2015/148860 Thymic Aplasia (DiGeorge Immune system, deletion of 30 to 40 genes in the Syndrome; 22q11.2 deletion thymus middle of chromosome 22 at syndrome) a location known as 22q11.2, including TBX1, DGCR8 Transthyretin amyloidosis liver TTR (transthyretin) (ATTR) trimethylaminuria Metabolism FMO3 disease Trinucleotide Repeat Disorders Various HTT; SBMA/SMAX1/AR; (generally) FXN/X25 ATX3; ATXN1; ATXN2; DMPK; Atrophin-1 and Atn1 (DRPLA Dx); CBP (Creb-BP - global instability); VLDLR; Atxn7; Atxn10; FEN1, TNRC6A, PABPN1, JPH3, MED15, ATXN1, ATXN3, TBP, CACNA1A, ATXN80S, PPP2R2B, ATXN7, TNRC6B, TNRC6C, CELF3, MAB21L1, MSH2, TMEM185A, SIX5, CNPY3, RAXE, GNB2, RPL14, ATXN8, ISR, TTR, EP400, GIGYF2, OGG1, STC1, CNDP1, C10ORF2, MAML3, DKC1, PAXIP1, CASK, MAPT, SP1, POLG, AFF2, THBS1, TP53, ESR1, CGGBP1, ABT1, KLK3, PRNP, JUN, KCNN3, BAX, FRAXA, KBTBD10, MBNL1, RAD51, NCOA3, ERDA1, TSC1, COMP, GGLC, RRAD, MSH3, DRD2, CD44, CTCF, CCND1, CLSPN, MEF2A, PTPRU, GAPDH, TRIM22, WT1, AHR, GPX1, TPMT, NDP, ARX, TYR, EGR1, UNG, NUMBL, FABP2, EN2, CRYGC, SRP14, CRYGB, PDCD1, HOXA1, ATXN2L, PMS2, GLA, CBL, FTH1, IL12RB2, OTX2, HOXA5, POLG2, DLX2, AHRR, MANF, RMEM158, see also 20110016540 Turner's Syndrome (XO) Various - Monosomy X reproductive organs, and sex characteristics, vasculature Tuberous Sclerosis CNS, heart, TSC1, TSC2 kidneys Usher syndrome (Types I, II, and Ears, eyes ABHD12, CDH23, CIB2, CLRN1, III) DFNB31, GPR98, HARS, MYO7A, PCDH15, USH1C, USH1G, USH2A, USH11A, those described in WO2015134812A1 Velocardiofacial syndrome (aka Various - Many genes are deleted, COM, TBX1, 22q11.2 deletion syndrome, skeletal, heart, and other are associated with DiGeorge syndrome, conotruncal kidney, immune symptoms anomaly face syndrome (CTAF), system, brain autosomal dominant Opitz G/BB syndrome or Cayler cardiofacial syndrome) Von Gierke's Disease (Glycogen Glycogen Various - liver, G6PC and SLC37A4 Storage Disease type I) Storage disease kidney Von Hippel-Lindau Syndrome Various - cell CNS, Kidney, VHL growth Eye, visceral regulation organs disorder Von Willebrand Disease (Types blood VWF I, II and III) Wilson Disease Various - Liver, brains, ATP7B Copper Storage eyes, other Disease tissues where copper builds up Wiskott-Aldrich Syndrome Immune System WAS Xeroderma Pigmentosum Skin Nervous system POLH XXX Syndrome Endocrine, brain X chromosome trisomy

TABLE B Exemplary Genes controlling Cellular Functions CELLULAR FUNCTION GENES PI3K/AKT Signaling PRKCE; ITGAM; ITGA5; IRAK1; PRKAA2; EIF2AK2; PTEN; EIF4E; PRKCZ; GRK6; MAPK1; TSC1; PLK1; AKT2; IKBKB; PIK3CA; CDK8; CDKN1B; NFKB2; BCL2; PIK3CB; PPP2R1A; MAPK8; BCL2L1; MAPK3; TSC2; ITGA1; KRAS; EIF4EBP1; RELA; PRKCD; NOS3; PRKAA1; MAPK9; CDK2; PPP2CA; PIM1; ITGB7; YWHAZ; ILK; TP53; RAF1; IKBKG; RELB; DYRK1A; CDKN1A; ITGB1; MAP2K2; JAK1; AKT1; JAK2; PIK3R1; CHUK; PDPK1; PPP2R5C; CTNNB1; MAP2K1; NFKB1; PAK3; ITGB3; CCND1; GSK3A; FRAP1; SFN; ITGA2; TTK; CSNK1A1; BRAF; GSK3B; AKT3; FOXO1; SGK; HSP90AA1; RPS6KB1 ERK/MAPK Signaling PRKCE; ITGAM; ITGA5; HSPB1; IRAK1; PRKAA2; EIF2AK2; RAC1; RAP1A; TLN1; EIF4E; ELK1; GRK6; MAPK1; RAC2; PLK1; AKT2; PIK3CA; CDK8; CREB1; PRKCI; PTK2; FOS; RPS6KA4; PIK3CB; PPP2R1A; PIK3C3; MAPK8; MAPK3; ITGA1; ETS1; KRAS; MYCN; EIF4EBP1; PPARG; PRKCD; PRKAA1; MAPK9; SRC; CDK2; PPP2CA; PIM1; PIK3C2A; ITGB7; YWHAZ; PPP1CC; KSR1; PXN; RAF1; FYN; DYRK1A; ITGB1; MAP2K2; PAK4; PIK3R1; STAT3; PPP2R5C; MAP2K1; PAK3; ITGB3; ESR1; ITGA2; MYC; TTK; CSNK1A1; CRKL; BRAF; ATF4; PRKCA; SRF; STAT1; SGK Glucocorticoid Receptor RAC1; TAF4B; EP300; SMAD2; TRAF6; PCAF; ELK1; Signaling MAPK1; SMAD3; AKT2; IKBKB; NCOR2; UBE2I; PIK3CA; CREB1; FOS; HSPA5; NFKB2; BCL2; MAP3K14; STAT5B; PIK3CB; PIK3C3; MAPK8; BCL2L1; MAPK3; TSC22D3; MAPK10; NRIP1; KRAS; MAPK13; RELA; STAT5A; MAPK9; NOS2A; PBX1; NR3C1; PIK3C2A; CDKN1C; TRAF2; SERPINE1; NCOA3; MAPK14; TNF; RAF1; IKBKG; MAP3K7; CREBBP; CDKN1A; MAP2K2; JAK1; IL8; NCOA2; AKT1; JAK2; PIK3R1; CHUK; STAT3; MAP2K1; NFKB1; TGFBR1; ESR1; SMAD4; CEBPB; JUN; AR; AKT3; CCL2; MMP1; STAT1; IL6; HSP90AA1 Axonal Guidance Signaling PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; ADAM12; IGF1; RAC1; RAP1A; EIF4E; PRKCZ; NRP1; NTRK2; ARHGEF7; SMO; ROCK2; MAPK1; PGF; RAC2; PTPN11; GNAS; AKT2; PIK3CA; ERBB2; PRKCI; PTK2; CFL1; GNAQ; PIK3CB; CXCL12; PIK3C3; WNT11; PRKD1; GNB2L1; ABL1; MAPK3; ITGA1; KRAS; RHOA; PRKCD; PIK3C2A; ITGB7; GLI2; PXN; VASP; RAF1; FYN; ITGB1; MAP2K2; PAK4; ADAM17; AKT1; PIK3R1; GLI1; WNT5A; ADAM10; MAP2K1; PAK3; ITGB3; CDC42; VEGFA; ITGA2; EPHA8; CRKL; RND1; GSK3B; AKT3; PRKCA Ephrin Receptor Signaling PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; IRAK1; Actin Cytoskeleton PRKAA2; EIF2AK2; RAC1; RAP1A; GRK6; ROCK2; Signaling MAPK1; PGF; RAC2; PTPN11; GNAS; PLK1; AKT2; DOK1; CDK8; CREB1; PTK2; CFL1; GNAQ; MAP3K14; CXCL12; MAPK8; GNB2L1; ABL1; MAPK3; ITGA1; KRAS; RHOA; PRKCD; PRKAA1; MAPK9; SRC; CDK2; PIM1; ITGB7; PXN; RAF1; FYN; DYRK1A; ITGB1; MAP2K2; PAK4; AKT1; JAK2; STAT3; ADAM10; MAP2K1; PAK3; ITGB3; CDC42; VEGFA; ITGA2; EPHA8; TTK; CSNK1A1; CRKL; BRAF; PTPN13; ATF4; AKT3; SGK ACTN4; PRKCE; ITGAM; ROCK1; ITGA5; IRAK1; PRKAA2; EIF2AK2; RAC1; INS; ARHGEF7; GRK6; ROCK2; MAPK1; RAC2; PLK1; AKT2; PIK3CA; CDK8; PTK2; CFL1; PIK3CB; MYH9; DIAPH1; PIK3C3; MAPK8; F2R; MAPK3; SLC9A1; ITGA1; KRAS; RHOA; PRKCD; PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A; ITGB7; PPP1CC; PXN; VIL2; RAF1; GSN; DYRK1A; ITGB1; MAP2K2; PAK4; PIP5K1A; PIK3R1; MAP2K1; PAK3; ITGB3; CDC42; APC; ITGA2; TTK; CSNK1A1; CRKL; BRAF; VAV3; SGK Huntington's Disease PRKCE; IGF1; EP300; RCOR1; PRKCZ; HDAC4; TGM2; Signaling MAPK1; CAPNS1; AKT2; EGFR; NCOR2; SP1; CAPN2; PIK3CA; HDAC5; CREB1; PRKCI; HSPA5; REST; GNAQ; PIK3CB; PIK3C3; MAPK8; IGF1R; PRKD1; GNB2L1; BCL2L1; CAPN1; MAPK3; CASP8; HDAC2; HDAC7A; PRKCD; HDAC11; MAPK9; HDAC9; PIK3C2A; HDAC3; TP53; CASP9; CREBBP; AKT1; PIK3R1; PDPK1; CASP1; APAF1; FRAP1; CASP2; JUN; BAX; ATF4; AKT3; PRKCA; CLTC; SGK; HDAC6; CASP3 Apoptosis Signaling PRKCE; ROCK1; BID; IRAK1; PRKAA2; EIF2AK2; BAK1; BIRC4; GRK6; MAPK1; CAPNS1; PLK1; AKT2; IKBKB; CAPN2; CDK8; FAS; NFKB2; BCL2; MAP3K14; MAPK8; BCL2L1; CAPN1; MAPK3; CASP8; KRAS; RELA; PRKCD; PRKAA1; MAPK9; CDK2; PIM1; TP53; TNF; RAF1; IKBKG; RELB; CASP9; DYRK1A; MAP2K2; CHUK; APAF1; MAP2K1; NFKB1; PAK3; LMNA; CASP2; BIRC2; TTK; CSNK1A1; BRAF; BAX; PRKCA; SGK; CASP3; BIRC3; PARP1 B Cell Receptor Signaling RAC1; PTEN; LYN; ELK1; MAPK1; RAC2; PTPN11; AKT2; IKBKB; PIK3CA; CREB1; SYK; NFKB2; CAMK2A; MAP3K14; PIK3CB; PIK3C3; MAPK8; BCL2L1; ABL1; MAPK3; ETS1; KRAS; MAPK13; RELA; PTPN6; MAPK9; EGR1; PIK3C2A; BTK; MAPK14; RAF1; IKBKG; RELB; MAP3K7; MAP2K2; AKT1; PIK3R1; CHUK; MAP2K1; NFKB1; CDC42; GSK3A; FRAP1; BCL6; BCL10; JUN; GSK3B; ATF4; AKT3; VAV3; RPS6KB1 Leukocyte Extravasation ACTN4; CD44; PRKCE; ITGAM; ROCK1; CXCR4; CYBA; Signaling RAC1; RAP1A; PRKCZ; ROCK2; RAC2; PTPN11; MMP14; PIK3CA; PRKCI; PTK2; PIK3CB; CXCL12; PIK3C3; MAPK8; PRKD1; ABL1; MAPK10; CYBB; MAPK13; RHOA; PRKCD; MAPK9; SRC; PIK3C2A; BTK; MAPK14; NOX1; PXN; VIL2; VASP; ITGB1; MAP2K2; CTNND1; PIK3R1; CTNNB1; CLDN1; CDC42; F11R; ITK; CRKL; VAV3; CTTN; PRKCA; MMP1; MMP9 Integrin Signaling ACTN4; ITGAM; ROCK1; ITGA5; RAC1; PTEN; RAP1A; TLN1; ARHGEF7; MAPK1; RAC2; CAPNS1; AKT2; CAPN2; PIK3CA; PTK2; PIK3CB; PIK3C3; MAPK8; CAV1; CAPN1; ABL1; MAPK3; ITGA1; KRAS; RHOA; SRC; PIK3C2A; ITGB7; PPP1CC; ILK; PXN; VASP; RAF1; FYN; ITGB1; MAP2K2; PAK4; AKT1; PIK3R1; TNK2; MAP2K1; PAK3; ITGB3; CDC42; RND3; ITGA2; CRKL; BRAF; GSK3B; AKT3 Acute Phase Response IRAK1; SOD2; MYD88; TRAF6; ELK1; MAPK1; PTPN11; Signaling AKT2; IKBKB; PIK3CA; FOS; NFKB2; MAP3K14; PIK3CB; MAPK8; RIPK1; MAPK3; IL6ST; KRAS; MAPK13; IL6R; RELA; SOCS1; MAPK9; FTL; NR3C1; TRAF2; SERPINE1; MAPK14; TNF; RAF1; PDK1; IKBKG; RELB; MAP3K7; MAP2K2; AKT1; JAK2; PIK3R1; CHUK; STAT3; MAP2K1; NFKB1; FRAP1; CEBPB; JUN; AKT3; IL1R1; IL6 PTEN Signaling ITGAM; ITGA5; RAC1; PTEN; PRKCZ; BCL2L11; MAPK1; RAC2; AKT2; EGFR; IKBKB; CBL; PIK3CA; CDKN1B; PTK2; NFKB2; BCL2; PIK3CB; BCL2L1; MAPK3; ITGA1; KRAS; ITGB7; ILK; PDGFRB; INSR; RAF1; IKBKG; CASP9; CDKN1A; ITGB1; MAP2K2; AKT1; PIK3R1; CHUK; PDGFRA; PDPK1; MAP2K1; NFKB1; ITGB3; CDC42; CCND1; GSK3A; ITGA2; GSK3B; AKT3; FOXO1; CASP3; RPS6KB1 p53 Signaling PTEN; EP300; BBC3; PCAF; FASN; BRCA1; GADD45A; Aryl Hydrocarbon Receptor BIRC5; AKT2; PIK3CA; CHEK1; TP53INP1; BCL2; Signaling PIK3CB; PIK3C3; MAPK8; THBS1; ATR; BCL2L1; E2F1; PMAIP1; CHEK2; TNFRSF10B; TP73; RB1; HDAC9; CDK2; PIK3C2A; MAPK14; TP53; LRDD; CDKN1A; HIPK2; AKT1; PIK3R1; RRM2B; APAF1; CTNNB1; SIRT1; CCND1; PRKDC; ATM; SFN; CDKN2A; JUN; SNAI2; GSK3B; BAX; AKT3 HSPB1; EP300; FASN; TGM2; RXRA; MAPK1; NQO1; NCOR2; SP1; ARNT; CDKN1B; FOS; CHEK1; SMARCA4; NFKB2; MAPK8; ALDH1A1; ATR; E2F1; MAPK3; NRIP1; CHEK2; RELA; TP73; GSTP1; RB1; SRC; CDK2; AHR; NFE2L2; NCOA3; TP53; TNF; CDKN1A; NCOA2; APAF1; NFKB1; CCND1; ATM; ESR1; CDKN2A; MYC; JUN; ESR2; BAX; IL6; CYP1B1; HSP90AA1 Xenobiotic Metabolism PRKCE; EP300; PRKCZ; RXRA; MAPK1; NQO1; Signaling NCOR2; PIK3CA; ARNT; PRKCI; NFKB2; CAMK2A; PIK3CB; PPP2R1A; PIK3C3; MAPK8; PRKD1; ALDH1A1; MAPK3; NRIP1; KRAS; MAPK13; PRKCD; GSTP1; MAPK9; NOS2A; ABCB1; AHR; PPP2CA; FTL; NFE2L2; PIK3C2A; PPARGC1A; MAPK14; TNF; RAF1; CREBBP; MAP2K2; PIK3R1; PPP2R5C; MAP2K1; NFKB1; KEAP1; PRKCA; EIF2AK3; IL6; CYP1B1; HSP90AA1 SAPK/JNK Signaling PRKCE; IRAK1; PRKAA2; EIF2AK2; RAC1; ELK1; GRK6; MAPK1; GADD45A; RAC2; PLK1; AKT2; PIK3CA; FADD; CDK8; PIK3CB; PIK3C3; MAPK8; RIPK1; GNB2L1; IRS1; MAPK3; MAPK10; DAXX; KRAS; PRKCD; PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A; TRAF2; TP53; LCK; MAP3K7; DYRK1A; MAP2K2; PIK3R1; MAP2K1; PAK3; CDC42; JUN; TTK; CSNK1A1; CRKL; BRAF; SGK PPAr/RXR Signaling PRKAA2; EP300; INS; SMAD2; TRAF6; PPARA; FASN; RXRA; MAPK1; SMAD3; GNAS; IKBKB; NCOR2; ABCA1; GNAQ; NFKB2; MAP3K14; STAT5B; MAPK8; IRS1; MAPK3; KRAS; RELA; PRKAA1; PPARGC1A; NCOA3; MAPK14; INSR; RAF1; IKBKG; RELB; MAP3K7; CREBBP; MAP2K2; JAK2; CHUK; MAP2K1; NFKB1; TGFBR1; SMAD4; JUN; IL1R1; PRKCA; IL6; HSP90AA1; ADIPOQ NF-KB Signaling IRAK1; EIF2AK2; EP300; INS; MYD88; PRKCZ; TRAF6; TBK1; AKT2; EGFR; IKBKB; PIK3CA; BTRC; NFKB2; MAP3K14; PIK3CB; PIK3C3; MAPK8; RIPK1; HDAC2; KRAS; RELA; PIK3C2A; TRAF2; TLR4; PDGFRB; TNF; INSR; LCK; IKBKG; RELB; MAP3K7; CREBBP; AKT1; PIK3R1; CHUK; PDGFRA; NFKB1; TLR2; BCL10; GSK3B; AKT3; TNFAIP3; IL1R1 Neuregulin Signaling ERBB4; PRKCE; ITGAM; ITGA5; PTEN; PRKCZ; ELK1; Wnt & Beta catenin MAPK1; PTPN11; AKT2; EGFR; ERBB2; PRKCI; Signaling CDKN1B; STAT5B; PRKD1; MAPK3; ITGA1; KRAS; PRKCD; STAT5A; SRC; ITGB7; RAF1; ITGB1; MAP2K2; ADAM17; AKT1; PIK3R1; PDPK1; MAP2K1; ITGB3; EREG; FRAP1; PSEN1; ITGA2; MYC; NRG1; CRKL; AKT3; PRKCA; HSP90AA1; RPS6KB1 CD44; EP300; LRP6; DVL3; CSNK1E; GJA1; SMO; AKT2; PIN1; CDH1; BTRC; GNAQ; MARK2; PPP2R1A; WNT11; SRC; DKK1; PPP2CA; SOX6; SFRP2; ILK; LEF1; SOX9; TP53; MAP3K7; CREBBP; TCF7L2; AKT1; PPP2R5C; WNT5A; LRP5; CTNNB1; TGFBR1; CCND1; GSK3A; DVL1; APC; CDKN2A; MYC; CSNK1A1; GSK3B; AKT3; SOX2 Insulin Receptor Signaling PTEN; INS; EIF4E; PTPN1; PRKCZ; MAPK1; TSC1; PTPN11; AKT2; CBL; PIK3CA; PRKCI; PIK3CB; PIK3C3; MAPK8; IRS1; MAPK3; TSC2; KRAS; EIF4EBP1; SLC2A4; PIK3C2A; PPP1CC; INSR; RAF1; FYN; MAP2K2; JAK1; AKT1; JAK2; PIK3R1; PDPK1; MAP2K1; GSK3A; FRAP1; CRKL; GSK3B; AKT3; FOXO1; SGK; RPS6KB1 IL-6 Signaling HSPB1; TRAF6; MAPKAPK2; ELK1; MAPK1; PTPN11; IKBKB; FOS; NFKB2; MAP3K14; MAPK8; MAPK3; MAPK10; IL6ST; KRAS; MAPK13; IL6R; RELA; SOCS1; MAPK9; ABCB1; TRAF2; MAPK14; TNF; RAF1; IKBKG; RELB; MAP3K7; MAP2K2; IL8; JAK2; CHUK; STAT3; MAP2K1; NFKB1; CEBPB; JUN; IL1R1; SRF; IL6 Hepatic Cholestasis PRKCE; IRAK1; INS; MYD88; PRKCZ; TRAF6; PPARA; RXRA; IKBKB; PRKCI; NFKB2; MAP3K14; MAPK8; PRKD1; MAPK10; RELA; PRKCD; MAPK9; ABCB1; TRAF2; TLR4; TNF; INSR; IKBKG; RELB; MAP3K7; IL8; CHUK; NR1H2; TJP2; NFKB1; ESR1; SREBF1; FGFR4; JUN; IL1R1; PRKCA; IL6 IGF-1 Signaling IGF1; PRKCZ; ELK1; MAPK1; PTPN11; NEDD4; AKT2; PIK3CA; PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8; IGF1R; IRS1; MAPK3; IGFBP7; KRAS; PIK3C2A; YWHAZ; PXN; RAF1; CASP9; MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; IGFBP2; SFN; JUN; CYR61; AKT3; FOXO1; SRF; CTGF; RPS6KB1 NRF2-mediated Oxidative PRKCE; EP300; SOD2; PRKCZ; MAPK1; SQSTM1; Stress Response NQO1; PIK3CA; PRKCI; FOS; PIK3CB; PIK3C3; MAPK8; PRKD1; MAPK3; KRAS; PRKCD; GSTP1; MAPK9; FTL; NFE2L2; PIK3C2A; MAPK14; RAF1; MAP3K7; CREBBP; MAP2K2; AKT1; PIK3R1; MAP2K1; PPIB; JUN; KEAP1; GSK3B; ATF4; PRKCA; EIF2AK3; HSP90AA1 Hepatic Fibrosis/Hepatic EDN1; IGF1; KDR; FLT1; SMAD2; FGFR1; MET; PGF; Stellate Cell Activation SMAD3; EGFR; FAS; CSF1; NFKB2; BCL2; MYH9; IGF1R; IL6R; RELA; TLR4; PDGFRB; TNF; RELB; IL8; PDGFRA; NFKB1; TGFBR1; SMAD4; VEGFA; BAX; IL1R1; CCL2; HGF; MMP1; STAT1; IL6; CTGF; MMP9 PPAR Signaling EP300; INS; TRAF6; PPARA; RXRA; MAPK1; IKBKB; NCOR2; FOS; NFKB2; MAP3K14; STAT5B; MAPK3; NRIP1; KRAS; PPARG; RELA; STAT5A; TRAF2; PPARGC1A; PDGFRB; TNF; INSR; RAF1; IKBKG; RELB; MAP3K7; CREBBP; MAP2K2; CHUK; PDGFRA; MAP2K1; NFKB1; JUN; IL1R1; HSP90AA1 Fc Epsilon RI Signaling PRKCE; RAC1; PRKCZ; LYN; MAPK1; RAC2; PTPN11; AKT2; PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; MAPK8; PRKD1; MAPK3; MAPK10; KRAS; MAPK13; PRKCD; MAPK9; PIK3C2A; BTK; MAPK14; TNF; RAF1; FYN; MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; AKT3; VAV3; PRKCA G-Protein Coupled PRKCE; RAP1A; RGS16; MAPK1; GNAS; AKT2; IKBKB; Receptor Signaling PIK3CA; CREB1; GNAQ; NFKB2; CAMK2A; PIK3CB; PIK3C3; MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1; IKBKG; RELB; FYN; MAP2K2; AKT1; PIK3R1; CHUK; PDPK1; STAT3; MAP2K1; NFKB1; BRAF; ATF4; AKT3; PRKCA Inositol Phosphate PRKCE; IRAK1; PRKAA2; EIF2AK2; PTEN; GRK6; Metabolism MAPK1; PLK1; AKT2; PIK3CA; CDK8; PIK3CB; PIK3C3; MAPK8; MAPK3; PRKCD; PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A; DYRK1A; MAP2K2; PIP5K1A; PIK3R1; MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK PDGF Signaling EIF2AK2; ELK1; ABL2; MAPK1; PIK3CA; FOS; PIK3CB; PIK3C3; MAPK8; CAV1; ABL1; MAPK3; KRAS; SRC; PIK3C2A; PDGFRB; RAF1; MAP2K2; JAK1; JAK2; PIK3R1; PDGFRA; STAT3; SPHK1; MAP2K1; MYC; JUN; CRKL; PRKCA; SRF; STAT1; SPHK2 VEGF Signaling ACTN4; ROCK1; KDR; FLT1; ROCK2; MAPK1; PGF; AKT2; PIK3CA; ARNT; PTK2; BCL2; PIK3CB; PIK3C3; BCL2L1; MAPK3; KRAS; HIF1A; NOS3; PIK3C2A; PXN; RAF1; MAP2K2; ELAVL1; AKT1; PIK3R1; MAP2K1; SFN; VEGFA; AKT3; FOXO1; PRKCA Natural Killer Cell Signaling PRKCE; RAC1; PRKCZ; MAPK1; RAC2; PTPN11; KIR2DL3; AKT2; PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; PRKD1; MAPK3; KRAS; PRKCD; PTPN6; PIK3C2A; LCK; RAF1; FYN; MAP2K2; PAK4; AKT1; PIK3R1; MAP2K1; PAK3; AKT3; VAV3; PRKCA Cell Cycle: G1/S HDAC4; SMAD3; SUV39H1; HDAC5; CDKN1B; BTRC; Checkpoint Regulation ATR; ABL1; E2F1; HDAC2; HDAC7A; RB1; HDAC11; HDAC9; CDK2; E2F2; HDAC3; TP53; CDKN1A; CCND1; E2F4; ATM; RBL2; SMAD4; CDKN2A; MYC; NRG1; GSK3B; RBL1; HDAC6 T Cell Receptor Signaling RAC1; ELK1; MAPK1; IKBKB; CBL; PIK3CA; FOS; NFKB2; PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS; RELA; PIK3C2A; BTK; LCK; RAF1; IKBKG; RELB; FYN; MAP2K2; PIK3R1; CHUK; MAP2K1; NFKB1; ITK; BCL10; JUN; VAV3 Death Receptor Signaling CRADD; HSPB1; BID; BIRC4; TBK1; IKBKB; FADD; FAS; NFKB2; BCL2; MAP3K14; MAPK8; RIPK1; CASP8; DAXX; TNFRSF10B; RELA; TRAF2; TNF; IKBKG; RELB; CASP9; CHUK; APAF1; NFKB1; CASP2; BIRC2; CASP3; BIRC3 FGF Signaling RAC1; FGFR1; MET; MAPKAPK2; MAPK1; PTPN11; AKT2; PIK3CA; CREB1; PIK3CB; PIK3C3; MAPK8; MAPK3; MAPK13; PTPN6; PIK3C2A; MAPK14; RAF1; AKT1; PIK3R1; STAT3; MAP2K1; FGFR4; CRKL; ATF4; AKT3; PRKCA; HGF GM-CSF Signaling LYN; ELK1; MAPK1; PTPN11; AKT2; PIK3CA; CAMK2A; STAT5B; PIK3CB; PIK3C3; GNB2L1; BCL2L1; MAPK3; ETS1; KRAS; RUNX1; PIM1; PIK3C2A; RAF1; MAP2K2; AKT1; JAK2; PIK3R1; STAT3; MAP2K1; CCND1; AKT3; STAT1 Amyotrophic Lateral BID; IGF1; RAC1; BIRC4; PGF; CAPNS1; CAPN2; Sclerosis Signaling PIK3CA; BCL2; PIK3CB; PIK3C3; BCL2L1; CAPN1; PIK3C2A; TP53; CASP9; PIK3R1; RAB5A; CASP1; APAF1; VEGFA; BIRC2; BAX; AKT3; CASP3; BIRC3 JAK/Stat Signaling PTPN1; MAPK1; PTPN11; AKT2; PIK3CA; STAT5B; PIK3CB; PIK3C3; MAPK3; KRAS; SOCS1; STAT5A; PTPN6; PIK3C2A; RAF1; CDKN1A; MAP2K2; JAK1; AKT1; JAK2; PIK3R1; STAT3; MAP2K1; FRAP1; AKT3; STAT1 Nicotinate and Nicotinamide PRKCE; IRAK1; PRKAA2; EIF2AK2; GRK6; MAPK1; Metabolism PLK1; AKT2; CDK8; MAPK8; MAPK3; PRKCD; PRKAA1; PBEF1; MAPK9; CDK2; PIM1; DYRK1A; MAP2K2; MAP2K1; PAK3; NT5E; TTK; CSNK1A1; BRAF; SGK Chemokine Signaling CXCR4; ROCK2; MAPK1; PTK2; FOS; CFL1; GNAQ; CAMK2A; CXCL12; MAPK8; MAPK3; KRAS; MAPK13; RHOA; CCR3; SRC; PPP1CC; MAPK14; NOX1; RAF1; MAP2K2; MAP2K1; JUN; CCL2; PRKCA IL-2 Signaling ELK1; MAPK1; PTPN11; AKT2; PIK3CA; SYK; FOS; STAT5B; PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS; SOCS1; STAT5A; PIK3C2A; LCK; RAF1; MAP2K2; JAK1; AKT1; PIK3R1; MAP2K1; JUN; AKT3 Synaptic Long Term PRKCE; IGF1; PRKCZ; PRDX6; LYN; MAPK1; GNAS; Depression PRKCI; GNAQ; PPP2R1A; IGF1R; PRKD1; MAPK3; KRAS; GRN; PRKCD; NOS3; NOS2A; PPP2CA; YWHAZ; RAF1; MAP2K2; PPP2R5C; MAP2K1; PRKCA Estrogen Receptor TAF4B; EP300; CARMI; PCAF; MAPK1; NCOR2; Signaling SMARCA4; MAPK3; NRIP1; KRAS; SRC; NR3C1; HDAC3; PPARGC1A; RBM9; NCOA3; RAF1; CREBBP; MAP2K2; NCOA2; MAP2K1; PRKDC; ESR1; ESR2 Protein Ubiquitination TRAF6; SMURF1; BIRC4; BRCA1; UCHL1; NEDD4; Pathway CBL; UBE2I; BTRC; HSPA5; USP7; USP10; FBXW7; USP9X; STUB1; USP22; B2M; BIRC2; PARK2; USP8; USP1; VHL; HSP90AA1; BIRC3 IL-10 Signaling TRAF6; CCR1; ELK1; IKBKB; SP1; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; MAPK14; TNF; IKBKG; RELB; MAP3K7; JAK1; CHUK; STAT3; NFKB1; JUN; IL1R1; IL6 VDR/RXR Activation PRKCE; EP300; PRKCZ; RXRA; GADD45A; HES1; NCOR2; SP1; PRKCI; CDKN1B; PRKD1; PRKCD; RUNX2; KLF4; YY1; NCOA3; CDKN1A; NCOA2; SPP1; LRP5; CEBPB; FOXO1; PRKCA TGF-beta Signaling EP300; SMAD2; SMURF1; MAPK1; SMAD3; SMAD1; FOS; MAPK8; MAPK3; KRAS; MAPK9; RUNX2; SERPINE1; RAF1; MAP3K7; CREBBP; MAP2K2; MAP2K1; TGFBR1; SMAD4; JUN; SMAD5 Toll-like Receptor Signaling IRAK1; EIF2AK2; MYD88; TRAF6; PPARA; ELK1; IKBKB; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; TLR4; MAPK14; IKBKG; RELB; MAP3K7; CHUK; NFKB1; TLR2; JUN p38 MAPK Signaling HSPB1; IRAK1; TRAF6; MAPKAPK2; ELK1; FADD; FAS; CREB1; DDIT3; RPS6KA4; DAXX; MAPK13; TRAF2; MAPK14; TNF; MAP3K7; TGFBR1; MYC; ATF4; IL1R1; SRF; STAT1 Neurotrophin/TRK Signaling NTRK2; MAPK1; PTPN11; PIK3CA; CREB1; FOS; PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS; PIK3C2A; RAF1; MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; CDC42; JUN; ATF4 FXR/RXR Activation INS; PPARA; FASN; RXRA; AKT2; SDC1; MAPK8; APOB; MAPK10; PPARG; MTTP; MAPK9; PPARGC1A; TNF; CREBBP; AKT1; SREBF1; FGFR4; AKT3; FOXO1 Synaptic Long Term PRKCE; RAP1A; EP300; PRKCZ; MAPK1; CREB1; Potentiation PRKCI; GNAQ; CAMK2A; PRKD1; MAPK3; KRAS; PRKCD; PPP1CC; RAF1; CREBBP; MAP2K2; MAP2K1; ATF4; PRKCA Calcium Signaling RAP1A; EP300; HDAC4; MAPK1; HDAC5; CREB1; CAMK2A; MYH9; MAPK3; HDAC2; HDAC7A; HDAC11; HDAC9; HDAC3; CREBBP; CALR; CAMKK2; ATF4; HDAC6 EGF Signaling ELK1; MAPK1; EGFR; PIK3CA; FOS; PIK3CB; PIK3C3; MAPK8; MAPK3; PIK3C2A; RAF1; JAK1; PIK3R1; STAT3; MAP2K1; JUN; PRKCA; SRF; STAT1 Hypoxia Signaling in the EDN1; PTEN; EP300; NQO1; UBE2I; CREB1; ARNT; Cardiovascular System HIF1A; SLC2A4; NOS3; TP53; LDHA; AKT1; ATM; VEGFA; JUN; ATF4; VHL; HSP90AA1 LPS/IL-1 Mediated Inhibition IRAK1; MYD88; TRAF6; PPARA; RXRA; ABCA1; of RXR Function MAPK8; ALDH1A1; GSTP1; MAPK9; ABCB1; TRAF2; TLR4; TNF; MAP3K7; NR1H2; SREBF1; JUN; IL1R1 LXR/RXR Activation FASN; RXRA; NCOR2; ABCA1; NFKB2; IRF3; RELA; NOS2A; TLR4; TNF; RELB; LDLR; NR1H2; NFKB1; SREBF1; IL1R1; CCL2; IL6; MMP9 Amyloid Processing PRKCE; CSNK1E; MAPK1; CAPNS1; AKT2; CAPN2; CAPN1; MAPK3; MAPK13; MAPT; MAPK14; AKT1; PSEN1; CSNK1A1; GSK3B; AKT3; APP IL-4 Signaling AKT2; PIK3CA; PIK3CB; PIK3C3; IRS1; KRAS; SOCS1; PTPN6; NR3C1; PIK3C2A; JAK1; AKT1; JAK2; PIK3R1; FRAP1; AKT3; RPS6KB1 Cell Cycle: G2/M DNA EP300; PCAF; BRCA1; GADD45A; PLK1; BTRC; Damage Checkpoint CHEK1; ATR; CHEK2; YWHAZ; TP53; CDKN1A; Regulation PRKDC; ATM; SFN; CDKN2A Nitric Oxide Signaling in the KDR; FLT1; PGF; AKT2; PIK3CA; PIK3CB; PIK3C3; Cardiovascular System CAV1; PRKCD; NOS3; PIK3C2A; AKT1; PIK3R1; VEGFA; AKT3; HSP90AA1 Purine Metabolism NME2; SMARCA4; MYH9; RRM2; ADAR; EIF2AK4; PKM2; ENTPD1; RAD51; RRM2B; TJP2; RAD51C; NT5E; POLDI; NME1 cAMP-mediated Signaling RAP1A; MAPK1; GNAS; CREB1; CAMK2A; MAPK3; SRC; RAF1; MAP2K2; STAT3; MAP2K1; BRAF; ATF4 Mitochondrial Dysfunction SOD2; MAPK8; CASP8; MAPK10; MAPK9; CASP9; Notch Signaling PARK7; PSEN1; PARK2; APP; CASP3 HES1; JAG1; NUMB; NOTCH4; ADAM17; NOTCH2; PSEN1; NOTCH3; NOTCH1; DLL4 Endoplasmic Reticulum HSPA5; MAPK8; XBP1; TRAF2; ATF6; CASP9; ATF4; Stress Pathway EIF2AK3; CASP3 Pyrimidine Metabolism NME2; AICDA; RRM2; EIF2AK4; ENTPD1; RRM2B; NT5E; POLD1; NME1 Parkinson's Signaling UCHL1; MAPK8; MAPK13; MAPK14; CASP9; PARK7; PARK2; CASP3 Cardiac & Beta Adrenergic GNAS; GNAQ; PPP2R1A; GNB2L1; PPP2CA; PPP1CC; Signaling PPP2R5C Glycolysis/Gluconeogenesis HK2; GCK; GPI; ALDH1A1; PKM2; LDHA; HK1 Interferon Signaling IRF1; SOCS1; JAK1; JAK2; IFITM1; STAT1; IFIT3 Sonic Hedgehog Signaling ARRB2; SMO; GLI2; DYRK1A; GLI1; GSK3B; DYRK1B Glycerophospholipid PLD1; GRN; GPAM; YWHAZ; SPHK1; SPHK2 Metabolism Phospholipid Degradation PRDX6; PLD1; GRN; YWHAZ; SPHK1; SPHK2 Tryptophan Metabolism SIAH2; PRMT5; NEDD4; ALDH1A1; CYP1B1; SIAH1 Lysine Degradation SUV39H1; EHMT2; NSD1; SETD7; PPP2R5C Nucleotide Excision Repair ERCC5; ERCC4; XPA; XPC; ERCC1 Pathway Starch and Sucrose UCHL1; HK2; GCK; GPI; HK1 Metabolism Aminosugars Metabolism NQO1; HK2; GCK; HK1 Arachidonic Acid PRDX6; GRN; YWHAZ; CYP1B1 Metabolism Circadian Rhythm Signaling CSNK1E; CREB1; ATF4; NR1D1 Coagulation System BDKRB1; F2R; SERPINE1; F3 Dopamine Receptor PPP2R1A; PPP2CA; PPP1CC; PPP2R5C Signaling Glutathione Metabolism IDH2; GSTP1; ANPEP; IDH1 Glycerolipid Metabolism ALDH1A1; GPAM; SPHK1; SPHK2 Linoleic Acid Metabolism PRDX6; GRN; YWHAZ; CYP1B1 Methionine Metabolism DNMT1; DNMT3B; AHCY; DNMT3A Pyruvate Metabolism GLO1; ALDH1A1; PKM2; LDHA Arginine and Proline ALDH1A1; NOS3; NOS2A Metabolism Eicosanoid Signaling PRDX6; GRN; YWHAZ Fructose and Mannose HK2; GCK; HK1 Metabolism Galactose Metabolism HK2; GCK; HK1 Stilbene, Coumarine and PRDX6; PRDX1; TYR Lignin Biosynthesis Antigen Presentation CALR; B2M Pathway Biosynthesis of Steroids NQO1; DHCR7 Butanoate Metabolism ALDH1A1; NLGN1 Citrate Cycle IDH2; IDH1 Fatty Acid Metabolism ALDH1A1; CYP1B1 Glycerophospholipid PRDX6; CHKA Metabolism Histidine Metabolism PRMT5; ALDH1A1 Inositol Metabolism ERO1L; APEX1 Metabolism of Xenobiotics GSTP1; CYP1B1 by Cytochrome p450 Methane Metabolism PRDX6; PRDX1 Phenylalanine Metabolism PRDX6; PRDX1 Propanoate Metabolism ALDH1A1; LDHA Selenoamino Acid PRMT5; AHCY Metabolism Sphingolipid Metabolism SPHK1; SPHK2 Aminophosphonate PRMT5 Metabolism Androgen and Estrogen PRMT5 Metabolism Ascorbate and Aldarate ALDH1A1 Metabolism Bile Acid Biosynthesis ALDH1A1 Cysteine Metabolism LDHA Fatty Acid Biosynthesis FASN Glutamate Receptor GNB2L1 Signaling NRF2-mediated Oxidative PRDX1 Stress Response Pentose Phosphate GPI Pathway Pentose and Glucuronate UCHL1 Interconversions Retinol Metabolism ALDH1A1 Riboflavin Metabolism TYR Tyrosine Metabolism PRMT5, TYR Ubiquinone Biosynthesis PRMT5 Valine, Leucine and ALDH1A1 Isoleucine Degradation Glycine, Serine and CHKA Threonine Metabolism Lysine Degradation ALDH1A1 Pain/Taste TRPM5; TRPA1 Pain TRPM7; TRPC5; TRPC6; TRPC1; Cnr1; cnr2; Grk2; Trpa1; Pomc; Cgrp; Crf; Pka; Era; Nr2b; TRPM5; Prkaca; Prkacb; Prkar1a; Prkar2a Mitochondrial Function AIF; CytC; SMAC (Diablo); Aifm-1; Aifm-2 Developmental Neurology BMP-4; Chordin (Chrd); Noggin (Nog); WNT (Wnt2; Wnt2b; Wnt3a; Wnt4; Wnt5a; Wnt6; Wnt7b; Wnt8b; Wnt9a; Wnt9b; Wnt10a; Wnt10b; Wnt16); beta-catenin; Dkk-1; Frizzled related proteins; Otx-2; Gbx2; FGF-8; Reelin; Dab1; unc-86 (Pou4f1 or Brn3a); Numb; Reln

Thus, also described herein are methods of inducing one or more mutations in a eukaryotic or prokaryotic cell (in vitro, i.e. in an isolated eukaryotic cell) as herein discussed comprising delivering to cell a vector as described herein. The mutation(s) can include the introduction, deletion, or substitution of one or more nucleotides at a target sequence of cell(s). In some embodiments, the mutations can include the introduction, deletion, or substitution of 1-75 nucleotides at each target sequence of said cell(s). The mutations can include the introduction, deletion, or substitution of 1, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence. The mutations can include the introduction, deletion, or substitution of 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of said cell(s). The mutations include the introduction, deletion, or substitution of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of said cell(s). The mutations can include the introduction, deletion, or substitution of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of said cell(s). The mutations can include the introduction, deletion, or substitution of 40, 45, 50, 75, 100, 200, 300, 400 or 500 nucleotides at each target sequence of said cell(s). The mutations can include the introduction, deletion, or substitution of 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, or 9900 to 10000 nucleotides at each target sequence of said cell(s).

In some embodiments, the modifications can include the introduction, deletion, or substitution of nucleotides at each target sequence of said cell(s) via nucleic acid components (e.g. guide(s) RNA(s) or sgRNA(s)), such as those mediated by a CRISPR-Cas system.

In some embodiments, the modifications can include the introduction, deletion, or substitution of nucleotides at a target or random sequence of said cell(s) via a non CRISPR-Cas system or technique. Such techniques are discussed elsewhere herein, such as where engineered cells and methods of generating the engineered cells and organisms are discussed.

For minimization of toxicity and off-target effect when using a CRISPR-Cas system, it may be important to control the concentration of Cas mRNA and guide RNA delivered. Optimal concentrations of Cas mRNA and guide RNA can be determined by testing different concentrations in a cellular or non-human eukaryote animal model and using deep sequencing the analyze the extent of modification at potential off-target genomic loci. Alternatively, to minimize the level of toxicity and off-target effect, Cas nickase mRNA (for example S. pyogenes Cas9-like with the D10A mutation) can be delivered with a pair of guide RNAs targeting a site of interest. Guide sequences and strategies to minimize toxicity and off-target effects can be as in WO 2014/093622 (PCT/US2013/074667); or, via mutation as herein.

Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theory, a tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to a guide sequence.

In one embodiment, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method includes delivering an engineered cell described herein and/or an engineered AAV capsid particle described herein having a CRISPR-Cas molecule as a cargo molecule to a subject and/or cell. The CRISPR-Cas system molecule(s) delivered can complex to bind to the target polynucleotide, e.g., to effect cleavage of said target polynucleotide, thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence can be linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein one or more vectors comprise the CRISPR enzyme and one or more vectors drive expression of one or more of: the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said CRISPR enzyme drive expression of one or more of: the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments such CRISPR enzyme are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject. In some embodiments, the isolated cells can be returned to the subject after delivery of one or more engineered viral particles or other engineered delivery vehicles to the isolated cell. In some embodiments, the isolated cells can be returned to the subject after delivering one or more molecules of the engineered delivery system described herein to the isolated cell, thus making the isolated cells engineered cells as previously described.

Screening and Cell Selection

The engineered muscle-specific delivery system vectors, engineered cells, engineered viral particles, and/or engineered muscle-specific delivery systems described herein can be used in a screening assay and/or cell selection assay. The engineered delivery system vectors, engineered cells, and/or engineered viral particles, and/or other engineered delivery system of the present invention can be delivered to a subject and/or cell. In some embodiments, the cell is a eukaryotic cell. The cell can be in vitro, ex vivo, in situ, or in vivo. The engineered delivery system molecules, delivery vehicles, vectors, engineered cells, and/or engineered viral particles described herein can introduce an exogenous molecule or compound to subject or cell to which they are delivered. The presence of an exogenous molecule or compound can be detected which can allow for identification of a cell and/or attribute thereof. In some embodiments, the delivered molecules or particles can impart a gene or other nucleotide modification (e.g. mutations, gene or polynucleotide insertion and/or deletion, etc.). In some embodiments the nucleotide modification can be detected in a cell by sequencing. In some embodiments, the nucleotide modification can result in a physiological and/or biological modification to the cell that results in a detectable phenotypic change in the cell, which can allow for detection, identification, and/or selection of the cell. In some embodiments, the phenotypic change can be cell death, such as embodiments where binding of a CRISPR complex to a target polynucleotide results in cell death. Embodiments of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system. The cell(s) may be prokaryotic or eukaryotic cells.

In one embodiment the invention provides for a method of selecting one or more cell(s) by introducing one or more mutations in a gene in the one or more cell (s), the method comprising: introducing one or more vectors, which can include one or more engineered delivery system molecules or vectors described elsewhere herein, into the cell (s), wherein the one or more vectors can include a CRISPR enzyme and/or drive expression of one or more of: a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template; or other polynucleotide to be inserted into the cell and/or genome thereof; wherein, for example that which is being expressed is within and expressed in vivo by the CRISPR enzyme and/or the editing template, when included, comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRISPR enzyme is a Cas protein. In another embodiment of the invention the cell to be selected may be a eukaryotic cell.

The screening methods involving the engineered AAV capsid system molecules, vectors, engineered cells, and/or engineered AAV capsid particles, including but not limited to those that deliver one more CRISPR-Cas system molecules to cell, can be used in detection methods such as fluorescence in situ hybridization (FISH). In some embodiments, one or more components of an engineered CRISPR-Cas system that includes a catalytically inactive Cas protein, can be delivered by an engineered delivery system molecule (such as an engineered virus particle or other engineered delivery vehicle), engineered cell, or other composition including an engineered muscle-specific targeting moiety described elsewhere herein to a cell and used in a FISH method. The CRISPR-Cas system can include an inactivated Cas protein (dCas) (e.g. a dCas9), which lacks the ability to produce DNA double-strand breaks may be fused with a marker, such as fluorescent protein, such as the enhanced green fluorescent protein (eEGFP) and co-expressed with small guide RNAs to target pericentric, centric and teleomeric repeats in vivo. The dCas system can be used to visualize both repetitive sequences and individual genes in the human genome. Such new applications of labelled dCas, dCas CRISPR-Cas systems, engineered AAV delivery system molecules, engineered cells, and/or engineered delivery particles (viral or non-viral) can be used in imaging cells and studying the functional nuclear architecture, especially in cases with a small nucleus volume or complex 3-D structures. (Chen B, Gilbert L A, Cimini B A, Schnitzbauer J, Zhang W, Li G W, Park J, Blackburn E H, Weissman J S, Qi L S, Huang B. 2013. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155(7):1479-91. doi: 10.1016/j.cell.2013.12.001., the teachings of which can be applied and/or adapted to the CRISPR systems described herein. A similar approach involving a polynucleotide fused to a marker (e.g. a fluorescent marker) can be delivered to a cell via an engineered AAV capsid system molecule, vector, engineered cell, and/or engineered AAV capsid particle described herein and integrated into the genome of the cell and/or otherwise interact with a region of the genome of a cell for FISH analysis.

Similar approaches for studying other cell organelles and other cell structures can be accomplished by delivering to the cell (e.g. via an engineered delivery AAV capsid molecule, engineered cell, and/or engineered AAV capsid particle described herein) one or more molecules fused to a marker (such as a fluorescent marker), wherein the molecules fused to the marker are capable of targeting one or more cell structures. By analyzing the presence of the markers, one can identify and/or image specific cell structures.

In some embodiments, the engineered muscle-specific delivery system molecules can be used in a screening assay inside or outside of a cell. In some embodiments, the screening assay can include delivering a CRISPR-Cas cargo molecule(s) via an engineered muscle-specific delivery particle of the present invention.

Use of the present system in screening is also provided by the present invention, e.g., gain of function screens. Cells which are artificially forced to overexpress a gene are be able to down regulate the gene over time (re-establishing equilibrium) e.g. by negative feedback loops. By the time the screen starts the unregulated gene might be reduced again. Other screening assays are discussed elsewhere herein.

In an embodiment, the invention provides a cell from or of an in vitro method of delivery, wherein the method comprises contacting the delivery system with a cell, optionally a eukaryotic cell, whereby there is delivery into the cell of constituents of the delivery system, and optionally obtaining data or results from the contacting, and transmitting the data or results.

In an embodiment, the invention provides a cell from or of an in vitro method of delivery, wherein the method comprises contacting the delivery system with a cell, optionally a eukaryotic cell, whereby there is delivery into the cell of constituents of the delivery system, and optionally obtaining data or results from the contacting, and transmitting the data or results; and wherein the cell product is altered compared to the cell not contacted with the delivery system, for example altered from that which would have been wild type of the cell but for the contacting. In an embodiment, the cell product is non-human or animal. In some embodiments, the cell product is human.

In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject optionally to be reintroduced therein. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell obtained from or is derived from cells taken from a subject, such as a cell line. Delivery mechanisms and techniques of the engineered muscle-specific delivery system and particles thereof that are described elsewhere herein.

In some embodiments it is envisaged to introduce the engineered muscle-specific delivery system molecule(s)) directly to the host cell. For instance, the engineered muscle-specific delivery system molecule(s) can be delivered together with one or more cargo molecules that are packaged into an engineered muscle-specific viral particle or contained in or coupled to a non-viral engineered muscle-specific delivery particle.

In some embodiments, the invention provides a method of expressing an engineered delivery molecule and cargo molecule to be packaged in an engineered viral particle (such as an engineered muscle-specific AAV particle) in a cell that can include the step of introducing the vector according any of the vector delivery systems disclosed herein.

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES Example 1—mRNA Based Detection Methods are More Stringent for Selection of AAV Variants

FIG. 1 demonstrates the adeno-associated virus (AAV) transduction mechanism, which results in production of mRNA. As is demonstrated in FIG. 1, functional transduction of a cell by an AAV particle can result in the production of an mRNA strand. Non-functional transduction would not produce such a product despite the viral genome being detectable using a DNA-based assay. Thus, mRNA-based detection assays to detect transduction by e.g. an AAV can be more stringent and provide feedback as to the functionality of a virus particle that is able to functionally transduce a cell. FIG. 2 shows a graph that can demonstrate that mRNA-based selection of AAV variants can be more stringent than DNA-based selection. The virus library was expressed under the control of a CMV promoter.

Example 2—mRNA Based Detection Methods can be Used to Detect AAV Capsid Variants from a Capsid Variant Library

FIGS. 3A-3B show graphs that can demonstrate a correlation between the virus library and vector genome DNA (FIG. 3A) and mRNA (FIG. 3B) in the liver. FIGS. 4A-4F show graphs that can demonstrate capsid variants expressed at the mRNA level identified in different tissues.

Example 3—Capsid mRNA Expression can be Driven by Tissue Specific Promoters

FIGS. 5A-5C show graphs that can demonstrate capsid mRNA expression in different tissues under the control of cell-type specific promoters (as noted on x-axis). CMV was included as an exemplary constitutive promoter. CK8 is a muscle-specific promoter. MHCK7 is a muscle-specific promoter. hSyn is a neuron specific promoter.

Example 4—Capsid Variant Library Generation, Variant Screening, and Variant Identification

Generally, an AAV capsid library can be generated by expressing engineered capsid vectors each containing an engineered AAV capsid polynucleotide previously described in an appropriate AAV producer cell line. See e.g. FIG. 8. This can generate an AAV capsid library that can contain one more desired cell-specific engineered AAV capsid variant. FIG. 7 shows a schematic demonstrating embodiments of generating an AAV capsid variant library, particularly insertion of a random n-mer (n=3-15 amino acids) into a wild-type AAV, e.g. AAV9. In this example, random 7-mers were inserted between aa588-589 of variable region VIII of AAV9 viral protein and used to form the viral genome containing vectors with one variant per vector. As shown in FIG. 8, the capsid variant vector library was used to generate AAV particles where each capsid variant encapsulated its coding sequence as the vector genome. FIG. 9 shows vector maps of representative AAV capsid plasmid library vectors (see e.g. FIG. 8) that can be used in an AAV vector system to generate an AAV capsid variant library. The library can be generated with the capsid variant polynucleotide under the control of a tissue specific promoter or constitutive promoter. The library was also made with capsid variant polynucleotide that included a polyadenylation signal.

As shown in FIG. 6 the AAV capsid library can be administered to various non-human animals for a first round of mRNA-based selection. As shown in FIG. 1, the transduction process by AAVs and related vectors can result in the production of an mRNA molecule that is reflective of the genome of the virus that transduced the cell. As is at least demonstrated in the Examples herein, mRNA based-selection can be more specific and effective to determine a virus particle capable of functionally transducing a cell because it is based on the functional product produced as opposed to just detecting the presence of a virus particle in the cell by measuring the presence of viral DNA.

After first-round administration, one or more engineered AAV virus particles having a desired capsid variant can then be used to form a filtered AAV capsid library. Desirable AAV virus particles can be identified by measuring the mRNA expression of the capsid variants and determining which variants are highly expressed in the desired cell type(s) as compared to non-desired cells type(s). Those that are highly expressed in the desired cell, tissue, and/or organ type are the desired AAV capsid variant particles. In some embodiments, the AAV capsid variant encoding polynucleotide is under control of a tissue-specific promoter that has selective activity in the desired cell, tissue, or organ.

The engineered AAV capsid variant particles identified from the first round can then be administered to various non-human animals. In some embodiments, the animals used in the second round of selection and identification are not the same as those animals used for first round selection and identification. Similar to round 1, after administration the top expressing variants in the desired cell, tissue, and/or organ type(s) can be identified by measuring viral mRNA expression in the cells. The top variants identified after round two can then be optionally barcoded and optionally pooled. In some embodiments, top variants from the second round can then be administered to a non-human primate to identify the top cell-specific variant(s), particularly if the end use for the top variant is in humans. Administration at each round can be systemic.

FIG. 10 shows a graph that can demonstrate the viral titer (calculated as AAV9 vector genome/15 cm dish) produced by libraries generated using different promoters. As demonstrated in FIG. 10, virus titer was not affected significantly be the use of different promoters.

FIGS. 11A-11F show graphs that can demonstrate the results obtained after the first round of selection in C57BL/6 mice using a capsid library expressed under the control of the MHCK7 muscle-specific promoter.

FIGS. 12A-12D show graphs that can demonstrate the results obtained after the second round of selection in C57BL/6 mice.

FIGS. 13A-13B shows graphs that can demonstrate a correlation between the abundance of variants encoded by synonymous codons. This graph can demonstrate that there is little to no codon bias in both the virus library and the functional virus particles.

FIG. 14 shows a graph that can demonstrate a correlation between the abundance of the same variants expressed under the control of two different muscle specific promoters (MHCK7 and CK8). This graph can demonstrate that there is little effect of which tissue-specific promoter is used to generate the capsid variant library, at least for muscle cells.

Example 5—Muscle-Tropic rAAV Capsids

FIG. 15 shows a graph that can demonstrate muscle-tropic capsid variants that produce rAAV with similar titers to wild-type AAV9 capsid.

FIG. 16 shows images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 17 shows a panel of images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 18 shows a panel of images that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 19 shows a schematic of selection of potent capsid variants for muscle-directed gene delivery across species.

FIGS. 20A-20C show tables that can demonstrate selection in different strains of mice identifies the same variants as the top muscle-tropic hits.

Example 6—Comparison of MyoAAV and AAV9 and AAV8

As previously discussed, FIG. 17 can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 21 shows images that can demonstrate a comparison of mouse muscle transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 22 shows graphs that can demonstrate a comparison of mouse tissue transduction between rAAV9-GFP and rMyoAAV-GFP.

FIG. 23 shows graphs that can demonstrate a comparison of vector genome biodistribution between rAAV9-GFP and rMyoAAV-GFP.

FIGS. 24A-24B show images that can demonstrate faster kinetics of in vivo gene expression in muscle by MyoAAV as compared to AAV9 and AAV8.

FIG. 25 can demonstrate a mechanism of correction of a DMD mutation in model mdx mice by MyoAAV-CRISPR or AAV9-CRISPR.

FIGS. 26A-26C can demonstrate correction of a DMD mutation in model mdx mice with MyoAAV-CRISPR as compared to AAV9-CRISPR.

FIG. 27 can demonstrate that MyoAAV uses integrin heterodimers as the receptor to enter cells.

FIG. 28 shows graphs that can demonstrate that myoAAV can transduce both mouse and human primary myotubes more effectively than AAV9.

FIGS. 29A-29B can demonstrate that integrin alpha V small molecule inhibitors suppress transduction of human and mouse primary myotubes by MyoAAV.

Example 7—Top n-mer Motifs in Non-Human Primates

Muscle specific AAV capsids were developed using a muscle specific promoter and the resulting capsid libraries were screened in non-human primates as described elsewhere herein and/or in U.S. Provisional Application Ser. Nos. 62/899,453, 62/916,207, 63/018,454, 63/055,252, and 62/916,221 and International Application No. PCT/US20/50534. Tables 8 and 9 show the top hits of muscle specific n-mer motifs and their encoding sequence in rank order within each table.

TABLE 8 SEQ SEQ N-Mer ID ID Motif NO: Encoding Sequence score NO: RGDYHAI 8314 AGGGGCGACTACCACGCCATC 4178 8503 RGDYASL 8315 CGGGGCGACTACGCAAGCCTG 3851 8504 RGDYVGL 8316 CGGGGTGATTATGTGGGGCTG 3686 8505 RGDLRPT 8317 CGTGGGGATCTTAGGCCGACG 3610 8506 RGDHVSL 8318 CGTGGGGATCATGTGTCTTTG 3050 8507 DVRSLHG 8319 GACGTTAGATCCCTTCACGGC 2985 8508 RGDYHAI 8320 CGTGGTGATTATCATGCTATT 2944 8509 RGDYGGL 8321 CGTGGTGATTATGGTGGGCTG 2816 8510 RGDHGVL 8322 CGGGGTGATCATGGGGTTCTT 2692 8511 RGDYREL 8323 AGAGGAGACTACCGGGAACTC 2690 8512 VSRGDVP 8324 GTTAGTCGGGGTGATGTGCCT 2675 8513 RGDYVGL 8325 CGCGGGGACTACGTAGGTTTA 2666 8514 RGDYSGL 8326 CGGGGTGATTATTCGGGGTTG 2642 8515 RGDLTVT 8327 AGGGGGGACCTGACAGTCACG 2604 8516 RGDHASW 8328 CGTGGTGATCATGCTTCTTGG 2603 8517 RGDLVGY 8329 AGGGGGGATCTTGTGGGGTAT 2543 8518 RGDGAAM 8330 CGTGGGGATGGTGCGGCGATG 2439 8519 VSAARSL 8331 GTGAGTGCGGCGCGTTCTCTG 2437 8520 LTAQYVT 8332 TTGACTGCTCAGTATGTGACG 2430 8521 RGDHGVL 8333 CGCGGAGACCACGGTGTATTA 2429 8522 VGNRFSP 8334 GTTGGGAATAGGTTTTCGCCG 2410 8523 TGVHTRV 8335 ACGGGTGTTCATACGAGGGTG 2405 8524 VRTGDAS 8336 GTGCGTACTGGTGATGCGTCG 2401 8525 MVVRGGV 8337 ATGGTGGTGCGTGGGGGTGTT 2393 8526 RGDRESH 8338 CGCGGAGACCGAGAAAGCCAC 2370 8527 RGDYSGL 8339 CGTGGCGACTACTCTGGTCTA 2306 8528 RGDLSSV 8340 CGGGGTGATCTTTCGAGTGTT 2292 8529 LLGQRAA 8341 CTGCTTGGTCAGAGGGCTGCT 2269 8530 GKGTVPS 8342 GGGAAGGGGACTGTGCCGAGT 2262 8531 SSIGVKI 8343 TCGTCGATTGGTGTGAAGATT 2256 8532 ANKGLGT 8344 GCAAACAAAGGCCTGGGCACG 2246 8533 RGDHASW 8345 CGGGGGGATCATGCTTCTTGG 2245 8534 RGDRLVI 8346 AGAGGAGACAGGCTGGTCATC 2219 8535 GQGHRGD 8347 GGACAAGGCCACCGGGGAGAC 2215 8536 ERTRAGE 8348 GAGAGGACTCGGGCGGGTGAG 2209 8537 RGDLSGT 8349 AGGGGCGACCTGTCTGGCACC 2203 8538 RGDYREM 8350 CGGGGGGATTATCGTGAGATG 2201 8539 RGDLAHN 8351 AGGGGTGATCTTGCGCATAAT 2183 8540 GFSGRTV 8352 GGGTTTAGTGGGAGGACGGTG 2183 8541 VMRAGAT 8353 GTTATGCGAGCAGGTGCGACG 2173 8542 EGGIYRV 8354 GAAGGAGGAATCTACCGTGTT 2168 8543 RGDYREL 8355 CGTGGTGATTATCGTGAGTTG 2168 8544 QSVSIKS 8356 CAGAGTGTGTCTATTAAGTCT 2167 8545 RGDLVHV 8357 CGAGGAGACTTGGTCCACGTC 2161 8546 YRGDIRV 8358 TACCGTGGTGACATACGGGTG 2156 8547 RGDASTW 8359 CGTGGGGACGCCAGTACCTGG 2148 8548 RGDYGGI 8360 CGTGGGGATTATGGTGGTATT 2146 8549 VGTRGDT 8361 GTGGGTACGCGGGGGGATACG 2146 8550 RGDLTTV 8362 CGGGGGGATCTGACGACTGTT 2133 8551 RGDMRPV 8363 CGTGGTGATATGCGTCCGGTT 2126 8552 AAGRLTT 8364 GCTGCTGGTAGGCTTACGACG 2125 8553 NAGRSTL 8365 AACGCAGGGCGCTCTACCTTA 2108 8554 ERDRISG 8366 GAGCGGGATCGGATTTCGGGT 2091 8555 RGDLTTT 8367 CGGGGTGACCTGACAACCACG 2082 8556 TTGLRLA 8368 ACGACTGGGCTTCGTCTGGCT 2082 8557 RGDHSGW 8369 CGTGGTGATCATAGTGGTTGG 2080 8558 SGGTYLA 8370 AGCGGGGGAACGTACCTTGCC 2078 8559 AVVRGGP 8371 GCTGTTGTGCGGGGTGGTCCT 2064 8560 IVRGLSD 8372 ATTGTGAGGGGTCTGAGTGAT 2054 8561 RGDTMRL 8373 CGCGGAGACACGATGAGACTG 2054 8562 TRVPVSG 8374 ACGCGAGTACCGGTGAGCGGG 2052 8563 RTYDSNV 8375 CGAACGTACGACTCAAACGTA 2052 8564 RGDRMGV 8376 CGGGGTGATCGTATGGGTGTG 2043 8565 QLNAYSG 8377 CAGTTGAATGCGTATAGTGGG 2042 8566 SLGITSG 8378 TCATTGGGTATAACCTCGGGC 2040 8567 TAAVRTY 8379 ACGGCTGCGGTGCGTACGTAT 2031 8568 RGDLTTT 8380 CGTGGGGATCTTACTACGACT 2031 8569 RGDYATF 8381 CGGGGTGATTATGCTACTTTT 2028 8570 RGDIVGL 8382 AGGGGTGACATAGTGGGCCTC 2027 8571 GSRGDLS 8383 GGTAGTCGTGGCGACTTATCG 2027 8572 RGDVTHI 8384 AGAGGAGACGTTACGCACATC 2024 8573 IGGTRVQ 8385 ATTGGTGGGACTCGGGTGCAG 2023 8574 ENHTHRA 8386 GAGAATCATACTCATAGGGCT 2023 8575 RGDLTYA 8387 CGTGGTGATCTGACGTATGCT 2022 8576 LLHESRV 8388 TTGTTGCATGAGTCGCGGGTT 2021 8577 RGDVSGI 8389 CGTGGTGATGTTAGTGGGATT 2018 8578 LNSAMRT 8390 CTGAATTCTGCGATGCGTACT 2015 8579 RGDYATL 8391 AGGGGGGACTACGCCACACTG 2010 8580 SANVVRG 8392 TCTGCGAATGTTGTGAGGGGG 2010 8581 VAGQRSV 8393 GTTGCTGGGCAGCGTTCTGTT 2008 8582 RGDREHF 8394 CGTGGTGATAGGGAGCATTTT 2007 8583 RGDYVTI 8395 CGCGGAGACTACGTTACAATA 1999 8584 RLVSTAP 8396 CGTCTTGTTTCGACTGCTCCG 1998 8585 HQSFHGA 8397 CACCAATCATTCCACGGCGCA 1996 8586 VRGDSRF 8398 GTAAGGGGCGACAGCAGATTC 1991 8587 RGDFGGV 8399 AGGGGTGACTTCGGAGGTGTC 1990 8588 LVRTTVS 8400 CTTGTCAGAACTACAGTGTCC 1989 8589 RGDYVSV 8401 CGTGGGGATTATGTGTCTGTG 1989 8590 RGDYASL 8402 AGGGGTGATTATGCGTCTCTT 1983 8591 IVRDGRL 8403 ATCGTCCGAGACGGAAGACTT 1978 8592 LTHGMIG 8404 CTGACGCATGGTATGATTGGT 1973 8593 RGDVRVI 8405 CGAGGCGACGTTCGGGTCATA 1964 8594 KAQPSSS 8406 AAGGCTCAGCCGTCTTCGTCT 1964 8595 GMRGASV 8407 GGGATGAGGGGTGCTTCGGTG 1961 8596 AAGRVGT 8408 GCTGCGGGTAGGGTTGGGACG 1955 8597 QMGRVQV 8409 CAGATGGGTCGGGTTCAGGTG 1954 8598 LMSRGDT 8410 TTGATGTCGCGGGGTGATACT 1953 8599 VHSRGDM 8411 GTCCACTCTCGCGGAGACATG 1952 8600 RGDLVTV 8412 CGGGGGGATCTGGTTACGGTT 1952 8601 RNYGDHS 8413 AGAAACTACGGCGACCACTCG 1951 8602 RGDYSQI 8414 AGAGGCGACTACAGCCAAATA 1950 8603 RGDLANS 8415 AGGGGTGATTTGGCTAATTCT 1945 8604 RSSHLDV 8416 CGTTCCAGTCACCTTGACGTT 1940 8605 RSGTVGL 8417 CGCTCCGGGACCGTTGGACTG 1939 8606 IGARGDT 8418 ATAGGAGCGAGGGGGGACACG 1938 8607 SNAVPGT 8419 TCGAATGCGGTTCCTGGTACT 1935 8608 LDARGHL 8420 TTGGATGCTAGGGGGCATCTG 1930 8609 TSVSVKY 8421 ACTTCTGTGTCGGTGAAGTAT 1928 8610 TRVMGAT 8422 ACGCGGGTGATGGGGGCGACT 1920 8611 RGGTGVN 8423 CGAGGCGGGACTGGAGTAAAC 1919 8612 VASRTSV 8424 GTGGCTAGTCGTACGTCTGTT 1918 8613 RGDRLQI 8425 CGTGGTGATCGGCTTCAGATT 1917 8614 RGDYERL 8426 CGCGGTGACTACGAACGACTA 1916 8615 LAAKALV 8427 CTTGCGGCTAAGGCTCTGGTT 1915 8616 LGTTSAS 8428 CTGGGGACGACTTCTGCGTCG 1914 8617 RGDHGTI 8429 CGTGGGGATCATGGGACGATT 1914 8618 GLRVVQA 8430 GGACTCCGAGTAGTCCAAGCC 1913 8619 RQTVGMG 8431 CGTCAGACTGTGGGGATGGGT 1909 8620 RGDLLTN 8432 AGGGGGGATCTGTTGACGAAT 1905 8621 YGHGMVG 8433 TACGGACACGGCATGGTCGGG 1904 8622 VVAALRG 8434 GTTGTTGCTGCTCTTCGGGGT 1904 8623 QLSRSGT 8435 CAGTTGTCGAGGAGTGGTACG 1902 8624 GLSRTGV 8436 GGTCTTTCGAGGACGGGGGTG 1902 8625 MGGGRLT 8437 ATGGGTGGTGGTCGTCTTACT 1896 8626 RGDLVMV 8438 AGAGGCGACTTAGTGATGGTG 1896 8627 RGDVVGL 8439 AGGGGTGACGTCGTAGGCCTG 1888 8628 VTKVGVL 8440 GTGACGAAGGTTGGGGTGCTG 1887 8629 RTSYPEA 8441 CGCACCTCATACCCTGAAGCC 1887 8630 ESRATMS 8442 GAATCGCGGGCAACGATGTCT 1885 8631 SRVGVGA 8443 AGTCGGGTGGGTGTTGGTGCG 1883 8632 RGDYVTM 8444 CGAGGCGACTACGTGACTATG 1880 8633 RAQGPQA 8445 AGGGCTCAGGGTCCTCAGGCG 1878 8634 VTSHAMA 8446 GTCACATCCCACGCCATGGCC 1877 8635 RGDLGGV 8447 CGAGGGGACTTAGGCGGCGTC 1873 8636 SIRGELG 8448 AGTATTCGTGGTGAGCTGGGT 1867 8637 RGDGSAL 8449 CGTGGTGATGGGAGTGCTCTT 1863 8638 SRSGIAI 8450 TCTAGGAGTGGTATTGCGATT 1860 8639 QAGTLGY 8451 CAGGCGGGGACGCTTGGGTAT 1860 8640 RGDLTTA 8452 AGGGGTGATCTTACGACTGCG 1859 8641 LGHRGDV 8453 CTTGGTCATCGGGGTGATGTT 1859 8642 RGDLTIT 8454 AGAGGCGACCTGACCATCACA 1856 8643 RGDLRVP 8455 CGTGGGGATCTTCGGGTGCCT 1856 8644 NSDHRIL 8456 AACTCGGACCACCGCATACTC 1852 8645 RGDYHSF 8457 CGTGGAGACTACCACTCATTC 1851 8646 GTGRYVS 8458 GGGACAGGTCGATACGTGAGC 1851 8647 PLLRSGT 8459 CCGTTGTTGAGGAGTGGGACG 1849 8648 RGDVVSW 8460 CGTGGAGACGTCGTAAGTTGG 1849 8649 VMRVGHA 8461 GTGATGCGTGTGGGGCATGCT 1848 8650 RGDLVSV 8462 AGGGGGGATCTGGTGTCTGTT 1847 8651 RGDLTGV 8463 CGGGGTGATTTGACGGGGGTG 1845 8652 VSSTKMA 8464 GTGTCGTCTACGAAGATGGCT 1844 8653 RGDHTQW 8465 CGCGGAGACCACACGCAATGG 1843 8654 VVRGVTD 8466 GTAGTTAGAGGTGTGACCGAC 1842 8655 VQVAVQR 8467 GTTCAGGTTGCGGTGCAGAGG 1838 8656 RTVTAVE 8468 CGTACTGTGACGGCGGTGGAG 1838 8657 RTQLGMA 8469 CGAACTCAATTAGGAATGGCG 1835 8658 GGSVRGS 8470 GGGGGTTCGGTGAGGGGTTCG 1835 8659 RGDHSSL 8471 AGGGGGGATCATTCTAGTCTG 1834 8660 LAGTSGA 8472 CTTGCTGGGACTAGTGGGGCG 1831 8661 LRTGTLS 8473 CTTAGGACTGGGACTTTGAGT 1830 8662 WKAQVQA 8474 TGGAAAGCCCAAGTTCAAGCT 1827 8663 NSTALRG 8475 AATTCTACGGCTCTTCGTGGG 1825 8664 DGGRMAY 8476 GACGGTGGGCGAATGGCTTAC 1825 8665 TRTPSPA 8477 ACAAGAACACCTTCTCCCGCT 1824 8666 STVARGD 8478 TCAACGGTCGCAAGGGGGGAC 1823 8667 RAGTAMS 8479 AGGGCTGGCACGGCCATGAGT 1822 8668 RGDRESH 8480 AGGGGGGATCGTGAGAGTCAT 1820 8669 LSRSGEL 8481 CTGAGTCGGAGTGGTGAGCTG 1819 8670 TAGRVQV 8482 ACTGCTGGGCGTGTTCAGGTG 1813 8671 VTTRGDV 8483 GTGACGACTCGTGGTGATGTG 1809 8672 VMRAGTS 8484 GTTATGCGTGCGGGGACTAGT 1809 8673 LSRSGDL 8485 TTGTCTCGGAGTGGTGATCTT 1808 8674 GYGHDRS 8486 GGTTATGGTCATGATCGGAGT 1807 8675 HAYKTSP 8487 CATGCTTATAAGACGTCTCCT 1804 8676 SPGKSGG 8488 AGTCCGGGTAAGTCTGGGGGT 1802 8677 SAGKTVV 8489 TCGGCGGGGAAGACGGTTGTT 1799 8678 VRGQQND 8490 GTGAGGGGGCAGCAGAATGAT 1799 8679 AVTRGGF 8491 GCTGTGACTAGGGGTGGTTTT 1796 8680 RGDLYTP 8492 AGGGGTGATCTTTATACGCCG 1796 8681 RAGTAIT 8493 CGTGCGGGTACTGCTATTACT 1796 8682 SLVRAAA 8494 TCGTTGGTTCGTGCTGCTGCT 1795 8683 VVRGDVG 8495 GTCGTCCGAGGCGACGTCGGC 1793 8684 RGDLSGT 8496 CGTGGTGATCTTTCGGGTACG 1792 8685 RYGATGT 8497 AGGTATGGTGCTACGGGGACT 1787 8686 PGLRGVA 8498 CCTGGTCTGAGGGGGGTTGCG 1782 8687 IPMRGQM 8499 ATTCCGATGAGGGGTCAGATG 1781 8688 SAGRSQG 8500 AGTGCTGGTCGTAGTCAGGGG 1779 8689 VRGVGTA 8501 GTTCGGGGGGTTGGTACGGCT 1778 8690 RGDYVSV 8502 CGGGGAGACTACGTCAGTGTC 1777 8691

TABLE 9 N-mer SEQ ID SEQ ID Rank motif NO: Encoding sequence NO: 1 RGDYVGL 8692 CGGGGTGATTATGTGGGGCTG 8890 2 RGDYSSV 8693 CGGGGTGATTATTCGAGTGTT 8891 3 RGDYSGL 8694 CGGGGTGATTATTCGGGGTTG 8892 4 RGDHERL 8695 CGTGGTGATCATGAGCGTTTG 8893 5 RGDLTVT 8696 AGGGGGGACCTGACAGTCACG 8894 6 RGDYHAI 8697 AGGGGCGACTACCACGCCATC 8895 7 RGDYREL 8698 AGAGGAGACTACCGGGAACTC 8896 8 RGDHGVL 8699 CGGGGTGATCATGGGGTTCTT 8897 9 RGDHASW 8700 CGTGGTGATCATGCTTCTTGG 8898 10 RGDYSGL 8701 CGTGGCGACTACTCTGGTCTA 8899 11 RGDAMHL 8702 CGTGGGGATGCGATGCATCTG 8900 12 RGDHVSL 8703 CGTGGGGATCATGTGTCTTTG 8901 13 RGDHGQL 8704 CGGGGGGATCATGGGCAGTTG 8902 14 RGDYGGL 8705 CGTGGTGATTATGGTGGGCTG 8903 15 RGDYVTM 8706 CGAGGCGACTACGTGACTATG 8904 16 RGDHSTW 8707 CGCGGGGACCACTCTACCTGG 8905 17 RGDLSGT 8708 AGGGGCGACCTGTCTGGCACC 8906 18 RGDYREM 8709 CGGGGGGATTATCGTGAGATG 8907 19 RGDTERL 8710 AGAGGGGACACCGAAAGATTG 8908 20 RGDHSTW 8711 CGGGGTGATCATAGTACTTGG 8909 21 RGDLSGT 8712 CGTGGTGATCTTTCGGGTACG 8910 22 RGDHASW 8713 CGGGGGGATCATGCTTCTTGG 8911 23 RGDLSSV 8714 CGGGGTGATCTTTCGAGTGTT 8912 24 RGDTVVL 8715 CGAGGAGACACGGTGGTCCTA 8913 25 RGDAAGL 8716 CGTGGGGACGCGGCTGGGTTG 8914 26 RGDGATL 8717 CGGGGTGATGGTGCGACTCTG 8915 27 RGDYASL 8718 AGGGGTGATTATGCGTCTCTT 8916 28 MTARNPM 8719 ATGACTGCTCGGAATCCGATG 8917 29 YVVGSRS 8720 TATGTGGTGGGGAGTAGGAGT 8918 30 YAVGSRS 8721 TATGCGGTGGGGAGTAGGAGT 8919 31 RGDYVGL 8722 CGCGGGGACTACGTAGGTTTA 8920 32 RGDLTTT 8723 CGGGGTGACCTGACAACCACG 8921 33 RGDYERL 8724 CGCGGTGACTACGAACGACTA 8922 34 RGDYREL 8725 CGTGGTGATTATCGTGAGTTG 8923 35 RGDHGVL 8726 CGCGGAGACCACGGTGTATTA 8924 36 RGDYHAI 8727 CGTGGTGATTATCATGCTATT 8925 37 RGDHTQW 8728 CGCGGAGACCACACGCAATGG 8926 38 RGDLLGT 8729 CGGGGTGATTTGTTGGGGACT 8927 39 RGDLTGV 8730 CGGGGTGATTTGACGGGGGTG 8928 40 RGDSYTL 8731 CGTGGCGACTCCTACACCTTG 8929 41 RGDYGTV 8732 CGCGGAGACTACGGAACGGTC 8930 42 RGDVVGL 8733 AGGGGTGACGTCGTAGGCCTG 8931 43 RGDTERL 8734 CGGGGTGATACTGAGCGTCTG 8932 44 RGDHSSL 8735 CGCGGCGACCACTCCTCATTG 8933 45 RGDHGQL 8736 AGGGGCGACCACGGTCAACTT 8934 46 RGDVTGM 8737 CGTGGCGACGTAACTGGAATG 8935 47 RGDYGGL 8738 CGCGGCGACTACGGGGGCTTA 8936 48 RGDYAGH 8739 CGTGGGGATTATGCGGGGCAT 8937 49 RGDIVGL 8740 AGGGGTGACATAGTGGGCCTC 8938 50 RGDLVGY 8741 AGGGGGGATCTTGTGGGGTAT 8939 51 RGDGAHL 8742 CGTGGTGATGGTGCTCATCTG 8940 52 RGDQVVV 8743 CGTGGTGATCAGGTTGTGGTT 8941 53 RGDTMGM 8744 CGTGGGGATACGATGGGTATG 8942 54 RGDLLGT 8745 CGTGGGGATTTGTTGGGGACT 8943 55 RGDLSGN 8746 CGTGGGGATCTTTCTGGTAAT 8944 56 FNVSTRT 8747 TTCAACGTAAGTACGAGAACA 8945 57 RGDRTVI 8748 CGTGGTGATCGTACTGTGATT 8946 58 RGDVSGI 8749 CGTGGTGATGTTAGTGGGATT 8947 59 RGDYASL 8750 CGGGGCGACTACGCAAGCCTG 8948 60 RGDQALI 8751 CGTGGTGATCAGGCGCTTATT 8949 61 RGDRDSW 8752 CGTGGTGATCGTGATTCGTGG 8950 62 RGDREGL 8753 CGTGGTGATCGTGAGGGTCTT 8951 63 RGDYVSV 8754 CGGGGAGACTACGTCAGTGTC 8952 64 RGDTMRL 8755 CGCGGAGACACGATGAGACTG 8953 65 RGDYAHT 8756 AGGGGTGACTACGCTCACACG 8954 66 RGDTEKL 8757 CGGGGTGATACGGAGAAGTTG 8955 67 RGDQWQV 8758 AGGGGGGATCAGTGGCAGGTG 8956 68 RGDILNV 8759 CGGGGTGATATTCTGAATGTG 8957 69 RGDREQV 8760 CGTGGTGATCGTGAGCAGGTT 8958 70 RGDNWQM 8761 CGAGGCGACAACTGGCAAATG 8959 71 RGDYGGM 8762 AGGGGGGATTATGGTGGGATG 8960 72 RGDLDGR 8763 CGTGGTGATCTGGATGGGCGG 8961 73 RGDHERL 8764 AGAGGGGACCACGAACGGCTT 8962 74 RGDLGVV 8765 AGGGGTGATCTGGGTGTGGTG 8963 75 RGDRESH 8766 CGCGGAGACCGAGAAAGCCAC 8964 76 RGDAATM 8767 CGGGGGGATGCTGCGACGATG 8965 77 RGDLGGV 8768 CGTGGTGATTTGGGTGGGGTG 8966 78 RGDAGQL 8769 CGGGGTGATGCGGGGCAGCTT 8967 79 RGDRGEI 8770 CGGGGGGATCGTGGTGAGATT 8968 80 RGDVVSW 8771 CGTGGAGACGTCGTAAGTTGG 8969 81 MTARSPM 8772 ATGACTGCTCGGAGTCCGATG 8970 82 TIRDGRL 8773 ACGATCCGTGACGGCAGGTTG 8971 83 RGDIVGL 8774 CGTGGGGATATTGTMGTCTG 8972 84 RGDYQAV 8775 CGCGGTGACTACCAAGCAGTG 8973 85 RGDGAHM 8776 CGTGGTGATGGGGCGCATATG 8974 86 RGDAASI 8777 CGGGGTGATGCTGCTTCGATT 8975 87 RGDNSQW 8778 CGTGGGGATAATTCTCAGTGG 8976 88 RGDHSGL 8779 AGAGGCGACCACTCGGGCCTC 8977 89 RGDMGGT 8780 CGAGGCGACATGGGAGGCACC 8978 90 RGDLTGV 8781 AGGGGAGACCTCACAGGTGTA 8979 91 RGDVSGY 8782 CGGGGTGATGTGTCTGGTTAT 8980 92 RGDLTTT 8783 CGTGGGGATCTTACTACGACT 8981 93 RGDYGTV 8784 AGGGGTGATTATGGGACTGTT 8982 94 RGDTMGM 8785 CGCGGTGACACCATGGGCATG 8983 95 RGDYSSV 8786 CGTGGGGATTATTCGTCTGTG 8984 96 RGDYGGM 8787 CGGGGTGACTACGGCGGTATG 8985 97 RGDYVSV 8788 CGTGGGGATTATGTGTCTGTG 8986 98 RGDVTGL 8789 CGTGGAGACGTGACCGGACTG 8987 99 RGDLLTN 8790 CGAGGTGACCTTCTCACAAAC 8988 100 RGDHSGW 8791 CGTGGTGATCATAGTGGTTGG 8989 101 VSRGDVP 8792 GTTAGTCGGGGTGATGTGCCT 8990 102 RGDVSGM 8793 CGTGGTGATGTGAGTGGGATG 8991 103 RGDRVGM 8794 CGGGGAGACCGCGTGGGCATG 8992 104 RGDGGVL 8795 CGTGGGGATGGTGGTGTGCTT 8993 105 RGDYVTI 8796 AGGGGTGATTATGTGACGATT 8994 106 RGDIAGV 8797 CGGGGTGATATTGCTGGTGTT 8995 107 RGDREQV 8798 CGCGGAGACAGAGAACAAGTG 8996 108 RGDLDNK 8799 CGTGGGGATTTGGATAATAAG 8997 109 RGDLTSV 8800 CGTGGTGATCTGACGTCTGTT 8998 110 FNVSVRN 8801 TTCAACGTAAGTGTTCGCAAC 8999 111 RGDLVHT 8802 CGTGGTGATCTGGTTCATACT 9000 112 RGDHGVI 8803 AGGGGTGACCACGGTGTGATA 9001 113 RGDAREM 8804 CGTGGTGATGCTCGTGAGATG 9002 114 RGDQASY 8805 CGTGGTGATCAGGCGTCTTAT 9003 115 RGDHSSL 8806 AGGGGGGATCATTCTAGTCTG 9004 116 RGDVRVI 8807 CGAGGCGACGTTCGGGTCATA 9005 117 TVGRGDT 8808 ACGGTTGGTCGTGGTGATACG 9006 118 RGDHGSL 8809 CGAGGCGACCACGGTTCACTG 9007 119 RGDFERT 8810 CGAGGGGACTTCGAACGAACC 9008 120 RGDHSGL 8811 CGTGGTGATCATAGTGGGCTT 9009 121 RGDMSTV 8812 AGAGGCGACATGTCTACGGTG 9010 122 RGDYATL 8813 CGGGGTGATTATGCTACGCTT 9011 123 LPGVGHA 8814 CTGCCTGGTGTGGGTCATGCT 9012 124 RGDALHL 8815 AGGGGCGACGCGCTCCACCTT 9013 125 SGGTYLA 8816 AGCGGGGGAACGTACCTTGCC 9014 126 RGDVVHL 8817 AGGGGTGATGTTGTGCATCTG 9015 127 RGDQVQL 8818 CGGGGTGATCAGGTGCAGCTG 9016 128 SSIGVKI 8819 TCGTCGATTGGTGTGAAGATT 9017 129 RGDHMSL 8820 CGCGGCGACCACATGTCTCTA 9018 130 RGDMSTV 8821 AGGGGGGATATGAGTACTGTT 9019 131 VMRAGAT 8822 GTTATGCGAGCAGGTGCGACG 9020 132 RGDVVGL 8823 CGGGGGGATGTTGTTGGGCTT 9021 133 RGDTVVL 8824 CGTGGTGATACTGTTGTGTTG 9022 134 GTKVGVL 8825 GGGACGAAGGTTGGTGTGCTG 9023 135 TGVHTRV 8826 ACAGGAGTGCACACCCGGGTT 9024 136 RGDAGVL 8827 CGTGGTGATGCTGGGGTTCTT 9025 137 RGDLSTT 8828 CGTGGTGATCTTTCGACTACT 9026 138 RGDRLQI 8829 CGTGGTGATCGGCTTCAGATT 9027 139 RGDAVTL 8830 CGTGGGGATGCGGTGACTTTG 9028 140 RGDMVSV 8831 CGGGGGGATATGGTTAGTGTG 9029 141 RGDRENL 8832 CGTGGGGATAGGGAGAATCTT 9030 142 RGDGAAM 8833 CGTGGGGATGGTGCGGCGATG 9031 143 RGDLTRT 8834 CGGGGGGATCTTACTAGGACG 9032 144 RGDYGGI 8835 CGTGGGGATTATGGTGGTATT 9033 145 RGDMEPR 8836 CGGGGTGATATGGAGCCTCGT 9034 146 RGDTAVQ 8837 CGTGGGGATACGGCGGTTCAG 9035 147 AVTRGGV 8838 GCTGTGACTAGGGGTGGTGTT 9036 148 VSAARSL 8839 GTGAGTGCGGCGCGTTCTCTG 9037 149 GRLPQQT 8840 GGTCGGCTTCCTCAGCAGACT 9038 150 RGDLVGY 8841 CGAGGCGACTTGGTTGGTTAC 9039 151 RGDLVTV 8842 CGGGGGGATCTGGTTACGGTT 9040 152 RGDYVVH 8843 CGCGGGGACTACGTCGTTCAC 9041 153 RGDAARL 8844 CGCGGCGACGCTGCACGACTA 9042 154 RGDYTGV 8845 AGGGGTGACTACACAGGCGTC 9043 155 RGDLGGT 8846 AGGGGTGATCTTGGGGGTACG 9044 156 RGDTVYL 8847 CGGGGTGATACGGTGTATCTG 9045 157 RGDLMGS 8848 CGGGGGGATCTTATGGGGAGT 9046 158 LGRGDVS 8849 TTGGGTCGGGGTGATGTGTCG 9047 159 TAGRVQV 8850 ACTGCTGGGCGTGTTCAGGTG 9048 160 VVVRGGV 8851 GTGGTGGTGCGTGGTGGGGTT 9049 161 RGDHTNI 8852 AGAGGGGACCACACTAACATC 9050 162 RGDLVGI 8853 AGGGGCGACTTAGTAGGAATC 9051 163 RGDLSPV 8854 AGAGGAGACTTGTCCCCGGTG 9052 164 RGDLSGV 8855 CGGGGTGATTTGTCGGGGGTT 9053 165 YGIAARS 8856 TACGGCATCGCAGCAAGATCT 9054 166 RGDREGL 8857 CGGGGGGACCGAGAAGGGCTA 9055 167 RGDLHST 8858 CGTGGTGATTTGCATTCGACG 9056 168 RGDATGW 8859 CGGGGTGATGCGACGGGTTGG 9057 169 RGDQSHV 8860 CGAGGCGACCAAAGCCACGTA 9058 170 DKRVGTP 8861 GATAAGAGGGTTGGGACTCCT 9059 171 RGDLVVT 8862 AGAGGCGACCTGGTCGTAACT 9060 172 RGDFGGV 8863 AGGGGTGACTTCGGAGGTGTC 9061 173 RGDLSNT 8864 CGTGGAGACCTCAGCAACACA 9062 174 HRGQAVD 8865 CATCGGGGTCAGGCGGTGGAT 9063 175 SMVRSGT 8866 AGTATGGTTCGTTCGGGGACG 9064 176 TSVSVKY 8867 ACTTCTGTGTCGGTGAAGTAT 9065 177 RGDYSQI 8868 AGAGGCGACTACAGCCAAATA 9066 178 RGDISGV 8869 CGGGGTGATATTTCGGGGGTT 9067 179 RGDVAGV 8870 CGGGGTGATGTGGCGGGGGTT 9068 180 RGDQVTI 8871 AGGGGTGATCAGGTTACTATT 9069 181 RGDRLVI 8872 AGAGGAGACAGGCTGGTCATC 9070 182 PLLRSGT 8873 CCGTTGTTGAGGAGTGGGACG 9071 183 RGDFGSV 8874 CGGGGTGATTTTGGTAGTGTG 9072 184 RGDVAYV 8875 CGGGGTGATGTTGCTTATGTG 9073 185 ARMGTGV 8876 GCTCGTATGGGTACGGGTGTG 9074 186 VMRVGHA 8877 GTGATGCGTGTGGGGCATGCT 9075 187 ARVQSSP 8878 GCTCGTGTTCAGAGTTCGCCT 9076 188 RGDGGIL 8879 CGGGGTGATGGGGGGATTCTT 9077 189 RSDLGAL 8880 AGGTCTGATCTTGGGGCTTTG 9078 190 SYSRSAV 8881 TCGTATTCGCGGAGTGCGGTT 9079 191 RGDVLLV 8882 AGGGGGGATGTTCTTCTGGTG 9080 192 TGVHTRV 8883 ACGGGTGTTCATACGAGGGTG 9081 193 TVGNLRG 8884 ACTGTGGGGAATTTGCGTGGT 9082 194 TVVGQGY 8885 ACTGTCGTCGGACAAGGTTAC 9083 195 RGDGGAL 8886 CGTGGTGATGGTGGTGCTCTG 9084 196 NSYHAGA 8887 AACAGCTACCACGCTGGGGCC 9085 197 RGDLTVT 8888 CGGGGTGATTTGACTGTGACT 9086 198 RGDVHGF 8889 CGGGGAGACGTCCACGGCTTC 9087

Muscle specific AAV capsids were developed using expression from two different muscle specific promoters and the resulting capsid libraries for each promoter were screened in non-human primates as described elsewhere herein and/or in U.S. Provisional Application Ser. Nos. 62/899,453, 62/916,207, 63/018,454, 63/055,252, and 62/916,221 and International Application No. PCT/US20/50534.

Various modifications and variations of the described methods, pharmaceutical compositions, and kits of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it will be understood that it is capable of further modifications and that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known customary practice within the art to which the invention pertains and may be applied to the essential features herein before set forth. 

What is claimed is:
 1. A composition comprising: a targeting moiety effective to target a muscle cell, wherein the targeting moiety comprises an n-mer motif; and a cargo, wherein the cargo is coupled to or is otherwise associated with the targeting moiety.
 2. The composition of claim 1, wherein the n-mer motif comprises an RGD motif or a non-RGD n-mer motif.
 3. The composition of claim 2, wherein the RGD motif has a formula of X_(m)RGDX_(n), wherein m is 0-4 amino acids, wherein n is 0-15 amino acids, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.
 4. The composition of claim 3, wherein the RGD motif has the formula RGDXn, wherein n is 4 or 5, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.
 5. The compositions of claim 2, wherein the n-mer motif is any one of SEQ ID NO: 13-50, 1277-2493, 3737-4979, 6647-8313, 8314-8502, or 8692-8889.
 6. The composition of claim 1, wherein the targeting moiety comprises a polypeptide, a polynucleotide, a lipid, a polymer, a sugar, or a combination thereof.
 7. The composition of claim 1, wherein the targeting moiety comprises a viral protein.
 8. The composition of claim 7, wherein the viral protein is a capsid protein.
 9. The composition of claim 7 wherein the viral protein is an adeno associated virus (AAV) protein.
 10. The composition of claim 7, wherein the n-mer motif is located between two amino acids of the viral protein such that the n-mer motif is external to a viral capsid of which the viral capsid protein is part.
 11. The composition of claim 10, wherein the n-mer motif is inserted between any two contiguous amino acids between amino acids 262-269, 327-332, 382-386, 452-460, 488-505, 527-539, 545-558, 581-593, 704-714, or any combination thereof in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.
 12. The composition of claim 11, wherein the n-mer motif is inserted between amino acids 588 and 589 in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.
 13. The composition of claim 1, wherein the composition is an engineered viral particle.
 14. The composition of claim 13, wherein the engineered viral particle is an engineered AAV viral particle.
 15. The composition of claim 14, wherein the engineered AAV viral particle is an engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, or AAV rh.10 viral particle.
 16. The composition of claim 1, wherein the cargo is capable of treating or preventing a muscle disease or disorder.
 17. The composition of claim 16, wherein the muscle disease or disorder is a. an auto immune disease; b. a cancer; c. a muscular dystrophy; d. a neuro-muscular disease; e. a sugar or glycogen storage disease; f. an expanded repeat disease; g. a dominant negative disease; h. a cardiomyopathy; i. a viral disease; j. a progeroid disease; or k. any combination thereof.
 18. The composition of claim 1, wherein the cargo is a. a morpholino; b. a peptide-linked morpholino; c. an antisense oligonucleotide; d. a PMO, a therapeutic transgene; e. a polynucleotide encoding a therapeutic polypeptide or peptide; f. a PPMO; g. one or more peptides or polypeptides; h. one or more polynucleotides encoding a CRISPR-Cas protein, a guide RNA, or both; i. a ribonucleoprotein, wherein the ribonucleoprotein comprises a CRISPR-Cas system molecule; j. a therapeutic transgene RNA, or other gene modifying or therapeutic RNA and/or protein; or k. any combination thereof.
 19. The composition of claim 1, wherein the cargo is capable of inducing exon skipping in a gene.
 20. The composition of claim 1, wherein the cargo is capable of inducing exon skipping in a dystrophin gene.
 21. The composition of claim 1, wherein the cargo is a mini- or micro-dystrophin gene.
 22. The composition of claim 21, wherein the mini- or micro-dystrophin gene comprises spectrin-like repeats 1, 1′, 2, 3, 16, 17, 20, 21, 22, 23, 24, or any combination thereof, and optionally an nNOS domain, an actin binding domain, one or more hinge regions, a dystroglycan binding domain, or any combination thereof.
 23. The composition of claim 1, wherein the cargo is operably coupled to a muscle specific promoter.
 24. The composition of claim 17, wherein the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).
 25. The composition of claim 17, wherein the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.
 26. The composition of claim 25, wherein the myotonic dystrophy is a Type 1 or a Type 2 myotonic dystrophy.
 27. The composition of claim 17, wherein the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, Duchene muscular dystrophy-associated cardiomyopathy, or Dannon disease.
 28. The composition of claim 17, wherein the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.
 29. The composition of claim 28, wherein the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID.
 30. The composition of claim 17, wherein the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.
 31. The composition of claim 1, wherein the composition has increased muscle cell potency, muscle cell specificity, reduced immunogenicity, or any combination thereof.
 32. A vector system comprising: a vector comprising: one or more polynucleotides each encoding all or part of one or more targeting moieties effective to target a muscle cell, wherein each targeting moiety comprises one or more n-mer motifs, wherein each n-mer motif an RGD motif or a non-RGD n-mer motif, and wherein each polynucleotide at least encodes one or more of the one or more n-mer motifs; and optionally, a regulatory element operatively coupled to one or more of the one or more polynucleotides.
 33. The vector system of claim 32, wherein the RGD motif has a formula of X_(m)RGDX_(n), wherein m is 0-4 amino acids, wherein n is 0-15 amino acids, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid.
 34. The vector system of claim 33, wherein the RGD motif has the formula RGDXn, wherein n is 4 or 5, wherein X is any amino acid, and wherein each X amino acid present is independently selected from the others from the group consisting of: any amino acid
 35. The vector system of claim 33, wherein the n-mer motif is any one of SEQ ID NO: 13-50, 1277-2493, 3737-4979, 6647-8313, 8314-8502, or 8692-8889.
 36. The vector system of claim 32, further comprising a cargo.
 37. The vector system of claim 36, wherein the cargo is a cargo polynucleotide and is optionally coupled to one or more of the one or more polynucleotides encoding the targeting moiety, the regulatory element, or both.
 38. The vector system of claim 36, wherein the cargo polynucleotide is present on the same vector or a different vector as the one or more polynucleotides encoding the targeting moiety.
 39. The vector system of claim 36, wherein the vector system is capable of producing virus particles that contain the cargo.
 40. The vector system of claim 32, wherein the vector system is capable of producing a viral capsid polypeptide comprising one or more of the targeting moieties.
 41. The vector system of claim 32, wherein the vector system is capable of producing AAV virus particles.
 42. The vector system of any of claim 41, wherein AAV viral particles are engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, or AAV rh.10 viral particle.
 43. The vector system of claim 40, wherein the capsid polypeptide is an engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV rh.74, AAV rh.10 capsid polypeptide.
 44. The vector system of claim 39, wherein at least one of the one or more polynucleotides encoding the n-mer motif(s) is inserted between two codons corresponding to two amino acids of the viral protein such that at least one of the n-mer motifs is external to the viral capsid.
 45. The vector system of claim 44, wherein the two codons correspond to any two contiguous amino acids between amino acids 262-269, 327-332, 382-386, 452-460, 488-505, 527-539, 545-558, 581-593, 704-714, or any combination thereof in an AAV9 capsid polypeptide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.
 46. The vector system of claim 45, wherein the two codons correspond to amino acid 588 and 589 in the AAV9 capsid polynucleotide or in an analogous position in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV rh.74, or AAV rh.10 capsid polypeptide.
 47. The vector system of any of claim 32, wherein the vector comprising the one or more polynucleotides each encoding all or part of one or more targeting moieties does not comprise splice regulatory elements.
 48. The vector system of claim 32, further comprising a polynucleotide encoding a viral rep protein.
 49. The vector system of claim 48, wherein the viral rep protein is an AAV rep protein.
 50. The vector system of claim 48, wherein the polynucleotide encoding the viral rep protein is on the same vector or different vector as the one or more polynucleotides each encoding all or part of one or more targeting moieties.
 51. The vector system of claim 48, wherein the viral rep protein is operatively coupled to a regulatory element.
 52. A polypeptide produced by expressing a vector system as in any one of claims 32-51.
 53. The polypeptide of claim 52, wherein the polypeptide is a viral polypeptide.
 54. The polypeptide of claim 53, wherein the viral polypeptide is an AAV polypeptide.
 55. A particle produced by expressing a vector system as in any one of claims 32-51.
 56. The particle of claim 55, wherein the particle is a viral particle.
 57. The particle of claim 56, wherein the viral particle is an adeno-associated virus (AAV) particle.
 58. The particle of claim 56, wherein the viral particle has a muscle-specific tropism.
 59. The vector system of any one of claims 36-51, a polypeptide as in any one of claims 52-54, or a particle as in any one of claims 55-58, wherein the cargo is capable of treating or preventing a muscle disease or disorder.
 60. The vector system, the polypeptide, or the particle of claim 59, wherein the muscle disease or disorder is a. an auto immune disease; b. a cancer; c. a muscular dystrophy; d. a neuro-muscular disease; e. a sugar or glycogen storage disease; f. an expanded repeat disease; g. a dominant negative disease; h. a cardiomyopathy; i. a viral disease; j. a progeroid disease; or k. any combination thereof.
 61. The vector system, the polypeptide, or the particle of claim 60, wherein the cargo is a morpholino; a. a peptide-linked morpholino; b. an antisense oligonucleotide; c. a PMO, a therapeutic transgene; d. a polynucleotide encoding a therapeutic polypeptide or peptide; e. a PPMO; f. one or more peptides or polypeptides; g. one or more polynucleotides encoding a CRISPR-Cas protein, a guide RNA, or both; h. a ribonucleoprotein, wherein the ribonucleoprotein comprises a CRISPR-Cas system molecule; i. a therapeutic transgene RNA, or other gene modifying or therapeutic RNA and/or protein; or j. any combination thereof.
 62. The vector system, the polypeptide, or the particle of claim 59, wherein the cargo is capable of inducing exon skipping in a gene.
 63. The vector system, the polypeptide, or the particle of claim 59, wherein the cargo is capable of inducing exon skipping in a dystrophin gene.
 64. The vector system, the polypeptide, or the particle of claim 59, wherein the cargo is a mini- or micro-dystrophin gene.
 65. The vector system, the polypeptide, or the particle of claim 64, wherein the mini- or micro-dystrophin gene comprises spectrin-like repeats 1, 1′, 2, 3, 16, 17, 20, 21, 22, 23, 24, or any combination thereof, and optionally an nNOS domain, an actin binding domain, one or more hinge regions, a dystroglycan binding domain, or any combination thereof.
 66. The vector system, the polypeptide, or the particle of claim 60, wherein the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).
 67. The vector system, the polypeptide, or the particle of claim 60, wherein the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.
 68. The vector system, the polypeptide, or the particle of claim 67, wherein the myotonic dystrophy is Type 1 or Type
 2. 69. The vector system, the polypeptide, or the particle of claim 60, wherein the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, DMD-associated cardiomyopathy, or Dannon disease.
 70. The vector system, the polypeptide, or the particle of claim 60, wherein the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.
 71. The vector system, the polypeptide, or the particle of claim 70, wherein the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or IIID.
 72. The vector system, the polypeptide, or the particle of claim 60, wherein the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia.
 73. The polypeptide or the particle of any one of claims 52-58, wherein the polypeptide, the particle, or both have increased muscle cell potency, muscle cell specificity, reduced immunogenicity, or any combination thereof.
 74. A cell comprising: a. a composition as in any of claims 1-31; b. a vector system as in any one of claim 32-51 or 59-72; c. a polypeptide as in any one of claim 52-54 or 59-73; d. a particle as in any one of claims 55-73; or e. a combination thereof.
 75. The cell of claim 74, wherein the cell is prokaryotic.
 76. The cell of claim 74, wherein the cell is eukaryotic.
 77. A pharmaceutical formulation comprising: a. a composition as in any of claims 1-31; b. a vector system as in any one of claim 32-51 or 59-72; c. a polypeptide as in any one of claim 52-54 or 59-73; d. a particle as in any one of claims 55-73; e. a cell as in any one of claims 74-76; or f. a combination thereof; and a pharmaceutically acceptable carrier.
 78. A method comprising: administering, to a subject in need thereof, a a. composition as in any of claims 1-31; b. vector system as in any one of claim 32-51 or 59-72; c. polypeptide as in any one of claim 52-54 or 59-73; d. particle as in any one of claims 55-73; e. cell as in any one of claims 74-76; f. pharmaceutical formulation as in claim 77; or g. combination thereof.
 79. The method of claim 78, wherein the subject in need thereof has a muscle disease or disorder.
 80. The method of claim 79, wherein the muscle disease or disorder is a. an auto immune disease; b. a cancer; c. a muscular dystrophy; d. a neuro-muscular disease; e. a sugar or glycogen storage disease; f. an expanded repeat disease; g. a dominant negative disease; h. a cardiomyopathy; i. a viral disease; j. a progeroid disease; or k. any combination thereof.
 81. The method of claim 80, wherein the expanded repeat disease is Huntington's disease, a Myotonic Dystrophy, or Facioscapulohumeral muscular dystrophy (FSHD).
 82. The method of claim 80, wherein the muscular dystrophy is Duchene muscular dystrophy, Becker Muscular dystrophy, a Limb-Girdle muscular dystrophy, an Emery Dreifuss muscular dystrophy, a myotonic dystrophy, or FSHD.
 83. The method of claim 82, wherein the myotonic dystrophy is Type 1 or Type
 2. 84. The method of claim 80, wherein the cardiomyopathy is dilated cardiomyopathy, hypertrophic cardiomyopathy, DMD-associated cardiomyopathy, or Dannon disease.
 85. The method of claim 80, wherein the sugar or glycogen storage disease is a MPS type III disease or Pompe disease.
 86. The method of claim 85, wherein the MPS type III disease, is MPS Type IIIA, IIIB, IIIC, or HID.
 87. The method of claim 80, wherein the neuro-muscular disease is Charcot-Marie-Tooth disease or Friedreich's Ataxia. 